<http://covid19.aksw.org/69eb6f3994e9038a39895bc685be0d3aac1c2746> {
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"It has been observed that NSAIDs may have an inhibitory action of leukocyte adhesion, phagocytosis, and bactericidal activity in vitro. [25] [26] [27] [28] [29] Finally, it was observed that low concentrations of ibuprofen, such as those obtained during antipyretic use, may have a proinflammatory action that promotes the recruitment and influx of neutrophils. 30 The use of NSAIDs also reflects delayed effective treatment, because NSAIDs might mask the onset of bacterial disease by decreasing the inflammatory response to infection. Associations between bacterial infections and NSAIDs were reported for necrotizing fasciitis during primary varicella 31, 32 or for invasive group A streptococcal infection. 33 The occurrence of new symptoms or complications were slightly more frequent in children receiving ibuprofen than in those advised to take acetaminophen during respiratory tract infections. 34 Empyema was thought to be associated with outpatient use of NSAIDs in children and adults 3, [9] [10] [11] [12] [13] ; however, NSAIDs could not be causally implicated. These analysis were hampered by protopathic bias, 35 ie, the possibility of more frequent use of NSAIDs because patients who developed empyema had more febrile (severe) early infection than those with uncomplicated acute bacterial pneumonia. It was impossible to clearly state whether NSAIDs had been started before or after empyema onset. The strength of our case-control study is that it was specifically designed to minimize this bias as much as possible. First, paired case and control were from the same source population. Children with initial acute viral infection that could lead to antipyretic exposure were diagnosed by the same physician. Because controls were recruited by the same doctor, physician-related and geographic variations of exposure were controlled. Second, for LRTVIs, to avoid protopathic bias as much as possible, children without at least 24 hours of apyrexia between recovery from LRTVI symptoms and a diagnosis of empyema were excluded. Third, when the time between onset of acute viral infection and diagnosis of empyema was less than 72 hours, children were excluded to avoid drug exposure for pyrexia and/or pain linked with empyema onset. Fourth, the analysis phase considered drug exposure only when first drug intake occurred within 72 hours after the onset of acute viral infection symptoms. The increased risk of empyema associated with NSAID intake during acute viral infection is our primary observation; the fact that the association is significant as of the first day of NSAID use strengthens our results.\",\"cite_spans\":[{\"start\":136.0,\"end\":140.0,\"text\":\"[25]\",\"ref_id\":\"BIBREF24\"},{\"start\":141.0,\"end\":145.0,\"text\":\"[26]\",\"ref_id\":\"BIBREF25\"},{\"start\":146.0,\"end\":150.0,\"text\":\"[27]\",\"ref_id\":\"BIBREF26\"},{\"start\":151.0,\"end\":155.0,\"text\":\"[28]\",\"ref_id\":\"BIBREF27\"},{\"start\":156.0,\"end\":160.0,\"text\":\"[29]\",\"ref_id\":\"BIBREF28\"},{\"start\":362.0,\"end\":364.0,\"text\":\"30\",\"ref_id\":\"BIBREF29\"},{\"start\":655.0,\"end\":658.0,\"text\":\"31,\",\"ref_id\":\"BIBREF30\"},{\"start\":659.0,\"end\":661.0,\"text\":\"32\",\"ref_id\":\"BIBREF31\"},{\"start\":711.0,\"end\":713.0,\"text\":\"33\",\"ref_id\":\"BIBREF32\"},{\"start\":903.0,\"end\":905.0,\"text\":\"34\",\"ref_id\":\"BIBREF33\"},{\"start\":996.0,\"end\":998.0,\"text\":\"3,\",\"ref_id\":\"BIBREF2\"},{\"start\":999.0,\"end\":1002.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":1003.0,\"end\":1007.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":1008.0,\"end\":1012.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1013.0,\"end\":1017.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1018.0,\"end\":1022.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1125.0,\"end\":1127.0,\"text\":\"35\",\"ref_id\":\"BIBREF34\"}],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-903-905> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-362-364> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1003-1007> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-146-150> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-151-155> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-141-145> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-711-713> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1013-1017> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-156-160> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-136-140> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1125-1127> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1008-1012> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-659-661> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-996-998> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1018-1022> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-999-1002> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-655-658> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "It has been observed that NSAIDs may have an inhibitory action of leukocyte adhesion, phagocytosis, and bactericidal activity in vitro. [25] [26] [27] [28] [29] Finally, it was observed that low concentrations of ibuprofen, such as those obtained during antipyretic use, may have a proinflammatory action that promotes the recruitment and influx of neutrophils. 30 The use of NSAIDs also reflects delayed effective treatment, because NSAIDs might mask the onset of bacterial disease by decreasing the inflammatory response to infection. Associations between bacterial infections and NSAIDs were reported for necrotizing fasciitis during primary varicella 31, 32 or for invasive group A streptococcal infection. 33 The occurrence of new symptoms or complications were slightly more frequent in children receiving ibuprofen than in those advised to take acetaminophen during respiratory tract infections. 34 Empyema was thought to be associated with outpatient use of NSAIDs in children and adults 3, [9] [10] [11] [12] [13] ; however, NSAIDs could not be causally implicated. These analysis were hampered by protopathic bias, 35 ie, the possibility of more frequent use of NSAIDs because patients who developed empyema had more febrile (severe) early infection than those with uncomplicated acute bacterial pneumonia. It was impossible to clearly state whether NSAIDs had been started before or after empyema onset. The strength of our case-control study is that it was specifically designed to minimize this bias as much as possible. First, paired case and control were from the same source population. Children with initial acute viral infection that could lead to antipyretic exposure were diagnosed by the same physician. Because controls were recruited by the same doctor, physician-related and geographic variations of exposure were controlled. Second, for LRTVIs, to avoid protopathic bias as much as possible, children without at least 24 hours of apyrexia between recovery from LRTVI symptoms and a diagnosis of empyema were excluded. Third, when the time between onset of acute viral infection and diagnosis of empyema was less than 72 hours, children were excluded to avoid drug exposure for pyrexia and/or pain linked with empyema onset. Fourth, the analysis phase considered drug exposure only when first drug intake occurred within 72 hours after the onset of acute viral infection symptoms. The increased risk of empyema associated with NSAID intake during acute viral infection is our primary observation; the fact that the association is significant as of the first day of NSAID use strengthens our results." ;
            <http://www.example.org/textHash>
                    "367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1" .
    
    <http://covid19.aksw.org/text-53e722f1e4fc5218d489361108217b855cf426091bbe5dd1057fd37e659e69a0_refspan-1005-1013>
            <http://www.example.org/end>    "1013.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF6" ;
            <http://www.example.org/start>  "1005.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Table V" .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-505-507>
            <http://www.example.org/end>    "507.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "505.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "1," .
    
    <http://covid19.aksw.org/text-b1c729efec4cf0addae2ad4555240984e11484927c83846ba47e299148c6d8ef>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A case-control study was conducted in 15 centers. Cases and controls were enrolled for a source population of children 3-15 years of age with acute viral infections between 2006 and 2009.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "A case-control study was conducted in 15 centers. Cases and controls were enrolled for a source population of children 3-15 years of age with acute viral infections between 2006 and 2009." ;
            <http://www.example.org/textHash>
                    "b1c729efec4cf0addae2ad4555240984e11484927c83846ba47e299148c6d8ef" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1003-1007>
            <http://www.example.org/end>    "1007.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1003.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-edbf0801ea680729ffce194c68981fb47f192cd228732cdfd46724bda5e5055f_citespan-407-409>
            <http://www.example.org/end>    "409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16" .
    
    <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-1176-1184>
            <http://www.example.org/end>    "1184.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "1176.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Figure 4" .
    
    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-204-205>
            <http://www.example.org/end>    "205.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "204.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "1" .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-520-523>
            <http://www.example.org/end>    "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[6]" .
    
    <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Of 215 potential cases and 94 potential controls, 83 matched pairs of eligible cases and controls were identified (Figure 2 ; available at www.jpeds.com). In each group, 53.0% were boys. Mean duration of exposure defined as delay between onset of acute viral infection and diagnosis of empyema in cases was 10 days. No significant differences were observed between cases and controls for age, siblings, parents\\u0027 occupations, the acute viral infection site, PVC-7 vaccination, and fever at the acute viral infection onset ( Table I) . Acute viral infections were mostly upper respiratory tract viral infections. More than one-half of the subjects in each group had received at least 1 PCV-7 dose. For children with respiratory viral identification, no differences were found between the types of viruses identified for cases and controls ( Table II ; available at www.jpeds.com). Among the 79 cases with identified bacteria, S pneumoniae accounted for 86% ( Figure 3 ; available at www.jpeds.com). Among S pneumoniae with an identified serotype (n \\u003d 32), serotypes 1, 19A, and 3 were the most frequent, with the vast majority (31/32) belonging to non-PCV-7 vaccine serotypes ( Figure 4 ; available at www.jpeds.com).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":114.0,\"end\":123.0,\"text\":\"(Figure 2\",\"ref_id\":\"FIGREF1\"},{\"start\":523.0,\"end\":531.0,\"text\":\"Table I)\",\"ref_id\":\"TABREF1\"},{\"start\":839.0,\"end\":847.0,\"text\":\"Table II\",\"ref_id\":\"TABREF1\"},{\"start\":957.0,\"end\":965.0,\"text\":\"Figure 3\",\"ref_id\":\"FIGREF3\"},{\"start\":1176.0,\"end\":1184.0,\"text\":\"Figure 4\",\"ref_id\":\"FIGREF2\"}],\"section\":\"Results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-114-123> , <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-523-531> , <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-839-847> , <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-957-965> , <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-1176-1184> ;
            <http://www.example.org/section>
                    "Results" ;
            <http://www.example.org/text>  "Of 215 potential cases and 94 potential controls, 83 matched pairs of eligible cases and controls were identified (Figure 2 ; available at www.jpeds.com). In each group, 53.0% were boys. Mean duration of exposure defined as delay between onset of acute viral infection and diagnosis of empyema in cases was 10 days. No significant differences were observed between cases and controls for age, siblings, parents' occupations, the acute viral infection site, PVC-7 vaccination, and fever at the acute viral infection onset ( Table I) . Acute viral infections were mostly upper respiratory tract viral infections. More than one-half of the subjects in each group had received at least 1 PCV-7 dose. For children with respiratory viral identification, no differences were found between the types of viruses identified for cases and controls ( Table II ; available at www.jpeds.com). Among the 79 cases with identified bacteria, S pneumoniae accounted for 86% ( Figure 3 ; available at www.jpeds.com). Among S pneumoniae with an identified serotype (n = 32), serotypes 1, 19A, and 3 were the most frequent, with the vast majority (31/32) belonging to non-PCV-7 vaccine serotypes ( Figure 4 ; available at www.jpeds.com)." ;
            <http://www.example.org/textHash>
                    "cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01" .
    
    <http://covid19.aksw.org/text-a1f76c9f97f3bc583d49be1792e488dddceb745929b712c4cb185623d341f1ac>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Some study limitations are noteworthy. The relatively small numbers of cases and controls limit the statistical po-wer to identify associations. It was relatively difficult to find matched controls despite the efforts of primary providers. In addition, the daily dosage of medicine taken was not precise enough to permit analysis for a dose effect.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "Some study limitations are noteworthy. The relatively small numbers of cases and controls limit the statistical po-wer to identify associations. It was relatively difficult to find matched controls despite the efforts of primary providers. In addition, the daily dosage of medicine taken was not precise enough to permit analysis for a dose effect." ;
            <http://www.example.org/textHash>
                    "a1f76c9f97f3bc583d49be1792e488dddceb745929b712c4cb185623d341f1ac" .
    
    <http://covid19.aksw.org/text-c3a8c634797215cc9f4e17c11829e1fcb0d4b9d4ffd7308ef9a12d768200e2a6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The analysis phase considered drug exposure from the onset of acute viral infection symptoms. Drug use was considered when exposure began within the 72 hours after the onset of acute viral infection and before apyrexia for LRTVIs. For each control, the period of time at risk for drug exposure was defined as the time between onset of acute viral infection and empyema diagnosis for the paired case. Drug exposuredurations considered were of at least 3 or 6 consecutive days for antibiotics and 1, 2, or 3 consecutive days for NSAIDs and acetaminophen. Conditional logistic regression was used to compare cases and matched controls for general characteristics. All variables achieving P # .20 were included in the multivariable analysis. Estimated matched ORs for proposed exposure definitions used the same P-value threshold. The final model was determined via a manual backwardselection procedure. When appropriate, interactions between variables were tested. More specifically, we used subgroup modeling to thoroughly investigate interactions between final significant variables. When the conditional logistic model did not converge, unpaired classical logistic regression was used. In that case, compared with conditional logistic model, greater significance might be observed. A 2-tailed P \\u003c .05 in the multivariable model defined significance. All computations were made with Stata v10.0 software (Stata-Corp, College Station, Texas).\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Statistical Analyses\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Statistical Analyses" ;
            <http://www.example.org/text>  "The analysis phase considered drug exposure from the onset of acute viral infection symptoms. Drug use was considered when exposure began within the 72 hours after the onset of acute viral infection and before apyrexia for LRTVIs. For each control, the period of time at risk for drug exposure was defined as the time between onset of acute viral infection and empyema diagnosis for the paired case. Drug exposuredurations considered were of at least 3 or 6 consecutive days for antibiotics and 1, 2, or 3 consecutive days for NSAIDs and acetaminophen. Conditional logistic regression was used to compare cases and matched controls for general characteristics. All variables achieving P # .20 were included in the multivariable analysis. Estimated matched ORs for proposed exposure definitions used the same P-value threshold. The final model was determined via a manual backwardselection procedure. When appropriate, interactions between variables were tested. More specifically, we used subgroup modeling to thoroughly investigate interactions between final significant variables. When the conditional logistic model did not converge, unpaired classical logistic regression was used. In that case, compared with conditional logistic model, greater significance might be observed. A 2-tailed P < .05 in the multivariable model defined significance. All computations were made with Stata v10.0 software (Stata-Corp, College Station, Texas)." ;
            <http://www.example.org/textHash>
                    "c3a8c634797215cc9f4e17c11829e1fcb0d4b9d4ffd7308ef9a12d768200e2a6" .
    
    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-1100-1103>
            <http://www.example.org/end>    "1103.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "1100.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14," .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-512-515>
            <http://www.example.org/end>    "515.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "512.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[4]" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1125-1127>
            <http://www.example.org/end>    "1127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "1125.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35" .
    
    <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-839-847>
            <http://www.example.org/end>    "847.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "839.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table II" .
    
    <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-957-965>
            <http://www.example.org/end>    "965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF3" ;
            <http://www.example.org/start>  "957.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Figure 3" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-136-140>
            <http://www.example.org/end>    "140.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[25]" .
    
    <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"After identification in the laboratory of the hospital at which the case was admitted, bacterial strains from pleural fluids were sent for identity confirmation to the University Hospital Necker-Enfants Malades microbiology laboratory as, when feasible, a sample of pleural fluid was sent for pneumococcal antigen testing and polymerase chain reaction (PCR) testing for atypical bacteria (Mycoplasma pneumoniae and Chlamydophila pneumoniae). When cultures were negative, pneumococcal and universal bacterial PCRs were performed. DNA was extracted from 100 mL of pleural fluid samples previously stored at À80 C with the automated MagNA Pure LC System (Roche Diagnostics, Meylan, France) and eluted in 100 mL of elution buffer using the DNA III Magna Pure DNA Isolation Kit (Roche Diagnostics). In-house C pneumoniae (OMP1 gene) and M pneumoniae (P1 cytadhesin gene) PCRs were performed as described previously. 17, 18 S pneumoniae pneumolysin gene real-time PCR was performed according to Corless et al. 19 For negative pneumococcal PCR samples, real-time amplification of universal bacterial 16S rDNA was performed and the amplified product was sequenced, as previously reported. 20 Pneumococcal antigen was detected with the immunochromatographic test BinaxNOW for Streptococcus pneumoniae (Binax Inc, Portland, Maine), according to Le Monnier et al. 21 Pneumococcal strains were serotyped at the French National Reference Center for Pneumococci (NRCP) via the use of latex particles coated with a complete panel of antisera and factor serum (provided by the Statens Serum Institute, Copenhagen, Denmark), which is able to identify the 91 known serotypes. Pneumococcal strains of known serotypes from the Statens Serum Institute and from French NRCP were used as internal controls. When available, DNA from individual pleural fluid samples with positive pneumolysin PCRs also were sent to the NRCP for serotyping with conventional multiplex PCR. PCR and PCR-products detection on 2% agarose gels were performed as described by the Centers for Disease Control and Prevention (http://www.cdc.gov/ncidod/biotech/strep/pcr.htm).\",\"cite_spans\":[{\"start\":911.0,\"end\":914.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":915.0,\"end\":917.0,\"text\":\"18\",\"ref_id\":\"BIBREF17\"},{\"start\":1004.0,\"end\":1006.0,\"text\":\"19\",\"ref_id\":\"BIBREF18\"},{\"start\":1181.0,\"end\":1183.0,\"text\":\"20\",\"ref_id\":\"BIBREF19\"},{\"start\":1353.0,\"end\":1355.0,\"text\":\"21\",\"ref_id\":\"BIBREF20\"}],\"ref_spans\":[],\"section\":\"Microbiology\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-911-914> , <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-915-917> , <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-1004-1006> , <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-1181-1183> , <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-1353-1355> ;
            <http://www.example.org/section>
                    "Microbiology" ;
            <http://www.example.org/text>  "After identification in the laboratory of the hospital at which the case was admitted, bacterial strains from pleural fluids were sent for identity confirmation to the University Hospital Necker-Enfants Malades microbiology laboratory as, when feasible, a sample of pleural fluid was sent for pneumococcal antigen testing and polymerase chain reaction (PCR) testing for atypical bacteria (Mycoplasma pneumoniae and Chlamydophila pneumoniae). When cultures were negative, pneumococcal and universal bacterial PCRs were performed. DNA was extracted from 100 mL of pleural fluid samples previously stored at À80 C with the automated MagNA Pure LC System (Roche Diagnostics, Meylan, France) and eluted in 100 mL of elution buffer using the DNA III Magna Pure DNA Isolation Kit (Roche Diagnostics). In-house C pneumoniae (OMP1 gene) and M pneumoniae (P1 cytadhesin gene) PCRs were performed as described previously. 17, 18 S pneumoniae pneumolysin gene real-time PCR was performed according to Corless et al. 19 For negative pneumococcal PCR samples, real-time amplification of universal bacterial 16S rDNA was performed and the amplified product was sequenced, as previously reported. 20 Pneumococcal antigen was detected with the immunochromatographic test BinaxNOW for Streptococcus pneumoniae (Binax Inc, Portland, Maine), according to Le Monnier et al. 21 Pneumococcal strains were serotyped at the French National Reference Center for Pneumococci (NRCP) via the use of latex particles coated with a complete panel of antisera and factor serum (provided by the Statens Serum Institute, Copenhagen, Denmark), which is able to identify the 91 known serotypes. Pneumococcal strains of known serotypes from the Statens Serum Institute and from French NRCP were used as internal controls. When available, DNA from individual pleural fluid samples with positive pneumolysin PCRs also were sent to the NRCP for serotyping with conventional multiplex PCR. PCR and PCR-products detection on 2% agarose gels were performed as described by the Centers for Disease Control and Prevention (http://www.cdc.gov/ncidod/biotech/strep/pcr.htm)." ;
            <http://www.example.org/textHash>
                    "5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9" .
    
    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A lthough relatively infrequent, empyema is a serious bacterial infection of the pleural space that remains a cause of substantial morbidity, with an in-hospital case-fatality ratio of 0.4% for children. 1 Late diagnosis and onset of appropriate therapy contribute to increased morbidity. In addition, the in-hospital management of patients with empyema is associated with substantial economic costs. 2 In the 2000s, the incidence rate of empyema in children increased worldwide as in France without clear explanations. 1,3-6 This trend was not modified by 7-valent pneumococcal conjugate vaccine (PCV-7) programs, 1,3-7 but hospitalizations for uncomplicated pneumonia clearly declined thereafter. 8 Previous retrospective studies suggested that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during community-acquired pneumonia may be associated with an increased risk of empyema, 3,9-13 but a protopathic bias could not be excluded. This case-control study was undertaken to investigate children\\u0027s risk factors for empyema after acute viral infection and determine whether some viruses, 14, 15 use of NSAIDs, or both were associated.\",\"cite_spans\":[{\"start\":204.0,\"end\":205.0,\"text\":\"1\"},{\"start\":401.0,\"end\":402.0,\"text\":\"2\",\"ref_id\":\"BIBREF1\"},{\"start\":699.0,\"end\":700.0,\"text\":\"8\",\"ref_id\":\"BIBREF7\"},{\"start\":1100.0,\"end\":1103.0,\"text\":\"14,\",\"ref_id\":\"BIBREF13\"},{\"start\":1104.0,\"end\":1106.0,\"text\":\"15\",\"ref_id\":\"BIBREF14\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-204-205> , <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-401-402> , <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-699-700> , <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-1100-1103> , <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-1104-1106> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "A lthough relatively infrequent, empyema is a serious bacterial infection of the pleural space that remains a cause of substantial morbidity, with an in-hospital case-fatality ratio of 0.4% for children. 1 Late diagnosis and onset of appropriate therapy contribute to increased morbidity. In addition, the in-hospital management of patients with empyema is associated with substantial economic costs. 2 In the 2000s, the incidence rate of empyema in children increased worldwide as in France without clear explanations. 1,3-6 This trend was not modified by 7-valent pneumococcal conjugate vaccine (PCV-7) programs, 1,3-7 but hospitalizations for uncomplicated pneumonia clearly declined thereafter. 8 Previous retrospective studies suggested that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during community-acquired pneumonia may be associated with an increased risk of empyema, 3,9-13 but a protopathic bias could not be excluded. This case-control study was undertaken to investigate children's risk factors for empyema after acute viral infection and determine whether some viruses, 14, 15 use of NSAIDs, or both were associated." ;
            <http://www.example.org/textHash>
                    "d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-655-658>
            <http://www.example.org/end>    "658.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "655.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31," .
    
    <http://covid19.aksw.org/text-742b1f7aa898f9c5d43c9b87c5cb5e395c67cf4ea6ffc26d8d11aa59cea4717c_citespan-117-119>
            <http://www.example.org/end>    "119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "117.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-401-402>
            <http://www.example.org/end>    "402.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "2" .
    
    <http://covid19.aksw.org/text-ff07e841405fb1de9209fa3840d9393084a9bf6657bfbcd9df0ec09a48a8c076>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"This case-control study provided strong support for an increased risk of empyema for children with acute viral infections exposed to NSAIDs. NSAIDs previously have been a suspected risk factor for severe bacterial infections. The biological mechanisms of how NSAID can influence the pathogenesis of bacterial infections remain controversial. Based on the ability of NSAIDS to modify the host\\u0027s inflammatory pathway and innate immune response, a direct role for NSAIDs in development of severe group A streptococcal infection was proposed by Stevens in 1995. 24 This hypothesis was based on the ability of NSAIDS to induce increased production of cytokines such as tumor necrosis factor, interleukin 1, and interleukin 6.\",\"cite_spans\":[{\"start\":558.0,\"end\":560.0,\"text\":\"24\",\"ref_id\":\"BIBREF23\"}],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ff07e841405fb1de9209fa3840d9393084a9bf6657bfbcd9df0ec09a48a8c076_citespan-558-560> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "This case-control study provided strong support for an increased risk of empyema for children with acute viral infections exposed to NSAIDs. NSAIDs previously have been a suspected risk factor for severe bacterial infections. The biological mechanisms of how NSAID can influence the pathogenesis of bacterial infections remain controversial. Based on the ability of NSAIDS to modify the host's inflammatory pathway and innate immune response, a direct role for NSAIDs in development of severe group A streptococcal infection was proposed by Stevens in 1995. 24 This hypothesis was based on the ability of NSAIDS to induce increased production of cytokines such as tumor necrosis factor, interleukin 1, and interleukin 6." ;
            <http://www.example.org/textHash>
                    "ff07e841405fb1de9209fa3840d9393084a9bf6657bfbcd9df0ec09a48a8c076" .
    
    <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421_citespan-332-334>
            <http://www.example.org/end>    "334.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37" .
    
    <http://covid19.aksw.org/text-0790e469cc4d0b3a250f275f3d3d88e5af502e209ae39ff7af795c949875bd2f_citespan-84-86>
            <http://www.example.org/end>    "86.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "84.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "22" .
    
    <http://covid19.aksw.org/text-15f3d695fed75a8de5d4a35f9f266b7cf166b983d3a3adddde1ccd7aa9aa4a88_refspan-753-762>
            <http://www.example.org/end>    "762.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "753.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Figure 1)" .
    
    <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-114-123>
            <http://www.example.org/end>    "123.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Figure 2" .
    
    <http://covid19.aksw.org/69eb6f3994e9038a39895bc685be0d3aac1c2746>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "69eb6f3994e9038a39895bc685be0d3aac1c2746" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17> , <http://covid19.aksw.org/text-7ae9136407dbe7ccf4b81f25980e0460a5c05fa39038e6efce0b8be175446943> , <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92> , <http://covid19.aksw.org/text-a1f76c9f97f3bc583d49be1792e488dddceb745929b712c4cb185623d341f1ac> , <http://covid19.aksw.org/text-71b473e7734b167c78381924ba4c015cea98187a46643e07c622902f605c975c> , <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01> , <http://covid19.aksw.org/text-53e722f1e4fc5218d489361108217b855cf426091bbe5dd1057fd37e659e69a0> , <http://covid19.aksw.org/text-742b1f7aa898f9c5d43c9b87c5cb5e395c67cf4ea6ffc26d8d11aa59cea4717c> , <http://covid19.aksw.org/text-0790e469cc4d0b3a250f275f3d3d88e5af502e209ae39ff7af795c949875bd2f> , <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421> , <http://covid19.aksw.org/text-83df2700da6e148bf930c174a8879d0eb5cfe6003ea773a4de79f469cb89a28f> , <http://covid19.aksw.org/text-9c5002ae305fd9c13bfb7db458941aab872b098322925f272e941e7edc6403de> , <http://covid19.aksw.org/text-2da71b0eb558ab6790605ddbf36dc304b46af8a20b389f80847bf81c966ca69c> , <http://covid19.aksw.org/text-ae305c007fbb906eb34b195161d278afe52ed7aeb947c2dcccb1d8b5a20ea90e> , <http://covid19.aksw.org/text-e60b1f75412098d6c6e7e9a645bfd1b68b97e7475a9a8c587a2f9e20d17499a2> , <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9> , <http://covid19.aksw.org/text-715f8e9d7827e796cfce5bf15501c4ef145afe9a79c190adacfb52d7fddc85f4> , <http://covid19.aksw.org/text-c3a8c634797215cc9f4e17c11829e1fcb0d4b9d4ffd7308ef9a12d768200e2a6> , <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1> , <http://covid19.aksw.org/text-705a1f86b8738a301912585d699bd80f7c5fe6d15517361e7455faad18446dc3> , <http://covid19.aksw.org/text-15f3d695fed75a8de5d4a35f9f266b7cf166b983d3a3adddde1ccd7aa9aa4a88> , <http://covid19.aksw.org/text-7f84fd7ad88b2d50b4c0c6b5c0f1735f61ee766befc6b7026b1f08507b75acab> , <http://covid19.aksw.org/text-b1c729efec4cf0addae2ad4555240984e11484927c83846ba47e299148c6d8ef> , <http://covid19.aksw.org/text-edbf0801ea680729ffce194c68981fb47f192cd228732cdfd46724bda5e5055f> , <http://covid19.aksw.org/text-9948531b5d26f7ed69f89e3cbee08e14d85fc5accea8cb685e4a097be413bb9a> , <http://covid19.aksw.org/text-a1ac81a97e737c2c314b4bc33e1103d30f35bb30f7d398809e8f7f9f90a29240> , <http://covid19.aksw.org/text-6b3d8c67284e7f631e9565b34e3676ffeaaf4f855f7a6150a1e1f3f43ce6cf52> , <http://covid19.aksw.org/text-ff07e841405fb1de9209fa3840d9393084a9bf6657bfbcd9df0ec09a48a8c076> .
    
    <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-1181-1183>
            <http://www.example.org/end>    "1183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "1181.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "20" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-141-145>
            <http://www.example.org/end>    "145.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "141.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[26]" .
    
    <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-915-917>
            <http://www.example.org/end>    "917.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "915.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "18" .
    
    <http://covid19.aksw.org/text-e60b1f75412098d6c6e7e9a645bfd1b68b97e7475a9a8c587a2f9e20d17499a2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Results Among 215 empyemas, 83 cases (children with empyema and acute viral infection within the 15 preceding days) were included, and 83 controls (children with acute viral infection) were matched to cases. Considering the intake of any drug within 72 hours after acute viral infection onset and at least 6 consecutive days of antibiotic use and at least 1 day of NSAIDs exposure, the multivariable analysis retained an increased risk of empyema associated with NSAIDs exposure (aOR 2.79, 95% CI 1.4-5.58, P \\u003d .004), and a decreased risk associated with antibiotic use (aOR 0.32, 95% CI 0.11-0.97, P \\u003d .04). The risk of empyema associated with NSAIDs exposure was greater for children not prescribed an antibiotic and antibiotic intake diminished that risk for children given NSAIDs.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "Results Among 215 empyemas, 83 cases (children with empyema and acute viral infection within the 15 preceding days) were included, and 83 controls (children with acute viral infection) were matched to cases. Considering the intake of any drug within 72 hours after acute viral infection onset and at least 6 consecutive days of antibiotic use and at least 1 day of NSAIDs exposure, the multivariable analysis retained an increased risk of empyema associated with NSAIDs exposure (aOR 2.79, 95% CI 1.4-5.58, P = .004), and a decreased risk associated with antibiotic use (aOR 0.32, 95% CI 0.11-0.97, P = .04). The risk of empyema associated with NSAIDs exposure was greater for children not prescribed an antibiotic and antibiotic intake diminished that risk for children given NSAIDs." ;
            <http://www.example.org/textHash>
                    "e60b1f75412098d6c6e7e9a645bfd1b68b97e7475a9a8c587a2f9e20d17499a2" .
    
    <http://covid19.aksw.org/text-742b1f7aa898f9c5d43c9b87c5cb5e395c67cf4ea6ffc26d8d11aa59cea4717c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Acute viral infection itself likely enhances the risk of bacterial infection and may vary by virus and syndrome. 12, 39 To reduce this bias, cases and controls were matched for initial viral syndrome. Moreover, virus detection rates and viruses identified were very similar for cases and controls, suggesting that viral species causing the acute viral infection did not influence the complication of empyema.\",\"cite_spans\":[{\"start\":113.0,\"end\":116.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":117.0,\"end\":119.0,\"text\":\"39\",\"ref_id\":\"BIBREF38\"}],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-742b1f7aa898f9c5d43c9b87c5cb5e395c67cf4ea6ffc26d8d11aa59cea4717c_citespan-113-116> , <http://covid19.aksw.org/text-742b1f7aa898f9c5d43c9b87c5cb5e395c67cf4ea6ffc26d8d11aa59cea4717c_citespan-117-119> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "Acute viral infection itself likely enhances the risk of bacterial infection and may vary by virus and syndrome. 12, 39 To reduce this bias, cases and controls were matched for initial viral syndrome. Moreover, virus detection rates and viruses identified were very similar for cases and controls, suggesting that viral species causing the acute viral infection did not influence the complication of empyema." ;
            <http://www.example.org/textHash>
                    "742b1f7aa898f9c5d43c9b87c5cb5e395c67cf4ea6ffc26d8d11aa59cea4717c" .
    
    <http://covid19.aksw.org/text-705a1f86b8738a301912585d699bd80f7c5fe6d15517361e7455faad18446dc3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The lack of finding a significant interaction between antibiotics plus NSAIDs and empyema likely was related to lack of power because of small numbers of subjects. Still, the risk of empyema associated with NSAID exposure was greater for children not prescribed an antibiotic, and antibiotic intake reduced the risk for children given NSAIDs. NSAIDs recommended as antipyretics are used widely during acute viral infections in children and also have been sold over-the-counter for many years. NSAIDS constitute one of the most widely used classes of drugs, with probably several million prescriptions and several billion over-the-counter tablets sold for children as antipyretics in developed countries. Regardless of the efficacies of these drugs to control fever, our results suggest that their use is associated with complicated bacterial infection associated with acute viral infection and should be reconsidered.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "The lack of finding a significant interaction between antibiotics plus NSAIDs and empyema likely was related to lack of power because of small numbers of subjects. Still, the risk of empyema associated with NSAID exposure was greater for children not prescribed an antibiotic, and antibiotic intake reduced the risk for children given NSAIDs. NSAIDs recommended as antipyretics are used widely during acute viral infections in children and also have been sold over-the-counter for many years. NSAIDS constitute one of the most widely used classes of drugs, with probably several million prescriptions and several billion over-the-counter tablets sold for children as antipyretics in developed countries. Regardless of the efficacies of these drugs to control fever, our results suggest that their use is associated with complicated bacterial infection associated with acute viral infection and should be reconsidered." ;
            <http://www.example.org/textHash>
                    "705a1f86b8738a301912585d699bd80f7c5fe6d15517361e7455faad18446dc3" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-156-160>
            <http://www.example.org/end>    "160.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[29]" .
    
    <http://covid19.aksw.org/text-71b473e7734b167c78381924ba4c015cea98187a46643e07c622902f605c975c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"This matched case-control study included cases and controls from a source population of children with acute viral infections and was conducted in 15 French pediatric respiratory clinical departments from September 2006 to June 2009. Acute viral infection was diagnosed by clinical symptoms by the provider. The following acute viral infections were as follows: herpes virus infection; varicella; gastroenteritis, defined as acute diarrhea, with at least 3 loose stools per day; nasopharyngitis, defined as runny nose, nasal congestion, and cough; bronchiolitis, defined as cough, shortness of breath, and wheeze at auscultation; flu-like syndrome, defined as cough with fever and myalgia; bronchitis, defined as cough and bronchial congestion; and viral pharyngitis documented by a negative test for rapid diagnosis of group A streptococcal infection. Acute viral infections were divided into 3 groups: upper respiratory tract viral infections, lower respiratory tract viral infections (LRTVIs) (bronchiolitis, bronchitis, and flu), and others. All acute viral infections were not severe and did not require hospitalization.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "This matched case-control study included cases and controls from a source population of children with acute viral infections and was conducted in 15 French pediatric respiratory clinical departments from September 2006 to June 2009. Acute viral infection was diagnosed by clinical symptoms by the provider. The following acute viral infections were as follows: herpes virus infection; varicella; gastroenteritis, defined as acute diarrhea, with at least 3 loose stools per day; nasopharyngitis, defined as runny nose, nasal congestion, and cough; bronchiolitis, defined as cough, shortness of breath, and wheeze at auscultation; flu-like syndrome, defined as cough with fever and myalgia; bronchitis, defined as cough and bronchial congestion; and viral pharyngitis documented by a negative test for rapid diagnosis of group A streptococcal infection. Acute viral infections were divided into 3 groups: upper respiratory tract viral infections, lower respiratory tract viral infections (LRTVIs) (bronchiolitis, bronchitis, and flu), and others. All acute viral infections were not severe and did not require hospitalization." ;
            <http://www.example.org/textHash>
                    "71b473e7734b167c78381924ba4c015cea98187a46643e07c622902f605c975c" .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increased incidence of empyema has been reported in many countries, and some authors have suggested this phenomenon is caused by the dissemination of a particular pathogenic S pneumoniae. In our study, pathogens associated with empyema were S pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Our findings strongly argue against an oligoclonal or monoclonal phenomenon. The S pneumoniae serotype diversity (mostly non-PCV-7 serotypes) in our patients was similar to that observed for empyema 1, [3] [4] [5] [6] [7] and for other invasive S pneumoniae infections in France, 40 and no dominant serotype was observed.\",\"cite_spans\":[{\"start\":505.0,\"end\":507.0,\"text\":\"1,\"},{\"start\":508.0,\"end\":511.0,\"text\":\"[3]\",\"ref_id\":\"BIBREF2\"},{\"start\":512.0,\"end\":515.0,\"text\":\"[4]\",\"ref_id\":\"BIBREF3\"},{\"start\":516.0,\"end\":519.0,\"text\":\"[5]\",\"ref_id\":\"BIBREF4\"},{\"start\":520.0,\"end\":523.0,\"text\":\"[6]\",\"ref_id\":\"BIBREF5\"},{\"start\":524.0,\"end\":527.0,\"text\":\"[7]\",\"ref_id\":\"BIBREF6\"},{\"start\":586.0,\"end\":588.0,\"text\":\"40\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-586-588> , <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-520-523> , <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-505-507> , <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-512-515> , <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-524-527> , <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-516-519> , <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-508-511> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "Increased incidence of empyema has been reported in many countries, and some authors have suggested this phenomenon is caused by the dissemination of a particular pathogenic S pneumoniae. In our study, pathogens associated with empyema were S pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Our findings strongly argue against an oligoclonal or monoclonal phenomenon. The S pneumoniae serotype diversity (mostly non-PCV-7 serotypes) in our patients was similar to that observed for empyema 1, [3] [4] [5] [6] [7] and for other invasive S pneumoniae infections in France, 40 and no dominant serotype was observed." ;
            <http://www.example.org/textHash>
                    "bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92" .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-524-527>
            <http://www.example.org/end>    "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "524.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[7]" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-996-998>
            <http://www.example.org/end>    "998.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "996.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "3," .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-362-364>
            <http://www.example.org/end>    "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "362.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "30" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-903-905>
            <http://www.example.org/end>    "905.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "903.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "34" .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-516-519>
            <http://www.example.org/end>    "519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[5]" .
    
    <http://covid19.aksw.org/text-7f84fd7ad88b2d50b4c0c6b5c0f1735f61ee766befc6b7026b1f08507b75acab>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Nasal swabs were deposited in 1.5 mL of transport medium containing 29.5 g of tryptose phosphate broth (Becton Dickinson, Le Pont de Claix, France), 5.0 g of gelatin (Becton Dickinson), 50 000 units of penicillin, 50 mg of streptomycin, and 12.5 mg amphotericin B (Antibiotic antimycotic solution; Sigma, Saint-Quentin-Fallavier, France). Viral RNA or DNA was isolated with the automated MagNA Pure LC System (Roche Diagnostics) from 200 mL of nasal samples and eluted in 100 mL of elution buffer via the Total Nucleic Acid Isolation Kit (Roche Diagnostics).\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Microbiology\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Microbiology" ;
            <http://www.example.org/text>  "Nasal swabs were deposited in 1.5 mL of transport medium containing 29.5 g of tryptose phosphate broth (Becton Dickinson, Le Pont de Claix, France), 5.0 g of gelatin (Becton Dickinson), 50 000 units of penicillin, 50 mg of streptomycin, and 12.5 mg amphotericin B (Antibiotic antimycotic solution; Sigma, Saint-Quentin-Fallavier, France). Viral RNA or DNA was isolated with the automated MagNA Pure LC System (Roche Diagnostics) from 200 mL of nasal samples and eluted in 100 mL of elution buffer via the Total Nucleic Acid Isolation Kit (Roche Diagnostics)." ;
            <http://www.example.org/textHash>
                    "7f84fd7ad88b2d50b4c0c6b5c0f1735f61ee766befc6b7026b1f08507b75acab" .
    
    <http://covid19.aksw.org/text-cdf3ae8978fbcb0138ffef54a9138cc1fbef284f1145c176f032270dfcffeb01_refspan-523-531>
            <http://www.example.org/end>    "531.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table I)" .
    
    <http://covid19.aksw.org/text-83df2700da6e148bf930c174a8879d0eb5cfe6003ea773a4de79f469cb89a28f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Exclusion criteria for cases and controls were chronic respiratory disease, acquired and/or congenital immunological disorders, malignancy, collagen vascular disease, sickle cell disease, congenital heart defects, neuromuscular disease, hemophilia, and/or heart failure; treatment with corticosteroids or immunosuppressive agents during the month preceding identification; and known intolerance of NSAIDs or acetaminophen.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "Exclusion criteria for cases and controls were chronic respiratory disease, acquired and/or congenital immunological disorders, malignancy, collagen vascular disease, sickle cell disease, congenital heart defects, neuromuscular disease, hemophilia, and/or heart failure; treatment with corticosteroids or immunosuppressive agents during the month preceding identification; and known intolerance of NSAIDs or acetaminophen." ;
            <http://www.example.org/textHash>
                    "83df2700da6e148bf930c174a8879d0eb5cfe6003ea773a4de79f469cb89a28f" .
    
    <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-1004-1006>
            <http://www.example.org/end>    "1006.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "1004.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19" .
    
    <http://covid19.aksw.org/text-7ae9136407dbe7ccf4b81f25980e0460a5c05fa39038e6efce0b8be175446943>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The study was approved by the Institutional Review Board of University Hospital Necker-Enfants Malades (CCP06-03-09). All participating parents and case and control children older than 7 years of age were given oral and written information and provided written consent.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "The study was approved by the Institutional Review Board of University Hospital Necker-Enfants Malades (CCP06-03-09). All participating parents and case and control children older than 7 years of age were given oral and written information and provided written consent." ;
            <http://www.example.org/textHash>
                    "7ae9136407dbe7ccf4b81f25980e0460a5c05fa39038e6efce0b8be175446943" .
    
    <http://covid19.aksw.org/text-edbf0801ea680729ffce194c68981fb47f192cd228732cdfd46724bda5e5055f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Consecutive patients 3 months to 15 years of age who were hospitalized for empyema in 1 of the 15 participating centers were eligible. Empyema was defined as the presence of a pleural effusion on chest radiograph and at least 1 of the following results of tests on pleural fluid: pH \\u003c 7.2, lactate dehydrogenase \\u003e1000 IU/L, glucose \\u003c2.2 mmol/L, protein \\u003e3000 mg/dL, white blood cell count \\u003e50 000 cells/mL, 16 and/or a positive bacterial culture or Gram stain. To be a case, the empyema had to follow doctor-diagnosed acute viral infection based on clinical symptoms and identified within a maximum of 15 days preceding the date of the first pleural puncture.\",\"cite_spans\":[{\"start\":407.0,\"end\":409.0,\"text\":\"16\",\"ref_id\":\"BIBREF15\"}],\"ref_spans\":[],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-edbf0801ea680729ffce194c68981fb47f192cd228732cdfd46724bda5e5055f_citespan-407-409> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "Consecutive patients 3 months to 15 years of age who were hospitalized for empyema in 1 of the 15 participating centers were eligible. Empyema was defined as the presence of a pleural effusion on chest radiograph and at least 1 of the following results of tests on pleural fluid: pH < 7.2, lactate dehydrogenase >1000 IU/L, glucose <2.2 mmol/L, protein >3000 mg/dL, white blood cell count >50 000 cells/mL, 16 and/or a positive bacterial culture or Gram stain. To be a case, the empyema had to follow doctor-diagnosed acute viral infection based on clinical symptoms and identified within a maximum of 15 days preceding the date of the first pleural puncture." ;
            <http://www.example.org/textHash>
                    "edbf0801ea680729ffce194c68981fb47f192cd228732cdfd46724bda5e5055f" .
    
    <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The diminished risk of empyema associated with antibiotic treatment of acute viral infection is our second important observation. The reduced risk of pneumonia after antibiotic treatment for LRTVIs has been reported previously. 36 Antibiotics slightly diminished the risk of suppurative complications of acute sore throat in adults 37 and of mastoiditis after otitis in children. 38 In our study, antibiotic exposure reached significance only when therapy was given for at least 6 days. The physician\\u0027s indication to prescribe antibiotics was not known. Acetaminophen had no impact on empyema.\",\"cite_spans\":[{\"start\":228.0,\"end\":230.0,\"text\":\"36\",\"ref_id\":\"BIBREF35\"},{\"start\":332.0,\"end\":334.0,\"text\":\"37\",\"ref_id\":\"BIBREF36\"},{\"start\":380.0,\"end\":382.0,\"text\":\"38\",\"ref_id\":\"BIBREF37\"}],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421_citespan-228-230> , <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421_citespan-332-334> , <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421_citespan-380-382> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "The diminished risk of empyema associated with antibiotic treatment of acute viral infection is our second important observation. The reduced risk of pneumonia after antibiotic treatment for LRTVIs has been reported previously. 36 Antibiotics slightly diminished the risk of suppurative complications of acute sore throat in adults 37 and of mastoiditis after otitis in children. 38 In our study, antibiotic exposure reached significance only when therapy was given for at least 6 days. The physician's indication to prescribe antibiotics was not known. Acetaminophen had no impact on empyema." ;
            <http://www.example.org/textHash>
                    "ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421" .
    
    <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421_citespan-228-230>
            <http://www.example.org/end>    "230.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "228.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "36" .
    
    <http://covid19.aksw.org/text-742b1f7aa898f9c5d43c9b87c5cb5e395c67cf4ea6ffc26d8d11aa59cea4717c_citespan-113-116>
            <http://www.example.org/end>    "116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "113.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-146-150>
            <http://www.example.org/end>    "150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[27]" .
    
    <http://covid19.aksw.org/text-ff07e841405fb1de9209fa3840d9393084a9bf6657bfbcd9df0ec09a48a8c076_citespan-558-560>
            <http://www.example.org/end>    "560.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "558.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "24" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-999-1002>
            <http://www.example.org/end>    "1002.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "999.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-ae54331281ca243bde31b0da5f60ef68246c858baf6e5ee7bb5b55cd0cbd5421_citespan-380-382>
            <http://www.example.org/end>    "382.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "380.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1008-1012>
            <http://www.example.org/end>    "1012.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1008.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-ae305c007fbb906eb34b195161d278afe52ed7aeb947c2dcccb1d8b5a20ea90e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Our results strongly support the idea that NSAIDs increase risk of empyema in children with previous acute viral infection and suggest that NSAIDs interact with antibiotics. These findings suggest that NSAIDs should not be recommended as a first-line antipyretic treatment during acute viral infections in children. n We thank the study\\u0027s Scientific Advisory Board that provided useful advice: Lucien Abenhaim (previously employed by Paris Descartes \",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "Our results strongly support the idea that NSAIDs increase risk of empyema in children with previous acute viral infection and suggest that NSAIDs interact with antibiotics. These findings suggest that NSAIDs should not be recommended as a first-line antipyretic treatment during acute viral infections in children. n We thank the study's Scientific Advisory Board that provided useful advice: Lucien Abenhaim (previously employed by Paris Descartes " ;
            <http://www.example.org/textHash>
                    "ae305c007fbb906eb34b195161d278afe52ed7aeb947c2dcccb1d8b5a20ea90e" .
    
    <http://covid19.aksw.org/text-6b3d8c67284e7f631e9565b34e3676ffeaaf4f855f7a6150a1e1f3f43ce6cf52>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Exclusion criteria for cases were absence of at least 24 hours of apyrexia between recovering from LRTVI symptoms and a diagnosis of empyema and time between onset of acute viral infection and a diagnosis of empyema \\u003c72 hours (to decrease the possibility that symptom onset was possible onset of the bacterial infection).\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "Exclusion criteria for cases were absence of at least 24 hours of apyrexia between recovering from LRTVI symptoms and a diagnosis of empyema and time between onset of acute viral infection and a diagnosis of empyema <72 hours (to decrease the possibility that symptom onset was possible onset of the bacterial infection)." ;
            <http://www.example.org/textHash>
                    "6b3d8c67284e7f631e9565b34e3676ffeaaf4f855f7a6150a1e1f3f43ce6cf52" .
    
    <http://covid19.aksw.org/text-9c5002ae305fd9c13bfb7db458941aab872b098322925f272e941e7edc6403de>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Controls were children 3 months to 15 years of age with acute viral infections from the same \\\"source population\\\" as case children, which was defined as children evaluated by the same private practitioner for acute viral infections. Controls were recruited as follows: upon case identification, the doctor who referred the child to the hospital was contacted to identify, among his/her patients, children matched for age (+/À1 year) who consulted for same viral symptoms during the 15 preceding days with the similar time window as the matched case ( Figure 1 ; available at www.jpeds.com).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":550.0,\"end\":558.0,\"text\":\"Figure 1\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-9c5002ae305fd9c13bfb7db458941aab872b098322925f272e941e7edc6403de_refspan-550-558> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "Controls were children 3 months to 15 years of age with acute viral infections from the same \"source population\" as case children, which was defined as children evaluated by the same private practitioner for acute viral infections. Controls were recruited as follows: upon case identification, the doctor who referred the child to the hospital was contacted to identify, among his/her patients, children matched for age (+/À1 year) who consulted for same viral symptoms during the 15 preceding days with the similar time window as the matched case ( Figure 1 ; available at www.jpeds.com)." ;
            <http://www.example.org/textHash>
                    "9c5002ae305fd9c13bfb7db458941aab872b098322925f272e941e7edc6403de" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-659-661>
            <http://www.example.org/end>    "661.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "659.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32" .
    
    <http://covid19.aksw.org/text-9c5002ae305fd9c13bfb7db458941aab872b098322925f272e941e7edc6403de_refspan-550-558>
            <http://www.example.org/end>    "558.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "550.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Figure 1" .
    
    <http://covid19.aksw.org/text-53e722f1e4fc5218d489361108217b855cf426091bbe5dd1057fd37e659e69a0_refspan-378-387>
            <http://www.example.org/end>    "387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table IV)" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-711-713>
            <http://www.example.org/end>    "713.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "711.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "33" .
    
    <http://covid19.aksw.org/text-9948531b5d26f7ed69f89e3cbee08e14d85fc5accea8cb685e4a097be413bb9a_refspan-448-459>
            <http://www.example.org/end>    "459.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "448.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Table III)" .
    
    <http://covid19.aksw.org/text-15f3d695fed75a8de5d4a35f9f266b7cf166b983d3a3adddde1ccd7aa9aa4a88>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For each hospital case, after questioning the parents, a trained doctor or nurse completed a detailed and standardized form, recording symptoms, treatment concerning the period between onset of acute viral infection (first day of clinical symptom), and empyema diagnosis by pleural puncture, corresponding to the time of exposure. For the controls, the parents were contacted after the consultation with the treating physician and data recorded retrospectively exactly as done for the cases, with the same detailed and standardized form, recording clinical items concerning the same exposure window-timing from the acute viral infection onset as the matched case. Primary providers went at controls\\u0027 home to obtain nasal swab specimen and record data ( Figure 1) . Symptoms, treatments (antibiotics, glucocorticoids, NSAIDs, acetaminophen) according to the doctors\\u0027 prescriptions, and self-administered medications were recorded daily. The following information also was recorded for all enrolled children: demographics, immunization status, and type of acute viral infection as stated by the doctors. In addition, a nasal swab was obtained for respiratory virus screening.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":753.0,\"end\":762.0,\"text\":\"Figure 1)\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-15f3d695fed75a8de5d4a35f9f266b7cf166b983d3a3adddde1ccd7aa9aa4a88_refspan-753-762> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "For each hospital case, after questioning the parents, a trained doctor or nurse completed a detailed and standardized form, recording symptoms, treatment concerning the period between onset of acute viral infection (first day of clinical symptom), and empyema diagnosis by pleural puncture, corresponding to the time of exposure. For the controls, the parents were contacted after the consultation with the treating physician and data recorded retrospectively exactly as done for the cases, with the same detailed and standardized form, recording clinical items concerning the same exposure window-timing from the acute viral infection onset as the matched case. Primary providers went at controls' home to obtain nasal swab specimen and record data ( Figure 1) . Symptoms, treatments (antibiotics, glucocorticoids, NSAIDs, acetaminophen) according to the doctors' prescriptions, and self-administered medications were recorded daily. The following information also was recorded for all enrolled children: demographics, immunization status, and type of acute viral infection as stated by the doctors. In addition, a nasal swab was obtained for respiratory virus screening." ;
            <http://www.example.org/textHash>
                    "15f3d695fed75a8de5d4a35f9f266b7cf166b983d3a3adddde1ccd7aa9aa4a88" .
    
    <http://covid19.aksw.org/text-53e722f1e4fc5218d489361108217b855cf426091bbe5dd1057fd37e659e69a0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Considering drug-use onset within 72 hours after the onset of acute viral infection and at least 6 consecutive days of antibiotic use and at least 1 day of NSAIDs or antipyretic exposure, the multivariable analysis retained increased risk of empyema associated with NSAID exposure (aOR 2.79, P \\u003d .004), decreased risk of empyema associated with antibiotic (aOR 0.32, P \\u003d .04) ( Table IV) , and no association with acetaminophen. No interaction between antibiotic use and NSAIDs exposure was statistically significant in the link with empyema (P \\u003d .23). Subgroup analyses carried out to examine potential interaction(s) between antibiotic and NSAID use and empyema showed that the risk of empyema associated with NSAID was greater when antibiotics were used for less than 6 consecutive days (unconditional aOR 3.01, P \\u003d .002), and empyema risk associated with antibiotics was lower for the subgroup of children exposed to NSAIDs (unconditional aOR 0.24, P \\u003d .06) compared with children unexposed to NSAIDS (Table V ; available at www.jpeds.com).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":378.0,\"end\":387.0,\"text\":\"Table IV)\",\"ref_id\":\"TABREF1\"},{\"start\":1005.0,\"end\":1013.0,\"text\":\"(Table V\",\"ref_id\":\"TABREF6\"}],\"section\":\"Results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-53e722f1e4fc5218d489361108217b855cf426091bbe5dd1057fd37e659e69a0_refspan-378-387> , <http://covid19.aksw.org/text-53e722f1e4fc5218d489361108217b855cf426091bbe5dd1057fd37e659e69a0_refspan-1005-1013> ;
            <http://www.example.org/section>
                    "Results" ;
            <http://www.example.org/text>  "Considering drug-use onset within 72 hours after the onset of acute viral infection and at least 6 consecutive days of antibiotic use and at least 1 day of NSAIDs or antipyretic exposure, the multivariable analysis retained increased risk of empyema associated with NSAID exposure (aOR 2.79, P = .004), decreased risk of empyema associated with antibiotic (aOR 0.32, P = .04) ( Table IV) , and no association with acetaminophen. No interaction between antibiotic use and NSAIDs exposure was statistically significant in the link with empyema (P = .23). Subgroup analyses carried out to examine potential interaction(s) between antibiotic and NSAID use and empyema showed that the risk of empyema associated with NSAID was greater when antibiotics were used for less than 6 consecutive days (unconditional aOR 3.01, P = .002), and empyema risk associated with antibiotics was lower for the subgroup of children exposed to NSAIDs (unconditional aOR 0.24, P = .06) compared with children unexposed to NSAIDS (Table V ; available at www.jpeds.com)." ;
            <http://www.example.org/textHash>
                    "53e722f1e4fc5218d489361108217b855cf426091bbe5dd1057fd37e659e69a0" .
    
    <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-1353-1355>
            <http://www.example.org/end>    "1355.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "1353.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "21" .
    
    <http://covid19.aksw.org/text-5f5ff72e8a0bebeab709c36e146876f2f3c9d886c00fa4807fe6ea073e0ee7d9_citespan-911-914>
            <http://www.example.org/end>    "914.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "911.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-508-511>
            <http://www.example.org/end>    "511.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[3]" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-151-155>
            <http://www.example.org/end>    "155.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "151.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[28]" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1018-1022>
            <http://www.example.org/end>    "1022.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1018.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-a1ac81a97e737c2c314b4bc33e1103d30f35bb30f7d398809e8f7f9f90a29240>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Conclusions NSAIDs use during acute viral infection is associated with an increased risk of empyema in children, and antibiotics are associated with a decreased risk. The presence of antibiotic-NSAIDs interaction with this risk is suggested. These findings suggest that NSAIDs should not be recommended as a first-line antipyretic treatment during acute viral infections in children. (J Pediatr 2016;175:47-53).\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "Conclusions NSAIDs use during acute viral infection is associated with an increased risk of empyema in children, and antibiotics are associated with a decreased risk. The presence of antibiotic-NSAIDs interaction with this risk is suggested. These findings suggest that NSAIDs should not be recommended as a first-line antipyretic treatment during acute viral infections in children. (J Pediatr 2016;175:47-53)." ;
            <http://www.example.org/textHash>
                    "a1ac81a97e737c2c314b4bc33e1103d30f35bb30f7d398809e8f7f9f90a29240" .
    
    <http://covid19.aksw.org/text-0790e469cc4d0b3a250f275f3d3d88e5af502e209ae39ff7af795c949875bd2f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In-house, real-time PCRs were used to detect adenoviruses, as previously described, 22 and in-house, 1-step, real-time reverse transcripted PCRs were used to detect metapneumovirus, influenza virus A and B, parainfluenza viruses (1, 2, and 3), respiratory syncytial viruses A and B, and rhinovirus, as reported elsewhere. 23 \",\"cite_spans\":[{\"start\":84.0,\"end\":86.0,\"text\":\"22\",\"ref_id\":\"BIBREF21\"},{\"start\":322.0,\"end\":324.0,\"text\":\"23\",\"ref_id\":\"BIBREF22\"}],\"ref_spans\":[],\"section\":\"Microbiology\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0790e469cc4d0b3a250f275f3d3d88e5af502e209ae39ff7af795c949875bd2f_citespan-84-86> , <http://covid19.aksw.org/text-0790e469cc4d0b3a250f275f3d3d88e5af502e209ae39ff7af795c949875bd2f_citespan-322-324> ;
            <http://www.example.org/section>
                    "Microbiology" ;
            <http://www.example.org/text>  "In-house, real-time PCRs were used to detect adenoviruses, as previously described, 22 and in-house, 1-step, real-time reverse transcripted PCRs were used to detect metapneumovirus, influenza virus A and B, parainfluenza viruses (1, 2, and 3), respiratory syncytial viruses A and B, and rhinovirus, as reported elsewhere. 23 " ;
            <http://www.example.org/textHash>
                    "0790e469cc4d0b3a250f275f3d3d88e5af502e209ae39ff7af795c949875bd2f" .
    
    <http://covid19.aksw.org/text-0790e469cc4d0b3a250f275f3d3d88e5af502e209ae39ff7af795c949875bd2f_citespan-322-324>
            <http://www.example.org/end>    "324.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "23" .
    
    <http://covid19.aksw.org/text-2da71b0eb558ab6790605ddbf36dc304b46af8a20b389f80847bf81c966ca69c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For the cases, initial clinical findings, results of biochemistry and microbiology tests, radiograph findings, management, and length of stay were recorded. Two doctors reviewed the medical records of all identified patients and independently validated each case.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Methods\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Methods" ;
            <http://www.example.org/text>  "For the cases, initial clinical findings, results of biochemistry and microbiology tests, radiograph findings, management, and length of stay were recorded. Two doctors reviewed the medical records of all identified patients and independently validated each case." ;
            <http://www.example.org/textHash>
                    "2da71b0eb558ab6790605ddbf36dc304b46af8a20b389f80847bf81c966ca69c" .
    
    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-699-700>
            <http://www.example.org/end>    "700.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "699.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8" .
    
    <http://covid19.aksw.org/text-367eb8e9aa808bce19e5377565e112bd2fd0b8c3e753d1a622eb7e5eeca0c5d1_citespan-1013-1017>
            <http://www.example.org/end>    "1017.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1013.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-d9198b6ce2d3410bfae18f5ee71313775364081354860e32d5caf209578d8d17_citespan-1104-1106>
            <http://www.example.org/end>    "1106.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF14" ;
            <http://www.example.org/start>  "1104.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "15" .
    
    <http://covid19.aksw.org/text-9948531b5d26f7ed69f89e3cbee08e14d85fc5accea8cb685e4a097be413bb9a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Considering the drug exposure-duration (6 days for antibiotics and 1or 3 consecutive days for NSAIDs) and the interval between onset of acute viral infection and starting treatment of 72 hours for any drug, NSAIDs were systematically used more often and antibiotics systematically less often for cases than controls. Acetaminophen also was prescribed more frequently for cases than controls, particularly when taken for at least 3 consecutive days (Table III) .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":448.0,\"end\":459.0,\"text\":\"(Table III)\",\"ref_id\":\"TABREF1\"}],\"section\":\"Results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-9948531b5d26f7ed69f89e3cbee08e14d85fc5accea8cb685e4a097be413bb9a_refspan-448-459> ;
            <http://www.example.org/section>
                    "Results" ;
            <http://www.example.org/text>  "Considering the drug exposure-duration (6 days for antibiotics and 1or 3 consecutive days for NSAIDs) and the interval between onset of acute viral infection and starting treatment of 72 hours for any drug, NSAIDs were systematically used more often and antibiotics systematically less often for cases than controls. Acetaminophen also was prescribed more frequently for cases than controls, particularly when taken for at least 3 consecutive days (Table III) ." ;
            <http://www.example.org/textHash>
                    "9948531b5d26f7ed69f89e3cbee08e14d85fc5accea8cb685e4a097be413bb9a" .
    
    <http://covid19.aksw.org/text-715f8e9d7827e796cfce5bf15501c4ef145afe9a79c190adacfb52d7fddc85f4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Objective To investigate the risk factors of empyema after acute viral infection and to clarify the hypothesized association(s) between empyema and some viruses and/or the use of nonsteroidal anti-inflammatory drugs (NSAIDs).\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "Objective To investigate the risk factors of empyema after acute viral infection and to clarify the hypothesized association(s) between empyema and some viruses and/or the use of nonsteroidal anti-inflammatory drugs (NSAIDs)." ;
            <http://www.example.org/textHash>
                    "715f8e9d7827e796cfce5bf15501c4ef145afe9a79c190adacfb52d7fddc85f4" .
    
    <http://covid19.aksw.org/text-bb1416ff88f818e3a37e566aba2b97e357cba8b2df0844bc3c120226e4c8cc92_citespan-586-588>
            <http://www.example.org/end>    "588.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40" .
}
<http://covid19.aksw.org/8c55abb5f141dd742253a1682cf2e5e5c05a31bc> {
    <http://covid19.aksw.org/text-785eea8ec616e3e45ffb0c904d2c4672768013042d13020b5db73cb89f1ef7af>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"I n d i a N i g e r i a P a k i s t a n A f g h a n i s t a n up and implemented in regions with extremely weak health systems, or that were affected by conflict, or both. Such proof is essential for obtaining and sustaining the political and financial support required for the 10-20 years needed to pursue most international health goals. The second lesson is that any international health goal should be strongly endorsed at the highest possible level, arguably the World Health Assembly. Such endorsement will be essential for dealing with the debate and concerns that will arise as the programme is scaled up and opportunity and other costs are increasingly evident and better understood. Although prominent champions had a major role in promoting global eradication of poliomyelitis, the decision to launch the initiative followed debate at the World Health Assembly. 12 Despite consensus at that forum, an often heated debate has flared as to whether the opportunity costs of eradication outweigh benefits. Of especial concern has been whether the deployment of resources has compromised the strengthening of health systems in resource-poor countries, or limited their capacity to control other diseases. It has also been noted that some delegates to the assembly in 1988 might not have made a truly informed decision on the launching of the initiative, since there had been no clear statement on resource requirements or strategies. 58 These debates have contributed to the programme\\u0027s chronic funding gap, and to the late introduction of key strategies in some countries. The cost-effectiveness analyses summarised in this paper suggest that all countries stand to benefit from this investment irrespective of income level, but this assessment is not universally accepted.\",\"cite_spans\":[{\"start\":873.0,\"end\":875.0,\"text\":\"12\",\"ref_id\":\"BIBREF11\"},{\"start\":1440.0,\"end\":1442.0,\"text\":\"58\",\"ref_id\":\"BIBREF57\"}],\"ref_spans\":[],\"section\":\"Reported cases\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-785eea8ec616e3e45ffb0c904d2c4672768013042d13020b5db73cb89f1ef7af_citespan-873-875> , <http://covid19.aksw.org/text-785eea8ec616e3e45ffb0c904d2c4672768013042d13020b5db73cb89f1ef7af_citespan-1440-1442> ;
            <http://www.example.org/section>
                    "Reported cases" ;
            <http://www.example.org/text>  "I n d i a N i g e r i a P a k i s t a n A f g h a n i s t a n up and implemented in regions with extremely weak health systems, or that were affected by conflict, or both. Such proof is essential for obtaining and sustaining the political and financial support required for the 10-20 years needed to pursue most international health goals. The second lesson is that any international health goal should be strongly endorsed at the highest possible level, arguably the World Health Assembly. Such endorsement will be essential for dealing with the debate and concerns that will arise as the programme is scaled up and opportunity and other costs are increasingly evident and better understood. Although prominent champions had a major role in promoting global eradication of poliomyelitis, the decision to launch the initiative followed debate at the World Health Assembly. 12 Despite consensus at that forum, an often heated debate has flared as to whether the opportunity costs of eradication outweigh benefits. Of especial concern has been whether the deployment of resources has compromised the strengthening of health systems in resource-poor countries, or limited their capacity to control other diseases. It has also been noted that some delegates to the assembly in 1988 might not have made a truly informed decision on the launching of the initiative, since there had been no clear statement on resource requirements or strategies. 58 These debates have contributed to the programme's chronic funding gap, and to the late introduction of key strategies in some countries. The cost-effectiveness analyses summarised in this paper suggest that all countries stand to benefit from this investment irrespective of income level, but this assessment is not universally accepted." ;
            <http://www.example.org/textHash>
                    "785eea8ec616e3e45ffb0c904d2c4672768013042d13020b5db73cb89f1ef7af" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-656-657>
            <http://www.example.org/end>    "657.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "656.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-755-757>
            <http://www.example.org/end>    "757.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "755.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26" .
    
    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-258-260>
            <http://www.example.org/end>    "260.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "258.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17" .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-1399-1403>
            <http://www.example.org/end>    "1403.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "1399.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-502-503>
            <http://www.example.org/end>    "503.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "502.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "7" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1491-1493>
            <http://www.example.org/end>    "1493.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "1491.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "53" .
    
    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-592-595>
            <http://www.example.org/end>    "595.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "592.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40," .
    
    <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71_citespan-545-547>
            <http://www.example.org/end>    "547.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "545.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "33" .
    
    <http://covid19.aksw.org/text-9555dc846e059a077f203cc323899bdb2017de3df24d44fa4eab933d5ba87354>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increasing travel and globalisation of commerce has farreaching implications for health. 1,2 Substantial attention has been given to the threats that globalisation poses to the management of infectious diseases, but less to its opportunities. 1, 2 Heightened international awareness of the burden and threat of many infectious diseases has spawned partnerships and alliances to coordinate additional resources for their control.\",\"cite_spans\":[{\"start\":243.0,\"end\":245.0,\"text\":\"1,\",\"ref_id\":\"BIBREF0\"},{\"start\":246.0,\"end\":247.0,\"text\":\"2\",\"ref_id\":\"BIBREF1\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-9555dc846e059a077f203cc323899bdb2017de3df24d44fa4eab933d5ba87354_citespan-243-245> , <http://covid19.aksw.org/text-9555dc846e059a077f203cc323899bdb2017de3df24d44fa4eab933d5ba87354_citespan-246-247> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Increasing travel and globalisation of commerce has farreaching implications for health. 1,2 Substantial attention has been given to the threats that globalisation poses to the management of infectious diseases, but less to its opportunities. 1, 2 Heightened international awareness of the burden and threat of many infectious diseases has spawned partnerships and alliances to coordinate additional resources for their control." ;
            <http://www.example.org/textHash>
                    "9555dc846e059a077f203cc323899bdb2017de3df24d44fa4eab933d5ba87354" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-983-985>
            <http://www.example.org/end>    "985.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "983.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27" .
    
    <http://covid19.aksw.org/text-b3b392a681f6fa802b350fbcb4db71e232a561cf436dff503fd498f0b886804a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Direct costs A conservative estimate of the financial and in-kind expenditures in poliomyelits-endemic countries was generated on the basis of the number of hours worked per country to implement NIDs, the most expensive and labour-intensive eradication strategy. Without wishing to diminish the broader significance of this largely volunteer effort to the success of the initiative, for the purposes of economic evaluation it has been valued by use of labour market rates from the statistical database for the year 2000 world development indicators. 30 On the basis of these calculations, poliomyelitis-endemic countries will have contributed at least $2·35 billion in wages alone between 1988 and 2005. 31 This figure does not include substantial government and private-sector resources to pay for petrol, social mobilisation, training, and other costs. Many of these people were government employees who were temporarily released from regular duties.\",\"cite_spans\":[{\"start\":550.0,\"end\":552.0,\"text\":\"30\",\"ref_id\":\"BIBREF29\"},{\"start\":704.0,\"end\":706.0,\"text\":\"31\",\"ref_id\":\"BIBREF30\"}],\"ref_spans\":[],\"section\":\"Financing and economics\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b3b392a681f6fa802b350fbcb4db71e232a561cf436dff503fd498f0b886804a_citespan-550-552> , <http://covid19.aksw.org/text-b3b392a681f6fa802b350fbcb4db71e232a561cf436dff503fd498f0b886804a_citespan-704-706> ;
            <http://www.example.org/section>
                    "Financing and economics" ;
            <http://www.example.org/text>  "Direct costs A conservative estimate of the financial and in-kind expenditures in poliomyelits-endemic countries was generated on the basis of the number of hours worked per country to implement NIDs, the most expensive and labour-intensive eradication strategy. Without wishing to diminish the broader significance of this largely volunteer effort to the success of the initiative, for the purposes of economic evaluation it has been valued by use of labour market rates from the statistical database for the year 2000 world development indicators. 30 On the basis of these calculations, poliomyelitis-endemic countries will have contributed at least $2·35 billion in wages alone between 1988 and 2005. 31 This figure does not include substantial government and private-sector resources to pay for petrol, social mobilisation, training, and other costs. Many of these people were government employees who were temporarily released from regular duties." ;
            <http://www.example.org/textHash>
                    "b3b392a681f6fa802b350fbcb4db71e232a561cf436dff503fd498f0b886804a" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The decision to pursue eradication The successful conclusion of the international smallpox eradication campaign in 1977 created substantial interest in further eradication efforts. However, enthusiasm was countered by concerns that targeted objectives could compromise efforts to develop strong primary health-care systems 12 and by doubts about the technical feasibility of eradicating any organism after smallpox. 13, 14 The most important factor in overcoming scientific concerns was the interruption of poliovirus transmission in large areas of the Americas by use of a four-pronged strategy. 15 The leadership for launching a global poliomyelitis eradication initiative was secured at a meeting in March, 1988, at which the WHO Director-General was convinced of the merit of such an effort. 12,16 2 months later, the World Health Assembly, consisting of the ministers of health of all member states, unanimously adopted a poliomyelitis eradication resolution. 17 The eradication goal was subsequently reviewed and endorsed by the 1990 World Summit for Children-the largest ever gathering of heads of state. 18 Leaders from lowincome, middle-income, and high-income countries have continued to reaffirm their commitment to poliomyelitis eradication through resolutions adopted in forums such as the Organization of African Unity, the South Asian Association for Regional Cooperation, and G8 summits. [19] [20] [21] Implementation of strategies By the end of 2000, every country had introduced the WHO-recommended poliomyelitis eradication strategies or a variant thereof, but the effort required to do so was correlated inversely with countries\\u0027 incomes. In the few high-income countries in which poliomyelitis cases were reported in 1988 (eg, France and Spain) elimination of the virus was relatively straightforward because of temperate climate, higher vaccine effectiveness in such settings, high levels of sanitation, and strong health systems. By contrast, eliminating endemic poliomyelitis from low-income countries has required massive efforts sustained for 5-10 years. Implementation of National Immunisation Days (NIDs) has been a huge challenge; in China and India, for example, about 80 million and 150 million children, respectively, were immunised in a few days-the achievement was repeated 1 month later, and then annually Global health goals: lessons from the worldwide effort to eradicate poliomyelitis\",\"cite_spans\":[{\"start\":323.0,\"end\":325.0,\"text\":\"12\",\"ref_id\":\"BIBREF11\"},{\"start\":416.0,\"end\":419.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":420.0,\"end\":422.0,\"text\":\"14\",\"ref_id\":\"BIBREF13\"},{\"start\":597.0,\"end\":599.0,\"text\":\"15\",\"ref_id\":\"BIBREF14\"},{\"start\":965.0,\"end\":967.0,\"text\":\"17\",\"ref_id\":\"BIBREF16\"},{\"start\":1112.0,\"end\":1114.0,\"text\":\"18\",\"ref_id\":\"BIBREF17\"},{\"start\":1404.0,\"end\":1408.0,\"text\":\"[19]\",\"ref_id\":\"BIBREF18\"},{\"start\":1409.0,\"end\":1413.0,\"text\":\"[20]\",\"ref_id\":\"BIBREF19\"},{\"start\":1414.0,\"end\":1418.0,\"text\":\"[21]\",\"ref_id\":\"BIBREF20\"}],\"ref_spans\":[],\"section\":\"Politics and process\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-965-967> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-416-419> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1409-1413> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-420-422> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1414-1418> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1112-1114> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-597-599> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-323-325> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1404-1408> ;
            <http://www.example.org/section>
                    "Politics and process" ;
            <http://www.example.org/text>  "The decision to pursue eradication The successful conclusion of the international smallpox eradication campaign in 1977 created substantial interest in further eradication efforts. However, enthusiasm was countered by concerns that targeted objectives could compromise efforts to develop strong primary health-care systems 12 and by doubts about the technical feasibility of eradicating any organism after smallpox. 13, 14 The most important factor in overcoming scientific concerns was the interruption of poliovirus transmission in large areas of the Americas by use of a four-pronged strategy. 15 The leadership for launching a global poliomyelitis eradication initiative was secured at a meeting in March, 1988, at which the WHO Director-General was convinced of the merit of such an effort. 12,16 2 months later, the World Health Assembly, consisting of the ministers of health of all member states, unanimously adopted a poliomyelitis eradication resolution. 17 The eradication goal was subsequently reviewed and endorsed by the 1990 World Summit for Children-the largest ever gathering of heads of state. 18 Leaders from lowincome, middle-income, and high-income countries have continued to reaffirm their commitment to poliomyelitis eradication through resolutions adopted in forums such as the Organization of African Unity, the South Asian Association for Regional Cooperation, and G8 summits. [19] [20] [21] Implementation of strategies By the end of 2000, every country had introduced the WHO-recommended poliomyelitis eradication strategies or a variant thereof, but the effort required to do so was correlated inversely with countries' incomes. In the few high-income countries in which poliomyelitis cases were reported in 1988 (eg, France and Spain) elimination of the virus was relatively straightforward because of temperate climate, higher vaccine effectiveness in such settings, high levels of sanitation, and strong health systems. By contrast, eliminating endemic poliomyelitis from low-income countries has required massive efforts sustained for 5-10 years. Implementation of National Immunisation Days (NIDs) has been a huge challenge; in China and India, for example, about 80 million and 150 million children, respectively, were immunised in a few days-the achievement was repeated 1 month later, and then annually Global health goals: lessons from the worldwide effort to eradicate poliomyelitis" ;
            <http://www.example.org/textHash>
                    "ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-874-876>
            <http://www.example.org/end>    "876.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF48" ;
            <http://www.example.org/start>  "874.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "49" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-167-169>
            <http://www.example.org/end>    "169.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF54" ;
            <http://www.example.org/start>  "167.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "55" .
    
    <http://covid19.aksw.org/text-785eea8ec616e3e45ffb0c904d2c4672768013042d13020b5db73cb89f1ef7af_citespan-873-875>
            <http://www.example.org/end>    "875.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "873.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5_citespan-627-629>
            <http://www.example.org/end>    "629.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF59" ;
            <http://www.example.org/start>  "627.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "60" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-121-122>
            <http://www.example.org/end>    "122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "3" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-1309-1311>
            <http://www.example.org/end>    "1311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "1309.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1054-1057>
            <http://www.example.org/end>    "1057.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1054.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40," .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-1088-1091>
            <http://www.example.org/end>    "1091.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1088.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1112-1114>
            <http://www.example.org/end>    "1114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "1112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "18" .
    
    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-1037-1039>
            <http://www.example.org/end>    "1039.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "1037.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "44" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1414-1418>
            <http://www.example.org/end>    "1418.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "1414.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[21]" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-690-692>
            <http://www.example.org/end>    "692.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "690.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25" .
    
    <http://covid19.aksw.org/text-785eea8ec616e3e45ffb0c904d2c4672768013042d13020b5db73cb89f1ef7af_citespan-1440-1442>
            <http://www.example.org/end>    "1442.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF57" ;
            <http://www.example.org/start>  "1440.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "58" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-23-26>
            <http://www.example.org/end>    "26.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "23.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "22," .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-288-290>
            <http://www.example.org/end>    "290.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "288.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "24" .
    
    <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71_refspan-236-245>
            <http://www.example.org/end>    "245.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "236.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(table 1)" .
    
    <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Between 1988 and 2005, external sources will have provided at least $3 billion to poliomyelitis-endemic countries. 32 Of more than 100 external donors to date, 26 have already contributed more than $1million and 12 at least $25 million (table 1) ; some, such as Rotary International, are not traditional sources of overseas development assistance. Central tracking of resource requirements and funding flows, and multilateral and bilateral funding mechanisms, have enabled efficient accommodation of the needs of donors and recipient countries. 33 The total cost of poliomyelitis eradication during 1988-2005 will be more than $5 billion.\",\"cite_spans\":[{\"start\":115.0,\"end\":117.0,\"text\":\"32\",\"ref_id\":\"BIBREF31\"},{\"start\":545.0,\"end\":547.0,\"text\":\"33\",\"ref_id\":\"BIBREF32\"}],\"ref_spans\":[{\"start\":236.0,\"end\":245.0,\"text\":\"(table 1)\",\"ref_id\":\"TABREF1\"}],\"section\":\"Financing and economics\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71_citespan-115-117> , <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71_citespan-545-547> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71_refspan-236-245> ;
            <http://www.example.org/section>
                    "Financing and economics" ;
            <http://www.example.org/text>  "Between 1988 and 2005, external sources will have provided at least $3 billion to poliomyelitis-endemic countries. 32 Of more than 100 external donors to date, 26 have already contributed more than $1million and 12 at least $25 million (table 1) ; some, such as Rotary International, are not traditional sources of overseas development assistance. Central tracking of resource requirements and funding flows, and multilateral and bilateral funding mechanisms, have enabled efficient accommodation of the needs of donors and recipient countries. 33 The total cost of poliomyelitis eradication during 1988-2005 will be more than $5 billion." ;
            <http://www.example.org/textHash>
                    "4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1409-1413>
            <http://www.example.org/end>    "1413.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "1409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[20]" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-27-29>
            <http://www.example.org/end>    "29.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "27.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "23" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1058-1060>
            <http://www.example.org/end>    "1060.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF49" ;
            <http://www.example.org/start>  "1058.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "50" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-75-79>
            <http://www.example.org/end>    "79.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "75.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[45]" .
    
    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-846-848>
            <http://www.example.org/end>    "848.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF42" ;
            <http://www.example.org/start>  "846.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "43" .
    
    <http://covid19.aksw.org/text-79a2dc53abe782011b7b218b0f578a0c21e19530b6a0ae6ab8df8bd59bda85a3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Fourth, given the amount of external financing required to achieve international health goals, strategies will usually necessitate targeting political decision-makers, by means such as professional lobbying firms and international forums to establish the commitment of heads of state. Because all countries will benefit economically from poliomyelitis eradication, Rotary International, as part of its advocacy strategy, calculated so-called fair shares of the total budget to be financed by each major donor country, based on their contributions to WHO\\u0027s regular budget. However, only 16 of the 22 WHO member states that traditionally give overseas development assistance had contributed to the eradication initiative by mid-2002. Of these, seven contributed the equivalent or more than their estimated fair share and nine substantially less. The six countries that did not contribute are free riders in economic terms, since they will share in the benefits. While the fairshare concept is of great value for setting resource mobilisation targets and negotiating appropriate contributions with interested donors, it has substantial limitations. Most importantly, it will not mobilise funds from donors who did not fully endorse the goal in the first place. Pursuing the fair-share argument can also unveil basic, irreconcilable disagreements on their calculation. Such limitations must be recognised early and alternate strategies developed for settings where this argument alone is not sufficient.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Reported cases\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Reported cases" ;
            <http://www.example.org/text>  "Fourth, given the amount of external financing required to achieve international health goals, strategies will usually necessitate targeting political decision-makers, by means such as professional lobbying firms and international forums to establish the commitment of heads of state. Because all countries will benefit economically from poliomyelitis eradication, Rotary International, as part of its advocacy strategy, calculated so-called fair shares of the total budget to be financed by each major donor country, based on their contributions to WHO's regular budget. However, only 16 of the 22 WHO member states that traditionally give overseas development assistance had contributed to the eradication initiative by mid-2002. Of these, seven contributed the equivalent or more than their estimated fair share and nine substantially less. The six countries that did not contribute are free riders in economic terms, since they will share in the benefits. While the fairshare concept is of great value for setting resource mobilisation targets and negotiating appropriate contributions with interested donors, it has substantial limitations. Most importantly, it will not mobilise funds from donors who did not fully endorse the goal in the first place. Pursuing the fair-share argument can also unveil basic, irreconcilable disagreements on their calculation. Such limitations must be recognised early and alternate strategies developed for settings where this argument alone is not sufficient." ;
            <http://www.example.org/textHash>
                    "79a2dc53abe782011b7b218b0f578a0c21e19530b6a0ae6ab8df8bd59bda85a3" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-597-599>
            <http://www.example.org/end>    "599.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF14" ;
            <http://www.example.org/start>  "597.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "15" .
    
    <http://covid19.aksw.org/text-b3b392a681f6fa802b350fbcb4db71e232a561cf436dff503fd498f0b886804a_citespan-704-706>
            <http://www.example.org/end>    "706.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "704.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-1404-1408>
            <http://www.example.org/end>    "1408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "1404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[19]" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-1167-1169>
            <http://www.example.org/end>    "1169.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "1167.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"By the end of 2001, poliomyelitis was on the brink of eradication, with only ten countries in which it was endemic and 483 virologically confirmed cases that year. 54 55 By the end of 2002, only seven countries-the lowest number ever-were known to have endemic poliomyelitis (figure 2). 56 The total number of cases exceeded that of 2001, however, because of marked increases in India and Nigeria ( figure 3 ). In India, the increase was due to an epidemic that originated in the northern state of Uttar Pradesh and spread rapidly to adjoining and distant states, many of which had been free from poliomyelitis for some years. By contrast, the increase in Nigeria was largely due to improved reporting in the north of the country. Complete eradication of poliovirus transmission will require overcoming challenges at national and international levels. At the national level, it will be essential to close gaps in the quality of supplementary immunisation activities in the six states or provinces of India, Nigeria, and Pakistan that accounted for 80% of poliomyelitis cases in 2002. Northern India in particular poses challenges, since the combination of a weak health infrastructure, fragile political alliances and, to a lesser degree, suspicion of government services by minority communities, has hampered efforts to mobilise all sectors of society and reach every child. In parts of Afghanistan, eastern Angola, and the Mogadishu area of Somalia, continued improvement in access to children is needed to break the few remaining chains of virus transmission in these areas. Internationally, the main challenge will be closing the $210 million funding gap for activities planned for 2003-05, while maintaining political visibility of, and commitment to, the eradication of a disappearing disease. 57 Increasingly, international discussion and debate has focussed on future poliomyelitis immunisation policy. From the outset of the eradication initiative, much of the attraction of this international health goal has been the argument that its achievement would reap economic as well as humanitarian benefits. These economic benefits would accrue mainly if and when poliomyelitis immunisation could stop. That these economic benefits could accumulate in perpetuity underpinned the arguments of the champions of poliomyelitis eradication, engaged political leadership, and mobilised stakeholders, in particular those from the private sector. However, several factors have complicated the development of, and consensus on, future immunisation policy. These factors range from increasing evidence that vaccine-derived polioviruses can, albeit rarely, regain the capacity to circulate and cause outbreaks, to increasing concerns about the use of biological agents. [36] [37] [38] [39] Although cessation of immunisation with the oral poliovirus vaccine remains a major objective of the eradication initiative, much work is required to establish the scientific soundness, operational feasibility, and economic rationale for the strategies that have been proposed to achieve this end. 36 \",\"cite_spans\":[{\"start\":164.0,\"end\":166.0,\"text\":\"54\",\"ref_id\":\"BIBREF53\"},{\"start\":167.0,\"end\":169.0,\"text\":\"55\",\"ref_id\":\"BIBREF54\"},{\"start\":287.0,\"end\":289.0,\"text\":\"56\",\"ref_id\":\"BIBREF55\"},{\"start\":1800.0,\"end\":1802.0,\"text\":\"57\",\"ref_id\":\"BIBREF56\"},{\"start\":2763.0,\"end\":2767.0,\"text\":\"[36]\",\"ref_id\":\"BIBREF35\"},{\"start\":2768.0,\"end\":2772.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF36\"},{\"start\":2773.0,\"end\":2777.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF37\"},{\"start\":2778.0,\"end\":2782.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF38\"},{\"start\":3081.0,\"end\":3083.0,\"text\":\"36\",\"ref_id\":\"BIBREF35\"}],\"ref_spans\":[{\"start\":399.0,\"end\":407.0,\"text\":\"figure 3\"}],\"section\":\"Indirect benefits and costs\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-287-289> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2778-2782> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-1800-1802> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-167-169> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2763-2767> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2768-2772> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-164-166> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2773-2777> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-3081-3083> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_refspan-399-407> ;
            <http://www.example.org/section>
                    "Indirect benefits and costs" ;
            <http://www.example.org/text>  "By the end of 2001, poliomyelitis was on the brink of eradication, with only ten countries in which it was endemic and 483 virologically confirmed cases that year. 54 55 By the end of 2002, only seven countries-the lowest number ever-were known to have endemic poliomyelitis (figure 2). 56 The total number of cases exceeded that of 2001, however, because of marked increases in India and Nigeria ( figure 3 ). In India, the increase was due to an epidemic that originated in the northern state of Uttar Pradesh and spread rapidly to adjoining and distant states, many of which had been free from poliomyelitis for some years. By contrast, the increase in Nigeria was largely due to improved reporting in the north of the country. Complete eradication of poliovirus transmission will require overcoming challenges at national and international levels. At the national level, it will be essential to close gaps in the quality of supplementary immunisation activities in the six states or provinces of India, Nigeria, and Pakistan that accounted for 80% of poliomyelitis cases in 2002. Northern India in particular poses challenges, since the combination of a weak health infrastructure, fragile political alliances and, to a lesser degree, suspicion of government services by minority communities, has hampered efforts to mobilise all sectors of society and reach every child. In parts of Afghanistan, eastern Angola, and the Mogadishu area of Somalia, continued improvement in access to children is needed to break the few remaining chains of virus transmission in these areas. Internationally, the main challenge will be closing the $210 million funding gap for activities planned for 2003-05, while maintaining political visibility of, and commitment to, the eradication of a disappearing disease. 57 Increasingly, international discussion and debate has focussed on future poliomyelitis immunisation policy. From the outset of the eradication initiative, much of the attraction of this international health goal has been the argument that its achievement would reap economic as well as humanitarian benefits. These economic benefits would accrue mainly if and when poliomyelitis immunisation could stop. That these economic benefits could accumulate in perpetuity underpinned the arguments of the champions of poliomyelitis eradication, engaged political leadership, and mobilised stakeholders, in particular those from the private sector. However, several factors have complicated the development of, and consensus on, future immunisation policy. These factors range from increasing evidence that vaccine-derived polioviruses can, albeit rarely, regain the capacity to circulate and cause outbreaks, to increasing concerns about the use of biological agents. [36] [37] [38] [39] Although cessation of immunisation with the oral poliovirus vaccine remains a major objective of the eradication initiative, much work is required to establish the scientific soundness, operational feasibility, and economic rationale for the strategies that have been proposed to achieve this end. 36 " ;
            <http://www.example.org/textHash>
                    "4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-1536-1538>
            <http://www.example.org/end>    "1538.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "1536.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29" .
    
    <http://covid19.aksw.org/text-b3b392a681f6fa802b350fbcb4db71e232a561cf436dff503fd498f0b886804a_citespan-550-552>
            <http://www.example.org/end>    "552.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "550.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "30" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2778-2782>
            <http://www.example.org/end>    "2782.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "2778.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-80-84>
            <http://www.example.org/end>    "84.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "80.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[46]" .
    
    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-596-598>
            <http://www.example.org/end>    "598.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "596.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "41" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2773-2777>
            <http://www.example.org/end>    "2777.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "2773.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-979-982>
            <http://www.example.org/end>    "982.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "979.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-1800-1802>
            <http://www.example.org/end>    "1802.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF56" ;
            <http://www.example.org/start>  "1800.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "57" .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_refspan-1663-1672>
            <http://www.example.org/end>    "1672.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF2" ;
            <http://www.example.org/start>  "1663.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(table 2)" .
    
    <http://covid19.aksw.org/text-345271adf613710f38ecab3e5f27f1a30c98642beb6e4c0f7e240597a183666b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"First, and perhaps foremost, is the need for proven tools and technically sound strategies. Additionally, their operational feasibility should be demonstrated conclusively on a large geographical scale, under as many conditions as possible, before attempting to launch a worldwide effort. International consensus on poliomyelitis eradication was achieved only after it had been shown in the Americas during the 1980s that strategies could be massively scaled \",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Lessons learned\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Lessons learned" ;
            <http://www.example.org/text>  "First, and perhaps foremost, is the need for proven tools and technically sound strategies. Additionally, their operational feasibility should be demonstrated conclusively on a large geographical scale, under as many conditions as possible, before attempting to launch a worldwide effort. International consensus on poliomyelitis eradication was achieved only after it had been shown in the Americas during the 1980s that strategies could be massively scaled " ;
            <http://www.example.org/textHash>
                    "345271adf613710f38ecab3e5f27f1a30c98642beb6e4c0f7e240597a183666b" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2768-2772>
            <http://www.example.org/end>    "2772.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "2768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A cost-benefit analysis of the PAHO regional programme noted \\\". . . polio eradication appeared economically justified solely in terms of reduced treatment costs, irrespective of reduced pain, suffering and incapacitation\\\", calculating that the net present value of discounted savings during a 15-year period from the start of the campaign was $62·1 million. 34 A similar analysis for worldwide eradication throughout 1988-2040 showed that even when including only the savings in direct costs for treatment and rehabilitation, \\\" . . . the \\u0027break-even\\u0027 point at which benefits exceeded costs was the year 2007, with a saving of US$13 600 million by the year 2040\\\". 35 The cost-effectiveness of global poliomyelitis eradication was reassessed for 2001-2040 to analyse the potential effects of poliomyelitis immunisation policies that might be adopted after worldwide certification of eradication. 36 From an economic perspective, the best-case scenario was assumed to be cessation of routine immunisation with the oral poliomyelitis vaccine as soon as possible after interruption of wild poliovirus. The worst-case scenario was assumed to be replacement of this vaccine by universal childhood immunisation with the more expensive inactivated poliovirus vaccine to reduce the risk of vaccine-associated paralytic poliomyelitis or poliomyelitis outbreaks due to a circulating vaccine-derived poliovirus. [37] [38] [39] In this analysis, even in the worst-case scenario, poliomyelitis eradication would save money in all countries, apart from low-income countries where the cost per discounted disabilityadjusted life-year (DALY) saved would still be low, at about $50 (table 2) .\",\"cite_spans\":[{\"start\":358.0,\"end\":360.0,\"text\":\"34\",\"ref_id\":\"BIBREF33\"},{\"start\":663.0,\"end\":665.0,\"text\":\"35\",\"ref_id\":\"BIBREF34\"},{\"start\":894.0,\"end\":896.0,\"text\":\"36\",\"ref_id\":\"BIBREF35\"},{\"start\":1399.0,\"end\":1403.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF36\"},{\"start\":1404.0,\"end\":1408.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF37\"},{\"start\":1409.0,\"end\":1413.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF38\"}],\"ref_spans\":[{\"start\":1663.0,\"end\":1672.0,\"text\":\"(table 2)\",\"ref_id\":\"TABREF2\"}],\"section\":\"Direct benefits\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-663-665> , <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-358-360> , <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-1404-1408> , <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-1399-1403> , <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-894-896> , <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-1409-1413> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_refspan-1663-1672> ;
            <http://www.example.org/section>
                    "Direct benefits" ;
            <http://www.example.org/text>  "A cost-benefit analysis of the PAHO regional programme noted \". . . polio eradication appeared economically justified solely in terms of reduced treatment costs, irrespective of reduced pain, suffering and incapacitation\", calculating that the net present value of discounted savings during a 15-year period from the start of the campaign was $62·1 million. 34 A similar analysis for worldwide eradication throughout 1988-2040 showed that even when including only the savings in direct costs for treatment and rehabilitation, \" . . . the 'break-even' point at which benefits exceeded costs was the year 2007, with a saving of US$13 600 million by the year 2040\". 35 The cost-effectiveness of global poliomyelitis eradication was reassessed for 2001-2040 to analyse the potential effects of poliomyelitis immunisation policies that might be adopted after worldwide certification of eradication. 36 From an economic perspective, the best-case scenario was assumed to be cessation of routine immunisation with the oral poliomyelitis vaccine as soon as possible after interruption of wild poliovirus. The worst-case scenario was assumed to be replacement of this vaccine by universal childhood immunisation with the more expensive inactivated poliovirus vaccine to reduce the risk of vaccine-associated paralytic poliomyelitis or poliomyelitis outbreaks due to a circulating vaccine-derived poliovirus. [37] [38] [39] In this analysis, even in the worst-case scenario, poliomyelitis eradication would save money in all countries, apart from low-income countries where the cost per discounted disabilityadjusted life-year (DALY) saved would still be low, at about $50 (table 2) ." ;
            <http://www.example.org/textHash>
                    "02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0" .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"for more than 5 years. 22, 23 Because of the huge numbers of people and vehicles required to implement NIDs, governments of many countries have drawn heavily on the private sector, as well as on ministries of information, transport, and defence, among others, to help reach all children. 24 People crossing borders can transmit poliomyelitis during the interval between NIDs being held in one country and in its neighbour. Recognising this factor, many countries have synchronised their NIDs (figure 1). In Operation MECACAR for example, 18 Asian, European, and Middle Eastern countries immunised 55 million children in April and May, 1995, and repeated the activity each year for 3 years. 25 Similar coordination followed in south Asia, West Africa, 20, 26 and then Central Africa, where the conflict-affected countries of the Democratic Republic of the Congo, Angola, Congo, and Gabon synchronised three rounds of NIDs in July-September, 2001, to immunise 15 million children. 26, 27 By the year 2000, all poliomyelitis-affected countries were reporting standardised data for acutely paralysed children and surveillance performance to WHO either weekly or monthly. 28 Central to this surveillance capacity has been a worldwide laboratory network for enterovirus diagnosis that now comprises 145 facilities. 27 Even in conflict-affected areas such as Afghanistan, the Democratic Republic of the Congo, and Somalia, surveillance in 2001 was nearing the international standard that will be required for poliomyelitis-free certification. 29 Coordination Though poliomyelitis eradication activities have been led, coordinated, and implemented by the governments of poliomyelitis-affected countries, the support of a publicprivate partnership has been essential. This partnership, spearheaded by WHO, Rotary International, the US Centers for Disease Control and Prevention (CDC), and UNICEF has facilitated the inputs of donor governments and a vast array of other organisations. The most remarkable of these partners is Rotary International, a private-sector service organisation, which will have contributed nearly US$600 million of its own resources by the end of 2005 in addition to mobilising much of the money contributed by governments.\",\"cite_spans\":[{\"start\":23.0,\"end\":26.0,\"text\":\"22,\",\"ref_id\":\"BIBREF21\"},{\"start\":27.0,\"end\":29.0,\"text\":\"23\",\"ref_id\":\"BIBREF22\"},{\"start\":288.0,\"end\":290.0,\"text\":\"24\",\"ref_id\":\"BIBREF23\"},{\"start\":690.0,\"end\":692.0,\"text\":\"25\",\"ref_id\":\"BIBREF24\"},{\"start\":751.0,\"end\":754.0,\"text\":\"20,\",\"ref_id\":\"BIBREF19\"},{\"start\":755.0,\"end\":757.0,\"text\":\"26\",\"ref_id\":\"BIBREF25\"},{\"start\":979.0,\"end\":982.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":983.0,\"end\":985.0,\"text\":\"27\",\"ref_id\":\"BIBREF26\"},{\"start\":1167.0,\"end\":1169.0,\"text\":\"28\",\"ref_id\":\"BIBREF27\"},{\"start\":1309.0,\"end\":1311.0,\"text\":\"27\",\"ref_id\":\"BIBREF26\"},{\"start\":1536.0,\"end\":1538.0,\"text\":\"29\",\"ref_id\":\"BIBREF28\"}],\"ref_spans\":[],\"section\":\"Public health\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-751-754> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-755-757> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-1167-1169> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-1536-1538> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-983-985> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-27-29> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-690-692> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-23-26> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-979-982> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-288-290> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-1309-1311> ;
            <http://www.example.org/section>
                    "Public health" ;
            <http://www.example.org/text>  "for more than 5 years. 22, 23 Because of the huge numbers of people and vehicles required to implement NIDs, governments of many countries have drawn heavily on the private sector, as well as on ministries of information, transport, and defence, among others, to help reach all children. 24 People crossing borders can transmit poliomyelitis during the interval between NIDs being held in one country and in its neighbour. Recognising this factor, many countries have synchronised their NIDs (figure 1). In Operation MECACAR for example, 18 Asian, European, and Middle Eastern countries immunised 55 million children in April and May, 1995, and repeated the activity each year for 3 years. 25 Similar coordination followed in south Asia, West Africa, 20, 26 and then Central Africa, where the conflict-affected countries of the Democratic Republic of the Congo, Angola, Congo, and Gabon synchronised three rounds of NIDs in July-September, 2001, to immunise 15 million children. 26, 27 By the year 2000, all poliomyelitis-affected countries were reporting standardised data for acutely paralysed children and surveillance performance to WHO either weekly or monthly. 28 Central to this surveillance capacity has been a worldwide laboratory network for enterovirus diagnosis that now comprises 145 facilities. 27 Even in conflict-affected areas such as Afghanistan, the Democratic Republic of the Congo, and Somalia, surveillance in 2001 was nearing the international standard that will be required for poliomyelitis-free certification. 29 Coordination Though poliomyelitis eradication activities have been led, coordinated, and implemented by the governments of poliomyelitis-affected countries, the support of a publicprivate partnership has been essential. This partnership, spearheaded by WHO, Rotary International, the US Centers for Disease Control and Prevention (CDC), and UNICEF has facilitated the inputs of donor governments and a vast array of other organisations. The most remarkable of these partners is Rotary International, a private-sector service organisation, which will have contributed nearly US$600 million of its own resources by the end of 2005 in addition to mobilising much of the money contributed by governments." ;
            <http://www.example.org/textHash>
                    "87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951" .
    
    <http://covid19.aksw.org/8c55abb5f141dd742253a1682cf2e5e5c05a31bc>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "8c55abb5f141dd742253a1682cf2e5e5c05a31bc" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-e45097a8afbf8ea6ee0bc3ec7c61d5171ac33199d105b45e29ff2fef9e954bb4> , <http://covid19.aksw.org/text-b3b392a681f6fa802b350fbcb4db71e232a561cf436dff503fd498f0b886804a> , <http://covid19.aksw.org/text-e9b9940f6be7bd7952dd3e36eb10523faf4195127494b64b6d915cc55f2efe4a> , <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0> , <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951> , <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315> , <http://covid19.aksw.org/text-fb5e7680ff2fc4b23c5b4edcf90d903767fcc8d485c73df6d71cd431e125fee8> , <http://covid19.aksw.org/text-9555dc846e059a077f203cc323899bdb2017de3df24d44fa4eab933d5ba87354> , <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5> , <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1> , <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac> , <http://covid19.aksw.org/text-e9acd423b9ef64149217932be16206a26d8723bbaeedfd73d17ecd78bbc72780> , <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65> , <http://covid19.aksw.org/text-aa219b9baecaa806e9ba0cbb77c356bfbcd2561a7e65d644273cb238838837b8> , <http://covid19.aksw.org/text-64423a68610f7c0d28f7f96657b72461a9c8606b50ef0b61c5012af302eb5725> , <http://covid19.aksw.org/text-785eea8ec616e3e45ffb0c904d2c4672768013042d13020b5db73cb89f1ef7af> , <http://covid19.aksw.org/text-79a2dc53abe782011b7b218b0f578a0c21e19530b6a0ae6ab8df8bd59bda85a3> , <http://covid19.aksw.org/text-345271adf613710f38ecab3e5f27f1a30c98642beb6e4c0f7e240597a183666b> .
    
    <http://covid19.aksw.org/text-e9b9940f6be7bd7952dd3e36eb10523faf4195127494b64b6d915cc55f2efe4a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The Global Polio Eradication Initiative was launched in 1988. Assessment of the politics, production, financing, and economics of this international effort has suggested six lessons that might be pertinent to the pursuit of other global health goals. First, such goals should be based on technically sound strategies with proven operational feasibility in a large geographical area. Second, before launching an initiative, an informed collective decision must be negotiated and agreed in an appropriate international forum to keep to a minimum long-term risks in financing and implementation. Third, if substantial community engagement is envisaged, efficient deployment of sufficient resources at that level necessitates a defined, time-limited input by the community within a properly managed partnership. Fourth, although the so-called fair-share concept is arguably the best way to finance such goals, its limitations must be recognised early and alternative strategies developed for settings where it does not work. Fifth, international health goals must be designed and pursued within existing health systems if they are to secure and sustain broad support. Finally, countries, regions, or populations most likely to delay the achievement of a global health goal should be identified at the outset to ensure provision of sufficient resources and attention. The greatest threats to poliomyelitis eradication are a financing gap of US$210 million and difficulties in strategy implementation in at most five countries.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"R Bruce Aylward, Arnab Acharya, Sarah England, Mary Agocs, Jennifer Linkins\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "R Bruce Aylward, Arnab Acharya, Sarah England, Mary Agocs, Jennifer Linkins" ;
            <http://www.example.org/text>  "The Global Polio Eradication Initiative was launched in 1988. Assessment of the politics, production, financing, and economics of this international effort has suggested six lessons that might be pertinent to the pursuit of other global health goals. First, such goals should be based on technically sound strategies with proven operational feasibility in a large geographical area. Second, before launching an initiative, an informed collective decision must be negotiated and agreed in an appropriate international forum to keep to a minimum long-term risks in financing and implementation. Third, if substantial community engagement is envisaged, efficient deployment of sufficient resources at that level necessitates a defined, time-limited input by the community within a properly managed partnership. Fourth, although the so-called fair-share concept is arguably the best way to finance such goals, its limitations must be recognised early and alternative strategies developed for settings where it does not work. Fifth, international health goals must be designed and pursued within existing health systems if they are to secure and sustain broad support. Finally, countries, regions, or populations most likely to delay the achievement of a global health goal should be identified at the outset to ensure provision of sufficient resources and attention. The greatest threats to poliomyelitis eradication are a financing gap of US$210 million and difficulties in strategy implementation in at most five countries." ;
            <http://www.example.org/textHash>
                    "e9b9940f6be7bd7952dd3e36eb10523faf4195127494b64b6d915cc55f2efe4a" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-2763-2767>
            <http://www.example.org/end>    "2767.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "2763.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[36]" .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-358-360>
            <http://www.example.org/end>    "360.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "34" .
    
    <http://covid19.aksw.org/text-9555dc846e059a077f203cc323899bdb2017de3df24d44fa4eab933d5ba87354_citespan-246-247>
            <http://www.example.org/end>    "247.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "246.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "2" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Though the most cited example of international collaboration is the Global Fund to Fight AIDS, Tuberculosis and Malaria, 3 it is only the most recent. Perhaps the best example of such collaboration was the successful international effort to eradicate smallpox in the 1960s and 1970s. 4 More recently, coordinated efforts to combat global health threats have included the Global Partnership to STOP TB, 5 the Roll Back Malaria Initiative, 6 and the Global Alliance for Vaccines and Immunization (GAVI). 7 Innovative strategies have also been established to tackle non-communicable diseases, most notably through the Framework Convention on Tobacco Control. 8 Common to these initiatives has been the conviction that coordinated international action is in the interest of all countries. It has even been argued that these initiatives are \\\"global public goods for health\\\". 9 The effort to eradicate poliomyelitis is one such initiative, since once eradication has been achieved, everyone will be protected from the virus and one person\\u0027s protection will not reduce that available to others. 10, 11 In this paper, we assess the politics, production, financing, and economics of poliomyelitis eradication to identify lessons that might be relevant to the pursuit of other global health goals.\",\"cite_spans\":[{\"start\":121.0,\"end\":122.0,\"text\":\"3\",\"ref_id\":\"BIBREF2\"},{\"start\":284.0,\"end\":285.0,\"text\":\"4\",\"ref_id\":\"BIBREF3\"},{\"start\":402.0,\"end\":403.0,\"text\":\"5\",\"ref_id\":\"BIBREF4\"},{\"start\":438.0,\"end\":439.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":502.0,\"end\":503.0,\"text\":\"7\",\"ref_id\":\"BIBREF6\"},{\"start\":656.0,\"end\":657.0,\"text\":\"8\",\"ref_id\":\"BIBREF7\"},{\"start\":870.0,\"end\":871.0,\"text\":\"9\",\"ref_id\":\"BIBREF8\"},{\"start\":1088.0,\"end\":1091.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":1092.0,\"end\":1094.0,\"text\":\"11\",\"ref_id\":\"BIBREF10\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-402-403> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-121-122> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-656-657> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-438-439> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-1092-1094> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-870-871> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-502-503> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-284-285> , <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-1088-1091> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Though the most cited example of international collaboration is the Global Fund to Fight AIDS, Tuberculosis and Malaria, 3 it is only the most recent. Perhaps the best example of such collaboration was the successful international effort to eradicate smallpox in the 1960s and 1970s. 4 More recently, coordinated efforts to combat global health threats have included the Global Partnership to STOP TB, 5 the Roll Back Malaria Initiative, 6 and the Global Alliance for Vaccines and Immunization (GAVI). 7 Innovative strategies have also been established to tackle non-communicable diseases, most notably through the Framework Convention on Tobacco Control. 8 Common to these initiatives has been the conviction that coordinated international action is in the interest of all countries. It has even been argued that these initiatives are \"global public goods for health\". 9 The effort to eradicate poliomyelitis is one such initiative, since once eradication has been achieved, everyone will be protected from the virus and one person's protection will not reduce that available to others. 10, 11 In this paper, we assess the politics, production, financing, and economics of poliomyelitis eradication to identify lessons that might be relevant to the pursuit of other global health goals." ;
            <http://www.example.org/textHash>
                    "638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-1092-1094>
            <http://www.example.org/end>    "1094.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1092.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_refspan-399-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "399.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "figure 3" .
    
    <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The final lesson is the need to identify countries, regions, or populations where strategy implementation will be particularly challenging, and to establish appropriate contingency plans. Failure in just one country could be catastrophic for an eradication effort. However, other international health goals might be similarly compromised. For example, the emergence of multidrug-resistant strains of tuberculosis in one country could hamper worldwide efforts to combat that disease. 59 Similarly, uncontrolled use of antibiotics in a few countries could seriously affect international work to contain antimicrobial resistance. 60 As the poliomyelitis eradication programme began to be implemented on a truly worldwide scale in the mid-1990s, substantial attention was given to the ten countries that had been identified as at particularly high risk for delaying global eradication. As a result of focusing additional human, financial, and political resources in these areas, five of those countries (Bangladesh, the Democratic Republic of the Congo, Sudan, Ethiopia, Angola) now seem to have eradicated poliomyelitis, and only three (India, Nigeria, Pakistan) continue to have high-intensity transmission. Although it is tempting to suggest that even greater attention earlier in the programme might have accelerated progress in these areas, the reality is that scant resources necessitated a more pragmatic approach. Other international health goals will require a similar, pragmatic approach to achieve and secure gains where possible, while developing the necessary political, financial, and human resources to address the most challenging areas. 58 Contributors R B Aylward wrote the introductory, status, and lessons sections, and edited the manuscript. S England developed the concept and original structure and wrote the first draft of the manuscript. M Agocs did research, in particular on the background, history, and indirect benefits of poliomyelitis eradication, and wrote those sections. A Acharya did the cost-effectiveness analysis. J Linkins did the analysis of the direct national and international costs of poliomyelitis eradication and wrote the section in which they are detailed.\",\"cite_spans\":[{\"start\":483.0,\"end\":485.0,\"text\":\"59\",\"ref_id\":\"BIBREF58\"},{\"start\":627.0,\"end\":629.0,\"text\":\"60\",\"ref_id\":\"BIBREF59\"},{\"start\":1650.0,\"end\":1652.0,\"text\":\"58\",\"ref_id\":\"BIBREF57\"}],\"ref_spans\":[],\"section\":\"Reported cases\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5_citespan-483-485> , <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5_citespan-627-629> , <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5_citespan-1650-1652> ;
            <http://www.example.org/section>
                    "Reported cases" ;
            <http://www.example.org/text>  "The final lesson is the need to identify countries, regions, or populations where strategy implementation will be particularly challenging, and to establish appropriate contingency plans. Failure in just one country could be catastrophic for an eradication effort. However, other international health goals might be similarly compromised. For example, the emergence of multidrug-resistant strains of tuberculosis in one country could hamper worldwide efforts to combat that disease. 59 Similarly, uncontrolled use of antibiotics in a few countries could seriously affect international work to contain antimicrobial resistance. 60 As the poliomyelitis eradication programme began to be implemented on a truly worldwide scale in the mid-1990s, substantial attention was given to the ten countries that had been identified as at particularly high risk for delaying global eradication. As a result of focusing additional human, financial, and political resources in these areas, five of those countries (Bangladesh, the Democratic Republic of the Congo, Sudan, Ethiopia, Angola) now seem to have eradicated poliomyelitis, and only three (India, Nigeria, Pakistan) continue to have high-intensity transmission. Although it is tempting to suggest that even greater attention earlier in the programme might have accelerated progress in these areas, the reality is that scant resources necessitated a more pragmatic approach. Other international health goals will require a similar, pragmatic approach to achieve and secure gains where possible, while developing the necessary political, financial, and human resources to address the most challenging areas. 58 Contributors R B Aylward wrote the introductory, status, and lessons sections, and edited the manuscript. S England developed the concept and original structure and wrote the first draft of the manuscript. M Agocs did research, in particular on the background, history, and indirect benefits of poliomyelitis eradication, and wrote those sections. A Acharya did the cost-effectiveness analysis. J Linkins did the analysis of the direct national and international costs of poliomyelitis eradication and wrote the section in which they are detailed." ;
            <http://www.example.org/textHash>
                    "ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5" .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-663-665>
            <http://www.example.org/end>    "665.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "663.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-870-873>
            <http://www.example.org/end>    "873.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "48," .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-420-422>
            <http://www.example.org/end>    "422.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "420.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1411-1413>
            <http://www.example.org/end>    "1413.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF50" ;
            <http://www.example.org/start>  "1411.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "51" .
    
    <http://covid19.aksw.org/text-64423a68610f7c0d28f7f96657b72461a9c8606b50ef0b61c5012af302eb5725>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A third lesson is that efficient management is needed to achieve the necessary scale of collective action. Two major factors facilitated participation in the eradication initiative: a well defined, time-limited (1-5 days) demand on the community, and sufficient resources to enable the community to implement activities. Ensuring sufficient resources required moving beyond building an international health partnership to managing one efficiently. Critical to achieving efficiency was the use of common strategic plans, clear roles and responsibilities, and national and international forums to coordinate financing, human resources, and institutional arrangements.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Reported cases\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Reported cases" ;
            <http://www.example.org/text>  "A third lesson is that efficient management is needed to achieve the necessary scale of collective action. Two major factors facilitated participation in the eradication initiative: a well defined, time-limited (1-5 days) demand on the community, and sufficient resources to enable the community to implement activities. Ensuring sufficient resources required moving beyond building an international health partnership to managing one efficiently. Critical to achieving efficiency was the use of common strategic plans, clear roles and responsibilities, and national and international forums to coordinate financing, human resources, and institutional arrangements." ;
            <http://www.example.org/textHash>
                    "64423a68610f7c0d28f7f96657b72461a9c8606b50ef0b61c5012af302eb5725" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-438-439>
            <http://www.example.org/end>    "439.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "438.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The World Health Assembly resolution that launched the Global Polio Eradication Initiative stated that eradication should be pursued in ways that strengthened the delivery of primary health-care services in general and immunisation programmes in particular. 17 What has been the effect of poliomyelitis eradication activities on the delivery of specific health services or the development of health systems? Three irrefutable benefits have included widespread vitamin A distribution, enhanced global surveillance capacity, and improved worldwide cooperation between enterovirus laboratories. 40, 41 By distributing vitamin A supplements during poliomyelitis NIDs, an estimated 400 000 childhood deaths were averted during 1998-99 alone, and the value of using immunisation contacts to deliver micronutrient supplements was widely reinforced. 42, 43 The surveillance capacity developed for poliomyelitis eradication has also been used to detect and respond to outbreaks of diseases such as measles, meningitis, cholera, and yellow fever. 44 The poliomyelitis-eradication infrastructure and capacity was also used to assist in the international effort to control severe acute respiratory syndrome (SARS).\",\"cite_spans\":[{\"start\":258.0,\"end\":260.0,\"text\":\"17\",\"ref_id\":\"BIBREF16\"},{\"start\":592.0,\"end\":595.0,\"text\":\"40,\",\"ref_id\":\"BIBREF39\"},{\"start\":596.0,\"end\":598.0,\"text\":\"41\",\"ref_id\":\"BIBREF40\"},{\"start\":842.0,\"end\":845.0,\"text\":\"42,\",\"ref_id\":\"BIBREF41\"},{\"start\":846.0,\"end\":848.0,\"text\":\"43\",\"ref_id\":\"BIBREF42\"},{\"start\":1037.0,\"end\":1039.0,\"text\":\"44\",\"ref_id\":\"BIBREF43\"}],\"ref_spans\":[],\"section\":\"Indirect benefits and costs\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-596-598> , <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-842-845> , <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-1037-1039> , <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-258-260> , <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-846-848> , <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-592-595> ;
            <http://www.example.org/section>
                    "Indirect benefits and costs" ;
            <http://www.example.org/text>  "The World Health Assembly resolution that launched the Global Polio Eradication Initiative stated that eradication should be pursued in ways that strengthened the delivery of primary health-care services in general and immunisation programmes in particular. 17 What has been the effect of poliomyelitis eradication activities on the delivery of specific health services or the development of health systems? Three irrefutable benefits have included widespread vitamin A distribution, enhanced global surveillance capacity, and improved worldwide cooperation between enterovirus laboratories. 40, 41 By distributing vitamin A supplements during poliomyelitis NIDs, an estimated 400 000 childhood deaths were averted during 1998-99 alone, and the value of using immunisation contacts to deliver micronutrient supplements was widely reinforced. 42, 43 The surveillance capacity developed for poliomyelitis eradication has also been used to detect and respond to outbreaks of diseases such as measles, meningitis, cholera, and yellow fever. 44 The poliomyelitis-eradication infrastructure and capacity was also used to assist in the international effort to control severe acute respiratory syndrome (SARS)." ;
            <http://www.example.org/textHash>
                    "c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-164-166>
            <http://www.example.org/end>    "166.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF53" ;
            <http://www.example.org/start>  "164.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "54" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-284-285>
            <http://www.example.org/end>    "285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "284.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "4" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"However, effects on routine immunisation services have been controversial. [45] [46] [47] The poliomyelitis initiative has invested heavily in physical and human resources for routine immunisation. The cold chain, communications, and transport capacity have been replaced or refurbished in many low-income countries, especially in sub-Saharan Africa, and tens of thousands of people have been trained or retrained worldwide in giving vaccinations. Questions have been asked, however, as to whether short-term disruptions by NIDs in the delivery of routine immunisation and other services will have long-term consequences. Evaluation of the effect on health systems has been hampered by a lack of credible baseline data, the absence of control groups, and the concurrent implementation of major health-system reforms, such as decentralisation and sector-wide approaches. 48, 49 Most commentators agree that there are positive synergies between poliomyelitis eradication and development of health systems, but opportunities have yet to be fully exploited. 40, 50 Status of eradication and risks to completion When the World Health Assembly voted to eradicate poliomyelitis in 1988, more than 125 countries (defined by year 2000 geographic borders) on five continents were known or suspected to have indigenous transmission of wild poliovirus (figure 2). Though only 35 031 cases were reported worldwide that year 51 it is estimated that more than 350 000 children were actually paralysed. 52, 53 More than 90% of the reported cases in 1988 were in low or lower-middle income countries and half were in the Asian subcontinent-mostly in India. Outside the Americas, few areas were free of poliomyelitis-mainly industrialised countries and small island nations.\",\"cite_spans\":[{\"start\":75.0,\"end\":79.0,\"text\":\"[45]\",\"ref_id\":\"BIBREF44\"},{\"start\":80.0,\"end\":84.0,\"text\":\"[46]\",\"ref_id\":\"BIBREF45\"},{\"start\":85.0,\"end\":89.0,\"text\":\"[47]\",\"ref_id\":\"BIBREF46\"},{\"start\":870.0,\"end\":873.0,\"text\":\"48,\",\"ref_id\":\"BIBREF47\"},{\"start\":874.0,\"end\":876.0,\"text\":\"49\",\"ref_id\":\"BIBREF48\"},{\"start\":1054.0,\"end\":1057.0,\"text\":\"40,\",\"ref_id\":\"BIBREF39\"},{\"start\":1058.0,\"end\":1060.0,\"text\":\"50\",\"ref_id\":\"BIBREF49\"},{\"start\":1411.0,\"end\":1413.0,\"text\":\"51\",\"ref_id\":\"BIBREF50\"},{\"start\":1487.0,\"end\":1490.0,\"text\":\"52,\",\"ref_id\":\"BIBREF51\"},{\"start\":1491.0,\"end\":1493.0,\"text\":\"53\",\"ref_id\":\"BIBREF52\"}],\"ref_spans\":[],\"section\":\"Indirect benefits and costs\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-874-876> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-80-84> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1058-1060> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1491-1493> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-85-89> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1487-1490> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-870-873> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1411-1413> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-75-79> , <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1054-1057> ;
            <http://www.example.org/section>
                    "Indirect benefits and costs" ;
            <http://www.example.org/text>  "However, effects on routine immunisation services have been controversial. [45] [46] [47] The poliomyelitis initiative has invested heavily in physical and human resources for routine immunisation. The cold chain, communications, and transport capacity have been replaced or refurbished in many low-income countries, especially in sub-Saharan Africa, and tens of thousands of people have been trained or retrained worldwide in giving vaccinations. Questions have been asked, however, as to whether short-term disruptions by NIDs in the delivery of routine immunisation and other services will have long-term consequences. Evaluation of the effect on health systems has been hampered by a lack of credible baseline data, the absence of control groups, and the concurrent implementation of major health-system reforms, such as decentralisation and sector-wide approaches. 48, 49 Most commentators agree that there are positive synergies between poliomyelitis eradication and development of health systems, but opportunities have yet to be fully exploited. 40, 50 Status of eradication and risks to completion When the World Health Assembly voted to eradicate poliomyelitis in 1988, more than 125 countries (defined by year 2000 geographic borders) on five continents were known or suspected to have indigenous transmission of wild poliovirus (figure 2). Though only 35 031 cases were reported worldwide that year 51 it is estimated that more than 350 000 children were actually paralysed. 52, 53 More than 90% of the reported cases in 1988 were in low or lower-middle income countries and half were in the Asian subcontinent-mostly in India. Outside the Americas, few areas were free of poliomyelitis-mainly industrialised countries and small island nations." ;
            <http://www.example.org/textHash>
                    "8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65" .
    
    <http://covid19.aksw.org/text-e9acd423b9ef64149217932be16206a26d8723bbaeedfd73d17ecd78bbc72780>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In this review of the poliomyelitis eradication initiative, we have derived six lessons that could assist the planning and pursuit of worldwide health goals, whether global public goods for health or other health efforts in which international collective action might be warranted.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Lessons learned\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Lessons learned" ;
            <http://www.example.org/text>  "In this review of the poliomyelitis eradication initiative, we have derived six lessons that could assist the planning and pursuit of worldwide health goals, whether global public goods for health or other health efforts in which international collective action might be warranted." ;
            <http://www.example.org/textHash>
                    "e9acd423b9ef64149217932be16206a26d8723bbaeedfd73d17ecd78bbc72780" .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-1409-1413>
            <http://www.example.org/end>    "1413.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "1409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-287-289>
            <http://www.example.org/end>    "289.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF55" ;
            <http://www.example.org/start>  "287.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "56" .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-1487-1490>
            <http://www.example.org/end>    "1490.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF51" ;
            <http://www.example.org/start>  "1487.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "52," .
    
    <http://covid19.aksw.org/text-87b7eb5fbac4c79a87aee656b1483738f7569a542724afa21146b5a23393f951_citespan-751-754>
            <http://www.example.org/end>    "754.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "751.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "20," .
    
    <http://covid19.aksw.org/text-c54bf219164405f45d97e7fa6f74ab39cf5e48fc51f1edf0aa3e71544068c315_citespan-842-845>
            <http://www.example.org/end>    "845.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF41" ;
            <http://www.example.org/start>  "842.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "42," .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-402-403>
            <http://www.example.org/end>    "403.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "402.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "5" .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-1404-1408>
            <http://www.example.org/end>    "1408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-323-325>
            <http://www.example.org/end>    "325.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "323.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-4fe690697b554c4d82e89775d2eac1a4b55d1b40debcf00702313f2657406c71_citespan-115-117>
            <http://www.example.org/end>    "117.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "115.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32" .
    
    <http://covid19.aksw.org/text-fb5e7680ff2fc4b23c5b4edcf90d903767fcc8d485c73df6d71cd431e125fee8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To coordinate this partnership, mechanisms were established at global, regional, and country levels for strategic planning, policy development and priority setting, resource mobilisation, and financing. Additional mechanisms were established to manage the laboratory network and govern the process for eventually certifying the world as free from poliomyelitis.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Public health\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Public health" ;
            <http://www.example.org/text>  "To coordinate this partnership, mechanisms were established at global, regional, and country levels for strategic planning, policy development and priority setting, resource mobilisation, and financing. Additional mechanisms were established to manage the laboratory network and govern the process for eventually certifying the world as free from poliomyelitis." ;
            <http://www.example.org/textHash>
                    "fb5e7680ff2fc4b23c5b4edcf90d903767fcc8d485c73df6d71cd431e125fee8" .
    
    <http://covid19.aksw.org/text-9555dc846e059a077f203cc323899bdb2017de3df24d44fa4eab933d5ba87354_citespan-243-245>
            <http://www.example.org/end>    "245.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "243.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "1," .
    
    <http://covid19.aksw.org/text-02ba6c4e6536b55fe94a33bb3577f03f311841e54827d4b2073eaf90502993d0_citespan-894-896>
            <http://www.example.org/end>    "896.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "894.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "36" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-416-419>
            <http://www.example.org/end>    "419.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "416.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-8337508cf15035aed2745b3d2efe968b37dbf7592336c0dc510061bfd8385f65_citespan-85-89>
            <http://www.example.org/end>    "89.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF46" ;
            <http://www.example.org/start>  "85.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[47]" .
    
    <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5_citespan-1650-1652>
            <http://www.example.org/end>    "1652.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF57" ;
            <http://www.example.org/start>  "1650.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "58" .
    
    <http://covid19.aksw.org/text-e45097a8afbf8ea6ee0bc3ec7c61d5171ac33199d105b45e29ff2fef9e954bb4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"None declared.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Conflict of interest statement\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Conflict of interest statement" ;
            <http://www.example.org/text>  "None declared." ;
            <http://www.example.org/textHash>
                    "e45097a8afbf8ea6ee0bc3ec7c61d5171ac33199d105b45e29ff2fef9e954bb4" .
    
    <http://covid19.aksw.org/text-ecb5e36940d034f26158ef34fe4514952ffaeaf6cbbfef8123d159be697881a5_citespan-483-485>
            <http://www.example.org/end>    "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF58" ;
            <http://www.example.org/start>  "483.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "59" .
    
    <http://covid19.aksw.org/text-638219481faf0499bfde3f9a5400b6af39b53215bc68839b21ba619412f6bdf1_citespan-870-871>
            <http://www.example.org/end>    "871.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9" .
    
    <http://covid19.aksw.org/text-aa219b9baecaa806e9ba0cbb77c356bfbcd2561a7e65d644273cb238838837b8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Fifth, worldwide health goals should be designed so that they can be pursued within existing health systems and, ideally, contribute to the strengthening of these systems. Although proponents have stated that poliomyelitis eradication strengthens other health services, they and their detractors have used anecdotal information to argue their cases because of a lack of objective criteria and indicators. Of note, some of the largest donors to poliomyelitis eradication are those who are institutionally committed to the strengthening of health systems, but who joined the initiative after reconciliation of concerns about the effect on the delivery of other services. However, proponents of future worldwide health goals should recognise the challenge of measuring such indirect benefits, be modest in arguing their worth, and ensure there are agreed indicators and the capacity and mechanisms for their monitoring.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Reported cases\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Reported cases" ;
            <http://www.example.org/text>  "Fifth, worldwide health goals should be designed so that they can be pursued within existing health systems and, ideally, contribute to the strengthening of these systems. Although proponents have stated that poliomyelitis eradication strengthens other health services, they and their detractors have used anecdotal information to argue their cases because of a lack of objective criteria and indicators. Of note, some of the largest donors to poliomyelitis eradication are those who are institutionally committed to the strengthening of health systems, but who joined the initiative after reconciliation of concerns about the effect on the delivery of other services. However, proponents of future worldwide health goals should recognise the challenge of measuring such indirect benefits, be modest in arguing their worth, and ensure there are agreed indicators and the capacity and mechanisms for their monitoring." ;
            <http://www.example.org/textHash>
                    "aa219b9baecaa806e9ba0cbb77c356bfbcd2561a7e65d644273cb238838837b8" .
    
    <http://covid19.aksw.org/text-ee00bb02570c637c425dcc9f4c80dcfc71f2a69c9662be3d8480a1dca95ba701_citespan-965-967>
            <http://www.example.org/end>    "967.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17" .
    
    <http://covid19.aksw.org/text-4b22f90a96ddcc5a32b26057693f4e3cd1d71ec076a0f0f2d4de6ae8df9015ac_citespan-3081-3083>
            <http://www.example.org/end>    "3083.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "3081.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "36" .
}
<http://covid19.aksw.org/e05286fdb2fa80e08773c24161f3ef5d85a7ef29> {
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Protein synthesis is a highly regulated process that controls mRNA translation. Alterations of this process are associated with the development and progression of cancer. As we described, the components of the translation machinery are regulated by several fundamental signaling pathways that are often disrupted in cancer. Thus, the protein translation process becomes oncogenic. Sonenberg et al. were the first to show the involvement of eIF4E in oncogenesis in 1990. Since then, the oncogenic potential due to eIF4E hyperactivity has been widely described in vitro and in vivo. The overexpression of eIF4E can induce primary epithelial cells and fibroblast transformation. Similarly, an extended overexpression of eIF4E in NIH 3T3 and CHO cell lines leads to an oncogenic transformation and to a metastatic phenotype (Avdulov et al., 2004; De Benedetti \\u0026 Graff, 2004; Zimmer et al., 2000) . In vivo, an eIF4E overexpression leads to lymphoma, angiosarcoma, and lung carcinoma development in transgenic mice (Ruggero et al., 2004) . In addition, it is described to be capable to increase cellular proliferation and inhibit apoptosis (Li et al., 2004; Ruggero et al., 2004; Wendel et al., 2004) . It can act as a survival factor in serum-deprived cells or cells whose ras and c-Myc oncogene expression is deregulated (Li et al., 2003; Polunovsky et al., 2000; Tan et al., 2000) . Upstream signaling pathways that are mutated or amplified in cancers have a direct impact on eIF4E activity. For example, the eIF4E promoter contains two domains that are the oncogene c-Myc\\u0027s targets. The mTOR pathway\\u0027s activation, which occurs in many cancers, also allows the 4E-BP1 phosphorylation and consequently eIF4E hyperactivation. The 4E-BP1 hyperphosphorylation is also associated with malignant progression of breast, ovarian, prostate, and colon cancer (Armengol et al., 2007; Coleman et al., 2009; Graff et al., 2009 ). Finally, an eIF4E level increase was observed in the following human tumors: breast, bladder, colon, lung, skin, head and neck, ovarian, and prostate cancer, compared to healthy tissues (Berkel et al., 2001; Coleman et al., 2009; Crew et al., 2000; Graff et al., 2009; Holm et al., 2008; Matthews-Greer et al., 2005; Nathan et al., 2004; Salehi, Mashayekhi, \\u0026 Shahosseini, 2007; Thumma \\u0026 Kratzke, 2007; Wang et al., 2009) . Although high eIF4E expression levels seem to correlate with aggressive and metastatic tumors and that this protein is given as a diagnostic marker for cancer (Berkel et al., 2001; De Benedetti \\u0026 Graff, 2004; DeFatta, Li, \\u0026 De Benedetti, 2002; Li et al., 2002) , it is not found in some aggressive cancers (Yang et al., 2007) . In breast cancer, it was shown that patients who, after therapy, have low eIF4E levels have a better survival rate (Hiller et al., 2009 ). However, those who have high eIF4E levels have a higher risk of recurrence (Holm et al., 2008) . eIF4E overexpression also leads to the TLK1B protein overexpression that induces resistance to doxorubicin treatment as well as to radiotherapy (Li et al., 2001; Sillje \\u0026 Nigg, 2001) . In prostate cancer, immunohistochemistry studies on 148 tissues showed that eIF4E\\u0027s and 4E-BP1\\u0027s phosphorylated form expressions were significantly increased in the advanced prostate cancer compared to benign hyperplasia (Graff et al., 2009 ). In addition, it has been shown that phosphorylation of eIF4E is required for the translation of several proteins involved in tumorigenesis. Furthermore, phosphorylated eIF4E levels are correlated with pancreas and prostate cancer progression (Baylot et al., 2011; Bianchini et al., 2008; Furic et al., 2010) . Moreover, we previously showed that Hsp27 knockdown leads to eIF4E ubiquitination and degradation by the ubiquitin-proteasome pathway and that a decrease in eIF4E ubiquitination and degradation is associated with resistance to androgen withdrawal and paclitaxel in prostate cancer and gemcitabine in pancreatic cancers (Andrieu et al., 2010; Baylot et al., 2011) . In vivo studies show that blocking eIF4E\\u0027s hyperactivity by inhibiting the mTOR pathway (PP242) causes an inhibition of tumor growth after its formation in a transgenic mouse model developing thymus lymphomas (Hsieh et al., 2010) . All these works demonstrate eIF4E\\u0027s oncogenic potential and the interest of therapeutically targeting this protein\\u0027s activity.\",\"cite_spans\":[{\"start\":381.0,\"end\":397.0,\"text\":\"Sonenberg et al.\"},{\"start\":820.0,\"end\":842.0,\"text\":\"(Avdulov et al., 2004;\",\"ref_id\":\"BIBREF4\"},{\"start\":843.0,\"end\":870.0,\"text\":\"De Benedetti \\u0026 Graff, 2004;\",\"ref_id\":\"BIBREF24\"},{\"start\":871.0,\"end\":891.0,\"text\":\"Zimmer et al., 2000)\",\"ref_id\":\"BIBREF124\"},{\"start\":1010.0,\"end\":1032.0,\"text\":\"(Ruggero et al., 2004)\",\"ref_id\":\"BIBREF92\"},{\"start\":1135.0,\"end\":1152.0,\"text\":\"(Li et al., 2004;\",\"ref_id\":\"BIBREF69\"},{\"start\":1153.0,\"end\":1174.0,\"text\":\"Ruggero et al., 2004;\",\"ref_id\":\"BIBREF92\"},{\"start\":1175.0,\"end\":1195.0,\"text\":\"Wendel et al., 2004)\",\"ref_id\":\"BIBREF119\"},{\"start\":1318.0,\"end\":1335.0,\"text\":\"(Li et al., 2003;\",\"ref_id\":\"BIBREF68\"},{\"start\":1336.0,\"end\":1360.0,\"text\":\"Polunovsky et al., 2000;\",\"ref_id\":\"BIBREF84\"},{\"start\":1361.0,\"end\":1378.0,\"text\":\"Tan et al., 2000)\",\"ref_id\":\"BIBREF104\"},{\"start\":1847.0,\"end\":1870.0,\"text\":\"(Armengol et al., 2007;\",\"ref_id\":\"BIBREF2\"},{\"start\":1871.0,\"end\":1892.0,\"text\":\"Coleman et al., 2009;\",\"ref_id\":\"BIBREF18\"},{\"start\":1893.0,\"end\":1911.0,\"text\":\"Graff et al., 2009\",\"ref_id\":\"BIBREF44\"},{\"start\":2101.0,\"end\":2122.0,\"text\":\"(Berkel et al., 2001;\",\"ref_id\":\"BIBREF7\"},{\"start\":2123.0,\"end\":2144.0,\"text\":\"Coleman et al., 2009;\",\"ref_id\":\"BIBREF18\"},{\"start\":2145.0,\"end\":2163.0,\"text\":\"Crew et al., 2000;\",\"ref_id\":\"BIBREF19\"},{\"start\":2164.0,\"end\":2183.0,\"text\":\"Graff et al., 2009;\",\"ref_id\":\"BIBREF44\"},{\"start\":2184.0,\"end\":2202.0,\"text\":\"Holm et al., 2008;\",\"ref_id\":\"BIBREF50\"},{\"start\":2203.0,\"end\":2231.0,\"text\":\"Matthews-Greer et al., 2005;\",\"ref_id\":\"BIBREF72\"},{\"start\":2232.0,\"end\":2252.0,\"text\":\"Nathan et al., 2004;\",\"ref_id\":\"BIBREF78\"},{\"start\":2253.0,\"end\":2293.0,\"text\":\"Salehi, Mashayekhi, \\u0026 Shahosseini, 2007;\",\"ref_id\":\"BIBREF93\"},{\"start\":2294.0,\"end\":2317.0,\"text\":\"Thumma \\u0026 Kratzke, 2007;\",\"ref_id\":\"BIBREF106\"},{\"start\":2318.0,\"end\":2336.0,\"text\":\"Wang et al., 2009)\",\"ref_id\":\"BIBREF118\"},{\"start\":2498.0,\"end\":2519.0,\"text\":\"(Berkel et al., 2001;\",\"ref_id\":\"BIBREF7\"},{\"start\":2520.0,\"end\":2547.0,\"text\":\"De Benedetti \\u0026 Graff, 2004;\",\"ref_id\":\"BIBREF24\"},{\"start\":2548.0,\"end\":2582.0,\"text\":\"DeFatta, Li, \\u0026 De Benedetti, 2002;\",\"ref_id\":\"BIBREF25\"},{\"start\":2583.0,\"end\":2599.0,\"text\":\"Li et al., 2002)\",\"ref_id\":\"BIBREF67\"},{\"start\":2645.0,\"end\":2664.0,\"text\":\"(Yang et al., 2007)\",\"ref_id\":\"BIBREF122\"},{\"start\":2782.0,\"end\":2802.0,\"text\":\"(Hiller et al., 2009\",\"ref_id\":\"BIBREF49\"},{\"start\":2881.0,\"end\":2900.0,\"text\":\"(Holm et al., 2008)\",\"ref_id\":\"BIBREF50\"},{\"start\":3047.0,\"end\":3064.0,\"text\":\"(Li et al., 2001;\",\"ref_id\":\"BIBREF66\"},{\"start\":3065.0,\"end\":3085.0,\"text\":\"Sillje \\u0026 Nigg, 2001)\",\"ref_id\":\"BIBREF99\"},{\"start\":3309.0,\"end\":3328.0,\"text\":\"(Graff et al., 2009\",\"ref_id\":\"BIBREF44\"},{\"start\":3574.0,\"end\":3595.0,\"text\":\"(Baylot et al., 2011;\",\"ref_id\":\"BIBREF6\"},{\"start\":3596.0,\"end\":3619.0,\"text\":\"Bianchini et al., 2008;\",\"ref_id\":\"BIBREF8\"},{\"start\":3620.0,\"end\":3639.0,\"text\":\"Furic et al., 2010)\",\"ref_id\":\"BIBREF35\"},{\"start\":3961.0,\"end\":3983.0,\"text\":\"(Andrieu et al., 2010;\",\"ref_id\":\"BIBREF1\"},{\"start\":3984.0,\"end\":4004.0,\"text\":\"Baylot et al., 2011)\",\"ref_id\":\"BIBREF6\"},{\"start\":4216.0,\"end\":4236.0,\"text\":\"(Hsieh et al., 2010)\",\"ref_id\":\"BIBREF51\"}],\"ref_spans\":[],\"section\":\"eIF4E in Cancers\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2645-2664> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1175-1195> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3961-3983> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2294-2317> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1010-1032> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-4216-4236> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1135-1152> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2498-2519> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3620-3639> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2881-2900> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2782-2802> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1847-1870> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2164-2183> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2101-2122> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2583-2599> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-871-891> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2520-2547> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3065-3085> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3596-3619> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1361-1378> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2548-2582> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3309-3328> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2123-2144> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2203-2231> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-820-842> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1871-1892> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2253-2293> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1153-1174> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1893-1911> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2232-2252> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1336-1360> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3047-3064> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2184-2202> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3984-4004> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2145-2163> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-843-870> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-381-397> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1318-1335> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3574-3595> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2318-2336> ;
            <http://www.example.org/section>
                    "eIF4E in Cancers" ;
            <http://www.example.org/text>  "Protein synthesis is a highly regulated process that controls mRNA translation. Alterations of this process are associated with the development and progression of cancer. As we described, the components of the translation machinery are regulated by several fundamental signaling pathways that are often disrupted in cancer. Thus, the protein translation process becomes oncogenic. Sonenberg et al. were the first to show the involvement of eIF4E in oncogenesis in 1990. Since then, the oncogenic potential due to eIF4E hyperactivity has been widely described in vitro and in vivo. The overexpression of eIF4E can induce primary epithelial cells and fibroblast transformation. Similarly, an extended overexpression of eIF4E in NIH 3T3 and CHO cell lines leads to an oncogenic transformation and to a metastatic phenotype (Avdulov et al., 2004; De Benedetti & Graff, 2004; Zimmer et al., 2000) . In vivo, an eIF4E overexpression leads to lymphoma, angiosarcoma, and lung carcinoma development in transgenic mice (Ruggero et al., 2004) . In addition, it is described to be capable to increase cellular proliferation and inhibit apoptosis (Li et al., 2004; Ruggero et al., 2004; Wendel et al., 2004) . It can act as a survival factor in serum-deprived cells or cells whose ras and c-Myc oncogene expression is deregulated (Li et al., 2003; Polunovsky et al., 2000; Tan et al., 2000) . Upstream signaling pathways that are mutated or amplified in cancers have a direct impact on eIF4E activity. For example, the eIF4E promoter contains two domains that are the oncogene c-Myc's targets. The mTOR pathway's activation, which occurs in many cancers, also allows the 4E-BP1 phosphorylation and consequently eIF4E hyperactivation. The 4E-BP1 hyperphosphorylation is also associated with malignant progression of breast, ovarian, prostate, and colon cancer (Armengol et al., 2007; Coleman et al., 2009; Graff et al., 2009 ). Finally, an eIF4E level increase was observed in the following human tumors: breast, bladder, colon, lung, skin, head and neck, ovarian, and prostate cancer, compared to healthy tissues (Berkel et al., 2001; Coleman et al., 2009; Crew et al., 2000; Graff et al., 2009; Holm et al., 2008; Matthews-Greer et al., 2005; Nathan et al., 2004; Salehi, Mashayekhi, & Shahosseini, 2007; Thumma & Kratzke, 2007; Wang et al., 2009) . Although high eIF4E expression levels seem to correlate with aggressive and metastatic tumors and that this protein is given as a diagnostic marker for cancer (Berkel et al., 2001; De Benedetti & Graff, 2004; DeFatta, Li, & De Benedetti, 2002; Li et al., 2002) , it is not found in some aggressive cancers (Yang et al., 2007) . In breast cancer, it was shown that patients who, after therapy, have low eIF4E levels have a better survival rate (Hiller et al., 2009 ). However, those who have high eIF4E levels have a higher risk of recurrence (Holm et al., 2008) . eIF4E overexpression also leads to the TLK1B protein overexpression that induces resistance to doxorubicin treatment as well as to radiotherapy (Li et al., 2001; Sillje & Nigg, 2001) . In prostate cancer, immunohistochemistry studies on 148 tissues showed that eIF4E's and 4E-BP1's phosphorylated form expressions were significantly increased in the advanced prostate cancer compared to benign hyperplasia (Graff et al., 2009 ). In addition, it has been shown that phosphorylation of eIF4E is required for the translation of several proteins involved in tumorigenesis. Furthermore, phosphorylated eIF4E levels are correlated with pancreas and prostate cancer progression (Baylot et al., 2011; Bianchini et al., 2008; Furic et al., 2010) . Moreover, we previously showed that Hsp27 knockdown leads to eIF4E ubiquitination and degradation by the ubiquitin-proteasome pathway and that a decrease in eIF4E ubiquitination and degradation is associated with resistance to androgen withdrawal and paclitaxel in prostate cancer and gemcitabine in pancreatic cancers (Andrieu et al., 2010; Baylot et al., 2011) . In vivo studies show that blocking eIF4E's hyperactivity by inhibiting the mTOR pathway (PP242) causes an inhibition of tumor growth after its formation in a transgenic mouse model developing thymus lymphomas (Hsieh et al., 2010) . All these works demonstrate eIF4E's oncogenic potential and the interest of therapeutically targeting this protein's activity." ;
            <http://www.example.org/textHash>
                    "35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1175-1195>
            <http://www.example.org/end>    "1195.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF119" ;
            <http://www.example.org/start>  "1175.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Wendel et al., 2004)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4198-4222>
            <http://www.example.org/end>    "4222.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "4198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Culjkovic et al., 2007)" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1398-1422>
            <http://www.example.org/end>    "1422.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "1398.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Assouline et al., 2009)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1153-1174>
            <http://www.example.org/end>    "1174.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF92" ;
            <http://www.example.org/start>  "1153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ruggero et al., 2004;" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1138-1156>
            <http://www.example.org/end>    "1156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "1138.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fan et al., 2010)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2232-2252>
            <http://www.example.org/end>    "2252.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF78" ;
            <http://www.example.org/start>  "2232.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Nathan et al., 2004;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1847-1870>
            <http://www.example.org/end>    "1870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "1847.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Armengol et al., 2007;" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-239-257>
            <http://www.example.org/end>    "257.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "239.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ghosh et al., 2005" .
    
    <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-527-545>
            <http://www.example.org/end>    "545.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF117" ;
            <http://www.example.org/start>  "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Wang et al., 2005)" .
    
    <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-116-131>
            <http://www.example.org/end>    "131.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF96" ;
            <http://www.example.org/start>  "116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schmidt, 2004)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-843-870>
            <http://www.example.org/end>    "870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "843.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "De Benedetti & Graff, 2004;" .
    
    <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac_citespan-352-375>
            <http://www.example.org/end>    "375.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "352.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Chaudhry et al., 2006)" .
    
    <http://covid19.aksw.org/text-7af57dd65b76cda2d57dd6dc06819c83a9a909c94faf7b5b1fcc26c881e28737>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Cancer cells depend on cap-dependent translation more than normal tissue. This explains the emergence of proteins involved in the cap-dependent translation as targets for potential anticancer drugs. Cap-dependent translation starts when eIF4E binds to mRNA cap domain. This review will present eIF4E\\u0027s structure and functions. It will also expose the use of eIF4E as a therapeutic target in cancer.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "Cancer cells depend on cap-dependent translation more than normal tissue. This explains the emergence of proteins involved in the cap-dependent translation as targets for potential anticancer drugs. Cap-dependent translation starts when eIF4E binds to mRNA cap domain. This review will present eIF4E's structure and functions. It will also expose the use of eIF4E as a therapeutic target in cancer." ;
            <http://www.example.org/textHash>
                    "7af57dd65b76cda2d57dd6dc06819c83a9a909c94faf7b5b1fcc26c881e28737" .
    
    <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"More recently, targeting Hsp27-eIF4E interaction has been described as an interesting alternative strategy to target eIF4E. We previously found that Hsp27 interacts directly with the eukaryotic translational initiation factor eIF4E. Our work demonstrated that Hsp27 interaction protects eIF4E from its degradation by the ubiquitin-proteasome pathways leading to Hsp27 cytoprotection in pancreas and CRPC (Andrieu et al., 2010; Baylot et al., 2011) . Using several Hsp27 deletion mutants, we found that eIF4E interacts with the C-terminal domain of Hsp27. Inhibition of Hsp27-eIF4E interaction using deletion mutants drives resistance to apoptosis induced by gemcitabine in pancreatic cancers (Baylot et al., 2011) and androgen withdrawal and docetaxel in castrate-resistant prostate cancers (unpublished data). This experiment confirmed that this stress-induced cellular pathway is involved in cell death blockade leading to therapy resistance in cancers. Targeting the Hsp27-eIF4E interaction seems to be a promising therapeutic strategy in advanced prostate and pancreatic cancers.\",\"cite_spans\":[{\"start\":404.0,\"end\":426.0,\"text\":\"(Andrieu et al., 2010;\",\"ref_id\":\"BIBREF1\"},{\"start\":427.0,\"end\":447.0,\"text\":\"Baylot et al., 2011)\",\"ref_id\":\"BIBREF6\"},{\"start\":692.0,\"end\":713.0,\"text\":\"(Baylot et al., 2011)\",\"ref_id\":\"BIBREF6\"}],\"ref_spans\":[],\"section\":\"Inhibition of the eIF4E/Hsp27 Interaction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227_citespan-404-426> , <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227_citespan-427-447> , <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227_citespan-692-713> ;
            <http://www.example.org/section>
                    "Inhibition of the eIF4E/Hsp27 Interaction" ;
            <http://www.example.org/text>  "More recently, targeting Hsp27-eIF4E interaction has been described as an interesting alternative strategy to target eIF4E. We previously found that Hsp27 interacts directly with the eukaryotic translational initiation factor eIF4E. Our work demonstrated that Hsp27 interaction protects eIF4E from its degradation by the ubiquitin-proteasome pathways leading to Hsp27 cytoprotection in pancreas and CRPC (Andrieu et al., 2010; Baylot et al., 2011) . Using several Hsp27 deletion mutants, we found that eIF4E interacts with the C-terminal domain of Hsp27. Inhibition of Hsp27-eIF4E interaction using deletion mutants drives resistance to apoptosis induced by gemcitabine in pancreatic cancers (Baylot et al., 2011) and androgen withdrawal and docetaxel in castrate-resistant prostate cancers (unpublished data). This experiment confirmed that this stress-induced cellular pathway is involved in cell death blockade leading to therapy resistance in cancers. Targeting the Hsp27-eIF4E interaction seems to be a promising therapeutic strategy in advanced prostate and pancreatic cancers." ;
            <http://www.example.org/textHash>
                    "a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-1957-1978>
            <http://www.example.org/end>    "1978.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "1957.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Baylot et al., 2011)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-1606-1632>
            <http://www.example.org/end>    "1632.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF80" ;
            <http://www.example.org/start>  "1606.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Niedzwiecka et al., 2002;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-4216-4236>
            <http://www.example.org/end>    "4236.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF51" ;
            <http://www.example.org/start>  "4216.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hsieh et al., 2010)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2101-2122>
            <http://www.example.org/end>    "2122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "2101.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Berkel et al., 2001;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1871-1892>
            <http://www.example.org/end>    "1892.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "1871.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Coleman et al., 2009;" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-209-228>
            <http://www.example.org/end>    "228.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF55" ;
            <http://www.example.org/start>  "209.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Joshi et al. (2005)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-888-909>
            <http://www.example.org/end>    "909.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "888.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Dostie et al., 2000a)" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-211-231>
            <http://www.example.org/end>    "231.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF124" ;
            <http://www.example.org/start>  "211.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Zimmer et al., 2000)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-867-887>
            <http://www.example.org/end>    "887.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "867.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001;" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-975-996>
            <http://www.example.org/end>    "996.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF58" ;
            <http://www.example.org/start>  "975.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kentsis et al., 2004" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-2961-2978>
            <http://www.example.org/end>    "2978.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF82" ;
            <http://www.example.org/start>  "2961.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(O'Farrell, 2001)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3313-3335>
            <http://www.example.org/end>    "3335.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "3313.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dostie et al., 2000a)" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-1346-1369>
            <http://www.example.org/end>    "1369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF94" ;
            <http://www.example.org/start>  "1346.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Scheper & Proud, 2002)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-725-744>
            <http://www.example.org/end>    "744.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "725.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-0a0360bd083c6139c40898a98731b72be82ca2c96be65b59c2806590206a7c76_refspan-202-209>
            <http://www.example.org/end>    "209.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "202.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-460-474>
            <http://www.example.org/end>    "474.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF60" ;
            <http://www.example.org/start>  "460.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kimball, 2001)" .
    
    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-400-421>
            <http://www.example.org/end>    "421.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF61" ;
            <http://www.example.org/start>  "400.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Konicek et al., 2011;" .
    
    <http://covid19.aksw.org/text-ecc2abc2c1414e0cf58429ea4657eb8e4c43e388957470bd98460a639848bd9c_citespan-610-635>
            <http://www.example.org/end>    "635.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF101" ;
            <http://www.example.org/start>  "610.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stoneley & Willis, 2004)" .
    
    <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Serum, growth factors, and the immunologic activation of T lymphocyte lead to an increase in the gene transcription (Schmidt, 2004) . There are also consensus binding sites to transcription factors (such as c-Myc and hnRNPK) that are involved in the control of the gene transcription in response to stimuli (Lynch et al., 2005) . For example, 4E-BP1 has at least seven phosphorylation sites among which four are known to be regulated by signaling pathways such as mTOR (Gingras, Raught, \\u0026 Sonenberg, 2001; Heesom et al., 2001; Wang et al., 2005) . When c-Myc is overexpressed, due to growth factors, eIF4E\\u0027s expression rises.\",\"cite_spans\":[{\"start\":116.0,\"end\":131.0,\"text\":\"(Schmidt, 2004)\",\"ref_id\":\"BIBREF96\"},{\"start\":307.0,\"end\":327.0,\"text\":\"(Lynch et al., 2005)\",\"ref_id\":\"BIBREF70\"},{\"start\":469.0,\"end\":505.0,\"text\":\"(Gingras, Raught, \\u0026 Sonenberg, 2001;\",\"ref_id\":\"BIBREF39\"},{\"start\":506.0,\"end\":526.0,\"text\":\"Heesom et al., 2001;\",\"ref_id\":\"BIBREF46\"},{\"start\":527.0,\"end\":545.0,\"text\":\"Wang et al., 2005)\",\"ref_id\":\"BIBREF117\"}],\"ref_spans\":[],\"section\":\"Transcription Levels\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-116-131> , <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-307-327> , <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-469-505> , <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-506-526> , <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-527-545> ;
            <http://www.example.org/section>
                    "Transcription Levels" ;
            <http://www.example.org/text>  "Serum, growth factors, and the immunologic activation of T lymphocyte lead to an increase in the gene transcription (Schmidt, 2004) . There are also consensus binding sites to transcription factors (such as c-Myc and hnRNPK) that are involved in the control of the gene transcription in response to stimuli (Lynch et al., 2005) . For example, 4E-BP1 has at least seven phosphorylation sites among which four are known to be regulated by signaling pathways such as mTOR (Gingras, Raught, & Sonenberg, 2001; Heesom et al., 2001; Wang et al., 2005) . When c-Myc is overexpressed, due to growth factors, eIF4E's expression rises." ;
            <http://www.example.org/textHash>
                    "a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-500-527>
            <http://www.example.org/end>    "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF76" ;
            <http://www.example.org/start>  "500.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Murata & Shimotohno, 2006;" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-996-1027>
            <http://www.example.org/end>    "1027.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "996.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cuesta, Xi, & Schneider, 2000)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2498-2519>
            <http://www.example.org/end>    "2519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "2498.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Berkel et al., 2001;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4012-4031>
            <http://www.example.org/end>    "4031.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "4012.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Another strategy is based on inhibition of the synthesis of mRNA cap analogs that would compete with the eIF4FE/cap interaction and block it (Quiocho, Hu, \\u0026 Gershon, 2000) . A series of cap analogs have been developed (Brown et al., 2007; Ghosh et al., 2005 Ghosh et al., , 2009 Kowalska et al., 2009 ), but only ribavirin is currently used (Fig. 6C) . Indeed, using these analogs as drugs is difficult because of the low membrane permeability, due to the nature of the extremely charged phosphate groups, and the metabolic lability, due to the instability of the glycosidic bond. Ribavirin is a broadspectrum antiviral drug used for the treatment of hepatitis C. The similarities between ribavirin structure and mRNA cap have suggested that this drug can act as an eIF4E inhibitor by mimicking the cap. Later studies showed that ribavirin interacts with eIF4E and prevents it from binding to the mRNA cap. This inhibits the cap-dependent translation and cell transformation (Kentsis et al., 2004 (Kentsis et al., , 2005 Tan et al., 2008) . However, questions arise as to the specificity of action of ribavirin on eIF4E and studies are controversial (Westman et al., 2005; Yan et al., 2005) . Nevertheless, this molecule is currently in a clinical trial phase II in the treatment of acute myeloid leukemia and the first clinical results show that it stabilized or at least partially cured patients (Assouline et al., 2009) . This study was the first to show that the capdependent translation inhibition has a clinical utility in cancers that overexpress eIF4E (Borden \\u0026 Culjkovic-Kraljacic, 2010) .\",\"cite_spans\":[{\"start\":141.0,\"end\":171.0,\"text\":\"(Quiocho, Hu, \\u0026 Gershon, 2000)\",\"ref_id\":\"BIBREF86\"},{\"start\":218.0,\"end\":238.0,\"text\":\"(Brown et al., 2007;\",\"ref_id\":\"BIBREF11\"},{\"start\":239.0,\"end\":257.0,\"text\":\"Ghosh et al., 2005\",\"ref_id\":\"BIBREF37\"},{\"start\":258.0,\"end\":278.0,\"text\":\"Ghosh et al., , 2009\",\"ref_id\":\"BIBREF38\"},{\"start\":279.0,\"end\":300.0,\"text\":\"Kowalska et al., 2009\",\"ref_id\":\"BIBREF62\"},{\"start\":975.0,\"end\":996.0,\"text\":\"(Kentsis et al., 2004\",\"ref_id\":\"BIBREF58\"},{\"start\":997.0,\"end\":1020.0,\"text\":\"(Kentsis et al., , 2005\",\"ref_id\":\"BIBREF59\"},{\"start\":1021.0,\"end\":1038.0,\"text\":\"Tan et al., 2008)\",\"ref_id\":\"BIBREF105\"},{\"start\":1150.0,\"end\":1172.0,\"text\":\"(Westman et al., 2005;\",\"ref_id\":\"BIBREF120\"},{\"start\":1173.0,\"end\":1190.0,\"text\":\"Yan et al., 2005)\",\"ref_id\":\"BIBREF121\"},{\"start\":1398.0,\"end\":1422.0,\"text\":\"(Assouline et al., 2009)\",\"ref_id\":\"BIBREF3\"},{\"start\":1560.0,\"end\":1596.0,\"text\":\"(Borden \\u0026 Culjkovic-Kraljacic, 2010)\",\"ref_id\":\"BIBREF10\"}],\"ref_spans\":[{\"start\":341.0,\"end\":350.0,\"text\":\"(Fig. 6C)\"}],\"section\":\"mRNA Cap Analogs\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1560-1596> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1173-1190> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1398-1422> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-218-238> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-997-1020> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-258-278> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-279-300> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-975-996> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1021-1038> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1150-1172> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-141-171> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-239-257> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_refspan-341-350> ;
            <http://www.example.org/section>
                    "mRNA Cap Analogs" ;
            <http://www.example.org/text>  "Another strategy is based on inhibition of the synthesis of mRNA cap analogs that would compete with the eIF4FE/cap interaction and block it (Quiocho, Hu, & Gershon, 2000) . A series of cap analogs have been developed (Brown et al., 2007; Ghosh et al., 2005 Ghosh et al., , 2009 Kowalska et al., 2009 ), but only ribavirin is currently used (Fig. 6C) . Indeed, using these analogs as drugs is difficult because of the low membrane permeability, due to the nature of the extremely charged phosphate groups, and the metabolic lability, due to the instability of the glycosidic bond. Ribavirin is a broadspectrum antiviral drug used for the treatment of hepatitis C. The similarities between ribavirin structure and mRNA cap have suggested that this drug can act as an eIF4E inhibitor by mimicking the cap. Later studies showed that ribavirin interacts with eIF4E and prevents it from binding to the mRNA cap. This inhibits the cap-dependent translation and cell transformation (Kentsis et al., 2004 (Kentsis et al., , 2005 Tan et al., 2008) . However, questions arise as to the specificity of action of ribavirin on eIF4E and studies are controversial (Westman et al., 2005; Yan et al., 2005) . Nevertheless, this molecule is currently in a clinical trial phase II in the treatment of acute myeloid leukemia and the first clinical results show that it stabilized or at least partially cured patients (Assouline et al., 2009) . This study was the first to show that the capdependent translation inhibition has a clinical utility in cancers that overexpress eIF4E (Borden & Culjkovic-Kraljacic, 2010) ." ;
            <http://www.example.org/textHash>
                    "2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5" .
    
    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"As mentioned earlier, signaling pathway upstream of eIF4E is also involved in tumorigenesis and represent therapeutic targets. Thus, several inhibitors have been developed to target these components and indirectly eIF4E, such as Mnk kinase inhibitors (cercosporamide) and mTOR pathway inhibitors (rapamycin, temsirolimus, etc.) (Choo et al., 2008; Feldman et al., 2009; Garcia-Martinez et al., 2009; Konicek et al., 2011; Yu et al., 2010) . In 2007, temsirolimus was approved by the FDA for the treatment of patients with advanced renal-cell cancer, as trials demonstrated that it had significantly outperformed the standard of care in terms of progression-free survival and overall survival by 2.4 and 3.6 months, respectively. Furthermore, preclinical evaluation of two TORKinibs (second-generation small-molecule inhibitors), PP242 and PP30, demonstrates stronger inhibition of protein synthesis and cell proliferation than sirolimus (Blagden \\u0026 Willis, 2011) .\",\"cite_spans\":[{\"start\":328.0,\"end\":347.0,\"text\":\"(Choo et al., 2008;\",\"ref_id\":\"BIBREF16\"},{\"start\":348.0,\"end\":369.0,\"text\":\"Feldman et al., 2009;\",\"ref_id\":\"BIBREF34\"},{\"start\":370.0,\"end\":399.0,\"text\":\"Garcia-Martinez et al., 2009;\",\"ref_id\":\"BIBREF36\"},{\"start\":400.0,\"end\":421.0,\"text\":\"Konicek et al., 2011;\",\"ref_id\":\"BIBREF61\"},{\"start\":422.0,\"end\":438.0,\"text\":\"Yu et al., 2010)\",\"ref_id\":\"BIBREF123\"},{\"start\":937.0,\"end\":961.0,\"text\":\"(Blagden \\u0026 Willis, 2011)\",\"ref_id\":\"BIBREF9\"}],\"ref_spans\":[],\"section\":\"eIF4E Upstream Pathway Inhibitors\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-400-421> , <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-328-347> , <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-348-369> , <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-422-438> , <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-370-399> , <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-937-961> ;
            <http://www.example.org/section>
                    "eIF4E Upstream Pathway Inhibitors" ;
            <http://www.example.org/text>  "As mentioned earlier, signaling pathway upstream of eIF4E is also involved in tumorigenesis and represent therapeutic targets. Thus, several inhibitors have been developed to target these components and indirectly eIF4E, such as Mnk kinase inhibitors (cercosporamide) and mTOR pathway inhibitors (rapamycin, temsirolimus, etc.) (Choo et al., 2008; Feldman et al., 2009; Garcia-Martinez et al., 2009; Konicek et al., 2011; Yu et al., 2010) . In 2007, temsirolimus was approved by the FDA for the treatment of patients with advanced renal-cell cancer, as trials demonstrated that it had significantly outperformed the standard of care in terms of progression-free survival and overall survival by 2.4 and 3.6 months, respectively. Furthermore, preclinical evaluation of two TORKinibs (second-generation small-molecule inhibitors), PP242 and PP30, demonstrates stronger inhibition of protein synthesis and cell proliferation than sirolimus (Blagden & Willis, 2011) ." ;
            <http://www.example.org/textHash>
                    "3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-218-238>
            <http://www.example.org/end>    "238.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "218.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Brown et al., 2007;" .
    
    <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-506-526>
            <http://www.example.org/end>    "526.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF46" ;
            <http://www.example.org/start>  "506.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Heesom et al., 2001;" .
    
    <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-307-327>
            <http://www.example.org/end>    "327.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF70" ;
            <http://www.example.org/start>  "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lynch et al., 2005)" .
    
    <http://covid19.aksw.org/text-85d8d4a62bb547bd45fa23ed5d37b334e392f5811256d1adf2e86fc6fbd927b1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Figure 3 eIF4E\\u0027s implication in the mRNA translation initiation. The translation initiation of most mRNAs occurs due to a cap-dependent mechanism that involves eIF4E. This mechanism is regulated by eIF4E\\u0027s phosphorylation by Mnk proteins, as well as by 4E-BP factors. ? ¼ activator or repressor role of eIF4E phosphorylation on translation.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"4E-BP\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "4E-BP" ;
            <http://www.example.org/text>  "Figure 3 eIF4E's implication in the mRNA translation initiation. The translation initiation of most mRNAs occurs due to a cap-dependent mechanism that involves eIF4E. This mechanism is regulated by eIF4E's phosphorylation by Mnk proteins, as well as by 4E-BP factors. ? ¼ activator or repressor role of eIF4E phosphorylation on translation." ;
            <http://www.example.org/textHash>
                    "85d8d4a62bb547bd45fa23ed5d37b334e392f5811256d1adf2e86fc6fbd927b1" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3202-3221>
            <http://www.example.org/end>    "3221.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "3202.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-ecc2abc2c1414e0cf58429ea4657eb8e4c43e388957470bd98460a639848bd9c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are two types of mRNA translation initiation: the cap-dependent translation initiation and the cap-independent translation initiation. Furthermore, there is another mRNA category (10%) that is translated in a cap-and eIF4E-independent manner. These mRNAs have a structure called \\\"IRES\\\" (internal ribosome entry sites) that allows the ribosome\\u0027s 40S subunit to bind directly. Originally identified as a translation mechanism of viral genes, it is now identified as playing an important role during the death cell\\u0027s process, mitosis, and stress conditions, where cap-dependent protein synthesis is reduced (Stoneley \\u0026 Willis, 2004) .\",\"cite_spans\":[{\"start\":610.0,\"end\":635.0,\"text\":\"(Stoneley \\u0026 Willis, 2004)\",\"ref_id\":\"BIBREF101\"}],\"ref_spans\":[],\"section\":\"mRNA Translation Initiation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ecc2abc2c1414e0cf58429ea4657eb8e4c43e388957470bd98460a639848bd9c_citespan-610-635> ;
            <http://www.example.org/section>
                    "mRNA Translation Initiation" ;
            <http://www.example.org/text>  "There are two types of mRNA translation initiation: the cap-dependent translation initiation and the cap-independent translation initiation. Furthermore, there is another mRNA category (10%) that is translated in a cap-and eIF4E-independent manner. These mRNAs have a structure called \"IRES\" (internal ribosome entry sites) that allows the ribosome's 40S subunit to bind directly. Originally identified as a translation mechanism of viral genes, it is now identified as playing an important role during the death cell's process, mitosis, and stress conditions, where cap-dependent protein synthesis is reduced (Stoneley & Willis, 2004) ." ;
            <http://www.example.org/textHash>
                    "ecc2abc2c1414e0cf58429ea4657eb8e4c43e388957470bd98460a639848bd9c" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1995-2017>
            <http://www.example.org/end>    "2017.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF14" ;
            <http://www.example.org/start>  "1995.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cencic et al., 2011b)" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-595-617>
            <http://www.example.org/end>    "617.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF111" ;
            <http://www.example.org/start>  "595.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tschopp et al., 2000)" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-289-328>
            <http://www.example.org/end>    "328.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "289.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(DeFatta, Nathan, & De Benedetti, 2000)" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The protein family 4E-BP regulates eIF4E capacity to form the cap-binding complex (eIF4F). Currently, three 4E-BPs are known in mammals: 4E-BP1, 4E-BP2, and 4E-BP3. Their interaction strength is regulated by phosphorylation. The 4E-BPs are phosphorylated in response to growth factors, amino acids, or hormones such as insulin which activates the mTOR pathway (molecular target of rapamycin) (Fig. 3) (Gingras et al., 2001; Gingras, Raught, \\u0026 Sonenberg, 2004; Kimball, 2001) . For example, 4E-BP1 has at least seven phosphorylation sites, among which four are known to be regulated by signaling pathways such as mTOR (Gingras et al., 2001; Heesom et al., 2001; Wang et al., 2005) . In contrast, hypoxia induces a phosphorylation decrease in 4E-BP1 (Shenberger et al., 2005) . When 4E-BPs are hypophosphorylated, they can sequestrate eIF4E and There are also consensus binding sites to transcription factors (such as c-Myc and hnRNPK) that are involved in the control of the gene transcription in response to stimuli. When c-Myc is overexpressed, eIF4E\\u0027s expression rises. eIF4E\\u0027s overexpression leads to a selective increase in the translation of mRNAs that have a structure called \\\"sensible to eIF4E elements\\\" and that are involved in tumorigenesis.\",\"cite_spans\":[{\"start\":401.0,\"end\":423.0,\"text\":\"(Gingras et al., 2001;\",\"ref_id\":\"BIBREF39\"},{\"start\":424.0,\"end\":459.0,\"text\":\"Gingras, Raught, \\u0026 Sonenberg, 2004;\",\"ref_id\":\"BIBREF40\"},{\"start\":460.0,\"end\":474.0,\"text\":\"Kimball, 2001)\",\"ref_id\":\"BIBREF60\"},{\"start\":617.0,\"end\":639.0,\"text\":\"(Gingras et al., 2001;\",\"ref_id\":\"BIBREF39\"},{\"start\":640.0,\"end\":660.0,\"text\":\"Heesom et al., 2001;\",\"ref_id\":\"BIBREF46\"},{\"start\":661.0,\"end\":679.0,\"text\":\"Wang et al., 2005)\",\"ref_id\":\"BIBREF117\"},{\"start\":748.0,\"end\":773.0,\"text\":\"(Shenberger et al., 2005)\",\"ref_id\":\"BIBREF97\"}],\"ref_spans\":[{\"start\":392.0,\"end\":400.0,\"text\":\"(Fig. 3)\"}],\"section\":\"4E-BP\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-661-679> , <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-401-423> , <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-617-639> , <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-748-773> , <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-460-474> , <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-424-459> , <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-640-660> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_refspan-392-400> ;
            <http://www.example.org/section>
                    "4E-BP" ;
            <http://www.example.org/text>  "The protein family 4E-BP regulates eIF4E capacity to form the cap-binding complex (eIF4F). Currently, three 4E-BPs are known in mammals: 4E-BP1, 4E-BP2, and 4E-BP3. Their interaction strength is regulated by phosphorylation. The 4E-BPs are phosphorylated in response to growth factors, amino acids, or hormones such as insulin which activates the mTOR pathway (molecular target of rapamycin) (Fig. 3) (Gingras et al., 2001; Gingras, Raught, & Sonenberg, 2004; Kimball, 2001) . For example, 4E-BP1 has at least seven phosphorylation sites, among which four are known to be regulated by signaling pathways such as mTOR (Gingras et al., 2001; Heesom et al., 2001; Wang et al., 2005) . In contrast, hypoxia induces a phosphorylation decrease in 4E-BP1 (Shenberger et al., 2005) . When 4E-BPs are hypophosphorylated, they can sequestrate eIF4E and There are also consensus binding sites to transcription factors (such as c-Myc and hnRNPK) that are involved in the control of the gene transcription in response to stimuli. When c-Myc is overexpressed, eIF4E's expression rises. eIF4E's overexpression leads to a selective increase in the translation of mRNAs that have a structure called \"sensible to eIF4E elements\" and that are involved in tumorigenesis." ;
            <http://www.example.org/textHash>
                    "d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633" .
    
    <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-84-112>
            <http://www.example.org/end>    "112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF88" ;
            <http://www.example.org/start>  "84.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Richter and Sonenberg (2005)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3984-4004>
            <http://www.example.org/end>    "4004.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "3984.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Baylot et al., 2011)" .
    
    <http://covid19.aksw.org/text-d9682aa5f2491a2546ef2daca7ed8531916e76ca4b2f5e35237c4dc0a58048ff_citespan-468-496>
            <http://www.example.org/end>    "496.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF113" ;
            <http://www.example.org/start>  "468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Van Der Kelen et al., 2009)" .
    
    <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227_citespan-427-447>
            <http://www.example.org/end>    "447.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "427.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Baylot et al., 2011)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-1633-1670>
            <http://www.example.org/end>    "1670.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF116" ;
            <http://www.example.org/start>  "1633.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "von Der Haar, Ball, & McCarthy, 2000)" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The translation initiation of most cellular mRNAs takes place due to a capdependent mechanism. The 7-methylguanosine (m7GDP) structure (also called cap) is located on the 5 0 extremity of the cytoplasmic mRNAs that process a cap-dependent translational process. It is a posttranscriptional modification introduced by the successive action of several nuclear enzymes. The cap has many roles. It protects the mRNA against degradation by ribonuclease, it intervenes in the nuclear export, and it allows the ribosome recruitment. In fact, this structure is specifically recognized by eIF4E, enabling recruitment of the eIF4F complex to bind to the cap (Fig. 3) . This complex is formed by eIF4E associated to eIF4A and eIF4G and allows the recruitment of the ribosome on the mRNAs. The protein eIF4A is a helicase that catalyzes the separation of the paired strands of the RNA, in an ATP-dependent manner. Its activity is slow and requires stimulation by eIF4B/eIF4H and eIF4G (Rogers, Komar, \\u0026 Merrick, 2002) . The protein eIF4G acts like a scaffolding protein by linking the mRNA to the 40S subunit of the ribosome through its interaction with eIF3, which stabilizes the complex (Gross et al., 2003; Prevot, Darlix, \\u0026 Ohlmann, 2003) . This step leads to the recruitment of the preinitiation complex 43S (40S + eIF3 + eIF1 + eIF1A + eIF5 + eIF2-GTP-Met-tRNAi) on the mRNA cap and to the formation of the initiation complex 48S (ARNm + 43S + eIF4F) (Fig. 3) . The mRNA is then scanned in the 5 0 -3 0 direction in order to find the start codon (Kozak, 2002) . This is due to the following initiation factors: eIF1, eIF1A, eIF5, and the complex eIF2-GTP-Met-tRNAi. Once the initiation codon is located, eIF5 interacts with eIF2 and promotes the intrinsic hydrolysis of the GTP associated to eIF2. This hydrolysis leads to the detachment of the initiation factor from the ribosome\\u0027s subunit 40S and to the recruitment of the 60S subunit resulting in the formation of the 80S complex (Fig. 3) . The protein synthesis can now begin. The 5 0 and 3 0 UTR extremities (untranslated region) also play an important role in the translation initiation mechanism. In fact, on the 5 0 extremity, the sequence surrounding the start codon plays a role in the initiation site selection by the 48S complex and gives an indication about the translation efficiency that might be weak or strong. In mammals, the Kozak sequence is the best sequence to initiate translation. At the 3 0 extremity, the poly-A tail is capable of interacting with the cap in 5 0 through the PABPs (polyadenylate-binding proteins) (Fig. 3) . This interaction promotes the ribosome\\u0027s 40S subunit recruitment through direct interaction between PABPs and eIF4G. This interaction gives a circular conformation to the mRNA which improves the translation initiation. So the eIF4E protein plays a major role in mRNA cap-dependent translation regulation (Sonenberg, 2008) and therefore in the cell cycle progression (O\\u0027Farrell, 2001) .\",\"cite_spans\":[{\"start\":973.0,\"end\":1005.0,\"text\":\"(Rogers, Komar, \\u0026 Merrick, 2002)\",\"ref_id\":\"BIBREF90\"},{\"start\":1177.0,\"end\":1197.0,\"text\":\"(Gross et al., 2003;\",\"ref_id\":\"BIBREF45\"},{\"start\":1198.0,\"end\":1230.0,\"text\":\"Prevot, Darlix, \\u0026 Ohlmann, 2003)\",\"ref_id\":\"BIBREF85\"},{\"start\":1540.0,\"end\":1553.0,\"text\":\"(Kozak, 2002)\",\"ref_id\":\"BIBREF63\"},{\"start\":2899.0,\"end\":2916.0,\"text\":\"(Sonenberg, 2008)\",\"ref_id\":\"BIBREF100\"},{\"start\":2961.0,\"end\":2978.0,\"text\":\"(O\\u0027Farrell, 2001)\",\"ref_id\":\"BIBREF82\"}],\"ref_spans\":[{\"start\":648.0,\"end\":656.0,\"text\":\"(Fig. 3)\"},{\"start\":1445.0,\"end\":1453.0,\"text\":\"(Fig. 3)\"},{\"start\":1977.0,\"end\":1985.0,\"text\":\"(Fig. 3)\"},{\"start\":2584.0,\"end\":2592.0,\"text\":\"(Fig. 3)\"}],\"section\":\"The CaP-Dependent Translation Initiation Mechanism\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-973-1005> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-2961-2978> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-2899-2916> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-1198-1230> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-1540-1553> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-1177-1197> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-1977-1985> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-1445-1453> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-648-656> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-2584-2592> ;
            <http://www.example.org/section>
                    "The CaP-Dependent Translation Initiation Mechanism" ;
            <http://www.example.org/text>  "The translation initiation of most cellular mRNAs takes place due to a capdependent mechanism. The 7-methylguanosine (m7GDP) structure (also called cap) is located on the 5 0 extremity of the cytoplasmic mRNAs that process a cap-dependent translational process. It is a posttranscriptional modification introduced by the successive action of several nuclear enzymes. The cap has many roles. It protects the mRNA against degradation by ribonuclease, it intervenes in the nuclear export, and it allows the ribosome recruitment. In fact, this structure is specifically recognized by eIF4E, enabling recruitment of the eIF4F complex to bind to the cap (Fig. 3) . This complex is formed by eIF4E associated to eIF4A and eIF4G and allows the recruitment of the ribosome on the mRNAs. The protein eIF4A is a helicase that catalyzes the separation of the paired strands of the RNA, in an ATP-dependent manner. Its activity is slow and requires stimulation by eIF4B/eIF4H and eIF4G (Rogers, Komar, & Merrick, 2002) . The protein eIF4G acts like a scaffolding protein by linking the mRNA to the 40S subunit of the ribosome through its interaction with eIF3, which stabilizes the complex (Gross et al., 2003; Prevot, Darlix, & Ohlmann, 2003) . This step leads to the recruitment of the preinitiation complex 43S (40S + eIF3 + eIF1 + eIF1A + eIF5 + eIF2-GTP-Met-tRNAi) on the mRNA cap and to the formation of the initiation complex 48S (ARNm + 43S + eIF4F) (Fig. 3) . The mRNA is then scanned in the 5 0 -3 0 direction in order to find the start codon (Kozak, 2002) . This is due to the following initiation factors: eIF1, eIF1A, eIF5, and the complex eIF2-GTP-Met-tRNAi. Once the initiation codon is located, eIF5 interacts with eIF2 and promotes the intrinsic hydrolysis of the GTP associated to eIF2. This hydrolysis leads to the detachment of the initiation factor from the ribosome's subunit 40S and to the recruitment of the 60S subunit resulting in the formation of the 80S complex (Fig. 3) . The protein synthesis can now begin. The 5 0 and 3 0 UTR extremities (untranslated region) also play an important role in the translation initiation mechanism. In fact, on the 5 0 extremity, the sequence surrounding the start codon plays a role in the initiation site selection by the 48S complex and gives an indication about the translation efficiency that might be weak or strong. In mammals, the Kozak sequence is the best sequence to initiate translation. At the 3 0 extremity, the poly-A tail is capable of interacting with the cap in 5 0 through the PABPs (polyadenylate-binding proteins) (Fig. 3) . This interaction promotes the ribosome's 40S subunit recruitment through direct interaction between PABPs and eIF4G. This interaction gives a circular conformation to the mRNA which improves the translation initiation. So the eIF4E protein plays a major role in mRNA cap-dependent translation regulation (Sonenberg, 2008) and therefore in the cell cycle progression (O'Farrell, 2001) ." ;
            <http://www.example.org/textHash>
                    "6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3065-3085>
            <http://www.example.org/end>    "3085.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF99" ;
            <http://www.example.org/start>  "3065.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sillje & Nigg, 2001)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3990-4011>
            <http://www.example.org/end>    "4011.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF57" ;
            <http://www.example.org/start>  "3990.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kentsis et al., 2001;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2548-2582>
            <http://www.example.org/end>    "2582.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "2548.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "DeFatta, Li, & De Benedetti, 2002;" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-174-195>
            <http://www.example.org/end>    "195.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF71" ;
            <http://www.example.org/start>  "174.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Mamane et al., 2004;" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2307-2327>
            <http://www.example.org/end>    "2327.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF114" ;
            <http://www.example.org/start>  "2307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Volpon et al., 2006;" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1173-1190>
            <http://www.example.org/end>    "1190.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF121" ;
            <http://www.example.org/start>  "1173.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Yan et al., 2005)" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-1699-1723>
            <http://www.example.org/end>    "1723.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF98" ;
            <http://www.example.org/start>  "1699.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Shveygert et al., 2010)" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-911-932>
            <http://www.example.org/end>    "932.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "911.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Andrieu et al. showed" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1113-1147>
            <http://www.example.org/end>    "1147.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "1113.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Evsikov & Marin de Evsikova, 2009;" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-514-535>
            <http://www.example.org/end>    "535.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF54" ;
            <http://www.example.org/start>  "514.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "( Joshi et al., 2004;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1010-1032>
            <http://www.example.org/end>    "1032.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF92" ;
            <http://www.example.org/start>  "1010.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ruggero et al., 2004)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-999-1008>
            <http://www.example.org/end>    "1008.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "999.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1B)" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-196-210>
            <http://www.example.org/end>    "210.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF96" ;
            <http://www.example.org/start>  "196.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schmidt, 2004;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3047-3064>
            <http://www.example.org/end>    "3064.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF66" ;
            <http://www.example.org/start>  "3047.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Li et al., 2001;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1893-1911>
            <http://www.example.org/end>    "1911.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "1893.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Graff et al., 2009" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-381-397>
            <http://www.example.org/end>    "397.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "381.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sonenberg et al." .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_refspan-392-400>
            <http://www.example.org/end>    "400.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "392.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3)" .
    
    <http://covid19.aksw.org/text-435feb00930a2d0a735628bc218d72dea9f94c6f8c1ae12e6df1a87717db82e6_citespan-842-862>
            <http://www.example.org/end>    "862.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "842.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Graff et al., 2008)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-685-724>
            <http://www.example.org/end>    "724.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "685.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Dostie, Lejbkowicz, & Sonenberg, 2000a;" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2260-2306>
            <http://www.example.org/end>    "2306.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF79" ;
            <http://www.example.org/start>  "2260.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Niedzwiecka, Darzynkiewicz, & Stolarski, 2004;" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-401-423>
            <http://www.example.org/end>    "423.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gingras et al., 2001;" .
    
    <http://covid19.aksw.org/text-e6c1540fe257c69bae2387ba04eecccffb4fa14f2599ccbdb3621ff1756b0508_citespan-487-506>
            <http://www.example.org/end>    "506.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "487.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Graff et al. (2008)" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-1147-1170>
            <http://www.example.org/end>    "1170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1147.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Banerjee et al., 2002)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2782-2802>
            <http://www.example.org/end>    "2802.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF49" ;
            <http://www.example.org/start>  "2782.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hiller et al., 2009" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-1541-1563>
            <http://www.example.org/end>    "1563.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "1541.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Andrieu et al., 2010)" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_refspan-500-508>
            <http://www.example.org/end>    "508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "500.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Figure 6" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In mammals, eIF4E is phosphorylated at the 209th serine residue located in a C-terminal motif which is conserved in all species except for plants and S. cerevisiae. The Mnk1 and Mnk2 kinases (MAPK-integrating kinases) (Ueda et al., 2004) bind to the C-terminal end of eIF4G, to be close to eIF4E to phosphorylate it. These kinases are themselves activated by phosphorylation realized by the Erk kinase (extracellular signal-regulated kinase) and by the p38 MAP kinase (Fig. 2) (Scheper et al., 2001) . Growth factors, phorbol esters, and insulin can activate the Mnk kinases via the Erk pathway (Tschopp et al., 2000) . Cytokines and some stress conditions can activate the p38 MAP kinase pathway. Phosphorylation can also be regulated during viral infection. For example, during an adenovirus infection, eIF4E is dephosphorylated because the 100K viral protein binds to eIF4G and moves the Mnk kinases from the eIF4F complex. The same phenomenon was observed during an influenza virus infection (Cuesta, Xi, \\u0026 Schneider, 2000) . However, a coronavirus infection activates Mnk1 and increases eIF4E\\u0027s phosphorylation via the p38 MaP kinase pathway (Banerjee et al., 2002) . Although eIF4E\\u0027s phosphorylation mechanism is known, the consequences of this phosphorylation on translation initiation are still unclear and depend on the cellular context (Scheper \\u0026 Proud, 2002) . By a modulation of the Mnk-eIF4G interaction, eIF4E\\u0027s phosphorylation is controlled: eIF4G binding is controlled by MAPK-mediated phosphorylation of the Mnk1 active site. Furthermore in the absence of MAPK signaling, eIF4E phosphorylation is prevented by the C-terminal domain of Mnk1 that restricts its interaction with eIF4G (Shveygert et al., 2010) .\",\"cite_spans\":[{\"start\":218.0,\"end\":237.0,\"text\":\"(Ueda et al., 2004)\",\"ref_id\":\"BIBREF112\"},{\"start\":477.0,\"end\":499.0,\"text\":\"(Scheper et al., 2001)\",\"ref_id\":\"BIBREF95\"},{\"start\":595.0,\"end\":617.0,\"text\":\"(Tschopp et al., 2000)\",\"ref_id\":\"BIBREF111\"},{\"start\":996.0,\"end\":1027.0,\"text\":\"(Cuesta, Xi, \\u0026 Schneider, 2000)\",\"ref_id\":\"BIBREF20\"},{\"start\":1147.0,\"end\":1170.0,\"text\":\"(Banerjee et al., 2002)\",\"ref_id\":\"BIBREF5\"},{\"start\":1346.0,\"end\":1369.0,\"text\":\"(Scheper \\u0026 Proud, 2002)\",\"ref_id\":\"BIBREF94\"},{\"start\":1699.0,\"end\":1723.0,\"text\":\"(Shveygert et al., 2010)\",\"ref_id\":\"BIBREF98\"}],\"ref_spans\":[{\"start\":468.0,\"end\":476.0,\"text\":\"(Fig. 2)\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Phosphorylation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-1147-1170> , <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-996-1027> , <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-1699-1723> , <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-595-617> , <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-218-237> , <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-1346-1369> , <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-477-499> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_refspan-468-476> ;
            <http://www.example.org/section>
                    "Phosphorylation" ;
            <http://www.example.org/text>  "In mammals, eIF4E is phosphorylated at the 209th serine residue located in a C-terminal motif which is conserved in all species except for plants and S. cerevisiae. The Mnk1 and Mnk2 kinases (MAPK-integrating kinases) (Ueda et al., 2004) bind to the C-terminal end of eIF4G, to be close to eIF4E to phosphorylate it. These kinases are themselves activated by phosphorylation realized by the Erk kinase (extracellular signal-regulated kinase) and by the p38 MAP kinase (Fig. 2) (Scheper et al., 2001) . Growth factors, phorbol esters, and insulin can activate the Mnk kinases via the Erk pathway (Tschopp et al., 2000) . Cytokines and some stress conditions can activate the p38 MAP kinase pathway. Phosphorylation can also be regulated during viral infection. For example, during an adenovirus infection, eIF4E is dephosphorylated because the 100K viral protein binds to eIF4G and moves the Mnk kinases from the eIF4F complex. The same phenomenon was observed during an influenza virus infection (Cuesta, Xi, & Schneider, 2000) . However, a coronavirus infection activates Mnk1 and increases eIF4E's phosphorylation via the p38 MaP kinase pathway (Banerjee et al., 2002) . Although eIF4E's phosphorylation mechanism is known, the consequences of this phosphorylation on translation initiation are still unclear and depend on the cellular context (Scheper & Proud, 2002) . By a modulation of the Mnk-eIF4G interaction, eIF4E's phosphorylation is controlled: eIF4G binding is controlled by MAPK-mediated phosphorylation of the Mnk1 active site. Furthermore in the absence of MAPK signaling, eIF4E phosphorylation is prevented by the C-terminal domain of Mnk1 that restricts its interaction with eIF4G (Shveygert et al., 2010) ." ;
            <http://www.example.org/textHash>
                    "c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The first of these strategies was the development of antisense oligonucleotides (ASOs) that block eIF4E\\u0027s mRNA translation. Thus, Defatta et al. had shown that eIF4E translation inhibition through ASOs eliminates tumorigenic and angiogenic properties in FaDu human squamous carcinoma cell (DeFatta, Nathan, \\u0026 De Benedetti, 2000) . More recently, a secondgeneration ASO (4E-ASO4) was designed by Graff et al. to resist nuclease (Fig. 6A) (Graff et al., 2007) . Nanomolar concentrations of 4E-ASO4 are Figure 6 eIF4E\\u0027s inhibitors. Diagram showing the different strategies to inhibit eIF4E in cancer therapy: inhibition of eIF4E\\u0027s production by ASOs (e.g., 4E-ASO4). (A) Inhibition of eIF4E\\u0027s interaction with its ligands 4E-BPs and eIF4G through inhibitory molecules (e.g., 4EGI-1, 4E1RCat) (B) and inhibition of the eIF4E/cap interaction through mRNA\\u0027s cap analogs (e.g., the ribavirin) (C). able to reduce eIF4E level and thus induce apoptosis in several cancer cell lines in vitro. In vivo models of breast cancer, 4E-ASO4 significantly inhibited tumor growth without side effects or weight loss. eIF4E\\u0027s expression is reduced by 64% in the observed tissues. Moreover, similar results were observed in prostate cancer xenografts after treatment (Graff et al., 2007) . On the other hand, siRNAs targeting eIF4E have recently been described for their ability to inhibit tumor growth, induce apoptosis, and enhance the effect of chemotherapy with cisplatin in breast carcinomas in vitro and in vivo (Dong et al., 2009) . In prostate cancer models, in vivo, eIF4E knockdown using siRNA reverses the cytoprotection to androgen withdrawal (serumfree media) and paclitaxel treatment normally conferred by Hsp27 overexpression. Moreover, eIF4E\\u0027s overexpression confers resistance to combine treatment with paclitaxel and androgen withdrawal in LNCaP cells (Andrieu et al., 2010) .\",\"cite_spans\":[{\"start\":130.0,\"end\":148.0,\"text\":\"Defatta et al. had\"},{\"start\":289.0,\"end\":328.0,\"text\":\"(DeFatta, Nathan, \\u0026 De Benedetti, 2000)\",\"ref_id\":\"BIBREF26\"},{\"start\":395.0,\"end\":407.0,\"text\":\"Graff et al.\"},{\"start\":437.0,\"end\":457.0,\"text\":\"(Graff et al., 2007)\",\"ref_id\":\"BIBREF42\"},{\"start\":1246.0,\"end\":1266.0,\"text\":\"(Graff et al., 2007)\",\"ref_id\":\"BIBREF42\"},{\"start\":1497.0,\"end\":1516.0,\"text\":\"(Dong et al., 2009)\",\"ref_id\":\"BIBREF28\"},{\"start\":1849.0,\"end\":1871.0,\"text\":\"(Andrieu et al., 2010)\",\"ref_id\":\"BIBREF1\"}],\"ref_spans\":[{\"start\":427.0,\"end\":436.0,\"text\":\"(Fig. 6A)\"},{\"start\":500.0,\"end\":508.0,\"text\":\"Figure 6\"}],\"section\":\"ASOs and siRNAs\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-395-407> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-1497-1516> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-289-328> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-437-457> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-1849-1871> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-130-148> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-1246-1266> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_refspan-500-508> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_refspan-427-436> ;
            <http://www.example.org/section>
                    "ASOs and siRNAs" ;
            <http://www.example.org/text>  "The first of these strategies was the development of antisense oligonucleotides (ASOs) that block eIF4E's mRNA translation. Thus, Defatta et al. had shown that eIF4E translation inhibition through ASOs eliminates tumorigenic and angiogenic properties in FaDu human squamous carcinoma cell (DeFatta, Nathan, & De Benedetti, 2000) . More recently, a secondgeneration ASO (4E-ASO4) was designed by Graff et al. to resist nuclease (Fig. 6A) (Graff et al., 2007) . Nanomolar concentrations of 4E-ASO4 are Figure 6 eIF4E's inhibitors. Diagram showing the different strategies to inhibit eIF4E in cancer therapy: inhibition of eIF4E's production by ASOs (e.g., 4E-ASO4). (A) Inhibition of eIF4E's interaction with its ligands 4E-BPs and eIF4G through inhibitory molecules (e.g., 4EGI-1, 4E1RCat) (B) and inhibition of the eIF4E/cap interaction through mRNA's cap analogs (e.g., the ribavirin) (C). able to reduce eIF4E level and thus induce apoptosis in several cancer cell lines in vitro. In vivo models of breast cancer, 4E-ASO4 significantly inhibited tumor growth without side effects or weight loss. eIF4E's expression is reduced by 64% in the observed tissues. Moreover, similar results were observed in prostate cancer xenografts after treatment (Graff et al., 2007) . On the other hand, siRNAs targeting eIF4E have recently been described for their ability to inhibit tumor growth, induce apoptosis, and enhance the effect of chemotherapy with cisplatin in breast carcinomas in vitro and in vivo (Dong et al., 2009) . In prostate cancer models, in vivo, eIF4E knockdown using siRNA reverses the cytoprotection to androgen withdrawal (serumfree media) and paclitaxel treatment normally conferred by Hsp27 overexpression. Moreover, eIF4E's overexpression confers resistance to combine treatment with paclitaxel and androgen withdrawal in LNCaP cells (Andrieu et al., 2010) ." ;
            <http://www.example.org/textHash>
                    "4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2054-2074>
            <http://www.example.org/end>    "2074.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF115" ;
            <http://www.example.org/start>  "2054.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Volpon et al., 2010)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3961-3983>
            <http://www.example.org/end>    "3983.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "3961.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Andrieu et al., 2010;" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-528-553>
            <http://www.example.org/end>    "553.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF83" ;
            <http://www.example.org/start>  "528.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Othumpangat et al., 2005)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2032-2053>
            <http://www.example.org/end>    "2053.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF57" ;
            <http://www.example.org/start>  "2032.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kentsis et al., 2001;" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-536-558>
            <http://www.example.org/end>    "558.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF89" ;
            <http://www.example.org/start>  "536.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Robalino et al., 2004;" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1150-1172>
            <http://www.example.org/end>    "1172.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF120" ;
            <http://www.example.org/start>  "1150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Westman et al., 2005;" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2328-2347>
            <http://www.example.org/end>    "2347.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF107" ;
            <http://www.example.org/start>  "2328.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tomoo et al., 2002)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-810-829>
            <http://www.example.org/end>    "829.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF108" ;
            <http://www.example.org/start>  "810.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tomoo et al., 2003)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2520-2547>
            <http://www.example.org/end>    "2547.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "2520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "De Benedetti & Graff, 2004;" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-617-639>
            <http://www.example.org/end>    "639.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "617.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gingras et al., 2001;" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-1977-1985>
            <http://www.example.org/end>    "1985.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1977.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3627-3647>
            <http://www.example.org/end>    "3647.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "3627.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001;" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-437-457>
            <http://www.example.org/end>    "457.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF42" ;
            <http://www.example.org/start>  "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Graff et al., 2007)" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-141-171>
            <http://www.example.org/end>    "171.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF86" ;
            <http://www.example.org/start>  "141.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Quiocho, Hu, & Gershon, 2000)" .
    
    <http://covid19.aksw.org/text-2cf4e9d8eee86c74baf0142bf48cb86f5768c71b681deaae247671e506ffd94c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Studies show that the eIF4E inhibition can lead to HeLa cancer cell death and its absence is lethal for Saccharomyces cerevisiae. When overexpressed, eIF4E can act like an oncogene, by promoting malignant transformation and lymphomagenesis in rodent cells. An overproduction of eIF4E causes uncontrollable cell growth or oncogenesis, which indicates its importance in protein synthesis (Andrieu et al., 2010) . Given the important function of this protein, it is not surprising to find its activity highly regulated.\",\"cite_spans\":[{\"start\":386.0,\"end\":408.0,\"text\":\"(Andrieu et al., 2010)\",\"ref_id\":\"BIBREF1\"}],\"ref_spans\":[],\"section\":\"Regulation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2cf4e9d8eee86c74baf0142bf48cb86f5768c71b681deaae247671e506ffd94c_citespan-386-408> ;
            <http://www.example.org/section>
                    "Regulation" ;
            <http://www.example.org/text>  "Studies show that the eIF4E inhibition can lead to HeLa cancer cell death and its absence is lethal for Saccharomyces cerevisiae. When overexpressed, eIF4E can act like an oncogene, by promoting malignant transformation and lymphomagenesis in rodent cells. An overproduction of eIF4E causes uncontrollable cell growth or oncogenesis, which indicates its importance in protein synthesis (Andrieu et al., 2010) . Given the important function of this protein, it is not surprising to find its activity highly regulated." ;
            <http://www.example.org/textHash>
                    "2cf4e9d8eee86c74baf0142bf48cb86f5768c71b681deaae247671e506ffd94c" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"When eIF4E was discovered, it was considered as an isolated protein, not belonging to any known protein family. Research of the last decade showed that all eukaryotes have several members of the eIF4E family. Joshi et al. (2005) identified, through sequence analysis, 411 eIF4E family members, in 230 species. Three isoforms (eIFF-1, 4EHP, and eIF4E-3) are present in mammals ( Joshi, Cameron, \\u0026 Jagus, 2004) . Not all proteins from eIF4E\\u0027s family bind to 7 methylguanosine mRNA cap (m7GDP) and to the same ligand ( Joshi et al., 2004; Robalino et al., 2004; Rosettani et al., 2007) , which give them different physiological functions. Hernandez and Vazquez-Pianzola (2005) suggested that in each organism, there is one member of the eIF4E family expressed that intervenes in translation and that other members have other functions (development, translation repression, specific mRNA nuclear transport). This hypothesis is being confirmed since eIF4E\\u0027s isoforms are thought to be involved in many functions such as spermatogenesis, oogenesis, aging, and other functions (Amiri et al., 2001; Dinkova et al., 2005; Evsikov \\u0026 Marin de Evsikova, 2009; Minshall et al., 2007; Syntichaki, Troulinaki, \\u0026 Tavernarakis, 2007) . Cap-dependent translation starts when eIF4E binds to the mRNA cap domain. Cancer cells depend on cap-dependent translation more than normal tissues ( Jia et al., 2012) . This review will expose eIF4E\\u0027s structure and functions and will expose the use of eIF4E as an anticancer target.\",\"cite_spans\":[{\"start\":209.0,\"end\":228.0,\"text\":\"Joshi et al. (2005)\",\"ref_id\":\"BIBREF55\"},{\"start\":376.0,\"end\":408.0,\"text\":\"( Joshi, Cameron, \\u0026 Jagus, 2004)\",\"ref_id\":\"BIBREF54\"},{\"start\":514.0,\"end\":535.0,\"text\":\"( Joshi et al., 2004;\",\"ref_id\":\"BIBREF54\"},{\"start\":536.0,\"end\":558.0,\"text\":\"Robalino et al., 2004;\",\"ref_id\":\"BIBREF89\"},{\"start\":559.0,\"end\":582.0,\"text\":\"Rosettani et al., 2007)\",\"ref_id\":\"BIBREF91\"},{\"start\":636.0,\"end\":673.0,\"text\":\"Hernandez and Vazquez-Pianzola (2005)\",\"ref_id\":\"BIBREF48\"},{\"start\":1070.0,\"end\":1090.0,\"text\":\"(Amiri et al., 2001;\",\"ref_id\":\"BIBREF0\"},{\"start\":1091.0,\"end\":1112.0,\"text\":\"Dinkova et al., 2005;\",\"ref_id\":\"BIBREF27\"},{\"start\":1113.0,\"end\":1147.0,\"text\":\"Evsikov \\u0026 Marin de Evsikova, 2009;\",\"ref_id\":\"BIBREF32\"},{\"start\":1148.0,\"end\":1170.0,\"text\":\"Minshall et al., 2007;\",\"ref_id\":\"BIBREF73\"},{\"start\":1171.0,\"end\":1216.0,\"text\":\"Syntichaki, Troulinaki, \\u0026 Tavernarakis, 2007)\",\"ref_id\":\"BIBREF103\"},{\"start\":1367.0,\"end\":1386.0,\"text\":\"( Jia et al., 2012)\",\"ref_id\":\"BIBREF53\"}],\"ref_spans\":[],\"section\":\"INTRODUCTION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1171-1216> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1091-1112> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1070-1090> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-536-558> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-376-408> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-514-535> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1148-1170> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1367-1386> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-559-582> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-209-228> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1113-1147> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-636-673> ;
            <http://www.example.org/section>
                    "INTRODUCTION" ;
            <http://www.example.org/text>  "When eIF4E was discovered, it was considered as an isolated protein, not belonging to any known protein family. Research of the last decade showed that all eukaryotes have several members of the eIF4E family. Joshi et al. (2005) identified, through sequence analysis, 411 eIF4E family members, in 230 species. Three isoforms (eIFF-1, 4EHP, and eIF4E-3) are present in mammals ( Joshi, Cameron, & Jagus, 2004) . Not all proteins from eIF4E's family bind to 7 methylguanosine mRNA cap (m7GDP) and to the same ligand ( Joshi et al., 2004; Robalino et al., 2004; Rosettani et al., 2007) , which give them different physiological functions. Hernandez and Vazquez-Pianzola (2005) suggested that in each organism, there is one member of the eIF4E family expressed that intervenes in translation and that other members have other functions (development, translation repression, specific mRNA nuclear transport). This hypothesis is being confirmed since eIF4E's isoforms are thought to be involved in many functions such as spermatogenesis, oogenesis, aging, and other functions (Amiri et al., 2001; Dinkova et al., 2005; Evsikov & Marin de Evsikova, 2009; Minshall et al., 2007; Syntichaki, Troulinaki, & Tavernarakis, 2007) . Cap-dependent translation starts when eIF4E binds to the mRNA cap domain. Cancer cells depend on cap-dependent translation more than normal tissues ( Jia et al., 2012) . This review will expose eIF4E's structure and functions and will expose the use of eIF4E as an anticancer target." ;
            <http://www.example.org/textHash>
                    "5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-279-300>
            <http://www.example.org/end>    "300.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF62" ;
            <http://www.example.org/start>  "279.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kowalska et al., 2009" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2184-2202>
            <http://www.example.org/end>    "2202.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF50" ;
            <http://www.example.org/start>  "2184.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Holm et al., 2008;" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-1043-1063>
            <http://www.example.org/end>    "1063.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "1043.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001)" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-973-1005>
            <http://www.example.org/end>    "1005.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF90" ;
            <http://www.example.org/start>  "973.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rogers, Komar, & Merrick, 2002)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-409-432>
            <http://www.example.org/end>    "432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF75" ;
            <http://www.example.org/start>  "409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Monzingo et al., 2007;" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1021-1038>
            <http://www.example.org/end>    "1038.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF105" ;
            <http://www.example.org/start>  "1021.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tan et al., 2008)" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-258-278>
            <http://www.example.org/end>    "278.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "258.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ghosh et al., , 2009" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_refspan-993-1001>
            <http://www.example.org/end>    "1001.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "993.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 6B" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1361-1378>
            <http://www.example.org/end>    "1378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF104" ;
            <http://www.example.org/start>  "1361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tan et al., 2000)" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-558-578>
            <http://www.example.org/end>    "578.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF71" ;
            <http://www.example.org/start>  "558.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mamane et al., 2004)" .
    
    <http://covid19.aksw.org/text-5971d9854701373172b07e1dcfbf6fae2609dbc4f0027b1913a62c535d53376f_citespan-129-153>
            <http://www.example.org/end>    "153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "129.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Culjkovic et al., 2007)" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-218-237>
            <http://www.example.org/end>    "237.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF112" ;
            <http://www.example.org/start>  "218.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ueda et al., 2004)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_refspan-3934-3942>
            <http://www.example.org/end>    "3942.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "3934.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4C" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_refspan-500-508>
            <http://www.example.org/end>    "508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "500.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 5)" .
    
    <http://covid19.aksw.org/text-08fa96bac71e38ff74aa5c3dabb0bb71bfbd98dd400e2643e10225af249f61c8_refspan-257-265>
            <http://www.example.org/end>    "265.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "257.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 5)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3409-3429>
            <http://www.example.org/end>    "3429.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "3409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2123-2144>
            <http://www.example.org/end>    "2144.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "2123.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Coleman et al., 2009;" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-509-537>
            <http://www.example.org/end>    "537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "509.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(De Benedetti & Graff, 2004;" .
    
    <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac_citespan-540-565>
            <http://www.example.org/end>    "565.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF41" ;
            <http://www.example.org/start>  "540.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Goodfellow et al., 2005)" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-1177-1197>
            <http://www.example.org/end>    "1197.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "1177.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gross et al., 2003;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-664-684>
            <http://www.example.org/end>    "684.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4483-4503>
            <http://www.example.org/end>    "4503.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "4483.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Iborra et al., 2001)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2011-2031>
            <http://www.example.org/end>    "2031.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "2011.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001;" .
    
    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-348-369>
            <http://www.example.org/end>    "369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "348.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Feldman et al., 2009;" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-1198-1230>
            <http://www.example.org/end>    "1230.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF85" ;
            <http://www.example.org/start>  "1198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Prevot, Darlix, & Ohlmann, 2003)" .
    
    <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac_citespan-701-724>
            <http://www.example.org/end>    "724.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "701.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dreher & Miller, 2006)" .
    
    <http://covid19.aksw.org/text-435feb00930a2d0a735628bc218d72dea9f94c6f8c1ae12e6df1a87717db82e6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Tumorigenesis is highly affected by the regulation of the capdependent translation. The cap-dependent translation consists of the eukaryotic translation initiation factor 4F complex that can recognize the 5 0 end of cellular mRNAs at the 7-methylguanosine cap structure. eIF4E is a component of this complex which makes it crucial to the cap-dependent translation initiation and regulation of tumor cell apoptosis, proliferation, and, potentially, metastasis. Indeed, since eIF4E\\u0027s inhibition induces cellular death, we are entitled to ask about this inhibition\\u0027s consequence on normal cells. It seems however that eIF4E\\u0027s residual and low levels after drug treatment are tolerated and without adverse effects on normal tissues. In contrast, eIF4E\\u0027s activity is so important in cancerous cells that its inhibitions have a more visible effect (Graff et al., 2008) . Many approaches over the years have been used to try to inhibit eIF4E\\u0027s function, particularly by using small-molecule inhibitors that can disrupt the eIF4E-eIF4G interaction, the use of cap analogs to directly target the eIF4E cap-binding site, or ASOs that have been proved to be efficient in reducing the expression level of eIF4E and have advanced to clinical trials in prostate cancer patients. More recently, targeting Hsp27-eIF4E interaction has been described as an interesting alternative strategy to target eIF4E. Taken together, these data seem to show eIF4E to be a promising target for cancer therapy and new approaches of inhibition deserve further studies.\",\"cite_spans\":[{\"start\":842.0,\"end\":862.0,\"text\":\"(Graff et al., 2008)\",\"ref_id\":\"BIBREF43\"}],\"ref_spans\":[],\"section\":\"CONCLUSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-435feb00930a2d0a735628bc218d72dea9f94c6f8c1ae12e6df1a87717db82e6_citespan-842-862> ;
            <http://www.example.org/section>
                    "CONCLUSION" ;
            <http://www.example.org/text>  "Tumorigenesis is highly affected by the regulation of the capdependent translation. The cap-dependent translation consists of the eukaryotic translation initiation factor 4F complex that can recognize the 5 0 end of cellular mRNAs at the 7-methylguanosine cap structure. eIF4E is a component of this complex which makes it crucial to the cap-dependent translation initiation and regulation of tumor cell apoptosis, proliferation, and, potentially, metastasis. Indeed, since eIF4E's inhibition induces cellular death, we are entitled to ask about this inhibition's consequence on normal cells. It seems however that eIF4E's residual and low levels after drug treatment are tolerated and without adverse effects on normal tissues. In contrast, eIF4E's activity is so important in cancerous cells that its inhibitions have a more visible effect (Graff et al., 2008) . Many approaches over the years have been used to try to inhibit eIF4E's function, particularly by using small-molecule inhibitors that can disrupt the eIF4E-eIF4G interaction, the use of cap analogs to directly target the eIF4E cap-binding site, or ASOs that have been proved to be efficient in reducing the expression level of eIF4E and have advanced to clinical trials in prostate cancer patients. More recently, targeting Hsp27-eIF4E interaction has been described as an interesting alternative strategy to target eIF4E. Taken together, these data seem to show eIF4E to be a promising target for cancer therapy and new approaches of inhibition deserve further studies." ;
            <http://www.example.org/textHash>
                    "435feb00930a2d0a735628bc218d72dea9f94c6f8c1ae12e6df1a87717db82e6" .
    
    <http://covid19.aksw.org/e05286fdb2fa80e08773c24161f3ef5d85a7ef29>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "e05286fdb2fa80e08773c24161f3ef5d85a7ef29" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-7af57dd65b76cda2d57dd6dc06819c83a9a909c94faf7b5b1fcc26c881e28737> , <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939> , <http://covid19.aksw.org/text-2cf4e9d8eee86c74baf0142bf48cb86f5768c71b681deaae247671e506ffd94c> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf> , <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619> , <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5> , <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e> , <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e> , <http://covid19.aksw.org/text-08fa96bac71e38ff74aa5c3dabb0bb71bfbd98dd400e2643e10225af249f61c8> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86> , <http://covid19.aksw.org/text-85d8d4a62bb547bd45fa23ed5d37b334e392f5811256d1adf2e86fc6fbd927b1> , <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916> , <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3> , <http://covid19.aksw.org/text-435feb00930a2d0a735628bc218d72dea9f94c6f8c1ae12e6df1a87717db82e6> , <http://covid19.aksw.org/text-ecc2abc2c1414e0cf58429ea4657eb8e4c43e388957470bd98460a639848bd9c> , <http://covid19.aksw.org/text-d9682aa5f2491a2546ef2daca7ed8531916e76ca4b2f5e35237c4dc0a58048ff> , <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68> , <http://covid19.aksw.org/text-e6c1540fe257c69bae2387ba04eecccffb4fa14f2599ccbdb3621ff1756b0508> , <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac> , <http://covid19.aksw.org/text-0a0360bd083c6139c40898a98731b72be82ca2c96be65b59c2806590206a7c76> , <http://covid19.aksw.org/text-5971d9854701373172b07e1dcfbf6fae2609dbc4f0027b1913a62c535d53376f> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e> , <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227> , <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633> , <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666> , <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b> .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4460-4482>
            <http://www.example.org/end>    "4482.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "4460.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dostie et al., 2000a;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3648-3667>
            <http://www.example.org/end>    "3667.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "3648.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-424-459>
            <http://www.example.org/end>    "459.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "424.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gingras, Raught, & Sonenberg, 2004;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2600-2620>
            <http://www.example.org/end>    "2620.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "2600.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2693-2713>
            <http://www.example.org/end>    "2713.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "2693.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3786-3810>
            <http://www.example.org/end>    "3810.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "3786.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Culjkovic et al., 2007)" .
    
    <http://covid19.aksw.org/text-5971d9854701373172b07e1dcfbf6fae2609dbc4f0027b1913a62c535d53376f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"All known data on eIF4E\\u0027s role in translation initiation and nuclear export led to the hypothesis that there is an eIF4E regulon (Culjkovic et al., 2007) . The \\\"regulons\\\" are a set of genes regulated by the same protein. The hypothesis has suggested that mRNAs belonging to the eIF4E regulon have a signal that allows its recruitment. The eIF4E protein is considered as regulatory since it allows, on the one hand, the nuclear export through the 4E-SE site recognition and, on the other hand, the protein translation through another unknown signal. In some cases, eIF4E acts on both mechanisms likely due to the presence of both of these signals. The eIF4E protein can thus orchestrate genes\\u0027 expression and control the cell cycle progression.\",\"cite_spans\":[{\"start\":129.0,\"end\":153.0,\"text\":\"(Culjkovic et al., 2007)\",\"ref_id\":\"BIBREF21\"}],\"ref_spans\":[],\"section\":\"Nuclear Export\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5971d9854701373172b07e1dcfbf6fae2609dbc4f0027b1913a62c535d53376f_citespan-129-153> ;
            <http://www.example.org/section>
                    "Nuclear Export" ;
            <http://www.example.org/text>  "All known data on eIF4E's role in translation initiation and nuclear export led to the hypothesis that there is an eIF4E regulon (Culjkovic et al., 2007) . The \"regulons\" are a set of genes regulated by the same protein. The hypothesis has suggested that mRNAs belonging to the eIF4E regulon have a signal that allows its recruitment. The eIF4E protein is considered as regulatory since it allows, on the one hand, the nuclear export through the 4E-SE site recognition and, on the other hand, the protein translation through another unknown signal. In some cases, eIF4E acts on both mechanisms likely due to the presence of both of these signals. The eIF4E protein can thus orchestrate genes' expression and control the cell cycle progression." ;
            <http://www.example.org/textHash>
                    "5971d9854701373172b07e1dcfbf6fae2609dbc4f0027b1913a62c535d53376f" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1259-1299>
            <http://www.example.org/end>    "1299.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "1259.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Culjkovic, Topisirovic, & Borden, 2007)" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-2135-2153>
            <http://www.example.org/end>    "2153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF65" ;
            <http://www.example.org/start>  "2135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lee et al., 2007)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-303-329>
            <http://www.example.org/end>    "329.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF102" ;
            <http://www.example.org/start>  "303.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Strudwick & Borden, 2002)" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-130-148>
            <http://www.example.org/end>    "148.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "130.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Defatta et al. had" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1672-1692>
            <http://www.example.org/end>    "1692.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "1672.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001;" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-648-656>
            <http://www.example.org/end>    "656.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "648.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3)" .
    
    <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227_citespan-692-713>
            <http://www.example.org/end>    "713.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "692.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Baylot et al., 2011)" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-1560-1596>
            <http://www.example.org/end>    "1596.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1560.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Borden & Culjkovic-Kraljacic, 2010)" .
    
    <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-834-874>
            <http://www.example.org/end>    "874.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF77" ;
            <http://www.example.org/start>  "834.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Nakamura, Sato, & Hanyu-Nakamura, 2004;" .
    
    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-328-347>
            <http://www.example.org/end>    "347.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "328.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Choo et al., 2008;" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-433-452>
            <http://www.example.org/end>    "452.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF107" ;
            <http://www.example.org/start>  "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tomoo et al., 2002)" .
    
    <http://covid19.aksw.org/text-08fa96bac71e38ff74aa5c3dabb0bb71bfbd98dd400e2643e10225af249f61c8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The exact mechanism by which eIF4E and the eIF4F complex induce oncogenic transformation is highly debated, but it is described that it may partly be mediated by an mRNA subset\\u0027s translation increase, rather than an overall increase in the translation rate (Fig. 5) . The classification and regression tree (CART) divides the mRNAs according to their 5 0 UTR end (Davuluri et al., 2000) . The vast majority of mRNAs have a short, unstructured 5 0 UTR end and are strongly translated. These mRNAs encode the \\\"housekeeping\\\" proteins. However, there are also mRNAs whose 5 0 UTR end is long, structured, and rich in G/C nucleic acids and are poorly translated under normal cellular conditions. This 5 0 UTR end prevents an effective eIF4F activity and binding to ribosomes. In this second category, the mRNAs encode proteins that have an important role in oncogenesis.\",\"cite_spans\":[{\"start\":363.0,\"end\":386.0,\"text\":\"(Davuluri et al., 2000)\",\"ref_id\":\"BIBREF23\"}],\"ref_spans\":[{\"start\":257.0,\"end\":265.0,\"text\":\"(Fig. 5)\",\"ref_id\":\"FIGREF2\"}],\"section\":\"EIF4E\\u0027s Mechanisms in Cancer\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-08fa96bac71e38ff74aa5c3dabb0bb71bfbd98dd400e2643e10225af249f61c8_citespan-363-386> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-08fa96bac71e38ff74aa5c3dabb0bb71bfbd98dd400e2643e10225af249f61c8_refspan-257-265> ;
            <http://www.example.org/section>
                    "EIF4E's Mechanisms in Cancer" ;
            <http://www.example.org/text>  "The exact mechanism by which eIF4E and the eIF4F complex induce oncogenic transformation is highly debated, but it is described that it may partly be mediated by an mRNA subset's translation increase, rather than an overall increase in the translation rate (Fig. 5) . The classification and regression tree (CART) divides the mRNAs according to their 5 0 UTR end (Davuluri et al., 2000) . The vast majority of mRNAs have a short, unstructured 5 0 UTR end and are strongly translated. These mRNAs encode the \"housekeeping\" proteins. However, there are also mRNAs whose 5 0 UTR end is long, structured, and rich in G/C nucleic acids and are poorly translated under normal cellular conditions. This 5 0 UTR end prevents an effective eIF4F activity and binding to ribosomes. In this second category, the mRNAs encode proteins that have an important role in oncogenesis." ;
            <http://www.example.org/textHash>
                    "08fa96bac71e38ff74aa5c3dabb0bb71bfbd98dd400e2643e10225af249f61c8" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2583-2599>
            <http://www.example.org/end>    "2599.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF67" ;
            <http://www.example.org/start>  "2583.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Li et al., 2002)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2253-2293>
            <http://www.example.org/end>    "2293.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF93" ;
            <http://www.example.org/start>  "2253.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Salehi, Mashayekhi, & Shahosseini, 2007;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3309-3328>
            <http://www.example.org/end>    "3328.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "3309.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Graff et al., 2009" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"2. eIF4E\\u0027S STRUCTURE AND EXPRESSION 2.1 Structure eIF4E\\u0027s primary structure (Fig. 1A) is highly conserved in all eukaryotes because of the important role they play in the cell. In the N-terminal end, sequences are variable between different organisms, but this end does not seem to be involved in the initiation to translation function. The tertiary structure was characterized in mice, men, yeast, and wheat (Monzingo et al., 2007; Tomoo et al., 2002) . This structure is composed of eight antiparallel β strands and three helices on the convex side (Fig. 1B) . eIF4E binds to the m7GDP of the mRNA cap to allow the translation initiation. eIF4E tridimensional structures that interact with cap analogs were identified, allowing to identify the interaction site (Gross et al., 2003; Niedzwiecka et al., 2002; Tomoo et al., 2003) . The cap interaction happens in a hydrophobic pocket on eIF4E\\u0027s concave side, due to the interaction with two highly conserved tryptophan residues (56 and 102 in mice) (Fig. 1B) . This interaction is stabilized by three hydrogen bonds. The interaction with partner proteins involved in translation regulation, such as eIF4G or 4E binding proteins (4E-BP), takes place in a hydrophobic region on the convex side, and it involves two conserved tryptophan residues (43 and 73 in mice) (Fig. 1B) . These proteins interact with eIF4E through a bonding pattern, which consensus sequence is: Y(X) 4 LΦ, with X being any amino acid and Φ being a hydrophobic residue. The eIF4G or the 4E-BPs\\u0027 binding to eIF4E causes conformational changes which increases eIF4E\\u0027s affinity to the cap (Niedzwiecka et al., 2002; von Der Haar, Ball, \\u0026 McCarthy, 2000) . The PML protein (promyelocytic leukemia protein) and the viral protein Z (VPZ) represent a second class of eIF4E regulators that intervene in the mRNA nuclear export function. These proteins bind to eIF4E\\u0027s convex side using their RING domain, which, in contrast to the bond to eIF4G and 4E-BP, decreases the affinity of eIF4E to the cap (Cohen et al., 2001; Kentsis et al., 2001; Volpon et al., 2010) . Structural studies show that eIF4E has different conformations and different ligand binding affinities depending on whether it is binding to the cap or not (Niedzwiecka et al., 2002; Niedzwiecka, Darzynkiewicz, \\u0026 Stolarski, 2004; Volpon et al., 2006; Tomoo et al., 2002) .\",\"cite_spans\":[{\"start\":409.0,\"end\":432.0,\"text\":\"(Monzingo et al., 2007;\",\"ref_id\":\"BIBREF75\"},{\"start\":433.0,\"end\":452.0,\"text\":\"Tomoo et al., 2002)\",\"ref_id\":\"BIBREF107\"},{\"start\":763.0,\"end\":783.0,\"text\":\"(Gross et al., 2003;\",\"ref_id\":\"BIBREF45\"},{\"start\":784.0,\"end\":809.0,\"text\":\"Niedzwiecka et al., 2002;\",\"ref_id\":\"BIBREF80\"},{\"start\":810.0,\"end\":829.0,\"text\":\"Tomoo et al., 2003)\",\"ref_id\":\"BIBREF108\"},{\"start\":1606.0,\"end\":1632.0,\"text\":\"(Niedzwiecka et al., 2002;\",\"ref_id\":\"BIBREF80\"},{\"start\":1633.0,\"end\":1670.0,\"text\":\"von Der Haar, Ball, \\u0026 McCarthy, 2000)\",\"ref_id\":\"BIBREF116\"},{\"start\":2011.0,\"end\":2031.0,\"text\":\"(Cohen et al., 2001;\",\"ref_id\":\"BIBREF17\"},{\"start\":2032.0,\"end\":2053.0,\"text\":\"Kentsis et al., 2001;\",\"ref_id\":\"BIBREF57\"},{\"start\":2054.0,\"end\":2074.0,\"text\":\"Volpon et al., 2010)\",\"ref_id\":\"BIBREF115\"},{\"start\":2233.0,\"end\":2259.0,\"text\":\"(Niedzwiecka et al., 2002;\",\"ref_id\":\"BIBREF80\"},{\"start\":2260.0,\"end\":2306.0,\"text\":\"Niedzwiecka, Darzynkiewicz, \\u0026 Stolarski, 2004;\",\"ref_id\":\"BIBREF79\"},{\"start\":2307.0,\"end\":2327.0,\"text\":\"Volpon et al., 2006;\",\"ref_id\":\"BIBREF114\"},{\"start\":2328.0,\"end\":2347.0,\"text\":\"Tomoo et al., 2002)\",\"ref_id\":\"BIBREF107\"}],\"ref_spans\":[{\"start\":76.0,\"end\":85.0,\"text\":\"(Fig. 1A)\"},{\"start\":551.0,\"end\":560.0,\"text\":\"(Fig. 1B)\"},{\"start\":999.0,\"end\":1008.0,\"text\":\"(Fig. 1B)\"},{\"start\":1313.0,\"end\":1322.0,\"text\":\"(Fig. 1B)\"}],\"section\":\"INTRODUCTION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2328-2347> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-784-809> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2307-2327> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-810-829> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2011-2031> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-409-432> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-1606-1632> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2032-2053> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2260-2306> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-1633-1670> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-763-783> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2054-2074> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2233-2259> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-433-452> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-1313-1322> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-999-1008> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-551-560> , <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-76-85> ;
            <http://www.example.org/section>
                    "INTRODUCTION" ;
            <http://www.example.org/text>  "2. eIF4E'S STRUCTURE AND EXPRESSION 2.1 Structure eIF4E's primary structure (Fig. 1A) is highly conserved in all eukaryotes because of the important role they play in the cell. In the N-terminal end, sequences are variable between different organisms, but this end does not seem to be involved in the initiation to translation function. The tertiary structure was characterized in mice, men, yeast, and wheat (Monzingo et al., 2007; Tomoo et al., 2002) . This structure is composed of eight antiparallel β strands and three helices on the convex side (Fig. 1B) . eIF4E binds to the m7GDP of the mRNA cap to allow the translation initiation. eIF4E tridimensional structures that interact with cap analogs were identified, allowing to identify the interaction site (Gross et al., 2003; Niedzwiecka et al., 2002; Tomoo et al., 2003) . The cap interaction happens in a hydrophobic pocket on eIF4E's concave side, due to the interaction with two highly conserved tryptophan residues (56 and 102 in mice) (Fig. 1B) . This interaction is stabilized by three hydrogen bonds. The interaction with partner proteins involved in translation regulation, such as eIF4G or 4E binding proteins (4E-BP), takes place in a hydrophobic region on the convex side, and it involves two conserved tryptophan residues (43 and 73 in mice) (Fig. 1B) . These proteins interact with eIF4E through a bonding pattern, which consensus sequence is: Y(X) 4 LΦ, with X being any amino acid and Φ being a hydrophobic residue. The eIF4G or the 4E-BPs' binding to eIF4E causes conformational changes which increases eIF4E's affinity to the cap (Niedzwiecka et al., 2002; von Der Haar, Ball, & McCarthy, 2000) . The PML protein (promyelocytic leukemia protein) and the viral protein Z (VPZ) represent a second class of eIF4E regulators that intervene in the mRNA nuclear export function. These proteins bind to eIF4E's convex side using their RING domain, which, in contrast to the bond to eIF4G and 4E-BP, decreases the affinity of eIF4E to the cap (Cohen et al., 2001; Kentsis et al., 2001; Volpon et al., 2010) . Structural studies show that eIF4E has different conformations and different ligand binding affinities depending on whether it is binding to the cap or not (Niedzwiecka et al., 2002; Niedzwiecka, Darzynkiewicz, & Stolarski, 2004; Volpon et al., 2006; Tomoo et al., 2002) ." ;
            <http://www.example.org/textHash>
                    "022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-551-560>
            <http://www.example.org/end>    "560.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "551.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1B)" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Another eIF4E\\u0027s posttranslational modification is ubiquitination. It has been demonstrated that it does not prevent the eIF4E mRNA cap binding but it prevents the eIF4G bond and thus eIF4E phosphorylation is reduced (Murata \\u0026 Shimotohno, 2006; Othumpangat, Kashon, \\u0026 Joseph, 2005) . However, the ubiquitination consequences on the translation initiation are still unknown. eIF4E degradation depends on the proteasome and happens principally when ligases such as Chip ubiquitinate the Lys-159 residue (Murata \\u0026 Shimotohno, 2006; Othumpangat et al., 2005) . This ubiquitination does not prevent the bond to the mRNA cap, but the bond with eIF4G and eIF4E\\u0027s phosphorylation is reduced. Moreover, Hsp27 interacts directly with eIF4E and regulates it. After Hsp27 knockdown, eIF4E is ubiquitinated and degraded through the ubiquitin-proteasome pathway indicating that cytoprotection induced by Hsp27 involves eIF4E. Andrieu et al. showed in castrate-resistant prostate cancers that forced overexpression of Hsp27 increases the protein expression level of eIF4E without affecting its mRNA expression level. They also showed that Hsp27 could exert an effect directly on eIF4E and that the effect of Hsp27 on eIF4E level is independent of 4E-BP1. They showed that a decrease in eIF4E ubiquitination is associated with resistance to androgen withdrawal and paclitaxel, concluding that Hsp27 knockdown reduces eIF4E stability, enhancing its ubiquitination and degradation, thereby reducing cell viability after androgen withdrawal and/or chemotherapy (Andrieu et al., 2010) . In pancreatic cancer cells, Baylot et al. demonstrated that the C-terminal part of Hsp27 interacts with eIF4E and that Hsp27 phosphorylation enhances this interaction and eIF4E expression level and gemcitabine resistance. Hsp27 enhances eIF4E protein expression by inducing a decrease of approximately 30% in the amount of ubiquitinated eIF4E, thereby inhibiting its proteasomal degradation (Baylot et al., 2011) . It has also been described that the DIAP1 protein of the IAP family (inhibitor of apoptosis protein) interacts with eIF4E and leads to its ubiquitination (Lee et al., 2007) .\",\"cite_spans\":[{\"start\":216.0,\"end\":243.0,\"text\":\"(Murata \\u0026 Shimotohno, 2006;\",\"ref_id\":\"BIBREF76\"},{\"start\":244.0,\"end\":280.0,\"text\":\"Othumpangat, Kashon, \\u0026 Joseph, 2005)\",\"ref_id\":\"BIBREF83\"},{\"start\":500.0,\"end\":527.0,\"text\":\"(Murata \\u0026 Shimotohno, 2006;\",\"ref_id\":\"BIBREF76\"},{\"start\":528.0,\"end\":553.0,\"text\":\"Othumpangat et al., 2005)\",\"ref_id\":\"BIBREF83\"},{\"start\":911.0,\"end\":932.0,\"text\":\"Andrieu et al. showed\"},{\"start\":1541.0,\"end\":1563.0,\"text\":\"(Andrieu et al., 2010)\",\"ref_id\":\"BIBREF1\"},{\"start\":1957.0,\"end\":1978.0,\"text\":\"(Baylot et al., 2011)\",\"ref_id\":\"BIBREF6\"},{\"start\":2135.0,\"end\":2153.0,\"text\":\"(Lee et al., 2007)\",\"ref_id\":\"BIBREF65\"}],\"ref_spans\":[],\"section\":\"Ubiquitination\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-911-932> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-244-280> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-528-553> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-500-527> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-1541-1563> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-1957-1978> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-216-243> , <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-2135-2153> ;
            <http://www.example.org/section>
                    "Ubiquitination" ;
            <http://www.example.org/text>  "Another eIF4E's posttranslational modification is ubiquitination. It has been demonstrated that it does not prevent the eIF4E mRNA cap binding but it prevents the eIF4G bond and thus eIF4E phosphorylation is reduced (Murata & Shimotohno, 2006; Othumpangat, Kashon, & Joseph, 2005) . However, the ubiquitination consequences on the translation initiation are still unknown. eIF4E degradation depends on the proteasome and happens principally when ligases such as Chip ubiquitinate the Lys-159 residue (Murata & Shimotohno, 2006; Othumpangat et al., 2005) . This ubiquitination does not prevent the bond to the mRNA cap, but the bond with eIF4G and eIF4E's phosphorylation is reduced. Moreover, Hsp27 interacts directly with eIF4E and regulates it. After Hsp27 knockdown, eIF4E is ubiquitinated and degraded through the ubiquitin-proteasome pathway indicating that cytoprotection induced by Hsp27 involves eIF4E. Andrieu et al. showed in castrate-resistant prostate cancers that forced overexpression of Hsp27 increases the protein expression level of eIF4E without affecting its mRNA expression level. They also showed that Hsp27 could exert an effect directly on eIF4E and that the effect of Hsp27 on eIF4E level is independent of 4E-BP1. They showed that a decrease in eIF4E ubiquitination is associated with resistance to androgen withdrawal and paclitaxel, concluding that Hsp27 knockdown reduces eIF4E stability, enhancing its ubiquitination and degradation, thereby reducing cell viability after androgen withdrawal and/or chemotherapy (Andrieu et al., 2010) . In pancreatic cancer cells, Baylot et al. demonstrated that the C-terminal part of Hsp27 interacts with eIF4E and that Hsp27 phosphorylation enhances this interaction and eIF4E expression level and gemcitabine resistance. Hsp27 enhances eIF4E protein expression by inducing a decrease of approximately 30% in the amount of ubiquitinated eIF4E, thereby inhibiting its proteasomal degradation (Baylot et al., 2011) . It has also been described that the DIAP1 protein of the IAP family (inhibitor of apoptosis protein) interacts with eIF4E and leads to its ubiquitination (Lee et al., 2007) ." ;
            <http://www.example.org/textHash>
                    "b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf" .
    
    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-370-399>
            <http://www.example.org/end>    "399.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Garcia-Martinez et al., 2009;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"It is described that eIF4E is mainly located into the cytoplasm where it fulfills its role in the translation initiation, but it is also found in the nucleus. Recently, it has been described that eIF4E has a function in the regulation of translation but at a different level than that of the initiation (Strudwick \\u0026 Borden, 2002) . Lejbkowicz et al. were the first one to describe eIF4E\\u0027s expression in the nucleus\\u0027 small structures called nuclear bodies (Fig. 4A  and B) . This was then observed in a variety of mammalian cell lines and would be conserved among eukaryotes. We can find 10-20 nuclear bodies per nucleus, and their size varies between 0.1 and 1 μm (Cohen et al., 2001; Dostie, Lejbkowicz, \\u0026 Sonenberg, 2000a; Lai \\u0026 Borden, 2000) . These bodies are not affected by RNases or DNases, which indicates that these structures are not formed by nucleic acid (Cohen et al., 2001; Dostie et al., 2000a) . eIF4E is exported to the nucleus via importin active pathways involving 4E-T protein (eIF4E-transporter) that binds to eIF4E in a similar region than eiF4G and 4E-BP (Dostie et al., 2000b) . About 68% of the eIF4E proteins are found in the nuclear bodies where they are involved in the export of an mRNA category from the nucleus to the cytoplasm (Culjkovic, Topisirovic, \\u0026 Borden, 2007) . This mRNA category has a structure called \\\"sensible to eIF4E elements\\\" 4E-SE that allows eIF4E to recognize these mRNAs (Fig. 4C ) (Culjkovic et al., 2005) . Normally, mRNAs are prepared for export through a process regulated by the nuclear complex CBC (cap-binding complex), but for this category of mRNAs, eIF4E nuclear bodies are able to regulate their own transport (Cohen et al., 2001; Lai \\u0026 Borden, 2000) . These mRNAs \\\"sensitive to eIF4E\\\" also have a long and complex 5 0 UTR end that it is hardly decondensed by helicases eIF4A/4B (Zimmer, DeBenedetti, \\u0026 Graff, 2000) . Theoretically, since eIF4E is a limiting factor for the helicase recruitment, an eIF4E increase should rise the helicase activity and thus increase these specific mRNAs\\u0027 protein synthesis (Zimmer et al., 2000) . However, these mRNAs \\\"sensitive to eIF4E\\\" do not show an increase in their translation initiation rate. This mRNA protein synthesis is regulated by their export from the nucleus to the cytoplasm (Lai \\u0026 Borden, 2000) . Indeed, when eIF4E is overexpressed, the cyclin D1 mRNA level does not change, but the level of nuclear mRNA decreases and the level of cytoplasmic mRNA is increased. These results show that an increased in eIF4E expression increases the export of these mRNAs and thus the level of protein (Lai \\u0026 Borden, 2000) . This export mechanism contributes to the oncogenic potential of eIF4E (Cohen et al., 2001) . It is therefore possible that there are, in the nucleus, negative regulators to this process identical to 4E-BPs in the cytoplasm. Several proteins can associate with eIF4E nuclear bodies such as the ribosomal protein L7 and P, eIF4G (Iborra, Jackson, \\u0026 Cook, 2001) , the PRH protein (proline-rich homeodomain protein) (Topisirovic et al., 2003a) , the homeodomain proteins, the Z protein, and the PML protein which is the most studied (Campbell Dwyer et al., 2000; Cohen et al., 2001; Lai \\u0026 Borden, 2000) . These proteins regulate the eIF4E-cap bond, a bond that is necessary for the mRNA export (Dostie et al., 2000a) . The majority of eIF4E nuclear protein colocalizes with the PML protein (Lai \\u0026 Borden, 2000) as a result of stress, viral infection, or an interferon treatment (Regad \\u0026 Chelbi-Alix, 2001 ). This protein interacts on the convex side through its RING domain using the 73th tryptophan residue (Cohen et al., 2001; Lai \\u0026 Borden, 2000) . Even though this interaction site is far from the cap-binding site, this bond can inhibit the eIF4E-cap interaction (Culjkovic et al., 2007) . The PML protein binds to eIF4E and lowers its mRNA\\u0027s cap affinity (100 times), thereby changing its mRNA export function (Fig. 4C ) (Cohen et al., 2001; Culjkovic et al., 2007; Kentsis et al., 2001; Lai \\u0026 Borden, 2000) . PML would have an antitumor function. There are approximately 200 homeodomain proteins containing potential binding sites for eIF4E and could therefore regulate it (Culjkovic et al., 2007) . So it seems that the ability to modulate eIF4E\\u0027s activity by acting on its binding to the cap is conserved from the cytoplasm to the nucleus. Finally, it has been suggested that eIF4E contributes to the mRNA translation in the nucleus (Dostie et al., 2000a; Iborra et al., 2001) . This nuclear translating phenomenon has already been observed in mammals\\u0027 cells (Iborra et al., 2001) and an increasing number of proteins from the translation machinery are involved in nuclear processes. This translation may be involved in aberrant transcript elimination, by an mRNA quality control system: NMD (nonsense-mediated decay). Indeed, this system requires an active protein synthesis in order to detect the appearance of premature STOP codons leading to the synthesis of truncated proteins.\",\"cite_spans\":[{\"start\":303.0,\"end\":329.0,\"text\":\"(Strudwick \\u0026 Borden, 2002)\",\"ref_id\":\"BIBREF102\"},{\"start\":664.0,\"end\":684.0,\"text\":\"(Cohen et al., 2001;\",\"ref_id\":\"BIBREF17\"},{\"start\":685.0,\"end\":724.0,\"text\":\"Dostie, Lejbkowicz, \\u0026 Sonenberg, 2000a;\"},{\"start\":725.0,\"end\":744.0,\"text\":\"Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":867.0,\"end\":887.0,\"text\":\"(Cohen et al., 2001;\",\"ref_id\":\"BIBREF17\"},{\"start\":888.0,\"end\":909.0,\"text\":\"Dostie et al., 2000a)\"},{\"start\":1078.0,\"end\":1100.0,\"text\":\"(Dostie et al., 2000b)\"},{\"start\":1259.0,\"end\":1299.0,\"text\":\"(Culjkovic, Topisirovic, \\u0026 Borden, 2007)\",\"ref_id\":\"BIBREF21\"},{\"start\":1433.0,\"end\":1457.0,\"text\":\"(Culjkovic et al., 2005)\",\"ref_id\":\"BIBREF22\"},{\"start\":1672.0,\"end\":1692.0,\"text\":\"(Cohen et al., 2001;\",\"ref_id\":\"BIBREF17\"},{\"start\":1693.0,\"end\":1712.0,\"text\":\"Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":1841.0,\"end\":1877.0,\"text\":\"(Zimmer, DeBenedetti, \\u0026 Graff, 2000)\",\"ref_id\":\"BIBREF124\"},{\"start\":2068.0,\"end\":2089.0,\"text\":\"(Zimmer et al., 2000)\",\"ref_id\":\"BIBREF124\"},{\"start\":2287.0,\"end\":2307.0,\"text\":\"(Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":2600.0,\"end\":2620.0,\"text\":\"(Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":2693.0,\"end\":2713.0,\"text\":\"(Cohen et al., 2001)\",\"ref_id\":\"BIBREF17\"},{\"start\":2950.0,\"end\":2981.0,\"text\":\"(Iborra, Jackson, \\u0026 Cook, 2001)\",\"ref_id\":\"BIBREF52\"},{\"start\":3035.0,\"end\":3062.0,\"text\":\"(Topisirovic et al., 2003a)\",\"ref_id\":\"BIBREF109\"},{\"start\":3152.0,\"end\":3181.0,\"text\":\"(Campbell Dwyer et al., 2000;\",\"ref_id\":\"BIBREF12\"},{\"start\":3182.0,\"end\":3201.0,\"text\":\"Cohen et al., 2001;\",\"ref_id\":\"BIBREF17\"},{\"start\":3202.0,\"end\":3221.0,\"text\":\"Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":3313.0,\"end\":3335.0,\"text\":\"(Dostie et al., 2000a)\"},{\"start\":3409.0,\"end\":3429.0,\"text\":\"(Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":3497.0,\"end\":3523.0,\"text\":\"(Regad \\u0026 Chelbi-Alix, 2001\",\"ref_id\":\"BIBREF87\"},{\"start\":3627.0,\"end\":3647.0,\"text\":\"(Cohen et al., 2001;\",\"ref_id\":\"BIBREF17\"},{\"start\":3648.0,\"end\":3667.0,\"text\":\"Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":3786.0,\"end\":3810.0,\"text\":\"(Culjkovic et al., 2007)\",\"ref_id\":\"BIBREF21\"},{\"start\":3945.0,\"end\":3965.0,\"text\":\"(Cohen et al., 2001;\",\"ref_id\":\"BIBREF17\"},{\"start\":3966.0,\"end\":3989.0,\"text\":\"Culjkovic et al., 2007;\",\"ref_id\":\"BIBREF21\"},{\"start\":3990.0,\"end\":4011.0,\"text\":\"Kentsis et al., 2001;\",\"ref_id\":\"BIBREF57\"},{\"start\":4012.0,\"end\":4031.0,\"text\":\"Lai \\u0026 Borden, 2000)\",\"ref_id\":\"BIBREF64\"},{\"start\":4198.0,\"end\":4222.0,\"text\":\"(Culjkovic et al., 2007)\",\"ref_id\":\"BIBREF21\"},{\"start\":4460.0,\"end\":4482.0,\"text\":\"(Dostie et al., 2000a;\"},{\"start\":4483.0,\"end\":4503.0,\"text\":\"Iborra et al., 2001)\",\"ref_id\":\"BIBREF52\"},{\"start\":4586.0,\"end\":4607.0,\"text\":\"(Iborra et al., 2001)\",\"ref_id\":\"BIBREF52\"}],\"ref_spans\":[{\"start\":455.0,\"end\":471.0,\"text\":\"(Fig. 4A  and B)\",\"ref_id\":\"FIGREF1\"},{\"start\":1422.0,\"end\":1430.0,\"text\":\"(Fig. 4C\",\"ref_id\":\"FIGREF1\"},{\"start\":3934.0,\"end\":3942.0,\"text\":\"(Fig. 4C\",\"ref_id\":\"FIGREF1\"}],\"section\":\"Nuclear Export\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-664-684> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3497-3523> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4460-4482> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1841-1877> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3152-3181> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-685-724> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1693-1712> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3202-3221> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2287-2307> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3990-4011> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1433-1457> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4586-4607> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3409-3429> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1259-1299> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3182-3201> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1078-1100> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-867-887> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2950-2981> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4012-4031> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-888-909> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3313-3335> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4483-4503> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3786-3810> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3035-3062> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-725-744> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1672-1692> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4198-4222> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2693-2713> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-303-329> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3945-3965> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3966-3989> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3648-3667> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3627-3647> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2068-2089> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2600-2620> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_refspan-3934-3942> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_refspan-455-471> , <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_refspan-1422-1430> ;
            <http://www.example.org/section>
                    "Nuclear Export" ;
            <http://www.example.org/text>  "It is described that eIF4E is mainly located into the cytoplasm where it fulfills its role in the translation initiation, but it is also found in the nucleus. Recently, it has been described that eIF4E has a function in the regulation of translation but at a different level than that of the initiation (Strudwick & Borden, 2002) . Lejbkowicz et al. were the first one to describe eIF4E's expression in the nucleus' small structures called nuclear bodies (Fig. 4A  and B) . This was then observed in a variety of mammalian cell lines and would be conserved among eukaryotes. We can find 10-20 nuclear bodies per nucleus, and their size varies between 0.1 and 1 μm (Cohen et al., 2001; Dostie, Lejbkowicz, & Sonenberg, 2000a; Lai & Borden, 2000) . These bodies are not affected by RNases or DNases, which indicates that these structures are not formed by nucleic acid (Cohen et al., 2001; Dostie et al., 2000a) . eIF4E is exported to the nucleus via importin active pathways involving 4E-T protein (eIF4E-transporter) that binds to eIF4E in a similar region than eiF4G and 4E-BP (Dostie et al., 2000b) . About 68% of the eIF4E proteins are found in the nuclear bodies where they are involved in the export of an mRNA category from the nucleus to the cytoplasm (Culjkovic, Topisirovic, & Borden, 2007) . This mRNA category has a structure called \"sensible to eIF4E elements\" 4E-SE that allows eIF4E to recognize these mRNAs (Fig. 4C ) (Culjkovic et al., 2005) . Normally, mRNAs are prepared for export through a process regulated by the nuclear complex CBC (cap-binding complex), but for this category of mRNAs, eIF4E nuclear bodies are able to regulate their own transport (Cohen et al., 2001; Lai & Borden, 2000) . These mRNAs \"sensitive to eIF4E\" also have a long and complex 5 0 UTR end that it is hardly decondensed by helicases eIF4A/4B (Zimmer, DeBenedetti, & Graff, 2000) . Theoretically, since eIF4E is a limiting factor for the helicase recruitment, an eIF4E increase should rise the helicase activity and thus increase these specific mRNAs' protein synthesis (Zimmer et al., 2000) . However, these mRNAs \"sensitive to eIF4E\" do not show an increase in their translation initiation rate. This mRNA protein synthesis is regulated by their export from the nucleus to the cytoplasm (Lai & Borden, 2000) . Indeed, when eIF4E is overexpressed, the cyclin D1 mRNA level does not change, but the level of nuclear mRNA decreases and the level of cytoplasmic mRNA is increased. These results show that an increased in eIF4E expression increases the export of these mRNAs and thus the level of protein (Lai & Borden, 2000) . This export mechanism contributes to the oncogenic potential of eIF4E (Cohen et al., 2001) . It is therefore possible that there are, in the nucleus, negative regulators to this process identical to 4E-BPs in the cytoplasm. Several proteins can associate with eIF4E nuclear bodies such as the ribosomal protein L7 and P, eIF4G (Iborra, Jackson, & Cook, 2001) , the PRH protein (proline-rich homeodomain protein) (Topisirovic et al., 2003a) , the homeodomain proteins, the Z protein, and the PML protein which is the most studied (Campbell Dwyer et al., 2000; Cohen et al., 2001; Lai & Borden, 2000) . These proteins regulate the eIF4E-cap bond, a bond that is necessary for the mRNA export (Dostie et al., 2000a) . The majority of eIF4E nuclear protein colocalizes with the PML protein (Lai & Borden, 2000) as a result of stress, viral infection, or an interferon treatment (Regad & Chelbi-Alix, 2001 ). This protein interacts on the convex side through its RING domain using the 73th tryptophan residue (Cohen et al., 2001; Lai & Borden, 2000) . Even though this interaction site is far from the cap-binding site, this bond can inhibit the eIF4E-cap interaction (Culjkovic et al., 2007) . The PML protein binds to eIF4E and lowers its mRNA's cap affinity (100 times), thereby changing its mRNA export function (Fig. 4C ) (Cohen et al., 2001; Culjkovic et al., 2007; Kentsis et al., 2001; Lai & Borden, 2000) . PML would have an antitumor function. There are approximately 200 homeodomain proteins containing potential binding sites for eIF4E and could therefore regulate it (Culjkovic et al., 2007) . So it seems that the ability to modulate eIF4E's activity by acting on its binding to the cap is conserved from the cytoplasm to the nucleus. Finally, it has been suggested that eIF4E contributes to the mRNA translation in the nucleus (Dostie et al., 2000a; Iborra et al., 2001) . This nuclear translating phenomenon has already been observed in mammals' cells (Iborra et al., 2001) and an increasing number of proteins from the translation machinery are involved in nuclear processes. This translation may be involved in aberrant transcript elimination, by an mRNA quality control system: NMD (nonsense-mediated decay). Indeed, this system requires an active protein synthesis in order to detect the appearance of premature STOP codons leading to the synthesis of truncated proteins." ;
            <http://www.example.org/textHash>
                    "6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1693-1712>
            <http://www.example.org/end>    "1712.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "1693.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-1313-1322>
            <http://www.example.org/end>    "1322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1313.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1B)" .
    
    <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"It has to be noted that other modes of translation initiation are described. The protein eIF4E is, for example, involved in the translation of viral mRNAs that do not have a cap. In fact, it has recently been demonstrated that the calicivirus mRNAs are linked covalently to a viral protein (VPg) that acts like a substitute to the cap to recruit eIF4E (Chaudhry et al., 2006) . The VPg-binding site to eIF4E is different from the cap-binding site and from the 4E-BP protein binding site since the complex VPg/eIF4E/4E-BP1 has been isolated (Goodfellow et al., 2005) . This interaction is unique within known virus in mammals, but we can find a similar interaction in the potyvirus that infects plants (Dreher \\u0026 Miller, 2006) .\",\"cite_spans\":[{\"start\":352.0,\"end\":375.0,\"text\":\"(Chaudhry et al., 2006)\",\"ref_id\":\"BIBREF15\"},{\"start\":540.0,\"end\":565.0,\"text\":\"(Goodfellow et al., 2005)\",\"ref_id\":\"BIBREF41\"},{\"start\":701.0,\"end\":724.0,\"text\":\"(Dreher \\u0026 Miller, 2006)\",\"ref_id\":\"BIBREF31\"}],\"ref_spans\":[],\"section\":\"The CaP-Independent Translation Initiation Mechanism\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac_citespan-352-375> , <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac_citespan-540-565> , <http://covid19.aksw.org/text-e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac_citespan-701-724> ;
            <http://www.example.org/section>
                    "The CaP-Independent Translation Initiation Mechanism" ;
            <http://www.example.org/text>  "It has to be noted that other modes of translation initiation are described. The protein eIF4E is, for example, involved in the translation of viral mRNAs that do not have a cap. In fact, it has recently been demonstrated that the calicivirus mRNAs are linked covalently to a viral protein (VPg) that acts like a substitute to the cap to recruit eIF4E (Chaudhry et al., 2006) . The VPg-binding site to eIF4E is different from the cap-binding site and from the 4E-BP protein binding site since the complex VPg/eIF4E/4E-BP1 has been isolated (Goodfellow et al., 2005) . This interaction is unique within known virus in mammals, but we can find a similar interaction in the potyvirus that infects plants (Dreher & Miller, 2006) ." ;
            <http://www.example.org/textHash>
                    "e17f931d010af57c0455462f9d545eb4df801ce5eff1ae672c6a4fd5079318ac" .
    
    <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-875-908>
            <http://www.example.org/end>    "908.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF81" ;
            <http://www.example.org/start>  "875.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Niessing, Blanke, & Jackle, 2002)" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_refspan-468-476>
            <http://www.example.org/end>    "476.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 2)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1433-1457>
            <http://www.example.org/end>    "1457.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "1433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Culjkovic et al., 2005)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2645-2664>
            <http://www.example.org/end>    "2664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF122" ;
            <http://www.example.org/start>  "2645.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Yang et al., 2007)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3182-3201>
            <http://www.example.org/end>    "3201.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "3182.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cohen et al., 2001;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1078-1100>
            <http://www.example.org/end>    "1100.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1078.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dostie et al., 2000b)" .
    
    <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A new translation repression mechanism of some specific mRNAs has been described by Richter and Sonenberg (2005) . In Xenopus laevis, during oocyte development, there is a translation regulation mechanism based on the length of the poly-A tail. Some dormant but stable mRNAs have a short poly-A tail, unlike the majority of mRNAs who have a long tail. The CPEB protein controls polyadenylation by interacting with the CPE element on the mRNA 3 0 extremity. CPEB also binds to the Maskin protein which sequestrates eIF4E and prevents the translation of these specific mRNAs. When the oocytes are stimulated, a signaling cascade takes place and allows the poly-A tail\\u0027s elongation by CPEB and the Maskin protein\\u0027s moving. The translation can now start. A similar mechanism is observed in the drosophila with the Bicoid and Cup proteins (Nakamura, Sato, \\u0026 Hanyu-Nakamura, 2004; Niessing, Blanke, \\u0026 Jackle, 2002) or during neurogenesis, where the neuroguidin protein binds to eIF4E to prevent the translation ( Jung, Lorenz, \\u0026 Richter, 2006) .\",\"cite_spans\":[{\"start\":84.0,\"end\":112.0,\"text\":\"Richter and Sonenberg (2005)\",\"ref_id\":\"BIBREF88\"},{\"start\":834.0,\"end\":874.0,\"text\":\"(Nakamura, Sato, \\u0026 Hanyu-Nakamura, 2004;\",\"ref_id\":\"BIBREF77\"},{\"start\":875.0,\"end\":908.0,\"text\":\"Niessing, Blanke, \\u0026 Jackle, 2002)\",\"ref_id\":\"BIBREF81\"},{\"start\":1005.0,\"end\":1037.0,\"text\":\"( Jung, Lorenz, \\u0026 Richter, 2006)\",\"ref_id\":\"BIBREF56\"}],\"ref_spans\":[],\"section\":\"Poly-A\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-84-112> , <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-834-874> , <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-875-908> , <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-1005-1037> ;
            <http://www.example.org/section>
                    "Poly-A" ;
            <http://www.example.org/text>  "A new translation repression mechanism of some specific mRNAs has been described by Richter and Sonenberg (2005) . In Xenopus laevis, during oocyte development, there is a translation regulation mechanism based on the length of the poly-A tail. Some dormant but stable mRNAs have a short poly-A tail, unlike the majority of mRNAs who have a long tail. The CPEB protein controls polyadenylation by interacting with the CPE element on the mRNA 3 0 extremity. CPEB also binds to the Maskin protein which sequestrates eIF4E and prevents the translation of these specific mRNAs. When the oocytes are stimulated, a signaling cascade takes place and allows the poly-A tail's elongation by CPEB and the Maskin protein's moving. The translation can now start. A similar mechanism is observed in the drosophila with the Bicoid and Cup proteins (Nakamura, Sato, & Hanyu-Nakamura, 2004; Niessing, Blanke, & Jackle, 2002) or during neurogenesis, where the neuroguidin protein binds to eIF4E to prevent the translation ( Jung, Lorenz, & Richter, 2006) ." ;
            <http://www.example.org/textHash>
                    "3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-763-783>
            <http://www.example.org/end>    "783.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "763.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gross et al., 2003;" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Another strategy for inhibition of the eukaryotic factor eIF4E is to target its interaction with eIF4G, which prevents the formation of the eIF4F complex and leads to inhibition of cap-dependent translation. For example, some peptides able to disrupt eIF4E-eIF4G interaction (Hu4G, W4G, 4E-BP2) are developed. These peptides are described to induce apoptosis in MRC5 lung cells in a dose-dependent manner (Herbert et al., 2000) . More recently, a high-throughput screening was performed to identify inhibitors of the eIF4E/eIF4G interaction. The compound 4EGI-1 has been identified as a hit by binding to eIF4E and blocking its interaction with eIF4G (Moerke et al., 2007) . Although eIF4G and 4E-BPs share the same interaction site on eIF4E, 4E-BPs seem to take a larger space because 4EGI-1 does not block the eIF4E/4E-BP1 interaction. It has even been reported that 4EGI-1 increases the interaction between eIF4E and 4E-BP1, which results in the inhibition of the cap-dependent translation (Fig. 6B ). This compound has been shown to reduce the c-Myc and Bcl-2 level, to induce apoptosis, and to inhibit lung cancer cell proliferation (Fan et al., 2010) . It would be interesting to know this compound specificity to inhibit the eIF4E/ eIF4G interaction by determining all protein-protein interactions and signaling pathways that are blocked. In fact, studies have shown that it can induce apoptosis through an eIF4E/eIF4G interaction-independent mechanism, by degrading the antiapoptotic protein c-FLIP (Fan et al., 2010) . More recently, the 4E1RCat compound was characterized as an inhibitor of the interaction of eIF4E with eIF4G and 4E-BP1 (Fig. 6B) (Cencic et al., 2011a) . It has been reported that this compound may partially inhibit the cap-dependent translation and restore the chemosensitivity in a lymphoma mouse model. Another compound from the same screen, 4E2Rcat, inhibits the cap-dependent translation and the coronavirus 229E replication which is dependent on complex eIF4F (Cencic et al., 2011b) .\",\"cite_spans\":[{\"start\":405.0,\"end\":427.0,\"text\":\"(Herbert et al., 2000)\",\"ref_id\":\"BIBREF47\"},{\"start\":651.0,\"end\":672.0,\"text\":\"(Moerke et al., 2007)\",\"ref_id\":\"BIBREF74\"},{\"start\":1138.0,\"end\":1156.0,\"text\":\"(Fan et al., 2010)\",\"ref_id\":\"BIBREF33\"},{\"start\":1507.0,\"end\":1525.0,\"text\":\"(Fan et al., 2010)\",\"ref_id\":\"BIBREF33\"},{\"start\":1658.0,\"end\":1680.0,\"text\":\"(Cencic et al., 2011a)\",\"ref_id\":\"BIBREF13\"},{\"start\":1995.0,\"end\":2017.0,\"text\":\"(Cencic et al., 2011b)\",\"ref_id\":\"BIBREF14\"}],\"ref_spans\":[{\"start\":993.0,\"end\":1001.0,\"text\":\"(Fig. 6B\"},{\"start\":1648.0,\"end\":1657.0,\"text\":\"(Fig. 6B)\"}],\"section\":\"Inhibition of the eIF4E/eIF4G Interaction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1658-1680> , <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-651-672> , <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1995-2017> , <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-405-427> , <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1138-1156> , <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1507-1525> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_refspan-993-1001> , <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_refspan-1648-1657> ;
            <http://www.example.org/section>
                    "Inhibition of the eIF4E/eIF4G Interaction" ;
            <http://www.example.org/text>  "Another strategy for inhibition of the eukaryotic factor eIF4E is to target its interaction with eIF4G, which prevents the formation of the eIF4F complex and leads to inhibition of cap-dependent translation. For example, some peptides able to disrupt eIF4E-eIF4G interaction (Hu4G, W4G, 4E-BP2) are developed. These peptides are described to induce apoptosis in MRC5 lung cells in a dose-dependent manner (Herbert et al., 2000) . More recently, a high-throughput screening was performed to identify inhibitors of the eIF4E/eIF4G interaction. The compound 4EGI-1 has been identified as a hit by binding to eIF4E and blocking its interaction with eIF4G (Moerke et al., 2007) . Although eIF4G and 4E-BPs share the same interaction site on eIF4E, 4E-BPs seem to take a larger space because 4EGI-1 does not block the eIF4E/4E-BP1 interaction. It has even been reported that 4EGI-1 increases the interaction between eIF4E and 4E-BP1, which results in the inhibition of the cap-dependent translation (Fig. 6B ). This compound has been shown to reduce the c-Myc and Bcl-2 level, to induce apoptosis, and to inhibit lung cancer cell proliferation (Fan et al., 2010) . It would be interesting to know this compound specificity to inhibit the eIF4E/ eIF4G interaction by determining all protein-protein interactions and signaling pathways that are blocked. In fact, studies have shown that it can induce apoptosis through an eIF4E/eIF4G interaction-independent mechanism, by degrading the antiapoptotic protein c-FLIP (Fan et al., 2010) . More recently, the 4E1RCat compound was characterized as an inhibitor of the interaction of eIF4E with eIF4G and 4E-BP1 (Fig. 6B) (Cencic et al., 2011a) . It has been reported that this compound may partially inhibit the cap-dependent translation and restore the chemosensitivity in a lymphoma mouse model. Another compound from the same screen, 4E2Rcat, inhibits the cap-dependent translation and the coronavirus 229E replication which is dependent on complex eIF4F (Cencic et al., 2011b) ." ;
            <http://www.example.org/textHash>
                    "a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3620-3639>
            <http://www.example.org/end>    "3639.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "3620.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Furic et al., 2010)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1135-1152>
            <http://www.example.org/end>    "1152.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF69" ;
            <http://www.example.org/start>  "1135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Li et al., 2004;" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1070-1090>
            <http://www.example.org/end>    "1090.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "1070.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Amiri et al., 2001;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2145-2163>
            <http://www.example.org/end>    "2163.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "2145.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Crew et al., 2000;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2294-2317>
            <http://www.example.org/end>    "2317.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF106" ;
            <http://www.example.org/start>  "2294.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Thumma & Kratzke, 2007;" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-661-679>
            <http://www.example.org/end>    "679.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF117" ;
            <http://www.example.org/start>  "661.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Wang et al., 2005)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3945-3965>
            <http://www.example.org/end>    "3965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "3945.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cohen et al., 2001;" .
    
    <http://covid19.aksw.org/text-a0bd8433542963bc29a0e0f7584d57055f64850d2d4683acf270dd5a33d04227_citespan-404-426>
            <http://www.example.org/end>    "426.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Andrieu et al., 2010;" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-784-809>
            <http://www.example.org/end>    "809.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF80" ;
            <http://www.example.org/start>  "784.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Niedzwiecka et al., 2002;" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1148-1170>
            <http://www.example.org/end>    "1170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF73" ;
            <http://www.example.org/start>  "1148.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Minshall et al., 2007;" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-244-280>
            <http://www.example.org/end>    "280.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF83" ;
            <http://www.example.org/start>  "244.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Othumpangat, Kashon, & Joseph, 2005)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2164-2183>
            <http://www.example.org/end>    "2183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "2164.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Graff et al., 2009;" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-405-427>
            <http://www.example.org/end>    "427.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "405.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Herbert et al., 2000)" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_refspan-341-350>
            <http://www.example.org/end>    "350.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "341.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 6C)" .
    
    <http://covid19.aksw.org/text-0a0360bd083c6139c40898a98731b72be82ca2c96be65b59c2806590206a7c76>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"prevent the interaction with eIF4G and inhibit the translation. When they are hyperphosphorylated, they cannot bind to eIF4E, which is then released to participate in the protein translation initiation (Fig. 3 ) (Gingras et al., 2001) . The 4E-BP proteins and eIF4G have the same binding site to eIF4E. So there is a competition between these proteins. On the other hand, the bond between eIF4E and 4E-BP does not prevent its bond to the cap. Otherwise, some viruses can modulate eIF4E\\u0027s activity by acting on the 4E-BP phosphorylation. For example, the picornaviruses induce 4E-BP\\u0027s dephosphorylation which inhibits protein synthesis. So the 4E-BPs work as inhibitors of the cap-dependent translation.\",\"cite_spans\":[{\"start\":212.0,\"end\":234.0,\"text\":\"(Gingras et al., 2001)\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[{\"start\":202.0,\"end\":209.0,\"text\":\"(Fig. 3\"}],\"section\":\"4E-BP\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0a0360bd083c6139c40898a98731b72be82ca2c96be65b59c2806590206a7c76_citespan-212-234> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-0a0360bd083c6139c40898a98731b72be82ca2c96be65b59c2806590206a7c76_refspan-202-209> ;
            <http://www.example.org/section>
                    "4E-BP" ;
            <http://www.example.org/text>  "prevent the interaction with eIF4G and inhibit the translation. When they are hyperphosphorylated, they cannot bind to eIF4E, which is then released to participate in the protein translation initiation (Fig. 3 ) (Gingras et al., 2001) . The 4E-BP proteins and eIF4G have the same binding site to eIF4E. So there is a competition between these proteins. On the other hand, the bond between eIF4E and 4E-BP does not prevent its bond to the cap. Otherwise, some viruses can modulate eIF4E's activity by acting on the 4E-BP phosphorylation. For example, the picornaviruses induce 4E-BP's dephosphorylation which inhibits protein synthesis. So the 4E-BPs work as inhibitors of the cap-dependent translation." ;
            <http://www.example.org/textHash>
                    "0a0360bd083c6139c40898a98731b72be82ca2c96be65b59c2806590206a7c76" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-871-891>
            <http://www.example.org/end>    "891.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF124" ;
            <http://www.example.org/start>  "871.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Zimmer et al., 2000)" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-748-773>
            <http://www.example.org/end>    "773.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF97" ;
            <http://www.example.org/start>  "748.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Shenberger et al., 2005)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2287-2307>
            <http://www.example.org/end>    "2307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "2287.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lai & Borden, 2000)" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-651-672>
            <http://www.example.org/end>    "672.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF74" ;
            <http://www.example.org/start>  "651.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moerke et al., 2007)" .
    
    <http://covid19.aksw.org/text-2d156dbcfb112d3f68ce7c33a0398ec7a83f5bca26a31f9447cf04108f5e16b5_citespan-997-1020>
            <http://www.example.org/end>    "1020.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF59" ;
            <http://www.example.org/start>  "997.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kentsis et al., , 2005" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3497-3523>
            <http://www.example.org/end>    "3523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF87" ;
            <http://www.example.org/start>  "3497.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Regad & Chelbi-Alix, 2001" .
    
    <http://covid19.aksw.org/text-08fa96bac71e38ff74aa5c3dabb0bb71bfbd98dd400e2643e10225af249f61c8_citespan-363-386>
            <http://www.example.org/end>    "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "363.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Davuluri et al., 2000)" .
    
    <http://covid19.aksw.org/text-2cf4e9d8eee86c74baf0142bf48cb86f5768c71b681deaae247671e506ffd94c_citespan-386-408>
            <http://www.example.org/end>    "408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Andrieu et al., 2010)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3966-3989>
            <http://www.example.org/end>    "3989.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "3966.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Culjkovic et al., 2007;" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_citespan-2233-2259>
            <http://www.example.org/end>    "2259.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF80" ;
            <http://www.example.org/start>  "2233.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Niedzwiecka et al., 2002;" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-1540-1553>
            <http://www.example.org/end>    "1553.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF63" ;
            <http://www.example.org/start>  "1540.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kozak, 2002)" .
    
    <http://covid19.aksw.org/text-d8c3d56d9d958ce483ac0ee81a3b92342783342e1f553102cb09b7e53733b633_citespan-640-660>
            <http://www.example.org/end>    "660.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF46" ;
            <http://www.example.org/start>  "640.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Heesom et al., 2001;" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1658-1680>
            <http://www.example.org/end>    "1680.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "1658.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cencic et al., 2011a)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-1841-1877>
            <http://www.example.org/end>    "1877.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF124" ;
            <http://www.example.org/start>  "1841.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Zimmer, DeBenedetti, & Graff, 2000)" .
    
    <http://covid19.aksw.org/text-022f5b0debc3f8b26e64b9e50ae5c8d7d4acb7bf7083c23fb15d443804e68c86_refspan-76-85>
            <http://www.example.org/end>    "85.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "76.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1A)" .
    
    <http://covid19.aksw.org/text-0a0360bd083c6139c40898a98731b72be82ca2c96be65b59c2806590206a7c76_citespan-212-234>
            <http://www.example.org/end>    "234.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "212.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gingras et al., 2001)" .
    
    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-937-961>
            <http://www.example.org/end>    "961.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "937.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Blagden & Willis, 2011)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-4586-4607>
            <http://www.example.org/end>    "4607.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "4586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Iborra et al., 2001)" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-1497-1516>
            <http://www.example.org/end>    "1516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "1497.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dong et al., 2009)" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_refspan-1648-1657>
            <http://www.example.org/end>    "1657.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1648.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 6B)" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-636-673>
            <http://www.example.org/end>    "673.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF48" ;
            <http://www.example.org/start>  "636.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Hernandez and Vazquez-Pianzola (2005)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2318-2336>
            <http://www.example.org/end>    "2336.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF118" ;
            <http://www.example.org/start>  "2318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Wang et al., 2009)" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1171-1216>
            <http://www.example.org/end>    "1216.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF103" ;
            <http://www.example.org/start>  "1171.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Syntichaki, Troulinaki, & Tavernarakis, 2007)" .
    
    <http://covid19.aksw.org/text-a9bec2bbb4574a8938e498434c8ba146e8b48c35c1ad0f5dc9e54189dc0dd0bf_citespan-1507-1525>
            <http://www.example.org/end>    "1525.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "1507.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fan et al., 2010)" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-376-408>
            <http://www.example.org/end>    "408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF54" ;
            <http://www.example.org/start>  "376.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "( Joshi, Cameron, & Jagus, 2004)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2203-2231>
            <http://www.example.org/end>    "2231.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF72" ;
            <http://www.example.org/start>  "2203.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Matthews-Greer et al., 2005;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2068-2089>
            <http://www.example.org/end>    "2089.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF124" ;
            <http://www.example.org/start>  "2068.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Zimmer et al., 2000)" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-395-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "395.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Graff et al." .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-1445-1453>
            <http://www.example.org/end>    "1453.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1445.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1336-1360>
            <http://www.example.org/end>    "1360.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF84" ;
            <http://www.example.org/start>  "1336.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Polunovsky et al., 2000;" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_refspan-427-436>
            <http://www.example.org/end>    "436.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "427.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 6A)" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-1849-1871>
            <http://www.example.org/end>    "1871.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "1849.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Andrieu et al., 2010)" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-827-854>
            <http://www.example.org/end>    "854.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF110" ;
            <http://www.example.org/start>  "827.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Topisirovic et al., 2003b)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3152-3181>
            <http://www.example.org/end>    "3181.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "3152.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Campbell Dwyer et al., 2000;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_refspan-1422-1430>
            <http://www.example.org/end>    "1430.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "1422.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4C" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-3035-3062>
            <http://www.example.org/end>    "3062.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF109" ;
            <http://www.example.org/start>  "3035.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Topisirovic et al., 2003a)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3574-3595>
            <http://www.example.org/end>    "3595.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "3574.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Baylot et al., 2011;" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_refspan-455-471>
            <http://www.example.org/end>    "471.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "455.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4A  and B)" .
    
    <http://covid19.aksw.org/text-e6c1540fe257c69bae2387ba04eecccffb4fa14f2599ccbdb3621ff1756b0508>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Due to eIF4E\\u0027s important involvement in the process of tumorigenesis, several inhibitory strategies have been developed to block its functions. Cellular mRNAs can be divided into two categories: the majority of mRNAs that are \\\"highly translated\\\" even when eIF4E expression is limited and a minority of mRNAs (\\\"weakly translated\\\") which are translated when eIF4E is overexpressed like during cancer development. This second category includes genes involved in tumorigenesis. Adapted from Graff et al. (2008) .\",\"cite_spans\":[{\"start\":487.0,\"end\":506.0,\"text\":\"Graff et al. (2008)\",\"ref_id\":\"BIBREF43\"}],\"ref_spans\":[],\"section\":\"Targeting eIF4E in Cancers\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e6c1540fe257c69bae2387ba04eecccffb4fa14f2599ccbdb3621ff1756b0508_citespan-487-506> ;
            <http://www.example.org/section>
                    "Targeting eIF4E in Cancers" ;
            <http://www.example.org/text>  "Due to eIF4E's important involvement in the process of tumorigenesis, several inhibitory strategies have been developed to block its functions. Cellular mRNAs can be divided into two categories: the majority of mRNAs that are \"highly translated\" even when eIF4E expression is limited and a minority of mRNAs (\"weakly translated\") which are translated when eIF4E is overexpressed like during cancer development. This second category includes genes involved in tumorigenesis. Adapted from Graff et al. (2008) ." ;
            <http://www.example.org/textHash>
                    "e6c1540fe257c69bae2387ba04eecccffb4fa14f2599ccbdb3621ff1756b0508" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-820-842>
            <http://www.example.org/end>    "842.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "820.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Avdulov et al., 2004;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-2881-2900>
            <http://www.example.org/end>    "2900.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF50" ;
            <http://www.example.org/start>  "2881.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Holm et al., 2008)" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-538-557>
            <http://www.example.org/end>    "557.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "538.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Graff et al., 2008;" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1367-1386>
            <http://www.example.org/end>    "1386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF53" ;
            <http://www.example.org/start>  "1367.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "( Jia et al., 2012)" .
    
    <http://covid19.aksw.org/text-6404511e091643bbde30ad31e10ede7b23594c7764b980c62d0239942603c61e_citespan-2950-2981>
            <http://www.example.org/end>    "2981.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "2950.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Iborra, Jackson, & Cook, 2001)" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-1318-1335>
            <http://www.example.org/end>    "1335.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF68" ;
            <http://www.example.org/start>  "1318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Li et al., 2003;" .
    
    <http://covid19.aksw.org/text-b86c0f7117dc74f6019a6a4eef2a26df3889d5883e847c04e768ada36615b3cf_citespan-216-243>
            <http://www.example.org/end>    "243.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF76" ;
            <http://www.example.org/start>  "216.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Murata & Shimotohno, 2006;" .
    
    <http://covid19.aksw.org/text-3734f8c7c87ddd41e9ddb1d2832d8ca9571e97b13024282b695f37d56cf7e916_citespan-422-438>
            <http://www.example.org/end>    "438.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF123" ;
            <http://www.example.org/start>  "422.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Yu et al., 2010)" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-675-697>
            <http://www.example.org/end>    "697.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "675.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Avdulov et al., 2004)" .
    
    <http://covid19.aksw.org/text-a96d58fcf7e3c63f722afca3bda8b8a499df15589407acd4ecb08a01fdf3d619_citespan-469-505>
            <http://www.example.org/end>    "505.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "469.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gingras, Raught, & Sonenberg, 2001;" .
    
    <http://covid19.aksw.org/text-c75ce4d97f9e4471a4f631821321b96087ac45dbbd28cb66db4d618dd3194939_citespan-477-499>
            <http://www.example.org/end>    "499.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF95" ;
            <http://www.example.org/start>  "477.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Scheper et al., 2001)" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_citespan-2899-2916>
            <http://www.example.org/end>    "2916.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF100" ;
            <http://www.example.org/start>  "2899.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sonenberg, 2008)" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-1091-1112>
            <http://www.example.org/end>    "1112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "1091.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Dinkova et al., 2005;" .
    
    <http://covid19.aksw.org/text-35dbecda28a56f8599650000c03bc979137c5d8cd04a330340b7292cb9291c7b_citespan-3596-3619>
            <http://www.example.org/end>    "3619.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "3596.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Bianchini et al., 2008;" .
    
    <http://covid19.aksw.org/text-d9682aa5f2491a2546ef2daca7ed8531916e76ca4b2f5e35237c4dc0a58048ff>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Cell and tissue growth depend on protein synthesis. eIF4E\\u0027s expression is significantly higher in human malignant tissues than in normal tissues. For cells to be viable, it is important for protein translation to be closely regulated to prevent malignant transformation and cancer development. The translation control is rather at initiation, even though there are controls during elongation phase. eIF4E\\u0027s activity is controlled by several mechanisms described below (Van Der Kelen et al., 2009) . Although eIF4E is well studied for its role in the translation initiation and for its involvement in tumorigenesis, little is known about its expression regulation. Surprisingly, eIF4E\\u0027s overexpression does not lead to a global increase in the proteins\\u0027 translation, but it leads to a selective increase in the translation of mRNAs that have a structure called \\\"sensible elements to eIF4E\\\" and that are involved in tumorigenesis.\",\"cite_spans\":[{\"start\":468.0,\"end\":496.0,\"text\":\"(Van Der Kelen et al., 2009)\",\"ref_id\":\"BIBREF113\"}],\"ref_spans\":[],\"section\":\"Expression\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d9682aa5f2491a2546ef2daca7ed8531916e76ca4b2f5e35237c4dc0a58048ff_citespan-468-496> ;
            <http://www.example.org/section>
                    "Expression" ;
            <http://www.example.org/text>  "Cell and tissue growth depend on protein synthesis. eIF4E's expression is significantly higher in human malignant tissues than in normal tissues. For cells to be viable, it is important for protein translation to be closely regulated to prevent malignant transformation and cancer development. The translation control is rather at initiation, even though there are controls during elongation phase. eIF4E's activity is controlled by several mechanisms described below (Van Der Kelen et al., 2009) . Although eIF4E is well studied for its role in the translation initiation and for its involvement in tumorigenesis, little is known about its expression regulation. Surprisingly, eIF4E's overexpression does not lead to a global increase in the proteins' translation, but it leads to a selective increase in the translation of mRNAs that have a structure called \"sensible elements to eIF4E\" and that are involved in tumorigenesis." ;
            <http://www.example.org/textHash>
                    "d9682aa5f2491a2546ef2daca7ed8531916e76ca4b2f5e35237c4dc0a58048ff" .
    
    <http://covid19.aksw.org/text-6a8360e72ec32e350a9696c542978e6c95f72cfb4ec871fd26fe7a00e0acc7d3_refspan-2584-2592>
            <http://www.example.org/end>    "2592.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "2584.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3)" .
    
    <http://covid19.aksw.org/text-3c1f57df04be9f434e4183f6c163ee505ae8a6f0bbca1f13605c0ee78774aa1e_citespan-1005-1037>
            <http://www.example.org/end>    "1037.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF56" ;
            <http://www.example.org/start>  "1005.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "( Jung, Lorenz, & Richter, 2006)" .
    
    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Thus, there are proteins involved in proliferation (cyclin D1, c-Myc, CDK2), apoptosis (survivin, Bcl-2, Mcl-1), angiogenesis (VEGF, FGF2), and metastasis (MMP9, heparanase) (Mamane et al., 2004; Schmidt, 2004; Zimmer et al., 2000) . Given that eIF4E is the limiting factor in the translation initiation mechanism, mRNAs compete in normal cellular conditions. However, if eIF4E\\u0027s level is increased like in cancers, the mRNAs that are poorly translated are selected and translated disproportionately (Fig. 5) (De Benedetti \\u0026 Graff, 2004; Graff et al., 2008; Mamane et al., 2004) . Thus, the eIF4E factor governs cancer\\u0027s progression by coordinating certain genes\\u0027 expression (Avdulov et al., 2004) . In addition, it is described that eIF4E overexpression increases specific mRNAs \\\"sensitive to eIF4E\\\" transport and translation (Topisirovic et al., 2003b) . Some of these mRNAs encode proteins involved in cell proliferation and tumorigenesis, such as cyclin D1. This transport mechanism would therefore contribute to eIF4E oncogenic potential (Cohen et al., 2001) .\",\"cite_spans\":[{\"start\":174.0,\"end\":195.0,\"text\":\"(Mamane et al., 2004;\",\"ref_id\":\"BIBREF71\"},{\"start\":196.0,\"end\":210.0,\"text\":\"Schmidt, 2004;\",\"ref_id\":\"BIBREF96\"},{\"start\":211.0,\"end\":231.0,\"text\":\"Zimmer et al., 2000)\",\"ref_id\":\"BIBREF124\"},{\"start\":509.0,\"end\":537.0,\"text\":\"(De Benedetti \\u0026 Graff, 2004;\",\"ref_id\":\"BIBREF24\"},{\"start\":538.0,\"end\":557.0,\"text\":\"Graff et al., 2008;\",\"ref_id\":\"BIBREF43\"},{\"start\":558.0,\"end\":578.0,\"text\":\"Mamane et al., 2004)\",\"ref_id\":\"BIBREF71\"},{\"start\":675.0,\"end\":697.0,\"text\":\"(Avdulov et al., 2004)\",\"ref_id\":\"BIBREF4\"},{\"start\":827.0,\"end\":854.0,\"text\":\"(Topisirovic et al., 2003b)\",\"ref_id\":\"BIBREF110\"},{\"start\":1043.0,\"end\":1063.0,\"text\":\"(Cohen et al., 2001)\",\"ref_id\":\"BIBREF17\"}],\"ref_spans\":[{\"start\":500.0,\"end\":508.0,\"text\":\"(Fig. 5)\",\"ref_id\":\"FIGREF2\"}],\"section\":\"EIF4E\\u0027s Mechanisms in Cancer\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-211-231> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-675-697> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-1043-1063> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-509-537> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-174-195> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-558-578> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-538-557> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-827-854> , <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_citespan-196-210> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e_refspan-500-508> ;
            <http://www.example.org/section>
                    "EIF4E's Mechanisms in Cancer" ;
            <http://www.example.org/text>  "Thus, there are proteins involved in proliferation (cyclin D1, c-Myc, CDK2), apoptosis (survivin, Bcl-2, Mcl-1), angiogenesis (VEGF, FGF2), and metastasis (MMP9, heparanase) (Mamane et al., 2004; Schmidt, 2004; Zimmer et al., 2000) . Given that eIF4E is the limiting factor in the translation initiation mechanism, mRNAs compete in normal cellular conditions. However, if eIF4E's level is increased like in cancers, the mRNAs that are poorly translated are selected and translated disproportionately (Fig. 5) (De Benedetti & Graff, 2004; Graff et al., 2008; Mamane et al., 2004) . Thus, the eIF4E factor governs cancer's progression by coordinating certain genes' expression (Avdulov et al., 2004) . In addition, it is described that eIF4E overexpression increases specific mRNAs \"sensitive to eIF4E\" transport and translation (Topisirovic et al., 2003b) . Some of these mRNAs encode proteins involved in cell proliferation and tumorigenesis, such as cyclin D1. This transport mechanism would therefore contribute to eIF4E oncogenic potential (Cohen et al., 2001) ." ;
            <http://www.example.org/textHash>
                    "e3caa408a51c3b089c2d8794650ba74f9430bac134d44244da56fc75e6d3de6e" .
    
    <http://covid19.aksw.org/text-5092c5f649b6e2f6d0158d84ff8a598120122a00b845753669ad0abf29008f68_citespan-559-582>
            <http://www.example.org/end>    "582.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF91" ;
            <http://www.example.org/start>  "559.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Rosettani et al., 2007)" .
    
    <http://covid19.aksw.org/text-4783c43ec2d158747e966db5df26a1f2fc85d2f480867ab3093dcfb3979f1666_citespan-1246-1266>
            <http://www.example.org/end>    "1266.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF42" ;
            <http://www.example.org/start>  "1246.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Graff et al., 2007)" .
}
<http://covid19.aksw.org/73e3951a5f89df179c51837227923c5e6cc883f5> {
    <http://covid19.aksw.org/text-1b036157680b075b9c12ad3f77dbb973dde0aa5d621d13d19d364e120038c531_citespan-140-142>
            <http://www.example.org/end>    "142.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "140.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "64" .
    
    <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-1098-1100>
            <http://www.example.org/end>    "1100.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF78" ;
            <http://www.example.org/start>  "1098.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "78" .
    
    <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a_citespan-99-101>
            <http://www.example.org/end>    "101.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF65" ;
            <http://www.example.org/start>  "99.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "65" .
    
    <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The gastrointestinal tract and liver are often affected by acute graft-versus-host disease (GVHD). 65 Acute hepatic GVHD occurs in the first 100 days after allogeneic stem-cell transplantation. GVHD arises from expansion of the population of donor T cells in the transplant recipient. Risk factors for developing GVHD include an HLA mismatch, gender mismatch, and high number of T cells transfused from the donor. Liver involvement typically follows skin and gastrointestinal involvement. When profound cholestasis develops, the prognosis is poor. A serum bilirubin level greater than 6.1 mg/dL establishes a diagnosis of severe GVHD. 66 The pathophysiology is complex and likely involves a constellation of immune-mediated features, including cytokine activation, endothelial damage from conditioning regimens, and many antigen-presenting cells in target organs. Histologically, lymphocytes are seen infiltrating small bile ducts, and epithelial cells undergo apoptosis. Ursodeoxycholic acid is effective in preventing hepatic GVHD and is administered as prophylaxis for the first 80 days after hematopoietic stem-cell transplantation. 67 Immunosuppression is the foundation of therapy for GVHD. When chronic liver GVHD occurs, destructive bile duct damage is also characteristic, but progressive fibrosis is unusual except in cases of concomitant chronic liver disease such as hepatitis C.\",\"cite_spans\":[{\"start\":99.0,\"end\":101.0,\"text\":\"65\",\"ref_id\":\"BIBREF65\"},{\"start\":635.0,\"end\":637.0,\"text\":\"66\",\"ref_id\":\"BIBREF66\"},{\"start\":1137.0,\"end\":1139.0,\"text\":\"67\",\"ref_id\":\"BIBREF67\"}],\"ref_spans\":[],\"section\":\"HEPATIC GRAFT-VERSUS-HOST DISEASE\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a_citespan-99-101> , <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a_citespan-635-637> , <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a_citespan-1137-1139> ;
            <http://www.example.org/section>
                    "HEPATIC GRAFT-VERSUS-HOST DISEASE" ;
            <http://www.example.org/text>  "The gastrointestinal tract and liver are often affected by acute graft-versus-host disease (GVHD). 65 Acute hepatic GVHD occurs in the first 100 days after allogeneic stem-cell transplantation. GVHD arises from expansion of the population of donor T cells in the transplant recipient. Risk factors for developing GVHD include an HLA mismatch, gender mismatch, and high number of T cells transfused from the donor. Liver involvement typically follows skin and gastrointestinal involvement. When profound cholestasis develops, the prognosis is poor. A serum bilirubin level greater than 6.1 mg/dL establishes a diagnosis of severe GVHD. 66 The pathophysiology is complex and likely involves a constellation of immune-mediated features, including cytokine activation, endothelial damage from conditioning regimens, and many antigen-presenting cells in target organs. Histologically, lymphocytes are seen infiltrating small bile ducts, and epithelial cells undergo apoptosis. Ursodeoxycholic acid is effective in preventing hepatic GVHD and is administered as prophylaxis for the first 80 days after hematopoietic stem-cell transplantation. 67 Immunosuppression is the foundation of therapy for GVHD. When chronic liver GVHD occurs, destructive bile duct damage is also characteristic, but progressive fibrosis is unusual except in cases of concomitant chronic liver disease such as hepatitis C." ;
            <http://www.example.org/textHash>
                    "a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a" .
    
    <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Viral diseases can occur as latent infections that reactivate in immunocompromised hosts or de novo infections in otherwise healthy persons. Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are DNA viruses in the herpesvirus family that can involve the liver in either scenario. Jaundice in acute mononucleosis occurs in up to 10% of cases. 37 By contrast, EBV reactivation with subsequent development of posttransplant lymphoproliferative disorder (PTLD) is often characterized by jaundice in liver transplant recipients (see later discussion). A similar mononucleosislike illness can occur in healthy patients with acute CMV infection, which is characterized pathologically by focal hepatocyte and bile duct damage. 38 CMV infection has specific cholestatic features in certain immunocompromised settings, as in neonates, in whom obstructive biliary disease and neonatal giant cell hepatitis with cholestasis can occur. 39 Jaundice was found in 9 of 9 infants infected perinatally with CMV in a case series from Saudi Arabia. 40 CMV infection in patients with AIDS has been a cause of HIV cholangiopathy, an infectious form of sclerosing cholangitis that is rarely seen. CMV infection usually occurs 1 to 4 months after solid organ transplantation and is typically characterized by acute hepatitis with pathologic features in the liver of CMV inclusions and foci of microabscesses. Agarwal and colleagues 41 reported a case of fibrosing cholestatic hepatitis caused by CMV infection in a renal transplant recipient. After solid organ transplantation, CMV-positive recipients or recipients of CMV-positive donor organs should receive prophylaxis with valganciclovir.\",\"cite_spans\":[{\"start\":343.0,\"end\":345.0,\"text\":\"37\",\"ref_id\":\"BIBREF37\"},{\"start\":720.0,\"end\":722.0,\"text\":\"38\",\"ref_id\":\"BIBREF38\"},{\"start\":924.0,\"end\":926.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1030.0,\"end\":1032.0,\"text\":\"40\",\"ref_id\":\"BIBREF40\"},{\"start\":1409.0,\"end\":1411.0,\"text\":\"41\",\"ref_id\":\"BIBREF41\"}],\"ref_spans\":[],\"section\":\"SYSTEMIC VIRAL INFECTIONS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-343-345> , <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-720-722> , <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-924-926> , <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-1030-1032> , <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-1409-1411> ;
            <http://www.example.org/section>
                    "SYSTEMIC VIRAL INFECTIONS" ;
            <http://www.example.org/text>  "Viral diseases can occur as latent infections that reactivate in immunocompromised hosts or de novo infections in otherwise healthy persons. Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are DNA viruses in the herpesvirus family that can involve the liver in either scenario. Jaundice in acute mononucleosis occurs in up to 10% of cases. 37 By contrast, EBV reactivation with subsequent development of posttransplant lymphoproliferative disorder (PTLD) is often characterized by jaundice in liver transplant recipients (see later discussion). A similar mononucleosislike illness can occur in healthy patients with acute CMV infection, which is characterized pathologically by focal hepatocyte and bile duct damage. 38 CMV infection has specific cholestatic features in certain immunocompromised settings, as in neonates, in whom obstructive biliary disease and neonatal giant cell hepatitis with cholestasis can occur. 39 Jaundice was found in 9 of 9 infants infected perinatally with CMV in a case series from Saudi Arabia. 40 CMV infection in patients with AIDS has been a cause of HIV cholangiopathy, an infectious form of sclerosing cholangitis that is rarely seen. CMV infection usually occurs 1 to 4 months after solid organ transplantation and is typically characterized by acute hepatitis with pathologic features in the liver of CMV inclusions and foci of microabscesses. Agarwal and colleagues 41 reported a case of fibrosing cholestatic hepatitis caused by CMV infection in a renal transplant recipient. After solid organ transplantation, CMV-positive recipients or recipients of CMV-positive donor organs should receive prophylaxis with valganciclovir." ;
            <http://www.example.org/textHash>
                    "106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba" .
    
    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-926-928>
            <http://www.example.org/end>    "928.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "926.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "45" .
    
    <http://covid19.aksw.org/73e3951a5f89df179c51837227923c5e6cc883f5>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "73e3951a5f89df179c51837227923c5e6cc883f5" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552> , <http://covid19.aksw.org/text-80d6f3cefce92ead123d4898b5db8bc0a2331cd9f7cb9c1a062a7f55a24ed87f> , <http://covid19.aksw.org/text-dd60a0a0c2ac73203ce4424491eb010c41d0b50188dab7da779f6420829a250e> , <http://covid19.aksw.org/text-41ab4517985b7aeceef69ced4ef7051dc78406ae73a67101338fabbadcf2b396> , <http://covid19.aksw.org/text-ffc08f0dcd1af315a478ffa4685a0bed8e808827fe80ea7f7e64b9b548e8d57f> , <http://covid19.aksw.org/text-5ed7ddba5f2d9d883d54db5468d94d009b6af499d285c7a9d681f44a60b0d20f> , <http://covid19.aksw.org/text-8b62842eb29f8edc5f2d8a7b8a83d135b7f2bfbf7a080ccd715ecdcc401a17a9> , <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba> , <http://covid19.aksw.org/text-d35a99bc1a3faa6de348d851dd83cee1895ebf816be08b52ffbbd08c76a36e4e> , <http://covid19.aksw.org/text-d68e0b5cf9b35bdc8e9dc39e2c5430946ed3ae7e01c9c8cff78c1ff82381bfcb> , <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a> , <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3> , <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026> , <http://covid19.aksw.org/text-63f54dd42e18a82ad912df3b320deefa3a98358969551e9de5ae744502ddac3a> , <http://covid19.aksw.org/text-85193ced2cdff58fd1953d48f161c1393e0810c35e86190f83a26794b3cca16e> , <http://covid19.aksw.org/text-1b036157680b075b9c12ad3f77dbb973dde0aa5d621d13d19d364e120038c531> , <http://covid19.aksw.org/text-dae15f946d1f95d9223d551c68fb994ca16a970b8d1cf70a0adb716e94ea10a5> , <http://covid19.aksw.org/text-9e2cc9b75784f698d6cf71d4e5104b243005709e908d126507a7466594c80863> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050> , <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48> , <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb> , <http://covid19.aksw.org/text-5d2f7d8adc501cd3a46c34063f802a85705f4f68ab6b734977b8e028b284b816> , <http://covid19.aksw.org/text-4a9b7eeae1db8c0d0b7fbeeb0717d374d507d6471210480912d29f8c7f9aaaa5> .
    
    <http://covid19.aksw.org/text-5d2f7d8adc501cd3a46c34063f802a85705f4f68ab6b734977b8e028b284b816_citespan-760-762>
            <http://www.example.org/end>    "762.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF72" ;
            <http://www.example.org/start>  "760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "72" .
    
    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_refspan-969-977>
            <http://www.example.org/end>    "977.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "969.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 2)" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2175-2178>
            <http://www.example.org/end>    "2178.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "2175.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "15," .
    
    <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a_citespan-635-637>
            <http://www.example.org/end>    "637.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF66" ;
            <http://www.example.org/start>  "635.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "66" .
    
    <http://covid19.aksw.org/text-85193ced2cdff58fd1953d48f161c1393e0810c35e86190f83a26794b3cca16e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Heart failure can cause a variety of hepatic manifestations, from asymptomatic increases of liver biochemical test levels to cirrhosis and acute hepatic failure. 73 Acute and chronic hepatic congestion are associated with a modest hyperbilirubinemia in 1.2% to 20% of patients, respectively. In a retrospective cohort study of 661 patients from the Royal Cornwall Hospital in England who were referred over a 4-year to 5-year period to a jaundice hotline, 8 of the 661 (1.2%) were found to have a primary cardiac cause of cholestasis. 74 The hyperbilirubinemia of heart failure is typically unconjugated, with a serum bilirubin level of less than 3 mg/dL, but it can be conjugated and associated with higher bilirubin levels. Jaundice may become worse with repeated episodes of heart failure, often in association with a cardiac index less than 1.5 L/min/m 2 . Pathologically, the low-flow state of heart failure and resulting reduced oxygen tension cause zone 3 hepatic necrosis and ischemic biliary changes with cholestasis from bile thrombi formation. Bilirubinostasis is also postulated to occur as a result of extrinsic compression from sinusoidal and hepatic venule dilatation. Ischemic hepatitis (shock liver), which can result from myocardial infarction, massive pulmonary embolus, arrhythmia, or cardiac tamponade, is a distinct entity characterized by increased serum aminotransferase levels of at least 20 times the upper limit of normal and a rapid return to normal. Similarly high serum lactate dehydrogenase levels are characteristic. Seeto and colleagues 75 compared 31 patients with ischemic hepatitis with 31 patients with hypovolemic shock secondary to trauma and found an average total bilirubin level of 2.8 mg/dL in the ischemic hepatitis cohort compared with 0.8 mg/dL in the traumatic shock group. Classically, the peak in serum bilirubin occurs as the aminotransferase levels are declining.\",\"cite_spans\":[{\"start\":162.0,\"end\":164.0,\"text\":\"73\",\"ref_id\":\"BIBREF73\"},{\"start\":535.0,\"end\":537.0,\"text\":\"74\",\"ref_id\":\"BIBREF74\"}],\"ref_spans\":[],\"section\":\"CARDIAC DISEASE\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-85193ced2cdff58fd1953d48f161c1393e0810c35e86190f83a26794b3cca16e_citespan-162-164> , <http://covid19.aksw.org/text-85193ced2cdff58fd1953d48f161c1393e0810c35e86190f83a26794b3cca16e_citespan-535-537> ;
            <http://www.example.org/section>
                    "CARDIAC DISEASE" ;
            <http://www.example.org/text>  "Heart failure can cause a variety of hepatic manifestations, from asymptomatic increases of liver biochemical test levels to cirrhosis and acute hepatic failure. 73 Acute and chronic hepatic congestion are associated with a modest hyperbilirubinemia in 1.2% to 20% of patients, respectively. In a retrospective cohort study of 661 patients from the Royal Cornwall Hospital in England who were referred over a 4-year to 5-year period to a jaundice hotline, 8 of the 661 (1.2%) were found to have a primary cardiac cause of cholestasis. 74 The hyperbilirubinemia of heart failure is typically unconjugated, with a serum bilirubin level of less than 3 mg/dL, but it can be conjugated and associated with higher bilirubin levels. Jaundice may become worse with repeated episodes of heart failure, often in association with a cardiac index less than 1.5 L/min/m 2 . Pathologically, the low-flow state of heart failure and resulting reduced oxygen tension cause zone 3 hepatic necrosis and ischemic biliary changes with cholestasis from bile thrombi formation. Bilirubinostasis is also postulated to occur as a result of extrinsic compression from sinusoidal and hepatic venule dilatation. Ischemic hepatitis (shock liver), which can result from myocardial infarction, massive pulmonary embolus, arrhythmia, or cardiac tamponade, is a distinct entity characterized by increased serum aminotransferase levels of at least 20 times the upper limit of normal and a rapid return to normal. Similarly high serum lactate dehydrogenase levels are characteristic. Seeto and colleagues 75 compared 31 patients with ischemic hepatitis with 31 patients with hypovolemic shock secondary to trauma and found an average total bilirubin level of 2.8 mg/dL in the ischemic hepatitis cohort compared with 0.8 mg/dL in the traumatic shock group. Classically, the peak in serum bilirubin occurs as the aminotransferase levels are declining." ;
            <http://www.example.org/textHash>
                    "85193ced2cdff58fd1953d48f161c1393e0810c35e86190f83a26794b3cca16e" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1912-1914>
            <http://www.example.org/end>    "1914.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF58" ;
            <http://www.example.org/start>  "1912.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "58" .
    
    <http://covid19.aksw.org/text-41ab4517985b7aeceef69ced4ef7051dc78406ae73a67101338fabbadcf2b396_citespan-493-495>
            <http://www.example.org/end>    "495.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF42" ;
            <http://www.example.org/start>  "493.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "42" .
    
    <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The consequences of parenteral nutrition on the development of cholestatic liver disease are reviewed in detail elsewhere. Cholestasis in neonates is especially problematic and can progress to life-threatening liver dysfunction. The incidence of parenteral nutrition-associated liver complications has decreased in neonates over time. 80 The duration of parenteral nutrition in infants correlates with the risk of developing more progressive cholestatic jaundice. After 10 days of parenteral nutrition, canalicular cholestasis was present in 84.2% of infants, and after 3 weeks, bile duct proliferation was found in 63.6% of infants. 81 The pathogenesis of parenteral nutrition-associated cholestasis is multifactorial. The neonatal liver is immature and unable to excrete bile salts at a normal rate, thereby leading to bile acid toxicity, particularly from the secondary bile acid lithocholate. Bacterial translocation across an underdeveloped or unused segment of intestine causes systemic endotoxemia and contributes to cholestasis in the context of altered postsurgical anatomy (eg, bypass, short bowel, absent ileocecal valve). Enteral intake stimulates bile flow as a result of cholecystokinin (CCK) release, and in the absence of CCK, gallbladder dysmotility occurs and can result in biliary sludge, gallstones, and even acalculous cholecystitis. Hepatic steatosis is a more common manifestation in adult patients on parenteral nutrition, but cholestasis from biliary sludge and gallstones is also encountered. Early resumption of oral intake is critical to preventing the development of parenteral nutrition-associated cholestasis, as is cycling of the parenteral nutrition infusion to allow for normalization of insulin and counterregulatory hormone levels. Ursodeoxycholic acid is effective for the prevention of cholestasis in patients with short bowel syndrome on long-term parenteral nutrition. 82 \",\"cite_spans\":[{\"start\":335.0,\"end\":337.0,\"text\":\"80\",\"ref_id\":\"BIBREF80\"},{\"start\":634.0,\"end\":636.0,\"text\":\"81\",\"ref_id\":\"BIBREF81\"},{\"start\":1909.0,\"end\":1911.0,\"text\":\"82\",\"ref_id\":\"BIBREF82\"}],\"ref_spans\":[],\"section\":\"TOTAL PARENTERAL NUTRITION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48_citespan-335-337> , <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48_citespan-634-636> , <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48_citespan-1909-1911> ;
            <http://www.example.org/section>
                    "TOTAL PARENTERAL NUTRITION" ;
            <http://www.example.org/text>  "The consequences of parenteral nutrition on the development of cholestatic liver disease are reviewed in detail elsewhere. Cholestasis in neonates is especially problematic and can progress to life-threatening liver dysfunction. The incidence of parenteral nutrition-associated liver complications has decreased in neonates over time. 80 The duration of parenteral nutrition in infants correlates with the risk of developing more progressive cholestatic jaundice. After 10 days of parenteral nutrition, canalicular cholestasis was present in 84.2% of infants, and after 3 weeks, bile duct proliferation was found in 63.6% of infants. 81 The pathogenesis of parenteral nutrition-associated cholestasis is multifactorial. The neonatal liver is immature and unable to excrete bile salts at a normal rate, thereby leading to bile acid toxicity, particularly from the secondary bile acid lithocholate. Bacterial translocation across an underdeveloped or unused segment of intestine causes systemic endotoxemia and contributes to cholestasis in the context of altered postsurgical anatomy (eg, bypass, short bowel, absent ileocecal valve). Enteral intake stimulates bile flow as a result of cholecystokinin (CCK) release, and in the absence of CCK, gallbladder dysmotility occurs and can result in biliary sludge, gallstones, and even acalculous cholecystitis. Hepatic steatosis is a more common manifestation in adult patients on parenteral nutrition, but cholestasis from biliary sludge and gallstones is also encountered. Early resumption of oral intake is critical to preventing the development of parenteral nutrition-associated cholestasis, as is cycling of the parenteral nutrition infusion to allow for normalization of insulin and counterregulatory hormone levels. Ursodeoxycholic acid is effective for the prevention of cholestasis in patients with short bowel syndrome on long-term parenteral nutrition. 82 " ;
            <http://www.example.org/textHash>
                    "2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48" .
    
    <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-674-676>
            <http://www.example.org/end>    "676.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF76" ;
            <http://www.example.org/start>  "674.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "76" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-383-385>
            <http://www.example.org/end>    "385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF53" ;
            <http://www.example.org/start>  "383.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "53" .
    
    <http://covid19.aksw.org/text-8b62842eb29f8edc5f2d8a7b8a83d135b7f2bfbf7a080ccd715ecdcc401a17a9_citespan-964-966>
            <http://www.example.org/end>    "966.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF51" ;
            <http://www.example.org/start>  "964.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "51" .
    
    <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Thyroid disease may affect hepatic dysfunction in a few distinct circumstances. Primary biliary cirrhosis and hypothyroidism may occur together because of their shared autoimmune pathogenesis. Jaundice in patients with myxedema coma is typically caused by acute hepatic congestion from heart failure. 68 Several reports in the adult and pediatric literature describe cholestatic hepatitis occurring in patients with Graves disease. 69, 70 A mild increase in the serum alkaline phosphatase level occurs in 65% of patients with hyperthyroidism, although the increase can also arise from bone. Simultaneous heart failure may complicate the recognition of hepatic dysfunction caused by thyrotoxic crisis, which can eventuate in acute liver failure.\",\"cite_spans\":[{\"start\":301.0,\"end\":303.0,\"text\":\"68\",\"ref_id\":\"BIBREF68\"},{\"start\":432.0,\"end\":435.0,\"text\":\"69,\",\"ref_id\":\"BIBREF69\"},{\"start\":436.0,\"end\":438.0,\"text\":\"70\",\"ref_id\":\"BIBREF70\"}],\"ref_spans\":[],\"section\":\"ENDOCRINE DYSFUNCTION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3_citespan-301-303> , <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3_citespan-432-435> , <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3_citespan-436-438> ;
            <http://www.example.org/section>
                    "ENDOCRINE DYSFUNCTION" ;
            <http://www.example.org/text>  "Thyroid disease may affect hepatic dysfunction in a few distinct circumstances. Primary biliary cirrhosis and hypothyroidism may occur together because of their shared autoimmune pathogenesis. Jaundice in patients with myxedema coma is typically caused by acute hepatic congestion from heart failure. 68 Several reports in the adult and pediatric literature describe cholestatic hepatitis occurring in patients with Graves disease. 69, 70 A mild increase in the serum alkaline phosphatase level occurs in 65% of patients with hyperthyroidism, although the increase can also arise from bone. Simultaneous heart failure may complicate the recognition of hepatic dysfunction caused by thyrotoxic crisis, which can eventuate in acute liver failure." ;
            <http://www.example.org/textHash>
                    "2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3" .
    
    <http://covid19.aksw.org/text-8b62842eb29f8edc5f2d8a7b8a83d135b7f2bfbf7a080ccd715ecdcc401a17a9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Hemophagocytic syndrome, or hemophagocytic lymphohistiocytosis (HLH), is a rare condition involving the proliferation of macrophages responsible for phagocytosis of blood cells in hematopoietic organs. Hematologic malignancies, infections (histoplasmosis, tuberculosis, CMV infection, HIV infection), or autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, Still disease) provoke a sustained immune activation of histiocytes, natural killer (NK) cells, and cytotoxic lymphocytes. Germline mutations in perforin have been found in familial cases of HLH. 50 Perforin is a cytolytic protein expressed by NK cells and cytotoxic T cells that is critical for inducing apoptosis of infected cells. Clinically, the features of HLH include fever, hepatosplenomegaly, cytopenias in at least 2 cell lines, hypertriglyceridemia or hypofibrinogenemia (or both), and a high serum ferritin level. In a case series from France of 30 patients with hepatic HLH, 51 22 had a previous diagnosis of lymphoma or leukemia. Nineteen of the 30 patients were admitted to the hospital because of hepatic manifestations of the disease, including 50% with jaundice. Liver biopsies were performed in 25 patients and in all cases showed hemophagocytosis, Kupffer cell hyperplasia, and sinusoidal dilatation. Of the original cohort, there were 12 deaths caused by multiorgan failure or sepsis. Fifteen of 21 patients who could be treated achieved a complete remission. A high serum bilirubin or alkaline phosphatase level was associated with a poorer prognosis. HLH is a glucocorticoid-responsive disease, and current therapy combines dexamethasone with etoposide followed by an allogeneic hematopoietic stem-cell transplant in cases of genetic HLH or in the context of hematologic malignancy.\",\"cite_spans\":[{\"start\":573.0,\"end\":575.0,\"text\":\"50\",\"ref_id\":\"BIBREF50\"},{\"start\":964.0,\"end\":966.0,\"text\":\"51\",\"ref_id\":\"BIBREF51\"}],\"ref_spans\":[],\"section\":\"HEMOPHAGOCYTIC SYNDROME\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-8b62842eb29f8edc5f2d8a7b8a83d135b7f2bfbf7a080ccd715ecdcc401a17a9_citespan-573-575> , <http://covid19.aksw.org/text-8b62842eb29f8edc5f2d8a7b8a83d135b7f2bfbf7a080ccd715ecdcc401a17a9_citespan-964-966> ;
            <http://www.example.org/section>
                    "HEMOPHAGOCYTIC SYNDROME" ;
            <http://www.example.org/text>  "Hemophagocytic syndrome, or hemophagocytic lymphohistiocytosis (HLH), is a rare condition involving the proliferation of macrophages responsible for phagocytosis of blood cells in hematopoietic organs. Hematologic malignancies, infections (histoplasmosis, tuberculosis, CMV infection, HIV infection), or autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, Still disease) provoke a sustained immune activation of histiocytes, natural killer (NK) cells, and cytotoxic lymphocytes. Germline mutations in perforin have been found in familial cases of HLH. 50 Perforin is a cytolytic protein expressed by NK cells and cytotoxic T cells that is critical for inducing apoptosis of infected cells. Clinically, the features of HLH include fever, hepatosplenomegaly, cytopenias in at least 2 cell lines, hypertriglyceridemia or hypofibrinogenemia (or both), and a high serum ferritin level. In a case series from France of 30 patients with hepatic HLH, 51 22 had a previous diagnosis of lymphoma or leukemia. Nineteen of the 30 patients were admitted to the hospital because of hepatic manifestations of the disease, including 50% with jaundice. Liver biopsies were performed in 25 patients and in all cases showed hemophagocytosis, Kupffer cell hyperplasia, and sinusoidal dilatation. Of the original cohort, there were 12 deaths caused by multiorgan failure or sepsis. Fifteen of 21 patients who could be treated achieved a complete remission. A high serum bilirubin or alkaline phosphatase level was associated with a poorer prognosis. HLH is a glucocorticoid-responsive disease, and current therapy combines dexamethasone with etoposide followed by an allogeneic hematopoietic stem-cell transplant in cases of genetic HLH or in the context of hematologic malignancy." ;
            <http://www.example.org/textHash>
                    "8b62842eb29f8edc5f2d8a7b8a83d135b7f2bfbf7a080ccd715ecdcc401a17a9" .
    
    <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3_citespan-301-303>
            <http://www.example.org/end>    "303.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF68" ;
            <http://www.example.org/start>  "301.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "68" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2179-2181>
            <http://www.example.org/end>    "2181.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "2179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16" .
    
    <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48_citespan-335-337>
            <http://www.example.org/end>    "337.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF80" ;
            <http://www.example.org/start>  "335.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "80" .
    
    <http://covid19.aksw.org/text-d68e0b5cf9b35bdc8e9dc39e2c5430946ed3ae7e01c9c8cff78c1ff82381bfcb_refspan-111-119>
            <http://www.example.org/end>    "119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF3" ;
            <http://www.example.org/start>  "111.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4)" .
    
    <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3_citespan-432-435>
            <http://www.example.org/end>    "435.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF69" ;
            <http://www.example.org/start>  "432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "69," .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2774-2778>
            <http://www.example.org/end>    "2778.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "2774.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[21]" .
    
    <http://covid19.aksw.org/text-d35a99bc1a3faa6de348d851dd83cee1895ebf816be08b52ffbbd08c76a36e4e_citespan-365-366>
            <http://www.example.org/end>    "366.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "3" .
    
    <http://covid19.aksw.org/text-9e2cc9b75784f698d6cf71d4e5104b243005709e908d126507a7466594c80863>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Secondary, or AA, amyloidosis develops in the setting of systemic inflammatory disorders such as rheumatoid arthritis or chronic infections such as osteomyelitis or tuberculosis. The pathologic protein involved is serum amyloid A, which is an acutephase reactant produced perpetually in the liver in response to inflammatory cytokines, such as TNF-a, IL-1, and IL-6. Amyloidogenic proteins deposit in the extracellular matrices of various organs, as in AL disease. Preventing this process from occurring by identifying and treating the underlying inflammatory condition is paramount in the management of affected patients. AA amyloidosis is less common than AL amyloidosis, but the histopathologic findings are similar, with protein deposition in the space of Disse, portal tracts, and vessel walls causing architectural distortion and cholestasis (Fig. 3) . Congo Red staining continues to be the mainstay of identifying tissue-based amyloid.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":848.0,\"end\":856.0,\"text\":\"(Fig. 3)\",\"ref_id\":\"FIGREF2\"}],\"section\":\"HEPATIC AMYLOIDOSIS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-9e2cc9b75784f698d6cf71d4e5104b243005709e908d126507a7466594c80863_refspan-848-856> ;
            <http://www.example.org/section>
                    "HEPATIC AMYLOIDOSIS" ;
            <http://www.example.org/text>  "Secondary, or AA, amyloidosis develops in the setting of systemic inflammatory disorders such as rheumatoid arthritis or chronic infections such as osteomyelitis or tuberculosis. The pathologic protein involved is serum amyloid A, which is an acutephase reactant produced perpetually in the liver in response to inflammatory cytokines, such as TNF-a, IL-1, and IL-6. Amyloidogenic proteins deposit in the extracellular matrices of various organs, as in AL disease. Preventing this process from occurring by identifying and treating the underlying inflammatory condition is paramount in the management of affected patients. AA amyloidosis is less common than AL amyloidosis, but the histopathologic findings are similar, with protein deposition in the space of Disse, portal tracts, and vessel walls causing architectural distortion and cholestasis (Fig. 3) . Congo Red staining continues to be the mainstay of identifying tissue-based amyloid." ;
            <http://www.example.org/textHash>
                    "9e2cc9b75784f698d6cf71d4e5104b243005709e908d126507a7466594c80863" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-113-115>
            <http://www.example.org/end>    "115.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "113.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "52" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-1904-1906>
            <http://www.example.org/end>    "1906.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "1904.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3430-3432>
            <http://www.example.org/end>    "3432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "3430.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "24" .
    
    <http://covid19.aksw.org/text-85193ced2cdff58fd1953d48f161c1393e0810c35e86190f83a26794b3cca16e_citespan-535-537>
            <http://www.example.org/end>    "537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF74" ;
            <http://www.example.org/start>  "535.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "74" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2769-2773>
            <http://www.example.org/end>    "2773.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "2769.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[20]" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-940-942>
            <http://www.example.org/end>    "942.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF54" ;
            <http://www.example.org/start>  "940.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "54" .
    
    <http://covid19.aksw.org/text-dd60a0a0c2ac73203ce4424491eb010c41d0b50188dab7da779f6420829a250e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Liver involvement in NHL has pathologic characteristics similar to those in HL, including a nodular tumor infiltrate in portal tracts and epithelioid granulomas. However, primary hepatic lymphoma (PHL) is rare, accounting for less than 1% of cases of NHL. 61 PHL is defined by an absence of lymphoma involvement in the spleen, lymph nodes, and bone marrow at the time of diagnosis. B symptoms of fever and weight loss occur in one-third of patients. The most common presentation is with abdominal pain caused by hepatomegaly. Serum alkaline phosphatase and bilirubin levels are increased in 70% of cases. A solitary lesion is the most frequent finding deLemos \\u0026 Friedman radiographically and is encountered in 50% to 60% of cases. Estimating the prognosis of PHL is difficult because the condition is rare. Nodular as opposed to diffusely infiltrative disease may have a more favorable outcome with chemotherapy, with 3-year survival rates of 57% and 18%, respectively. Although there are some case reports of hepatitis C-associated PHL, an increased risk of NHL (diffuse large B-cell lymphoma, marginal zone lymphoma, and lymphoplasmocytic lymphoma) in patients with chronic hepatitis C is not specifically associated with an increased risk of PHL.\",\"cite_spans\":[{\"start\":256.0,\"end\":258.0,\"text\":\"61\",\"ref_id\":\"BIBREF61\"}],\"ref_spans\":[],\"section\":\"SICKLE CELL DISEASE\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-dd60a0a0c2ac73203ce4424491eb010c41d0b50188dab7da779f6420829a250e_citespan-256-258> ;
            <http://www.example.org/section>
                    "SICKLE CELL DISEASE" ;
            <http://www.example.org/text>  "Liver involvement in NHL has pathologic characteristics similar to those in HL, including a nodular tumor infiltrate in portal tracts and epithelioid granulomas. However, primary hepatic lymphoma (PHL) is rare, accounting for less than 1% of cases of NHL. 61 PHL is defined by an absence of lymphoma involvement in the spleen, lymph nodes, and bone marrow at the time of diagnosis. B symptoms of fever and weight loss occur in one-third of patients. The most common presentation is with abdominal pain caused by hepatomegaly. Serum alkaline phosphatase and bilirubin levels are increased in 70% of cases. A solitary lesion is the most frequent finding deLemos & Friedman radiographically and is encountered in 50% to 60% of cases. Estimating the prognosis of PHL is difficult because the condition is rare. Nodular as opposed to diffusely infiltrative disease may have a more favorable outcome with chemotherapy, with 3-year survival rates of 57% and 18%, respectively. Although there are some case reports of hepatitis C-associated PHL, an increased risk of NHL (diffuse large B-cell lymphoma, marginal zone lymphoma, and lymphoplasmocytic lymphoma) in patients with chronic hepatitis C is not specifically associated with an increased risk of PHL." ;
            <http://www.example.org/textHash>
                    "dd60a0a0c2ac73203ce4424491eb010c41d0b50188dab7da779f6420829a250e" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-2061-2063>
            <http://www.example.org/end>    "2063.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF59" ;
            <http://www.example.org/start>  "2061.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "59" .
    
    <http://covid19.aksw.org/text-dd60a0a0c2ac73203ce4424491eb010c41d0b50188dab7da779f6420829a250e_citespan-256-258>
            <http://www.example.org/end>    "258.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF61" ;
            <http://www.example.org/start>  "256.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "61" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3171-3173>
            <http://www.example.org/end>    "3173.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "3171.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "23" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_refspan-4563-4571>
            <http://www.example.org/end>    "4571.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "4563.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1)" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-92-93>
            <http://www.example.org/end>    "93.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "92.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2764-2768>
            <http://www.example.org/end>    "2768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "2764.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[19]" .
    
    <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235_citespan-384-386>
            <http://www.example.org/end>    "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "384.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35" .
    
    <http://covid19.aksw.org/text-85193ced2cdff58fd1953d48f161c1393e0810c35e86190f83a26794b3cca16e_citespan-162-164>
            <http://www.example.org/end>    "164.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF73" ;
            <http://www.example.org/start>  "162.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "73" .
    
    <http://covid19.aksw.org/text-41ab4517985b7aeceef69ced4ef7051dc78406ae73a67101338fabbadcf2b396>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Severe viral infections such as influenza and severe acute respiratory syndrome are believed to be associated with immune-mediated liver damage as a result of cytokine activation; neither infection generally leads to cholestasis. By contrast, measles (rubeola) may result in 1 of 2 patterns of hepatic dysfunction: most commonly, asymptomatic increase of the serum aminotransferase levels and rarely, prolonged jaundice and cholestasis, which develop as the usual symptoms of measles resolve. 42 \",\"cite_spans\":[{\"start\":493.0,\"end\":495.0,\"text\":\"42\",\"ref_id\":\"BIBREF42\"}],\"ref_spans\":[],\"section\":\"SYSTEMIC VIRAL INFECTIONS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-41ab4517985b7aeceef69ced4ef7051dc78406ae73a67101338fabbadcf2b396_citespan-493-495> ;
            <http://www.example.org/section>
                    "SYSTEMIC VIRAL INFECTIONS" ;
            <http://www.example.org/text>  "Severe viral infections such as influenza and severe acute respiratory syndrome are believed to be associated with immune-mediated liver damage as a result of cytokine activation; neither infection generally leads to cholestasis. By contrast, measles (rubeola) may result in 1 of 2 patterns of hepatic dysfunction: most commonly, asymptomatic increase of the serum aminotransferase levels and rarely, prolonged jaundice and cholestasis, which develop as the usual symptoms of measles resolve. 42 " ;
            <http://www.example.org/textHash>
                    "41ab4517985b7aeceef69ced4ef7051dc78406ae73a67101338fabbadcf2b396" .
    
    <http://covid19.aksw.org/text-dae15f946d1f95d9223d551c68fb994ca16a970b8d1cf70a0adb716e94ea10a5>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Systemic amyloidosis may be primary (AL) or secondary (AA). The precipitation of immunoglobulin light chains characterizes AL amyloid and develops in the context of plasma cell dyscrasias such as Waldenstrom macroglobulinemia or multiple myeloma. Although the heart, kidney, and peripheral nerves are the most commonly affected organs, 1 autopsy series of primary amyloidosis reported liver involvement in 70% of cases. A Mayo Clinic study reported on the natural history of 98 patients with liver biopsy-proven AL amyloid over a 20-year period. 49 Unintentional weight loss, with hepatomegaly on examination, was the most frequent presenting symptom. Serum alkaline phosphatase levels were strikingly increased, with a median value of 657 U/L (normal level \\u003c250 U/L), and were more than normal in 86% of patients. The median survival was 5.4 months in patients with an alkaline phosphatase level deLemos \\u0026 Friedman greater than 500 U/L and 1 month in those with a total bilirubin level greater than 34 mmol/L (2 mg/dL). Most patients (82%) had amyloid deposits detected in biopsy specimens from extrahepatic tissue as well. The treatment of choice for primary amyloidosis is chemotherapy and, when possible, hematopoietic stem-cell transplantation.\",\"cite_spans\":[{\"start\":546.0,\"end\":548.0,\"text\":\"49\",\"ref_id\":\"BIBREF49\"}],\"ref_spans\":[],\"section\":\"HEPATIC AMYLOIDOSIS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-dae15f946d1f95d9223d551c68fb994ca16a970b8d1cf70a0adb716e94ea10a5_citespan-546-548> ;
            <http://www.example.org/section>
                    "HEPATIC AMYLOIDOSIS" ;
            <http://www.example.org/text>  "Systemic amyloidosis may be primary (AL) or secondary (AA). The precipitation of immunoglobulin light chains characterizes AL amyloid and develops in the context of plasma cell dyscrasias such as Waldenstrom macroglobulinemia or multiple myeloma. Although the heart, kidney, and peripheral nerves are the most commonly affected organs, 1 autopsy series of primary amyloidosis reported liver involvement in 70% of cases. A Mayo Clinic study reported on the natural history of 98 patients with liver biopsy-proven AL amyloid over a 20-year period. 49 Unintentional weight loss, with hepatomegaly on examination, was the most frequent presenting symptom. Serum alkaline phosphatase levels were strikingly increased, with a median value of 657 U/L (normal level <250 U/L), and were more than normal in 86% of patients. The median survival was 5.4 months in patients with an alkaline phosphatase level deLemos & Friedman greater than 500 U/L and 1 month in those with a total bilirubin level greater than 34 mmol/L (2 mg/dL). Most patients (82%) had amyloid deposits detected in biopsy specimens from extrahepatic tissue as well. The treatment of choice for primary amyloidosis is chemotherapy and, when possible, hematopoietic stem-cell transplantation." ;
            <http://www.example.org/textHash>
                    "dae15f946d1f95d9223d551c68fb994ca16a970b8d1cf70a0adb716e94ea10a5" .
    
    <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-1409-1411>
            <http://www.example.org/end>    "1411.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF41" ;
            <http://www.example.org/start>  "1409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "41" .
    
    <http://covid19.aksw.org/text-5ed7ddba5f2d9d883d54db5468d94d009b6af499d285c7a9d681f44a60b0d20f_citespan-316-318>
            <http://www.example.org/end>    "318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF63" ;
            <http://www.example.org/start>  "316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "63" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1316-1318>
            <http://www.example.org/end>    "1318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF56" ;
            <http://www.example.org/start>  "1316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "56" .
    
    <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-343-345>
            <http://www.example.org/end>    "345.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "343.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2759-2763>
            <http://www.example.org/end>    "2763.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "2759.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[18]" .
    
    <http://covid19.aksw.org/text-80d6f3cefce92ead123d4898b5db8bc0a2331cd9f7cb9c1a062a7f55a24ed87f_citespan-177-179>
            <http://www.example.org/end>    "179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "177.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "43" .
    
    <http://covid19.aksw.org/text-63f54dd42e18a82ad912df3b320deefa3a98358969551e9de5ae744502ddac3a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Both solid organ and hematopoietic stem-cell transplant recipients are at risk for PTLD, a type of NHL driven in most cases by EBV infection (see earlier discussion). PTLD complicates approximately 4% of liver transplantations. Liver and spleen involvement in PTLD is not unusual, occurring in 16% of patients in a 20-year experience at the University of Pittsburgh. 62 If present in the liver, PTLD can cause intrahepatic cholestasis or extrahepatic cholestasis from bulky lymphadenopathy around the porta hepatis.\",\"cite_spans\":[{\"start\":367.0,\"end\":369.0,\"text\":\"62\",\"ref_id\":\"BIBREF62\"}],\"ref_spans\":[],\"section\":\"SICKLE CELL DISEASE\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-63f54dd42e18a82ad912df3b320deefa3a98358969551e9de5ae744502ddac3a_citespan-367-369> ;
            <http://www.example.org/section>
                    "SICKLE CELL DISEASE" ;
            <http://www.example.org/text>  "Both solid organ and hematopoietic stem-cell transplant recipients are at risk for PTLD, a type of NHL driven in most cases by EBV infection (see earlier discussion). PTLD complicates approximately 4% of liver transplantations. Liver and spleen involvement in PTLD is not unusual, occurring in 16% of patients in a 20-year experience at the University of Pittsburgh. 62 If present in the liver, PTLD can cause intrahepatic cholestasis or extrahepatic cholestasis from bulky lymphadenopathy around the porta hepatis." ;
            <http://www.example.org/textHash>
                    "63f54dd42e18a82ad912df3b320deefa3a98358969551e9de5ae744502ddac3a" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3874-3876>
            <http://www.example.org/end>    "3876.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "3874.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27" .
    
    <http://covid19.aksw.org/text-d68e0b5cf9b35bdc8e9dc39e2c5430946ed3ae7e01c9c8cff78c1ff82381bfcb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The evaluation of a patient with systemic cholestasis requires careful attention to the clinical circumstances (Fig. 4) . In general, exclusion of drug-induced cholestasis, parenteral nutrition-induced cholestasis, and biliary obstruction is a useful first step in both inpatients and outpatients. Cholestasis in the intensive care unit should raise suspicion for sepsis syndrome, particularly in the pediatric patient population. Severe hypovolemic shock can cause ischemic cholangiopathy characterized by pronounced cholestasis. In adult inpatients with mild hyperbilirubinemia, a detailed cardiopulmonary physical examination and transthoracic echocardiography are useful to exclude heart failure; marked increase in serum aminotransferase levels accompanying jaundice suggests ischemic hepatitis. Cholestasis in immunocompromised patients should prompt a detailed clinical history for evidence of an infectious exposure. A comprehensive workup for infectious organisms should follow. Transplant recipients should be evaluated for PTLD; evaluation should include a serum lactate dehydrogenase level and an EBV viral load. Often, cross-sectional imaging with positron emission tomography and evaluation for obstructive lymphadenopathy with ultrasonography are warranted. Hepatic sarcoidosis is typically a histologic diagnosis, but chest imaging and a serum angiotensin-converting enzyme level are usually helpful. Striking cholestasis in the setting of weight loss and hepatosplenomegaly are highly suggestive of systemic malignancy with hepatic involvement, especially lymphoma, as well as amyloidosis. In either case, pursuing a tissue diagnosis is necessary, although liver tissue specifically is not essential. Cholestasis in the setting of a systemic autoimmune disease should prompt evaluation for a primary autoimmune cholestatic liver disease such as primary biliary cirrhosis or primary sclerosing cholangitis. An extrahepatic source of alkaline phosphatase should be excluded if the only evidence of cholestasis is an increased alkaline phosphatase level. Liver biopsy is usually definitive and the procedure of choice when the diagnosis remains uncertain after a comprehensive noninvasive evaluation. The evaluation of a patient with systemic cholestasis requires a meticulous approach, with treatment directed toward the underlying cause.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":111.0,\"end\":119.0,\"text\":\"(Fig. 4)\",\"ref_id\":\"FIGREF3\"}],\"section\":\"SUMMARY\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-d68e0b5cf9b35bdc8e9dc39e2c5430946ed3ae7e01c9c8cff78c1ff82381bfcb_refspan-111-119> ;
            <http://www.example.org/section>
                    "SUMMARY" ;
            <http://www.example.org/text>  "The evaluation of a patient with systemic cholestasis requires careful attention to the clinical circumstances (Fig. 4) . In general, exclusion of drug-induced cholestasis, parenteral nutrition-induced cholestasis, and biliary obstruction is a useful first step in both inpatients and outpatients. Cholestasis in the intensive care unit should raise suspicion for sepsis syndrome, particularly in the pediatric patient population. Severe hypovolemic shock can cause ischemic cholangiopathy characterized by pronounced cholestasis. In adult inpatients with mild hyperbilirubinemia, a detailed cardiopulmonary physical examination and transthoracic echocardiography are useful to exclude heart failure; marked increase in serum aminotransferase levels accompanying jaundice suggests ischemic hepatitis. Cholestasis in immunocompromised patients should prompt a detailed clinical history for evidence of an infectious exposure. A comprehensive workup for infectious organisms should follow. Transplant recipients should be evaluated for PTLD; evaluation should include a serum lactate dehydrogenase level and an EBV viral load. Often, cross-sectional imaging with positron emission tomography and evaluation for obstructive lymphadenopathy with ultrasonography are warranted. Hepatic sarcoidosis is typically a histologic diagnosis, but chest imaging and a serum angiotensin-converting enzyme level are usually helpful. Striking cholestasis in the setting of weight loss and hepatosplenomegaly are highly suggestive of systemic malignancy with hepatic involvement, especially lymphoma, as well as amyloidosis. In either case, pursuing a tissue diagnosis is necessary, although liver tissue specifically is not essential. Cholestasis in the setting of a systemic autoimmune disease should prompt evaluation for a primary autoimmune cholestatic liver disease such as primary biliary cirrhosis or primary sclerosing cholangitis. An extrahepatic source of alkaline phosphatase should be excluded if the only evidence of cholestasis is an increased alkaline phosphatase level. Liver biopsy is usually definitive and the procedure of choice when the diagnosis remains uncertain after a comprehensive noninvasive evaluation. The evaluation of a patient with systemic cholestasis requires a meticulous approach, with treatment directed toward the underlying cause." ;
            <http://www.example.org/textHash>
                    "d68e0b5cf9b35bdc8e9dc39e2c5430946ed3ae7e01c9c8cff78c1ff82381bfcb" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2415-2417>
            <http://www.example.org/end>    "2417.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "2415.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17" .
    
    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-1330-1332>
            <http://www.example.org/end>    "1332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "1330.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "47" .
    
    <http://covid19.aksw.org/text-63f54dd42e18a82ad912df3b320deefa3a98358969551e9de5ae744502ddac3a_citespan-367-369>
            <http://www.example.org/end>    "369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF62" ;
            <http://www.example.org/start>  "367.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "62" .
    
    <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-1402-1404>
            <http://www.example.org/end>    "1404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF79" ;
            <http://www.example.org/start>  "1402.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "79" .
    
    <http://covid19.aksw.org/text-a30949f177ad064fbf8c5992ca02eb7a3aa31e40f4d57d2a8c8a48949ee5343a_citespan-1137-1139>
            <http://www.example.org/end>    "1139.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF67" ;
            <http://www.example.org/start>  "1137.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "67" .
    
    <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48_citespan-634-636>
            <http://www.example.org/end>    "636.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF81" ;
            <http://www.example.org/start>  "634.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "81" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-241-242>
            <http://www.example.org/end>    "242.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "241.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "7" .
    
    <http://covid19.aksw.org/text-2c260d7c595e6b7552840a839345f8270be63206a08426a1f1a1bde3de55cdf3_citespan-436-438>
            <http://www.example.org/end>    "438.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF70" ;
            <http://www.example.org/start>  "436.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "70" .
    
    <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235_citespan-742-744>
            <http://www.example.org/end>    "744.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "742.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "36" .
    
    <http://covid19.aksw.org/text-dae15f946d1f95d9223d551c68fb994ca16a970b8d1cf70a0adb716e94ea10a5_citespan-546-548>
            <http://www.example.org/end>    "548.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF49" ;
            <http://www.example.org/start>  "546.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "49" .
    
    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A few patients (4%-7%) experience symptoms such as nausea, vomiting, and abdominal pain or signs such as hepatomegaly, jaundice, and portal hypertension. Abnormal liver biochemical test levels were identified in 58 of 100 patients who underwent a liver biopsy in 1 case series. 44 The serum alkaline phosphatase level is disproportionately high. In addition, 75% of untreated patients with sarcoidosis have an increase in the serum angiotensin-converting enzyme level. The pathognomonic lesion is the noncaseating granuloma, which results from a helper T cell type 1 response to an as-yetunidentified antigen. Pathologically, hepatic sarcoidosis can be indistinguishable from primary biliary cirrhosis or primary sclerosing cholangitis. Although granulomas can be seen within the hepatic lobule, the principal findings are in the portal tracts and include a variety of bile duct lesions, such as acute or chronic cholangitis, 45 periductal fibrosis, and bile duct loss (Fig. 2) . 46 Presinusoidal portal hypertension can develop from scarring of portal venules. In general, treatment is not recommended in patients with asymptomatic hepatic disease but is advised when symptoms of portal hypertension or severe cholestasis are apparent. Although patients may improve symptomatically with glucocorticoids and ursodeoxycholic acid, 47 structural changes to the bile ducts can progress to biliary cirrhosis, resulting in some cases in the need for liver transplantation. 48 \",\"cite_spans\":[{\"start\":278.0,\"end\":280.0,\"text\":\"44\",\"ref_id\":\"BIBREF44\"},{\"start\":926.0,\"end\":928.0,\"text\":\"45\",\"ref_id\":\"BIBREF45\"},{\"start\":980.0,\"end\":982.0,\"text\":\"46\",\"ref_id\":\"BIBREF46\"},{\"start\":1330.0,\"end\":1332.0,\"text\":\"47\",\"ref_id\":\"BIBREF47\"},{\"start\":1468.0,\"end\":1470.0,\"text\":\"48\",\"ref_id\":\"BIBREF48\"}],\"ref_spans\":[{\"start\":969.0,\"end\":977.0,\"text\":\"(Fig. 2)\",\"ref_id\":\"FIGREF1\"}],\"section\":\"Systemic Causes of Cholestasis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-980-982> , <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-1468-1470> , <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-278-280> , <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-1330-1332> , <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-926-928> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_refspan-969-977> ;
            <http://www.example.org/section>
                    "Systemic Causes of Cholestasis" ;
            <http://www.example.org/text>  "A few patients (4%-7%) experience symptoms such as nausea, vomiting, and abdominal pain or signs such as hepatomegaly, jaundice, and portal hypertension. Abnormal liver biochemical test levels were identified in 58 of 100 patients who underwent a liver biopsy in 1 case series. 44 The serum alkaline phosphatase level is disproportionately high. In addition, 75% of untreated patients with sarcoidosis have an increase in the serum angiotensin-converting enzyme level. The pathognomonic lesion is the noncaseating granuloma, which results from a helper T cell type 1 response to an as-yetunidentified antigen. Pathologically, hepatic sarcoidosis can be indistinguishable from primary biliary cirrhosis or primary sclerosing cholangitis. Although granulomas can be seen within the hepatic lobule, the principal findings are in the portal tracts and include a variety of bile duct lesions, such as acute or chronic cholangitis, 45 periductal fibrosis, and bile duct loss (Fig. 2) . 46 Presinusoidal portal hypertension can develop from scarring of portal venules. In general, treatment is not recommended in patients with asymptomatic hepatic disease but is advised when symptoms of portal hypertension or severe cholestasis are apparent. Although patients may improve symptomatically with glucocorticoids and ursodeoxycholic acid, 47 structural changes to the bile ducts can progress to biliary cirrhosis, resulting in some cases in the need for liver transplantation. 48 " ;
            <http://www.example.org/textHash>
                    "11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-4199-4201>
            <http://www.example.org/end>    "4201.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "4199.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28" .
    
    <http://covid19.aksw.org/text-ffc08f0dcd1af315a478ffa4685a0bed8e808827fe80ea7f7e64b9b548e8d57f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The systemic mycoses are considered opportunistic pathogens with only infrequent hepatic involvement. A high index of suspicion in the appropriate setting is crucial to expedite treatment. In the appropriate clinical context, fungal pathogens can disseminate to the liver and lead to varying degrees of cholestasis. Immunocompromised patients with hepatic candidiasis can present with suppurative granulomas, neutrophilic inflammation, and edema surrounding bile ducts. 30 High fever and an increased serum alkaline phosphatase level are typical features. Infection with the yeast Cryptococcus neoformans can present with several hepatic manifestations, including jaundice caused by cholangitis. Bucuvalas and colleagues 31 described a 15-year-old girl with right upper quadrant pain and jaundice in whom cryptococci were cultured from the bile duct. Tissue staining with India ink highlights the capsule, but detection of serum cryptococcal antigen is now the diagnostic test of choice. A hepatitislike picture may develop in 40% to 60% of cases of disseminated coccidioidomycosis, which is endemic in the southwest United States and can affect immunocompetent hosts. Pulmonary infiltrates with a granulomatous hepatitis, in conjunction with a markedly increased serum alkaline phosphatase level, are a classic presentation. 32 Histoplasmosis can spread from the lungs to the liver as well, generally in immunocompromised hosts. Cholestasis resulting from histoplasmosis typically occurs secondarily from development of hemophagocytic syndrome 33 (see later discussion). \",\"cite_spans\":[{\"start\":470.0,\"end\":472.0,\"text\":\"30\",\"ref_id\":\"BIBREF30\"},{\"start\":1326.0,\"end\":1328.0,\"text\":\"32\",\"ref_id\":\"BIBREF32\"}],\"ref_spans\":[],\"section\":\"FUNGAL HEPATITIS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ffc08f0dcd1af315a478ffa4685a0bed8e808827fe80ea7f7e64b9b548e8d57f_citespan-470-472> , <http://covid19.aksw.org/text-ffc08f0dcd1af315a478ffa4685a0bed8e808827fe80ea7f7e64b9b548e8d57f_citespan-1326-1328> ;
            <http://www.example.org/section>
                    "FUNGAL HEPATITIS" ;
            <http://www.example.org/text>  "The systemic mycoses are considered opportunistic pathogens with only infrequent hepatic involvement. A high index of suspicion in the appropriate setting is crucial to expedite treatment. In the appropriate clinical context, fungal pathogens can disseminate to the liver and lead to varying degrees of cholestasis. Immunocompromised patients with hepatic candidiasis can present with suppurative granulomas, neutrophilic inflammation, and edema surrounding bile ducts. 30 High fever and an increased serum alkaline phosphatase level are typical features. Infection with the yeast Cryptococcus neoformans can present with several hepatic manifestations, including jaundice caused by cholangitis. Bucuvalas and colleagues 31 described a 15-year-old girl with right upper quadrant pain and jaundice in whom cryptococci were cultured from the bile duct. Tissue staining with India ink highlights the capsule, but detection of serum cryptococcal antigen is now the diagnostic test of choice. A hepatitislike picture may develop in 40% to 60% of cases of disseminated coccidioidomycosis, which is endemic in the southwest United States and can affect immunocompetent hosts. Pulmonary infiltrates with a granulomatous hepatitis, in conjunction with a markedly increased serum alkaline phosphatase level, are a classic presentation. 32 Histoplasmosis can spread from the lungs to the liver as well, generally in immunocompromised hosts. Cholestasis resulting from histoplasmosis typically occurs secondarily from development of hemophagocytic syndrome 33 (see later discussion). " ;
            <http://www.example.org/textHash>
                    "ffc08f0dcd1af315a478ffa4685a0bed8e808827fe80ea7f7e64b9b548e8d57f" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-789-790>
            <http://www.example.org/end>    "790.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "789.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-9e2cc9b75784f698d6cf71d4e5104b243005709e908d126507a7466594c80863_refspan-848-856>
            <http://www.example.org/end>    "856.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "848.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3)" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-969-972>
            <http://www.example.org/end>    "972.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "969.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-980-982>
            <http://www.example.org/end>    "982.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF46" ;
            <http://www.example.org/start>  "980.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "46" .
    
    <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Henoch-Schö nlein purpura (HSP) is clearly associated with cholestasis. HSP is a common systemic vasculitis of childhood characterized by palpable purpura and at least 1 of the following: abdominal pain, IgA deposits in biopsy specimens, arthritis, or renal involvement. The disease typically evolves in the setting of a viral infection (parvovirus B19, upper respiratory infection) or bacterial infection (group A Streptococcus, Salmonella, Shigella, Campylobacter spp). A predisposing malignancy, such as nonsmall cell lung cancer or lymphoma, is often noted in adults. The leukocytoclastic vasculitis can involve the gallbladder and cause acute acalculous cholecystitis. 76 The peribiliary vessels may be affected, thereby resulting in biliary ischemia, stenosis of the bile ducts, and obstructive jaundice. 77 IBD may be associated with a primary autoimmune cholestatic liver disease (primary sclerosing cholangitis or IgG4-related disease). In addition, granulomatous hepatitis, characterized by an increased serum alkaline phosphatase level, is well described in patients with Crohn disease. 78 Bile salt malabsorption after ileal resection for Crohn disease increases the risk of cholelithiasis, which can cause biliary obstruction because of bile duct stones. Celiac disease has been associated with increased aminotransferase levels in many cases and occasionally with advanced liver disease. 79 Increase of the alkaline phosphatase level is less common and may be caused by bone involvement from secondary hyperparathyroidism.\",\"cite_spans\":[{\"start\":674.0,\"end\":676.0,\"text\":\"76\",\"ref_id\":\"BIBREF76\"},{\"start\":811.0,\"end\":813.0,\"text\":\"77\",\"ref_id\":\"BIBREF77\"},{\"start\":1098.0,\"end\":1100.0,\"text\":\"78\",\"ref_id\":\"BIBREF78\"},{\"start\":1402.0,\"end\":1404.0,\"text\":\"79\",\"ref_id\":\"BIBREF79\"}],\"ref_spans\":[],\"section\":\"SYSTEMIC AUTOIMMUNE DISEASES\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-674-676> , <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-811-813> , <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-1098-1100> , <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-1402-1404> ;
            <http://www.example.org/section>
                    "SYSTEMIC AUTOIMMUNE DISEASES" ;
            <http://www.example.org/text>  "Henoch-Schö nlein purpura (HSP) is clearly associated with cholestasis. HSP is a common systemic vasculitis of childhood characterized by palpable purpura and at least 1 of the following: abdominal pain, IgA deposits in biopsy specimens, arthritis, or renal involvement. The disease typically evolves in the setting of a viral infection (parvovirus B19, upper respiratory infection) or bacterial infection (group A Streptococcus, Salmonella, Shigella, Campylobacter spp). A predisposing malignancy, such as nonsmall cell lung cancer or lymphoma, is often noted in adults. The leukocytoclastic vasculitis can involve the gallbladder and cause acute acalculous cholecystitis. 76 The peribiliary vessels may be affected, thereby resulting in biliary ischemia, stenosis of the bile ducts, and obstructive jaundice. 77 IBD may be associated with a primary autoimmune cholestatic liver disease (primary sclerosing cholangitis or IgG4-related disease). In addition, granulomatous hepatitis, characterized by an increased serum alkaline phosphatase level, is well described in patients with Crohn disease. 78 Bile salt malabsorption after ileal resection for Crohn disease increases the risk of cholelithiasis, which can cause biliary obstruction because of bile duct stones. Celiac disease has been associated with increased aminotransferase levels in many cases and occasionally with advanced liver disease. 79 Increase of the alkaline phosphatase level is less common and may be caused by bone involvement from secondary hyperparathyroidism." ;
            <http://www.example.org/textHash>
                    "d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3870-3873>
            <http://www.example.org/end>    "3873.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "3870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-1602-1604>
            <http://www.example.org/end>    "1604.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1602.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-1b036157680b075b9c12ad3f77dbb973dde0aa5d621d13d19d364e120038c531>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Stauffer syndrome, originally termed nephrogenic hepatic dysfunction, refers to a rare paraneoplastic complication of renal cell carcinoma. 64 Overexpression of IL-6 by the tumor is believed to play a role in the pathophysiology. Cholestasis typically resolves within 1 to 2 months after surgical resection of the primary tumor. Hepatic dysfunction after resection may portend tumor recurrence. The presentation is with cholestasis, sometimes with jaundice, and usually with right upper quadrant pain caused by hepatomegaly. Liver biopsy specimens show nonspecific changes, including steatosis, portal lymphocytic inflammation, and Kupffer cell hyperplasia. Renal cell carcinoma can also metastasize to the pancreas and cause obstructive jaundice. Biliary obstruction caused by primary or metastatic cancer in the head of the pancreas, ampulla, or bile duct are more common causes of obstructive jaundice.\",\"cite_spans\":[{\"start\":140.0,\"end\":142.0,\"text\":\"64\",\"ref_id\":\"BIBREF64\"}],\"ref_spans\":[],\"section\":\"SOLID ORGAN MALIGNANCIES\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-1b036157680b075b9c12ad3f77dbb973dde0aa5d621d13d19d364e120038c531_citespan-140-142> ;
            <http://www.example.org/section>
                    "SOLID ORGAN MALIGNANCIES" ;
            <http://www.example.org/text>  "Stauffer syndrome, originally termed nephrogenic hepatic dysfunction, refers to a rare paraneoplastic complication of renal cell carcinoma. 64 Overexpression of IL-6 by the tumor is believed to play a role in the pathophysiology. Cholestasis typically resolves within 1 to 2 months after surgical resection of the primary tumor. Hepatic dysfunction after resection may portend tumor recurrence. The presentation is with cholestasis, sometimes with jaundice, and usually with right upper quadrant pain caused by hepatomegaly. Liver biopsy specimens show nonspecific changes, including steatosis, portal lymphocytic inflammation, and Kupffer cell hyperplasia. Renal cell carcinoma can also metastasize to the pancreas and cause obstructive jaundice. Biliary obstruction caused by primary or metastatic cancer in the head of the pancreas, ampulla, or bile duct are more common causes of obstructive jaundice." ;
            <http://www.example.org/textHash>
                    "1b036157680b075b9c12ad3f77dbb973dde0aa5d621d13d19d364e120038c531" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-973-977>
            <http://www.example.org/end>    "977.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "973.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235_citespan-222-224>
            <http://www.example.org/end>    "224.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "222.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "34" .
    
    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-278-280>
            <http://www.example.org/end>    "280.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "278.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "44" .
    
    <http://covid19.aksw.org/text-d35a99bc1a3faa6de348d851dd83cee1895ebf816be08b52ffbbd08c76a36e4e_refspan-198-205>
            <http://www.example.org/end>    "205.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 2" .
    
    <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-1030-1032>
            <http://www.example.org/end>    "1032.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "1030.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40" .
    
    <http://covid19.aksw.org/text-5ed7ddba5f2d9d883d54db5468d94d009b6af499d285c7a9d681f44a60b0d20f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive lymphoma that infiltrates the hepatic sinusoids. Male patients younger than 35 years with inflammatory bowel disease (IBD) and at least a 2-year history of exposure to combined thiopurine and biologic therapy may be at increased risk for developing HSTCL. 63 \",\"cite_spans\":[{\"start\":316.0,\"end\":318.0,\"text\":\"63\",\"ref_id\":\"BIBREF63\"}],\"ref_spans\":[],\"section\":\"SICKLE CELL DISEASE\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5ed7ddba5f2d9d883d54db5468d94d009b6af499d285c7a9d681f44a60b0d20f_citespan-316-318> ;
            <http://www.example.org/section>
                    "SICKLE CELL DISEASE" ;
            <http://www.example.org/text>  "Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive lymphoma that infiltrates the hepatic sinusoids. Male patients younger than 35 years with inflammatory bowel disease (IBD) and at least a 2-year history of exposure to combined thiopurine and biologic therapy may be at increased risk for developing HSTCL. 63 " ;
            <http://www.example.org/textHash>
                    "5ed7ddba5f2d9d883d54db5468d94d009b6af499d285c7a9d681f44a60b0d20f" .
    
    <http://covid19.aksw.org/text-8b62842eb29f8edc5f2d8a7b8a83d135b7f2bfbf7a080ccd715ecdcc401a17a9_citespan-573-575>
            <http://www.example.org/end>    "575.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF50" ;
            <http://www.example.org/start>  "573.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "50" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1908-1911>
            <http://www.example.org/end>    "1911.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF57" ;
            <http://www.example.org/start>  "1908.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "57," .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3565-3567>
            <http://www.example.org/end>    "3567.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "3565.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25" .
    
    <http://covid19.aksw.org/text-d81e0854fa70c608a07de1addaefb3a67880c3e461a632cafd6e5dce500327cb_citespan-811-813>
            <http://www.example.org/end>    "813.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF77" ;
            <http://www.example.org/start>  "811.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "77" .
    
    <http://covid19.aksw.org/text-5d2f7d8adc501cd3a46c34063f802a85705f4f68ab6b734977b8e028b284b816>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The liver can be affected in patients with diabetes mellitus, most commonly by nonalcoholic fatty liver disease. Harrison and colleagues 71 coined the term diabetic hepatosclerosis (DHS) in 2006, after reviewing liver biopsy specimens from patients with long-standing diabetes mellitus. Salient features included an absence of steatosis and dense perisinusoidal fibrosis. The original description included 14 patients with diabetes mellitus, most of whom had a normal body mass index (calculated as weight in kilograms divided by the square of height in meters), evidence of microvascular complications, and increased serum alkaline phosphatase level. A larger follow-up autopsy series from the same investigators did not find an association with cholestasis. 72 Nevertheless, DHS is believed to represent a hepatic form of microvascular disease in patients with diabetes mellitus.\",\"cite_spans\":[{\"start\":760.0,\"end\":762.0,\"text\":\"72\",\"ref_id\":\"BIBREF72\"}],\"ref_spans\":[],\"section\":\"ENDOCRINE DYSFUNCTION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5d2f7d8adc501cd3a46c34063f802a85705f4f68ab6b734977b8e028b284b816_citespan-760-762> ;
            <http://www.example.org/section>
                    "ENDOCRINE DYSFUNCTION" ;
            <http://www.example.org/text>  "The liver can be affected in patients with diabetes mellitus, most commonly by nonalcoholic fatty liver disease. Harrison and colleagues 71 coined the term diabetic hepatosclerosis (DHS) in 2006, after reviewing liver biopsy specimens from patients with long-standing diabetes mellitus. Salient features included an absence of steatosis and dense perisinusoidal fibrosis. The original description included 14 patients with diabetes mellitus, most of whom had a normal body mass index (calculated as weight in kilograms divided by the square of height in meters), evidence of microvascular complications, and increased serum alkaline phosphatase level. A larger follow-up autopsy series from the same investigators did not find an association with cholestasis. 72 Nevertheless, DHS is believed to represent a hepatic form of microvascular disease in patients with diabetes mellitus." ;
            <http://www.example.org/textHash>
                    "5d2f7d8adc501cd3a46c34063f802a85705f4f68ab6b734977b8e028b284b816" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"with sepsis, 4 and the incidence in adult patients is estimated to range from 6% to 54%. 5, 6 Cholestasis from infections and sepsis is the second most common cause of jaundice in hospitalized patients (after malignant biliary obstruction). 7 In adults, conjugated hyperbilirubinemia, typically less than 10 mg/dL, predominates; the bilirubin level can be higher in neonates as a consequence of their underdeveloped efflux capacity. Serum alkaline phosphatase levels 2 to 3 times the upper limit of normal are typical, whereas aminotransferase levels are either normal or only modestly increased. Apart from jaundice, symptoms such as pruritus and clinical signs such as hepatomegaly are uncommon. Treatment is supportive with fluid resuscitation and antibiotics. One prospective analysis 6 did not find an association between the presence of jaundice and increased mortality. The pathophysiology of cholestasis in sepsis is the topic of several excellent reviews. [8] [9] [10] Kupffer cells, and to a lesser extent hepatocytes and sinusoidal endothelial cells, react to bacterial endotoxins such as lipopolysaccharide by elaborating proinflammatory cytokines such as tumor necrosis factor a (TNF-a), interleukin 1 (IL-1), IL-2, IL-6, and IL-12. Endotoxemia in rats has been shown to cause downregulation of bile uptake (Na 1 -taurocholate cotransporting polypeptide and organic aniontransporting polypeptide) and export (bile salt export pump and multidrug resistance protein 2) transporters for cholestasis, 11 but a posttranscriptional mechanism is favored in studies involving human liver tissues. 12 Nitric oxide and free radicals in the hepatic microvasculature can contribute to endothelial damage and the formation of fibrin microthrombi. Histologically, hepatocellular and canalicular bilirubinostasis predominates, often with nonspecific portal-based inflammation and Kupffer cell hyperplasia. 13 A distinct cholestatic picture termed progressive sclerosing cholangitis can emerge in the setting of severe septic shock. 14 This entity may evolve as a result of biliary ischemia from systemic hypotension and has also been described after extensive trauma or burns. 15, 16 The pathophysiology is poorly understood but likely involves a similar diminution in the expression of bile transporters as a result of cytokine induction as well as stasis of toxic bile salts within the ducts. Cirrhosis can result. 17 Certain systemic bacterial organisms capable of infecting the liver directly have a predilection for cholestasis. An increase of serum alkaline phosphatase levels and jaundice frequently accompany pyogenic liver abscess. Recent case series indicate that up to 60% of liver abscesses are cryptogenic and therefore can be considered systemic. [18] [19] [20] [21] Actinomycosis, caused by Actinomyces israelii, a filamentous grampositive rod, can present with liver involvement in rare instances. Whereas hepatic abscess is the most common presentation of actinomycosis, 22 affected patients may also follow a more indolent course of fever, abdominal pain, and anorexia associated nearly universally with increases of the serum alkaline phosphatase level. 23 Biopsies of infected tissue show characteristic sulfur granules, and treatment with penicillin or tetracycline is usually curative. Severe shigellosis can cause a cholestatic hepatitis with portal and periportal polymorphonuclear inflammatory infiltrates, 24 whereas yersiniosis can produce a granulomatous hepatitis in patients with diabetes mellitus and those predisposed to iron loading. 25 Certain zoonotic infections, particularly brucellosis, also may lead to cholestasis, in which the development of jaundice may correlate with the severity of the illness. Necrotizing hepatic granulomas can occur in the hepatic lobules or portal tracts in association with focal mononuclear infiltrates. 26, 27 Weil syndrome develops in 5% to 10% of patients with leptospirosis, a spirochetal infection acquired in warm climates from water contaminated with the urine of wild or domestic animals. Jaundice over a few weeks may denote the first phase of the illness and is followed by fever and subsequently hepatic and renal injury. 28 Conjugated hyperbilirubinemia reflects intrahepatic cholestasis, which along with hypertrophy of Kupffer cells is apparent on liver biopsy specimens. Another spirochetal infection associated with cholestasis is syphilis, which can cause a lymphocytic portal triaditis with pericholangiolar inflammation and a markedly increased serum alkaline phosphatase level (Fig. 1) . Syphilitic hepatitis in persons infected with human immunodeficiency virus (HIV) is well described, and in 1 case series of 7 patients, the average serum bilirubin level at diagnosis was 4.1 mg/dL. 29 Tickborne illnesses such as Q fever, Rocky Mountain spotted fever, and ehrlichiosis can infect the liver and cause cholestasis in rare instances, but a component of hemolysis undoubtedly contributes to the jaundice.\",\"cite_spans\":[{\"start\":89.0,\"end\":91.0,\"text\":\"5,\",\"ref_id\":\"BIBREF4\"},{\"start\":92.0,\"end\":93.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":241.0,\"end\":242.0,\"text\":\"7\",\"ref_id\":\"BIBREF7\"},{\"start\":789.0,\"end\":790.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":965.0,\"end\":968.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF8\"},{\"start\":969.0,\"end\":972.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF9\"},{\"start\":973.0,\"end\":977.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF10\"},{\"start\":1602.0,\"end\":1604.0,\"text\":\"12\",\"ref_id\":\"BIBREF12\"},{\"start\":1904.0,\"end\":1906.0,\"text\":\"13\",\"ref_id\":\"BIBREF13\"},{\"start\":2175.0,\"end\":2178.0,\"text\":\"15,\",\"ref_id\":\"BIBREF15\"},{\"start\":2179.0,\"end\":2181.0,\"text\":\"16\",\"ref_id\":\"BIBREF16\"},{\"start\":2415.0,\"end\":2417.0,\"text\":\"17\",\"ref_id\":\"BIBREF17\"},{\"start\":2759.0,\"end\":2763.0,\"text\":\"[18]\",\"ref_id\":\"BIBREF18\"},{\"start\":2764.0,\"end\":2768.0,\"text\":\"[19]\",\"ref_id\":\"BIBREF19\"},{\"start\":2769.0,\"end\":2773.0,\"text\":\"[20]\",\"ref_id\":\"BIBREF20\"},{\"start\":2774.0,\"end\":2778.0,\"text\":\"[21]\",\"ref_id\":\"BIBREF21\"},{\"start\":2986.0,\"end\":2988.0,\"text\":\"22\",\"ref_id\":\"BIBREF22\"},{\"start\":3171.0,\"end\":3173.0,\"text\":\"23\",\"ref_id\":\"BIBREF23\"},{\"start\":3430.0,\"end\":3432.0,\"text\":\"24\",\"ref_id\":\"BIBREF24\"},{\"start\":3565.0,\"end\":3567.0,\"text\":\"25\",\"ref_id\":\"BIBREF25\"},{\"start\":3870.0,\"end\":3873.0,\"text\":\"26,\",\"ref_id\":\"BIBREF26\"},{\"start\":3874.0,\"end\":3876.0,\"text\":\"27\",\"ref_id\":\"BIBREF27\"},{\"start\":4199.0,\"end\":4201.0,\"text\":\"28\",\"ref_id\":\"BIBREF28\"},{\"start\":4772.0,\"end\":4774.0,\"text\":\"29\",\"ref_id\":\"BIBREF29\"}],\"ref_spans\":[{\"start\":4563.0,\"end\":4571.0,\"text\":\"(Fig. 1)\",\"ref_id\":\"FIGREF0\"}],\"section\":\"deLemos \\u0026 Friedman\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-965-968> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-789-790> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-969-972> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-4199-4201> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3430-3432> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2759-2763> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2774-2778> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2175-2178> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-92-93> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-1904-1906> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3874-3876> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-89-91> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3870-3873> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-241-242> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2179-2181> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3565-3567> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-3171-3173> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2764-2768> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-973-977> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2415-2417> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-1602-1604> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2769-2773> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2986-2988> , <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-4772-4774> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_refspan-4563-4571> ;
            <http://www.example.org/section>
                    "deLemos & Friedman" ;
            <http://www.example.org/text>  "with sepsis, 4 and the incidence in adult patients is estimated to range from 6% to 54%. 5, 6 Cholestasis from infections and sepsis is the second most common cause of jaundice in hospitalized patients (after malignant biliary obstruction). 7 In adults, conjugated hyperbilirubinemia, typically less than 10 mg/dL, predominates; the bilirubin level can be higher in neonates as a consequence of their underdeveloped efflux capacity. Serum alkaline phosphatase levels 2 to 3 times the upper limit of normal are typical, whereas aminotransferase levels are either normal or only modestly increased. Apart from jaundice, symptoms such as pruritus and clinical signs such as hepatomegaly are uncommon. Treatment is supportive with fluid resuscitation and antibiotics. One prospective analysis 6 did not find an association between the presence of jaundice and increased mortality. The pathophysiology of cholestasis in sepsis is the topic of several excellent reviews. [8] [9] [10] Kupffer cells, and to a lesser extent hepatocytes and sinusoidal endothelial cells, react to bacterial endotoxins such as lipopolysaccharide by elaborating proinflammatory cytokines such as tumor necrosis factor a (TNF-a), interleukin 1 (IL-1), IL-2, IL-6, and IL-12. Endotoxemia in rats has been shown to cause downregulation of bile uptake (Na 1 -taurocholate cotransporting polypeptide and organic aniontransporting polypeptide) and export (bile salt export pump and multidrug resistance protein 2) transporters for cholestasis, 11 but a posttranscriptional mechanism is favored in studies involving human liver tissues. 12 Nitric oxide and free radicals in the hepatic microvasculature can contribute to endothelial damage and the formation of fibrin microthrombi. Histologically, hepatocellular and canalicular bilirubinostasis predominates, often with nonspecific portal-based inflammation and Kupffer cell hyperplasia. 13 A distinct cholestatic picture termed progressive sclerosing cholangitis can emerge in the setting of severe septic shock. 14 This entity may evolve as a result of biliary ischemia from systemic hypotension and has also been described after extensive trauma or burns. 15, 16 The pathophysiology is poorly understood but likely involves a similar diminution in the expression of bile transporters as a result of cytokine induction as well as stasis of toxic bile salts within the ducts. Cirrhosis can result. 17 Certain systemic bacterial organisms capable of infecting the liver directly have a predilection for cholestasis. An increase of serum alkaline phosphatase levels and jaundice frequently accompany pyogenic liver abscess. Recent case series indicate that up to 60% of liver abscesses are cryptogenic and therefore can be considered systemic. [18] [19] [20] [21] Actinomycosis, caused by Actinomyces israelii, a filamentous grampositive rod, can present with liver involvement in rare instances. Whereas hepatic abscess is the most common presentation of actinomycosis, 22 affected patients may also follow a more indolent course of fever, abdominal pain, and anorexia associated nearly universally with increases of the serum alkaline phosphatase level. 23 Biopsies of infected tissue show characteristic sulfur granules, and treatment with penicillin or tetracycline is usually curative. Severe shigellosis can cause a cholestatic hepatitis with portal and periportal polymorphonuclear inflammatory infiltrates, 24 whereas yersiniosis can produce a granulomatous hepatitis in patients with diabetes mellitus and those predisposed to iron loading. 25 Certain zoonotic infections, particularly brucellosis, also may lead to cholestasis, in which the development of jaundice may correlate with the severity of the illness. Necrotizing hepatic granulomas can occur in the hepatic lobules or portal tracts in association with focal mononuclear infiltrates. 26, 27 Weil syndrome develops in 5% to 10% of patients with leptospirosis, a spirochetal infection acquired in warm climates from water contaminated with the urine of wild or domestic animals. Jaundice over a few weeks may denote the first phase of the illness and is followed by fever and subsequently hepatic and renal injury. 28 Conjugated hyperbilirubinemia reflects intrahepatic cholestasis, which along with hypertrophy of Kupffer cells is apparent on liver biopsy specimens. Another spirochetal infection associated with cholestasis is syphilis, which can cause a lymphocytic portal triaditis with pericholangiolar inflammation and a markedly increased serum alkaline phosphatase level (Fig. 1) . Syphilitic hepatitis in persons infected with human immunodeficiency virus (HIV) is well described, and in 1 case series of 7 patients, the average serum bilirubin level at diagnosis was 4.1 mg/dL. 29 Tickborne illnesses such as Q fever, Rocky Mountain spotted fever, and ehrlichiosis can infect the liver and cause cholestasis in rare instances, but a component of hemolysis undoubtedly contributes to the jaundice." ;
            <http://www.example.org/textHash>
                    "affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050" .
    
    <http://covid19.aksw.org/text-d35a99bc1a3faa6de348d851dd83cee1895ebf816be08b52ffbbd08c76a36e4e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Bacterial infections that do not necessarily involve the liver or bile ducts may lead to jaundice. Sepsis is most frequently linked to cholestasis, particularly in the intensive care unit setting ( Table 2 ). 2 Both gram-positive and gram-negative organisms are potentially culpable, with Escherichia coli being the most common isolate in 1 retrospective analysis. 3 Jaundice develops in up to one-third of neonates and infants \",\"cite_spans\":[{\"start\":365.0,\"end\":366.0,\"text\":\"3\",\"ref_id\":\"BIBREF2\"}],\"ref_spans\":[{\"start\":198.0,\"end\":205.0,\"text\":\"Table 2\",\"ref_id\":\"TABREF1\"}],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d35a99bc1a3faa6de348d851dd83cee1895ebf816be08b52ffbbd08c76a36e4e_citespan-365-366> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-d35a99bc1a3faa6de348d851dd83cee1895ebf816be08b52ffbbd08c76a36e4e_refspan-198-205> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Bacterial infections that do not necessarily involve the liver or bile ducts may lead to jaundice. Sepsis is most frequently linked to cholestasis, particularly in the intensive care unit setting ( Table 2 ). 2 Both gram-positive and gram-negative organisms are potentially culpable, with Escherichia coli being the most common isolate in 1 retrospective analysis. 3 Jaundice develops in up to one-third of neonates and infants " ;
            <http://www.example.org/textHash>
                    "d35a99bc1a3faa6de348d851dd83cee1895ebf816be08b52ffbbd08c76a36e4e" .
    
    <http://covid19.aksw.org/text-4a9b7eeae1db8c0d0b7fbeeb0717d374d507d6471210480912d29f8c7f9aaaa5>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Cholestasis may occur during the course of several autoimmune diseases. Autoimmune sclerosing cholangitis and IgG4-related disease are discussed elsewhere in this issue by Dr Marina Silveira. Several systemic autoimmune conditions may be associated with primary autoimmune liver disease; in particular, Sjö gren syndrome and systemic sclerosis may coexist with primary biliary cirrhosis. The serum alkaline phosphatase level may be increased in systemic lupus erythematosus and rheumatoid arthritis, but cholestasis is uncommon. Concomitant pharmacologic therapy and joint and bone involvement in both diseases may have led to misinterpretation of increased alkaline phosphatase levels as cholestasis in older case series.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"SYSTEMIC AUTOIMMUNE DISEASES\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "SYSTEMIC AUTOIMMUNE DISEASES" ;
            <http://www.example.org/text>  "Cholestasis may occur during the course of several autoimmune diseases. Autoimmune sclerosing cholangitis and IgG4-related disease are discussed elsewhere in this issue by Dr Marina Silveira. Several systemic autoimmune conditions may be associated with primary autoimmune liver disease; in particular, Sjö gren syndrome and systemic sclerosis may coexist with primary biliary cirrhosis. The serum alkaline phosphatase level may be increased in systemic lupus erythematosus and rheumatoid arthritis, but cholestasis is uncommon. Concomitant pharmacologic therapy and joint and bone involvement in both diseases may have led to misinterpretation of increased alkaline phosphatase levels as cholestasis in older case series." ;
            <http://www.example.org/textHash>
                    "4a9b7eeae1db8c0d0b7fbeeb0717d374d507d6471210480912d29f8c7f9aaaa5" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-89-91>
            <http://www.example.org/end>    "91.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "89.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "5," .
    
    <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Hepatobiliary tuberculosis is rare, although well documented. A 10-year experience of close to 2000 patients with tuberculosis identified only 14 cases of hepatobiliary tuberculosis, of which 9 had multiorgan involvement. 34 Jaundice is classically caused by extrahepatic biliary obstruction from bulky lymphadenopathy around the porta hepatis or postinflammatory biliary strictures. 35 A characteristic granulomatous hepatitis, marked by fever, anorexia, weight loss, and night sweats with an infiltrative cholestasis, is present in 90% of patients with miliary tuberculosis. Disseminated Mycobacterium avium complex (MAC) infection can also present with dramatic cholestasis with only minimal increase of the serum aminotransferase levels. 36 MAC infections have become infrequent in patients with HIV infection since the availability of effective antiretroviral therapy.\",\"cite_spans\":[{\"start\":222.0,\"end\":224.0,\"text\":\"34\",\"ref_id\":\"BIBREF34\"},{\"start\":384.0,\"end\":386.0,\"text\":\"35\",\"ref_id\":\"BIBREF35\"},{\"start\":742.0,\"end\":744.0,\"text\":\"36\",\"ref_id\":\"BIBREF36\"}],\"ref_spans\":[],\"section\":\"MYCOBACTERIAL INFECTIONS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235_citespan-222-224> , <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235_citespan-384-386> , <http://covid19.aksw.org/text-963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235_citespan-742-744> ;
            <http://www.example.org/section>
                    "MYCOBACTERIAL INFECTIONS" ;
            <http://www.example.org/text>  "Hepatobiliary tuberculosis is rare, although well documented. A 10-year experience of close to 2000 patients with tuberculosis identified only 14 cases of hepatobiliary tuberculosis, of which 9 had multiorgan involvement. 34 Jaundice is classically caused by extrahepatic biliary obstruction from bulky lymphadenopathy around the porta hepatis or postinflammatory biliary strictures. 35 A characteristic granulomatous hepatitis, marked by fever, anorexia, weight loss, and night sweats with an infiltrative cholestasis, is present in 90% of patients with miliary tuberculosis. Disseminated Mycobacterium avium complex (MAC) infection can also present with dramatic cholestasis with only minimal increase of the serum aminotransferase levels. 36 MAC infections have become infrequent in patients with HIV infection since the availability of effective antiretroviral therapy." ;
            <http://www.example.org/textHash>
                    "963ea1a2aa1ff4ac5bfc87783d4053b6c50fccbaa403a4dbfed6e0015e5cc235" .
    
    <http://covid19.aksw.org/text-ffc08f0dcd1af315a478ffa4685a0bed8e808827fe80ea7f7e64b9b548e8d57f_citespan-470-472>
            <http://www.example.org/end>    "472.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "470.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "30" .
    
    <http://covid19.aksw.org/text-11957162ce8ce28a491bb13ea6c215c14d521997935963488c048bd4f23d0026_citespan-1468-1470>
            <http://www.example.org/end>    "1470.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF48" ;
            <http://www.example.org/start>  "1468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "48" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1283-1285>
            <http://www.example.org/end>    "1285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF55" ;
            <http://www.example.org/start>  "1283.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "55" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-4772-4774>
            <http://www.example.org/end>    "4774.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "4772.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29" .
    
    <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-924-926>
            <http://www.example.org/end>    "926.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "924.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-2986-2988>
            <http://www.example.org/end>    "2988.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "2986.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "22" .
    
    <http://covid19.aksw.org/text-ffc08f0dcd1af315a478ffa4685a0bed8e808827fe80ea7f7e64b9b548e8d57f_citespan-1326-1328>
            <http://www.example.org/end>    "1328.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "1326.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32" .
    
    <http://covid19.aksw.org/text-2e4437c03a4f11ed73d36ba25b4f3bd34a453686546e51c0803347a315293e48_citespan-1909-1911>
            <http://www.example.org/end>    "1911.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF82" ;
            <http://www.example.org/start>  "1909.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "82" .
    
    <http://covid19.aksw.org/text-106c6bcd09ea57e7605b4420caa5fcaf3066eeb6fbdfc88b3aca38a3fff722ba_citespan-720-722>
            <http://www.example.org/end>    "722.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38" .
    
    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Cholestasis caused by sickle cell disease results from 1 of 2 processes (or both): extrahepatic or intrahepatic. 52 Extrahepatic cholestasis can be caused by choledocholithiasis. Pigment gallstones develop in roughly one-half of patients with sickle cell disease. In 1 series of 65 patients with sickle cell disease who underwent cholecystectomy, bile duct stones were found in 18%. 53 In 7% to 10% of patients hospitalized for sickle cell crisis, hepatic complications caused by sickling are found. Hepatic crisis can mimic acute cholecystitis or cholangitis, with right upper quadrant pain, jaundice, hepatomegaly, and fever. As much as 50% of the hyperbilirubinemia is attributable to conjugated bilirubin, and the total bilirubin level is relatively more increased than the aminotransferase levels. Sickle cell intrahepatic cholestasis (SCIC) is a term used in the literature to describe acute hepatic failure from sickle cell disease. 54 Bilirubinostasis identified pathologically in the liver is a consequence of sinusoidal distension from erythrocyte sickling. Erythrophagocytosis and hemosiderosis are also characteristic histologic findings. SCIC is associated with profound hyperbilirubinemia and has been treated successfully in occasional cases with exchange transfusion 55 and by liver transplantation. 56 LYMPHOMAS Important oncologic causes of cholestasis include Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Liver involvement is less frequent in HL than in NHL and typically occurs with disease above and below the diaphragm (stage III) or disseminated extranodal disease (stage IV). Five percent of patients with HL have liver involvement at the time of diagnosis, and Reed-Sternberg cells are pathognomonic. Forty percent of patients have an increased serum alkaline phosphatase level. Intrahepatic tumor infiltration has been seen in 45% of jaundiced patients with HL at autopsy. 57, 58 Several investigators have reported intrahepatic cholestasis caused by a vanishing bile duct syndrome in HL in the absence of tumor infiltration. 59 Ballonoff and colleagues 60 reviewed 37 cases described in the literature and found an association between an improvement in cholestasis and complete response to chemotherapy or radiation therapy (or both). Acute liver failure is a potential complication of HL, either directly caused by hepatic infiltration or secondarily caused by a paraneoplastic process.\",\"cite_spans\":[{\"start\":113.0,\"end\":115.0,\"text\":\"52\",\"ref_id\":\"BIBREF52\"},{\"start\":383.0,\"end\":385.0,\"text\":\"53\",\"ref_id\":\"BIBREF53\"},{\"start\":940.0,\"end\":942.0,\"text\":\"54\",\"ref_id\":\"BIBREF54\"},{\"start\":1283.0,\"end\":1285.0,\"text\":\"55\",\"ref_id\":\"BIBREF55\"},{\"start\":1316.0,\"end\":1318.0,\"text\":\"56\",\"ref_id\":\"BIBREF56\"},{\"start\":1908.0,\"end\":1911.0,\"text\":\"57,\",\"ref_id\":\"BIBREF57\"},{\"start\":1912.0,\"end\":1914.0,\"text\":\"58\",\"ref_id\":\"BIBREF58\"},{\"start\":2061.0,\"end\":2063.0,\"text\":\"59\",\"ref_id\":\"BIBREF59\"}],\"ref_spans\":[],\"section\":\"SICKLE CELL DISEASE\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-2061-2063> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1908-1911> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-113-115> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1283-1285> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-383-385> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1912-1914> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-940-942> , <http://covid19.aksw.org/text-1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552_citespan-1316-1318> ;
            <http://www.example.org/section>
                    "SICKLE CELL DISEASE" ;
            <http://www.example.org/text>  "Cholestasis caused by sickle cell disease results from 1 of 2 processes (or both): extrahepatic or intrahepatic. 52 Extrahepatic cholestasis can be caused by choledocholithiasis. Pigment gallstones develop in roughly one-half of patients with sickle cell disease. In 1 series of 65 patients with sickle cell disease who underwent cholecystectomy, bile duct stones were found in 18%. 53 In 7% to 10% of patients hospitalized for sickle cell crisis, hepatic complications caused by sickling are found. Hepatic crisis can mimic acute cholecystitis or cholangitis, with right upper quadrant pain, jaundice, hepatomegaly, and fever. As much as 50% of the hyperbilirubinemia is attributable to conjugated bilirubin, and the total bilirubin level is relatively more increased than the aminotransferase levels. Sickle cell intrahepatic cholestasis (SCIC) is a term used in the literature to describe acute hepatic failure from sickle cell disease. 54 Bilirubinostasis identified pathologically in the liver is a consequence of sinusoidal distension from erythrocyte sickling. Erythrophagocytosis and hemosiderosis are also characteristic histologic findings. SCIC is associated with profound hyperbilirubinemia and has been treated successfully in occasional cases with exchange transfusion 55 and by liver transplantation. 56 LYMPHOMAS Important oncologic causes of cholestasis include Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Liver involvement is less frequent in HL than in NHL and typically occurs with disease above and below the diaphragm (stage III) or disseminated extranodal disease (stage IV). Five percent of patients with HL have liver involvement at the time of diagnosis, and Reed-Sternberg cells are pathognomonic. Forty percent of patients have an increased serum alkaline phosphatase level. Intrahepatic tumor infiltration has been seen in 45% of jaundiced patients with HL at autopsy. 57, 58 Several investigators have reported intrahepatic cholestasis caused by a vanishing bile duct syndrome in HL in the absence of tumor infiltration. 59 Ballonoff and colleagues 60 reviewed 37 cases described in the literature and found an association between an improvement in cholestasis and complete response to chemotherapy or radiation therapy (or both). Acute liver failure is a potential complication of HL, either directly caused by hepatic infiltration or secondarily caused by a paraneoplastic process." ;
            <http://www.example.org/textHash>
                    "1ceaca459b4d1518667b19215a505be5f09e5073ad2de49e5e1ccf50046df552" .
    
    <http://covid19.aksw.org/text-affffe8f420922d331f87a4089a4e87189020dad16bb52d63287424881629050_citespan-965-968>
            <http://www.example.org/end>    "968.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-80d6f3cefce92ead123d4898b5db8bc0a2331cd9f7cb9c1a062a7f55a24ed87f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Typically, sarcoidosis presents with noncaseating granulomas in the lungs and lymph nodes. The liver is an occasional extrapulmonary site of disease. In 1 retrospective series, 43 liver biochemical test abnormalities were found in 204 of 837 (24.4%) patients with sarcoidosis, of whom 15.2% were believed to have hepatic sarcoidosis. Prevalence rates are highest among African American and Scandinavian persons between the ages of 20 and 40 years. Liver involvement in sarcoidosis is usually clinically silent.\",\"cite_spans\":[{\"start\":177.0,\"end\":179.0,\"text\":\"43\",\"ref_id\":\"BIBREF43\"}],\"ref_spans\":[],\"section\":\"HEPATIC SARCOIDOSIS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-80d6f3cefce92ead123d4898b5db8bc0a2331cd9f7cb9c1a062a7f55a24ed87f_citespan-177-179> ;
            <http://www.example.org/section>
                    "HEPATIC SARCOIDOSIS" ;
            <http://www.example.org/text>  "Typically, sarcoidosis presents with noncaseating granulomas in the lungs and lymph nodes. The liver is an occasional extrapulmonary site of disease. In 1 retrospective series, 43 liver biochemical test abnormalities were found in 204 of 837 (24.4%) patients with sarcoidosis, of whom 15.2% were believed to have hepatic sarcoidosis. Prevalence rates are highest among African American and Scandinavian persons between the ages of 20 and 40 years. Liver involvement in sarcoidosis is usually clinically silent." ;
            <http://www.example.org/textHash>
                    "80d6f3cefce92ead123d4898b5db8bc0a2331cd9f7cb9c1a062a7f55a24ed87f" .
}
<http://covid19.aksw.org/fd84dc607d49e49f0d2887344d3eab3f2b95e187> {
    <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-1013-1035>
            <http://www.example.org/end>    "1035.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "1013.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Krutzik et al., 2008;" .
    
    <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df_refspan-305-313>
            <http://www.example.org/end>    "313.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "305.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 7C" .
    
    <http://covid19.aksw.org/text-102bf4dfe7fbf624782e1bfbb7ef084cbe3b61f75a3a2999554c882d0a657f4d_refspan-133-142>
            <http://www.example.org/end>    "142.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF0" ;
            <http://www.example.org/start>  "133.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Table 1)" .
    
    <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Based on the results described above, we next focused on the phosphorylated states of STAT1 and S6 after drug treatment of cells. Monitoring pSTAT1 over time showed that pSTAT1 was upregulated, in a dose-dependent manner, as early as 0.5 h and this was extended up to 16 h after drug treatments ( Fig. 2A and B) . In contrast, adding drug combinations containing RIB lowered pS6 in a dose-dependent manner. pS6 signaling was not an instant marker for RIB, as pS6 decreased only after 8 h of drug treatments ( Fig. 2C and D) . When plotting pSTAT1 and pS6 signaling side-by-side along the time course, pSTAT1 was an instant and long-lasting marker for IFN, whereas pS6 was a later period marker for RIB (Fig. 2E) .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":297.0,\"end\":311.0,\"text\":\"Fig. 2A and B)\"},{\"start\":509.0,\"end\":523.0,\"text\":\"Fig. 2C and D)\"},{\"start\":702.0,\"end\":711.0,\"text\":\"(Fig. 2E)\"}],\"section\":\"Monitoring STAT1 and S6 as distinct signals of antiviral drug efficacy\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e_refspan-297-311> , <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e_refspan-509-523> , <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e_refspan-702-711> ;
            <http://www.example.org/section>
                    "Monitoring STAT1 and S6 as distinct signals of antiviral drug efficacy" ;
            <http://www.example.org/text>  "Based on the results described above, we next focused on the phosphorylated states of STAT1 and S6 after drug treatment of cells. Monitoring pSTAT1 over time showed that pSTAT1 was upregulated, in a dose-dependent manner, as early as 0.5 h and this was extended up to 16 h after drug treatments ( Fig. 2A and B) . In contrast, adding drug combinations containing RIB lowered pS6 in a dose-dependent manner. pS6 signaling was not an instant marker for RIB, as pS6 decreased only after 8 h of drug treatments ( Fig. 2C and D) . When plotting pSTAT1 and pS6 signaling side-by-side along the time course, pSTAT1 was an instant and long-lasting marker for IFN, whereas pS6 was a later period marker for RIB (Fig. 2E) ." ;
            <http://www.example.org/textHash>
                    "c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e" .
    
    <http://covid19.aksw.org/text-12593c1e86ce89c61582390a77c71eb2a21867a862f3ba38986349f94bad6961_citespan-3-45>
            <http://www.example.org/end>    "45.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "3.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ding, et al. Antiviral Research 171 (2019)" .
    
    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Now that we understood that modulation of the S6 phosphorylation state is critical target in the control of HSV-1 replication we sought to validate the cause-effect relationships between pS6 signaling and HSV-1 infection using the pS6 kinase inhibitor, SL0101. To evaluate the effect of down-regulating the S6 pathway on HSV-1 replication we looked at viral replication 16 h after treatment with SL0101. At 50 μM of SL0101 there is a slightly decreased GFP level in +HSV-1 samples, while SL0101 at 100 μM or RIB at 100 μM profoundly decrease the viral infection level (Fig. 6A) . We also examined the effects of these treatments on pAKT, pERK, pMAPKAPK2, p-p38, p-p70, p-p90 RSK , pS6, pSTAT1, and pSTAT3. When HSV-1 was not present, RIB and SL0101 both showed general signaling regulation across multiple pathways. With viral stimulation, however, SL0101 at 25 and 50 μM no longer resulted in dramatic signaling regulation. This result shows that HSV-1 infection could overcome changes induced by low dose SL0101. However, at 100 μM, SL0101 treatment resulted in a general decrease in signaling across multiple pathways. RIB at 100 μM appeared to be much more specific in signaling regulation, as only pS6 was significantly downregulated (Fig. 6B) . -infection) , pAKT, pMAPKAPK2, pNFĸB, pS6 and pSTAT1 were found to be involved during the viral infection and inhibition process. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). All experimental data shown is representative data from three independent experiments. Flow cytometry histograms are color-coded as in a heatmap with black being unchanged and shades of yellow denoting increases. Quantitation of pSTAT1 from B are shown in Supplemental Fig. 3 . Quantitation of plots from C are shown in Supplemental Fig. 4 with GFP levels in 4A, pAKT levels in 4B, pMAPKAPK2 levels in 4C, pNFĸB levels in 4D, pS6 levels in 4E and pSTAT1 levels in 4F. Red arrows in Supplemental Fig. 4 A, E and F indicate Optimal_B and Ribavirin treatments across the analysis.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":568.0,\"end\":577.0,\"text\":\"(Fig. 6A)\",\"ref_id\":\"FIGREF3\"},{\"start\":1239.0,\"end\":1248.0,\"text\":\"(Fig. 6B)\",\"ref_id\":\"FIGREF3\"},{\"start\":1251.0,\"end\":1262.0,\"text\":\"-infection)\"},{\"start\":1823.0,\"end\":1829.0,\"text\":\"Fig. 3\",\"ref_id\":\"FIGREF1\"},{\"start\":1887.0,\"end\":1893.0,\"text\":\"Fig. 4\"},{\"start\":2049.0,\"end\":2055.0,\"text\":\"Fig. 4\"}],\"section\":\"Translating cellular analysis of RIB signaling to discovery of a small molecule inhibitor of HSV-1 inhibition in vitro\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1239-1248> , <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1251-1262> , <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-568-577> , <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-2049-2055> , <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1823-1829> , <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1887-1893> ;
            <http://www.example.org/section>
                    "Translating cellular analysis of RIB signaling to discovery of a small molecule inhibitor of HSV-1 inhibition in vitro" ;
            <http://www.example.org/text>  "Now that we understood that modulation of the S6 phosphorylation state is critical target in the control of HSV-1 replication we sought to validate the cause-effect relationships between pS6 signaling and HSV-1 infection using the pS6 kinase inhibitor, SL0101. To evaluate the effect of down-regulating the S6 pathway on HSV-1 replication we looked at viral replication 16 h after treatment with SL0101. At 50 μM of SL0101 there is a slightly decreased GFP level in +HSV-1 samples, while SL0101 at 100 μM or RIB at 100 μM profoundly decrease the viral infection level (Fig. 6A) . We also examined the effects of these treatments on pAKT, pERK, pMAPKAPK2, p-p38, p-p70, p-p90 RSK , pS6, pSTAT1, and pSTAT3. When HSV-1 was not present, RIB and SL0101 both showed general signaling regulation across multiple pathways. With viral stimulation, however, SL0101 at 25 and 50 μM no longer resulted in dramatic signaling regulation. This result shows that HSV-1 infection could overcome changes induced by low dose SL0101. However, at 100 μM, SL0101 treatment resulted in a general decrease in signaling across multiple pathways. RIB at 100 μM appeared to be much more specific in signaling regulation, as only pS6 was significantly downregulated (Fig. 6B) . -infection) , pAKT, pMAPKAPK2, pNFĸB, pS6 and pSTAT1 were found to be involved during the viral infection and inhibition process. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). All experimental data shown is representative data from three independent experiments. Flow cytometry histograms are color-coded as in a heatmap with black being unchanged and shades of yellow denoting increases. Quantitation of pSTAT1 from B are shown in Supplemental Fig. 3 . Quantitation of plots from C are shown in Supplemental Fig. 4 with GFP levels in 4A, pAKT levels in 4B, pMAPKAPK2 levels in 4C, pNFĸB levels in 4D, pS6 levels in 4E and pSTAT1 levels in 4F. Red arrows in Supplemental Fig. 4 A, E and F indicate Optimal_B and Ribavirin treatments across the analysis." ;
            <http://www.example.org/textHash>
                    "fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46" .
    
    <http://covid19.aksw.org/text-2152bb262c7a1786fd2ce61fb62e0f5e933dee0b245416d5582ae508eef1053f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"This in vitro investigation was carried out in NIH 3T3 cells, which is a cell line derived from mouse embryo fibroblasts. NIH 3T3 cells were cultured in Dulbecco\\u0027s modified Eagle\\u0027s medium (DMEM) supplemented with 5% fetal bovine serum and 1% antibiotics (penicillin and streptomycin). Preparation and quantization of HSV-1 were conducted as previously described (Ding et al., 2012) . Viruses were diluted in DMEM to a multiplicity of infection (MOI) of 0.1.\",\"cite_spans\":[{\"start\":362.0,\"end\":381.0,\"text\":\"(Ding et al., 2012)\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[],\"section\":\"Cell culture and HSV-1 infections\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2152bb262c7a1786fd2ce61fb62e0f5e933dee0b245416d5582ae508eef1053f_citespan-362-381> ;
            <http://www.example.org/section>
                    "Cell culture and HSV-1 infections" ;
            <http://www.example.org/text>  "This in vitro investigation was carried out in NIH 3T3 cells, which is a cell line derived from mouse embryo fibroblasts. NIH 3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum and 1% antibiotics (penicillin and streptomycin). Preparation and quantization of HSV-1 were conducted as previously described (Ding et al., 2012) . Viruses were diluted in DMEM to a multiplicity of infection (MOI) of 0.1." ;
            <http://www.example.org/textHash>
                    "2152bb262c7a1786fd2ce61fb62e0f5e933dee0b245416d5582ae508eef1053f" .
    
    <http://covid19.aksw.org/text-91c201510e9c9d3000da5fe21332e78b5e51cdca09e7d736c83b3ba72c40ce75_citespan-982-999>
            <http://www.example.org/end>    "999.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "982.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Liu et al., 2012)" .
    
    <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Plaque assays were performed on Vero cell monolayers. Each lavage was serially diluted eight times with DMEM at a ratio of 1:10. During this process, 0.4 mL of lavage dilution was added to the Vero cell monolayer, and virus absorption was allowed to proceed for 1 h at 37°C with gentle shaking every 20 min. After absorption, excess virus was removed by three washes with DMEM. 1 mL of agar overlay medium was added on top of the Vero cell monolayer. After plaques started to form the agar overlay was removed, and the cell monolayer was stained with 0.1% crystal violet. Plaques were counted under a microscope and bar graphs were produced based on averages of three experimental data points. Statistical differences were determined using a t-Test between viral levels at day 2 or day 3, SL0101 or untreated samples, or fold Table 1 as well as each individual drugs. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). Drug treatments are indicated at the bottom of the panel. Samples were collected 0.5, 4, 8, and 16 h after drug stimulations. Although 12 phosphoproteins were examined for each sample (pAkt, pERK, pJNK, p-cJun, pMAP-KAPK2, pNFĸB, p-p38, pS6, pSTAT1, pSTAT3, pSTAT5, and pSTAT6), here we show only pS6 and pSTAT1. The complete panel is shown in Supplementary Fig. 1 . B. Comparison of pSTAT1 and pS6 signaling after 16 h of individual drug treatments indicates IFN up-regulated pSTAT1 signaling and RIB down-regulated pS6 signaling. C. Comparison of two optimal drug combination treatments shows that the IFN-rich treatment upregulated pSTAT1 signaling and RIB-rich treatment down-regulated pS6 signaling. All experimental data shown is representative data from three independent experiments. Flow cytometry histograms are color-coded as in a heatmap with black being unchanged and shades of yellow denoting increases. Quantitation of plots from B and C are shown in Supplemental Fig. 2. change in virus levels at day 2 versus day 1 and day 3 versus day 1.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":826.0,\"end\":833.0,\"text\":\"Table 1\",\"ref_id\":\"TABREF0\"},{\"start\":1385.0,\"end\":1405.0,\"text\":\"Supplementary Fig. 1\",\"ref_id\":\"FIGREF0\"},{\"start\":2020.0,\"end\":2027.0,\"text\":\"Fig. 2.\"}],\"section\":\"Plaque assay to quantify HSV-1 titer\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9_refspan-826-833> , <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9_refspan-1385-1405> , <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9_refspan-2020-2027> ;
            <http://www.example.org/section>
                    "Plaque assay to quantify HSV-1 titer" ;
            <http://www.example.org/text>  "Plaque assays were performed on Vero cell monolayers. Each lavage was serially diluted eight times with DMEM at a ratio of 1:10. During this process, 0.4 mL of lavage dilution was added to the Vero cell monolayer, and virus absorption was allowed to proceed for 1 h at 37°C with gentle shaking every 20 min. After absorption, excess virus was removed by three washes with DMEM. 1 mL of agar overlay medium was added on top of the Vero cell monolayer. After plaques started to form the agar overlay was removed, and the cell monolayer was stained with 0.1% crystal violet. Plaques were counted under a microscope and bar graphs were produced based on averages of three experimental data points. Statistical differences were determined using a t-Test between viral levels at day 2 or day 3, SL0101 or untreated samples, or fold Table 1 as well as each individual drugs. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). Drug treatments are indicated at the bottom of the panel. Samples were collected 0.5, 4, 8, and 16 h after drug stimulations. Although 12 phosphoproteins were examined for each sample (pAkt, pERK, pJNK, p-cJun, pMAP-KAPK2, pNFĸB, p-p38, pS6, pSTAT1, pSTAT3, pSTAT5, and pSTAT6), here we show only pS6 and pSTAT1. The complete panel is shown in Supplementary Fig. 1 . B. Comparison of pSTAT1 and pS6 signaling after 16 h of individual drug treatments indicates IFN up-regulated pSTAT1 signaling and RIB down-regulated pS6 signaling. C. Comparison of two optimal drug combination treatments shows that the IFN-rich treatment upregulated pSTAT1 signaling and RIB-rich treatment down-regulated pS6 signaling. All experimental data shown is representative data from three independent experiments. Flow cytometry histograms are color-coded as in a heatmap with black being unchanged and shades of yellow denoting increases. Quantitation of plots from B and C are shown in Supplemental Fig. 2. change in virus levels at day 2 versus day 1 and day 3 versus day 1." ;
            <http://www.example.org/textHash>
                    "7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9" .
    
    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-783-803>
            <http://www.example.org/end>    "803.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "783.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Crotty et al., 2002)" .
    
    <http://covid19.aksw.org/text-6b3f245dd42673de5d37dde2aa7865a92a1a96ba1ba102ce6b5f7d226508ba25>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The impact that modulation of S6 phosphorylation would have on viral replication is not a well-understood idea. While HSV-1 replication either induced or required upregulated levels of S6 phosphorylation, blocking these heightened levels of S6 phosphorylation by RIB was sufficient to block HSV-1 replicaiton. We used these findings to focus on the phosphorylation of S6 as a new target when developing therapeutics against HSV-1 infection. Using this focus, we used a small molecule (SL0101), an inhibitor of an S6 kinase that can reduce S6 phosphorulation and thereby mimic the efficacy of one of the drug combination by lowering S6 phosphorylation. We went on to show that SL0101 could effectively block the replication of HSV-1 in an animal model of Both drug combinations Optimal_A and Optimal_B profoundly reduced HSV-1 infection compared to unstimulated controls in the co-treated model. Data points are average of data from three experimental ± standard deviation. Flow cytometry histograms are color-coded as in a heatmap with black being unchanged and shades of yellow denoting increases. C. Drug treatments versus percent HSV-1 infection. Data points are average of data from three experimental ± standard deviation. D. Drug treatments versus pS6 level showed similar patterns as viral infection. E. HSV-1 infection levels and S6 phosphorylation levels followed a log-linear correlation. Data points are average of data from three experimental ± standard deviation. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). All experimental data shown is representative data from three independent experiments. For Parts C, D and E, data plotted is mean ± standard deviation. In Part E, the correlation coefficient, R 2 , is displayed.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Fig. 4. Drug Treatment of Viral Infection Affecting Distinct Signaling Nodes.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Fig. 4. Drug Treatment of Viral Infection Affecting Distinct Signaling Nodes." ;
            <http://www.example.org/text>  "The impact that modulation of S6 phosphorylation would have on viral replication is not a well-understood idea. While HSV-1 replication either induced or required upregulated levels of S6 phosphorylation, blocking these heightened levels of S6 phosphorylation by RIB was sufficient to block HSV-1 replicaiton. We used these findings to focus on the phosphorylation of S6 as a new target when developing therapeutics against HSV-1 infection. Using this focus, we used a small molecule (SL0101), an inhibitor of an S6 kinase that can reduce S6 phosphorulation and thereby mimic the efficacy of one of the drug combination by lowering S6 phosphorylation. We went on to show that SL0101 could effectively block the replication of HSV-1 in an animal model of Both drug combinations Optimal_A and Optimal_B profoundly reduced HSV-1 infection compared to unstimulated controls in the co-treated model. Data points are average of data from three experimental ± standard deviation. Flow cytometry histograms are color-coded as in a heatmap with black being unchanged and shades of yellow denoting increases. C. Drug treatments versus percent HSV-1 infection. Data points are average of data from three experimental ± standard deviation. D. Drug treatments versus pS6 level showed similar patterns as viral infection. E. HSV-1 infection levels and S6 phosphorylation levels followed a log-linear correlation. Data points are average of data from three experimental ± standard deviation. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). All experimental data shown is representative data from three independent experiments. For Parts C, D and E, data plotted is mean ± standard deviation. In Part E, the correlation coefficient, R 2 , is displayed." ;
            <http://www.example.org/textHash>
                    "6b3f245dd42673de5d37dde2aa7865a92a1a96ba1ba102ce6b5f7d226508ba25" .
    
    <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-728-754>
            <http://www.example.org/end>    "754.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "728.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Knickelbein et al., 2008)" .
    
    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-568-577>
            <http://www.example.org/end>    "577.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF3" ;
            <http://www.example.org/start>  "568.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 6A)" .
    
    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-560-579>
            <http://www.example.org/end>    "579.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "560.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Chong et al., 2015)" .
    
    <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_refspan-231-240>
            <http://www.example.org/end>    "240.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "231.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3B)" .
    
    <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-912-937>
            <http://www.example.org/end>    "937.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "912.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tognarelli et al., 2019;" .
    
    <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7_citespan-461-482>
            <http://www.example.org/end>    "482.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "461.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(George et al., 2015;" .
    
    <http://covid19.aksw.org/fd84dc607d49e49f0d2887344d3eab3f2b95e187>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "fd84dc607d49e49f0d2887344d3eab3f2b95e187" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7> , <http://covid19.aksw.org/text-97223eb5aad08437e8664278560117449f6796e1d8c42656024728062c50ec87> , <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b> , <http://covid19.aksw.org/text-91c201510e9c9d3000da5fe21332e78b5e51cdca09e7d736c83b3ba72c40ce75> , <http://covid19.aksw.org/text-245d6221c415e216894aae3df22fe41c258bbdd6f597d0c4cd42249490472571> , <http://covid19.aksw.org/text-13a5072dffbc082de8a97042dbb225cde28a3ebd09a4ffe89587a90cc9797fba> , <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791> , <http://covid19.aksw.org/text-1931a8f8ce01e29f96b5650b0ce823d3115928f3f12827e8cf694e6c49ff7ba4> , <http://covid19.aksw.org/text-3fc72d5dff3a4aae7673409bd6cf5b0eb380cb7bf59c58ebabb156a07a2aa3de> , <http://covid19.aksw.org/text-03fe897fe38b5c95702d6593152eab00fc1dd60a7f96ffcd69639d9b1d19ba1e> , <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2> , <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34> , <http://covid19.aksw.org/text-64a00beb55d15e07e8f8ecb41a69e179890faabe35108c8b45cc07c369b8cbfa> , <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46> , <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858> , <http://covid19.aksw.org/text-2dc32a49a40df41082dad3c7606062cf6cfea3895601d91a3d755aebe226536c> , <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7> , <http://covid19.aksw.org/text-12593c1e86ce89c61582390a77c71eb2a21867a862f3ba38986349f94bad6961> , <http://covid19.aksw.org/text-a92951390ecc5cf8be7d22d099ecd3948568d5c90e64478c4af2700287c39fd3> , <http://covid19.aksw.org/text-3b83c2d5c31e1a1692f17afce7660df0213730d210252a99077094bccce069d6> , <http://covid19.aksw.org/text-572ea1576f52d8c9afe3d99d32e9ea0de9f3499426ff4bf393cb7199afe413bc> , <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df> , <http://covid19.aksw.org/text-7db751d6558c769ad02a07bc5e85219bd459b82e4332c5ae667bb03e669aaa9c> , <http://covid19.aksw.org/text-210ad2dfb2c7ae766ee2393c667a806d5d151babb164e9e27e1222f271357e10> , <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a> , <http://covid19.aksw.org/text-dd0be00c875d195cbfefed2fcebf0ad8c43c024903bbf160394cc425a3a70679> , <http://covid19.aksw.org/text-9a396af812e79d5dfaa55ed47fb1cc9810b5bab6fbbe92cc7be82abd4e44cc66> , <http://covid19.aksw.org/text-168d046fb262bc7fe41efb63acfbe338fd1d5bdafa7e2e82057c912cc66cbc0f> , <http://covid19.aksw.org/text-6b3f245dd42673de5d37dde2aa7865a92a1a96ba1ba102ce6b5f7d226508ba25> , <http://covid19.aksw.org/text-2152bb262c7a1786fd2ce61fb62e0f5e933dee0b245416d5582ae508eef1053f> , <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f> , <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9> , <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4> , <http://covid19.aksw.org/text-102bf4dfe7fbf624782e1bfbb7ef084cbe3b61f75a3a2999554c882d0a657f4d> , <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca> , <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e> .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-926-945>
            <http://www.example.org/end>    "945.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "926.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ding et al., 2012)" .
    
    <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7_citespan-483-513>
            <http://www.example.org/end>    "513.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "483.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Hildebrand and Kubatzky, 2017;" .
    
    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1239-1248>
            <http://www.example.org/end>    "1248.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF3" ;
            <http://www.example.org/start>  "1239.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 6B)" .
    
    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1823-1829>
            <http://www.example.org/end>    "1829.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "1823.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 3" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-681-700>
            <http://www.example.org/end>    "700.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "681.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Weiss et al., 2015;" .
    
    <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34_refspan-297-319>
            <http://www.example.org/end>    "319.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "297.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Supplementary Fig. 5A" .
    
    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-717-726>
            <http://www.example.org/end>    "726.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "717.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 5D)" .
    
    <http://covid19.aksw.org/text-12593c1e86ce89c61582390a77c71eb2a21867a862f3ba38986349f94bad6961>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"X. Ding, et al. Antiviral Research 171 (2019) \",\"cite_spans\":[{\"start\":3.0,\"end\":45.0,\"text\":\"Ding, et al. Antiviral Research 171 (2019)\"}],\"ref_spans\":[],\"section\":\"Changes in distinct signaling nodes after post-infection treatment of viral infection\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-12593c1e86ce89c61582390a77c71eb2a21867a862f3ba38986349f94bad6961_citespan-3-45> ;
            <http://www.example.org/section>
                    "Changes in distinct signaling nodes after post-infection treatment of viral infection" ;
            <http://www.example.org/text>  "X. Ding, et al. Antiviral Research 171 (2019) " ;
            <http://www.example.org/textHash>
                    "12593c1e86ce89c61582390a77c71eb2a21867a862f3ba38986349f94bad6961" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-934-956>
            <http://www.example.org/end>    "956.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "934.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1B, right panel," .
    
    <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-573-592>
            <http://www.example.org/end>    "592.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "573.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ding et al., 2012)" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-651-680>
            <http://www.example.org/end>    "680.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "651.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Nowak-Sliwinska et al., 2016;" .
    
    <http://covid19.aksw.org/text-2152bb262c7a1786fd2ce61fb62e0f5e933dee0b245416d5582ae508eef1053f_citespan-362-381>
            <http://www.example.org/end>    "381.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "362.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ding et al., 2012)" .
    
    <http://covid19.aksw.org/text-dd0be00c875d195cbfefed2fcebf0ad8c43c024903bbf160394cc425a3a70679>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"IFN-α, IFN-β, and IFN-γ were purchased from PBL Interferon Source (Piscataway, NJ). RIB and ACV were purchased from Calbiochem (San Diego, CA). DMEM was purchased from CELLGRO (Manassas, VA), and penicillin and streptomycin were obtained from GIBCO (Grand Island, NY). Paraformaldehyde (PFA) was purchased from Electron Microscopy Sciences (Hatfield, PA), and phosphate buffered saline (PBS) was bought from EMD (Rockland, MA). All other plates and tubes were purchased from BD Falcon (San Jose, CA).\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Drugs and solutions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Drugs and solutions" ;
            <http://www.example.org/text>  "IFN-α, IFN-β, and IFN-γ were purchased from PBL Interferon Source (Piscataway, NJ). RIB and ACV were purchased from Calbiochem (San Diego, CA). DMEM was purchased from CELLGRO (Manassas, VA), and penicillin and streptomycin were obtained from GIBCO (Grand Island, NY). Paraformaldehyde (PFA) was purchased from Electron Microscopy Sciences (Hatfield, PA), and phosphate buffered saline (PBS) was bought from EMD (Rockland, MA). All other plates and tubes were purchased from BD Falcon (San Jose, CA)." ;
            <http://www.example.org/textHash>
                    "dd0be00c875d195cbfefed2fcebf0ad8c43c024903bbf160394cc425a3a70679" .
    
    <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_citespan-1034-1053>
            <http://www.example.org/end>    "1053.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "1034.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ding et al., 2012)" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-475-501>
            <http://www.example.org/end>    "501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "475.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(James and Prichard, 2014)" .
    
    <http://covid19.aksw.org/text-245d6221c415e216894aae3df22fe41c258bbdd6f597d0c4cd42249490472571_citespan-505-533>
            <http://www.example.org/end>    "533.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "505.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ruvinsky and Meyuhas, 2006)" .
    
    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-308-316>
            <http://www.example.org/end>    "316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4A" .
    
    <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-667-685>
            <http://www.example.org/end>    "685.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "667.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lee et al., 2017;" .
    
    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-240-249>
            <http://www.example.org/end>    "249.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "240.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 5A)" .
    
    <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-686-703>
            <http://www.example.org/end>    "703.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "686.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sun et al., 2013)" .
    
    <http://covid19.aksw.org/text-102bf4dfe7fbf624782e1bfbb7ef084cbe3b61f75a3a2999554c882d0a657f4d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Based on our previous work (Ding et al., 2012) , the following five drug combinations were applied and compared in the current study (Table 1) : high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). Each individual drug from the combinations was administrated alone or in combination at time 0 in duplicate. After treatment, samples at four time points (0.5, 4, 8, and 16 h) were collected.\",\"cite_spans\":[{\"start\":27.0,\"end\":46.0,\"text\":\"(Ding et al., 2012)\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[{\"start\":133.0,\"end\":142.0,\"text\":\"(Table 1)\",\"ref_id\":\"TABREF0\"}],\"section\":\"Drug combinations applied in the study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-102bf4dfe7fbf624782e1bfbb7ef084cbe3b61f75a3a2999554c882d0a657f4d_citespan-27-46> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-102bf4dfe7fbf624782e1bfbb7ef084cbe3b61f75a3a2999554c882d0a657f4d_refspan-133-142> ;
            <http://www.example.org/section>
                    "Drug combinations applied in the study" ;
            <http://www.example.org/text>  "Based on our previous work (Ding et al., 2012) , the following five drug combinations were applied and compared in the current study (Table 1) : high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). Each individual drug from the combinations was administrated alone or in combination at time 0 in duplicate. After treatment, samples at four time points (0.5, 4, 8, and 16 h) were collected." ;
            <http://www.example.org/textHash>
                    "102bf4dfe7fbf624782e1bfbb7ef084cbe3b61f75a3a2999554c882d0a657f4d" .
    
    <http://covid19.aksw.org/text-a92951390ecc5cf8be7d22d099ecd3948568d5c90e64478c4af2700287c39fd3_citespan-50-72>
            <http://www.example.org/end>    "72.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "50.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Krutzik et al., 2008)" .
    
    <http://covid19.aksw.org/text-03fe897fe38b5c95702d6593152eab00fc1dd60a7f96ffcd69639d9b1d19ba1e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"As antiviral drug resistance develops and new viruses emerge there is a pressing need to develop strategies to rapidly develop antiviral therapeutics. Here we use phospho-specific flow cytometry to assess perturbations of many different cellular signaling pathways during treatment with drug combinations that are highly effective in blocking Herpes simplex virus type 1 (HSV-1) infection. We discovered two antiviral drug combinations act on distinct signaling pathways, either STAT1 or S6 phosphorylation, to block HSV-1 infection. We focused on upregulation of S6 phosphorylation by HSV-1 infection, and our subsequent finding that ribavirin antagonizes this upregulation of S6 phosphorylation. We go on to show that the S6 kinase inhibitor SL0101 blocks HSV-1 replication in vitro and in an in vivo animal model of HSV-1 infection. Overall, we have used an unbiased analysis of cellular signaling pathways during treatment by antiviral drug combinations to discover a novel antiviral drug target against HSV-1 infection. The outcomes of the approach we present highlight the importance of analyzing how antiviral drugs modulate cellular and pathogen-induced signaling as a method to discover new drug therapy targets.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "As antiviral drug resistance develops and new viruses emerge there is a pressing need to develop strategies to rapidly develop antiviral therapeutics. Here we use phospho-specific flow cytometry to assess perturbations of many different cellular signaling pathways during treatment with drug combinations that are highly effective in blocking Herpes simplex virus type 1 (HSV-1) infection. We discovered two antiviral drug combinations act on distinct signaling pathways, either STAT1 or S6 phosphorylation, to block HSV-1 infection. We focused on upregulation of S6 phosphorylation by HSV-1 infection, and our subsequent finding that ribavirin antagonizes this upregulation of S6 phosphorylation. We go on to show that the S6 kinase inhibitor SL0101 blocks HSV-1 replication in vitro and in an in vivo animal model of HSV-1 infection. Overall, we have used an unbiased analysis of cellular signaling pathways during treatment by antiviral drug combinations to discover a novel antiviral drug target against HSV-1 infection. The outcomes of the approach we present highlight the importance of analyzing how antiviral drugs modulate cellular and pathogen-induced signaling as a method to discover new drug therapy targets." ;
            <http://www.example.org/textHash>
                    "03fe897fe38b5c95702d6593152eab00fc1dd60a7f96ffcd69639d9b1d19ba1e" .
    
    <http://covid19.aksw.org/text-91c201510e9c9d3000da5fe21332e78b5e51cdca09e7d736c83b3ba72c40ce75>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Here we present a study focusing on HSV-1 infection. While HSV-1 infection can be well controlled by currently available antivirals, we must develop alternative therapeutic strategies due to several reasons. These reasons include the appearance of anti-viral resistant strains, the possibility of HSV-1 inducing enhanced disease in immunocompromised individuals, and the lack of an effective HSV-1 vaccine. Here we analyze cellular signaling on a system level to determine how antiviral drug combinations modulate many different pathways and discovered that they have different molecular signatures when assayed by phosphoflow. Our results reveal that HSV-1 infection can be targeted using antivirals that modulate one of two pathways: STAT1 or S6. Combinations containing RIB cause changes in S6 phosphorylation, whereas IFN-containing combinations lead to changes in STAT1 phosphorylation. STAT1 is a well-known cellular inducer of the antiviral state (Horvath and Darnell, 1996; Liu et al., 2012) . This antiviral state efficiently blocks viral growth and thus it makes sense as a marker of antiviral activity.\",\"cite_spans\":[{\"start\":954.0,\"end\":981.0,\"text\":\"(Horvath and Darnell, 1996;\",\"ref_id\":\"BIBREF17\"},{\"start\":982.0,\"end\":999.0,\"text\":\"Liu et al., 2012)\",\"ref_id\":\"BIBREF26\"}],\"ref_spans\":[],\"section\":\"Fig. 4. Drug Treatment of Viral Infection Affecting Distinct Signaling Nodes.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-91c201510e9c9d3000da5fe21332e78b5e51cdca09e7d736c83b3ba72c40ce75_citespan-954-981> , <http://covid19.aksw.org/text-91c201510e9c9d3000da5fe21332e78b5e51cdca09e7d736c83b3ba72c40ce75_citespan-982-999> ;
            <http://www.example.org/section>
                    "Fig. 4. Drug Treatment of Viral Infection Affecting Distinct Signaling Nodes." ;
            <http://www.example.org/text>  "Here we present a study focusing on HSV-1 infection. While HSV-1 infection can be well controlled by currently available antivirals, we must develop alternative therapeutic strategies due to several reasons. These reasons include the appearance of anti-viral resistant strains, the possibility of HSV-1 inducing enhanced disease in immunocompromised individuals, and the lack of an effective HSV-1 vaccine. Here we analyze cellular signaling on a system level to determine how antiviral drug combinations modulate many different pathways and discovered that they have different molecular signatures when assayed by phosphoflow. Our results reveal that HSV-1 infection can be targeted using antivirals that modulate one of two pathways: STAT1 or S6. Combinations containing RIB cause changes in S6 phosphorylation, whereas IFN-containing combinations lead to changes in STAT1 phosphorylation. STAT1 is a well-known cellular inducer of the antiviral state (Horvath and Darnell, 1996; Liu et al., 2012) . This antiviral state efficiently blocks viral growth and thus it makes sense as a marker of antiviral activity." ;
            <http://www.example.org/textHash>
                    "91c201510e9c9d3000da5fe21332e78b5e51cdca09e7d736c83b3ba72c40ce75" .
    
    <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-1036-1061>
            <http://www.example.org/end>    "1061.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "1036.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Bodenmiller et al., 2010)" .
    
    <http://covid19.aksw.org/text-102bf4dfe7fbf624782e1bfbb7ef084cbe3b61f75a3a2999554c882d0a657f4d_citespan-27-46>
            <http://www.example.org/end>    "46.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "27.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ding et al., 2012)" .
    
    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1251-1262>
            <http://www.example.org/end>    "1262.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1251.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "-infection)" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Using this approach, we were able to discern the exact changes in treated cells that were signatures of the optimal drug combinations. An overview of the phosphoprotein panel shown in Supplementary Fig. 1 indicates that most proteins phosphorylation states were unaffected in cells treated with drug combinations. However, analysis of these panels of signaling nodes revealed that levels of phosphorylated STAT1 (pSTAT1) and phosphorylated S6 (pS6) were noticeably regulated by treatment with different drug combinations (Fig. 1A) . Sixteen hours after drug treatment, we found that stimulation with individual revealed that, as expected, Interferons including IFN-β and IFN-γ induced upregulation of pSTAT1 in a dose-dependent manner (Fig. 1B, left  panel, yellow histograms) . In addition, we see that most of the drugs individually cause minimal to no change to the high levels of pS6 proteins, except the higher dose of Ribavirin (Fig. 1B, right panel, black histogram). The optimal combinations followed these key individual drugs with the IFN-rich treatments (Optimal_A) inducing increased levels of pSTAT1 but induced no obvious changes in pS6 (Fig. 1C) . Conversely, RIB-rich treatments (Optimal_B) decreased levels of pS6 but induced no obvious changes in pSTAT1 (Fig. 1C) . While both of these drug combinations were discovered for their effectiveness at blocking HSV-1 replication (Ding et al., 2012) , these two drug combinations seems to change cellular signaling in distinct ways.\",\"cite_spans\":[{\"start\":1392.0,\"end\":1411.0,\"text\":\"(Ding et al., 2012)\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[{\"start\":184.0,\"end\":204.0,\"text\":\"Supplementary Fig. 1\",\"ref_id\":\"FIGREF0\"},{\"start\":521.0,\"end\":530.0,\"text\":\"(Fig. 1A)\",\"ref_id\":\"FIGREF0\"},{\"start\":735.0,\"end\":776.0,\"text\":\"(Fig. 1B, left  panel, yellow histograms)\",\"ref_id\":\"FIGREF0\"},{\"start\":934.0,\"end\":956.0,\"text\":\"(Fig. 1B, right panel,\",\"ref_id\":\"FIGREF0\"},{\"start\":1151.0,\"end\":1160.0,\"text\":\"(Fig. 1C)\",\"ref_id\":\"FIGREF0\"},{\"start\":1272.0,\"end\":1281.0,\"text\":\"(Fig. 1C)\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Cellular signaling analysis of cells stimulated with antiviral drug combinations\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_citespan-1392-1411> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-184-204> , <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-1151-1160> , <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-521-530> , <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-1272-1281> , <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-934-956> , <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-735-776> ;
            <http://www.example.org/section>
                    "Cellular signaling analysis of cells stimulated with antiviral drug combinations" ;
            <http://www.example.org/text>  "Using this approach, we were able to discern the exact changes in treated cells that were signatures of the optimal drug combinations. An overview of the phosphoprotein panel shown in Supplementary Fig. 1 indicates that most proteins phosphorylation states were unaffected in cells treated with drug combinations. However, analysis of these panels of signaling nodes revealed that levels of phosphorylated STAT1 (pSTAT1) and phosphorylated S6 (pS6) were noticeably regulated by treatment with different drug combinations (Fig. 1A) . Sixteen hours after drug treatment, we found that stimulation with individual revealed that, as expected, Interferons including IFN-β and IFN-γ induced upregulation of pSTAT1 in a dose-dependent manner (Fig. 1B, left  panel, yellow histograms) . In addition, we see that most of the drugs individually cause minimal to no change to the high levels of pS6 proteins, except the higher dose of Ribavirin (Fig. 1B, right panel, black histogram). The optimal combinations followed these key individual drugs with the IFN-rich treatments (Optimal_A) inducing increased levels of pSTAT1 but induced no obvious changes in pS6 (Fig. 1C) . Conversely, RIB-rich treatments (Optimal_B) decreased levels of pS6 but induced no obvious changes in pSTAT1 (Fig. 1C) . While both of these drug combinations were discovered for their effectiveness at blocking HSV-1 replication (Ding et al., 2012) , these two drug combinations seems to change cellular signaling in distinct ways." ;
            <http://www.example.org/textHash>
                    "a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7" .
    
    <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-955-980>
            <http://www.example.org/end>    "980.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "955.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Johnston and Corey, 2016)" .
    
    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-81-90>
            <http://www.example.org/end>    "90.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "81.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3C)" .
    
    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-576-585>
            <http://www.example.org/end>    "585.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "576.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4C)" .
    
    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Differences in phosphoprotein signaling became more complex 16 h after treatment (Fig. 3C) . pAKT, pMAPKAPK2, pNFĸB, pS6, and pSTAT1 were regulated to various extents by the different drug combinations. In particular, RIB treatments led to both a decrease in pS6 levels and a reduction in HSV-1 viral burden (Fig. 4A ). pSTAT1 levels were diminished in HSV-1 infected cells, but pSTAT1 levels were recovered by IFN treatments (Fig. 4B) . HSV-1 infection decreased pMAPKAPK2 levels, whereas blocking HSV-1 infection with ACV containing treatments increased pMAPKAPK2 signaling (Fig. 4C) . pNFĸB was induced in HSV-1 infected cells, but ACV treatments reduced pNFĸB levels to baseline (Fig. 4D) . ACV containing treatments that reduced HSV-1 levels appeared to induce pAKT levels in the HSV-1 positive population (Fig. 4E) . Overall, when HSV-1 viral infection was present, phosphoprotein changes became more complex. However, the most significant changes in phosphorylation status for drug combination optimal_A was still pSTAT1, and the most significant changes in phosphorylation status for drug combination optimal_B was still pS6. The correlation between IFN, pSTAT1 status, and HSV-1 infection has been widely reported and part of the known biology of IFN. However, the lack of agreement about the mechanisms of RIB and the high efficacy of the RIB-rich drug combination in blocking HSV-1 encouraged us to focus our further investigation into the correlations among RIB, pS6 levels, and HSV-1 infection.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":81.0,\"end\":90.0,\"text\":\"(Fig. 3C)\",\"ref_id\":\"FIGREF1\"},{\"start\":308.0,\"end\":316.0,\"text\":\"(Fig. 4A\"},{\"start\":426.0,\"end\":435.0,\"text\":\"(Fig. 4B)\"},{\"start\":576.0,\"end\":585.0,\"text\":\"(Fig. 4C)\"},{\"start\":683.0,\"end\":692.0,\"text\":\"(Fig. 4D)\"},{\"start\":811.0,\"end\":820.0,\"text\":\"(Fig. 4E)\"}],\"section\":\"Changes in distinct signaling nodes after post-infection treatment of viral infection\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-576-585> , <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-426-435> , <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-811-820> , <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-81-90> , <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-683-692> , <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-308-316> ;
            <http://www.example.org/section>
                    "Changes in distinct signaling nodes after post-infection treatment of viral infection" ;
            <http://www.example.org/text>  "Differences in phosphoprotein signaling became more complex 16 h after treatment (Fig. 3C) . pAKT, pMAPKAPK2, pNFĸB, pS6, and pSTAT1 were regulated to various extents by the different drug combinations. In particular, RIB treatments led to both a decrease in pS6 levels and a reduction in HSV-1 viral burden (Fig. 4A ). pSTAT1 levels were diminished in HSV-1 infected cells, but pSTAT1 levels were recovered by IFN treatments (Fig. 4B) . HSV-1 infection decreased pMAPKAPK2 levels, whereas blocking HSV-1 infection with ACV containing treatments increased pMAPKAPK2 signaling (Fig. 4C) . pNFĸB was induced in HSV-1 infected cells, but ACV treatments reduced pNFĸB levels to baseline (Fig. 4D) . ACV containing treatments that reduced HSV-1 levels appeared to induce pAKT levels in the HSV-1 positive population (Fig. 4E) . Overall, when HSV-1 viral infection was present, phosphoprotein changes became more complex. However, the most significant changes in phosphorylation status for drug combination optimal_A was still pSTAT1, and the most significant changes in phosphorylation status for drug combination optimal_B was still pS6. The correlation between IFN, pSTAT1 status, and HSV-1 infection has been widely reported and part of the known biology of IFN. However, the lack of agreement about the mechanisms of RIB and the high efficacy of the RIB-rich drug combination in blocking HSV-1 encouraged us to focus our further investigation into the correlations among RIB, pS6 levels, and HSV-1 infection." ;
            <http://www.example.org/textHash>
                    "bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4" .
    
    <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e_refspan-509-523>
            <http://www.example.org/end>    "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "509.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 2C and D)" .
    
    <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-358-384>
            <http://www.example.org/end>    "384.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Al-Lazikani et al., 2012;" .
    
    <http://covid19.aksw.org/text-7db751d6558c769ad02a07bc5e85219bd459b82e4332c5ae667bb03e669aaa9c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To validate the cause-effect relationships between pS6 signaling and HSV-1 infection, we used a pS6 kinase inhibitor, SL0101, to evaluate the effect of anti-HSV-1 drug combinations on down-regulating the S6 signaling pathway. SL0101 at three doses (25, 50, and 100 μM) was compared with RIB at 100 μM and ACV at 100 μM. Cells were infected with HSV-1 at the same time that drugs were administered. We also examined the effects of these treatments on pAKT, pERK, pMAPKAPK2, p-p38, p-p70, p-p90 RSK , pS6, pSTAT1, and pSTAT3 using phosphoflow.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Assessing pS6 kinase inhibitor on in vitro HSV-1 infection\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Assessing pS6 kinase inhibitor on in vitro HSV-1 infection" ;
            <http://www.example.org/text>  "To validate the cause-effect relationships between pS6 signaling and HSV-1 infection, we used a pS6 kinase inhibitor, SL0101, to evaluate the effect of anti-HSV-1 drug combinations on down-regulating the S6 signaling pathway. SL0101 at three doses (25, 50, and 100 μM) was compared with RIB at 100 μM and ACV at 100 μM. Cells were infected with HSV-1 at the same time that drugs were administered. We also examined the effects of these treatments on pAKT, pERK, pMAPKAPK2, p-p38, p-p70, p-p90 RSK , pS6, pSTAT1, and pSTAT3 using phosphoflow." ;
            <http://www.example.org/textHash>
                    "7db751d6558c769ad02a07bc5e85219bd459b82e4332c5ae667bb03e669aaa9c" .
    
    <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-1013-1038>
            <http://www.example.org/end>    "1038.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1013.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Bodenmiller et al., 2012;" .
    
    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-502-525>
            <http://www.example.org/end>    "525.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "502.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kamiyama et al., 2017;" .
    
    <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-408-428>
            <http://www.example.org/end>    "428.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "George et al., 2015)" .
    
    <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34_refspan-563-572>
            <http://www.example.org/end>    "572.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF3" ;
            <http://www.example.org/start>  "563.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 6C)" .
    
    <http://covid19.aksw.org/text-210ad2dfb2c7ae766ee2393c667a806d5d151babb164e9e27e1222f271357e10>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In vivo compound treatment and stimulations were performed on female KOS strain mice. All animal handling was performed in accordance with University of California, Los Angeles (UCLA) Animal Research Committee guidelines and animals were monitored for changes to health regularly. Each mouse received either 25 μL of 2.9 × 10 7 PFU/mL HSV-1 or 25 μL PBS vehicle via vaginal administration on day 0. HSV-1 infection was allowed to occur for 24 h post virus administration. The first vaginal lavage was collected at 24 h post infection (day 1) followed immediately by a 50 μL drug treatment via vaginal administration. The second vaginal lavage was collected at 48 h post-infection (this was 24 h post-first-round drug treatment) (day 2) followed immediately by a 50 μL drug treatment via vaginal administration. The third vaginal lavage was collected at 72 h post-infection (24 h post-second-round drug treatment) (day 3). HSV-1 viral copy number in vaginal lavage was quantified by plaque assay as described below. To assess Optimal_B efficacy, twenty-seven mice were randomly distributed into three groups each containing nine mice. One group was untreated, one was treated with ACV at 80 ng/mL, and one was treated with drug combination Optimal_B. To evaluate SL0101, an RSK p90 inhibitor, eighteen mice were divided into two groups (an untreated control group and a SL0101 treated group). SL0101 at dose of 200 μM was applied to the treated group.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Animal model of HSV-1 infection\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Animal model of HSV-1 infection" ;
            <http://www.example.org/text>  "In vivo compound treatment and stimulations were performed on female KOS strain mice. All animal handling was performed in accordance with University of California, Los Angeles (UCLA) Animal Research Committee guidelines and animals were monitored for changes to health regularly. Each mouse received either 25 μL of 2.9 × 10 7 PFU/mL HSV-1 or 25 μL PBS vehicle via vaginal administration on day 0. HSV-1 infection was allowed to occur for 24 h post virus administration. The first vaginal lavage was collected at 24 h post infection (day 1) followed immediately by a 50 μL drug treatment via vaginal administration. The second vaginal lavage was collected at 48 h post-infection (this was 24 h post-first-round drug treatment) (day 2) followed immediately by a 50 μL drug treatment via vaginal administration. The third vaginal lavage was collected at 72 h post-infection (24 h post-second-round drug treatment) (day 3). HSV-1 viral copy number in vaginal lavage was quantified by plaque assay as described below. To assess Optimal_B efficacy, twenty-seven mice were randomly distributed into three groups each containing nine mice. One group was untreated, one was treated with ACV at 80 ng/mL, and one was treated with drug combination Optimal_B. To evaluate SL0101, an RSK p90 inhibitor, eighteen mice were divided into two groups (an untreated control group and a SL0101 treated group). SL0101 at dose of 200 μM was applied to the treated group." ;
            <http://www.example.org/textHash>
                    "210ad2dfb2c7ae766ee2393c667a806d5d151babb164e9e27e1222f271357e10" .
    
    <http://covid19.aksw.org/text-3fc72d5dff3a4aae7673409bd6cf5b0eb380cb7bf59c58ebabb156a07a2aa3de>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The efficacy of the S6 phosphorylation inhibition in reducing HSV-1 replication in an animal model of vaginal HSV-1 infection shows how important it is to understand the changes in cellular signaling that are effective in blocking viral infection. However, results of this study revealed that even without HSV-1 infection, RIB directly lowers the level of phosphorylated S6. This finding is important because it underscores that regulation of S6 phosphorylation occurs in cells with and without viral infection. Consequently, the consequences of changing the phosphorylation state of a key ribosomal protein by any drug may be immense. We did not see any obvious changes in cellular morphology nor changes in cell viability as assessed by MTT assay when cells were treated with SL0101, suggesting that minimal cellular toxicity was induced by the SL0101. However, further investigations into how SL0101 can impact cellular physiology are warranted in order to develop effective counter measures against side effects that may be induced by this type of antiviral.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"vaginal HSV infection.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "vaginal HSV infection." ;
            <http://www.example.org/text>  "The efficacy of the S6 phosphorylation inhibition in reducing HSV-1 replication in an animal model of vaginal HSV-1 infection shows how important it is to understand the changes in cellular signaling that are effective in blocking viral infection. However, results of this study revealed that even without HSV-1 infection, RIB directly lowers the level of phosphorylated S6. This finding is important because it underscores that regulation of S6 phosphorylation occurs in cells with and without viral infection. Consequently, the consequences of changing the phosphorylation state of a key ribosomal protein by any drug may be immense. We did not see any obvious changes in cellular morphology nor changes in cell viability as assessed by MTT assay when cells were treated with SL0101, suggesting that minimal cellular toxicity was induced by the SL0101. However, further investigations into how SL0101 can impact cellular physiology are warranted in order to develop effective counter measures against side effects that may be induced by this type of antiviral." ;
            <http://www.example.org/textHash>
                    "3fc72d5dff3a4aae7673409bd6cf5b0eb380cb7bf59c58ebabb156a07a2aa3de" .
    
    <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9_refspan-1385-1405>
            <http://www.example.org/end>    "1405.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "1385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Supplementary Fig. 1" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-735-776>
            <http://www.example.org/end>    "776.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "735.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1B, left  panel, yellow histograms)" .
    
    <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df_refspan-80-88>
            <http://www.example.org/end>    "88.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "80.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 7A" .
    
    <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_refspan-1172-1180>
            <http://www.example.org/end>    "1180.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "1172.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3C" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-1272-1281>
            <http://www.example.org/end>    "1281.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "1272.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1C)" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-253-276>
            <http://www.example.org/end>    "276.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "253.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Piret and Boivin, 2011)" .
    
    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-811-820>
            <http://www.example.org/end>    "820.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "811.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4E)" .
    
    <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Treatment of different disease states through combinations of multiple drugs is used to achieve better therapeutic results, reduce the impact of drug resistance, and sustain high efficacy with low toxicity often with lower doses of the individual drug components. The use of drug combinations is well documented in both cancer and infectious disease therapy (Al-Lazikani et al., 2012; Arts and Hazuda, 2012; George et al., 2015) . Therapeutic drug combinations work by simultaneously controlling several cellular pathways in the complex network system. In a previous study (Ding et al., 2012) , two combinations of antiviral drugs, one combination rich in interferon and one rich in Ribavirin, were determined due to their ability to inhibit Herpes simplex virus type 1 (HSV-1) infection. These combinations were identified through a Feedback System Control (FSC) technique which uses an unbiased search based on the outcome of the drug combination treatment and can identify many unexpected drug combinations offering desired therapeutic outputs (Wong et al., 2008) . However, due to the focus on outputs, the FSC search methodology does not give any information on which cellular signaling pathways are stimulated by these drug combination or the mechanistic reasoning behind efficacy of the optimal drug combination.\",\"cite_spans\":[{\"start\":358.0,\"end\":384.0,\"text\":\"(Al-Lazikani et al., 2012;\",\"ref_id\":\"BIBREF0\"},{\"start\":385.0,\"end\":407.0,\"text\":\"Arts and Hazuda, 2012;\",\"ref_id\":\"BIBREF5\"},{\"start\":408.0,\"end\":428.0,\"text\":\"George et al., 2015)\",\"ref_id\":\"BIBREF15\"},{\"start\":573.0,\"end\":592.0,\"text\":\"(Ding et al., 2012)\",\"ref_id\":\"BIBREF13\"},{\"start\":1047.0,\"end\":1066.0,\"text\":\"(Wong et al., 2008)\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-358-384> , <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-385-407> , <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-408-428> , <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-573-592> , <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-1047-1066> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "Treatment of different disease states through combinations of multiple drugs is used to achieve better therapeutic results, reduce the impact of drug resistance, and sustain high efficacy with low toxicity often with lower doses of the individual drug components. The use of drug combinations is well documented in both cancer and infectious disease therapy (Al-Lazikani et al., 2012; Arts and Hazuda, 2012; George et al., 2015) . Therapeutic drug combinations work by simultaneously controlling several cellular pathways in the complex network system. In a previous study (Ding et al., 2012) , two combinations of antiviral drugs, one combination rich in interferon and one rich in Ribavirin, were determined due to their ability to inhibit Herpes simplex virus type 1 (HSV-1) infection. These combinations were identified through a Feedback System Control (FSC) technique which uses an unbiased search based on the outcome of the drug combination treatment and can identify many unexpected drug combinations offering desired therapeutic outputs (Wong et al., 2008) . However, due to the focus on outputs, the FSC search methodology does not give any information on which cellular signaling pathways are stimulated by these drug combination or the mechanistic reasoning behind efficacy of the optimal drug combination." ;
            <http://www.example.org/textHash>
                    "d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a" .
    
    <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9_refspan-2020-2027>
            <http://www.example.org/end>    "2027.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "2020.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 2." .
    
    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"RIB has become a go-to drug in antiviral therapy, especially when looking to target the replication of viruses with few options for treatment. At one time, RIB was the major treatment for Hepatitis C Virus infection but now RIB-independent therapies have become commonplace in the clinic (Kish et al., 2017) . RIB remains the first line of antiviral therapy against other viruses on the world stage, including MERS-CoV (Middle East Respiratory Syndrome-Corona Virus), Lassa Fever Virus, and Zika virus (Kamiyama et al., 2017; Carrillo-Bustamante et al., 2017; Chong et al., 2015) . However, a different mechanism of action may be at work for every virus that RIB effectively treats, including nucleoside base level changes and catastrophic error induction in cells (Te et al., 2007; Crotty et al., 2002) .\",\"cite_spans\":[{\"start\":288.0,\"end\":307.0,\"text\":\"(Kish et al., 2017)\",\"ref_id\":\"BIBREF21\"},{\"start\":502.0,\"end\":525.0,\"text\":\"(Kamiyama et al., 2017;\",\"ref_id\":\"BIBREF20\"},{\"start\":526.0,\"end\":559.0,\"text\":\"Carrillo-Bustamante et al., 2017;\",\"ref_id\":\"BIBREF9\"},{\"start\":560.0,\"end\":579.0,\"text\":\"Chong et al., 2015)\",\"ref_id\":\"BIBREF10\"},{\"start\":765.0,\"end\":782.0,\"text\":\"(Te et al., 2007;\",\"ref_id\":\"BIBREF35\"},{\"start\":783.0,\"end\":803.0,\"text\":\"Crotty et al., 2002)\",\"ref_id\":\"BIBREF12\"}],\"ref_spans\":[],\"section\":\"vaginal HSV infection.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-502-525> , <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-288-307> , <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-560-579> , <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-765-782> , <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-783-803> , <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-526-559> ;
            <http://www.example.org/section>
                    "vaginal HSV infection." ;
            <http://www.example.org/text>  "RIB has become a go-to drug in antiviral therapy, especially when looking to target the replication of viruses with few options for treatment. At one time, RIB was the major treatment for Hepatitis C Virus infection but now RIB-independent therapies have become commonplace in the clinic (Kish et al., 2017) . RIB remains the first line of antiviral therapy against other viruses on the world stage, including MERS-CoV (Middle East Respiratory Syndrome-Corona Virus), Lassa Fever Virus, and Zika virus (Kamiyama et al., 2017; Carrillo-Bustamante et al., 2017; Chong et al., 2015) . However, a different mechanism of action may be at work for every virus that RIB effectively treats, including nucleoside base level changes and catastrophic error induction in cells (Te et al., 2007; Crotty et al., 2002) ." ;
            <http://www.example.org/textHash>
                    "113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea" .
    
    <http://covid19.aksw.org/text-64a00beb55d15e07e8f8ecb41a69e179890faabe35108c8b45cc07c369b8cbfa>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In conclusion, we have used phosphoflow technology to evaluate possible mechanisms of therapeutic drug combination and elucidate how these drug combinations modulate cellular signaling so as to design better antiviral therapeutics. Specifically, we were able to identify STAT1 and S6 phosphorylation as a key signaling nodes involved in A. pS6 kinase inhibitor in HSV-1 inhibition. SL0101 displayed a RIB-like anti-HSV-1 behavior. B. SL0101 showed a general decrease in signaling across multiple pathways, particularly at 100 μM. C. SL0101 appeared to decrease all signaling pathways that have basal activity. SL0101 inhibited pS6 at 50 μM when no virus was present, but it was not effective at that dose when virus was present. When HSV-1 was present, SL0101 required as high as 100 μM to show inhibition on pS6. Flow cytometry histograms are color-coded as in a heatmap according to the scale in B. All experimental data shown is representative data from three independent experiments. In part C, *, p value \\u003c 0.05 **, p value \\u003c 0.01. Quantitation of plots from B are shown in Supplemental Fig. 6 with pAKT levels in 6A, pMAPKAPK2 levels in 6B, p-p70 S6K levels in 6C and pS6 levels in 6D.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":1092.0,\"end\":1098.0,\"text\":\"Fig. 6\",\"ref_id\":\"FIGREF3\"}],\"section\":\"Conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-64a00beb55d15e07e8f8ecb41a69e179890faabe35108c8b45cc07c369b8cbfa_refspan-1092-1098> ;
            <http://www.example.org/section>
                    "Conclusions" ;
            <http://www.example.org/text>  "In conclusion, we have used phosphoflow technology to evaluate possible mechanisms of therapeutic drug combination and elucidate how these drug combinations modulate cellular signaling so as to design better antiviral therapeutics. Specifically, we were able to identify STAT1 and S6 phosphorylation as a key signaling nodes involved in A. pS6 kinase inhibitor in HSV-1 inhibition. SL0101 displayed a RIB-like anti-HSV-1 behavior. B. SL0101 showed a general decrease in signaling across multiple pathways, particularly at 100 μM. C. SL0101 appeared to decrease all signaling pathways that have basal activity. SL0101 inhibited pS6 at 50 μM when no virus was present, but it was not effective at that dose when virus was present. When HSV-1 was present, SL0101 required as high as 100 μM to show inhibition on pS6. Flow cytometry histograms are color-coded as in a heatmap according to the scale in B. All experimental data shown is representative data from three independent experiments. In part C, *, p value < 0.05 **, p value < 0.01. Quantitation of plots from B are shown in Supplemental Fig. 6 with pAKT levels in 6A, pMAPKAPK2 levels in 6B, p-p70 S6K levels in 6C and pS6 levels in 6D." ;
            <http://www.example.org/textHash>
                    "64a00beb55d15e07e8f8ecb41a69e179890faabe35108c8b45cc07c369b8cbfa" .
    
    <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-1047-1066>
            <http://www.example.org/end>    "1066.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1047.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wong et al., 2008)" .
    
    <http://covid19.aksw.org/text-3b83c2d5c31e1a1692f17afce7660df0213730d210252a99077094bccce069d6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A. pSTAT1 signaling was identified as a marker for IFN rich treatment, but not for RIB rich treatment. B. pSTAT1 is an instant, long-lasting marker for IFN treatment. Activation of pSTAT1 was available as early as 0.5 h after drug stimulations and continued for up to 16 h after IFN drug treatments. C. pS6 signaling was identified as a marker for RIB rich treatment, but not for IFN rich treatment. D. pS6 signaling was not an instant marker but a later-period marker for RIB treatment, as pS6 level did not change until 8 h after drug treatments. E. Quantification of pSTAT1 and pS6 signaling in samples treated with Optimal_A and Optimal_B indicates pSTAT1 signaling is Optimal_A specific and pS6 is optimal_B specific. Unit for drugs is ng/ ml. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). For Part E, data plotted is mean ± standard deviation. All experimental data shown is representative data from three independent experiments.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Fig. 2. STAT1 and S6 Phosphorylation States After Antiviral Drug Stimulation.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Fig. 2. STAT1 and S6 Phosphorylation States After Antiviral Drug Stimulation." ;
            <http://www.example.org/text>  "A. pSTAT1 signaling was identified as a marker for IFN rich treatment, but not for RIB rich treatment. B. pSTAT1 is an instant, long-lasting marker for IFN treatment. Activation of pSTAT1 was available as early as 0.5 h after drug stimulations and continued for up to 16 h after IFN drug treatments. C. pS6 signaling was identified as a marker for RIB rich treatment, but not for IFN rich treatment. D. pS6 signaling was not an instant marker but a later-period marker for RIB treatment, as pS6 level did not change until 8 h after drug treatments. E. Quantification of pSTAT1 and pS6 signaling in samples treated with Optimal_A and Optimal_B indicates pSTAT1 signaling is Optimal_A specific and pS6 is optimal_B specific. Unit for drugs is ng/ ml. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). For Part E, data plotted is mean ± standard deviation. All experimental data shown is representative data from three independent experiments." ;
            <http://www.example.org/textHash>
                    "3b83c2d5c31e1a1692f17afce7660df0213730d210252a99077094bccce069d6" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-184-204>
            <http://www.example.org/end>    "204.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "184.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Supplementary Fig. 1" .
    
    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-765-782>
            <http://www.example.org/end>    "782.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "765.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Te et al., 2007;" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-630-650>
            <http://www.example.org/end>    "650.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "630.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Silva et al., 2016;" .
    
    <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Antivirals represent a class of drugs for which development is often focused on the singular outcome of limiting viral infection. However, side effects and potential off-label or secondary indications for the use of a drug are often only discovered after the drug is used with FDA approval. A prime example of a virus that is well studied with regards to antiviral therapy is HSV-1. HSV-1 frequently infects humans leading to diseases ranging from mild mucocutaneous lesions to life threatening infections, especially in elderly or immunocompromised patients (Whitley and Roizman, 2001) . HSV-1 is characterized by its ability to develop latency in neurons of sensory ganglia and lytic outbreaks that often require drug therapy (Knickelbein et al., 2008) . Although extensive research efforts have been made to unveil the mechanism of HSV-1 infection, new aspects of HSV-1 pathogenesis are frequently discovered (Tognarelli et al., 2019; Sauerbrei, 2016; Johnston and Corey, 2016) .\",\"cite_spans\":[{\"start\":559.0,\"end\":586.0,\"text\":\"(Whitley and Roizman, 2001)\",\"ref_id\":\"BIBREF38\"},{\"start\":728.0,\"end\":754.0,\"text\":\"(Knickelbein et al., 2008)\",\"ref_id\":\"BIBREF22\"},{\"start\":912.0,\"end\":937.0,\"text\":\"(Tognarelli et al., 2019;\",\"ref_id\":\"BIBREF36\"},{\"start\":938.0,\"end\":954.0,\"text\":\"Sauerbrei, 2016;\",\"ref_id\":\"BIBREF32\"},{\"start\":955.0,\"end\":980.0,\"text\":\"Johnston and Corey, 2016)\",\"ref_id\":\"BIBREF19\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-559-586> , <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-728-754> , <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-912-937> , <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-938-954> , <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-955-980> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "Antivirals represent a class of drugs for which development is often focused on the singular outcome of limiting viral infection. However, side effects and potential off-label or secondary indications for the use of a drug are often only discovered after the drug is used with FDA approval. A prime example of a virus that is well studied with regards to antiviral therapy is HSV-1. HSV-1 frequently infects humans leading to diseases ranging from mild mucocutaneous lesions to life threatening infections, especially in elderly or immunocompromised patients (Whitley and Roizman, 2001) . HSV-1 is characterized by its ability to develop latency in neurons of sensory ganglia and lytic outbreaks that often require drug therapy (Knickelbein et al., 2008) . Although extensive research efforts have been made to unveil the mechanism of HSV-1 infection, new aspects of HSV-1 pathogenesis are frequently discovered (Tognarelli et al., 2019; Sauerbrei, 2016; Johnston and Corey, 2016) ." ;
            <http://www.example.org/textHash>
                    "72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2" .
    
    <http://covid19.aksw.org/text-97223eb5aad08437e8664278560117449f6796e1d8c42656024728062c50ec87>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To better understand how these drugs induced changes to the cellular signaling network would lead to limiting HSV-1 replication, we next systemically evaluated changes in the phosphoprotein panel during viral infections treated with drug combinations. Compared to uninfected cells treated with drug combinations alone, cells pre-infected with HSV-1 followed by drug treatments provide a more realistic model for studying the changes in cellular physiology under optimal drug combination treatments, as drug treatments would almost always take place after infection is detected (Fig. 3A) . We used HSV-1 that was engineered to express GFP (Green Fluorescent Protein) as a way to track HSV-1 replication within infected cells. This allowed us to distinguish changes in cellular signaling induced by infection on the single cell level.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":577.0,\"end\":586.0,\"text\":\"(Fig. 3A)\",\"ref_id\":\"FIGREF1\"}],\"section\":\"Monitoring cellular signaling and HSV-1 infection after post-infection treatment\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-97223eb5aad08437e8664278560117449f6796e1d8c42656024728062c50ec87_refspan-577-586> ;
            <http://www.example.org/section>
                    "Monitoring cellular signaling and HSV-1 infection after post-infection treatment" ;
            <http://www.example.org/text>  "To better understand how these drugs induced changes to the cellular signaling network would lead to limiting HSV-1 replication, we next systemically evaluated changes in the phosphoprotein panel during viral infections treated with drug combinations. Compared to uninfected cells treated with drug combinations alone, cells pre-infected with HSV-1 followed by drug treatments provide a more realistic model for studying the changes in cellular physiology under optimal drug combination treatments, as drug treatments would almost always take place after infection is detected (Fig. 3A) . We used HSV-1 that was engineered to express GFP (Green Fluorescent Protein) as a way to track HSV-1 replication within infected cells. This allowed us to distinguish changes in cellular signaling induced by infection on the single cell level." ;
            <http://www.example.org/textHash>
                    "97223eb5aad08437e8664278560117449f6796e1d8c42656024728062c50ec87" .
    
    <http://covid19.aksw.org/text-13a5072dffbc082de8a97042dbb225cde28a3ebd09a4ffe89587a90cc9797fba_citespan-828-877>
            <http://www.example.org/end>    "877.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "828.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ding, et al. Antiviral Research 171 (2019) 104598" .
    
    <http://covid19.aksw.org/text-168d046fb262bc7fe41efb63acfbe338fd1d5bdafa7e2e82057c912cc66cbc0f_refspan-973-981>
            <http://www.example.org/end>    "981.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "973.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 7B" .
    
    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-526-559>
            <http://www.example.org/end>    "559.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "526.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Carrillo-Bustamante et al., 2017;" .
    
    <http://covid19.aksw.org/text-64a00beb55d15e07e8f8ecb41a69e179890faabe35108c8b45cc07c369b8cbfa_refspan-1092-1098>
            <http://www.example.org/end>    "1098.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF3" ;
            <http://www.example.org/start>  "1092.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 6" .
    
    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-1035-1044>
            <http://www.example.org/end>    "1044.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "1035.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 5E)" .
    
    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-2049-2055>
            <http://www.example.org/end>    "2055.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "2049.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 4" .
    
    <http://covid19.aksw.org/text-91c201510e9c9d3000da5fe21332e78b5e51cdca09e7d736c83b3ba72c40ce75_citespan-954-981>
            <http://www.example.org/end>    "981.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "954.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Horvath and Darnell, 1996;" .
    
    <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"It is important to note that broad spectrum modulation of signaling pathways by a drug may lead to drug-induced toxicity. Therefore, it is possible that SL0101 could be more toxic than RIB even though such toxicity was not obvious based on observation of cellular morphology in our in vitro study (Supplementary Fig. 5A ) and SL0101 only induced toxicity in an MTT assay at concentrations above what we used in this study ( Supplementary Fig. 5B ). SL0101 inhibited pS6 at 50 μM when virus was absent, but it was not effective at that dose when virus was present (Fig. 6C) . When virus was present, SL0101 only down-regulated pS6 at 100 μM. Furthermore, with HSV infection present, SL0101 did not obviously reduce viral infection levels at 50 μM, but infection levels were diminished at 100 μM. Therefore, SL0101 regulates pS6 signaling in a dose-dependent manner in uninfected cells, but SL0101 treatment inhibits HSV infection at a high dose in concordance with changes in pS6 during viral infection.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":297.0,\"end\":319.0,\"text\":\"(Supplementary Fig. 5A\",\"ref_id\":\"FIGREF2\"},{\"start\":424.0,\"end\":445.0,\"text\":\"Supplementary Fig. 5B\",\"ref_id\":\"FIGREF2\"},{\"start\":563.0,\"end\":572.0,\"text\":\"(Fig. 6C)\",\"ref_id\":\"FIGREF3\"}],\"section\":\"Translating cellular analysis of RIB signaling to discovery of a small molecule inhibitor of HSV-1 inhibition in vitro\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34_refspan-297-319> , <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34_refspan-424-445> , <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34_refspan-563-572> ;
            <http://www.example.org/section>
                    "Translating cellular analysis of RIB signaling to discovery of a small molecule inhibitor of HSV-1 inhibition in vitro" ;
            <http://www.example.org/text>  "It is important to note that broad spectrum modulation of signaling pathways by a drug may lead to drug-induced toxicity. Therefore, it is possible that SL0101 could be more toxic than RIB even though such toxicity was not obvious based on observation of cellular morphology in our in vitro study (Supplementary Fig. 5A ) and SL0101 only induced toxicity in an MTT assay at concentrations above what we used in this study ( Supplementary Fig. 5B ). SL0101 inhibited pS6 at 50 μM when virus was absent, but it was not effective at that dose when virus was present (Fig. 6C) . When virus was present, SL0101 only down-regulated pS6 at 100 μM. Furthermore, with HSV infection present, SL0101 did not obviously reduce viral infection levels at 50 μM, but infection levels were diminished at 100 μM. Therefore, SL0101 regulates pS6 signaling in a dose-dependent manner in uninfected cells, but SL0101 treatment inhibits HSV infection at a high dose in concordance with changes in pS6 during viral infection." ;
            <http://www.example.org/textHash>
                    "212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34" .
    
    <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_refspan-512-521>
            <http://www.example.org/end>    "521.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "512.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3C)" .
    
    <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"All samples infected with HSV-1 were done so at a multiplicity of infection (MOI) of 0.1 (+HSV) for 8 h after which the cells were treated with drugs. All conditions had equivalent GFP levels/percentages 0.5 h after drug treatment (Fig. 3B) . The GFP level in +HSV samples was low across all treatments, indicating that viral infection was still in progress and that the majority of cells remained uninfected. Neither IFN-rich nor RIB-rich treatments lowered levels of viral infection in an instantaneous manner (Fig. 3C) . 16 h after drug treatments, GFP levels in +HSV samples increased extensively throughout the cell population indicating that the viral infection was able to infect the whole cell population during this time frame. In this model with virus infection prior to drug treatment, drug combination Optimal_B (RIB-rich combination) outperformed Optimal_A (IFN-rich combination) in viral inhibition at 16 h post treatment. Although Optimal_A and Optimal_B combinations were identified in a drug-virus co-infection model (Ding et al., 2012) , drug combination Optimal_A barely reduced the viral infection level in cells infected with virus prior to treatment (Fig. 3C ). This may be due to the previous work using a viral co-infection/treatment model for determining the optimal drug combinations.\",\"cite_spans\":[{\"start\":1034.0,\"end\":1053.0,\"text\":\"(Ding et al., 2012)\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[{\"start\":231.0,\"end\":240.0,\"text\":\"(Fig. 3B)\",\"ref_id\":\"FIGREF1\"},{\"start\":512.0,\"end\":521.0,\"text\":\"(Fig. 3C)\",\"ref_id\":\"FIGREF1\"},{\"start\":1172.0,\"end\":1180.0,\"text\":\"(Fig. 3C\",\"ref_id\":\"FIGREF1\"}],\"section\":\"Monitoring cellular signaling and HSV-1 infection after post-infection treatment\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_citespan-1034-1053> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_refspan-231-240> , <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_refspan-512-521> , <http://covid19.aksw.org/text-5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f_refspan-1172-1180> ;
            <http://www.example.org/section>
                    "Monitoring cellular signaling and HSV-1 infection after post-infection treatment" ;
            <http://www.example.org/text>  "All samples infected with HSV-1 were done so at a multiplicity of infection (MOI) of 0.1 (+HSV) for 8 h after which the cells were treated with drugs. All conditions had equivalent GFP levels/percentages 0.5 h after drug treatment (Fig. 3B) . The GFP level in +HSV samples was low across all treatments, indicating that viral infection was still in progress and that the majority of cells remained uninfected. Neither IFN-rich nor RIB-rich treatments lowered levels of viral infection in an instantaneous manner (Fig. 3C) . 16 h after drug treatments, GFP levels in +HSV samples increased extensively throughout the cell population indicating that the viral infection was able to infect the whole cell population during this time frame. In this model with virus infection prior to drug treatment, drug combination Optimal_B (RIB-rich combination) outperformed Optimal_A (IFN-rich combination) in viral inhibition at 16 h post treatment. Although Optimal_A and Optimal_B combinations were identified in a drug-virus co-infection model (Ding et al., 2012) , drug combination Optimal_A barely reduced the viral infection level in cells infected with virus prior to treatment (Fig. 3C ). This may be due to the previous work using a viral co-infection/treatment model for determining the optimal drug combinations." ;
            <http://www.example.org/textHash>
                    "5f2a9a93bb841bf3331a58fdd4169eaa2a8458ddc93d8774c472db97222a917f" .
    
    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To confirm the correlations among RIB, pS6 signaling, and HSV-1 infection obtained in the initial screening, we investigated the state of cellular signaling in cells simultaneously treated with the drug combinations and infected with HSV-1 (Fig. 5A) . In order to allow viral infection to propagate adequately, we focused on the time point 16 h after cells were treated with drug combinations and infected with HSV-1. In this model, Optimal_A and Optimal_B both profoundly reduced HSV-1 infections compared to unstimulated controls (Fig. 5B ). This result is in line with conclusions in the previously published findings (Ding et al., 2012) . When we further compared HSV-1 infection levels (Fig. 5C ) and pS6 levels (Fig. 5D) , HSV-1 infection induced an increase in pS6 levels by 5-10 fold, and RIB or the RIB-containing drug combination reduced percent infection and pS6 levels following a similar pattern. Percent infection plotted against pS6 levels revealed that viral infection followed a log-linear relationship with pS6 level (Fig. 5E) . Thus, using an unbiased screen to monitor changes in cellular phosphorylation states allowed us to identify the key changes in cellular physiology that connect the efficacy of a given antiviral drug combination to its antiviral effect.\",\"cite_spans\":[{\"start\":621.0,\"end\":640.0,\"text\":\"(Ding et al., 2012)\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[{\"start\":240.0,\"end\":249.0,\"text\":\"(Fig. 5A)\",\"ref_id\":\"FIGREF2\"},{\"start\":532.0,\"end\":540.0,\"text\":\"(Fig. 5B\",\"ref_id\":\"FIGREF2\"},{\"start\":691.0,\"end\":699.0,\"text\":\"(Fig. 5C\",\"ref_id\":\"FIGREF2\"},{\"start\":717.0,\"end\":726.0,\"text\":\"(Fig. 5D)\",\"ref_id\":\"FIGREF2\"},{\"start\":1035.0,\"end\":1044.0,\"text\":\"(Fig. 5E)\",\"ref_id\":\"FIGREF2\"}],\"section\":\"Monitoring cellular signaling and HSV-1 infection with simultaneous infection and treatment\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_citespan-621-640> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-717-726> , <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-240-249> , <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-1035-1044> , <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-691-699> , <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-532-540> ;
            <http://www.example.org/section>
                    "Monitoring cellular signaling and HSV-1 infection with simultaneous infection and treatment" ;
            <http://www.example.org/text>  "To confirm the correlations among RIB, pS6 signaling, and HSV-1 infection obtained in the initial screening, we investigated the state of cellular signaling in cells simultaneously treated with the drug combinations and infected with HSV-1 (Fig. 5A) . In order to allow viral infection to propagate adequately, we focused on the time point 16 h after cells were treated with drug combinations and infected with HSV-1. In this model, Optimal_A and Optimal_B both profoundly reduced HSV-1 infections compared to unstimulated controls (Fig. 5B ). This result is in line with conclusions in the previously published findings (Ding et al., 2012) . When we further compared HSV-1 infection levels (Fig. 5C ) and pS6 levels (Fig. 5D) , HSV-1 infection induced an increase in pS6 levels by 5-10 fold, and RIB or the RIB-containing drug combination reduced percent infection and pS6 levels following a similar pattern. Percent infection plotted against pS6 levels revealed that viral infection followed a log-linear relationship with pS6 level (Fig. 5E) . Thus, using an unbiased screen to monitor changes in cellular phosphorylation states allowed us to identify the key changes in cellular physiology that connect the efficacy of a given antiviral drug combination to its antiviral effect." ;
            <http://www.example.org/textHash>
                    "faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca" .
    
    <http://covid19.aksw.org/text-113daf04de3b45f67bead471288ec65d09d2e39112246ebdc50041dca52983ea_citespan-288-307>
            <http://www.example.org/end>    "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "288.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kish et al., 2017)" .
    
    <http://covid19.aksw.org/text-fcf7878fc071ea2f8d288432c2babc190845c22cffe1f40bf2583cf7f8b0bf46_refspan-1887-1893>
            <http://www.example.org/end>    "1893.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1887.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 4" .
    
    <http://covid19.aksw.org/text-245d6221c415e216894aae3df22fe41c258bbdd6f597d0c4cd42249490472571>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"HSV-1 is one of the most well studied viruses known so it is intriguing that our analysis of cellular signaling modulation in infected cells, using an unbiased approach to discovered that S6 phosphorylation is a new target for antivirals targeting HSV-1. Given the importance of the S6 protein control of ribosomal translation, further studies of how HSV-1 replication benefits from this change in S6 and how common this method of manipulation of cellular translation is among different viruses is needed (Ruvinsky and Meyuhas, 2006) . Could it be that the efficacy of RIB is conveyed via changes in S6 induced by viruses? If the theme of S6 manipulation by viruses is common in other viral disease, S6 phosphorylation modulators may be a new class of antivirals.\",\"cite_spans\":[{\"start\":505.0,\"end\":533.0,\"text\":\"(Ruvinsky and Meyuhas, 2006)\",\"ref_id\":\"BIBREF30\"}],\"ref_spans\":[],\"section\":\"vaginal HSV infection.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-245d6221c415e216894aae3df22fe41c258bbdd6f597d0c4cd42249490472571_citespan-505-533> ;
            <http://www.example.org/section>
                    "vaginal HSV infection." ;
            <http://www.example.org/text>  "HSV-1 is one of the most well studied viruses known so it is intriguing that our analysis of cellular signaling modulation in infected cells, using an unbiased approach to discovered that S6 phosphorylation is a new target for antivirals targeting HSV-1. Given the importance of the S6 protein control of ribosomal translation, further studies of how HSV-1 replication benefits from this change in S6 and how common this method of manipulation of cellular translation is among different viruses is needed (Ruvinsky and Meyuhas, 2006) . Could it be that the efficacy of RIB is conveyed via changes in S6 induced by viruses? If the theme of S6 manipulation by viruses is common in other viral disease, S6 phosphorylation modulators may be a new class of antivirals." ;
            <http://www.example.org/textHash>
                    "245d6221c415e216894aae3df22fe41c258bbdd6f597d0c4cd42249490472571" .
    
    <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e_refspan-297-311>
            <http://www.example.org/end>    "311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "297.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 2A and B)" .
    
    <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df_refspan-745-753>
            <http://www.example.org/end>    "753.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "745.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 7D" .
    
    <http://covid19.aksw.org/text-168d046fb262bc7fe41efb63acfbe338fd1d5bdafa7e2e82057c912cc66cbc0f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The ultimate goal of our system using phosphoflow is to better understand how drug therapies affect cellular physiology so that we can quickly develop more targeted therapeutic modalities for treating disease. In this study we used a mouse model of vaginal HSV-1 infection as a way to assess the in vivo efficacy of the drug combinations we previously discovered. In addition, this acts as a proof of principle that our platform can determine key signaling nodes that should be manipulated as therapy of disease. Fig. 7A depicts our setup of a model of HSV-1 vaginal infection in mice. To ensure that the animal model could be used to evaluate HSV-1 inhibition efficacy in vivo, we first tested ACV alone and drug combination Optimal_B (RIB-rich treatments). Mice treated with ACV showed decreased HSV-1 viral load, especially on day 3. Remarkably, mice treated with drug combination Optimal_B had HSV-1 levels that were 70-fold lower than those of untreated mice on day 3 (Fig. 7B ). This result indicated that this animal model could be applied as an effective in vivo model to examine HSV-1 inhibition efficacy of other drug treatments.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":513.0,\"end\":520.0,\"text\":\"Fig. 7A\"},{\"start\":973.0,\"end\":981.0,\"text\":\"(Fig. 7B\"}],\"section\":\"Translating cellular signaling analysis: small molecule inhibition of HSV-1 infection in an animal model\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-168d046fb262bc7fe41efb63acfbe338fd1d5bdafa7e2e82057c912cc66cbc0f_refspan-513-520> , <http://covid19.aksw.org/text-168d046fb262bc7fe41efb63acfbe338fd1d5bdafa7e2e82057c912cc66cbc0f_refspan-973-981> ;
            <http://www.example.org/section>
                    "Translating cellular signaling analysis: small molecule inhibition of HSV-1 infection in an animal model" ;
            <http://www.example.org/text>  "The ultimate goal of our system using phosphoflow is to better understand how drug therapies affect cellular physiology so that we can quickly develop more targeted therapeutic modalities for treating disease. In this study we used a mouse model of vaginal HSV-1 infection as a way to assess the in vivo efficacy of the drug combinations we previously discovered. In addition, this acts as a proof of principle that our platform can determine key signaling nodes that should be manipulated as therapy of disease. Fig. 7A depicts our setup of a model of HSV-1 vaginal infection in mice. To ensure that the animal model could be used to evaluate HSV-1 inhibition efficacy in vivo, we first tested ACV alone and drug combination Optimal_B (RIB-rich treatments). Mice treated with ACV showed decreased HSV-1 viral load, especially on day 3. Remarkably, mice treated with drug combination Optimal_B had HSV-1 levels that were 70-fold lower than those of untreated mice on day 3 (Fig. 7B ). This result indicated that this animal model could be applied as an effective in vivo model to examine HSV-1 inhibition efficacy of other drug treatments." ;
            <http://www.example.org/textHash>
                    "168d046fb262bc7fe41efb63acfbe338fd1d5bdafa7e2e82057c912cc66cbc0f" .
    
    <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"One approach to new therapeutic drug discovery is based on the efficacy of the drug against one particular target or outcome, such as stopping infection or limiting disease pathology. However, potential side effects and off-label indications are often not found until clinical trials or post-market drug safety monitoring. Consequently, this approach to drug discovery often leads to unexpected problems or misfires that delay or block significant advancements. Techniques that can determine the best drug or combination of drugs to optimally treat a disease without using conventional drug screening approaches are needed for rapid, efficient translational medicine (Lee et al., 2017; Sun et al., 2013) . Developing targeted therapies that focus on the key signaling pathways that lead to pathology and avoid bystander perturbations of the physiology of a cell are possible when looking at how a therapeutic drug combination impacts a cell using an unbiased analysis of cellular signaling (Bendall et al., 2011; Bodenmiller et al., 2012; Schweizer and Zhang, 2013) .\",\"cite_spans\":[{\"start\":667.0,\"end\":685.0,\"text\":\"(Lee et al., 2017;\",\"ref_id\":\"BIBREF25\"},{\"start\":686.0,\"end\":703.0,\"text\":\"Sun et al., 2013)\",\"ref_id\":\"BIBREF34\"},{\"start\":990.0,\"end\":1012.0,\"text\":\"(Bendall et al., 2011;\",\"ref_id\":\"BIBREF6\"},{\"start\":1013.0,\"end\":1038.0,\"text\":\"Bodenmiller et al., 2012;\",\"ref_id\":\"BIBREF8\"},{\"start\":1039.0,\"end\":1065.0,\"text\":\"Schweizer and Zhang, 2013)\",\"ref_id\":\"BIBREF33\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-667-685> , <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-686-703> , <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-990-1012> , <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-1013-1038> , <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-1039-1065> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "One approach to new therapeutic drug discovery is based on the efficacy of the drug against one particular target or outcome, such as stopping infection or limiting disease pathology. However, potential side effects and off-label indications are often not found until clinical trials or post-market drug safety monitoring. Consequently, this approach to drug discovery often leads to unexpected problems or misfires that delay or block significant advancements. Techniques that can determine the best drug or combination of drugs to optimally treat a disease without using conventional drug screening approaches are needed for rapid, efficient translational medicine (Lee et al., 2017; Sun et al., 2013) . Developing targeted therapies that focus on the key signaling pathways that lead to pathology and avoid bystander perturbations of the physiology of a cell are possible when looking at how a therapeutic drug combination impacts a cell using an unbiased analysis of cellular signaling (Bendall et al., 2011; Bodenmiller et al., 2012; Schweizer and Zhang, 2013) ." ;
            <http://www.example.org/textHash>
                    "d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_citespan-1392-1411>
            <http://www.example.org/end>    "1411.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "1392.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ding et al., 2012)" .
    
    <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Analysis of alternations in cellular signaling induced by any one drug, combination of drugs, or the disease state can rapidly elucidate the intricate changes in cellular signaling which is crucial for determining how to therapeutically apply drugs for a proper balance between therapeutic outcomes and potential side effects. Phosphoflow technology is a robust tool that can monitor many cellular signaling pathways that can be modulated during drug treatment (George et al., 2015; Hildebrand and Kubatzky, 2017; Coppin et al., 2017) . Using this technology one can rapidly interrogates the state of key signaling nodes in diverse cellular pathways. We focused our work on changes in phosphorylation states in a panel of key signaling nodes representative\",\"cite_spans\":[{\"start\":461.0,\"end\":482.0,\"text\":\"(George et al., 2015;\",\"ref_id\":\"BIBREF15\"},{\"start\":483.0,\"end\":513.0,\"text\":\"Hildebrand and Kubatzky, 2017;\",\"ref_id\":\"BIBREF16\"},{\"start\":514.0,\"end\":534.0,\"text\":\"Coppin et al., 2017)\",\"ref_id\":\"BIBREF11\"}],\"ref_spans\":[],\"section\":\"Discussion\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7_citespan-461-482> , <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7_citespan-483-513> , <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7_citespan-514-534> ;
            <http://www.example.org/section>
                    "Discussion" ;
            <http://www.example.org/text>  "Analysis of alternations in cellular signaling induced by any one drug, combination of drugs, or the disease state can rapidly elucidate the intricate changes in cellular signaling which is crucial for determining how to therapeutically apply drugs for a proper balance between therapeutic outcomes and potential side effects. Phosphoflow technology is a robust tool that can monitor many cellular signaling pathways that can be modulated during drug treatment (George et al., 2015; Hildebrand and Kubatzky, 2017; Coppin et al., 2017) . Using this technology one can rapidly interrogates the state of key signaling nodes in diverse cellular pathways. We focused our work on changes in phosphorylation states in a panel of key signaling nodes representative" ;
            <http://www.example.org/textHash>
                    "726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-521-530>
            <http://www.example.org/end>    "530.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "521.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1A)" .
    
    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_citespan-621-640>
            <http://www.example.org/end>    "640.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "621.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ding et al., 2012)" .
    
    <http://covid19.aksw.org/text-2dc32a49a40df41082dad3c7606062cf6cfea3895601d91a3d755aebe226536c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To better understand how the therapeutic drug combinations were able to inhibit HSV-1 replication, we used phosphoflow to simultaneously monitor the phosphorylated states of 12 cellular signaling nodes (Akt, ERK, JNK, cJun, MAPKAPK2, NFĸB, p38, S6, STAT1, STAT3, STAT5, and STAT6) in individual cells upon drug stimulation. We chose these different signaling nodes to highlight key signal transduction cascades that if modulated would lead to direct changes in the state of the cells. This system is robust enough to track the changes in cellular physiology, as indicated by changes in cellular signaling, induced by the different drug combinations to provide definitive insight into how the cell is affected by these drugs individually and in their optimal combinations by looking at the panel of phosphoproteins. Each individual drug from the combinations was administrated alone and in combination in duplicate at time 0. Samples were collected at four time points post simulation (0.5, 4, 8, and 16 h).\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Cellular signaling analysis of cells stimulated with antiviral drug combinations\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Cellular signaling analysis of cells stimulated with antiviral drug combinations" ;
            <http://www.example.org/text>  "To better understand how the therapeutic drug combinations were able to inhibit HSV-1 replication, we used phosphoflow to simultaneously monitor the phosphorylated states of 12 cellular signaling nodes (Akt, ERK, JNK, cJun, MAPKAPK2, NFĸB, p38, S6, STAT1, STAT3, STAT5, and STAT6) in individual cells upon drug stimulation. We chose these different signaling nodes to highlight key signal transduction cascades that if modulated would lead to direct changes in the state of the cells. This system is robust enough to track the changes in cellular physiology, as indicated by changes in cellular signaling, induced by the different drug combinations to provide definitive insight into how the cell is affected by these drugs individually and in their optimal combinations by looking at the panel of phosphoproteins. Each individual drug from the combinations was administrated alone and in combination in duplicate at time 0. Samples were collected at four time points post simulation (0.5, 4, 8, and 16 h)." ;
            <http://www.example.org/textHash>
                    "2dc32a49a40df41082dad3c7606062cf6cfea3895601d91a3d755aebe226536c" .
    
    <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-537-562>
            <http://www.example.org/end>    "562.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Krutzik and Nolan, 2006)" .
    
    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-532-540>
            <http://www.example.org/end>    "540.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "532.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 5B" .
    
    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-683-692>
            <http://www.example.org/end>    "692.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "683.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4D)" .
    
    <http://covid19.aksw.org/text-9a396af812e79d5dfaa55ed47fb1cc9810b5bab6fbbe92cc7be82abd4e44cc66>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The results in Fig. 3 suggest that IFN does not directly eradicate virus in already infected cells; instead IFN inhibits viral infection by targeting uninfected cells and preparing them to avoid further viral invasion, which is in line with the known biological mechanisms of IFN. Once viral infection had begun in the cell population, IFN could not reduce the level of viral infection. In contrast, Optimal_B (RIB-rich combination) was effective in this study, in which cells were infected prior to drug treatment. These results indicate that RIB can directly target viral replication inside the cells.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":15.0,\"end\":21.0,\"text\":\"Fig. 3\",\"ref_id\":\"FIGREF1\"}],\"section\":\"Changes in distinct signaling nodes after post-infection treatment of viral infection\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-9a396af812e79d5dfaa55ed47fb1cc9810b5bab6fbbe92cc7be82abd4e44cc66_refspan-15-21> ;
            <http://www.example.org/section>
                    "Changes in distinct signaling nodes after post-infection treatment of viral infection" ;
            <http://www.example.org/text>  "The results in Fig. 3 suggest that IFN does not directly eradicate virus in already infected cells; instead IFN inhibits viral infection by targeting uninfected cells and preparing them to avoid further viral invasion, which is in line with the known biological mechanisms of IFN. Once viral infection had begun in the cell population, IFN could not reduce the level of viral infection. In contrast, Optimal_B (RIB-rich combination) was effective in this study, in which cells were infected prior to drug treatment. These results indicate that RIB can directly target viral replication inside the cells." ;
            <http://www.example.org/textHash>
                    "9a396af812e79d5dfaa55ed47fb1cc9810b5bab6fbbe92cc7be82abd4e44cc66" .
    
    <http://covid19.aksw.org/text-1931a8f8ce01e29f96b5650b0ce823d3115928f3f12827e8cf694e6c49ff7ba4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"XD, DMJr, CMH, GPN, and DJS wrote the manuscript. XD, POK, AAG, YZ and DJS conducted experiments. XD, YZ, DMJr and DJS analyzed data. XD, POK, AAG, GC, CMH, GPN and DJS designed experiments.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Author contributions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Author contributions" ;
            <http://www.example.org/text>  "XD, DMJr, CMH, GPN, and DJS wrote the manuscript. XD, POK, AAG, YZ and DJS conducted experiments. XD, YZ, DMJr and DJS analyzed data. XD, POK, AAG, GC, CMH, GPN and DJS designed experiments." ;
            <http://www.example.org/textHash>
                    "1931a8f8ce01e29f96b5650b0ce823d3115928f3f12827e8cf694e6c49ff7ba4" .
    
    <http://covid19.aksw.org/text-a92951390ecc5cf8be7d22d099ecd3948568d5c90e64478c4af2700287c39fd3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Phosphoflow was performed as previously described (Krutzik et al., 2008) . Briefly, cells with or without treatment were fixed with formaldehyde (1.6% final concentration), permeabilized with 4°C pure methanol, washed twice with staining medium (PBS containing 0.5% bovine serum albumin and 0.02% sodium azide), and finally stained with phosphospecific antibodies in staining medium. Antibodies are against Akt (also known as Protein kinase B), ERK (extracellular signalrelated kinase), JNK (c-Jun N-terminal kinases), cJun, MAPKAPK2 (Mitogen-activated protein kinase-activated protein kinase 2), NFĸB (Nuclear Factor ĸB), p38 (Mitogen-activated protein kinase), S6 (ribosomal protein S6), STAT1 (signal transducer and activator of transcription), STAT3, STAT5, and STAT6. Flow cytometry was performed on a BD FACSCanto II flow cytometer. After acquisition, data were analyzed using FlowJo software to generate median fluorescent intensity (MFI) values for each phosphoprotein in each treatment group. The median values were exported to Microsoft Excel for further analysis. All experiments were done with isotype controls to determine background staining. In addition, all experiments were done in triplicates. Data presented as single flow cytometry plot is representative of all three experiments. Data from the triplicates was further converted to bar graphs by averaging data and plotting with error bars representing the standard error. \",\"cite_spans\":[{\"start\":50.0,\"end\":72.0,\"text\":\"(Krutzik et al., 2008)\",\"ref_id\":\"BIBREF24\"}],\"ref_spans\":[],\"section\":\"Phosphoflow\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a92951390ecc5cf8be7d22d099ecd3948568d5c90e64478c4af2700287c39fd3_citespan-50-72> ;
            <http://www.example.org/section>
                    "Phosphoflow" ;
            <http://www.example.org/text>  "Phosphoflow was performed as previously described (Krutzik et al., 2008) . Briefly, cells with or without treatment were fixed with formaldehyde (1.6% final concentration), permeabilized with 4°C pure methanol, washed twice with staining medium (PBS containing 0.5% bovine serum albumin and 0.02% sodium azide), and finally stained with phosphospecific antibodies in staining medium. Antibodies are against Akt (also known as Protein kinase B), ERK (extracellular signalrelated kinase), JNK (c-Jun N-terminal kinases), cJun, MAPKAPK2 (Mitogen-activated protein kinase-activated protein kinase 2), NFĸB (Nuclear Factor ĸB), p38 (Mitogen-activated protein kinase), S6 (ribosomal protein S6), STAT1 (signal transducer and activator of transcription), STAT3, STAT5, and STAT6. Flow cytometry was performed on a BD FACSCanto II flow cytometer. After acquisition, data were analyzed using FlowJo software to generate median fluorescent intensity (MFI) values for each phosphoprotein in each treatment group. The median values were exported to Microsoft Excel for further analysis. All experiments were done with isotype controls to determine background staining. In addition, all experiments were done in triplicates. Data presented as single flow cytometry plot is representative of all three experiments. Data from the triplicates was further converted to bar graphs by averaging data and plotting with error bars representing the standard error. " ;
            <http://www.example.org/textHash>
                    "a92951390ecc5cf8be7d22d099ecd3948568d5c90e64478c4af2700287c39fd3" .
    
    <http://covid19.aksw.org/text-212391dcbb3aba8d85575f2e4f9e906b16779d7ad288edb3cd1534fa59bcac34_refspan-424-445>
            <http://www.example.org/end>    "445.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "424.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Supplementary Fig. 5B" .
    
    <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-1039-1065>
            <http://www.example.org/end>    "1065.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "1039.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schweizer and Zhang, 2013)" .
    
    <http://covid19.aksw.org/text-97223eb5aad08437e8664278560117449f6796e1d8c42656024728062c50ec87_refspan-577-586>
            <http://www.example.org/end>    "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "577.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 3A)" .
    
    <http://covid19.aksw.org/text-c2a3cfc3210367b2360b5813e755a39c180698d68ad602384ef1e868f312c52e_refspan-702-711>
            <http://www.example.org/end>    "711.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "702.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 2E)" .
    
    <http://covid19.aksw.org/text-168d046fb262bc7fe41efb63acfbe338fd1d5bdafa7e2e82057c912cc66cbc0f_refspan-513-520>
            <http://www.example.org/end>    "520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "513.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 7A" .
    
    <http://covid19.aksw.org/text-726b675447219230cea8992f485f3472f8c7058bd65b7ab8bad8d814d0ec25d7_citespan-514-534>
            <http://www.example.org/end>    "534.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "514.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Coppin et al., 2017)" .
    
    <http://covid19.aksw.org/text-a2bb557d6e16b80418944182861550a0483dae450676b14b8dfab492da168ef7_refspan-1151-1160>
            <http://www.example.org/end>    "1160.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "1151.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 1C)" .
    
    <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In this study, we use phosphospecific flow cytometry, or phosphoflow, to understand the changes in cellular signaling using potent antiviral drug combinations as stimuli. The phosphorylation and dephosphorylation of proteins by kinases and phosphatases are part of the essential regulatory networks that drive the phenotype and function of cells, tissues, and organisms, especially after exposure to a drug or biological therapeutic (Sachs et al., 2005) . Advances in phosphoflow have made studies at the phosphoproteomic level possible (Krutzik and Nolan, 2006) . Using phosphoflow to monitor multiple indicators of cellular physiology allows us to determine how drug combinations affect the intricate cellular signaling by simultaneously interrogating distinct signaling nodes within treated cells. The insight afforded to us by phosphoflow analysis of a drug combination or disease state may allow us to better design specific therapeutics that modulate the activity of disease-related kinases or phosphatases (Krutzik et al., 2008; Bodenmiller et al., 2010) .\",\"cite_spans\":[{\"start\":433.0,\"end\":453.0,\"text\":\"(Sachs et al., 2005)\",\"ref_id\":\"BIBREF31\"},{\"start\":537.0,\"end\":562.0,\"text\":\"(Krutzik and Nolan, 2006)\",\"ref_id\":\"BIBREF23\"},{\"start\":1013.0,\"end\":1035.0,\"text\":\"(Krutzik et al., 2008;\",\"ref_id\":\"BIBREF24\"},{\"start\":1036.0,\"end\":1061.0,\"text\":\"Bodenmiller et al., 2010)\",\"ref_id\":\"BIBREF7\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-433-453> , <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-537-562> , <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-1013-1035> , <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-1036-1061> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "In this study, we use phosphospecific flow cytometry, or phosphoflow, to understand the changes in cellular signaling using potent antiviral drug combinations as stimuli. The phosphorylation and dephosphorylation of proteins by kinases and phosphatases are part of the essential regulatory networks that drive the phenotype and function of cells, tissues, and organisms, especially after exposure to a drug or biological therapeutic (Sachs et al., 2005) . Advances in phosphoflow have made studies at the phosphoproteomic level possible (Krutzik and Nolan, 2006) . Using phosphoflow to monitor multiple indicators of cellular physiology allows us to determine how drug combinations affect the intricate cellular signaling by simultaneously interrogating distinct signaling nodes within treated cells. The insight afforded to us by phosphoflow analysis of a drug combination or disease state may allow us to better design specific therapeutics that modulate the activity of disease-related kinases or phosphatases (Krutzik et al., 2008; Bodenmiller et al., 2010) ." ;
            <http://www.example.org/textHash>
                    "441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791" .
    
    <http://covid19.aksw.org/text-572ea1576f52d8c9afe3d99d32e9ea0de9f3499426ff4bf393cb7199afe413bc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"HSV-1 replication and demonstrate that therapeutic drug combinations that effectively block HSV-1 replication were modulating these signaling nodes to block HSV-1 replication. We extended our findings to develop a proof of principle in a mouse model of vaginal HSV-1 infection by targeting S6 phosphorylation directly with the S6 kinase inhibitor SL0101. The efficacy of targeting this phosphorylation step shows that using analysis of cellular signaling modulation can determine new, efficacious antivirals and drug targets.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Conclusions" ;
            <http://www.example.org/text>  "HSV-1 replication and demonstrate that therapeutic drug combinations that effectively block HSV-1 replication were modulating these signaling nodes to block HSV-1 replication. We extended our findings to develop a proof of principle in a mouse model of vaginal HSV-1 infection by targeting S6 phosphorylation directly with the S6 kinase inhibitor SL0101. The efficacy of targeting this phosphorylation step shows that using analysis of cellular signaling modulation can determine new, efficacious antivirals and drug targets." ;
            <http://www.example.org/textHash>
                    "572ea1576f52d8c9afe3d99d32e9ea0de9f3499426ff4bf393cb7199afe413bc" .
    
    <http://covid19.aksw.org/text-bc8dcf3b81f3135b3fdd09922cb8978934ac7d0584cd397691526dbd5159fad4_refspan-426-435>
            <http://www.example.org/end>    "435.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "426.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 4B)" .
    
    <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"We then tested SL0101 for its in vivo anti-HSV-1 effect using this animal model (Fig. 7A ). Mice treated with SL0101 did not show significant viral reduction compared to the untreated group on day 2. However, the treated group showed more than 12 fold viral reduction compared to untreated group on day 3 (Fig. 7C ). When we compared the fold change in HSV-1 levels (e.g. levels on day 2 divided by day 1 levels (day2/day1) and levels on day 3 divided by day 1 levels (day3/ day1)), the benefit of SL0101 treatment in limiting HSV-1 replication became much clearer, especially for day3/day1. Unlike drug combination Optimal_B, which started to show strong an anti-HSV-1 effect on day 2, the antiviral effect of SL0101 was delayed by about a day (Fig. 7D ).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":80.0,\"end\":88.0,\"text\":\"(Fig. 7A\"},{\"start\":305.0,\"end\":313.0,\"text\":\"(Fig. 7C\"},{\"start\":745.0,\"end\":753.0,\"text\":\"(Fig. 7D\"}],\"section\":\"Translating cellular signaling analysis: small molecule inhibition of HSV-1 infection in an animal model\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df_refspan-80-88> , <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df_refspan-305-313> , <http://covid19.aksw.org/text-60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df_refspan-745-753> ;
            <http://www.example.org/section>
                    "Translating cellular signaling analysis: small molecule inhibition of HSV-1 infection in an animal model" ;
            <http://www.example.org/text>  "We then tested SL0101 for its in vivo anti-HSV-1 effect using this animal model (Fig. 7A ). Mice treated with SL0101 did not show significant viral reduction compared to the untreated group on day 2. However, the treated group showed more than 12 fold viral reduction compared to untreated group on day 3 (Fig. 7C ). When we compared the fold change in HSV-1 levels (e.g. levels on day 2 divided by day 1 levels (day2/day1) and levels on day 3 divided by day 1 levels (day3/ day1)), the benefit of SL0101 treatment in limiting HSV-1 replication became much clearer, especially for day3/day1. Unlike drug combination Optimal_B, which started to show strong an anti-HSV-1 effect on day 2, the antiviral effect of SL0101 was delayed by about a day (Fig. 7D )." ;
            <http://www.example.org/textHash>
                    "60bb91b05b6038eca6cff72e57f403688f7d1e0a540a89bbc92248a51410c5df" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-701-719>
            <http://www.example.org/end>    "719.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF14" ;
            <http://www.example.org/start>  "701.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ding et al., 2014)" .
    
    <http://covid19.aksw.org/text-9a396af812e79d5dfaa55ed47fb1cc9810b5bab6fbbe92cc7be82abd4e44cc66_refspan-15-21>
            <http://www.example.org/end>    "21.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "15.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 3" .
    
    <http://covid19.aksw.org/text-7ef307ea441cd1e4f61c4cdaf1c741c3722aa2bd03ecc0120bcda86b68b224d9_refspan-826-833>
            <http://www.example.org/end>    "833.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF0" ;
            <http://www.example.org/start>  "826.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-faf4c0d39849b42d6917ce3306b75a7e190bd5f44cda79c7006dd0c1e85ef9ca_refspan-691-699>
            <http://www.example.org/end>    "699.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "691.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fig. 5C" .
    
    <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-938-954>
            <http://www.example.org/end>    "954.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "938.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sauerbrei, 2016;" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-224-252>
            <http://www.example.org/end>    "252.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "224.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Morfin and Thouvenot, 2003;" .
    
    <http://covid19.aksw.org/text-d3583723fe36b0065aa35c404b0bf3f3954e3517f1174817c8af48858ccb966a_citespan-385-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Arts and Hazuda, 2012;" .
    
    <http://covid19.aksw.org/text-441ce44b60599fddac3b01fd113599c7ecd92fc863ccbd2948e3a5867543f791_citespan-433-453>
            <http://www.example.org/end>    "453.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sachs et al., 2005)" .
    
    <http://covid19.aksw.org/text-d5a1547928796136cb677a918378605cd78fd17e2586b9f82dad93f561272858_citespan-990-1012>
            <http://www.example.org/end>    "1012.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "990.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bendall et al., 2011;" .
    
    <http://covid19.aksw.org/text-72276f91f8d04fb5f62626fae6fa523880aec4f9bce7a9030aa1b6700be1cef2_citespan-559-586>
            <http://www.example.org/end>    "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "559.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Whitley and Roizman, 2001)" .
    
    <http://covid19.aksw.org/text-13a5072dffbc082de8a97042dbb225cde28a3ebd09a4ffe89587a90cc9797fba>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Host cells were pre-infected with HSV-1 for 8h and then received drug treatments for 16 h. The signaling alterations became more complex compared to host cells treated only with drugs but without virus. A. RIB reduced both pS6 level and viral burden. B. pSTAT1 signaling was blocked in HSV-1 infected cells, but it was recovered by IFN treatments. C. pMAPKAPK2 level was decreased by HSV-1 treatment, whereas blocking HSV-1 infection increased pMAPKAPK2 signaling. D. pNFĸB was induced in HSV-1 infected cells, whereas ACV containing treatments reduced pNFĸB level to baseline. E. ACV treatments that reduced HSV-1 levels appeared to induce pAKT levels in the HSV-1 positive population. As a reminder: high dose IFNs and ACV (Optimal_A). All experimental data shown is representative data from three independent experiments. X. Ding, et al. Antiviral Research 171 (2019) 104598 of the major cellular processes that could be altered by the drug treatments being used.\",\"cite_spans\":[{\"start\":828.0,\"end\":877.0,\"text\":\"Ding, et al. Antiviral Research 171 (2019) 104598\"}],\"ref_spans\":[],\"section\":\"Fig. 4. Drug Treatment of Viral Infection Affecting Distinct Signaling Nodes.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-13a5072dffbc082de8a97042dbb225cde28a3ebd09a4ffe89587a90cc9797fba_citespan-828-877> ;
            <http://www.example.org/section>
                    "Fig. 4. Drug Treatment of Viral Infection Affecting Distinct Signaling Nodes." ;
            <http://www.example.org/text>  "Host cells were pre-infected with HSV-1 for 8h and then received drug treatments for 16 h. The signaling alterations became more complex compared to host cells treated only with drugs but without virus. A. RIB reduced both pS6 level and viral burden. B. pSTAT1 signaling was blocked in HSV-1 infected cells, but it was recovered by IFN treatments. C. pMAPKAPK2 level was decreased by HSV-1 treatment, whereas blocking HSV-1 infection increased pMAPKAPK2 signaling. D. pNFĸB was induced in HSV-1 infected cells, whereas ACV containing treatments reduced pNFĸB level to baseline. E. ACV treatments that reduced HSV-1 levels appeared to induce pAKT levels in the HSV-1 positive population. As a reminder: high dose IFNs and ACV (Optimal_A). All experimental data shown is representative data from three independent experiments. X. Ding, et al. Antiviral Research 171 (2019) 104598 of the major cellular processes that could be altered by the drug treatments being used." ;
            <http://www.example.org/textHash>
                    "13a5072dffbc082de8a97042dbb225cde28a3ebd09a4ffe89587a90cc9797fba" .
    
    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The standard therapy for HSV management includes acyclovir (ACV), a compound developed in the 1980s. Extensive use of ACV, as is expected with antiviral therapeutics, has led to resistance to ACV being increasingly reported (Morfin and Thouvenot, 2003; Piret and Boivin, 2011) . As the future clinical efficacy of ACV is being assessed, therapies with increased efficacy, reduced resistance potential, and improved pharmacokinetics will undoubtedly benefit clinical outcomes (James and Prichard, 2014) . Combinatorial drugs often provide better efficacy with reduced individual drug doses compared to treatment with a single drug (Silva et al., 2016; Nowak-Sliwinska et al., 2016; Weiss et al., 2015; Ding et al., 2014) . As mentioned above, two distinct drug combinations identified through the FSC technique (a mixture of ACV with either ribavirin (RIB) or interferons (IFNs)) could both effectively inhibit HSV-1 infection (Ding et al., 2012) . Though both drug combinations were effective in reducing HSV-1 infection, the underlying mechanisms as to why these particular drug combinations were so potent have not been fully explored. In this study, infected cells treated with either the RIB-rich drug combination or the IFN-rich drug combination were compared side-by-side using phosphoflow technology to determine how these drug combinations affect cellular signaling networks. By not focusing on one set pathway of cellular signaling we used an unbiased approach looking across various signaling nodes in cells to better understand the antiviral mechanisms of these two drug combinations and directly identify cellular signaling pathways that are critical in the control of HSV-1 replication. This study demonstrates the power of using this approach to analyze drug combinations and how to translate the findings. Importantly, we also directly translate our findings into the signaling changes involved in the HSV-1 infection to directly target those changes with antiviral therapies.\",\"cite_spans\":[{\"start\":224.0,\"end\":252.0,\"text\":\"(Morfin and Thouvenot, 2003;\",\"ref_id\":\"BIBREF27\"},{\"start\":253.0,\"end\":276.0,\"text\":\"Piret and Boivin, 2011)\",\"ref_id\":\"BIBREF29\"},{\"start\":475.0,\"end\":501.0,\"text\":\"(James and Prichard, 2014)\",\"ref_id\":\"BIBREF18\"},{\"start\":630.0,\"end\":650.0,\"text\":\"(Silva et al., 2016;\",\"ref_id\":\"BIBREF34\"},{\"start\":651.0,\"end\":680.0,\"text\":\"Nowak-Sliwinska et al., 2016;\",\"ref_id\":\"BIBREF28\"},{\"start\":681.0,\"end\":700.0,\"text\":\"Weiss et al., 2015;\",\"ref_id\":\"BIBREF37\"},{\"start\":701.0,\"end\":719.0,\"text\":\"Ding et al., 2014)\",\"ref_id\":\"BIBREF14\"},{\"start\":926.0,\"end\":945.0,\"text\":\"(Ding et al., 2012)\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-224-252> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-651-680> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-630-650> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-681-700> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-253-276> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-926-945> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-475-501> , <http://covid19.aksw.org/text-e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b_citespan-701-719> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "The standard therapy for HSV management includes acyclovir (ACV), a compound developed in the 1980s. Extensive use of ACV, as is expected with antiviral therapeutics, has led to resistance to ACV being increasingly reported (Morfin and Thouvenot, 2003; Piret and Boivin, 2011) . As the future clinical efficacy of ACV is being assessed, therapies with increased efficacy, reduced resistance potential, and improved pharmacokinetics will undoubtedly benefit clinical outcomes (James and Prichard, 2014) . Combinatorial drugs often provide better efficacy with reduced individual drug doses compared to treatment with a single drug (Silva et al., 2016; Nowak-Sliwinska et al., 2016; Weiss et al., 2015; Ding et al., 2014) . As mentioned above, two distinct drug combinations identified through the FSC technique (a mixture of ACV with either ribavirin (RIB) or interferons (IFNs)) could both effectively inhibit HSV-1 infection (Ding et al., 2012) . Though both drug combinations were effective in reducing HSV-1 infection, the underlying mechanisms as to why these particular drug combinations were so potent have not been fully explored. In this study, infected cells treated with either the RIB-rich drug combination or the IFN-rich drug combination were compared side-by-side using phosphoflow technology to determine how these drug combinations affect cellular signaling networks. By not focusing on one set pathway of cellular signaling we used an unbiased approach looking across various signaling nodes in cells to better understand the antiviral mechanisms of these two drug combinations and directly identify cellular signaling pathways that are critical in the control of HSV-1 replication. This study demonstrates the power of using this approach to analyze drug combinations and how to translate the findings. Importantly, we also directly translate our findings into the signaling changes involved in the HSV-1 infection to directly target those changes with antiviral therapies." ;
            <http://www.example.org/textHash>
                    "e289fad4fbac6a3e09d86298a49f2ead8a9fcefa4c4f482843a3ad954314f79b" .
}
<http://covid19.aksw.org/728372aa94ee6a40655d5e086a0e91569f9c0780> {
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-343-346>
            <http://www.example.org/end>    "346.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "343.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"All settings that administer health services will require an infection prevention program to prevent the spread of infectious organisms, including having access to an IP for consulting purposes (ie, having infection prevention coverage). 40 The need for IP coverage as part of an infection prevention program was identified by all authors as an integral component of emergency management; some researchers specified that this coverage needs to be available around the clock through either phone or face-to-face interaction. 27, 29, 47 Researchers indicate that this is not currently available at all US hospitals, 27, 29 but it is a standard to which health care facilities need to aspire. In addition to hospitals, it is important that long-term care, home health, alternative care sites, and community shelters have infection control coverage. 14, 17, 19, 39, 40 Because of limited Table 1 . Components of an emergency management plan that require IP input\",\"cite_spans\":[{\"start\":238.0,\"end\":240.0,\"text\":\"40\",\"ref_id\":\"BIBREF40\"},{\"start\":524.0,\"end\":527.0,\"text\":\"27,\",\"ref_id\":\"BIBREF26\"},{\"start\":528.0,\"end\":531.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":532.0,\"end\":534.0,\"text\":\"47\",\"ref_id\":\"BIBREF47\"},{\"start\":614.0,\"end\":617.0,\"text\":\"27,\",\"ref_id\":\"BIBREF26\"},{\"start\":618.0,\"end\":620.0,\"text\":\"29\",\"ref_id\":\"BIBREF28\"},{\"start\":846.0,\"end\":849.0,\"text\":\"14,\",\"ref_id\":\"BIBREF13\"},{\"start\":850.0,\"end\":853.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":854.0,\"end\":857.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":858.0,\"end\":861.0,\"text\":\"39,\",\"ref_id\":\"BIBREF39\"},{\"start\":862.0,\"end\":864.0,\"text\":\"40\",\"ref_id\":\"BIBREF40\"}],\"ref_spans\":[{\"start\":884.0,\"end\":891.0,\"text\":\"Table 1\"}],\"section\":\"Domain 3: Infection prevention coverage\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-850-853> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-238-240> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-532-534> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-618-620> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-854-857> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-858-861> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-614-617> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-862-864> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-524-527> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-846-849> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-528-531> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_refspan-884-891> ;
            <http://www.example.org/section>
                    "Domain 3: Infection prevention coverage" ;
            <http://www.example.org/text>  "All settings that administer health services will require an infection prevention program to prevent the spread of infectious organisms, including having access to an IP for consulting purposes (ie, having infection prevention coverage). 40 The need for IP coverage as part of an infection prevention program was identified by all authors as an integral component of emergency management; some researchers specified that this coverage needs to be available around the clock through either phone or face-to-face interaction. 27, 29, 47 Researchers indicate that this is not currently available at all US hospitals, 27, 29 but it is a standard to which health care facilities need to aspire. In addition to hospitals, it is important that long-term care, home health, alternative care sites, and community shelters have infection control coverage. 14, 17, 19, 39, 40 Because of limited Table 1 . Components of an emergency management plan that require IP input" ;
            <http://www.example.org/textHash>
                    "0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-367-369>
            <http://www.example.org/end>    "369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "367.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-485-487>
            <http://www.example.org/end>    "487.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2743-2746>
            <http://www.example.org/end>    "2746.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "2743.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-707-709>
            <http://www.example.org/end>    "709.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "707.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1369-1372>
            <http://www.example.org/end>    "1372.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1062-1065>
            <http://www.example.org/end>    "1065.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1062.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-181-185>
            <http://www.example.org/end>    "185.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "181.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-937-941>
            <http://www.example.org/end>    "941.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "937.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3348-3352>
            <http://www.example.org/end>    "3352.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "3348.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-848-850>
            <http://www.example.org/end>    "850.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "848.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-203-206>
            <http://www.example.org/end>    "206.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "203.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1883-1887>
            <http://www.example.org/end>    "1887.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1883.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-834-836>
            <http://www.example.org/end>    "836.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "834.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-67-69>
            <http://www.example.org/end>    "69.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "67.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1035-1039>
            <http://www.example.org/end>    "1039.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1035.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-165-167>
            <http://www.example.org/end>    "167.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "165.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3798-3801>
            <http://www.example.org/end>    "3801.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "3798.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-879-882>
            <http://www.example.org/end>    "882.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "879.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Mass casualty incidents pose a risk of infection transmission, especially if the event is an infectious disease disaster such as bioterrorism or a pandemic. IP input is needed when developing facility and community emergency management plans. In addition, it is important that IPs have a personal/family response Table 4 . Education topics requiring infection preventionist involvement Education topics IPs need to cover for staff, patients, and visitors Screening/triaging procedures 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Patient decontamination [11] [12] [13] 39 Patient management (patient discharge instructions, when to isolate, and others) 6, 9, 11 Disease-specific information on bioterrorism agents, emerging infections, and pandemic influenza 6,10,12,33 Self-screening and reporting of symptoms 10, 39 Isolation procedures 6, [8] [9] [10] [11] [12] [13] 25, 26, 32, [37] [38] [39] PPE use and reuse 6, [11] [12] [13] 16, 26, 29, 37, 39 Procedures for obtaining and handling patient specimens safely 9, 11, 32 Hand hygiene 6, 9, [11] [12] [13] 26, 28, 32, 39 Respiratory etiquette 6, [9] [10] [11] [12] [13] 26, 32, [37] [38] [39] Cleaning and disinfection of toys in shelters 39 Cot or sleeping area configuration for evacuation shelters 39 Waste management 9, 39 Emergency management procedures and policies that affect infection transmission 10, 13, 14, 26, 39 How to safely reuse respiratory protection when resources are insufficient or unavailable 16, 39 Postmortem care 6, 9, 11, 12, 39 plan so that they are prepared to assist during mass casualty incident response and recovery. This report outlines the role of IPs in emergency management. Nine domains were identified that describe the role of the IP in emergency management: knowledge of mass casualty incidents and emergency management, assessing readiness and emergency management plans, infection prevention coverage, participation in disaster response and recovery, health care policy development, surveillance, patient management, physical plant issues, and IP as educator. IPs should use information from this report as a guide for becoming more involved in emergency management at the personal, facility, and community level.\",\"cite_spans\":[{\"start\":485.0,\"end\":487.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":488.0,\"end\":491.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":492.0,\"end\":495.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":496.0,\"end\":500.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":501.0,\"end\":505.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":506.0,\"end\":510.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":511.0,\"end\":515.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":516.0,\"end\":519.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":520.0,\"end\":523.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":524.0,\"end\":527.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":528.0,\"end\":531.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":532.0,\"end\":535.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":536.0,\"end\":538.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":563.0,\"end\":567.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":568.0,\"end\":572.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":573.0,\"end\":577.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":578.0,\"end\":580.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":662.0,\"end\":664.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":665.0,\"end\":667.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":668.0,\"end\":670.0,\"text\":\"11\",\"ref_id\":\"BIBREF10\"},{\"start\":820.0,\"end\":823.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":824.0,\"end\":826.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":848.0,\"end\":850.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":851.0,\"end\":854.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":855.0,\"end\":858.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":859.0,\"end\":863.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":864.0,\"end\":868.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":869.0,\"end\":873.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":874.0,\"end\":878.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":879.0,\"end\":882.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":883.0,\"end\":886.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":887.0,\"end\":890.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":891.0,\"end\":895.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":896.0,\"end\":900.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":901.0,\"end\":905.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":924.0,\"end\":926.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":927.0,\"end\":931.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":932.0,\"end\":936.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":937.0,\"end\":941.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":942.0,\"end\":945.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":946.0,\"end\":949.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":950.0,\"end\":953.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":954.0,\"end\":957.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":958.0,\"end\":960.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1024.0,\"end\":1026.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":1027.0,\"end\":1030.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":1031.0,\"end\":1033.0,\"text\":\"32\",\"ref_id\":\"BIBREF31\"},{\"start\":1047.0,\"end\":1049.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1050.0,\"end\":1052.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":1053.0,\"end\":1057.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1058.0,\"end\":1062.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1063.0,\"end\":1067.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1068.0,\"end\":1071.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":1072.0,\"end\":1075.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":1076.0,\"end\":1079.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":1080.0,\"end\":1082.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1105.0,\"end\":1107.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1108.0,\"end\":1111.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":1112.0,\"end\":1116.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":1117.0,\"end\":1121.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1122.0,\"end\":1126.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1127.0,\"end\":1131.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1132.0,\"end\":1135.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":1136.0,\"end\":1139.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":1140.0,\"end\":1144.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":1145.0,\"end\":1149.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":1150.0,\"end\":1154.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":1201.0,\"end\":1203.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1263.0,\"end\":1265.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1283.0,\"end\":1285.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":1286.0,\"end\":1288.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1369.0,\"end\":1372.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":1373.0,\"end\":1376.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":1377.0,\"end\":1380.0,\"text\":\"14,\",\"ref_id\":\"BIBREF13\"},{\"start\":1381.0,\"end\":1384.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":1385.0,\"end\":1387.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1478.0,\"end\":1481.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":1482.0,\"end\":1484.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1501.0,\"end\":1503.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1504.0,\"end\":1506.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":1507.0,\"end\":1510.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":1511.0,\"end\":1514.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":1515.0,\"end\":1517.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[{\"start\":313.0,\"end\":320.0,\"text\":\"Table 4\"}],\"section\":\"CONCLUSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-524-527> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1047-1049> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-883-886> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-516-519> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-879-882> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-668-670> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-824-826> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-501-505> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1117-1121> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1024-1026> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1112-1116> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1068-1071> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-874-878> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1072-1075> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1050-1052> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-901-905> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1108-1111> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1132-1135> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-950-953> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1511-1514> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1501-1503> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-924-926> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-891-895> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1286-1288> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-864-868> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-578-580> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1283-1285> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1201-1203> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1373-1376> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1031-1033> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1263-1265> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-927-931> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1127-1131> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1063-1067> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-896-900> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-506-510> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1105-1107> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1381-1384> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-496-500> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-958-960> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1515-1517> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-820-823> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1385-1387> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-520-523> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-887-890> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1504-1506> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-511-515> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-869-873> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-492-495> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-532-535> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-488-491> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-942-945> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1145-1149> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1122-1126> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1076-1079> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1478-1481> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-932-936> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-954-957> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1369-1372> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-536-538> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-662-664> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1482-1484> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1027-1030> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-665-667> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-851-854> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-528-531> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1080-1082> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-563-567> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-573-577> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1377-1380> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1507-1510> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1150-1154> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-855-858> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-485-487> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-937-941> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1136-1139> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1053-1057> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-568-572> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-859-863> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-946-949> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1140-1144> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-848-850> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1058-1062> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_refspan-313-320> ;
            <http://www.example.org/section>
                    "CONCLUSION" ;
            <http://www.example.org/text>  "Mass casualty incidents pose a risk of infection transmission, especially if the event is an infectious disease disaster such as bioterrorism or a pandemic. IP input is needed when developing facility and community emergency management plans. In addition, it is important that IPs have a personal/family response Table 4 . Education topics requiring infection preventionist involvement Education topics IPs need to cover for staff, patients, and visitors Screening/triaging procedures 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Patient decontamination [11] [12] [13] 39 Patient management (patient discharge instructions, when to isolate, and others) 6, 9, 11 Disease-specific information on bioterrorism agents, emerging infections, and pandemic influenza 6,10,12,33 Self-screening and reporting of symptoms 10, 39 Isolation procedures 6, [8] [9] [10] [11] [12] [13] 25, 26, 32, [37] [38] [39] PPE use and reuse 6, [11] [12] [13] 16, 26, 29, 37, 39 Procedures for obtaining and handling patient specimens safely 9, 11, 32 Hand hygiene 6, 9, [11] [12] [13] 26, 28, 32, 39 Respiratory etiquette 6, [9] [10] [11] [12] [13] 26, 32, [37] [38] [39] Cleaning and disinfection of toys in shelters 39 Cot or sleeping area configuration for evacuation shelters 39 Waste management 9, 39 Emergency management procedures and policies that affect infection transmission 10, 13, 14, 26, 39 How to safely reuse respiratory protection when resources are insufficient or unavailable 16, 39 Postmortem care 6, 9, 11, 12, 39 plan so that they are prepared to assist during mass casualty incident response and recovery. This report outlines the role of IPs in emergency management. Nine domains were identified that describe the role of the IP in emergency management: knowledge of mass casualty incidents and emergency management, assessing readiness and emergency management plans, infection prevention coverage, participation in disaster response and recovery, health care policy development, surveillance, patient management, physical plant issues, and IP as educator. IPs should use information from this report as a guide for becoming more involved in emergency management at the personal, facility, and community level." ;
            <http://www.example.org/textHash>
                    "50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-563-567>
            <http://www.example.org/end>    "567.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "563.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-347-349>
            <http://www.example.org/end>    "349.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "347.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1601-1604>
            <http://www.example.org/end>    "1604.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1601.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-842-844>
            <http://www.example.org/end>    "844.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "842.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-405-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "405.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-475-479>
            <http://www.example.org/end>    "479.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "475.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1511-1514>
            <http://www.example.org/end>    "1514.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1511.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3122-3124>
            <http://www.example.org/end>    "3124.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "3122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-120-124>
            <http://www.example.org/end>    "124.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "120.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-864-868>
            <http://www.example.org/end>    "868.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "864.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3358-3361>
            <http://www.example.org/end>    "3361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "3358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2153-2157>
            <http://www.example.org/end>    "2157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "2153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4820-4823>
            <http://www.example.org/end>    "4823.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "4820.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1156-1157>
            <http://www.example.org/end>    "1157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "1156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "4" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1054-1057>
            <http://www.example.org/end>    "1057.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "1054.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1565-1567>
            <http://www.example.org/end>    "1567.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1565.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1108-1111>
            <http://www.example.org/end>    "1111.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1108.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2955-2959>
            <http://www.example.org/end>    "2959.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "2955.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-135-137>
            <http://www.example.org/end>    "137.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-884-886>
            <http://www.example.org/end>    "886.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "884.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1733-1734>
            <http://www.example.org/end>    "1734.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "1733.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "7" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1662-1665>
            <http://www.example.org/end>    "1665.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "1662.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-173-176>
            <http://www.example.org/end>    "176.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "173.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31," .
    
    <http://covid19.aksw.org/text-4c7204d0e4c7747a7b8ac7601749427c89e1aef462676e28cae806c293c05c5d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The aim of this project was to delineate the role of IPs in all phases of emergency management. The role of the IP in emergency management was developed using an evidence-based approach consisting of the following steps: (1) review of literature, (2) review of meeting Proceedings from the Mini Summit on Emergency Preparedness hosted by the Association for Professionals in Infection Control and Epidemiology, Inc (APIC) in May 2008, 14 (3) initial drafting of the IP\\u0027s role in emergency management, and (4) review by members of the APIC Emergency Preparedness Committee.\",\"cite_spans\":[{\"start\":435.0,\"end\":437.0,\"text\":\"14\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[],\"section\":\"METHODS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4c7204d0e4c7747a7b8ac7601749427c89e1aef462676e28cae806c293c05c5d_citespan-435-437> ;
            <http://www.example.org/section>
                    "METHODS" ;
            <http://www.example.org/text>  "The aim of this project was to delineate the role of IPs in all phases of emergency management. The role of the IP in emergency management was developed using an evidence-based approach consisting of the following steps: (1) review of literature, (2) review of meeting Proceedings from the Mini Summit on Emergency Preparedness hosted by the Association for Professionals in Infection Control and Epidemiology, Inc (APIC) in May 2008, 14 (3) initial drafting of the IP's role in emergency management, and (4) review by members of the APIC Emergency Preparedness Committee." ;
            <http://www.example.org/textHash>
                    "4c7204d0e4c7747a7b8ac7601749427c89e1aef462676e28cae806c293c05c5d" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-217-220>
            <http://www.example.org/end>    "220.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "217.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-630-633>
            <http://www.example.org/end>    "633.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "630.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2677-2681>
            <http://www.example.org/end>    "2681.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2677.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-517-519>
            <http://www.example.org/end>    "519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "517.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-631-635>
            <http://www.example.org/end>    "635.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "631.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[32]" .
    
    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"IPs should use competency-based curriculum whenever possible when developing infection prevention in emergency management education. Competencies for hospital-based health care workers related to infection prevention have been developed 54 but do not currently exist for other worker groups. These competencies should be used for education development for hospital-based health care workers and may serve as a starting point for creating training for other worker groups. Competency domains for hospital-based health care workers include basic microbiology, modes/mechanisms of infection transmission, standard and transmission-based precautions, occupational health, patient safety, critical thinking, and emergency preparedness. 54 Within the emergency preparedness domain, additional education topics have been identified. Education topics that IPs need to cover when developing training materials for staff, patients, and visitors are outlined in Table 4 . Examples of such topics include how and when to perform hand hygiene and respiratory etiquette, isolation precautions, PPE use, safely reuse respiratory protection, and screening procedures. Most of these topics are applicable for routine practice; differences between day-to-day activities and disaster situations need to be incorporated into the training. For instance, routine PPE use and procedures for safely reusing respiratory protection when resources are insufficient or depleted because of a disaster need to be included in staff education. 16 In addition, educational material needs to be targeted to each group. Previous research indicates that there are disciplinespecific competencies related to infection prevention. 54 IPs should take these differences into account when education is created for various groups of individuals. During response to a mass casualty incident, all responding staff will require some level of training that is specific to the event. Whenever possible, IPs should have \\u0027\\u0027just in time\\u0027\\u0027 training materials on hand to distribute during disaster response. 6 \",\"cite_spans\":[{\"start\":731.0,\"end\":733.0,\"text\":\"54\",\"ref_id\":\"BIBREF54\"},{\"start\":1512.0,\"end\":1514.0,\"text\":\"16\",\"ref_id\":\"BIBREF15\"},{\"start\":1693.0,\"end\":1695.0,\"text\":\"54\",\"ref_id\":\"BIBREF54\"},{\"start\":2056.0,\"end\":2057.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"}],\"ref_spans\":[{\"start\":951.0,\"end\":958.0,\"text\":\"Table 4\"}],\"section\":\"Domain 9: IP as educator\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-731-733> , <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-1512-1514> , <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-1693-1695> , <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-2056-2057> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_refspan-951-958> ;
            <http://www.example.org/section>
                    "Domain 9: IP as educator" ;
            <http://www.example.org/text>  "IPs should use competency-based curriculum whenever possible when developing infection prevention in emergency management education. Competencies for hospital-based health care workers related to infection prevention have been developed 54 but do not currently exist for other worker groups. These competencies should be used for education development for hospital-based health care workers and may serve as a starting point for creating training for other worker groups. Competency domains for hospital-based health care workers include basic microbiology, modes/mechanisms of infection transmission, standard and transmission-based precautions, occupational health, patient safety, critical thinking, and emergency preparedness. 54 Within the emergency preparedness domain, additional education topics have been identified. Education topics that IPs need to cover when developing training materials for staff, patients, and visitors are outlined in Table 4 . Examples of such topics include how and when to perform hand hygiene and respiratory etiquette, isolation precautions, PPE use, safely reuse respiratory protection, and screening procedures. Most of these topics are applicable for routine practice; differences between day-to-day activities and disaster situations need to be incorporated into the training. For instance, routine PPE use and procedures for safely reusing respiratory protection when resources are insufficient or depleted because of a disaster need to be included in staff education. 16 In addition, educational material needs to be targeted to each group. Previous research indicates that there are disciplinespecific competencies related to infection prevention. 54 IPs should take these differences into account when education is created for various groups of individuals. During response to a mass casualty incident, all responding staff will require some level of training that is specific to the event. Whenever possible, IPs should have ''just in time'' training materials on hand to distribute during disaster response. 6 " ;
            <http://www.example.org/textHash>
                    "6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1370-1373>
            <http://www.example.org/end>    "1373.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1557-1560>
            <http://www.example.org/end>    "1560.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "1557.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1644-1648>
            <http://www.example.org/end>    "1648.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1644.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-118-121>
            <http://www.example.org/end>    "121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-931-934>
            <http://www.example.org/end>    "934.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "931.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-572-576>
            <http://www.example.org/end>    "576.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "572.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[44]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1058-1062>
            <http://www.example.org/end>    "1062.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1058.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1305-1306>
            <http://www.example.org/end>    "1306.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "1305.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "5" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-850-853>
            <http://www.example.org/end>    "853.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "850.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-368-372>
            <http://www.example.org/end>    "372.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "368.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-275-279>
            <http://www.example.org/end>    "279.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "275.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-391-394>
            <http://www.example.org/end>    "394.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "391.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-294-297>
            <http://www.example.org/end>    "297.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "294.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-528-531>
            <http://www.example.org/end>    "531.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "528.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1478-1481>
            <http://www.example.org/end>    "1481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "1478.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-464-467>
            <http://www.example.org/end>    "467.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "464.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2130-2134>
            <http://www.example.org/end>    "2134.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "2130.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[14]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-210-214>
            <http://www.example.org/end>    "214.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "210.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1094-1098>
            <http://www.example.org/end>    "1098.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1094.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1654-1657>
            <http://www.example.org/end>    "1657.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "1654.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1056-1058>
            <http://www.example.org/end>    "1058.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1056.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-835-839>
            <http://www.example.org/end>    "839.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "835.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-1146-1148>
            <http://www.example.org/end>    "1148.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "1146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2114-2116>
            <http://www.example.org/end>    "2116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "2114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-946-949>
            <http://www.example.org/end>    "949.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "946.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-468-470>
            <http://www.example.org/end>    "470.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1175-1179>
            <http://www.example.org/end>    "1179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "1175.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[43]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1068-1071>
            <http://www.example.org/end>    "1071.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "1068.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1549-1552>
            <http://www.example.org/end>    "1552.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1549.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-195-197>
            <http://www.example.org/end>    "197.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "195.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-2056-2057>
            <http://www.example.org/end>    "2057.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "2056.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1197-1201>
            <http://www.example.org/end>    "1201.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1197.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-539-541>
            <http://www.example.org/end>    "541.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "539.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-68-72>
            <http://www.example.org/end>    "72.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "68.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3251-3255>
            <http://www.example.org/end>    "3255.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "3251.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2722-2724>
            <http://www.example.org/end>    "2724.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "2722.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1150-1154>
            <http://www.example.org/end>    "1154.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-546-549>
            <http://www.example.org/end>    "549.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "546.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-158-161>
            <http://www.example.org/end>    "161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "158.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-837-841>
            <http://www.example.org/end>    "841.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "837.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-400-404>
            <http://www.example.org/end>    "404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "400.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[25]" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-179-182>
            <http://www.example.org/end>    "182.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2109-2111>
            <http://www.example.org/end>    "2111.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "2109.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-202-204>
            <http://www.example.org/end>    "204.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "202.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-470-474>
            <http://www.example.org/end>    "474.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "470.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-852-854>
            <http://www.example.org/end>    "854.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "852.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-802-806>
            <http://www.example.org/end>    "806.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "802.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1185-1189>
            <http://www.example.org/end>    "1189.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "1185.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[45]" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"One critical health care policy area in which IPs need to be involved is the development of altered or crisis standards of care. 6, [9] [10] [11] [12] [13] [14] 16, 25, 29, 31, 39 Given the projected lack of resources that will be available during a mass casualty event, alternative approaches to patient care must be considered. Tough decisions need to be made regarding how to allocate limited numbers of ventilators or medications, where contagious patients will be housed if all isolation rooms are full, and which staff will be given PPE if stocks become depleted. Some of these decisions will have infectious disease implications and require IP input to determine the best course of action. Facility disaster planning teams and ethics committees will be responsible for development of crisis standards of care. IP\\u0027s responsibility in this process is to consult with these teams and committees to create the most protective crisis standards of care possible in relation to preventing the spread of infectious organisms in health care settings. To this end, IPs should be involved in all policy development decisions that have potential infectious disease implications. Examples of such decisions include which staff will care for potentially infectious patients, how and when to cohort potentially contagious patients, prioritization plans for limited supplies of antiinfective therapy for staff, what to do when hand hygiene or environmental decontamination supplies become insufficient, and how PPE will be allocated or reused if resources become depleted. Researchers and national organizations have begun work in this area, such as the development of guidelines on how to safely reuse respiratory protection when resources become insufficient or unavailable, 16 but more needs to be done.\",\"cite_spans\":[{\"start\":129.0,\"end\":131.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":132.0,\"end\":135.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":136.0,\"end\":140.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":141.0,\"end\":145.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":146.0,\"end\":150.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":151.0,\"end\":155.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":156.0,\"end\":160.0,\"text\":\"[14]\",\"ref_id\":\"BIBREF13\"},{\"start\":161.0,\"end\":164.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":165.0,\"end\":168.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":169.0,\"end\":172.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":173.0,\"end\":176.0,\"text\":\"31,\",\"ref_id\":\"BIBREF30\"},{\"start\":177.0,\"end\":179.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1768.0,\"end\":1770.0,\"text\":\"16\",\"ref_id\":\"BIBREF15\"}],\"ref_spans\":[],\"section\":\"Domain 5: Health care policy development\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-151-155> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-136-140> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-146-150> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-169-172> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-156-160> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-132-135> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-177-179> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-173-176> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-129-131> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-161-164> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-1768-1770> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-165-168> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-141-145> ;
            <http://www.example.org/section>
                    "Domain 5: Health care policy development" ;
            <http://www.example.org/text>  "One critical health care policy area in which IPs need to be involved is the development of altered or crisis standards of care. 6, [9] [10] [11] [12] [13] [14] 16, 25, 29, 31, 39 Given the projected lack of resources that will be available during a mass casualty event, alternative approaches to patient care must be considered. Tough decisions need to be made regarding how to allocate limited numbers of ventilators or medications, where contagious patients will be housed if all isolation rooms are full, and which staff will be given PPE if stocks become depleted. Some of these decisions will have infectious disease implications and require IP input to determine the best course of action. Facility disaster planning teams and ethics committees will be responsible for development of crisis standards of care. IP's responsibility in this process is to consult with these teams and committees to create the most protective crisis standards of care possible in relation to preventing the spread of infectious organisms in health care settings. To this end, IPs should be involved in all policy development decisions that have potential infectious disease implications. Examples of such decisions include which staff will care for potentially infectious patients, how and when to cohort potentially contagious patients, prioritization plans for limited supplies of antiinfective therapy for staff, what to do when hand hygiene or environmental decontamination supplies become insufficient, and how PPE will be allocated or reused if resources become depleted. Researchers and national organizations have begun work in this area, such as the development of guidelines on how to safely reuse respiratory protection when resources become insufficient or unavailable, 16 but more needs to be done." ;
            <http://www.example.org/textHash>
                    "97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1146-1150>
            <http://www.example.org/end>    "1150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1079-1082>
            <http://www.example.org/end>    "1082.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "1079.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1202-1206>
            <http://www.example.org/end>    "1206.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1202.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-164-168>
            <http://www.example.org/end>    "168.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "164.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-485-487>
            <http://www.example.org/end>    "487.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1946-1949>
            <http://www.example.org/end>    "1949.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1946.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-851-854>
            <http://www.example.org/end>    "854.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "851.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-118-121>
            <http://www.example.org/end>    "121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-820-823>
            <http://www.example.org/end>    "823.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "820.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2096-2098>
            <http://www.example.org/end>    "2098.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "2096.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-932-936>
            <http://www.example.org/end>    "936.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "932.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-901-905>
            <http://www.example.org/end>    "905.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "901.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-170-172>
            <http://www.example.org/end>    "172.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-242-245>
            <http://www.example.org/end>    "245.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "242.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-420-424>
            <http://www.example.org/end>    "424.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "420.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[29]" .
    
    <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-301-304>
            <http://www.example.org/end>    "304.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "301.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-127-131>
            <http://www.example.org/end>    "131.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1090-1093>
            <http://www.example.org/end>    "1093.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "1090.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2806-2810>
            <http://www.example.org/end>    "2810.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2806.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-298-301>
            <http://www.example.org/end>    "301.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "298.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-1910-1911>
            <http://www.example.org/end>    "1911.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1910.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-85-88>
            <http://www.example.org/end>    "88.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "85.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2159-2161>
            <http://www.example.org/end>    "2161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF53" ;
            <http://www.example.org/start>  "2159.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "53" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-129-131>
            <http://www.example.org/end>    "131.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "129.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3099-3103>
            <http://www.example.org/end>    "3103.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "3099.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-322-326>
            <http://www.example.org/end>    "326.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-846-849>
            <http://www.example.org/end>    "849.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "846.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-670-671>
            <http://www.example.org/end>    "671.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "670.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In addition to playing a key role in preparing for mass casualty incidents, IPs will be essential to an effective response and recovery from an emergency. 11-13 IP\\u0027s level of involvement will vary, depending on the type and scope of the event. Small incidents with no infectious disease cause will likely require little IP participation, whereas an infectious disease disaster will necessitate a great deal of time and input from IPs. The exact role of the IP in mass casualty incident response and recovery may vary from facility to facility; IPs need to verify their responsibilities by checking their facility emergency management plan for details. Regardless of the facility, or type or scope of the disaster, most IP\\u0027s primary responsibility during a mass casualty incident will be to prevent and control infectious disease spread during the event. This will involve implementation of infection prevention strategies outlined in facility policies and procedures and the facility emergency management plan, as well as monitoring the effectiveness of these interventions. 10, 26, 35 In some facilities, IPs may be asked or expected to fulfill a role in the incident command system (ICS). 6, 9, [11] [12] [13] Hospitals and health care systems are required to manage all emergencies using structures and principles in accordance with NIMS, including the implementation of an ICS. 48 Development and implementation of an ICS for health care facilities is not within the scope of the IP\\u0027s responsibilities. However, IPs may be designated by the health care facility as employees who need NIMS and ICS training. 48 This is most likely to occur in facilities that plan to utilize IPs as members of the ICS during a disaster. IPs should check with their facility emergency management committee to verify whether they will be assigned a position within the ICS during a disaster and require NIMS and ICS training. Regardless of whether or not an IP is assigned a position within the ICS, IPs will be expected to have a basic understanding of the system and be able to communicate important information concerning infection prevention through the proper channels. 12 Reporting events, communication, and coordination are vital components of disaster response and recovery and are functions that IPs will be expected to perform. Health care facility emergency management plans need to delineate procedures for reporting disasters internally and externally. IP involvement in developing reporting guidelines for most disasters, such as floods or fires, will not be needed. However, IP input will be vital when developing reporting protocols for all disasters involving an infectious agent, such as bioterrorism or a pandemic. 6, 8, 9, [11] [12] [13] 19, 26, 35, [37] [38] [39] Policies for internal reporting of infectious disease disasters should include, at the least, notification of the Infection Prevention and Control and/or Infectious Disease Department. [11] [12] [13] Other departments may also need notification, such as Nursing Services, Internal Medicine, Safety, and others. Rapid notification of the IP during any type of disaster is vital so that proper assessments can be made concerning the potential infectious disease implications of the event. Even events that might not seem to have an affect on infection transmission, such as a power outage, can cause unexpected complications that contribute to disease spread in health care facilities.\",\"cite_spans\":[{\"start\":1075.0,\"end\":1078.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":1079.0,\"end\":1082.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":1083.0,\"end\":1085.0,\"text\":\"35\",\"ref_id\":\"BIBREF34\"},{\"start\":1191.0,\"end\":1193.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1194.0,\"end\":1196.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":1197.0,\"end\":1201.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1202.0,\"end\":1206.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1207.0,\"end\":1211.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1382.0,\"end\":1384.0,\"text\":\"48\",\"ref_id\":\"BIBREF48\"},{\"start\":1611.0,\"end\":1613.0,\"text\":\"48\",\"ref_id\":\"BIBREF48\"},{\"start\":2159.0,\"end\":2161.0,\"text\":\"12\",\"ref_id\":\"BIBREF11\"},{\"start\":2719.0,\"end\":2721.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":2722.0,\"end\":2724.0,\"text\":\"8,\",\"ref_id\":\"BIBREF7\"},{\"start\":2725.0,\"end\":2727.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":2728.0,\"end\":2732.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":2733.0,\"end\":2737.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":2738.0,\"end\":2742.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":2743.0,\"end\":2746.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":2747.0,\"end\":2750.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":2751.0,\"end\":2754.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":2755.0,\"end\":2759.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":2760.0,\"end\":2764.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":2765.0,\"end\":2769.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":2955.0,\"end\":2959.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":2960.0,\"end\":2964.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":2965.0,\"end\":2969.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"}],\"ref_spans\":[],\"section\":\"Domain 4: Participation in disaster response and recovery\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1207-1211> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2722-2724> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2760-2764> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2965-2969> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1194-1196> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2719-2721> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1202-1206> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2725-2727> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1075-1078> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2733-2737> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2159-2161> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2747-2750> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2751-2754> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1191-1193> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1197-1201> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2955-2959> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1083-1085> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2765-2769> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2738-2742> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1382-1384> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2743-2746> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2755-2759> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2728-2732> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1611-1613> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1079-1082> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2960-2964> ;
            <http://www.example.org/section>
                    "Domain 4: Participation in disaster response and recovery" ;
            <http://www.example.org/text>  "In addition to playing a key role in preparing for mass casualty incidents, IPs will be essential to an effective response and recovery from an emergency. 11-13 IP's level of involvement will vary, depending on the type and scope of the event. Small incidents with no infectious disease cause will likely require little IP participation, whereas an infectious disease disaster will necessitate a great deal of time and input from IPs. The exact role of the IP in mass casualty incident response and recovery may vary from facility to facility; IPs need to verify their responsibilities by checking their facility emergency management plan for details. Regardless of the facility, or type or scope of the disaster, most IP's primary responsibility during a mass casualty incident will be to prevent and control infectious disease spread during the event. This will involve implementation of infection prevention strategies outlined in facility policies and procedures and the facility emergency management plan, as well as monitoring the effectiveness of these interventions. 10, 26, 35 In some facilities, IPs may be asked or expected to fulfill a role in the incident command system (ICS). 6, 9, [11] [12] [13] Hospitals and health care systems are required to manage all emergencies using structures and principles in accordance with NIMS, including the implementation of an ICS. 48 Development and implementation of an ICS for health care facilities is not within the scope of the IP's responsibilities. However, IPs may be designated by the health care facility as employees who need NIMS and ICS training. 48 This is most likely to occur in facilities that plan to utilize IPs as members of the ICS during a disaster. IPs should check with their facility emergency management committee to verify whether they will be assigned a position within the ICS during a disaster and require NIMS and ICS training. Regardless of whether or not an IP is assigned a position within the ICS, IPs will be expected to have a basic understanding of the system and be able to communicate important information concerning infection prevention through the proper channels. 12 Reporting events, communication, and coordination are vital components of disaster response and recovery and are functions that IPs will be expected to perform. Health care facility emergency management plans need to delineate procedures for reporting disasters internally and externally. IP involvement in developing reporting guidelines for most disasters, such as floods or fires, will not be needed. However, IP input will be vital when developing reporting protocols for all disasters involving an infectious agent, such as bioterrorism or a pandemic. 6, 8, 9, [11] [12] [13] 19, 26, 35, [37] [38] [39] Policies for internal reporting of infectious disease disasters should include, at the least, notification of the Infection Prevention and Control and/or Infectious Disease Department. [11] [12] [13] Other departments may also need notification, such as Nursing Services, Internal Medicine, Safety, and others. Rapid notification of the IP during any type of disaster is vital so that proper assessments can be made concerning the potential infectious disease implications of the event. Even events that might not seem to have an affect on infection transmission, such as a power outage, can cause unexpected complications that contribute to disease spread in health care facilities." ;
            <http://www.example.org/textHash>
                    "5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-610-612>
            <http://www.example.org/end>    "612.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "610.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"An important role of IPs is to help create or reform health care policy and practice related to emergency management. [9] [10] [11] 13, 16, 17, 26, 32 Many issues surrounding emergency management have potential policy implications, especially those involving creation of new standards and recommendations related to infection prevention during a mass casualty incident. Health care policy development needs to take place during emergency management planning; it will be much more difficult to implement change during disaster response. IPs should consult with facility emergency management planners and response agencies when developing and implementing emergency management plans to help shape decisions regarding how to prevent the spread of infections in all health care and community settings during mass casualty incidents. Health care policy needs to occur at the local, regional, state, and federal level. Most IPs will only be involved in policy development at the local level.\",\"cite_spans\":[{\"start\":118.0,\"end\":121.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":122.0,\"end\":126.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":127.0,\"end\":131.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":132.0,\"end\":135.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":136.0,\"end\":139.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":140.0,\"end\":143.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":144.0,\"end\":147.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":148.0,\"end\":150.0,\"text\":\"32\",\"ref_id\":\"BIBREF31\"}],\"ref_spans\":[],\"section\":\"Domain 5: Health care policy development\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-148-150> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-132-135> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-140-143> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-122-126> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-118-121> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-136-139> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-127-131> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-144-147> ;
            <http://www.example.org/section>
                    "Domain 5: Health care policy development" ;
            <http://www.example.org/text>  "An important role of IPs is to help create or reform health care policy and practice related to emergency management. [9] [10] [11] 13, 16, 17, 26, 32 Many issues surrounding emergency management have potential policy implications, especially those involving creation of new standards and recommendations related to infection prevention during a mass casualty incident. Health care policy development needs to take place during emergency management planning; it will be much more difficult to implement change during disaster response. IPs should consult with facility emergency management planners and response agencies when developing and implementing emergency management plans to help shape decisions regarding how to prevent the spread of infections in all health care and community settings during mass casualty incidents. Health care policy needs to occur at the local, regional, state, and federal level. Most IPs will only be involved in policy development at the local level." ;
            <http://www.example.org/textHash>
                    "58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-270-274>
            <http://www.example.org/end>    "274.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "270.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-858-861>
            <http://www.example.org/end>    "861.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "858.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Surveillance is a critical component of emergency management, especially for disasters involving a biologic agent. 6, [8] [9] [10] [11] [12] [13] 17, 25, 26, 32, 35, 39, 40 There are 2 types of surveillance programs needed for disasters: a system that aids in identifying a biologic event (ie, syndromic surveillance) and one to monitor an event once it has been identified. IPs need to be involved in the development of these surveillance programs to ensure that appropriate indicators are chosen. In addition, IPs need to assist in surveillance program evaluation to determine the effectiveness of the systems used. 10, 26, 35 In some facilities or communities, the IP may assist with data collection and reporting, but this is not required if a trained individual or group of people are available to do these functions. 11 In most communities, public health officials will be responsible for setting up and managing community-based surveillance programs. However, IP consultation may be needed when setting up surveillance in the community, such as in shelters for individuals displaced by the disaster and alternative care sites. 39 IPs need to communicate and coordinate with public health officials regarding setting up and managing/running surveillance systems for health care facilities and community settings.\",\"cite_spans\":[{\"start\":115.0,\"end\":117.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":118.0,\"end\":121.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":122.0,\"end\":125.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":126.0,\"end\":130.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":131.0,\"end\":135.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":136.0,\"end\":140.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":141.0,\"end\":145.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":146.0,\"end\":149.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":150.0,\"end\":153.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":154.0,\"end\":157.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":158.0,\"end\":161.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":162.0,\"end\":165.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":166.0,\"end\":169.0,\"text\":\"39,\",\"ref_id\":\"BIBREF39\"},{\"start\":170.0,\"end\":172.0,\"text\":\"40\",\"ref_id\":\"BIBREF40\"},{\"start\":618.0,\"end\":621.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":622.0,\"end\":625.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":626.0,\"end\":628.0,\"text\":\"35\",\"ref_id\":\"BIBREF34\"},{\"start\":823.0,\"end\":825.0,\"text\":\"11\",\"ref_id\":\"BIBREF10\"},{\"start\":1134.0,\"end\":1136.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[],\"section\":\"Domain 6: Surveillance\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-141-145> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-154-157> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-150-153> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-122-125> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-158-161> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-131-135> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-823-825> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-166-169> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-146-149> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-162-165> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-1134-1136> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-126-130> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-118-121> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-115-117> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-622-625> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-170-172> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-136-140> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-618-621> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-626-628> ;
            <http://www.example.org/section>
                    "Domain 6: Surveillance" ;
            <http://www.example.org/text>  "Surveillance is a critical component of emergency management, especially for disasters involving a biologic agent. 6, [8] [9] [10] [11] [12] [13] 17, 25, 26, 32, 35, 39, 40 There are 2 types of surveillance programs needed for disasters: a system that aids in identifying a biologic event (ie, syndromic surveillance) and one to monitor an event once it has been identified. IPs need to be involved in the development of these surveillance programs to ensure that appropriate indicators are chosen. In addition, IPs need to assist in surveillance program evaluation to determine the effectiveness of the systems used. 10, 26, 35 In some facilities or communities, the IP may assist with data collection and reporting, but this is not required if a trained individual or group of people are available to do these functions. 11 In most communities, public health officials will be responsible for setting up and managing community-based surveillance programs. However, IP consultation may be needed when setting up surveillance in the community, such as in shelters for individuals displaced by the disaster and alternative care sites. 39 IPs need to communicate and coordinate with public health officials regarding setting up and managing/running surveillance systems for health care facilities and community settings." ;
            <http://www.example.org/textHash>
                    "47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1085-1086>
            <http://www.example.org/end>    "1086.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "1085.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "3" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-752-755>
            <http://www.example.org/end>    "755.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "752.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-262-265>
            <http://www.example.org/end>    "265.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "262.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-895-899>
            <http://www.example.org/end>    "899.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "895.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1639-1643>
            <http://www.example.org/end>    "1643.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1639.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-343-347>
            <http://www.example.org/end>    "347.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "343.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-312-316>
            <http://www.example.org/end>    "316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "312.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2123-2126>
            <http://www.example.org/end>    "2126.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "2123.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-622-625>
            <http://www.example.org/end>    "625.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "622.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1001-1004>
            <http://www.example.org/end>    "1004.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "1001.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-516-519>
            <http://www.example.org/end>    "519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-364-368>
            <http://www.example.org/end>    "368.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3104-3108>
            <http://www.example.org/end>    "3108.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "3104.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-834-837>
            <http://www.example.org/end>    "837.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "834.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-528-531>
            <http://www.example.org/end>    "531.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "528.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-113-116>
            <http://www.example.org/end>    "116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "113.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1082-1085>
            <http://www.example.org/end>    "1085.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "1082.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-246-261>
            <http://www.example.org/end>    "261.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "246.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39 Isolation 6," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2135-2136>
            <http://www.example.org/end>    "2136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "2135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-45-48>
            <http://www.example.org/end>    "48.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "45.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_refspan-2254-2261>
            <http://www.example.org/end>    "2261.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF0" ;
            <http://www.example.org/start>  "2254.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 2" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2115-2119>
            <http://www.example.org/end>    "2119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "2115.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1674-1678>
            <http://www.example.org/end>    "1678.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1674.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-207-209>
            <http://www.example.org/end>    "209.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "207.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3986-3988>
            <http://www.example.org/end>    "3988.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "3986.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Infection transmission and infectious disease outbreaks can occur during or following any type of disaster. The greatest risk of infection transmission occurs during a disaster involving an infectious disease/agent (ie, an infectious disease disaster), such as a bioterrorism attack, outbreak of an emerging infectious disease, or pandemic. An infectious disease disaster can have a major impact on morbidity, mortality, and costs, regardless of whether it is an intentional event, such as bioterrorism, or a naturally occurring incident, such as a pandemic. For instance, the 2001 anthrax bioterrorism attack resulted in 22 cases of illness and 5 deaths and cost more than $2.5 billion. 1 Larger bioterrorism attacks or ones involving a communicable disease, such as smallpox, have the potential for an even greater public health impact. 2 The disaster that would likely result in the largest public health impact in terms of infectious disease-related morbidity, mortality, and costs would be a pandemic. The 1918 Spanish influenza pandemic caused 40 to 50 million deaths worldwide. 3 Estimated costs for a future pandemic range from $71 to $166 billion 4 and could require the need for 45 million additional outpatient visits to health care agencies and between 865,000 and 9,900,000 hospitalizations. 5 Even natural disasters can have a significant public health impact if infection prevention and control strategies are not implemented rapidly and appropriately. 6 Past natural disasters, such as Hurricane Katrina and other events requiring the sheltering of displaced individuals, resulted in infectious disease outbreaks because of overcrowding and the lack of hand hygiene or infection prevention procedures in shelters. 6, 7 Researchers who interviewed infection preventionists (IP) involved in past disaster response reported a variety of infection prevention issues that need to be addressed in future disasters. 6 Such topics include infection prevention for shelters; surveillance; occupational health during disasters; participation in the incident command structure; and need for patient, staff, and visitor education. 6 Historically, IPs have responded to health care-associated infections and public health infectious disease outbreaks. Toward the end of the 20th Century, many IPs expanded their role and became involved in bioterrorism preparedness planning. 8 More recent events, such as severe acute respiratory syndrome (SARS) and Hurricane Katrina, have illustrated the importance of IPs becoming involved in emergency management for all types of disasters to decrease secondary morbidity and mortality. The IP\\u0027s role in emergency management is considered to be essential, regardless of whether it is an infectious disease emergency or some other type of disaster. 6, [9] [10] [11] [12] [13] What is lacking is a delineation of the IP\\u0027s role in emergency management. 14 This is needed to help guide IPs as they are called to the emergency management table to help make important planning and response decisions.\",\"cite_spans\":[{\"start\":688.0,\"end\":689.0,\"text\":\"1\",\"ref_id\":\"BIBREF0\"},{\"start\":839.0,\"end\":840.0,\"text\":\"2\",\"ref_id\":\"BIBREF1\"},{\"start\":1085.0,\"end\":1086.0,\"text\":\"3\",\"ref_id\":\"BIBREF2\"},{\"start\":1156.0,\"end\":1157.0,\"text\":\"4\",\"ref_id\":\"BIBREF3\"},{\"start\":1305.0,\"end\":1306.0,\"text\":\"5\",\"ref_id\":\"BIBREF4\"},{\"start\":1468.0,\"end\":1469.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":1730.0,\"end\":1732.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1733.0,\"end\":1734.0,\"text\":\"7\",\"ref_id\":\"BIBREF6\"},{\"start\":1925.0,\"end\":1926.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":2135.0,\"end\":2136.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":2379.0,\"end\":2380.0,\"text\":\"8\",\"ref_id\":\"BIBREF7\"},{\"start\":2789.0,\"end\":2791.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":2792.0,\"end\":2795.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":2796.0,\"end\":2800.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":2801.0,\"end\":2805.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":2806.0,\"end\":2810.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":2811.0,\"end\":2815.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":2891.0,\"end\":2893.0,\"text\":\"14\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2811-2815> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1925-1926> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1085-1086> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-839-840> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2135-2136> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1468-1469> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2789-2791> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2796-2800> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1305-1306> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2806-2810> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2891-2893> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-688-689> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1733-1734> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2792-2795> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1730-1732> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2379-2380> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2801-2805> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1156-1157> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Infection transmission and infectious disease outbreaks can occur during or following any type of disaster. The greatest risk of infection transmission occurs during a disaster involving an infectious disease/agent (ie, an infectious disease disaster), such as a bioterrorism attack, outbreak of an emerging infectious disease, or pandemic. An infectious disease disaster can have a major impact on morbidity, mortality, and costs, regardless of whether it is an intentional event, such as bioterrorism, or a naturally occurring incident, such as a pandemic. For instance, the 2001 anthrax bioterrorism attack resulted in 22 cases of illness and 5 deaths and cost more than $2.5 billion. 1 Larger bioterrorism attacks or ones involving a communicable disease, such as smallpox, have the potential for an even greater public health impact. 2 The disaster that would likely result in the largest public health impact in terms of infectious disease-related morbidity, mortality, and costs would be a pandemic. The 1918 Spanish influenza pandemic caused 40 to 50 million deaths worldwide. 3 Estimated costs for a future pandemic range from $71 to $166 billion 4 and could require the need for 45 million additional outpatient visits to health care agencies and between 865,000 and 9,900,000 hospitalizations. 5 Even natural disasters can have a significant public health impact if infection prevention and control strategies are not implemented rapidly and appropriately. 6 Past natural disasters, such as Hurricane Katrina and other events requiring the sheltering of displaced individuals, resulted in infectious disease outbreaks because of overcrowding and the lack of hand hygiene or infection prevention procedures in shelters. 6, 7 Researchers who interviewed infection preventionists (IP) involved in past disaster response reported a variety of infection prevention issues that need to be addressed in future disasters. 6 Such topics include infection prevention for shelters; surveillance; occupational health during disasters; participation in the incident command structure; and need for patient, staff, and visitor education. 6 Historically, IPs have responded to health care-associated infections and public health infectious disease outbreaks. Toward the end of the 20th Century, many IPs expanded their role and became involved in bioterrorism preparedness planning. 8 More recent events, such as severe acute respiratory syndrome (SARS) and Hurricane Katrina, have illustrated the importance of IPs becoming involved in emergency management for all types of disasters to decrease secondary morbidity and mortality. The IP's role in emergency management is considered to be essential, regardless of whether it is an infectious disease emergency or some other type of disaster. 6, [9] [10] [11] [12] [13] What is lacking is a delineation of the IP's role in emergency management. 14 This is needed to help guide IPs as they are called to the emergency management table to help make important planning and response decisions." ;
            <http://www.example.org/textHash>
                    "de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1064-1068>
            <http://www.example.org/end>    "1068.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1064.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1031-1033>
            <http://www.example.org/end>    "1033.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "1031.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-496-500>
            <http://www.example.org/end>    "500.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "496.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1017-1019>
            <http://www.example.org/end>    "1019.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1017.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3370-3373>
            <http://www.example.org/end>    "3373.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "3370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-949-952>
            <http://www.example.org/end>    "952.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "949.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-388-392>
            <http://www.example.org/end>    "392.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "388.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[32]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3114-3117>
            <http://www.example.org/end>    "3117.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "3114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-141-145>
            <http://www.example.org/end>    "145.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "141.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2891-2893>
            <http://www.example.org/end>    "2893.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "2891.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1009-1012>
            <http://www.example.org/end>    "1012.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "1009.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2107-2110>
            <http://www.example.org/end>    "2110.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2107.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-452-454>
            <http://www.example.org/end>    "454.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "452.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3343-3347>
            <http://www.example.org/end>    "3347.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "3343.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-205-209>
            <http://www.example.org/end>    "209.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "205.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-125-127>
            <http://www.example.org/end>    "127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "125.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1127-1131>
            <http://www.example.org/end>    "1131.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-738-742>
            <http://www.example.org/end>    "742.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "738.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-132-135>
            <http://www.example.org/end>    "135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "132.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1074-1077>
            <http://www.example.org/end>    "1077.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "1074.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-915-918>
            <http://www.example.org/end>    "918.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "915.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-398-402>
            <http://www.example.org/end>    "402.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "398.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[34]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-221-223>
            <http://www.example.org/end>    "223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "221.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-177-179>
            <http://www.example.org/end>    "179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "177.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-927-930>
            <http://www.example.org/end>    "930.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "927.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-171-175>
            <http://www.example.org/end>    "175.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "171.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1925-1926>
            <http://www.example.org/end>    "1926.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1925.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-387-390>
            <http://www.example.org/end>    "390.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-950-953>
            <http://www.example.org/end>    "953.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "950.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-194-197>
            <http://www.example.org/end>    "197.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "34," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-634-637>
            <http://www.example.org/end>    "637.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "634.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3362-3365>
            <http://www.example.org/end>    "3365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "3362.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-122-125>
            <http://www.example.org/end>    "125.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-225-229>
            <http://www.example.org/end>    "229.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "225.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[14]" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-151-155>
            <http://www.example.org/end>    "155.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "151.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1136-1139>
            <http://www.example.org/end>    "1139.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "1136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"IPs need to be prepared for mass casualty events on a personal level, which includes having a personal/ family response plan and knowing their role in their workplace\\u0027s emergency management plan. It is important that IPs have a personal/family response plan for disasters that accommodates their specific needs. [11] [12] [13] 28, 29, 34 Individual strategies will vary, but there are essential components that need to be addressed, such as arrangements for back-up food and water supplies; alternative means of child, elderly individuals, or pet care; and transportation during nonnormal working hours. 41 IPs also are responsible for knowing their role in their workplace\\u0027s emergency management plan. 12, 13 Guidelines for the content of IP\\u0027s personal response plans have not been outlined in the literature, although necessary components of response plans have been described for the general public by agencies such as the Federal Emergency Management Agency. 42 In addition, IPs may have unique needs that the general public will not have, such as the ability to stay at work for extended periods of time if a work quarantine is implemented. 29 Each IP must assess their own family\\u0027s needs when developing a personal/family response plan for disasters.\",\"cite_spans\":[{\"start\":312.0,\"end\":316.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":317.0,\"end\":321.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":322.0,\"end\":326.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":327.0,\"end\":330.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":331.0,\"end\":334.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":335.0,\"end\":337.0,\"text\":\"34\",\"ref_id\":\"BIBREF33\"},{\"start\":604.0,\"end\":606.0,\"text\":\"41\",\"ref_id\":\"BIBREF41\"},{\"start\":703.0,\"end\":706.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":707.0,\"end\":709.0,\"text\":\"13\",\"ref_id\":\"BIBREF12\"},{\"start\":963.0,\"end\":965.0,\"text\":\"42\",\"ref_id\":\"BIBREF42\"},{\"start\":1146.0,\"end\":1148.0,\"text\":\"29\",\"ref_id\":\"BIBREF28\"}],\"ref_spans\":[],\"section\":\"Domain 1: Knowledge of disasters and emergency management\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-317-321> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-1146-1148> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-703-706> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-322-326> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-604-606> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-335-337> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-331-334> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-963-965> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-312-316> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-327-330> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-707-709> ;
            <http://www.example.org/section>
                    "Domain 1: Knowledge of disasters and emergency management" ;
            <http://www.example.org/text>  "IPs need to be prepared for mass casualty events on a personal level, which includes having a personal/ family response plan and knowing their role in their workplace's emergency management plan. It is important that IPs have a personal/family response plan for disasters that accommodates their specific needs. [11] [12] [13] 28, 29, 34 Individual strategies will vary, but there are essential components that need to be addressed, such as arrangements for back-up food and water supplies; alternative means of child, elderly individuals, or pet care; and transportation during nonnormal working hours. 41 IPs also are responsible for knowing their role in their workplace's emergency management plan. 12, 13 Guidelines for the content of IP's personal response plans have not been outlined in the literature, although necessary components of response plans have been described for the general public by agencies such as the Federal Emergency Management Agency. 42 In addition, IPs may have unique needs that the general public will not have, such as the ability to stay at work for extended periods of time if a work quarantine is implemented. 29 Each IP must assess their own family's needs when developing a personal/family response plan for disasters." ;
            <http://www.example.org/textHash>
                    "15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-532-534>
            <http://www.example.org/end>    "534.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "532.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "47" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3997-4000>
            <http://www.example.org/end>    "4000.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "3997.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40," .
    
    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-1512-1514>
            <http://www.example.org/end>    "1514.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "1512.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-854-856>
            <http://www.example.org/end>    "856.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "854.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-638-640>
            <http://www.example.org/end>    "640.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "638.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2738-2742>
            <http://www.example.org/end>    "2742.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2738.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-719-722>
            <http://www.example.org/end>    "722.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "719.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-805-808>
            <http://www.example.org/end>    "808.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "805.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-975-978>
            <http://www.example.org/end>    "978.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "975.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1561-1564>
            <http://www.example.org/end>    "1564.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "1561.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-817-820>
            <http://www.example.org/end>    "820.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "817.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2537-2539>
            <http://www.example.org/end>    "2539.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "2537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-979-981>
            <http://www.example.org/end>    "981.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "979.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1053-1057>
            <http://www.example.org/end>    "1057.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1053.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-122-126>
            <http://www.example.org/end>    "126.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-156-158>
            <http://www.example.org/end>    "158.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-97-101>
            <http://www.example.org/end>    "101.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "97.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2529-2532>
            <http://www.example.org/end>    "2532.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2529.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3485-3488>
            <http://www.example.org/end>    "3488.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "3485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1611-1613>
            <http://www.example.org/end>    "1613.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF48" ;
            <http://www.example.org/start>  "1611.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "48" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-492-495>
            <http://www.example.org/end>    "495.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "492.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-132-135>
            <http://www.example.org/end>    "135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "132.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-415-419>
            <http://www.example.org/end>    "419.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "415.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[28]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-573-577>
            <http://www.example.org/end>    "577.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "573.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-511-515>
            <http://www.example.org/end>    "515.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "511.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-621-625>
            <http://www.example.org/end>    "625.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "621.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2112-2114>
            <http://www.example.org/end>    "2114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "2112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2096-2100>
            <http://www.example.org/end>    "2100.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2096.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-63-67>
            <http://www.example.org/end>    "67.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "63.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-577-581>
            <http://www.example.org/end>    "581.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "577.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[45]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-130-134>
            <http://www.example.org/end>    "134.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "130.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-49-52>
            <http://www.example.org/end>    "52.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "49.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3452-3456>
            <http://www.example.org/end>    "3456.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "3452.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-874-878>
            <http://www.example.org/end>    "878.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "874.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-508-511>
            <http://www.example.org/end>    "511.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1072-1075>
            <http://www.example.org/end>    "1075.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "1072.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-162-165>
            <http://www.example.org/end>    "165.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "162.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1553-1556>
            <http://www.example.org/end>    "1556.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "1553.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1730-1732>
            <http://www.example.org/end>    "1732.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1730.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-183-186>
            <http://www.example.org/end>    "186.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-604-606>
            <http://www.example.org/end>    "606.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "604.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2110-2113>
            <http://www.example.org/end>    "2113.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "2110.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-832-834>
            <http://www.example.org/end>    "834.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "832.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-703-706>
            <http://www.example.org/end>    "706.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "703.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1669-1673>
            <http://www.example.org/end>    "1673.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1669.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1385-1387>
            <http://www.example.org/end>    "1387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-961-965>
            <http://www.example.org/end>    "965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "961.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-850-853>
            <http://www.example.org/end>    "853.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "850.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-641-645>
            <http://www.example.org/end>    "645.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "641.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[34]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-198-202>
            <http://www.example.org/end>    "202.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-238-241>
            <http://www.example.org/end>    "241.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "238.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-949-951>
            <http://www.example.org/end>    "951.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "949.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "36" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-443-447>
            <http://www.example.org/end>    "447.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "443.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-896-900>
            <http://www.example.org/end>    "900.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "896.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2101-2105>
            <http://www.example.org/end>    "2105.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2101.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-791-793>
            <http://www.example.org/end>    "793.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "791.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2792-2795>
            <http://www.example.org/end>    "2795.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "2792.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1377-1380>
            <http://www.example.org/end>    "1380.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "1377.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-979-981>
            <http://www.example.org/end>    "981.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "979.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2158-2162>
            <http://www.example.org/end>    "2162.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "2158.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[40]" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-75-79>
            <http://www.example.org/end>    "79.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "75.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-520-522>
            <http://www.example.org/end>    "522.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-839-840>
            <http://www.example.org/end>    "840.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "839.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "2" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-110-112>
            <http://www.example.org/end>    "112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "110.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-891-894>
            <http://www.example.org/end>    "894.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "891.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-285-289>
            <http://www.example.org/end>    "289.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f60ca261ea1e36be208e2447d3e884811b41b4fd875c32070d415b60928cb5e8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A literature review was conducted in September 2008 using the Cumulative Index to Nursing and Allied Health Literature, Healthstar, Psych Info, and Medline databases for years 1966 through 2008. The following terms were utilized as keyword searches: infection control, infection prevention, disaster, mass casualties, bioterrorism, pandemic, disaster planning, and emergency management. Only English language articles in peer-reviewed journals were utilized; articles that described hospital, community, or noninfection prevention professional preparedness were excluded unless they addressed some aspect of the IP\\u0027s role in emergency management. Seven hundred eighty-four references were identified and reviewed for relevance; most were eliminated based on the title or journal (nonpeer reviewed or did not meet inclusion criteria) alone. Three hundred sixty-six references were screened by reading the abstract. Of those screened, 21 articles were deemed relevant and were analyzed in their entirety. In addition, 13 Internet sources were used.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Literature review\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Literature review" ;
            <http://www.example.org/text>  "A literature review was conducted in September 2008 using the Cumulative Index to Nursing and Allied Health Literature, Healthstar, Psych Info, and Medline databases for years 1966 through 2008. The following terms were utilized as keyword searches: infection control, infection prevention, disaster, mass casualties, bioterrorism, pandemic, disaster planning, and emergency management. Only English language articles in peer-reviewed journals were utilized; articles that described hospital, community, or noninfection prevention professional preparedness were excluded unless they addressed some aspect of the IP's role in emergency management. Seven hundred eighty-four references were identified and reviewed for relevance; most were eliminated based on the title or journal (nonpeer reviewed or did not meet inclusion criteria) alone. Three hundred sixty-six references were screened by reading the abstract. Of those screened, 21 articles were deemed relevant and were analyzed in their entirety. In addition, 13 Internet sources were used." ;
            <http://www.example.org/textHash>
                    "f60ca261ea1e36be208e2447d3e884811b41b4fd875c32070d415b60928cb5e8" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-855-858>
            <http://www.example.org/end>    "858.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "855.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-427-429>
            <http://www.example.org/end>    "429.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "427.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1666-1669>
            <http://www.example.org/end>    "1669.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "1666.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-910-914>
            <http://www.example.org/end>    "914.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "910.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2796-2800>
            <http://www.example.org/end>    "2800.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "2796.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-42-44>
            <http://www.example.org/end>    "44.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "42.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2508-2510>
            <http://www.example.org/end>    "2510.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF51" ;
            <http://www.example.org/start>  "2508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "51" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1873-1877>
            <http://www.example.org/end>    "1877.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1873.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-127-131>
            <http://www.example.org/end>    "131.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-305-308>
            <http://www.example.org/end>    "308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "305.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1374-1377>
            <http://www.example.org/end>    "1377.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1374.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-748-751>
            <http://www.example.org/end>    "751.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "748.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2085-2087>
            <http://www.example.org/end>    "2087.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "2085.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-6cba40af069e925029d25f6fff9468fb77b62ae28cd1c2d84b3e8bc74f1e05e9_citespan-822-824>
            <http://www.example.org/end>    "824.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "822.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-862-864>
            <http://www.example.org/end>    "864.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "862.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40" .
    
    <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-309-311>
            <http://www.example.org/end>    "311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "309.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-618-621>
            <http://www.example.org/end>    "621.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "618.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-161-163>
            <http://www.example.org/end>    "163.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1892-1894>
            <http://www.example.org/end>    "1894.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1892.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-89-92>
            <http://www.example.org/end>    "92.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "89.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-733-737>
            <http://www.example.org/end>    "737.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "733.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-578-580>
            <http://www.example.org/end>    "580.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "578.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-992-996>
            <http://www.example.org/end>    "996.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "992.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3802-3804>
            <http://www.example.org/end>    "3804.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "3802.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-169-173>
            <http://www.example.org/end>    "173.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "169.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-109-112>
            <http://www.example.org/end>    "112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "109.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2801-2805>
            <http://www.example.org/end>    "2805.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "2801.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2143-2147>
            <http://www.example.org/end>    "2147.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "2143.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-756-759>
            <http://www.example.org/end>    "759.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "756.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-887-890>
            <http://www.example.org/end>    "890.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "887.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-266-269>
            <http://www.example.org/end>    "269.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "266.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-161-164>
            <http://www.example.org/end>    "164.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-798-801>
            <http://www.example.org/end>    "801.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "798.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-976-978>
            <http://www.example.org/end>    "978.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "976.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-963-965>
            <http://www.example.org/end>    "965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF42" ;
            <http://www.example.org/start>  "963.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "42" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-328-332>
            <http://www.example.org/end>    "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "328.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1151-1155>
            <http://www.example.org/end>    "1155.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1151.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-532-535>
            <http://www.example.org/end>    "535.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "532.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2667-2671>
            <http://www.example.org/end>    "2671.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "2667.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1075-1078>
            <http://www.example.org/end>    "1078.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1075.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-327-330>
            <http://www.example.org/end>    "330.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "327.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-410-414>
            <http://www.example.org/end>    "414.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "410.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[27]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1634-1638>
            <http://www.example.org/end>    "1638.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1634.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2159-2161>
            <http://www.example.org/end>    "2161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2159.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-360-364>
            <http://www.example.org/end>    "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "360.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[17]" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-238-240>
            <http://www.example.org/end>    "240.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "238.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "40" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1382-1384>
            <http://www.example.org/end>    "1384.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF48" ;
            <http://www.example.org/start>  "1382.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "48" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-467-469>
            <http://www.example.org/end>    "469.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "467.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-812-816>
            <http://www.example.org/end>    "816.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "812.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_refspan-951-958>
            <http://www.example.org/end>    "958.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "951.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 4" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-953-955>
            <http://www.example.org/end>    "955.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF49" ;
            <http://www.example.org/start>  "953.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "49" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-213-216>
            <http://www.example.org/end>    "216.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "213.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-463-467>
            <http://www.example.org/end>    "467.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[44]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_refspan-313-320>
            <http://www.example.org/end>    "320.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "313.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 4" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4817-4819>
            <http://www.example.org/end>    "4819.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "4817.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1145-1149>
            <http://www.example.org/end>    "1149.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "1145.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-858-860>
            <http://www.example.org/end>    "860.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "858.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28" .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-312-316>
            <http://www.example.org/end>    "316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "312.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-51-54>
            <http://www.example.org/end>    "54.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "51.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2811-2815>
            <http://www.example.org/end>    "2815.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2811.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Research indicates that the environment can play a part in infection transmission. 50 This is especially true in mass casualty events when bioburden may be higher than usual, staff shortages may prevent adequate environmental decontamination, and cleaning/disinfection products may be limited. 11, 12 IPs need to consult with facility emergency management planners, facilities engineering, and response agencies regarding assessing the physical plant for potential infectious disease implications and implementation of environmental controls for mass casualty incidents. 6.9,11-13,28,30,32,38,39 Examples of physical plant issues that have potential infectious disease implications include having sufficient airborne infectious isolation rooms or negative-pressure rooms/areas, procedures for environmental decontamination, and protocols for reprocessing of patient care equipment. Assessing the physical plant for potential infectious disease hazards and implementing prevention and control measures are important for all mass casualty incidents. However, certain disasters pose a greater risk of environmental contamination and need for intervention than other emergencies. For instance, environmental decontamination will be most critical after a flood or an outbreak of an infectious disease (such as smallpox or SARS) that is spread by direct and indirect contact. 11, 12, 38 IP input will also be important for making decision regarding when to reopen a room, floor, or building after it has been closed for a length of time and procedures to follow before patients are admitted to those areas. 11, 12 These decisions need to be made by a multidisciplinary team, such as the health care facility emergency management planning committee, of which the IP should be a member. A newly identified issue in emergency management that requires IP input is the need for policies related to pet management in health care facilities during disasters. 39, 51, 52 This is different from the issue of managing service animals or those involved in animal-assisted interventions in health care settings, which has long been identified as an infection prevention issue. 53 Pet management for community shelters and hospitals became an issue in 2005 during Hurricane Katrina when displaced individuals brought their pets with them to evacuation centers and hospital staff brought their pets with them to work. 39, 52 Many community shelters and all hospitals cannot accept pets because of health and safety regulations. 51 IPs should assist in development of community and health care facility emergency management policies related to pet management. This may include coordination with local and state animal rescue agencies or area veterinary services to provide shelter for pets.\",\"cite_spans\":[{\"start\":83.0,\"end\":85.0,\"text\":\"50\",\"ref_id\":\"BIBREF50\"},{\"start\":294.0,\"end\":297.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":298.0,\"end\":300.0,\"text\":\"12\",\"ref_id\":\"BIBREF11\"},{\"start\":571.0,\"end\":595.0,\"text\":\"6.9,11-13,28,30,32,38,39\"},{\"start\":1370.0,\"end\":1373.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":1374.0,\"end\":1377.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":1378.0,\"end\":1380.0,\"text\":\"38\",\"ref_id\":\"BIBREF38\"},{\"start\":1601.0,\"end\":1604.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":1605.0,\"end\":1607.0,\"text\":\"12\",\"ref_id\":\"BIBREF11\"},{\"start\":1946.0,\"end\":1949.0,\"text\":\"39,\",\"ref_id\":\"BIBREF39\"},{\"start\":1950.0,\"end\":1953.0,\"text\":\"51,\",\"ref_id\":\"BIBREF51\"},{\"start\":1954.0,\"end\":1956.0,\"text\":\"52\",\"ref_id\":\"BIBREF52\"},{\"start\":2159.0,\"end\":2161.0,\"text\":\"53\",\"ref_id\":\"BIBREF53\"},{\"start\":2398.0,\"end\":2401.0,\"text\":\"39,\",\"ref_id\":\"BIBREF39\"},{\"start\":2402.0,\"end\":2404.0,\"text\":\"52\",\"ref_id\":\"BIBREF52\"},{\"start\":2508.0,\"end\":2510.0,\"text\":\"51\",\"ref_id\":\"BIBREF51\"}],\"ref_spans\":[],\"section\":\"Domain 8: Physical plant issues\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1954-1956> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1378-1380> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2398-2401> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1601-1604> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-83-85> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-571-595> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1370-1373> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-298-300> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1950-1953> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-294-297> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2159-2161> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2402-2404> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1946-1949> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1374-1377> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2508-2510> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1605-1607> ;
            <http://www.example.org/section>
                    "Domain 8: Physical plant issues" ;
            <http://www.example.org/text>  "Research indicates that the environment can play a part in infection transmission. 50 This is especially true in mass casualty events when bioburden may be higher than usual, staff shortages may prevent adequate environmental decontamination, and cleaning/disinfection products may be limited. 11, 12 IPs need to consult with facility emergency management planners, facilities engineering, and response agencies regarding assessing the physical plant for potential infectious disease implications and implementation of environmental controls for mass casualty incidents. 6.9,11-13,28,30,32,38,39 Examples of physical plant issues that have potential infectious disease implications include having sufficient airborne infectious isolation rooms or negative-pressure rooms/areas, procedures for environmental decontamination, and protocols for reprocessing of patient care equipment. Assessing the physical plant for potential infectious disease hazards and implementing prevention and control measures are important for all mass casualty incidents. However, certain disasters pose a greater risk of environmental contamination and need for intervention than other emergencies. For instance, environmental decontamination will be most critical after a flood or an outbreak of an infectious disease (such as smallpox or SARS) that is spread by direct and indirect contact. 11, 12, 38 IP input will also be important for making decision regarding when to reopen a room, floor, or building after it has been closed for a length of time and procedures to follow before patients are admitted to those areas. 11, 12 These decisions need to be made by a multidisciplinary team, such as the health care facility emergency management planning committee, of which the IP should be a member. A newly identified issue in emergency management that requires IP input is the need for policies related to pet management in health care facilities during disasters. 39, 51, 52 This is different from the issue of managing service animals or those involved in animal-assisted interventions in health care settings, which has long been identified as an infection prevention issue. 53 Pet management for community shelters and hospitals became an issue in 2005 during Hurricane Katrina when displaced individuals brought their pets with them to evacuation centers and hospital staff brought their pets with them to work. 39, 52 Many community shelters and all hospitals cannot accept pets because of health and safety regulations. 51 IPs should assist in development of community and health care facility emergency management policies related to pet management. This may include coordination with local and state animal rescue agencies or area veterinary services to provide shelter for pets." ;
            <http://www.example.org/textHash>
                    "d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2120-2124>
            <http://www.example.org/end>    "2124.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2120.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-430-434>
            <http://www.example.org/end>    "434.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "430.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[31]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-668-670>
            <http://www.example.org/end>    "670.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "668.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-302-306>
            <http://www.example.org/end>    "306.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "302.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-190-193>
            <http://www.example.org/end>    "193.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "190.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-607-611>
            <http://www.example.org/end>    "611.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "607.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-380-384>
            <http://www.example.org/end>    "384.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "380.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[21]" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-524-527>
            <http://www.example.org/end>    "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "524.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-126-130>
            <http://www.example.org/end>    "130.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "126.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-194-196>
            <http://www.example.org/end>    "196.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3989-3992>
            <http://www.example.org/end>    "3992.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "3989.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14," .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-136-139>
            <http://www.example.org/end>    "139.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2088-2090>
            <http://www.example.org/end>    "2090.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "2088.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3494-3498>
            <http://www.example.org/end>    "3498.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "3494.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-514-516>
            <http://www.example.org/end>    "516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "514.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2765-2769>
            <http://www.example.org/end>    "2769.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "2765.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1013-1016>
            <http://www.example.org/end>    "1016.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1013.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-711-713>
            <http://www.example.org/end>    "713.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "711.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Having around the clock infection control coverage 27, 29, 47 Facility assessment/hazard vulnerability assessment 9, [11] [12] [13] Participation in disaster drills involving a biologic agent 6, 9, [11] [12] [13] 28, 29, 39 Strategies for receiving and posting health alert messages within the facility 29 Negative-pressure surge capacity 27, 29, 38, 39 Safe patient specimen collection procedures 9, 11, 32 Patient management 6, 9, [11] [12] [13] 38, 39 Food safety 6, [11] [12] [13] 39 Water management 6, 12, 13, 28, 39 Sanitation control 12, 13, 39 Pet management 39 Environmental decontamination 6, 9, [11] [12] [13] 28, 30, 32, 38, 39 Development of crisis standards of care that affect infection transmission 6, [9] [10] [11] [12] [13] [14] 16, 25, 29, 31, 38, 39 Prioritization for limited supplies of antiinfective therapy 9, [11] [12] [13] 26, 39 Screening/triage protocols 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Occupational health/safety procedures 6, 9, [11] [12] [13] 26, 28, 32, 35, 37, 39 Outbreak investigation coordination 6, [11] [12] [13] 19, 25, 31, 32, 35, [37] [38] [39] resources during a disaster, infection prevention coverage in nonhospital settings may need to be assigned to an infection prevention designee. 6, 28, 39 If an infection prevention designee is to be used, this individual or group of workers should receive training in infection prevention principles and practice before a disaster. In addition, an IP should be involved or consulted when setting up the infection prevention program for all health care settings to ensure that appropriate standards are implemented, even if an infection prevention designee will be responsible for managing the program during a disaster. 39 Identifying IP coverage and/or infection prevention designee(s) for nonhospital settings should be coordinated with local health care facilities and public health communicable disease officials who may be aware of additional local/regional resources to assist. 39\",\"cite_spans\":[{\"start\":51.0,\"end\":54.0,\"text\":\"27,\",\"ref_id\":\"BIBREF26\"},{\"start\":55.0,\"end\":58.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":59.0,\"end\":61.0,\"text\":\"47\",\"ref_id\":\"BIBREF47\"},{\"start\":114.0,\"end\":116.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":117.0,\"end\":121.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":122.0,\"end\":126.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":127.0,\"end\":131.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":192.0,\"end\":194.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":195.0,\"end\":197.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":198.0,\"end\":202.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":203.0,\"end\":207.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":208.0,\"end\":212.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":213.0,\"end\":216.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":217.0,\"end\":220.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":221.0,\"end\":223.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":339.0,\"end\":342.0,\"text\":\"27,\",\"ref_id\":\"BIBREF26\"},{\"start\":343.0,\"end\":346.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":347.0,\"end\":350.0,\"text\":\"38,\",\"ref_id\":\"BIBREF38\"},{\"start\":351.0,\"end\":353.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":398.0,\"end\":400.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":401.0,\"end\":404.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":405.0,\"end\":407.0,\"text\":\"32\",\"ref_id\":\"BIBREF31\"},{\"start\":427.0,\"end\":429.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":430.0,\"end\":432.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":433.0,\"end\":437.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":438.0,\"end\":442.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":443.0,\"end\":447.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":448.0,\"end\":451.0,\"text\":\"38,\",\"ref_id\":\"BIBREF38\"},{\"start\":452.0,\"end\":454.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":467.0,\"end\":469.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":470.0,\"end\":474.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":475.0,\"end\":479.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":480.0,\"end\":484.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":485.0,\"end\":487.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":505.0,\"end\":507.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":508.0,\"end\":511.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":512.0,\"end\":515.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":516.0,\"end\":519.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":520.0,\"end\":522.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":542.0,\"end\":545.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":546.0,\"end\":549.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":550.0,\"end\":552.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":568.0,\"end\":570.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":601.0,\"end\":603.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":604.0,\"end\":606.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":607.0,\"end\":611.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":612.0,\"end\":616.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":617.0,\"end\":621.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":622.0,\"end\":625.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":626.0,\"end\":629.0,\"text\":\"30,\",\"ref_id\":\"BIBREF29\"},{\"start\":630.0,\"end\":633.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":634.0,\"end\":637.0,\"text\":\"38,\",\"ref_id\":\"BIBREF38\"},{\"start\":638.0,\"end\":640.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":716.0,\"end\":718.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":719.0,\"end\":722.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":723.0,\"end\":727.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":728.0,\"end\":732.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":733.0,\"end\":737.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":738.0,\"end\":742.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":743.0,\"end\":747.0,\"text\":\"[14]\",\"ref_id\":\"BIBREF13\"},{\"start\":748.0,\"end\":751.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":752.0,\"end\":755.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":756.0,\"end\":759.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":760.0,\"end\":763.0,\"text\":\"31,\",\"ref_id\":\"BIBREF30\"},{\"start\":764.0,\"end\":767.0,\"text\":\"38,\",\"ref_id\":\"BIBREF38\"},{\"start\":768.0,\"end\":770.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":832.0,\"end\":834.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":835.0,\"end\":839.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":840.0,\"end\":844.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":845.0,\"end\":849.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":850.0,\"end\":853.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":854.0,\"end\":856.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":884.0,\"end\":886.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":887.0,\"end\":890.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":891.0,\"end\":894.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":895.0,\"end\":899.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":900.0,\"end\":904.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":905.0,\"end\":909.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":910.0,\"end\":914.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":915.0,\"end\":918.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":919.0,\"end\":922.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":923.0,\"end\":926.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":927.0,\"end\":930.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":931.0,\"end\":934.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":935.0,\"end\":937.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":976.0,\"end\":978.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":979.0,\"end\":981.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":982.0,\"end\":986.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":987.0,\"end\":991.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":992.0,\"end\":996.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":997.0,\"end\":1000.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":1001.0,\"end\":1004.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":1005.0,\"end\":1008.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":1009.0,\"end\":1012.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":1013.0,\"end\":1016.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":1017.0,\"end\":1019.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1056.0,\"end\":1058.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1059.0,\"end\":1063.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1064.0,\"end\":1068.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1069.0,\"end\":1073.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1074.0,\"end\":1077.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":1078.0,\"end\":1081.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":1082.0,\"end\":1085.0,\"text\":\"31,\",\"ref_id\":\"BIBREF30\"},{\"start\":1086.0,\"end\":1089.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":1090.0,\"end\":1093.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":1094.0,\"end\":1098.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":1099.0,\"end\":1103.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":1104.0,\"end\":1108.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":1253.0,\"end\":1255.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1256.0,\"end\":1259.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":1260.0,\"end\":1262.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1729.0,\"end\":1731.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[],\"section\":\"Issue/topic requiring infection prevention input\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-114-116> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1017-1019> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-850-853> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1064-1068> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-987-991> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-448-451> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-743-747> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-398-400> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-117-121> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-568-570> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-213-216> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1001-1004> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-55-58> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-748-751> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-997-1000> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-935-937> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-854-856> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-467-469> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-443-447> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-203-207> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-122-126> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-634-637> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-891-894> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-430-432> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-845-849> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1059-1063> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-884-886> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-485-487> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1256-1259> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-887-890> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-192-194> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-622-625> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1074-1077> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-339-342> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-516-519> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1099-1103> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-900-904> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1094-1098> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-756-759> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-905-909> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-612-616> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-480-484> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1729-1731> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1005-1008> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-716-718> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-195-197> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-438-442> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1069-1073> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-723-727> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-910-914> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-208-212> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-405-407> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1082-1085> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-127-131> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-719-722> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-604-606> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-979-981> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-343-346> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1013-1016> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-470-474> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-433-437> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-427-429> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-607-611> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-520-522> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-475-479> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-626-629> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1104-1108> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-542-545> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-752-755> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-51-54> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-923-926> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-835-839> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-351-353> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-768-770> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-508-511> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-915-918> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-927-930> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-601-603> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-738-742> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-198-202> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-512-515> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-546-549> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1086-1089> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-505-507> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-832-834> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-982-986> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-617-621> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-733-737> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1253-1255> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-840-844> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-630-633> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-221-223> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-764-767> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1260-1262> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1078-1081> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-638-640> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-760-763> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-992-996> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-976-978> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-347-350> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1009-1012> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-550-552> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-59-61> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-895-899> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-452-454> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-217-220> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1056-1058> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-401-404> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-919-922> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1090-1093> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-931-934> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-728-732> ;
            <http://www.example.org/section>
                    "Issue/topic requiring infection prevention input" ;
            <http://www.example.org/text>  "Having around the clock infection control coverage 27, 29, 47 Facility assessment/hazard vulnerability assessment 9, [11] [12] [13] Participation in disaster drills involving a biologic agent 6, 9, [11] [12] [13] 28, 29, 39 Strategies for receiving and posting health alert messages within the facility 29 Negative-pressure surge capacity 27, 29, 38, 39 Safe patient specimen collection procedures 9, 11, 32 Patient management 6, 9, [11] [12] [13] 38, 39 Food safety 6, [11] [12] [13] 39 Water management 6, 12, 13, 28, 39 Sanitation control 12, 13, 39 Pet management 39 Environmental decontamination 6, 9, [11] [12] [13] 28, 30, 32, 38, 39 Development of crisis standards of care that affect infection transmission 6, [9] [10] [11] [12] [13] [14] 16, 25, 29, 31, 38, 39 Prioritization for limited supplies of antiinfective therapy 9, [11] [12] [13] 26, 39 Screening/triage protocols 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Occupational health/safety procedures 6, 9, [11] [12] [13] 26, 28, 32, 35, 37, 39 Outbreak investigation coordination 6, [11] [12] [13] 19, 25, 31, 32, 35, [37] [38] [39] resources during a disaster, infection prevention coverage in nonhospital settings may need to be assigned to an infection prevention designee. 6, 28, 39 If an infection prevention designee is to be used, this individual or group of workers should receive training in infection prevention principles and practice before a disaster. In addition, an IP should be involved or consulted when setting up the infection prevention program for all health care settings to ensure that appropriate standards are implemented, even if an infection prevention designee will be responsible for managing the program during a disaster. 39 Identifying IP coverage and/or infection prevention designee(s) for nonhospital settings should be coordinated with local health care facilities and public health communicable disease officials who may be aware of additional local/regional resources to assist. 39" ;
            <http://www.example.org/textHash>
                    "f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-495-497>
            <http://www.example.org/end>    "497.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "495.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-801-804>
            <http://www.example.org/end>    "804.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "801.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2686-2688>
            <http://www.example.org/end>    "2688.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "2686.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-971-974>
            <http://www.example.org/end>    "974.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "971.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1140-1144>
            <http://www.example.org/end>    "1144.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1140.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1870-1872>
            <http://www.example.org/end>    "1872.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-125-129>
            <http://www.example.org/end>    "129.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "125.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1867-1869>
            <http://www.example.org/end>    "1869.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1867.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1358-1361>
            <http://www.example.org/end>    "1361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-954-957>
            <http://www.example.org/end>    "957.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "954.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3448-3451>
            <http://www.example.org/end>    "3451.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "3448.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1378-1380>
            <http://www.example.org/end>    "1380.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "1378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-378-382>
            <http://www.example.org/end>    "382.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-136-140>
            <http://www.example.org/end>    "140.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-958-960>
            <http://www.example.org/end>    "960.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "958.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1954-1956>
            <http://www.example.org/end>    "1956.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "1954.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "52" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1630-1633>
            <http://www.example.org/end>    "1633.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1630.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2398-2401>
            <http://www.example.org/end>    "2401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "2398.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-281-282>
            <http://www.example.org/end>    "282.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "281.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-794-797>
            <http://www.example.org/end>    "797.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "794.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3266-3269>
            <http://www.example.org/end>    "3269.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "3266.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-488-491>
            <http://www.example.org/end>    "491.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "488.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1504-1506>
            <http://www.example.org/end>    "1506.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1504.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-821-824>
            <http://www.example.org/end>    "824.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "821.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-61-63>
            <http://www.example.org/end>    "63.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "61.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-665-667>
            <http://www.example.org/end>    "667.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "665.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-63768b5051a3f4e61d2bf3f9bf1c65c2d0c51025dbb6689ca83170b51818b6cd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although most patient management issues that have infectious disease implications are covered in health care facilities routine infection prevention policies, procedures may need to be altered during a disaster. As mentioned previously, limited resources may necessitate the use of crisis standards of care for patient management. In addition, some patient management issues are unique to infectious disease disasters. One patient management issue that is unique to infectious \",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Domain 6: Surveillance\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Domain 6: Surveillance" ;
            <http://www.example.org/text>  "Although most patient management issues that have infectious disease implications are covered in health care facilities routine infection prevention policies, procedures may need to be altered during a disaster. As mentioned previously, limited resources may necessitate the use of crisis standards of care for patient management. In addition, some patient management issues are unique to infectious disease disasters. One patient management issue that is unique to infectious " ;
            <http://www.example.org/textHash>
                    "63768b5051a3f4e61d2bf3f9bf1c65c2d0c51025dbb6689ca83170b51818b6cd" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-115-117>
            <http://www.example.org/end>    "117.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "115.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-230-233>
            <http://www.example.org/end>    "233.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "230.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2760-2764>
            <http://www.example.org/end>    "2764.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "2760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-373-377>
            <http://www.example.org/end>    "377.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "373.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-187-190>
            <http://www.example.org/end>    "190.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "187.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2119-2122>
            <http://www.example.org/end>    "2122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "2119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1005-1008>
            <http://www.example.org/end>    "1008.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "1005.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-176-180>
            <http://www.example.org/end>    "180.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "176.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2103-2106>
            <http://www.example.org/end>    "2106.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2103.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-146-149>
            <http://www.example.org/end>    "149.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-192-194>
            <http://www.example.org/end>    "194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "192.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-122-126>
            <http://www.example.org/end>    "126.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1032-1034>
            <http://www.example.org/end>    "1034.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1032.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-905-909>
            <http://www.example.org/end>    "909.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "905.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1201-1203>
            <http://www.example.org/end>    "1203.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1201.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-618-620>
            <http://www.example.org/end>    "620.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "618.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1086-1089>
            <http://www.example.org/end>    "1089.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "1086.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2099-2102>
            <http://www.example.org/end>    "2102.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "2099.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10," .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-70-74>
            <http://www.example.org/end>    "74.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "70.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-156-160>
            <http://www.example.org/end>    "160.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[14]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4199-4201>
            <http://www.example.org/end>    "4201.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF46" ;
            <http://www.example.org/start>  "4199.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "46" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1194-1196>
            <http://www.example.org/end>    "1196.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-355-358>
            <http://www.example.org/end>    "358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "355.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Once a disaster is identified or underway, surveillance will be needed to monitor the event. Surveillance indicators for mass casualty incidents are specific to the nature of the event. For example, a natural disaster resulting in sheltered individuals displaced by the event would require surveillance for food-and waterborne illnesses, respiratory-related syndromes, and skin/wound infections, 39 whereas an influenza pandemic would likely focus on respiratory-related syndromes and laboratory specimen monitoring to identify new cases. 10 Screening is an important component of surveillance and the details of how, when, where, and whom will do the screening need to be outlined in the emergency management plan for health care facilities, alternative care sites, and community shelters. 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Possible screening mechanisms include setting up triage centers at entrances for staff, patients, and visitors [10] [11] [12] 19, 26, 39 ; following up on staff occupational exposures 6, 9, [11] [12] [13] 26, 32, 35, 37, 39 ; and floor or area surveillance cultures as part of outbreak investigation. [11] [12] [13] 31 IPs need to aid in development of these screening protocols, including outlining procedures for managing potentially contagious individuals who are identified through the screening/triage process. IPs must communicate information gathered from the screening process and outbreak investigation to local public health officials. 19, 37, 39 Domain 7: Patient management Patient surge is expected after any type of mass casualty incident, and, in some events, such as an infectious disease disaster, the patients may pose a risk of infection transmission. Health care disaster planners must develop protocols for managing patient surge, including procedures for minimizing the risk of disease transmission. 6, 9, [11] [12] [13] 38, 39 IPs need to consult with facility disaster planners and response agencies when developing and implementing emergency management plans to manage an influx of potentially contagious patients. 6, 8, [11] [12] [13] 32, 37, 38 Patient management issues that have infectious disease implications and need to be addressed in emergency management plans are listed in Table 2 . Examples of such patient management issues include how to identify, transport, and isolate potentially contagious patients.\",\"cite_spans\":[{\"start\":396.0,\"end\":398.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":539.0,\"end\":541.0,\"text\":\"10\",\"ref_id\":\"BIBREF9\"},{\"start\":791.0,\"end\":793.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":794.0,\"end\":797.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":798.0,\"end\":801.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":802.0,\"end\":806.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":807.0,\"end\":811.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":812.0,\"end\":816.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":817.0,\"end\":821.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":822.0,\"end\":825.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":826.0,\"end\":829.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":830.0,\"end\":833.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":834.0,\"end\":837.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":838.0,\"end\":841.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":842.0,\"end\":844.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":956.0,\"end\":960.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":961.0,\"end\":965.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":966.0,\"end\":970.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":971.0,\"end\":974.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":975.0,\"end\":978.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":979.0,\"end\":981.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1029.0,\"end\":1031.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1032.0,\"end\":1034.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":1035.0,\"end\":1039.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1040.0,\"end\":1044.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1045.0,\"end\":1049.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1050.0,\"end\":1053.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":1054.0,\"end\":1057.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":1058.0,\"end\":1061.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":1062.0,\"end\":1065.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":1066.0,\"end\":1068.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1146.0,\"end\":1150.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1151.0,\"end\":1155.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1156.0,\"end\":1160.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1161.0,\"end\":1163.0,\"text\":\"31\",\"ref_id\":\"BIBREF30\"},{\"start\":1491.0,\"end\":1494.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":1495.0,\"end\":1498.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":1499.0,\"end\":1501.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1867.0,\"end\":1869.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":1870.0,\"end\":1872.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":1873.0,\"end\":1877.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1878.0,\"end\":1882.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1883.0,\"end\":1887.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1888.0,\"end\":1891.0,\"text\":\"38,\",\"ref_id\":\"BIBREF38\"},{\"start\":1892.0,\"end\":1894.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":2085.0,\"end\":2087.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":2088.0,\"end\":2090.0,\"text\":\"8,\",\"ref_id\":\"BIBREF7\"},{\"start\":2091.0,\"end\":2095.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":2096.0,\"end\":2100.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":2101.0,\"end\":2105.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":2106.0,\"end\":2109.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":2110.0,\"end\":2113.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":2114.0,\"end\":2116.0,\"text\":\"38\",\"ref_id\":\"BIBREF38\"}],\"ref_spans\":[{\"start\":2254.0,\"end\":2261.0,\"text\":\"Table 2\",\"ref_id\":\"TABREF0\"}],\"section\":\"Domain 6: Surveillance\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2110-2113> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-802-806> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-834-837> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1045-1049> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-791-793> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-961-965> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-966-970> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1050-1053> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2114-2116> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1066-1068> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2085-2087> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1495-1498> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-979-981> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-794-797> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1873-1877> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-807-811> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-396-398> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-956-960> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1499-1501> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-539-541> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1878-1882> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-975-978> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2101-2105> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-812-816> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-842-844> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1151-1155> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1491-1494> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2096-2100> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1867-1869> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-822-825> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1062-1065> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1892-1894> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-830-833> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1161-1163> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2091-2095> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1883-1887> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1888-1891> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1156-1160> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-838-841> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1032-1034> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1035-1039> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-971-974> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-817-821> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1040-1044> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1054-1057> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-798-801> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2088-2090> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-826-829> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2106-2109> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1146-1150> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1870-1872> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1029-1031> , <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1058-1061> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_refspan-2254-2261> ;
            <http://www.example.org/section>
                    "Domain 6: Surveillance" ;
            <http://www.example.org/text>  "Once a disaster is identified or underway, surveillance will be needed to monitor the event. Surveillance indicators for mass casualty incidents are specific to the nature of the event. For example, a natural disaster resulting in sheltered individuals displaced by the event would require surveillance for food-and waterborne illnesses, respiratory-related syndromes, and skin/wound infections, 39 whereas an influenza pandemic would likely focus on respiratory-related syndromes and laboratory specimen monitoring to identify new cases. 10 Screening is an important component of surveillance and the details of how, when, where, and whom will do the screening need to be outlined in the emergency management plan for health care facilities, alternative care sites, and community shelters. 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Possible screening mechanisms include setting up triage centers at entrances for staff, patients, and visitors [10] [11] [12] 19, 26, 39 ; following up on staff occupational exposures 6, 9, [11] [12] [13] 26, 32, 35, 37, 39 ; and floor or area surveillance cultures as part of outbreak investigation. [11] [12] [13] 31 IPs need to aid in development of these screening protocols, including outlining procedures for managing potentially contagious individuals who are identified through the screening/triage process. IPs must communicate information gathered from the screening process and outbreak investigation to local public health officials. 19, 37, 39 Domain 7: Patient management Patient surge is expected after any type of mass casualty incident, and, in some events, such as an infectious disease disaster, the patients may pose a risk of infection transmission. Health care disaster planners must develop protocols for managing patient surge, including procedures for minimizing the risk of disease transmission. 6, 9, [11] [12] [13] 38, 39 IPs need to consult with facility disaster planners and response agencies when developing and implementing emergency management plans to manage an influx of potentially contagious patients. 6, 8, [11] [12] [13] 32, 37, 38 Patient management issues that have infectious disease implications and need to be addressed in emergency management plans are listed in Table 2 . Examples of such patient management issues include how to identify, transport, and isolate potentially contagious patients." ;
            <http://www.example.org/textHash>
                    "daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3270-3272>
            <http://www.example.org/end>    "3272.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "3270.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"One of the IP\\u0027s primary roles is to educate others regarding infection prevention and control strategies, 35, 40 and this remains true for emergency management. 6, [12] [13] [14] 19, 26, 28, 32, 34, 35, 37, 39 There are a variety of worker groups who need training on infection prevention in relation to emergency management. These groups, including both health care workers and response agency personnel, are outlined in Table 3 . Examples of health care worker and response agency groups for which IPs will need to develop training material include nurses, physicians, respiratory therapists, housekeepers, laboratory workers, environmental services, home health and hospice, first responders, governmental agencies, public health, and veterinarians. In addition, the general public needs education related to preventing infection transmission during disasters, and IPs are ideally suited for creating this type of training material.\",\"cite_spans\":[{\"start\":106.0,\"end\":109.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":110.0,\"end\":112.0,\"text\":\"40\",\"ref_id\":\"BIBREF40\"},{\"start\":161.0,\"end\":163.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":164.0,\"end\":168.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":169.0,\"end\":173.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":174.0,\"end\":178.0,\"text\":\"[14]\",\"ref_id\":\"BIBREF13\"},{\"start\":179.0,\"end\":182.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":183.0,\"end\":186.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":187.0,\"end\":190.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":191.0,\"end\":194.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":195.0,\"end\":198.0,\"text\":\"34,\",\"ref_id\":\"BIBREF33\"},{\"start\":199.0,\"end\":202.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":203.0,\"end\":206.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":207.0,\"end\":209.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[{\"start\":422.0,\"end\":429.0,\"text\":\"Table 3\",\"ref_id\":\"TABREF1\"}],\"section\":\"Domain 9: IP as educator\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-207-209> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-106-109> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-179-182> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-110-112> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-195-198> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-203-206> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-164-168> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-183-186> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-191-194> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-169-173> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-199-202> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-187-190> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-174-178> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-161-163> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_refspan-422-429> ;
            <http://www.example.org/section>
                    "Domain 9: IP as educator" ;
            <http://www.example.org/text>  "One of the IP's primary roles is to educate others regarding infection prevention and control strategies, 35, 40 and this remains true for emergency management. 6, [12] [13] [14] 19, 26, 28, 32, 34, 35, 37, 39 There are a variety of worker groups who need training on infection prevention in relation to emergency management. These groups, including both health care workers and response agency personnel, are outlined in Table 3 . Examples of health care worker and response agency groups for which IPs will need to develop training material include nurses, physicians, respiratory therapists, housekeepers, laboratory workers, environmental services, home health and hospice, first responders, governmental agencies, public health, and veterinarians. In addition, the general public needs education related to preventing infection transmission during disasters, and IPs are ideally suited for creating this type of training material." ;
            <http://www.example.org/textHash>
                    "18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-688-689>
            <http://www.example.org/end>    "689.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "688.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "1" .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-195-198>
            <http://www.example.org/end>    "198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "195.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "34," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1099-1103>
            <http://www.example.org/end>    "1103.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "1099.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-512-515>
            <http://www.example.org/end>    "515.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "512.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1069-1073>
            <http://www.example.org/end>    "1073.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1069.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2533-2536>
            <http://www.example.org/end>    "2536.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2533.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Screening/triaging patients for infection 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Patient decontamination [11] [12] [13] 39 Patient transport 9, 39 Patient placement and cohorting 6, [8] [9] [10] [11] [12] [13] [14] 17, 25, 35, 37, 39 Isolation 6, [8] [9] [10] [11] [12] [13] 25, 26, 32, [37] [38] [39] Quarantine [10] [11] [12] [13] Supply shortages 6, [11] [12] [13] 16, 26, 37, 39 Procedures for obtaining and handling patient specimens safely 9, 11, 32 Discharge management 9, 39 Postmortem care 6, 9, 11, 12, 39 disease disasters is quarantine. Quarantine would only be needed for the most potentially severe infectious diseases, such as smallpox and SARS, and may not be implemented at all. 12 If quarantine were implemented, it would likely be in the form of a community-or homebased system. However, hospital-based quarantines have been implemented in the past and remain a possibility for future infectious disease disasters. 10, 49 Patient decontamination to remove biologic particles is another patient management issue that is unique to infectious disease disasters. For most mass casualty incidents, patient decontamination will not be necessary or will only be needed to remove chemical or other toxic agents; these issues do not require IP input. Patient decontamination to remove biologic particles is an infection prevention issue because these contaminates can lead to secondary disease spread if they are not removed in a timely and appropriate manner. IPs need to aid health care facility and community disaster planners develop protocols for when and how patient decontamination to remove biologic particles should be performed. [11] [12] [13] 39 Patient decontamination to remove biologic particles is only needed after an announced bioterrorism attack occurs and then only if the event is known within 12 to 24 hours after the exposure. 11\",\"cite_spans\":[{\"start\":42.0,\"end\":44.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":45.0,\"end\":48.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":49.0,\"end\":52.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":53.0,\"end\":57.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":58.0,\"end\":62.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":63.0,\"end\":67.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":68.0,\"end\":72.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":73.0,\"end\":76.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":77.0,\"end\":80.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":81.0,\"end\":84.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":85.0,\"end\":88.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":89.0,\"end\":92.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":93.0,\"end\":95.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":120.0,\"end\":124.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":125.0,\"end\":129.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":130.0,\"end\":134.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":135.0,\"end\":137.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":156.0,\"end\":158.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":159.0,\"end\":161.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":194.0,\"end\":196.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":197.0,\"end\":200.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":201.0,\"end\":204.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":205.0,\"end\":209.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":210.0,\"end\":214.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":215.0,\"end\":219.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":220.0,\"end\":224.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":225.0,\"end\":229.0,\"text\":\"[14]\",\"ref_id\":\"BIBREF13\"},{\"start\":230.0,\"end\":233.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":234.0,\"end\":237.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":238.0,\"end\":241.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":242.0,\"end\":245.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":246.0,\"end\":261.0,\"text\":\"39 Isolation 6,\"},{\"start\":262.0,\"end\":265.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":266.0,\"end\":269.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":270.0,\"end\":274.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":275.0,\"end\":279.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":280.0,\"end\":284.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":285.0,\"end\":289.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":290.0,\"end\":293.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":294.0,\"end\":297.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":298.0,\"end\":301.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":302.0,\"end\":306.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":307.0,\"end\":311.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":312.0,\"end\":316.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":328.0,\"end\":332.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":333.0,\"end\":337.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":338.0,\"end\":342.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":343.0,\"end\":347.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":365.0,\"end\":367.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":368.0,\"end\":372.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":373.0,\"end\":377.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":378.0,\"end\":382.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":383.0,\"end\":386.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":387.0,\"end\":390.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":391.0,\"end\":394.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":395.0,\"end\":397.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":461.0,\"end\":463.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":464.0,\"end\":467.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":468.0,\"end\":470.0,\"text\":\"32\",\"ref_id\":\"BIBREF31\"},{\"start\":492.0,\"end\":494.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":495.0,\"end\":497.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":514.0,\"end\":516.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":517.0,\"end\":519.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":520.0,\"end\":523.0,\"text\":\"11,\",\"ref_id\":\"BIBREF10\"},{\"start\":524.0,\"end\":527.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":528.0,\"end\":530.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":711.0,\"end\":713.0,\"text\":\"12\",\"ref_id\":\"BIBREF11\"},{\"start\":949.0,\"end\":952.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":953.0,\"end\":955.0,\"text\":\"49\",\"ref_id\":\"BIBREF49\"},{\"start\":1664.0,\"end\":1668.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1669.0,\"end\":1673.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1674.0,\"end\":1678.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1679.0,\"end\":1681.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[],\"section\":\"Patient management issue/topic requiring infection prevention input\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-395-397> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-234-237> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-215-219> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-159-161> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-468-470> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-68-72> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-270-274> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-517-519> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-343-347> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-391-394> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-194-196> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1664-1668> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-197-200> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-514-516> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-492-494> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-53-57> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-520-523> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-58-62> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1669-1673> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-275-279> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-949-952> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-77-80> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-711-713> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-42-44> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-294-297> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-464-467> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-373-377> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-125-129> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-81-84> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-290-293> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-225-229> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-365-367> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-307-311> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-302-306> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-120-124> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-130-134> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-461-463> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-953-955> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-135-137> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-368-372> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-63-67> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-387-390> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-312-316> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-338-342> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-85-88> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-205-209> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-328-332> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-220-224> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-528-530> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-298-301> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-262-265> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-383-386> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-280-284> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-93-95> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-210-214> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-49-52> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-73-76> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-156-158> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1679-1681> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1674-1678> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-45-48> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-266-269> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-524-527> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-201-204> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-378-382> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-89-92> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-230-233> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-495-497> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-333-337> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-285-289> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-246-261> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-242-245> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-238-241> ;
            <http://www.example.org/section>
                    "Patient management issue/topic requiring infection prevention input" ;
            <http://www.example.org/text>  "Screening/triaging patients for infection 6, [8] [9] [10] [11] [12] [13] 17, 19, 25, 26, 37, 39 Patient decontamination [11] [12] [13] 39 Patient transport 9, 39 Patient placement and cohorting 6, [8] [9] [10] [11] [12] [13] [14] 17, 25, 35, 37, 39 Isolation 6, [8] [9] [10] [11] [12] [13] 25, 26, 32, [37] [38] [39] Quarantine [10] [11] [12] [13] Supply shortages 6, [11] [12] [13] 16, 26, 37, 39 Procedures for obtaining and handling patient specimens safely 9, 11, 32 Discharge management 9, 39 Postmortem care 6, 9, 11, 12, 39 disease disasters is quarantine. Quarantine would only be needed for the most potentially severe infectious diseases, such as smallpox and SARS, and may not be implemented at all. 12 If quarantine were implemented, it would likely be in the form of a community-or homebased system. However, hospital-based quarantines have been implemented in the past and remain a possibility for future infectious disease disasters. 10, 49 Patient decontamination to remove biologic particles is another patient management issue that is unique to infectious disease disasters. For most mass casualty incidents, patient decontamination will not be necessary or will only be needed to remove chemical or other toxic agents; these issues do not require IP input. Patient decontamination to remove biologic particles is an infection prevention issue because these contaminates can lead to secondary disease spread if they are not removed in a timely and appropriate manner. IPs need to aid health care facility and community disaster planners develop protocols for when and how patient decontamination to remove biologic particles should be performed. [11] [12] [13] 39 Patient decontamination to remove biologic particles is only needed after an announced bioterrorism attack occurs and then only if the event is known within 12 to 24 hours after the exposure. 11" ;
            <http://www.example.org/textHash>
                    "fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-166-169>
            <http://www.example.org/end>    "169.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "166.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-859-863>
            <http://www.example.org/end>    "863.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "859.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-924-926>
            <http://www.example.org/end>    "926.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "924.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1027-1030>
            <http://www.example.org/end>    "1030.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1027.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1362-1364>
            <http://www.example.org/end>    "1364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1362.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-208-212>
            <http://www.example.org/end>    "212.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "208.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-520-523>
            <http://www.example.org/end>    "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-887-890>
            <http://www.example.org/end>    "890.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "887.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2789-2791>
            <http://www.example.org/end>    "2791.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "2789.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3472-3476>
            <http://www.example.org/end>    "3476.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "3472.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[14]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-822-825>
            <http://www.example.org/end>    "825.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "822.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-854-857>
            <http://www.example.org/end>    "857.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "854.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2139-2142>
            <http://www.example.org/end>    "2142.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "2139.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-101-104>
            <http://www.example.org/end>    "104.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "101.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2664-2666>
            <http://www.example.org/end>    "2666.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "2664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-2379-2380>
            <http://www.example.org/end>    "2380.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "2379.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-842-846>
            <http://www.example.org/end>    "846.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "842.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1104-1108>
            <http://www.example.org/end>    "1108.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1104.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1491-1494>
            <http://www.example.org/end>    "1494.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "1491.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-626-630>
            <http://www.example.org/end>    "630.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-760-763>
            <http://www.example.org/end>    "763.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-347-350>
            <http://www.example.org/end>    "350.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "347.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-198-201>
            <http://www.example.org/end>    "201.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3_citespan-1468-1469>
            <http://www.example.org/end>    "1469.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-405-409>
            <http://www.example.org/end>    "409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "405.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[26]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In total, 34 relevant sources were identified from the peer-reviewed literature and Internet search. Many authors described the infectious disease impact of mass casualty incidents and infection prevention interventions that will be required for an effective disaster response but did not specify the role an IP will play in emergency management. 6, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Although it may seem that identifying the infection prevention interventions for a disaster is the same as outlining the role an IP will play in emergency management, they are different. Some interventions that can help prevent and contain infection transmission during a disaster, such as diagnosing infectious diseases rapidly and ordering confirmatory laboratory testing, will not be performed by an IP. However, many of the strategies to prevent infection transmission in health care and community settings following a disaster will be implemented and/or coordinated by the IP. There is a lot of crossover between the role of the IP in emergency management and the components of an infection prevention program for mass casualty events. This document focuses solely on the role or tasks of an IP in emergency management, which have been divided into themes or domains.\",\"cite_spans\":[{\"start\":347.0,\"end\":349.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":350.0,\"end\":354.0,\"text\":\"[15]\",\"ref_id\":\"BIBREF14\"},{\"start\":355.0,\"end\":359.0,\"text\":\"[16]\",\"ref_id\":\"BIBREF15\"},{\"start\":360.0,\"end\":364.0,\"text\":\"[17]\",\"ref_id\":\"BIBREF16\"},{\"start\":365.0,\"end\":369.0,\"text\":\"[18]\",\"ref_id\":\"BIBREF17\"},{\"start\":370.0,\"end\":374.0,\"text\":\"[19]\",\"ref_id\":\"BIBREF18\"},{\"start\":375.0,\"end\":379.0,\"text\":\"[20]\",\"ref_id\":\"BIBREF19\"},{\"start\":380.0,\"end\":384.0,\"text\":\"[21]\",\"ref_id\":\"BIBREF20\"},{\"start\":385.0,\"end\":389.0,\"text\":\"[22]\",\"ref_id\":\"BIBREF21\"},{\"start\":390.0,\"end\":394.0,\"text\":\"[23]\",\"ref_id\":\"BIBREF22\"},{\"start\":395.0,\"end\":399.0,\"text\":\"[24]\",\"ref_id\":\"BIBREF23\"},{\"start\":400.0,\"end\":404.0,\"text\":\"[25]\",\"ref_id\":\"BIBREF24\"},{\"start\":405.0,\"end\":409.0,\"text\":\"[26]\",\"ref_id\":\"BIBREF25\"},{\"start\":410.0,\"end\":414.0,\"text\":\"[27]\",\"ref_id\":\"BIBREF26\"},{\"start\":415.0,\"end\":419.0,\"text\":\"[28]\",\"ref_id\":\"BIBREF27\"},{\"start\":420.0,\"end\":424.0,\"text\":\"[29]\",\"ref_id\":\"BIBREF28\"},{\"start\":425.0,\"end\":429.0,\"text\":\"[30]\",\"ref_id\":\"BIBREF29\"},{\"start\":430.0,\"end\":434.0,\"text\":\"[31]\",\"ref_id\":\"BIBREF30\"}],\"ref_spans\":[],\"section\":\"RESULTS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-430-434> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-347-349> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-415-419> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-420-424> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-385-389> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-405-409> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-355-359> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-370-374> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-375-379> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-410-414> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-380-384> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-390-394> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-350-354> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-365-369> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-425-429> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-395-399> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-360-364> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-400-404> ;
            <http://www.example.org/section>
                    "RESULTS" ;
            <http://www.example.org/text>  "In total, 34 relevant sources were identified from the peer-reviewed literature and Internet search. Many authors described the infectious disease impact of mass casualty incidents and infection prevention interventions that will be required for an effective disaster response but did not specify the role an IP will play in emergency management. 6, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Although it may seem that identifying the infection prevention interventions for a disaster is the same as outlining the role an IP will play in emergency management, they are different. Some interventions that can help prevent and contain infection transmission during a disaster, such as diagnosing infectious diseases rapidly and ordering confirmatory laboratory testing, will not be performed by an IP. However, many of the strategies to prevent infection transmission in health care and community settings following a disaster will be implemented and/or coordinated by the IP. There is a lot of crossover between the role of the IP in emergency management and the components of an infection prevention program for mass casualty events. This document focuses solely on the role or tasks of an IP in emergency management, which have been divided into themes or domains." ;
            <http://www.example.org/textHash>
                    "686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db" .
    
    <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For most disasters, such as floods, hurricanes, and traditional terrorist events using an explosive device, surveillance will not be needed to identify that an event has occurred because there are immediate, obvious signs that something unusual has happened. However, surveillance will be needed to identify rapidly a disaster involving a biologic agent. [9] [10] [11] Surveillance to identify an infectious disease disaster consists of the collection and analysis of any non-traditional data and is referred to as syndromic surveillance. Syndromic surveillance systems are often regional or state-wide programs managed by public health authorities, and all health care facilities may be mandated to collect the same indicators. 10 IPs may not need to help design these programs but should participate if requested. IP input would be critical if a health care facility decides to collect additional indicators for early detection of a biologic event. IPs need to help design and evaluate syndromic surveillance programs when possible and train the data collectors/reporters or assist with data collection and reporting.\",\"cite_spans\":[{\"start\":355.0,\"end\":358.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":359.0,\"end\":363.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":364.0,\"end\":368.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":729.0,\"end\":731.0,\"text\":\"10\",\"ref_id\":\"BIBREF9\"}],\"ref_spans\":[],\"section\":\"Domain 6: Surveillance\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-355-358> , <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-359-363> , <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-364-368> , <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-729-731> ;
            <http://www.example.org/section>
                    "Domain 6: Surveillance" ;
            <http://www.example.org/text>  "For most disasters, such as floods, hurricanes, and traditional terrorist events using an explosive device, surveillance will not be needed to identify that an event has occurred because there are immediate, obvious signs that something unusual has happened. However, surveillance will be needed to identify rapidly a disaster involving a biologic agent. [9] [10] [11] Surveillance to identify an infectious disease disaster consists of the collection and analysis of any non-traditional data and is referred to as syndromic surveillance. Syndromic surveillance systems are often regional or state-wide programs managed by public health authorities, and all health care facilities may be mandated to collect the same indicators. 10 IPs may not need to help design these programs but should participate if requested. IP input would be critical if a health care facility decides to collect additional indicators for early detection of a biologic event. IPs need to help design and evaluate syndromic surveillance programs when possible and train the data collectors/reporters or assist with data collection and reporting." ;
            <http://www.example.org/textHash>
                    "8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1664-1668>
            <http://www.example.org/end>    "1668.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1283-1285>
            <http://www.example.org/end>    "1285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1283.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-501-505>
            <http://www.example.org/end>    "505.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-355-359>
            <http://www.example.org/end>    "359.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "355.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[16]" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-107-111>
            <http://www.example.org/end>    "111.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "107.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-524-527>
            <http://www.example.org/end>    "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "524.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-567-571>
            <http://www.example.org/end>    "571.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "567.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[43]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3366-3369>
            <http://www.example.org/end>    "3369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "3366.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1381-1384>
            <http://www.example.org/end>    "1384.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "1381.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-121-124>
            <http://www.example.org/end>    "124.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-448-451>
            <http://www.example.org/end>    "451.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "448.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3795-3797>
            <http://www.example.org/end>    "3797.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "3795.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3489-3493>
            <http://www.example.org/end>    "3493.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "3489.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-966-970>
            <http://www.example.org/end>    "970.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "966.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-290-293>
            <http://www.example.org/end>    "293.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "290.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-425-429>
            <http://www.example.org/end>    "429.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "425.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[30]" .
    
    <http://covid19.aksw.org/728372aa94ee6a40655d5e086a0e91569f9c0780>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "728372aa94ee6a40655d5e086a0e91569f9c0780" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c> , <http://covid19.aksw.org/text-4c7204d0e4c7747a7b8ac7601749427c89e1aef462676e28cae806c293c05c5d> , <http://covid19.aksw.org/text-fadd2e7950d40b557da079061605a00b77bbdb13684624e24f7c854e4a7f76c0> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34> , <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a> , <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb> , <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db> , <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307> , <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e> , <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6> , <http://covid19.aksw.org/text-b5831a59255128266b515f9574a911993aa7311c7c459de4df51f6f200496184> , <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77> , <http://covid19.aksw.org/text-45efcbb646b325f8d9d4f88ba93832d827ba8be1dc95e17669e5a0251193d9e8> , <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36> , <http://covid19.aksw.org/text-f60ca261ea1e36be208e2447d3e884811b41b4fd875c32070d415b60928cb5e8> , <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125> , <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f> , <http://covid19.aksw.org/text-de66420a8f2b3cea58cb814faa1ba9730c82a2b10d63a1bc9f46e37392abbfd3> , <http://covid19.aksw.org/text-6cba40af069e925029d25f6fff9468fb77b62ae28cd1c2d84b3e8bc74f1e05e9> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea> , <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c> , <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48> , <http://covid19.aksw.org/text-63768b5051a3f4e61d2bf3f9bf1c65c2d0c51025dbb6689ca83170b51818b6cd> , <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28> , <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258> , <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2> .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1045-1049>
            <http://www.example.org/end>    "1049.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1045.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1117-1121>
            <http://www.example.org/end>    "1121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1117.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-375-379>
            <http://www.example.org/end>    "379.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "375.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[20]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-433-437>
            <http://www.example.org/end>    "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-604-606>
            <http://www.example.org/end>    "606.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF41" ;
            <http://www.example.org/start>  "604.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "41" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-165-168>
            <http://www.example.org/end>    "168.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "165.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-536-538>
            <http://www.example.org/end>    "538.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "536.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-622-625>
            <http://www.example.org/end>    "625.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "622.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-331-334>
            <http://www.example.org/end>    "334.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "331.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-900-904>
            <http://www.example.org/end>    "904.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "900.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The infectious disease impact of a mass casualty incident and interventions needed to control the situation will vary, depending on the nature of the event. 12 Infectious disease disasters, such as a pandemic, will require much more involvement from an IP than a natural disaster. 6 IPs must be familiar with the potential consequences of various types of disasters. 6, 8, [11] [12] [13] [32] [33] [34] IPs must also understand the infection prevention strategies needed for mass casualty incidents, including surveillance, patient placement, reporting, outbreak investigation, and communication/coordination. 6, 8, [11] [12] [13] [32] [33] [34] In addition to understanding mass casualty incidents and the potential infectious disease impact of such events, IPs need to have a basic understanding of emergency management principles. 6, [11] [12] [13] 35 There are 4 phases of emergency management: mitigation, preparedness, response, and recovery. 36 Mitigation involves interventions to either prevent or reduce morbidity and mortality and ease the economic and social impact of the event on the affected community. The preparedness phase involves all of the measures taken to prepare for an emergency, such as developing an emergency management plan and educating the workforce. The response phase occurs after disaster strikes when the plan developed in the preparedness phase is implemented. The recovery phase of the emergency management model consists of the interventions needed to return a facility and/or community to its predisaster baseline as soon as possible. Other mass casualty incident-related topics with which IPs must be familiar include surge capacity, responding agencies\\u0027 roles in emergency management, incident command system, environmental concerns in the physical plant, occupational health during disasters, and prioritizing limited resources that may affect infection transmission. 6 Domain 2: Assessing readiness and emergency management plans IPs need to be involved in assessing all aspects of readiness for mass casualty events as it relates to potential disease transmission. 6, 9, [11] [12] [13] [14] 28, 29, [37] [38] [39] [40] This includes being involved in preparedness efforts at the personal, facility, and community level for all types of mass casualty events. An all-hazards approach to emergency management should be used because all types of mass casualty incidents can result in infectious disease implications and the type of emergency that might occur cannot always be anticipated. 12, 13, 35 Personal, facility, and community emergency management plans must be assessed, but the approach to each varies.\",\"cite_spans\":[{\"start\":157.0,\"end\":159.0,\"text\":\"12\",\"ref_id\":\"BIBREF11\"},{\"start\":281.0,\"end\":282.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":367.0,\"end\":369.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":370.0,\"end\":372.0,\"text\":\"8,\",\"ref_id\":\"BIBREF7\"},{\"start\":373.0,\"end\":377.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":378.0,\"end\":382.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":383.0,\"end\":387.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":388.0,\"end\":392.0,\"text\":\"[32]\",\"ref_id\":\"BIBREF31\"},{\"start\":393.0,\"end\":397.0,\"text\":\"[33]\",\"ref_id\":\"BIBREF32\"},{\"start\":398.0,\"end\":402.0,\"text\":\"[34]\",\"ref_id\":\"BIBREF33\"},{\"start\":610.0,\"end\":612.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":613.0,\"end\":615.0,\"text\":\"8,\",\"ref_id\":\"BIBREF7\"},{\"start\":616.0,\"end\":620.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":621.0,\"end\":625.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":626.0,\"end\":630.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":631.0,\"end\":635.0,\"text\":\"[32]\",\"ref_id\":\"BIBREF31\"},{\"start\":636.0,\"end\":640.0,\"text\":\"[33]\",\"ref_id\":\"BIBREF32\"},{\"start\":641.0,\"end\":645.0,\"text\":\"[34]\",\"ref_id\":\"BIBREF33\"},{\"start\":834.0,\"end\":836.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":837.0,\"end\":841.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":842.0,\"end\":846.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":847.0,\"end\":851.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":852.0,\"end\":854.0,\"text\":\"35\",\"ref_id\":\"BIBREF34\"},{\"start\":949.0,\"end\":951.0,\"text\":\"36\",\"ref_id\":\"BIBREF35\"},{\"start\":1910.0,\"end\":1911.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":2109.0,\"end\":2111.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":2112.0,\"end\":2114.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":2115.0,\"end\":2119.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":2120.0,\"end\":2124.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":2125.0,\"end\":2129.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":2130.0,\"end\":2134.0,\"text\":\"[14]\",\"ref_id\":\"BIBREF13\"},{\"start\":2135.0,\"end\":2138.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":2139.0,\"end\":2142.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":2143.0,\"end\":2147.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":2148.0,\"end\":2152.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":2153.0,\"end\":2157.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":2158.0,\"end\":2162.0,\"text\":\"[40]\",\"ref_id\":\"BIBREF40\"},{\"start\":2529.0,\"end\":2532.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":2533.0,\"end\":2536.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":2537.0,\"end\":2539.0,\"text\":\"35\",\"ref_id\":\"BIBREF34\"}],\"ref_spans\":[],\"section\":\"Domain 1: Knowledge of disasters and emergency management\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-378-382> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2135-2138> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2112-2114> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-388-392> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-852-854> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-949-951> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-393-397> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2537-2539> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2125-2129> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2120-2124> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-367-369> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2158-2162> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-847-851> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-370-372> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-636-640> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-281-282> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2139-2142> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-157-159> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-842-846> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-837-841> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-834-836> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-610-612> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-1910-1911> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2115-2119> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-373-377> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-398-402> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-616-620> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-626-630> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2109-2111> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-383-387> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-613-615> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2533-2536> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-631-635> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-621-625> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2130-2134> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-641-645> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2153-2157> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2529-2532> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2143-2147> , <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2148-2152> ;
            <http://www.example.org/section>
                    "Domain 1: Knowledge of disasters and emergency management" ;
            <http://www.example.org/text>  "The infectious disease impact of a mass casualty incident and interventions needed to control the situation will vary, depending on the nature of the event. 12 Infectious disease disasters, such as a pandemic, will require much more involvement from an IP than a natural disaster. 6 IPs must be familiar with the potential consequences of various types of disasters. 6, 8, [11] [12] [13] [32] [33] [34] IPs must also understand the infection prevention strategies needed for mass casualty incidents, including surveillance, patient placement, reporting, outbreak investigation, and communication/coordination. 6, 8, [11] [12] [13] [32] [33] [34] In addition to understanding mass casualty incidents and the potential infectious disease impact of such events, IPs need to have a basic understanding of emergency management principles. 6, [11] [12] [13] 35 There are 4 phases of emergency management: mitigation, preparedness, response, and recovery. 36 Mitigation involves interventions to either prevent or reduce morbidity and mortality and ease the economic and social impact of the event on the affected community. The preparedness phase involves all of the measures taken to prepare for an emergency, such as developing an emergency management plan and educating the workforce. The response phase occurs after disaster strikes when the plan developed in the preparedness phase is implemented. The recovery phase of the emergency management model consists of the interventions needed to return a facility and/or community to its predisaster baseline as soon as possible. Other mass casualty incident-related topics with which IPs must be familiar include surge capacity, responding agencies' roles in emergency management, incident command system, environmental concerns in the physical plant, occupational health during disasters, and prioritizing limited resources that may affect infection transmission. 6 Domain 2: Assessing readiness and emergency management plans IPs need to be involved in assessing all aspects of readiness for mass casualty events as it relates to potential disease transmission. 6, 9, [11] [12] [13] [14] 28, 29, [37] [38] [39] [40] This includes being involved in preparedness efforts at the personal, facility, and community level for all types of mass casualty events. An all-hazards approach to emergency management should be used because all types of mass casualty incidents can result in infectious disease implications and the type of emergency that might occur cannot always be anticipated. 12, 13, 35 Personal, facility, and community emergency management plans must be assessed, but the approach to each varies." ;
            <http://www.example.org/textHash>
                    "7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1373-1376>
            <http://www.example.org/end>    "1376.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1373.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "13," .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-1768-1770>
            <http://www.example.org/end>    "1770.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "1768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16" .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-140-143>
            <http://www.example.org/end>    "143.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "140.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_refspan-422-429>
            <http://www.example.org/end>    "429.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "422.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 3" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-923-926>
            <http://www.example.org/end>    "926.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "923.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_refspan-884-891>
            <http://www.example.org/end>    "891.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "884.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-395-399>
            <http://www.example.org/end>    "399.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "395.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[24]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-73-76>
            <http://www.example.org/end>    "76.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "73.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2965-2969>
            <http://www.example.org/end>    "2969.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-373-377>
            <http://www.example.org/end>    "377.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "373.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-383-386>
            <http://www.example.org/end>    "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "383.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3457-3461>
            <http://www.example.org/end>    "3461.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "3457.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2728-2732>
            <http://www.example.org/end>    "2732.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "2728.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1040-1044>
            <http://www.example.org/end>    "1044.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1040.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1076-1079>
            <http://www.example.org/end>    "1079.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "1076.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-159-161>
            <http://www.example.org/end>    "161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "159.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-723-727>
            <http://www.example.org/end>    "727.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "723.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-982-986>
            <http://www.example.org/end>    "986.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "982.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4001-4003>
            <http://www.example.org/end>    "4003.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "4001.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "45" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-927-931>
            <http://www.example.org/end>    "931.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "927.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-157-159>
            <http://www.example.org/end>    "159.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-396-398>
            <http://www.example.org/end>    "398.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "396.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-393-397>
            <http://www.example.org/end>    "397.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "393.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[33]" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-813-816>
            <http://www.example.org/end>    "816.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "813.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2747-2750>
            <http://www.example.org/end>    "2750.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "2747.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-935-937>
            <http://www.example.org/end>    "937.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "935.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-85-88>
            <http://www.example.org/end>    "88.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "85.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1050-1053>
            <http://www.example.org/end>    "1053.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "1050.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-395-397>
            <http://www.example.org/end>    "397.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "395.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-550-552>
            <http://www.example.org/end>    "552.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "550.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-817-821>
            <http://www.example.org/end>    "821.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "817.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1080-1082>
            <http://www.example.org/end>    "1082.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1080.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2960-2964>
            <http://www.example.org/end>    "2964.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2960.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3467-3471>
            <http://www.example.org/end>    "3471.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "3467.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-468-472>
            <http://www.example.org/end>    "472.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[45]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-350-354>
            <http://www.example.org/end>    "354.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF14" ;
            <http://www.example.org/start>  "350.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[15]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-743-747>
            <http://www.example.org/end>    "747.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "743.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[14]" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-150-153>
            <http://www.example.org/end>    "153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-317-321>
            <http://www.example.org/end>    "321.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "317.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2672-2676>
            <http://www.example.org/end>    "2676.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2672.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1878-1882>
            <http://www.example.org/end>    "1882.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1878.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3993-3996>
            <http://www.example.org/end>    "3996.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "3993.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-197-200>
            <http://www.example.org/end>    "200.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "197.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2106-2109>
            <http://www.example.org/end>    "2109.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "2106.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-203-207>
            <http://www.example.org/end>    "207.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "203.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-338-342>
            <http://www.example.org/end>    "342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "338.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-307-311>
            <http://www.example.org/end>    "311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1482-1484>
            <http://www.example.org/end>    "1484.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1482.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3261-3265>
            <http://www.example.org/end>    "3265.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "3261.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3248-3250>
            <http://www.example.org/end>    "3250.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "3248.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-114-116>
            <http://www.example.org/end>    "116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1066-1068>
            <http://www.example.org/end>    "1068.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1066.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-825-827>
            <http://www.example.org/end>    "827.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "825.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-244-245>
            <http://www.example.org/end>    "245.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "244.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3477-3480>
            <http://www.example.org/end>    "3480.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "3477.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "17," .
    
    <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-359-363>
            <http://www.example.org/end>    "363.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "359.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-613-615>
            <http://www.example.org/end>    "615.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "613.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8," .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-370-374>
            <http://www.example.org/end>    "374.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[19]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2682-2685>
            <http://www.example.org/end>    "2685.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "2682.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-398-400>
            <http://www.example.org/end>    "400.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "398.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2148-2152>
            <http://www.example.org/end>    "2152.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "2148.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1058-1061>
            <http://www.example.org/end>    "1061.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "1058.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1888-1891>
            <http://www.example.org/end>    "1891.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "1888.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-191-194>
            <http://www.example.org/end>    "194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "191.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-234-237>
            <http://www.example.org/end>    "237.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "234.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-102-106>
            <http://www.example.org/end>    "106.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "102.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1499-1501>
            <http://www.example.org/end>    "1501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1499.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1180-1184>
            <http://www.example.org/end>    "1184.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "1180.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[44]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1156-1160>
            <http://www.example.org/end>    "1160.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-716-718>
            <http://www.example.org/end>    "718.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "716.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-93-95>
            <http://www.example.org/end>    "95.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "93.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1605-1607>
            <http://www.example.org/end>    "1607.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1605.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-64-66>
            <http://www.example.org/end>    "66.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "64.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1515-1517>
            <http://www.example.org/end>    "1517.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1515.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-58-62>
            <http://www.example.org/end>    "62.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "58.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-339-342>
            <http://www.example.org/end>    "342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "339.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4379-4381>
            <http://www.example.org/end>    "4381.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "4379.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-1950-1953>
            <http://www.example.org/end>    "1953.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF51" ;
            <http://www.example.org/start>  "1950.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "51," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-55-58>
            <http://www.example.org/end>    "58.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "55.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-617-621>
            <http://www.example.org/end>    "621.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "617.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-390-394>
            <http://www.example.org/end>    "394.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "390.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[23]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_refspan-1861-1868>
            <http://www.example.org/end>    "1868.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1861.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-136-140>
            <http://www.example.org/end>    "140.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1507-1510>
            <http://www.example.org/end>    "1510.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1507.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3340-3342>
            <http://www.example.org/end>    "3342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "3340.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4824-4826>
            <http://www.example.org/end>    "4826.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "4824.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-516-519>
            <http://www.example.org/end>    "519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-106-109>
            <http://www.example.org/end>    "109.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "106.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-601-603>
            <http://www.example.org/end>    "603.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "601.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-77-80>
            <http://www.example.org/end>    "80.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "77.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1105-1107>
            <http://www.example.org/end>    "1107.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1105.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-731-733>
            <http://www.example.org/end>    "733.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF54" ;
            <http://www.example.org/start>  "731.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "54" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-824-826>
            <http://www.example.org/end>    "826.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "824.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3444-3447>
            <http://www.example.org/end>    "3447.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "3444.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1083-1085>
            <http://www.example.org/end>    "1085.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "1083.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-1679-1681>
            <http://www.example.org/end>    "1681.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1679.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-378-382>
            <http://www.example.org/end>    "382.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-520-523>
            <http://www.example.org/end>    "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-298-300>
            <http://www.example.org/end>    "300.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "298.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1658-1661>
            <http://www.example.org/end>    "1661.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "1658.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-524-527>
            <http://www.example.org/end>    "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "524.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-351-353>
            <http://www.example.org/end>    "353.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "351.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-891-895>
            <http://www.example.org/end>    "895.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "891.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-401-404>
            <http://www.example.org/end>    "404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-826-829>
            <http://www.example.org/end>    "829.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "826.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-505-507>
            <http://www.example.org/end>    "507.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "505.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-6df9b3c2e8ad7eb2d2769014fcb188c0e0e86c53195ecc5193c044ad6a965a28_citespan-1693-1695>
            <http://www.example.org/end>    "1695.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF54" ;
            <http://www.example.org/start>  "1693.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "54" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"External reporting must include local public health agencies 6, 8, 9, [11] [12] [13] 19, 26, 35, [37] [38] [39] ; in addition, notification of law enforcement will be needed for known or suspected bioterrorism attacks because they are a crime. 9 Other external response agencies may also need notification of infectious disease disasters; these agencies and their contact information should be included in the health care facility emergency management plan. [43] [44] [45] During disaster response, all communication should be coordinated through the incident command structure.\",\"cite_spans\":[{\"start\":61.0,\"end\":63.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":64.0,\"end\":66.0,\"text\":\"8,\",\"ref_id\":\"BIBREF7\"},{\"start\":67.0,\"end\":69.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":70.0,\"end\":74.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":75.0,\"end\":79.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":80.0,\"end\":84.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":85.0,\"end\":88.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":89.0,\"end\":92.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":93.0,\"end\":96.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":97.0,\"end\":101.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":102.0,\"end\":106.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":107.0,\"end\":111.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":244.0,\"end\":245.0,\"text\":\"9\",\"ref_id\":\"BIBREF8\"},{\"start\":458.0,\"end\":462.0,\"text\":\"[43]\",\"ref_id\":\"BIBREF43\"},{\"start\":463.0,\"end\":467.0,\"text\":\"[44]\",\"ref_id\":\"BIBREF44\"},{\"start\":468.0,\"end\":472.0,\"text\":\"[45]\",\"ref_id\":\"BIBREF45\"}],\"ref_spans\":[],\"section\":\"Domain 4: Participation in disaster response and recovery\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-458-462> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-463-467> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-64-66> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-89-92> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-107-111> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-80-84> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-85-88> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-61-63> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-70-74> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-75-79> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-93-96> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-97-101> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-102-106> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-67-69> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-244-245> , <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-468-472> ;
            <http://www.example.org/section>
                    "Domain 4: Participation in disaster response and recovery" ;
            <http://www.example.org/text>  "External reporting must include local public health agencies 6, 8, 9, [11] [12] [13] 19, 26, 35, [37] [38] [39] ; in addition, notification of law enforcement will be needed for known or suspected bioterrorism attacks because they are a crime. 9 Other external response agencies may also need notification of infectious disease disasters; these agencies and their contact information should be included in the health care facility emergency management plan. [43] [44] [45] During disaster response, all communication should be coordinated through the incident command structure." ;
            <http://www.example.org/textHash>
                    "c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-105-108>
            <http://www.example.org/end>    "108.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "105.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1501-1503>
            <http://www.example.org/end>    "1503.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-883-886>
            <http://www.example.org/end>    "886.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "883.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-838-841>
            <http://www.example.org/end>    "841.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "838.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-220-224>
            <http://www.example.org/end>    "224.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "220.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1649-1653>
            <http://www.example.org/end>    "1653.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1649.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-117-120>
            <http://www.example.org/end>    "120.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "117.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-528-530>
            <http://www.example.org/end>    "530.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "528.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-764-767>
            <http://www.example.org/end>    "767.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "764.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "38," .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-146-150>
            <http://www.example.org/end>    "150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-845-849>
            <http://www.example.org/end>    "849.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "845.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2115-2118>
            <http://www.example.org/end>    "2118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "2115.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2725-2727>
            <http://www.example.org/end>    "2727.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "2725.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-997-1000>
            <http://www.example.org/end>    "1000.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "997.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-169-172>
            <http://www.example.org/end>    "172.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "169.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1670-1672>
            <http://www.example.org/end>    "1672.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1670.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-768-770>
            <http://www.example.org/end>    "770.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-626-628>
            <http://www.example.org/end>    "628.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1191-1193>
            <http://www.example.org/end>    "1193.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1191.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2125-2129>
            <http://www.example.org/end>    "2129.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "2125.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-823-825>
            <http://www.example.org/end>    "825.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "823.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "11" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-568-570>
            <http://www.example.org/end>    "570.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "568.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1050-1052>
            <http://www.example.org/end>    "1052.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1050.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1047-1049>
            <http://www.example.org/end>    "1049.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1047.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-81-84>
            <http://www.example.org/end>    "84.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "81.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Every author stressed the importance of both internal and external communication/coordination. For IPs, this would include development of an internal communication plan to inform all health care facility staff, patients, and visitors about infection prevention strategies that need to be implemented. 10, 19, 37 Examples of infection prevention strategies that need to be communicated to employees, patients, and visitors include screening measures/procedures, the need for and appropriate use of isolation precautions, PPE, hand hygiene, social distancing practices, and postexposure follow-up. In addition, it is vital that IPs communicate changes in protocols related to PPE use or protective measures to staff, even if they occur middisaster response. This has been identified as being critical to effective infection prevention in previous emergencies. 28 Communication and coordination will also need to occur between the IP\\u0027s health care facility and external response agencies, such as other local hospitals and public health agencies. The IP\\u0027s role in external communication and coordination will depend on the health care facility emergency management plan. For some facilities, a member of the ICS will be responsible for all external communications. Other facilities may make this the responsibility of the IP. IPs should verify their role in internal and external communication and coordination by checking their facility emergency management plan for details.\",\"cite_spans\":[{\"start\":301.0,\"end\":304.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":305.0,\"end\":308.0,\"text\":\"19,\",\"ref_id\":\"BIBREF18\"},{\"start\":309.0,\"end\":311.0,\"text\":\"37\",\"ref_id\":\"BIBREF37\"},{\"start\":858.0,\"end\":860.0,\"text\":\"28\",\"ref_id\":\"BIBREF27\"}],\"ref_spans\":[],\"section\":\"Domain 4: Participation in disaster response and recovery\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-301-304> , <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-305-308> , <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-309-311> , <http://covid19.aksw.org/text-a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e_citespan-858-860> ;
            <http://www.example.org/section>
                    "Domain 4: Participation in disaster response and recovery" ;
            <http://www.example.org/text>  "Every author stressed the importance of both internal and external communication/coordination. For IPs, this would include development of an internal communication plan to inform all health care facility staff, patients, and visitors about infection prevention strategies that need to be implemented. 10, 19, 37 Examples of infection prevention strategies that need to be communicated to employees, patients, and visitors include screening measures/procedures, the need for and appropriate use of isolation precautions, PPE, hand hygiene, social distancing practices, and postexposure follow-up. In addition, it is vital that IPs communicate changes in protocols related to PPE use or protective measures to staff, even if they occur middisaster response. This has been identified as being critical to effective infection prevention in previous emergencies. 28 Communication and coordination will also need to occur between the IP's health care facility and external response agencies, such as other local hospitals and public health agencies. The IP's role in external communication and coordination will depend on the health care facility emergency management plan. For some facilities, a member of the ICS will be responsible for all external communications. Other facilities may make this the responsibility of the IP. IPs should verify their role in internal and external communication and coordination by checking their facility emergency management plan for details." ;
            <http://www.example.org/textHash>
                    "a1a71970f3a91686581dacf09728fe3aca647efa40bc3e331af22ecf9165632e" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-294-297>
            <http://www.example.org/end>    "297.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "294.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-fadd2e7950d40b557da079061605a00b77bbdb13684624e24f7c854e4a7f76c0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"An Internet search was conducted in September 2008 using the same search terms as above to identify existing book chapters, reports from response agencies, published standards and guidelines, and other relevant materials related to the role of IPs in emergency management that were outside the peerreviewed literature. Reports that did not address the role of IPs in emergency management were excluded. Data from the relevant sources identified through the literature review and Internet search were extracted. A spreadsheet was created that delineated the IP\\u0027s duty/task(s) or role(s) in emergency management identified by each source.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Literature review\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Literature review" ;
            <http://www.example.org/text>  "An Internet search was conducted in September 2008 using the same search terms as above to identify existing book chapters, reports from response agencies, published standards and guidelines, and other relevant materials related to the role of IPs in emergency management that were outside the peerreviewed literature. Reports that did not address the role of IPs in emergency management were excluded. Data from the relevant sources identified through the literature review and Internet search were extracted. A spreadsheet was created that delineated the IP's duty/task(s) or role(s) in emergency management identified by each source." ;
            <http://www.example.org/textHash>
                    "fadd2e7950d40b557da079061605a00b77bbdb13684624e24f7c854e4a7f76c0" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-847-851>
            <http://www.example.org/end>    "851.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "847.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-201-204>
            <http://www.example.org/end>    "204.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "201.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-117-121>
            <http://www.example.org/end>    "121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "117.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-1134-1136>
            <http://www.example.org/end>    "1136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1134.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1256-1259>
            <http://www.example.org/end>    "1259.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "1256.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-480-484>
            <http://www.example.org/end>    "484.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "480.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-919-922>
            <http://www.example.org/end>    "922.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "919.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "19," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-2091-2095>
            <http://www.example.org/end>    "2095.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "2091.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-568-572>
            <http://www.example.org/end>    "572.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "568.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-506-510>
            <http://www.example.org/end>    "510.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "506.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2755-2759>
            <http://www.example.org/end>    "2759.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "2755.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-616-620>
            <http://www.example.org/end>    "620.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "616.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3256-3260>
            <http://www.example.org/end>    "3260.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "3256.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-15107baefc70474b402ea9750a57e2123b7b26e5f6348bc3d060bb2979cadfa9_citespan-335-337>
            <http://www.example.org/end>    "337.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "335.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "34" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3353-3357>
            <http://www.example.org/end>    "3357.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "3353.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1161-1163>
            <http://www.example.org/end>    "1163.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "1161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-942-945>
            <http://www.example.org/end>    "945.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "942.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "16," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-2135-2138>
            <http://www.example.org/end>    "2138.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "2135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "28," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-89-92>
            <http://www.example.org/end>    "92.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "89.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-186-189>
            <http://www.example.org/end>    "189.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "186.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-174-178>
            <http://www.example.org/end>    "178.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "174.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[14]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-626-629>
            <http://www.example.org/end>    "629.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "30," .
    
    <http://covid19.aksw.org/text-18346d8b0244913e60be064eb766a9fb13738c8bf43b59e7d4191bc1eb0f1dd2_citespan-199-202>
            <http://www.example.org/end>    "202.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "199.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-869-873>
            <http://www.example.org/end>    "873.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "869.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1112-1116>
            <http://www.example.org/end>    "1116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-45efcbb646b325f8d9d4f88ba93832d827ba8be1dc95e17669e5a0251193d9e8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Following the analysis of published literature and reports, the primary author drafted the APIC State of the Art Report: The Role of the Infection Preventionist in Emergency Management document. Members of the 2008 APIC Emergency Preparedness Committee reviewed the initial draft document, and updates/edits were made as needed.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Drafting and review of IP\\u0027s role in emergency management\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Drafting and review of IP's role in emergency management" ;
            <http://www.example.org/text>  "Following the analysis of published literature and reports, the primary author drafted the APIC State of the Art Report: The Role of the Infection Preventionist in Emergency Management document. Members of the 2008 APIC Emergency Preparedness Committee reviewed the initial draft document, and updates/edits were made as needed." ;
            <http://www.example.org/textHash>
                    "45efcbb646b325f8d9d4f88ba93832d827ba8be1dc95e17669e5a0251193d9e8" .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-144-147>
            <http://www.example.org/end>    "147.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "144.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-59-61>
            <http://www.example.org/end>    "61.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "59.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "47" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-93-96>
            <http://www.example.org/end>    "96.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "93.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1286-1288>
            <http://www.example.org/end>    "1288.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1286.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-333-337>
            <http://www.example.org/end>    "337.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "333.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-80-84>
            <http://www.example.org/end>    "84.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "80.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-430-432>
            <http://www.example.org/end>    "432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "430.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1260-1262>
            <http://www.example.org/end>    "1262.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1260.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1626-1629>
            <http://www.example.org/end>    "1629.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "1626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-956-960>
            <http://www.example.org/end>    "960.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "956.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-542-545>
            <http://www.example.org/end>    "545.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "542.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "12," .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1024-1026>
            <http://www.example.org/end>    "1026.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "1024.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-1207-1211>
            <http://www.example.org/end>    "1211.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1207.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-636-640>
            <http://www.example.org/end>    "640.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "636.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[33]" .
    
    <http://covid19.aksw.org/text-58f94a8eab6a1e7deb1732ca5055645382968a2861bf86620c04e85663eeef48_citespan-148-150>
            <http://www.example.org/end>    "150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "148.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "32" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-809-812>
            <http://www.example.org/end>    "812.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "809.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-438-442>
            <http://www.example.org/end>    "442.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "438.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-b5831a59255128266b515f9574a911993aa7311c7c459de4df51f6f200496184>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Background: This report summarizes the scope and role of infection preventionists in emergency management for all types of disasters. Preventing the transmission of infectious agents during a disaster is an essential component of emergency management. Previous disasters have illustrated the need for better infection prevention and the involvement of an infection prevention professional in planning for and responding to such events. Methods: An evidence-based approach was used, consisting of a literature review and review by members of the Association for Professionals in Infection Control and Epidemiology, Inc, Emergency Preparedness Committee. Results: Nine domains were identified that describe the role of the infection preventionist in emergency management: knowledge of disasters and emergency management, assessing readiness and emergency management plans, infection prevention coverage, participation in disaster response and recovery, health care policy development, surveillance, patient management, physical plant issues, and infection preventionist as educator. Details for each domain are provided. Conclusion: Infection preventionists need to become more involved in emergency management at the personal, facility, and community level. This report outlines the infection preventionist\\u0027s responsibilities related to emergency management.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "Background: This report summarizes the scope and role of infection preventionists in emergency management for all types of disasters. Preventing the transmission of infectious agents during a disaster is an essential component of emergency management. Previous disasters have illustrated the need for better infection prevention and the involvement of an infection prevention professional in planning for and responding to such events. Methods: An evidence-based approach was used, consisting of a literature review and review by members of the Association for Professionals in Infection Control and Epidemiology, Inc, Emergency Preparedness Committee. Results: Nine domains were identified that describe the role of the infection preventionist in emergency management: knowledge of disasters and emergency management, assessing readiness and emergency management plans, infection prevention coverage, participation in disaster response and recovery, health care policy development, surveillance, patient management, physical plant issues, and infection preventionist as educator. Details for each domain are provided. Conclusion: Infection preventionists need to become more involved in emergency management at the personal, facility, and community level. This report outlines the infection preventionist's responsibilities related to emergency management." ;
            <http://www.example.org/textHash>
                    "b5831a59255128266b515f9574a911993aa7311c7c459de4df51f6f200496184" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-365-369>
            <http://www.example.org/end>    "369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[18]" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-83-85>
            <http://www.example.org/end>    "85.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF50" ;
            <http://www.example.org/start>  "83.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "50" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-280-284>
            <http://www.example.org/end>    "284.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "280.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2111-2114>
            <http://www.example.org/end>    "2114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "2111.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3441-3443>
            <http://www.example.org/end>    "3443.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "3441.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2719-2721>
            <http://www.example.org/end>    "2721.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "2719.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-2402-2404>
            <http://www.example.org/end>    "2404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "2402.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "52" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1122-1126>
            <http://www.example.org/end>    "1126.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "1122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1029-1031>
            <http://www.example.org/end>    "1031.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1029.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-1495-1498>
            <http://www.example.org/end>    "1498.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1495.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "37," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-370-372>
            <http://www.example.org/end>    "372.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-492-494>
            <http://www.example.org/end>    "494.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "492.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-461-463>
            <http://www.example.org/end>    "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "461.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-612-616>
            <http://www.example.org/end>    "616.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "612.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-840-844>
            <http://www.example.org/end>    "844.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "840.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-131-135>
            <http://www.example.org/end>    "135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "131.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1063-1067>
            <http://www.example.org/end>    "1067.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1063.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1263-1265>
            <http://www.example.org/end>    "1265.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1263.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-686ea9cdae9500235dc3afb61d21a60a4397ba849f410d8352bba785ee2611db_citespan-385-389>
            <http://www.example.org/end>    "389.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[22]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1059-1063>
            <http://www.example.org/end>    "1063.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1059.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-47f8c97d219123b00021e6fabbc82fc8cc662e4934fa19dbbbb454151924eb36_citespan-154-157>
            <http://www.example.org/end>    "157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "154.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2127-2129>
            <http://www.example.org/end>    "2129.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "2127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"At the facility level, IPs need to be involved in assessing mass casualty event readiness, including being involved in the facility hazard vulnerability assessment. 6, 9, [11] [12] [13] 31, 32, 34, 37, 38 Health care facilities need to assess all components of their all-hazards emergency management plan. Infection prevention-related aspects of the emergency management plan are only a small piece of the overall plan, but these issues require IP input to guide decision making. Various researchers have outlined strategies for assessing emergency management plans, [43] [44] [45] including an appendix in the APIC Bioterrorism Readiness Planning Suggestions document. 9 However, these assessment guides address all components of an emergency management plan, most of which do not require input from an IP. Examples would include information on how the hospital will address implementation activities required for adoption of the National Incident Management System (NIMS), development and evaluation of the emergency management plan, implementation of a staff education program related to emergency management, and set-up of an emergency operations center at the facility. [43] [44] [45] IPs would only be expected to address components of the facility emergency management plan that pertain to preventing or controlling the spread of disease, although IPs should be familiar with the findings from their facility and community hazard vulnerability assessments. 11-13 Some components of an emergency management plan that require IP input have been outlined, including surveillance, triage, patient placement, and isolation. [8] [9] [10] [11] [12] [13] 25, 26, 32, 38, 39 Although a comprehensive list of topics that require IP input have not been delineated in the literature, some issues that may affect infection transmission during disasters are listed in Table 1 . It is important that every health care facility have an IP as a member of the emergency management planning team to consult on issues that affect infection transmission in the health care setting during mass casualty events. 9, 10, 12, 13, 27, 29, 31, 37, 39 One component of facility readiness with which IPs need to be involved is resource assessment. 9,11-13,16,39 IPs will not need to help in assessing all health care facility resources for mass casualty incidents; only those that can affect infection transmission will require IP input. Examples of resources that may have an impact on infectious disease spread include personal protective equipment (PPE), hand hygiene products, antiinfective therapy, environmental decontamination products, patient linens, and isolation rooms/areas. 9, [11] [12] [13] 16, 39 It is anticipated that resources will be limited or unavailable during a mass casualty event, especially one involving an infectious agent such as a bioterrorism attack or a pandemic. Health care emergency management planning teams will need to make difficult decisions regarding how to allocate scare resources, and the potential infectious disease implications of these decisions must be taken into account. [11] [12] [13] 16, 29, 39 IP input will be vital in developing prioritization plans for therapy, prophylaxis, and vaccination when doses are limited 9, [11] [12] [13] 26, 39 ; allocation of PPE when resources are insufficient or unavailable 6, [11] [12] [13] 16, 26, 29, 37, 39 ; and safe patient placement when isolation rooms are depleted. 6, [8] [9] [10] [11] [12] [13] [14] 17, 25, 35, [37] [38] [39] A recent development in emergency management is the recognition that IP input is needed in community emergency management planning. Community disaster planners will need infection prevention guidance when setting up and running alternative care sites and shelters for displaced individuals. 6, 14, 28 Alternative care sites are needed for all events involving mass casualties in which the affected community needs to deliver medical care outside the traditional health care system. 6, 14, 28, 40, 45 Alternative care sites may consist of a hotel, closed hospital, converted warehouse, school, sports arena, convention center, or any building or space that is adapted for providing medical care. 46 Community shelters are buildings/areas used to house displaced individuals during a mass casualty incident and can range from a small evacuation center to a large sports arena. 39 The level of medical treatment provided at alternative care sites and community shelters will vary by the community and the size/scope of the event. Because health care staff and/or volunteers will deliver medical care at these sites, the risk of infection transmission exists. Therefore, it is essential that both alternative care sites and shelters have an infection prevention program to prevent the spread of infectious organisms. 6, 14, 28 This will require having IPs involved in community emergency management planning before an event and perhaps serving as a consultant during a mass casualty incident if resources allow.\",\"cite_spans\":[{\"start\":165.0,\"end\":167.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":168.0,\"end\":170.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":171.0,\"end\":175.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":176.0,\"end\":180.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":181.0,\"end\":185.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":186.0,\"end\":189.0,\"text\":\"31,\",\"ref_id\":\"BIBREF30\"},{\"start\":190.0,\"end\":193.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":194.0,\"end\":197.0,\"text\":\"34,\",\"ref_id\":\"BIBREF33\"},{\"start\":198.0,\"end\":201.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":202.0,\"end\":204.0,\"text\":\"38\",\"ref_id\":\"BIBREF38\"},{\"start\":567.0,\"end\":571.0,\"text\":\"[43]\",\"ref_id\":\"BIBREF43\"},{\"start\":572.0,\"end\":576.0,\"text\":\"[44]\",\"ref_id\":\"BIBREF44\"},{\"start\":577.0,\"end\":581.0,\"text\":\"[45]\",\"ref_id\":\"BIBREF45\"},{\"start\":670.0,\"end\":671.0,\"text\":\"9\",\"ref_id\":\"BIBREF8\"},{\"start\":1175.0,\"end\":1179.0,\"text\":\"[43]\",\"ref_id\":\"BIBREF43\"},{\"start\":1180.0,\"end\":1184.0,\"text\":\"[44]\",\"ref_id\":\"BIBREF44\"},{\"start\":1185.0,\"end\":1189.0,\"text\":\"[45]\",\"ref_id\":\"BIBREF45\"},{\"start\":1626.0,\"end\":1629.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":1630.0,\"end\":1633.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":1634.0,\"end\":1638.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":1639.0,\"end\":1643.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":1644.0,\"end\":1648.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":1649.0,\"end\":1653.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1654.0,\"end\":1657.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":1658.0,\"end\":1661.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":1662.0,\"end\":1665.0,\"text\":\"32,\",\"ref_id\":\"BIBREF31\"},{\"start\":1666.0,\"end\":1669.0,\"text\":\"38,\",\"ref_id\":\"BIBREF38\"},{\"start\":1670.0,\"end\":1672.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":2096.0,\"end\":2098.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":2099.0,\"end\":2102.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":2103.0,\"end\":2106.0,\"text\":\"12,\",\"ref_id\":\"BIBREF11\"},{\"start\":2107.0,\"end\":2110.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":2111.0,\"end\":2114.0,\"text\":\"27,\",\"ref_id\":\"BIBREF26\"},{\"start\":2115.0,\"end\":2118.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":2119.0,\"end\":2122.0,\"text\":\"31,\",\"ref_id\":\"BIBREF30\"},{\"start\":2123.0,\"end\":2126.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":2127.0,\"end\":2129.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":2664.0,\"end\":2666.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":2667.0,\"end\":2671.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":2672.0,\"end\":2676.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":2677.0,\"end\":2681.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":2682.0,\"end\":2685.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":2686.0,\"end\":2688.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":3099.0,\"end\":3103.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":3104.0,\"end\":3108.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":3109.0,\"end\":3113.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":3114.0,\"end\":3117.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":3118.0,\"end\":3121.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":3122.0,\"end\":3124.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":3248.0,\"end\":3250.0,\"text\":\"9,\",\"ref_id\":\"BIBREF8\"},{\"start\":3251.0,\"end\":3255.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":3256.0,\"end\":3260.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":3261.0,\"end\":3265.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":3266.0,\"end\":3269.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":3270.0,\"end\":3272.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":3340.0,\"end\":3342.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":3343.0,\"end\":3347.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":3348.0,\"end\":3352.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":3353.0,\"end\":3357.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":3358.0,\"end\":3361.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":3362.0,\"end\":3365.0,\"text\":\"26,\",\"ref_id\":\"BIBREF25\"},{\"start\":3366.0,\"end\":3369.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":3370.0,\"end\":3373.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":3374.0,\"end\":3376.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":3441.0,\"end\":3443.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":3444.0,\"end\":3447.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"},{\"start\":3448.0,\"end\":3451.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":3452.0,\"end\":3456.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":3457.0,\"end\":3461.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":3462.0,\"end\":3466.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":3467.0,\"end\":3471.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":3472.0,\"end\":3476.0,\"text\":\"[14]\",\"ref_id\":\"BIBREF13\"},{\"start\":3477.0,\"end\":3480.0,\"text\":\"17,\",\"ref_id\":\"BIBREF16\"},{\"start\":3481.0,\"end\":3484.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":3485.0,\"end\":3488.0,\"text\":\"35,\",\"ref_id\":\"BIBREF34\"},{\"start\":3489.0,\"end\":3493.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF37\"},{\"start\":3494.0,\"end\":3498.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF38\"},{\"start\":3499.0,\"end\":3503.0,\"text\":\"[39]\",\"ref_id\":\"BIBREF39\"},{\"start\":3795.0,\"end\":3797.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":3798.0,\"end\":3801.0,\"text\":\"14,\",\"ref_id\":\"BIBREF13\"},{\"start\":3802.0,\"end\":3804.0,\"text\":\"28\",\"ref_id\":\"BIBREF27\"},{\"start\":3986.0,\"end\":3988.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":3989.0,\"end\":3992.0,\"text\":\"14,\",\"ref_id\":\"BIBREF13\"},{\"start\":3993.0,\"end\":3996.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":3997.0,\"end\":4000.0,\"text\":\"40,\",\"ref_id\":\"BIBREF40\"},{\"start\":4001.0,\"end\":4003.0,\"text\":\"45\",\"ref_id\":\"BIBREF45\"},{\"start\":4199.0,\"end\":4201.0,\"text\":\"46\",\"ref_id\":\"BIBREF46\"},{\"start\":4379.0,\"end\":4381.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":4817.0,\"end\":4819.0,\"text\":\"6,\",\"ref_id\":\"BIBREF5\"},{\"start\":4820.0,\"end\":4823.0,\"text\":\"14,\",\"ref_id\":\"BIBREF13\"},{\"start\":4824.0,\"end\":4826.0,\"text\":\"28\",\"ref_id\":\"BIBREF27\"}],\"ref_spans\":[{\"start\":1861.0,\"end\":1868.0,\"text\":\"Table 1\"}],\"section\":\"Domain 1: Knowledge of disasters and emergency management\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3270-3272> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3462-3466> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4001-4003> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2103-2106> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1644-1648> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3798-3801> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1175-1179> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4820-4823> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2686-2688> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1634-1638> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3340-3342> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4379-4381> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3353-3357> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2672-2676> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1180-1184> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3358-3361> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1654-1657> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2119-2122> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1670-1672> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3099-3103> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-577-581> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-670-671> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3494-3498> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3485-3488> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-194-197> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3997-4000> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2099-2102> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-567-571> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-165-167> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1639-1643> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3343-3347> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4824-4826> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1658-1661> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3993-3996> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2107-2110> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3986-3988> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2664-2666> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1630-1633> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3374-3376> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3472-3476> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3266-3269> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-572-576> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-176-180> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3989-3992> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3489-3493> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-186-189> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2667-2671> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3366-3369> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1662-1665> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3109-3113> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4817-4819> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3118-3121> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-202-204> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3248-3250> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1185-1189> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2677-2681> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3256-3260> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1626-1629> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3348-3352> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3114-3117> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2127-2129> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3795-3797> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3467-3471> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2682-2685> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-190-193> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1649-1653> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3802-3804> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3370-3373> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-1666-1669> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3477-3480> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-181-185> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3441-3443> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2115-2118> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3444-3447> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3261-3265> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3499-3503> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-198-201> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3452-3456> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3457-3461> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-4199-4201> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3362-3365> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2111-2114> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-171-175> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-168-170> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3104-3108> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2096-2098> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3251-3255> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3122-3124> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-2123-2126> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3448-3451> , <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3481-3484> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_refspan-1861-1868> ;
            <http://www.example.org/section>
                    "Domain 1: Knowledge of disasters and emergency management" ;
            <http://www.example.org/text>  "At the facility level, IPs need to be involved in assessing mass casualty event readiness, including being involved in the facility hazard vulnerability assessment. 6, 9, [11] [12] [13] 31, 32, 34, 37, 38 Health care facilities need to assess all components of their all-hazards emergency management plan. Infection prevention-related aspects of the emergency management plan are only a small piece of the overall plan, but these issues require IP input to guide decision making. Various researchers have outlined strategies for assessing emergency management plans, [43] [44] [45] including an appendix in the APIC Bioterrorism Readiness Planning Suggestions document. 9 However, these assessment guides address all components of an emergency management plan, most of which do not require input from an IP. Examples would include information on how the hospital will address implementation activities required for adoption of the National Incident Management System (NIMS), development and evaluation of the emergency management plan, implementation of a staff education program related to emergency management, and set-up of an emergency operations center at the facility. [43] [44] [45] IPs would only be expected to address components of the facility emergency management plan that pertain to preventing or controlling the spread of disease, although IPs should be familiar with the findings from their facility and community hazard vulnerability assessments. 11-13 Some components of an emergency management plan that require IP input have been outlined, including surveillance, triage, patient placement, and isolation. [8] [9] [10] [11] [12] [13] 25, 26, 32, 38, 39 Although a comprehensive list of topics that require IP input have not been delineated in the literature, some issues that may affect infection transmission during disasters are listed in Table 1 . It is important that every health care facility have an IP as a member of the emergency management planning team to consult on issues that affect infection transmission in the health care setting during mass casualty events. 9, 10, 12, 13, 27, 29, 31, 37, 39 One component of facility readiness with which IPs need to be involved is resource assessment. 9,11-13,16,39 IPs will not need to help in assessing all health care facility resources for mass casualty incidents; only those that can affect infection transmission will require IP input. Examples of resources that may have an impact on infectious disease spread include personal protective equipment (PPE), hand hygiene products, antiinfective therapy, environmental decontamination products, patient linens, and isolation rooms/areas. 9, [11] [12] [13] 16, 39 It is anticipated that resources will be limited or unavailable during a mass casualty event, especially one involving an infectious agent such as a bioterrorism attack or a pandemic. Health care emergency management planning teams will need to make difficult decisions regarding how to allocate scare resources, and the potential infectious disease implications of these decisions must be taken into account. [11] [12] [13] 16, 29, 39 IP input will be vital in developing prioritization plans for therapy, prophylaxis, and vaccination when doses are limited 9, [11] [12] [13] 26, 39 ; allocation of PPE when resources are insufficient or unavailable 6, [11] [12] [13] 16, 26, 29, 37, 39 ; and safe patient placement when isolation rooms are depleted. 6, [8] [9] [10] [11] [12] [13] [14] 17, 25, 35, [37] [38] [39] A recent development in emergency management is the recognition that IP input is needed in community emergency management planning. Community disaster planners will need infection prevention guidance when setting up and running alternative care sites and shelters for displaced individuals. 6, 14, 28 Alternative care sites are needed for all events involving mass casualties in which the affected community needs to deliver medical care outside the traditional health care system. 6, 14, 28, 40, 45 Alternative care sites may consist of a hotel, closed hospital, converted warehouse, school, sports arena, convention center, or any building or space that is adapted for providing medical care. 46 Community shelters are buildings/areas used to house displaced individuals during a mass casualty incident and can range from a small evacuation center to a large sports arena. 39 The level of medical treatment provided at alternative care sites and community shelters will vary by the community and the size/scope of the event. Because health care staff and/or volunteers will deliver medical care at these sites, the risk of infection transmission exists. Therefore, it is essential that both alternative care sites and shelters have an infection prevention program to prevent the spread of infectious organisms. 6, 14, 28 This will require having IPs involved in community emergency management planning before an event and perhaps serving as a consultant during a mass casualty incident if resources allow." ;
            <http://www.example.org/textHash>
                    "97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2751-2754>
            <http://www.example.org/end>    "2754.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "2751.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "35," .
    
    <http://covid19.aksw.org/text-8546a39b17de5f9d7374258f2204e0d17d65ee2d7fc3b4b2a1fe0140cdd10a77_citespan-729-731>
            <http://www.example.org/end>    "731.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "729.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "10" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1729-1731>
            <http://www.example.org/end>    "1731.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "1729.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-728-732>
            <http://www.example.org/end>    "732.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "728.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-1132-1135>
            <http://www.example.org/end>    "1135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "1132.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "26," .
    
    <http://covid19.aksw.org/text-6cba40af069e925029d25f6fff9468fb77b62ae28cd1c2d84b3e8bc74f1e05e9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In May 2008, the APIC hosted a Mini Summit on Emergency Preparedness. 14 This meeting involved representatives from a variety of key organizations involved in emergency management, including local and state public health agencies, Department of Homeland Security, National Association of City and County Health Officials, Centers for Disease Control and Prevention (CDC), American Society of Healthcare Engineering, Federal Emergency Management Agency, first responder agencies, home health, long-term care, academic institutions, industry partners, and other agencies/groups. The goal of this Mini Summit was to begin a dialogue about the APIC and IPs\\u0027 roles in emergency management. The proceedings from the meeting were used as a source to help inform the development of the IP\\u0027s role in emergency management document. 14 \",\"cite_spans\":[{\"start\":822.0,\"end\":824.0,\"text\":\"14\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[],\"section\":\"APIC-sponsored emergency preparedness Mini Summit\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-6cba40af069e925029d25f6fff9468fb77b62ae28cd1c2d84b3e8bc74f1e05e9_citespan-822-824> ;
            <http://www.example.org/section>
                    "APIC-sponsored emergency preparedness Mini Summit" ;
            <http://www.example.org/text>  "In May 2008, the APIC hosted a Mini Summit on Emergency Preparedness. 14 This meeting involved representatives from a variety of key organizations involved in emergency management, including local and state public health agencies, Department of Homeland Security, National Association of City and County Health Officials, Centers for Disease Control and Prevention (CDC), American Society of Healthcare Engineering, Federal Emergency Management Agency, first responder agencies, home health, long-term care, academic institutions, industry partners, and other agencies/groups. The goal of this Mini Summit was to begin a dialogue about the APIC and IPs' roles in emergency management. The proceedings from the meeting were used as a source to help inform the development of the IP's role in emergency management document. 14 " ;
            <http://www.example.org/textHash>
                    "6cba40af069e925029d25f6fff9468fb77b62ae28cd1c2d84b3e8bc74f1e05e9" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-365-367>
            <http://www.example.org/end>    "367.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-987-991>
            <http://www.example.org/end>    "991.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "987.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-0feb584bfbf32b6f3d8233332052c90d8fb09f7d2705e8b843a48288cdf71307_citespan-614-617>
            <http://www.example.org/end>    "617.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "614.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "27," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3118-3121>
            <http://www.example.org/end>    "3121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "3118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "29," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-168-170>
            <http://www.example.org/end>    "170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "168.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "9," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3499-3503>
            <http://www.example.org/end>    "3503.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "3499.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[39]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3462-3466>
            <http://www.example.org/end>    "3466.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "3462.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-5ce0046b83233297cada1200c131ae306d824cb05c90e58f6a86caf5aec8c67a_citespan-2733-2737>
            <http://www.example.org/end>    "2737.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "2733.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-d1fde7d08a1117e78cc76a89e2295f2a93305c8b508153f25211d850d847b36c_citespan-571-595>
            <http://www.example.org/end>    "595.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "571.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6.9,11-13,28,30,32,38,39" .
    
    <http://covid19.aksw.org/text-50ab5727a3162f1410958bd104dbd5db89c1491cf2c6805bea46b86dcb187258_citespan-662-664>
            <http://www.example.org/end>    "664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "662.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3109-3113>
            <http://www.example.org/end>    "3113.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "3109.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1078-1081>
            <http://www.example.org/end>    "1081.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "1078.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-7f7c7f90e11b16e02fbfd467e278e791a59707176069b5275893d07065cf88ea_citespan-383-387>
            <http://www.example.org/end>    "387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "383.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"IPs need to create or inform health care policy related to staff safety during emergency management. 13, 16, 25, 28, 29, 37, 39 Protocol development should be coordinated with facility Occupational Health Department personnel. IPs will not be responsible for development of all occupational health policy related to emergency management; only issues that affect infection transmission will fall under the auspices of the IP. Examples of emergency management occupational health issues with infectious disease implications include developing protocols for monitoring and following up on staff work exposures, informing staff prioritization plans for antiinfective therapy and/ or vaccination, identifying staff at high-risk for infection development, and ensuring adequate stocks of PPE for staff use. 13, 16, 25, 28, 29, 37, 39 Although it will be the Occupational Health Department\\u0027s responsibility to track and follow-up on staff work exposures, it is important that IPs be involved in the development of these protocols as they relate to infection prevention. This includes defining an exposure, identifying appropriate postexposure prophylaxis, and informing decisions regarding staff reassignment or furlough. IPs should also be involved in developing protocols related to staff immunization, including seasonal influenza, smallpox, and other vaccines. 10, 37 Another occupational health emergency management policy with which IPs should be involved is the development of protocols for designating staff limited to work with infected patients. 13, 16, 25, 29, 39 This process includes both patient and health care worker cohorting procedures to decrease the risk of infection spread and maximize staff resources. 29\",\"cite_spans\":[{\"start\":101.0,\"end\":104.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":105.0,\"end\":108.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":109.0,\"end\":112.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":113.0,\"end\":116.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":117.0,\"end\":120.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":121.0,\"end\":124.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":125.0,\"end\":127.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":801.0,\"end\":804.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":805.0,\"end\":808.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":809.0,\"end\":812.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":813.0,\"end\":816.0,\"text\":\"28,\",\"ref_id\":\"BIBREF27\"},{\"start\":817.0,\"end\":820.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":821.0,\"end\":824.0,\"text\":\"37,\",\"ref_id\":\"BIBREF37\"},{\"start\":825.0,\"end\":827.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"},{\"start\":1358.0,\"end\":1361.0,\"text\":\"10,\",\"ref_id\":\"BIBREF9\"},{\"start\":1362.0,\"end\":1364.0,\"text\":\"37\",\"ref_id\":\"BIBREF37\"},{\"start\":1549.0,\"end\":1552.0,\"text\":\"13,\",\"ref_id\":\"BIBREF12\"},{\"start\":1553.0,\"end\":1556.0,\"text\":\"16,\",\"ref_id\":\"BIBREF15\"},{\"start\":1557.0,\"end\":1560.0,\"text\":\"25,\",\"ref_id\":\"BIBREF24\"},{\"start\":1561.0,\"end\":1564.0,\"text\":\"29,\",\"ref_id\":\"BIBREF28\"},{\"start\":1565.0,\"end\":1567.0,\"text\":\"39\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[],\"section\":\"Domain 5: Health care policy development\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-101-104> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-813-816> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-117-120> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-113-116> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1553-1556> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1549-1552> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-817-820> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1362-1364> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-809-812> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1358-1361> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-801-804> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-821-824> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-125-127> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-121-124> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-105-108> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1561-1564> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-109-112> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1557-1560> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-805-808> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-825-827> , <http://covid19.aksw.org/text-5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34_citespan-1565-1567> ;
            <http://www.example.org/section>
                    "Domain 5: Health care policy development" ;
            <http://www.example.org/text>  "IPs need to create or inform health care policy related to staff safety during emergency management. 13, 16, 25, 28, 29, 37, 39 Protocol development should be coordinated with facility Occupational Health Department personnel. IPs will not be responsible for development of all occupational health policy related to emergency management; only issues that affect infection transmission will fall under the auspices of the IP. Examples of emergency management occupational health issues with infectious disease implications include developing protocols for monitoring and following up on staff work exposures, informing staff prioritization plans for antiinfective therapy and/ or vaccination, identifying staff at high-risk for infection development, and ensuring adequate stocks of PPE for staff use. 13, 16, 25, 28, 29, 37, 39 Although it will be the Occupational Health Department's responsibility to track and follow-up on staff work exposures, it is important that IPs be involved in the development of these protocols as they relate to infection prevention. This includes defining an exposure, identifying appropriate postexposure prophylaxis, and informing decisions regarding staff reassignment or furlough. IPs should also be involved in developing protocols related to staff immunization, including seasonal influenza, smallpox, and other vaccines. 10, 37 Another occupational health emergency management policy with which IPs should be involved is the development of protocols for designating staff limited to work with infected patients. 13, 16, 25, 29, 39 This process includes both patient and health care worker cohorting procedures to decrease the risk of infection spread and maximize staff resources. 29" ;
            <http://www.example.org/textHash>
                    "5ea92a513583d4769d571a12c446faed67f5e8085fd81a64366a9aae1557cc34" .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-215-219>
            <http://www.example.org/end>    "219.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "215.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-97a6e847ff9ab2e6449610955f849ba27fe16a17f8fd14f5faecccc66a3fadb6_citespan-141-145>
            <http://www.example.org/end>    "145.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "141.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3374-3376>
            <http://www.example.org/end>    "3376.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "3374.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "39" .
    
    <http://covid19.aksw.org/text-4c7204d0e4c7747a7b8ac7601749427c89e1aef462676e28cae806c293c05c5d_citespan-435-437>
            <http://www.example.org/end>    "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "435.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "14" .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-807-811>
            <http://www.example.org/end>    "811.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "807.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-f44147f03ebda139e43360ba44f9043c23a5556b24174cfdc9a859b4408b6cfb_citespan-1253-1255>
            <http://www.example.org/end>    "1255.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "1253.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6," .
    
    <http://covid19.aksw.org/text-daf5f337bbfb9620779ceaf2eac6f2e53a618f9dbf5ee033cb770de07c2b3d2b_citespan-830-833>
            <http://www.example.org/end>    "833.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "830.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-fe37ff7b8d302715c0c9e523cda1d9fc519ec12860e75886cf919e86bfb04125_citespan-53-57>
            <http://www.example.org/end>    "57.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "53.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-97c2cfe40cfdc7550336ffa6cb330979d11e8a50989930860f3e79bc4884cb3c_citespan-3481-3484>
            <http://www.example.org/end>    "3484.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "3481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25," .
    
    <http://covid19.aksw.org/text-c9558de223ae873e030739d55c4346dedd7c852e02ac819cc754bbde13e4c32f_citespan-458-462>
            <http://www.example.org/end>    "462.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "458.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[43]" .
}
<http://covid19.aksw.org/daff6ac7ece180dfb53e12fbaf8a1902f1a31d83> {
    <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The index case was identified in 32 of the 64 outbreaks analyzed (50%), but the source could not be identified in 26 outbreaks (40.63%) ( Table 2) . Table 3 presents the numbers of patients and staff involved in the outbreaks, along with mortality stratified by the causative virus. In several reports, the fatality rate was not specified. Mortality was calculated based on number of deaths out of the total number of patients involved only when data were available. We identified 48 deaths out of 669 patients involved in 48 outbreaks. Mortality varied depending on the type of virus; overall average mortality was 7.17%, meaning that an average of 1 neonate died during each outbreak. Table 4 lists measures taken to contain the outbreaks. In most of the epidemics, multiple measures were implemented. Patient screening or surveillance, isolation or cohorting of patients, enforcement of hand hygiene measures, use of protective clothing, and personnel screening or surveillance were the most frequently introduced measures. In 26.56% of cases, the countermeasures were ineffective in stopping the outbreak, and the involved wards had to be closed. Correlating the epidemic episodes with the involved departments, 9 of 44 outbreaks (20.45%) that occurred in NICUs and 8 of 20 outbreaks (40%) in nonintensive care units led to ward closure.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":138.0,\"end\":146.0,\"text\":\"Table 2)\",\"ref_id\":\"TABREF1\"},{\"start\":149.0,\"end\":156.0,\"text\":\"Table 3\"},{\"start\":687.0,\"end\":694.0,\"text\":\"Table 4\"}],\"section\":\"RESULTS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d_refspan-138-146> , <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d_refspan-149-156> , <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d_refspan-687-694> ;
            <http://www.example.org/section>
                    "RESULTS" ;
            <http://www.example.org/text>  "The index case was identified in 32 of the 64 outbreaks analyzed (50%), but the source could not be identified in 26 outbreaks (40.63%) ( Table 2) . Table 3 presents the numbers of patients and staff involved in the outbreaks, along with mortality stratified by the causative virus. In several reports, the fatality rate was not specified. Mortality was calculated based on number of deaths out of the total number of patients involved only when data were available. We identified 48 deaths out of 669 patients involved in 48 outbreaks. Mortality varied depending on the type of virus; overall average mortality was 7.17%, meaning that an average of 1 neonate died during each outbreak. Table 4 lists measures taken to contain the outbreaks. In most of the epidemics, multiple measures were implemented. Patient screening or surveillance, isolation or cohorting of patients, enforcement of hand hygiene measures, use of protective clothing, and personnel screening or surveillance were the most frequently introduced measures. In 26.56% of cases, the countermeasures were ineffective in stopping the outbreak, and the involved wards had to be closed. Correlating the epidemic episodes with the involved departments, 9 of 44 outbreaks (20.45%) that occurred in NICUs and 8 of 20 outbreaks (40%) in nonintensive care units led to ward closure." ;
            <http://www.example.org/textHash>
                    "cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d" .
    
    <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d_refspan-687-694>
            <http://www.example.org/end>    "694.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "687.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 4" .
    
    <http://covid19.aksw.org/text-78619632a5a138d54d5f1985fd48b2cc3b89dc4022e4af26c32b0b5c2ca542ac>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The Gastmeier 4 database search was carried out in July 2005 and reported a total of 276 outbreaks in neonatology. The author pointed out that the published outbreaks are those with the largest number of patients involved, suggesting that the published outbreaks represent only the tip of the iceberg of the total number of NICU outbreaks.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "The Gastmeier 4 database search was carried out in July 2005 and reported a total of 276 outbreaks in neonatology. The author pointed out that the published outbreaks are those with the largest number of patients involved, suggesting that the published outbreaks represent only the tip of the iceberg of the total number of NICU outbreaks." ;
            <http://www.example.org/textHash>
                    "78619632a5a138d54d5f1985fd48b2cc3b89dc4022e4af26c32b0b5c2ca542ac" .
    
    <http://covid19.aksw.org/text-dcfbc605f6dfa7539539218b1b5731684047b85c10b5b2b33cad370379f29688_citespan-118-119>
            <http://www.example.org/end>    "119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "4" .
    
    <http://covid19.aksw.org/text-b5797f4922a4952bc5ce5e44de540ce156256b7f7e03ea5f9fd4ecaaf5839d38_citespan-479-480>
            <http://www.example.org/end>    "480.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "479.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "6" .
    
    <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d_refspan-149-156>
            <http://www.example.org/end>    "156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "149.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 3" .
    
    <http://covid19.aksw.org/text-79a59361e2aa06a0a43e2abadf1d68ec1bf0acbed7cfdbde82da988fb2c97d37>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Considering the number of reported outbreaks for any viral agent and the incidence of each agent on the total of neonatal outbreaks and on the total of neonatal viral outbreaks, the 5 most frequently reported viral agents were rotavirus (23.44%), respiratory syncytial virus (17.19%), enterovirus (15.63%), hepatitis A (10.94%), and adenovirus (9.38%). The predominant types of health careeassociated infections identified are listed in Table 1 . In most outbreaks, the virus caused more than 1 infection type. The most frequent type of infection was gastrointestinal system infection (inclusive of hepatitis; 54.69%), followed by lower respiratory tract infection other than pneumonia (34.38%). Lower respiratory tract infection other than pneumonia and pneumonia together accounted for 50.01% of the infections.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":437.0,\"end\":444.0,\"text\":\"Table 1\",\"ref_id\":\"TABREF0\"}],\"section\":\"RESULTS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-79a59361e2aa06a0a43e2abadf1d68ec1bf0acbed7cfdbde82da988fb2c97d37_refspan-437-444> ;
            <http://www.example.org/section>
                    "RESULTS" ;
            <http://www.example.org/text>  "Considering the number of reported outbreaks for any viral agent and the incidence of each agent on the total of neonatal outbreaks and on the total of neonatal viral outbreaks, the 5 most frequently reported viral agents were rotavirus (23.44%), respiratory syncytial virus (17.19%), enterovirus (15.63%), hepatitis A (10.94%), and adenovirus (9.38%). The predominant types of health careeassociated infections identified are listed in Table 1 . In most outbreaks, the virus caused more than 1 infection type. The most frequent type of infection was gastrointestinal system infection (inclusive of hepatitis; 54.69%), followed by lower respiratory tract infection other than pneumonia (34.38%). Lower respiratory tract infection other than pneumonia and pneumonia together accounted for 50.01% of the infections." ;
            <http://www.example.org/textHash>
                    "79a59361e2aa06a0a43e2abadf1d68ec1bf0acbed7cfdbde82da988fb2c97d37" .
    
    <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d_refspan-138-146>
            <http://www.example.org/end>    "146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "138.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 2)" .
    
    <http://covid19.aksw.org/text-c5dbdb3af8a0cbc732c81b379412f621f35d94d32cd99ed0aee6a0dc02b0a33b_citespan-230-231>
            <http://www.example.org/end>    "231.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "230.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "4" .
    
    <http://covid19.aksw.org/daff6ac7ece180dfb53e12fbaf8a1902f1a31d83>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "daff6ac7ece180dfb53e12fbaf8a1902f1a31d83" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-b5797f4922a4952bc5ce5e44de540ce156256b7f7e03ea5f9fd4ecaaf5839d38> , <http://covid19.aksw.org/text-79a59361e2aa06a0a43e2abadf1d68ec1bf0acbed7cfdbde82da988fb2c97d37> , <http://covid19.aksw.org/text-059c5c1ee254c2d9557ebec86f1d0ee22a06509aade525013541d5bca34b4943> , <http://covid19.aksw.org/text-78619632a5a138d54d5f1985fd48b2cc3b89dc4022e4af26c32b0b5c2ca542ac> , <http://covid19.aksw.org/text-aeb768c33cf30e71b6da857785f48e123494f404264fed693cb5ec81fb67b210> , <http://covid19.aksw.org/text-2c41dd8dcc0bcc9a87b2f8cf52175c8eb17d441d5f89afea7f503fc3b3139a51> , <http://covid19.aksw.org/text-cca6e623183dad06d37d791a166471a586f2d93db3521b05318ba9a189d13a9d> , <http://covid19.aksw.org/text-c5dbdb3af8a0cbc732c81b379412f621f35d94d32cd99ed0aee6a0dc02b0a33b> , <http://covid19.aksw.org/text-9c5d40f458cf25eed462b1563d000e93cd4570dee5f08ea6b562156b4290e8b6> , <http://covid19.aksw.org/text-f62e607fb03b281f0447b42cf26aaee04b484e533137fec7ba4ebcf7b9e1c27b> , <http://covid19.aksw.org/text-1990d0eb32f2912f6e8bf7dd7b65e922831dca290d5a700e10754f95a1cf11e4> , <http://covid19.aksw.org/text-674fac5c40f7890b987d4b3c6c04ac1edb4b8b91f7034d2948c0f02173c9db60> , <http://covid19.aksw.org/text-2dade2bffee0c09f92d2dd0786ad3db18bb80a1cd9020af768fa55351eb5481e> , <http://covid19.aksw.org/text-dcfbc605f6dfa7539539218b1b5731684047b85c10b5b2b33cad370379f29688> , <http://covid19.aksw.org/text-215e948d96edb244613a8c390c7387d99a3ea73dab0db0ed5acd37efae90ce42> , <http://covid19.aksw.org/text-bba4d21d402be665d75ac1b877ad2b657ed7e97fff71b77398e2bbddee438fdf> .
    
    <http://covid19.aksw.org/text-f62e607fb03b281f0447b42cf26aaee04b484e533137fec7ba4ebcf7b9e1c27b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"\\\"Change in antibiotic therapy\\\" in case of viral infections assume a different significance and importance, meaning the suspension of antibiotic therapy after the confirmation of the viral source of infection or, in most cases, the switch to antiviral agents or palivizumab for respiratory syncytial virus outbreaks. Yet in the field of vaccination, immunoglobulin administration (passive immunization) is included as a preventive measure.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"RESULTS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "RESULTS" ;
            <http://www.example.org/text>  "\"Change in antibiotic therapy\" in case of viral infections assume a different significance and importance, meaning the suspension of antibiotic therapy after the confirmation of the viral source of infection or, in most cases, the switch to antiviral agents or palivizumab for respiratory syncytial virus outbreaks. Yet in the field of vaccination, immunoglobulin administration (passive immunization) is included as a preventive measure." ;
            <http://www.example.org/textHash>
                    "f62e607fb03b281f0447b42cf26aaee04b484e533137fec7ba4ebcf7b9e1c27b" .
    
    <http://covid19.aksw.org/text-bba4d21d402be665d75ac1b877ad2b657ed7e97fff71b77398e2bbddee438fdf>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Our analysis of viral outbreaks in NICUs has some limitations. The Outbreak Database is the largest collection of reported nosocomial outbreaks, but still does not contain all health caree associated outbreaks, covering only approximately three-quarters of the total number of nosocomial outbreaks identified on a MEDLINE search. Moreover, not all outbreak descriptions are available in MEDLINE; indeed, only a small proportion of outbreaks have been published in the medical literature. Reasons for this include that some outbreaks were not considered worthy of publication, the number of involved patients was considered too small, or potential authors feared negative consequences for their own hospitals from reporting an epidemic event. Thus, we are well aware that our analysis does not include all of the NICU health careeassociated viral outbreaks that have ever occurred or ever been reported.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "Our analysis of viral outbreaks in NICUs has some limitations. The Outbreak Database is the largest collection of reported nosocomial outbreaks, but still does not contain all health caree associated outbreaks, covering only approximately three-quarters of the total number of nosocomial outbreaks identified on a MEDLINE search. Moreover, not all outbreak descriptions are available in MEDLINE; indeed, only a small proportion of outbreaks have been published in the medical literature. Reasons for this include that some outbreaks were not considered worthy of publication, the number of involved patients was considered too small, or potential authors feared negative consequences for their own hospitals from reporting an epidemic event. Thus, we are well aware that our analysis does not include all of the NICU health careeassociated viral outbreaks that have ever occurred or ever been reported." ;
            <http://www.example.org/textHash>
                    "bba4d21d402be665d75ac1b877ad2b657ed7e97fff71b77398e2bbddee438fdf" .
    
    <http://covid19.aksw.org/text-79a59361e2aa06a0a43e2abadf1d68ec1bf0acbed7cfdbde82da988fb2c97d37_refspan-437-444>
            <http://www.example.org/end>    "444.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF0" ;
            <http://www.example.org/start>  "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-2dade2bffee0c09f92d2dd0786ad3db18bb80a1cd9020af768fa55351eb5481e_citespan-991-992>
            <http://www.example.org/end>    "992.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "991.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "3" .
    
    <http://covid19.aksw.org/text-2dade2bffee0c09f92d2dd0786ad3db18bb80a1cd9020af768fa55351eb5481e_citespan-535-536>
            <http://www.example.org/end>    "536.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "535.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "1" .
    
    <http://covid19.aksw.org/text-2c41dd8dcc0bcc9a87b2f8cf52175c8eb17d441d5f89afea7f503fc3b3139a51>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The outbreak database contained a total of 590 neonatal outbreaks, 75 of which were sustained by viruses. Eleven of these 75 reported viral outbreaks were excluded from our analysis: 3 that were reported twice and 8 that were relevant to pediatric, not neonatal, patients. When we reported these studies to the authors of the database, they amended their list, and thus a total of 64 neonatal viral outbreaks were included in our analysis. Interestingly, 44 of these 64 outbreaks (68.75%) were reported from NICUs. The number of published reports of outbreaks has increased over time over the last several decades, from 3 before to 14 in the 1980s and 13 in the 1990 to 34 from 2000 to the present.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"RESULTS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "RESULTS" ;
            <http://www.example.org/text>  "The outbreak database contained a total of 590 neonatal outbreaks, 75 of which were sustained by viruses. Eleven of these 75 reported viral outbreaks were excluded from our analysis: 3 that were reported twice and 8 that were relevant to pediatric, not neonatal, patients. When we reported these studies to the authors of the database, they amended their list, and thus a total of 64 neonatal viral outbreaks were included in our analysis. Interestingly, 44 of these 64 outbreaks (68.75%) were reported from NICUs. The number of published reports of outbreaks has increased over time over the last several decades, from 3 before to 14 in the 1980s and 13 in the 1990 to 34 from 2000 to the present." ;
            <http://www.example.org/textHash>
                    "2c41dd8dcc0bcc9a87b2f8cf52175c8eb17d441d5f89afea7f503fc3b3139a51" .
    
    <http://covid19.aksw.org/text-674fac5c40f7890b987d4b3c6c04ac1edb4b8b91f7034d2948c0f02173c9db60>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In conclusion, to the best of our knowledge, this is the first study analyzing the viral origins of nosocomial infections in NICUs. Our findings can provide a valuable tool for those involved in the investigation of neonatal infections. The mortality rates reported in this analysis demonstrate the importance of noncongenital viral infections in NICUs and the need for more effective outbreak prevention.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "In conclusion, to the best of our knowledge, this is the first study analyzing the viral origins of nosocomial infections in NICUs. Our findings can provide a valuable tool for those involved in the investigation of neonatal infections. The mortality rates reported in this analysis demonstrate the importance of noncongenital viral infections in NICUs and the need for more effective outbreak prevention." ;
            <http://www.example.org/textHash>
                    "674fac5c40f7890b987d4b3c6c04ac1edb4b8b91f7034d2948c0f02173c9db60" .
    
    <http://covid19.aksw.org/text-dcfbc605f6dfa7539539218b1b5731684047b85c10b5b2b33cad370379f29688>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Unexpectedly, our analysis found a similar mortality rate in viral outbreaks and bacterial outbreaks (7.17% vs 6.4%), 4 confirming the importance of viral infections in NICU. The high average number of patients involved in the NICU outbreaks, as well as the high mortality rate, demonstrates the need for more effective prevention.\",\"cite_spans\":[{\"start\":118.0,\"end\":119.0,\"text\":\"4\",\"ref_id\":\"BIBREF3\"}],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-dcfbc605f6dfa7539539218b1b5731684047b85c10b5b2b33cad370379f29688_citespan-118-119> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "Unexpectedly, our analysis found a similar mortality rate in viral outbreaks and bacterial outbreaks (7.17% vs 6.4%), 4 confirming the importance of viral infections in NICU. The high average number of patients involved in the NICU outbreaks, as well as the high mortality rate, demonstrates the need for more effective prevention." ;
            <http://www.example.org/textHash>
                    "dcfbc605f6dfa7539539218b1b5731684047b85c10b5b2b33cad370379f29688" .
    
    <http://covid19.aksw.org/text-215e948d96edb244613a8c390c7387d99a3ea73dab0db0ed5acd37efae90ce42_citespan-401-402>
            <http://www.example.org/end>    "402.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "4" .
    
    <http://covid19.aksw.org/text-c5dbdb3af8a0cbc732c81b379412f621f35d94d32cd99ed0aee6a0dc02b0a33b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The measures adopted to stop outbreaks were similar in both analyses, with hand hygiene, patient screening, isolation and cohorting, and use of individual protective disposal identified as predominant strategies. Gastmeier et al, 4 reported that personnel screening was performed in 43.8% of the NICU outbreaks; this does not imply staff\\u0027s responsibility for the outbreaks, however. Personnel screening was applied in 35.94% of all viral outbreaks, but positive screening of health care personnel provided no conclusive evidence that these personnel were sources of infection. Nonetheless, asymptomatic infected individuals can shed viruses for prolonged periods, and thus personnel screening is important for enforcing hand hygiene.\",\"cite_spans\":[{\"start\":230.0,\"end\":231.0,\"text\":\"4\",\"ref_id\":\"BIBREF3\"}],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c5dbdb3af8a0cbc732c81b379412f621f35d94d32cd99ed0aee6a0dc02b0a33b_citespan-230-231> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "The measures adopted to stop outbreaks were similar in both analyses, with hand hygiene, patient screening, isolation and cohorting, and use of individual protective disposal identified as predominant strategies. Gastmeier et al, 4 reported that personnel screening was performed in 43.8% of the NICU outbreaks; this does not imply staff's responsibility for the outbreaks, however. Personnel screening was applied in 35.94% of all viral outbreaks, but positive screening of health care personnel provided no conclusive evidence that these personnel were sources of infection. Nonetheless, asymptomatic infected individuals can shed viruses for prolonged periods, and thus personnel screening is important for enforcing hand hygiene." ;
            <http://www.example.org/textHash>
                    "c5dbdb3af8a0cbc732c81b379412f621f35d94d32cd99ed0aee6a0dc02b0a33b" .
    
    <http://covid19.aksw.org/text-059c5c1ee254c2d9557ebec86f1d0ee22a06509aade525013541d5bca34b4943>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In bacterial outbreaks, the predominant type of infection reported is bloodstream infections. In viral outbreaks, the most In 48.6% of epidemic episodes described by Gastmeier et al 4 and in 40.63% of the reported viral outbreaks found in our analysis, the source of infection was not detectable, hindering the management of outbreaks.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "In bacterial outbreaks, the predominant type of infection reported is bloodstream infections. In viral outbreaks, the most In 48.6% of epidemic episodes described by Gastmeier et al 4 and in 40.63% of the reported viral outbreaks found in our analysis, the source of infection was not detectable, hindering the management of outbreaks." ;
            <http://www.example.org/textHash>
                    "059c5c1ee254c2d9557ebec86f1d0ee22a06509aade525013541d5bca34b4943" .
    
    <http://covid19.aksw.org/text-b5797f4922a4952bc5ce5e44de540ce156256b7f7e03ea5f9fd4ecaaf5839d38>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The 10 most frequently reported pathogens include only 1 viral agent, the hepatitis A virus. According to our analysis performed in January 2012, rotavirus is the most frequently reported viral agent, responsible for the majority of gastrointestinal infections. In addition, the most frequently reported pathogen over the last decade has been respiratory syncytial virus. Numerous new viruses have been identified recently, including human metapneumovirus, 5 human parechovirus, 6 human coronavirus NL63, 7 human coronavirus HKU-1, 8 and human enterovirus 104, 117, and 118, 9,10 whose clinical impact in newborns is still not fully appreciated.\",\"cite_spans\":[{\"start\":479.0,\"end\":480.0,\"text\":\"6\",\"ref_id\":\"BIBREF5\"},{\"start\":532.0,\"end\":533.0,\"text\":\"8\",\"ref_id\":\"BIBREF7\"}],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b5797f4922a4952bc5ce5e44de540ce156256b7f7e03ea5f9fd4ecaaf5839d38_citespan-479-480> , <http://covid19.aksw.org/text-b5797f4922a4952bc5ce5e44de540ce156256b7f7e03ea5f9fd4ecaaf5839d38_citespan-532-533> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "The 10 most frequently reported pathogens include only 1 viral agent, the hepatitis A virus. According to our analysis performed in January 2012, rotavirus is the most frequently reported viral agent, responsible for the majority of gastrointestinal infections. In addition, the most frequently reported pathogen over the last decade has been respiratory syncytial virus. Numerous new viruses have been identified recently, including human metapneumovirus, 5 human parechovirus, 6 human coronavirus NL63, 7 human coronavirus HKU-1, 8 and human enterovirus 104, 117, and 118, 9,10 whose clinical impact in newborns is still not fully appreciated." ;
            <http://www.example.org/textHash>
                    "b5797f4922a4952bc5ce5e44de540ce156256b7f7e03ea5f9fd4ecaaf5839d38" .
    
    <http://covid19.aksw.org/text-215e948d96edb244613a8c390c7387d99a3ea73dab0db0ed5acd37efae90ce42>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The aim of the present analysis was initially to review medical literature to establish the incidence, types of pathogens, and clinical features of noncongenital neonatal viral infections. However, this goal proved not easily achievable, owing to the lack of data in the literature. In this study, we used the same database of health careeassociated outbreaks used by Gastmeier et al in a 2007 study, 4 but focused our analysis on viral outbreaks in neonates.\",\"cite_spans\":[{\"start\":401.0,\"end\":402.0,\"text\":\"4\",\"ref_id\":\"BIBREF3\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-215e948d96edb244613a8c390c7387d99a3ea73dab0db0ed5acd37efae90ce42_citespan-401-402> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "The aim of the present analysis was initially to review medical literature to establish the incidence, types of pathogens, and clinical features of noncongenital neonatal viral infections. However, this goal proved not easily achievable, owing to the lack of data in the literature. In this study, we used the same database of health careeassociated outbreaks used by Gastmeier et al in a 2007 study, 4 but focused our analysis on viral outbreaks in neonates." ;
            <http://www.example.org/textHash>
                    "215e948d96edb244613a8c390c7387d99a3ea73dab0db0ed5acd37efae90ce42" .
    
    <http://covid19.aksw.org/text-2dade2bffee0c09f92d2dd0786ad3db18bb80a1cd9020af768fa55351eb5481e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The Centers for Disease Control and Prevention defines nosocomial infection as an infection occurring during hospitalization that was not present or incubating at the time of admission. Most descriptions of neonatal infection use the terms \\\"early-onset\\\" and \\\"late-onset\\\" infection. Early-onset infections are confirmed infections occurring during the first 3 days of life, and late-onset infections are those occurring from day 4 onward. Nosocomial infection is equivalent to late-onset, or infection after the first 72 hours of life. 1 The prevalence of nosocomial infections in NICUs has increased over the past decade, with reported rates per admission varying from 6.2% to 30%. 1 Incidences of 3 in 1,000 live births and 29 in 1,000 neonatal admissions were recently reported. 2 A retrospective study in a NICU in The Netherlands over a 29-year period found that the incidence of late onset sepsis increased from 7.1% in the years 1988-1992 to 17.4% in 1998-2002 and 13.9% in 2003-2006. 3 The vast majority of published scientific articles dealing with nosocomial infections have focused on bacterial or fungal infections, with viral agents often disregarded. Indeed, viral infections among hospitalized infants in NICUs is still a largely unexplored field in neonatology, owing to the diagnostic complexity of viral infection and to the fact that sensitive and specific diagnostic tests have become available only in the last few years. Vergnano et al, 2 in a prospective multicenter study based on data from a UK neonatal infection surveillance network, reported that gram-positive bacteria accounted for 49% of all late-onset nosocomial infections, gram-negative bacteria for 42%, and fungi for 9%; viral agents were not investigated. Indeed, the role of nosocomial virus infections is generally neglected in epidemiologic scenarios.\",\"cite_spans\":[{\"start\":535.0,\"end\":536.0,\"text\":\"1\",\"ref_id\":\"BIBREF0\"},{\"start\":991.0,\"end\":992.0,\"text\":\"3\",\"ref_id\":\"BIBREF2\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2dade2bffee0c09f92d2dd0786ad3db18bb80a1cd9020af768fa55351eb5481e_citespan-535-536> , <http://covid19.aksw.org/text-2dade2bffee0c09f92d2dd0786ad3db18bb80a1cd9020af768fa55351eb5481e_citespan-991-992> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "The Centers for Disease Control and Prevention defines nosocomial infection as an infection occurring during hospitalization that was not present or incubating at the time of admission. Most descriptions of neonatal infection use the terms \"early-onset\" and \"late-onset\" infection. Early-onset infections are confirmed infections occurring during the first 3 days of life, and late-onset infections are those occurring from day 4 onward. Nosocomial infection is equivalent to late-onset, or infection after the first 72 hours of life. 1 The prevalence of nosocomial infections in NICUs has increased over the past decade, with reported rates per admission varying from 6.2% to 30%. 1 Incidences of 3 in 1,000 live births and 29 in 1,000 neonatal admissions were recently reported. 2 A retrospective study in a NICU in The Netherlands over a 29-year period found that the incidence of late onset sepsis increased from 7.1% in the years 1988-1992 to 17.4% in 1998-2002 and 13.9% in 2003-2006. 3 The vast majority of published scientific articles dealing with nosocomial infections have focused on bacterial or fungal infections, with viral agents often disregarded. Indeed, viral infections among hospitalized infants in NICUs is still a largely unexplored field in neonatology, owing to the diagnostic complexity of viral infection and to the fact that sensitive and specific diagnostic tests have become available only in the last few years. Vergnano et al, 2 in a prospective multicenter study based on data from a UK neonatal infection surveillance network, reported that gram-positive bacteria accounted for 49% of all late-onset nosocomial infections, gram-negative bacteria for 42%, and fungi for 9%; viral agents were not investigated. Indeed, the role of nosocomial virus infections is generally neglected in epidemiologic scenarios." ;
            <http://www.example.org/textHash>
                    "2dade2bffee0c09f92d2dd0786ad3db18bb80a1cd9020af768fa55351eb5481e" .
    
    <http://covid19.aksw.org/text-9c5d40f458cf25eed462b1563d000e93cd4570dee5f08ea6b562156b4290e8b6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Nosocomial infections is among the most important causes of morbidity, prolonged hospital stay, increased hospital costs, and mortality in neonates, particularly those born preterm. Infants admitted to neonatal intensive care units (NICUs) are at particularly high risk for exposure to infection during their hospital stay because of their vulnerable condition and the presence of pathogens resistant to common antibiotics in NICUs.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Nosocomial infections is among the most important causes of morbidity, prolonged hospital stay, increased hospital costs, and mortality in neonates, particularly those born preterm. Infants admitted to neonatal intensive care units (NICUs) are at particularly high risk for exposure to infection during their hospital stay because of their vulnerable condition and the presence of pathogens resistant to common antibiotics in NICUs." ;
            <http://www.example.org/textHash>
                    "9c5d40f458cf25eed462b1563d000e93cd4570dee5f08ea6b562156b4290e8b6" .
    
    <http://covid19.aksw.org/text-1990d0eb32f2912f6e8bf7dd7b65e922831dca290d5a700e10754f95a1cf11e4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"We performed this analysis using the Outbreak Database, the worldwide database of health careeassociated outbreaks (http://www.outbreak-database.com). This freely accessible database was created to support outbreak investigation in medical institutions. We carried out the database search for this review on January 10, 2012. To investigate the reported outbreaks, we made queries through the \\\"advance search\\\" function using the keyword \\\"newborn\\\" in the \\\"outbreak/setting/age\\\" field and the keyword \\\"virus\\\" in the \\\"outbreak/microorganisms/microorganism/name\\\" field. Items studied included causative pathogens, types of infection, sources of the outbreaks, and measures taken to stop the outbreaks.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"METHODS\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "METHODS" ;
            <http://www.example.org/text>  "We performed this analysis using the Outbreak Database, the worldwide database of health careeassociated outbreaks (http://www.outbreak-database.com). This freely accessible database was created to support outbreak investigation in medical institutions. We carried out the database search for this review on January 10, 2012. To investigate the reported outbreaks, we made queries through the \"advance search\" function using the keyword \"newborn\" in the \"outbreak/setting/age\" field and the keyword \"virus\" in the \"outbreak/microorganisms/microorganism/name\" field. Items studied included causative pathogens, types of infection, sources of the outbreaks, and measures taken to stop the outbreaks." ;
            <http://www.example.org/textHash>
                    "1990d0eb32f2912f6e8bf7dd7b65e922831dca290d5a700e10754f95a1cf11e4" .
    
    <http://covid19.aksw.org/text-b5797f4922a4952bc5ce5e44de540ce156256b7f7e03ea5f9fd4ecaaf5839d38_citespan-532-533>
            <http://www.example.org/end>    "533.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "532.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "8" .
    
    <http://covid19.aksw.org/text-aeb768c33cf30e71b6da857785f48e123494f404264fed693cb5ec81fb67b210>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"An important difference between the 2 studies is the rate of quarantining of the affected location. Quarantining was implemented only in 16.3% of bacterial outbreaks, compared with 26.56% of viral outbreaks, because of viruses\\u0027 great propensity to spread. Moreover, in NICUs, 20.45% of outbreaks necessitated ward closure, compared with 40% in noneintensive care units. This finding may be surprising, considering that the NICU population is certainly at greater risk of infection. We can speculate that prevention and epidemiologic surveillance led to better containment of outbreaks in the NICUs.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"DISCUSSION\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "DISCUSSION" ;
            <http://www.example.org/text>  "An important difference between the 2 studies is the rate of quarantining of the affected location. Quarantining was implemented only in 16.3% of bacterial outbreaks, compared with 26.56% of viral outbreaks, because of viruses' great propensity to spread. Moreover, in NICUs, 20.45% of outbreaks necessitated ward closure, compared with 40% in noneintensive care units. This finding may be surprising, considering that the NICU population is certainly at greater risk of infection. We can speculate that prevention and epidemiologic surveillance led to better containment of outbreaks in the NICUs." ;
            <http://www.example.org/textHash>
                    "aeb768c33cf30e71b6da857785f48e123494f404264fed693cb5ec81fb67b210" .
}
<http://covid19.aksw.org/1c2ec5f7aa7133b58659aa5403e03f14da7ba1a1> {
    <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The production of platelets from megakaryocytes (thrombopoiesis) and the production of megakaryocytes (megakaryopoiesis) occur mainly in the bone marrow of adult animals. Common myeloid progenitors differentiate into megakaryocyte-erythroid progenitors. Further differentiation results in formation of the earliest committed megakaryocytic cell, the burst-forming unitmegakaryocyte (BFU-Mk), which further differentiates into the colony-forming unit-megakaryocyte (CFU-Mk). Subsequent stages of differentiation are megakaryoblasts, followed by promegakaryocytes, then megakaryocytes. These latter stages may be recognized during light microscopic evaluation of bone marrow. Extensions of megakaryocyte cytoplasm (proplatelets) enter sinuses, or the microvasculature of the bone marrow. Within sinuses, these proplatelets are detached from the megakaryocyte by the shear forces of blood, after which they are further fragmented into platelets (Harvey, 2012; Junt et al., 2007) . Thrombopoiesis, as well as megakaryopoiesis, is predominantly stimulated by TPO. However, SCF, stromal cell-derived factor 1 (SDF-1), IL-3, G-CSF, and GM-CSF may all contributed to platelet production (Boudreaux, 2010) .\",\"cite_spans\":[{\"start\":942.0,\"end\":956.0,\"text\":\"(Harvey, 2012;\",\"ref_id\":\"BIBREF166\"},{\"start\":957.0,\"end\":975.0,\"text\":\"Junt et al., 2007)\",\"ref_id\":\"BIBREF191\"},{\"start\":1179.0,\"end\":1196.0,\"text\":\"(Boudreaux, 2010)\",\"ref_id\":\"BIBREF40\"}],\"ref_spans\":[],\"section\":\"Platelets\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812_citespan-942-956> , <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812_citespan-957-975> , <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812_citespan-1179-1196> ;
            <http://www.example.org/section>
                    "Platelets" ;
            <http://www.example.org/text>  "The production of platelets from megakaryocytes (thrombopoiesis) and the production of megakaryocytes (megakaryopoiesis) occur mainly in the bone marrow of adult animals. Common myeloid progenitors differentiate into megakaryocyte-erythroid progenitors. Further differentiation results in formation of the earliest committed megakaryocytic cell, the burst-forming unitmegakaryocyte (BFU-Mk), which further differentiates into the colony-forming unit-megakaryocyte (CFU-Mk). Subsequent stages of differentiation are megakaryoblasts, followed by promegakaryocytes, then megakaryocytes. These latter stages may be recognized during light microscopic evaluation of bone marrow. Extensions of megakaryocyte cytoplasm (proplatelets) enter sinuses, or the microvasculature of the bone marrow. Within sinuses, these proplatelets are detached from the megakaryocyte by the shear forces of blood, after which they are further fragmented into platelets (Harvey, 2012; Junt et al., 2007) . Thrombopoiesis, as well as megakaryopoiesis, is predominantly stimulated by TPO. However, SCF, stromal cell-derived factor 1 (SDF-1), IL-3, G-CSF, and GM-CSF may all contributed to platelet production (Boudreaux, 2010) ." ;
            <http://www.example.org/textHash>
                    "f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812" .
    
    <http://covid19.aksw.org/text-92b5a29b064c99b374b26a0994786b872453b383774723a554d534b6030cc521_citespan-591-604>
            <http://www.example.org/end>    "604.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF193" ;
            <http://www.example.org/start>  "591.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kaneko, 2008)" .
    
    <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in neutrophil counts may be associated with viral infections, although viral-specific mechanisms vary. Decreased neutrophil counts associated with parvovirus likely represent both a primary effect due to infection causing death of rapidly dividing hematopoietic precursors in the bone marrow, as well as a secondary increase in tissue demand from disease and loss of integrity of the intestinal tract. Decreases in neutrophil counts associated with human immunodeficiency virus (HIV), infectious hepatitis, and infectious mononucleosis in people have also been associated with decreased or ineffective neutrophil production due to infection of hematopoietic precursors (Dale and Welte, 2016; Lima et al., 2006) . With measles and dengue virus, decreases in neutrophil counts have been observed with endothelial cell alterations leading to increased adhesion of neutrophils and therefore a shift from the circulating to the marginating pool (Dale and Welte, 2016) .\",\"cite_spans\":[{\"start\":679.0,\"end\":701.0,\"text\":\"(Dale and Welte, 2016;\",\"ref_id\":\"BIBREF85\"},{\"start\":702.0,\"end\":720.0,\"text\":\"Lima et al., 2006)\",\"ref_id\":\"BIBREF229\"},{\"start\":950.0,\"end\":972.0,\"text\":\"(Dale and Welte, 2016)\",\"ref_id\":\"BIBREF85\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752_citespan-679-701> , <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752_citespan-702-720> , <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752_citespan-950-972> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Decreases in neutrophil counts may be associated with viral infections, although viral-specific mechanisms vary. Decreased neutrophil counts associated with parvovirus likely represent both a primary effect due to infection causing death of rapidly dividing hematopoietic precursors in the bone marrow, as well as a secondary increase in tissue demand from disease and loss of integrity of the intestinal tract. Decreases in neutrophil counts associated with human immunodeficiency virus (HIV), infectious hepatitis, and infectious mononucleosis in people have also been associated with decreased or ineffective neutrophil production due to infection of hematopoietic precursors (Dale and Welte, 2016; Lima et al., 2006) . With measles and dengue virus, decreases in neutrophil counts have been observed with endothelial cell alterations leading to increased adhesion of neutrophils and therefore a shift from the circulating to the marginating pool (Dale and Welte, 2016) ." ;
            <http://www.example.org/textHash>
                    "631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752" .
    
    <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Chemotherapeutic agents are also frequently associated with decreases in lymphocyte counts, which may precede episodes of febrile neutropenia (Gergely, 1999) . Carboplatin, dacarbazine, and paclitaxel have been reported to induce decreases in CD4 þ T-cells, while epirubicin and mitomycin appear to affect CD8 þ T-cells to a greater degree than CD4 þ T-cells, and pentostatin affects both B-cell and T-cell populations (Gergely, 1999) . Antilymphocyte monoclonal antibodies have been used to treat autoimmune diseases as well as to cause immunosuppression to prevent acute transplant rejection. Examples of these monoclonal antibodies include Muromonab CD3 (OKT3) and CAMPATH-1H (Vial et al., 2002; Gergely, 1999) .\",\"cite_spans\":[{\"start\":142.0,\"end\":157.0,\"text\":\"(Gergely, 1999)\",\"ref_id\":\"BIBREF140\"},{\"start\":419.0,\"end\":434.0,\"text\":\"(Gergely, 1999)\",\"ref_id\":\"BIBREF140\"},{\"start\":679.0,\"end\":698.0,\"text\":\"(Vial et al., 2002;\",\"ref_id\":\"BIBREF407\"},{\"start\":699.0,\"end\":713.0,\"text\":\"Gergely, 1999)\",\"ref_id\":\"BIBREF140\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-142-157> , <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-419-434> , <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-679-698> , <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-699-713> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Chemotherapeutic agents are also frequently associated with decreases in lymphocyte counts, which may precede episodes of febrile neutropenia (Gergely, 1999) . Carboplatin, dacarbazine, and paclitaxel have been reported to induce decreases in CD4 þ T-cells, while epirubicin and mitomycin appear to affect CD8 þ T-cells to a greater degree than CD4 þ T-cells, and pentostatin affects both B-cell and T-cell populations (Gergely, 1999) . Antilymphocyte monoclonal antibodies have been used to treat autoimmune diseases as well as to cause immunosuppression to prevent acute transplant rejection. Examples of these monoclonal antibodies include Muromonab CD3 (OKT3) and CAMPATH-1H (Vial et al., 2002; Gergely, 1999) ." ;
            <http://www.example.org/textHash>
                    "bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-394-409>
            <http://www.example.org/end>    "409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "394.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-345-362>
            <http://www.example.org/end>    "362.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF237" ;
            <http://www.example.org/start>  "345.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lu et al., 2012;" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-2083-2103>
            <http://www.example.org/end>    "2103.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF72" ;
            <http://www.example.org/start>  "2083.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cines et al., 2009)" .
    
    <http://covid19.aksw.org/text-44e5305a92acd0b2f8c470d071bc3b59ca64a12d13ca4aeb540f61059fc63239>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Administration of G-CSF or GM-CSF may be used as a rescue therapy following chemotherapy that causes neutropenia and compromises the immune system\\u0027s ability to respond to infectious agents. While the goal for treatment in chemotherapy patients is to increase blood neutrophil counts to normal levels and not to achieve increased neutrophil counts, repeated or high dose administration of G-CSF or GM-CSF-related compounds to healthy laboratory animals results in markedly increased neutrophil counts. Typically these changes are associated with a left shift and cytoplasmic changes indicative of rapid neutropoiesis. Dysplastic changes may also occur, most commonly recognized by the presence of unusually large neutrophils or hypersegmented neutrophils in circulation. Several xenobiotics appear to induce increases in neutrophil counts by stimulating increases in endogenous G-CSF or an inflammatory stimulus. Early in the course of treatment with clozapine, an antipsychotic agent, rats have been shown to have spikes in G-CSF with concomitant increases in bone marrow granulopoiesis and release of less mature neutrophils into circulation (Lobach and Uetrecht, 2014) . However, other xenobiotics may directly cause an inflammatory stimulus and increase in endogenous proinflammatory stimuli, such as G-CSF and IL-1, which result in increases in neutrophil counts. For example, lithium, which has been used in treatment of bipolar disorder and in combination with antidepressants, also appears to cause increased neutrophil counts due to increased G-CSF (Focosi et al., 2009) .\",\"cite_spans\":[{\"start\":1143.0,\"end\":1170.0,\"text\":\"(Lobach and Uetrecht, 2014)\",\"ref_id\":\"BIBREF233\"},{\"start\":1557.0,\"end\":1578.0,\"text\":\"(Focosi et al., 2009)\",\"ref_id\":\"BIBREF119\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-44e5305a92acd0b2f8c470d071bc3b59ca64a12d13ca4aeb540f61059fc63239_citespan-1143-1170> , <http://covid19.aksw.org/text-44e5305a92acd0b2f8c470d071bc3b59ca64a12d13ca4aeb540f61059fc63239_citespan-1557-1578> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Administration of G-CSF or GM-CSF may be used as a rescue therapy following chemotherapy that causes neutropenia and compromises the immune system's ability to respond to infectious agents. While the goal for treatment in chemotherapy patients is to increase blood neutrophil counts to normal levels and not to achieve increased neutrophil counts, repeated or high dose administration of G-CSF or GM-CSF-related compounds to healthy laboratory animals results in markedly increased neutrophil counts. Typically these changes are associated with a left shift and cytoplasmic changes indicative of rapid neutropoiesis. Dysplastic changes may also occur, most commonly recognized by the presence of unusually large neutrophils or hypersegmented neutrophils in circulation. Several xenobiotics appear to induce increases in neutrophil counts by stimulating increases in endogenous G-CSF or an inflammatory stimulus. Early in the course of treatment with clozapine, an antipsychotic agent, rats have been shown to have spikes in G-CSF with concomitant increases in bone marrow granulopoiesis and release of less mature neutrophils into circulation (Lobach and Uetrecht, 2014) . However, other xenobiotics may directly cause an inflammatory stimulus and increase in endogenous proinflammatory stimuli, such as G-CSF and IL-1, which result in increases in neutrophil counts. For example, lithium, which has been used in treatment of bipolar disorder and in combination with antidepressants, also appears to cause increased neutrophil counts due to increased G-CSF (Focosi et al., 2009) ." ;
            <http://www.example.org/textHash>
                    "44e5305a92acd0b2f8c470d071bc3b59ca64a12d13ca4aeb540f61059fc63239" .
    
    <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In acute megakaryoblastic leukemia (AML M7), bone marrow contains ! 30% megakaryoblasts, and many cells of the megakaryocytic lineage have cytoplasmic blebs (Gassmann and Löffler, 1995) . Myelofibrosis is frequently also observed (Tallman et al., 2000) . Acute megakaryoblastic leukemia has been associated with increases in platelet counts, but decreases in platelet counts have also been described (Stockham and Scott, 2008c) . A majority of cases of acute megakaryoblastic leukemia in both adults and children are associated with chromosomal abnormalities, often chromosomal translocations (Duchayne et al., 2003; Lion et al., 1992) .\",\"cite_spans\":[{\"start\":157.0,\"end\":185.0,\"text\":\"(Gassmann and Löffler, 1995)\",\"ref_id\":\"BIBREF136\"},{\"start\":230.0,\"end\":252.0,\"text\":\"(Tallman et al., 2000)\",\"ref_id\":\"BIBREF379\"},{\"start\":400.0,\"end\":427.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":593.0,\"end\":616.0,\"text\":\"(Duchayne et al., 2003;\",\"ref_id\":\"BIBREF98\"},{\"start\":617.0,\"end\":635.0,\"text\":\"Lion et al., 1992)\",\"ref_id\":\"BIBREF231\"}],\"ref_spans\":[],\"section\":\"Neoplastic\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-157-185> , <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-230-252> , <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-400-427> , <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-593-616> , <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-617-635> ;
            <http://www.example.org/section>
                    "Neoplastic" ;
            <http://www.example.org/text>  "In acute megakaryoblastic leukemia (AML M7), bone marrow contains ! 30% megakaryoblasts, and many cells of the megakaryocytic lineage have cytoplasmic blebs (Gassmann and Löffler, 1995) . Myelofibrosis is frequently also observed (Tallman et al., 2000) . Acute megakaryoblastic leukemia has been associated with increases in platelet counts, but decreases in platelet counts have also been described (Stockham and Scott, 2008c) . A majority of cases of acute megakaryoblastic leukemia in both adults and children are associated with chromosomal abnormalities, often chromosomal translocations (Duchayne et al., 2003; Lion et al., 1992) ." ;
            <http://www.example.org/textHash>
                    "ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888" .
    
    <http://covid19.aksw.org/text-578bb563f947f04aba36cf955897ebe919ef4a1fb3cff88b984c5b2aea466a2d_citespan-624-639>
            <http://www.example.org/end>    "639.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF283" ;
            <http://www.example.org/start>  "624.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Packman, 2016)" .
    
    <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-958-981>
            <http://www.example.org/end>    "981.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF395" ;
            <http://www.example.org/start>  "958.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Trottier et al., 2008)" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Several metabolic defects of erythrocyte metabolism may also be associated with decreases in red cell mass and increases in reticulocyte counts. Deficiencies in erythrocyte pathways of glycolysis may result in decreased ATP concentrations that lead to erythrocyte membrane dysfunctions with shortened erythrocyte lifespan and occasionally hemolysis (Stockham and Scott, 2008b) . Pyruvate kinase (PK) is the enzyme that catalyzes the last step in aerobic glycolysis. Deficiencies of PK that result in hemolysis have been reported in humans (Baronciani and Beutler, 1993) , dogs including beagles (Harvey et al., 1977; Giger et al., 1991; Prasse et al., 1975) , and a few breeds of cats (Kohn and Fumi, 2008) . Phosphofructokinase (PFK) catalyzes the ratelimiting step of the glycolysis pathway. Deficiencies in PFK have also been described in humans (Etiemble et al., 1976) and dogs (Giger et al., 1985) . Respiratory alkalosis, which may be observed following intense exercise, is associated with acute hemolytic crises in patients with PFK deficiencies (Giger et al., 1985) .\",\"cite_spans\":[{\"start\":349.0,\"end\":376.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":539.0,\"end\":569.0,\"text\":\"(Baronciani and Beutler, 1993)\",\"ref_id\":\"BIBREF18\"},{\"start\":595.0,\"end\":616.0,\"text\":\"(Harvey et al., 1977;\",\"ref_id\":\"BIBREF167\"},{\"start\":617.0,\"end\":636.0,\"text\":\"Giger et al., 1991;\",\"ref_id\":\"BIBREF145\"},{\"start\":637.0,\"end\":657.0,\"text\":\"Prasse et al., 1975)\",\"ref_id\":\"BIBREF301\"},{\"start\":685.0,\"end\":706.0,\"text\":\"(Kohn and Fumi, 2008)\",\"ref_id\":\"BIBREF205\"},{\"start\":849.0,\"end\":872.0,\"text\":\"(Etiemble et al., 1976)\",\"ref_id\":\"BIBREF105\"},{\"start\":882.0,\"end\":902.0,\"text\":\"(Giger et al., 1985)\",\"ref_id\":\"BIBREF144\"},{\"start\":1054.0,\"end\":1074.0,\"text\":\"(Giger et al., 1985)\",\"ref_id\":\"BIBREF144\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-1054-1074> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-349-376> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-539-569> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-882-902> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-595-616> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-849-872> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-617-636> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-637-657> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-685-706> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Several metabolic defects of erythrocyte metabolism may also be associated with decreases in red cell mass and increases in reticulocyte counts. Deficiencies in erythrocyte pathways of glycolysis may result in decreased ATP concentrations that lead to erythrocyte membrane dysfunctions with shortened erythrocyte lifespan and occasionally hemolysis (Stockham and Scott, 2008b) . Pyruvate kinase (PK) is the enzyme that catalyzes the last step in aerobic glycolysis. Deficiencies of PK that result in hemolysis have been reported in humans (Baronciani and Beutler, 1993) , dogs including beagles (Harvey et al., 1977; Giger et al., 1991; Prasse et al., 1975) , and a few breeds of cats (Kohn and Fumi, 2008) . Phosphofructokinase (PFK) catalyzes the ratelimiting step of the glycolysis pathway. Deficiencies in PFK have also been described in humans (Etiemble et al., 1976) and dogs (Giger et al., 1985) . Respiratory alkalosis, which may be observed following intense exercise, is associated with acute hemolytic crises in patients with PFK deficiencies (Giger et al., 1985) ." ;
            <http://www.example.org/textHash>
                    "ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181" .
    
    <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9_citespan-129-153>
            <http://www.example.org/end>    "153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "129.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008)" .
    
    <http://covid19.aksw.org/text-a1d3748d4858de2185ca589f0c4ab13bf30f27253f0634ddddba54401816fbef>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in blood lymphocyte counts with the presence of atypical lymphocytes in circulation have been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), a form of drug-related hypersensitivity. Several anticonvulsant drugs, including phenobarbital and phenytoin, allopurinol, minocycline, sulfonamides, gold salts, and dapsone have been associated with DRESS (Roujeau, 2005; Callot et al., 1996) .\",\"cite_spans\":[{\"start\":389.0,\"end\":404.0,\"text\":\"(Roujeau, 2005;\",\"ref_id\":\"BIBREF327\"},{\"start\":405.0,\"end\":425.0,\"text\":\"Callot et al., 1996)\",\"ref_id\":\"BIBREF53\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a1d3748d4858de2185ca589f0c4ab13bf30f27253f0634ddddba54401816fbef_citespan-389-404> , <http://covid19.aksw.org/text-a1d3748d4858de2185ca589f0c4ab13bf30f27253f0634ddddba54401816fbef_citespan-405-425> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Increases in blood lymphocyte counts with the presence of atypical lymphocytes in circulation have been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), a form of drug-related hypersensitivity. Several anticonvulsant drugs, including phenobarbital and phenytoin, allopurinol, minocycline, sulfonamides, gold salts, and dapsone have been associated with DRESS (Roujeau, 2005; Callot et al., 1996) ." ;
            <http://www.example.org/textHash>
                    "a1d3748d4858de2185ca589f0c4ab13bf30f27253f0634ddddba54401816fbef" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-500-523>
            <http://www.example.org/end>    "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF220" ;
            <http://www.example.org/start>  "500.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "LevGur and Levie, 1995;" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3219-3235>
            <http://www.example.org/end>    "3235.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF161" ;
            <http://www.example.org/start>  "3219.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gu et al., 2004)" .
    
    <http://covid19.aksw.org/text-663afa110a1b6f3e53d05e97ed483ebb68a3d70eb7aeb52cb3b58f8d3f1f6f38>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.1.1.1 Dehydration Dehydration is a relatively common cause of secondary increases in red cell mass. Dehydration results in depletion of the water content of blood, and a relative increase in the other blood components, including cells (hemoconcentration). Due to the high number of erythrocytes present, increases in red cell mass are detectable, whereas increases in leukocyte subtypes are often not observed. These increases in red cell mass are usually observed in conjunction with increases in urea nitrogen and/or creatinine (prerenal azotemia) with concurrent decreases in urine volume and increases in urine specific gravity, as well as proportional increases in albumin and globulin. If evaluating plasma, fibrinogen may also be increased. In nonclinical toxicology studies in rodents, decreased food consumption is often associated with concurrent decreases in water intake, resulting in increases in red cell mass from subclinical or clinical dehydration. Resolution of these secondary increases in red cell mass will occur with adequate rehydration.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Relative increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Relative increases in red cell mass" ;
            <http://www.example.org/text>  "12.11.3.1.1.1 Dehydration Dehydration is a relatively common cause of secondary increases in red cell mass. Dehydration results in depletion of the water content of blood, and a relative increase in the other blood components, including cells (hemoconcentration). Due to the high number of erythrocytes present, increases in red cell mass are detectable, whereas increases in leukocyte subtypes are often not observed. These increases in red cell mass are usually observed in conjunction with increases in urea nitrogen and/or creatinine (prerenal azotemia) with concurrent decreases in urine volume and increases in urine specific gravity, as well as proportional increases in albumin and globulin. If evaluating plasma, fibrinogen may also be increased. In nonclinical toxicology studies in rodents, decreased food consumption is often associated with concurrent decreases in water intake, resulting in increases in red cell mass from subclinical or clinical dehydration. Resolution of these secondary increases in red cell mass will occur with adequate rehydration." ;
            <http://www.example.org/textHash>
                    "663afa110a1b6f3e53d05e97ed483ebb68a3d70eb7aeb52cb3b58f8d3f1f6f38" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1318-1331>
            <http://www.example.org/end>    "1331.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF376" ;
            <http://www.example.org/start>  "1318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Suter, 2010)" .
    
    <http://covid19.aksw.org/text-1cee1201d51cee2d66f0e07a971d33bab94882ade852c0c1df1cfa734070aac2_citespan-369-395>
            <http://www.example.org/end>    "395.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-364-389>
            <http://www.example.org/end>    "389.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF71" ;
            <http://www.example.org/start>  "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Christopher et al., 1995)" .
    
    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-317-335>
            <http://www.example.org/end>    "335.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF64" ;
            <http://www.example.org/start>  "317.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Chao et al., 2001)" .
    
    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-633-659>
            <http://www.example.org/end>    "659.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "633.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008b;" .
    
    <http://covid19.aksw.org/text-d76683337213c44f43b98a160d3d52137e06a3dfed9b8759d8b7dc67c7560610_citespan-218-252>
            <http://www.example.org/end>    "252.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF305" ;
            <http://www.example.org/start>  "218.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Provencher Bolliger et al., 2010)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-787-808>
            <http://www.example.org/end>    "808.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "787.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e_citespan-447-470>
            <http://www.example.org/end>    "470.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF88" ;
            <http://www.example.org/start>  "447.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(De Rossi et al., 1991)" .
    
    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-630-650>
            <http://www.example.org/end>    "650.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "630.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016;" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-2337-2351>
            <http://www.example.org/end>    "2351.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF38" ;
            <http://www.example.org/start>  "2337.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Borish, 2003)" .
    
    <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1_citespan-629-651>
            <http://www.example.org/end>    "651.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF399" ;
            <http://www.example.org/start>  "629.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Uppal and Gong, 2015)" .
    
    <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209_citespan-720-743>
            <http://www.example.org/end>    "743.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF373" ;
            <http://www.example.org/start>  "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sugimoto et al., 1986)" .
    
    <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-397-412>
            <http://www.example.org/end>    "412.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "397.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Russell, 2010;" .
    
    <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b_citespan-639-654>
            <http://www.example.org/end>    "654.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF283" ;
            <http://www.example.org/start>  "639.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Packman, 2016)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1930-1951>
            <http://www.example.org/end>    "1951.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF139" ;
            <http://www.example.org/start>  "1930.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(George et al., 1967)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-814-833>
            <http://www.example.org/end>    "833.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF69" ;
            <http://www.example.org/start>  "814.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Christopher, 1989)" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-815-827>
            <http://www.example.org/end>    "827.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "815.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Aster, 2005)" .
    
    <http://covid19.aksw.org/text-40543c581215d7f87d33a4c7dd8405ccc84f1bb5781ac6e73da8b536ed809c7a_citespan-41-42>
            <http://www.example.org/end>    "42.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "41.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "b" .
    
    <http://covid19.aksw.org/text-da02dd2d4020683e33331a78209d8ac3a590970addef3219c2a74f17b759624d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Secondary increases in red cell mass are dependent on stimulating factors and are not autonomous, in contrast to primary increases in red cell mass. These secondary increases in red cell mass are most commonly associated with increases in EPO concentrations due to hypoxia, and are therefore considered appropriate. However, hypoxia-independent (inappropriate) mechanisms may also cause secondary increases in red cell mass and are also described later.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Secondary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Secondary increases in red cell mass" ;
            <http://www.example.org/text>  "Secondary increases in red cell mass are dependent on stimulating factors and are not autonomous, in contrast to primary increases in red cell mass. These secondary increases in red cell mass are most commonly associated with increases in EPO concentrations due to hypoxia, and are therefore considered appropriate. However, hypoxia-independent (inappropriate) mechanisms may also cause secondary increases in red cell mass and are also described later." ;
            <http://www.example.org/textHash>
                    "da02dd2d4020683e33331a78209d8ac3a590970addef3219c2a74f17b759624d" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-624-651>
            <http://www.example.org/end>    "651.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "624.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-760-787>
            <http://www.example.org/end>    "787.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b;" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1420-1440>
            <http://www.example.org/end>    "1440.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "1420.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Magden et al., 2015;" .
    
    <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265_citespan-428-455>
            <http://www.example.org/end>    "455.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "428.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-0b708d860d23383562843f1ea6ff8dd0f6b9b8eba2fe7038b0d010967b009254>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The lower reference limit of historical control data in common laboratory species may include basophil counts of 0 cells mL À 1 . Due to these normally low blood basophil counts in health, decreases in basophil counts may not be detectable or recognizable. However, the following sections list some conditions in which decreased basophil counts have been reported.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Decreases in basophil counts (basopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Decreases in basophil counts (basopenia)" ;
            <http://www.example.org/text>  "The lower reference limit of historical control data in common laboratory species may include basophil counts of 0 cells mL À 1 . Due to these normally low blood basophil counts in health, decreases in basophil counts may not be detectable or recognizable. However, the following sections list some conditions in which decreased basophil counts have been reported." ;
            <http://www.example.org/textHash>
                    "0b708d860d23383562843f1ea6ff8dd0f6b9b8eba2fe7038b0d010967b009254" .
    
    <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Severe acute or overwhelming inflammation, such as associated with sepsis, may cause eosinopenia in conjunction with neutropenia. Studies in mice have demonstrated that the decrease in blood eosinophils associated with severe acute inflammation occurs more rapidly than increases in glucocorticoids (Bass, 1975) , and injection of material from an inflammatory exudate to adrenalectomized mice still resulted in deceases in eosinophil counts (Bass, 1977) , indicating the mechanism of eosinophil decrease in acute inflammation is independent of adrenal function. It is believed that acute inflammatory decreases in blood eosinophil counts are due to shifting of eosinophils from the circulating to the marginating pool and subsequent egress into tissues in response to chemotactic stimuli. Acute inflammation associated with fungal and viral infections also tends to cause decreases in eosinophil counts (Leder and Weller, 2000) .\",\"cite_spans\":[{\"start\":299.0,\"end\":311.0,\"text\":\"(Bass, 1975)\",\"ref_id\":\"BIBREF20\"},{\"start\":442.0,\"end\":454.0,\"text\":\"(Bass, 1977)\",\"ref_id\":\"BIBREF21\"},{\"start\":904.0,\"end\":928.0,\"text\":\"(Leder and Weller, 2000)\",\"ref_id\":\"BIBREF219\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c_citespan-299-311> , <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c_citespan-442-454> , <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c_citespan-904-928> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Severe acute or overwhelming inflammation, such as associated with sepsis, may cause eosinopenia in conjunction with neutropenia. Studies in mice have demonstrated that the decrease in blood eosinophils associated with severe acute inflammation occurs more rapidly than increases in glucocorticoids (Bass, 1975) , and injection of material from an inflammatory exudate to adrenalectomized mice still resulted in deceases in eosinophil counts (Bass, 1977) , indicating the mechanism of eosinophil decrease in acute inflammation is independent of adrenal function. It is believed that acute inflammatory decreases in blood eosinophil counts are due to shifting of eosinophils from the circulating to the marginating pool and subsequent egress into tissues in response to chemotactic stimuli. Acute inflammation associated with fungal and viral infections also tends to cause decreases in eosinophil counts (Leder and Weller, 2000) ." ;
            <http://www.example.org/textHash>
                    "ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c" .
    
    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-387-406>
            <http://www.example.org/end>    "406.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF192" ;
            <http://www.example.org/start>  "387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kabir et al., 1995;" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-925-940>
            <http://www.example.org/end>    "940.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "925.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-1330-1361>
            <http://www.example.org/end>    "1361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF117" ;
            <http://www.example.org/start>  "1330.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fibach and Rachmilewitz, 2008)" .
    
    <http://covid19.aksw.org/text-44e5305a92acd0b2f8c470d071bc3b59ca64a12d13ca4aeb540f61059fc63239_citespan-1143-1170>
            <http://www.example.org/end>    "1170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF233" ;
            <http://www.example.org/start>  "1143.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lobach and Uetrecht, 2014)" .
    
    <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-397-423>
            <http://www.example.org/end>    "423.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "397.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016;" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-755-776>
            <http://www.example.org/end>    "776.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "755.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Systemic lupus erythematosus (SLE) is an autoimmune condition that has been associated with decreases in neutrophil counts. These decreases in blood neutrophil counts appear to be relatively common with SLE, and are usually observed in conjunction with other manifestations of SLE, such as arthritis, skin lesions, or neurologic disorders (Stone, 2005) . There is an association between decreases in neutrophil counts and the presence of autoantibodies in SLE (Hsieh et al., 2003; Budman and Steinberg, 1977) , which lead to destruction or death of neutrophils. However, SLE-related anti-G-CSF autoantibodies have also been observed, causing decreased blood neutrophil counts due to decreased production rather than or in addition to direct neutrophil destruction or death (Hellmich et al., 2002) .\",\"cite_spans\":[{\"start\":339.0,\"end\":352.0,\"text\":\"(Stone, 2005)\",\"ref_id\":\"BIBREF371\"},{\"start\":460.0,\"end\":480.0,\"text\":\"(Hsieh et al., 2003;\",\"ref_id\":\"BIBREF174\"},{\"start\":481.0,\"end\":508.0,\"text\":\"Budman and Steinberg, 1977)\",\"ref_id\":\"BIBREF47\"},{\"start\":773.0,\"end\":796.0,\"text\":\"(Hellmich et al., 2002)\",\"ref_id\":\"BIBREF169\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-339-352> , <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-460-480> , <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-481-508> , <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-773-796> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Systemic lupus erythematosus (SLE) is an autoimmune condition that has been associated with decreases in neutrophil counts. These decreases in blood neutrophil counts appear to be relatively common with SLE, and are usually observed in conjunction with other manifestations of SLE, such as arthritis, skin lesions, or neurologic disorders (Stone, 2005) . There is an association between decreases in neutrophil counts and the presence of autoantibodies in SLE (Hsieh et al., 2003; Budman and Steinberg, 1977) , which lead to destruction or death of neutrophils. However, SLE-related anti-G-CSF autoantibodies have also been observed, causing decreased blood neutrophil counts due to decreased production rather than or in addition to direct neutrophil destruction or death (Hellmich et al., 2002) ." ;
            <http://www.example.org/textHash>
                    "75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe" .
    
    <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.5.1.4 Xenobiotic-induced Administration of G-CSF or GM-CSF may cause modest increases in blood basophil counts along with the more pronounced increases in neutrophil and eosinophil counts through stimulation of granulocyte production. Administration of phenylhydrazine as a rat model of hemolysis has been associated with increases in blood leukocyte counts, including basophil counts (Criswell et al., 2000) . Perhaps the most common xenobiotic-induced increases in blood basophil counts occur as a hypersensitivity or allergic reaction, and reports have included associated administration of heparin, penicillin, and novobiocin (Schultze, 2010; Shelley, 1963) .\",\"cite_spans\":[{\"start\":393.0,\"end\":416.0,\"text\":\"(Criswell et al., 2000)\",\"ref_id\":\"BIBREF79\"},{\"start\":638.0,\"end\":654.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":655.0,\"end\":669.0,\"text\":\"Shelley, 1963)\",\"ref_id\":\"BIBREF350\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd_citespan-393-416> , <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd_citespan-638-654> , <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd_citespan-655-669> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "12.11.2.5.1.4 Xenobiotic-induced Administration of G-CSF or GM-CSF may cause modest increases in blood basophil counts along with the more pronounced increases in neutrophil and eosinophil counts through stimulation of granulocyte production. Administration of phenylhydrazine as a rat model of hemolysis has been associated with increases in blood leukocyte counts, including basophil counts (Criswell et al., 2000) . Perhaps the most common xenobiotic-induced increases in blood basophil counts occur as a hypersensitivity or allergic reaction, and reports have included associated administration of heparin, penicillin, and novobiocin (Schultze, 2010; Shelley, 1963) ." ;
            <http://www.example.org/textHash>
                    "68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd" .
    
    <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752_citespan-950-972>
            <http://www.example.org/end>    "972.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF85" ;
            <http://www.example.org/start>  "950.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dale and Welte, 2016)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1378-1398>
            <http://www.example.org/end>    "1398.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF80" ;
            <http://www.example.org/start>  "1378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cromer et al., 2006)" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1036-1055>
            <http://www.example.org/end>    "1055.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF332" ;
            <http://www.example.org/start>  "1036.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sakka et al., 2006)" .
    
    <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb_citespan-318-344>
            <http://www.example.org/end>    "344.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016;" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1363-1384>
            <http://www.example.org/end>    "1384.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF432" ;
            <http://www.example.org/start>  "1363.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wilson et al., 1980)" .
    
    <http://covid19.aksw.org/text-73c0aead69c5ef6509f5402451b25224c5f4d577caefe7c77c73d4d9c480f4ef>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The earliest erythrocyte production, or primitive erythropoiesis, occurs in the yolk sac initially and eventually also in the liver during fetal development. Later in fetal development, erythrocyte production switches to predominantly the bone marrow, which is considered definitive erythropoiesis (Harvey, 2012) . In neonates, foci of extramedullary hematopoiesis may be observed within the liver histologically. In rats and mice, erythropoiesis within the spleen often significantly contributes to the maintenance of normal blood erythrocyte content. Increases in erythropoiesis in these species may be accompanied by increased extramedullary hematopoiesis in the spleen without appreciable changes in the bone marrow when observed histologically. Increased splenic hematopoiesis in these species may be sufficient to cause detectable changes in organ weight values.\",\"cite_spans\":[{\"start\":298.0,\"end\":312.0,\"text\":\"(Harvey, 2012)\",\"ref_id\":\"BIBREF166\"}],\"ref_spans\":[],\"section\":\"Erythrocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-73c0aead69c5ef6509f5402451b25224c5f4d577caefe7c77c73d4d9c480f4ef_citespan-298-312> ;
            <http://www.example.org/section>
                    "Erythrocytes" ;
            <http://www.example.org/text>  "The earliest erythrocyte production, or primitive erythropoiesis, occurs in the yolk sac initially and eventually also in the liver during fetal development. Later in fetal development, erythrocyte production switches to predominantly the bone marrow, which is considered definitive erythropoiesis (Harvey, 2012) . In neonates, foci of extramedullary hematopoiesis may be observed within the liver histologically. In rats and mice, erythropoiesis within the spleen often significantly contributes to the maintenance of normal blood erythrocyte content. Increases in erythropoiesis in these species may be accompanied by increased extramedullary hematopoiesis in the spleen without appreciable changes in the bone marrow when observed histologically. Increased splenic hematopoiesis in these species may be sufficient to cause detectable changes in organ weight values." ;
            <http://www.example.org/textHash>
                    "73c0aead69c5ef6509f5402451b25224c5f4d577caefe7c77c73d4d9c480f4ef" .
    
    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-470-496>
            <http://www.example.org/end>    "496.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF352" ;
            <http://www.example.org/start>  "470.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Shelley and Parnes, 1965)" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-654-674>
            <http://www.example.org/end>    "674.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF285" ;
            <http://www.example.org/start>  "654.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Palmer et al., 1999;" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-431-443>
            <http://www.example.org/end>    "443.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF190" ;
            <http://www.example.org/start>  "431.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Junod, 1987)" .
    
    <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-920-941>
            <http://www.example.org/end>    "941.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF322" ;
            <http://www.example.org/start>  "920.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rochet et al., 2013;" .
    
    <http://covid19.aksw.org/text-56a0f2e8df0b15b9ab1fdb7042da21859a72d2664093d2ce78e85cdd7e657c3a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In mice, automated hematology analyzer-generated blood eosinophil counts may be falsely elevated by large platelet clumps present in the specimen (O\\u0027Connell et al., 2015) . Platelet clumping in mice is extremely common, and blood smear evaluation is often necessary to confirm the automated leukocyte differential count.\",\"cite_spans\":[{\"start\":146.0,\"end\":170.0,\"text\":\"(O\\u0027Connell et al., 2015)\",\"ref_id\":\"BIBREF276\"}],\"ref_spans\":[],\"section\":\"Spurious\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-56a0f2e8df0b15b9ab1fdb7042da21859a72d2664093d2ce78e85cdd7e657c3a_citespan-146-170> ;
            <http://www.example.org/section>
                    "Spurious" ;
            <http://www.example.org/text>  "In mice, automated hematology analyzer-generated blood eosinophil counts may be falsely elevated by large platelet clumps present in the specimen (O'Connell et al., 2015) . Platelet clumping in mice is extremely common, and blood smear evaluation is often necessary to confirm the automated leukocyte differential count." ;
            <http://www.example.org/textHash>
                    "56a0f2e8df0b15b9ab1fdb7042da21859a72d2664093d2ce78e85cdd7e657c3a" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-942-955>
            <http://www.example.org/end>    "955.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF437" ;
            <http://www.example.org/start>  "942.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young, 2016)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-424-441>
            <http://www.example.org/end>    "441.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF411" ;
            <http://www.example.org/start>  "424.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Voehringer, 2009;" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Many of the agents that cause oxidative erythrocyte injury contain aromatic structures that can be metabolized, mostly commonly by cytochrome P450, to free radicals (Bradberry, 2003; Edwards and Fuller, 1996) , which overwhelm the normal protective antioxidant pathways of erythrocytes leading to both direct erythrocyte oxidative injury and oxidation of hemoglobin sulfhydryl groups resulting in methemoglobin formation. A few specific aromatic compounds that have been associated with free radical formation include dapsone, phenacetin, and anthracyclines such as doxorubicin (Edwards and Fuller, 1996; Coleman et al., 1991; Handa and Sato, 1975; Easley and Condon, 1974) . Phenacetin has also been associated with the formation of Heinz bodies (Boelsterli et al., 1983) . In dogs and cats, acetaminophen (paracetamol) may be metabolized to a minor reactive metabolite that causes oxidative damage to erythrocytes resulting in hemolysis and the formation of Heinz bodies and/or eccentrocytes, although methemoglobinemia has also been observed in cats (Desnoyers, 2010; Wallace et al., 2002; Mariani and Fulton, 2001; Aronson and Drobatz, 1996) . Xenobiotics that cause methemoglobinemia can also cause indirect oxidative damage through the peroxidation activity of methemoglobin itself (Edwards and Fuller, 1996) .\",\"cite_spans\":[{\"start\":165.0,\"end\":182.0,\"text\":\"(Bradberry, 2003;\"},{\"start\":183.0,\"end\":208.0,\"text\":\"Edwards and Fuller, 1996)\",\"ref_id\":\"BIBREF103\"},{\"start\":578.0,\"end\":604.0,\"text\":\"(Edwards and Fuller, 1996;\",\"ref_id\":\"BIBREF103\"},{\"start\":605.0,\"end\":626.0,\"text\":\"Coleman et al., 1991;\",\"ref_id\":\"BIBREF75\"},{\"start\":627.0,\"end\":648.0,\"text\":\"Handa and Sato, 1975;\",\"ref_id\":\"BIBREF164\"},{\"start\":649.0,\"end\":673.0,\"text\":\"Easley and Condon, 1974)\",\"ref_id\":\"BIBREF102\"},{\"start\":747.0,\"end\":772.0,\"text\":\"(Boelsterli et al., 1983)\",\"ref_id\":\"BIBREF36\"},{\"start\":1053.0,\"end\":1070.0,\"text\":\"(Desnoyers, 2010;\",\"ref_id\":\"BIBREF92\"},{\"start\":1071.0,\"end\":1092.0,\"text\":\"Wallace et al., 2002;\",\"ref_id\":\"BIBREF415\"},{\"start\":1093.0,\"end\":1118.0,\"text\":\"Mariani and Fulton, 2001;\",\"ref_id\":\"BIBREF245\"},{\"start\":1119.0,\"end\":1145.0,\"text\":\"Aronson and Drobatz, 1996)\",\"ref_id\":\"BIBREF10\"},{\"start\":1288.0,\"end\":1314.0,\"text\":\"(Edwards and Fuller, 1996)\",\"ref_id\":\"BIBREF103\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1053-1070> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-578-604> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1093-1118> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-627-648> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-183-208> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1071-1092> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-649-673> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-747-772> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-165-182> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1119-1145> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-605-626> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1288-1314> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Many of the agents that cause oxidative erythrocyte injury contain aromatic structures that can be metabolized, mostly commonly by cytochrome P450, to free radicals (Bradberry, 2003; Edwards and Fuller, 1996) , which overwhelm the normal protective antioxidant pathways of erythrocytes leading to both direct erythrocyte oxidative injury and oxidation of hemoglobin sulfhydryl groups resulting in methemoglobin formation. A few specific aromatic compounds that have been associated with free radical formation include dapsone, phenacetin, and anthracyclines such as doxorubicin (Edwards and Fuller, 1996; Coleman et al., 1991; Handa and Sato, 1975; Easley and Condon, 1974) . Phenacetin has also been associated with the formation of Heinz bodies (Boelsterli et al., 1983) . In dogs and cats, acetaminophen (paracetamol) may be metabolized to a minor reactive metabolite that causes oxidative damage to erythrocytes resulting in hemolysis and the formation of Heinz bodies and/or eccentrocytes, although methemoglobinemia has also been observed in cats (Desnoyers, 2010; Wallace et al., 2002; Mariani and Fulton, 2001; Aronson and Drobatz, 1996) . Xenobiotics that cause methemoglobinemia can also cause indirect oxidative damage through the peroxidation activity of methemoglobin itself (Edwards and Fuller, 1996) ." ;
            <http://www.example.org/textHash>
                    "90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f" .
    
    <http://covid19.aksw.org/text-d76683337213c44f43b98a160d3d52137e06a3dfed9b8759d8b7dc67c7560610>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In blood, neutrophils are typically the most numerous leukocyte in humans, rhesus monkeys, African green monkeys, and dogs. However, many New World monkeys tend to have lymphocyte counts greater than neutrophil counts (Provencher Bolliger et al., 2010) , and cynomolgus monkeys tend to initially have predominantly lymphocytes in circulation when they are young but shift to predominantly neutrophils with maturity (Sugimoto et al., 1986) . Neutrophil counts are lower than lymphocyte counts in rats and mice. Blood neutrophil counts may increase or decrease depending on the stimulus or insult.\",\"cite_spans\":[{\"start\":218.0,\"end\":252.0,\"text\":\"(Provencher Bolliger et al., 2010)\",\"ref_id\":\"BIBREF305\"},{\"start\":415.0,\"end\":438.0,\"text\":\"(Sugimoto et al., 1986)\",\"ref_id\":\"BIBREF373\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d76683337213c44f43b98a160d3d52137e06a3dfed9b8759d8b7dc67c7560610_citespan-218-252> , <http://covid19.aksw.org/text-d76683337213c44f43b98a160d3d52137e06a3dfed9b8759d8b7dc67c7560610_citespan-415-438> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "In blood, neutrophils are typically the most numerous leukocyte in humans, rhesus monkeys, African green monkeys, and dogs. However, many New World monkeys tend to have lymphocyte counts greater than neutrophil counts (Provencher Bolliger et al., 2010) , and cynomolgus monkeys tend to initially have predominantly lymphocytes in circulation when they are young but shift to predominantly neutrophils with maturity (Sugimoto et al., 1986) . Neutrophil counts are lower than lymphocyte counts in rats and mice. Blood neutrophil counts may increase or decrease depending on the stimulus or insult." ;
            <http://www.example.org/textHash>
                    "d76683337213c44f43b98a160d3d52137e06a3dfed9b8759d8b7dc67c7560610" .
    
    <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-968-981>
            <http://www.example.org/end>    "981.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF57" ;
            <http://www.example.org/start>  "968.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Carey, 2003)" .
    
    <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-672-695>
            <http://www.example.org/end>    "695.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF97" ;
            <http://www.example.org/start>  "672.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Duchayne et al., 1999)" .
    
    <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265_citespan-566-587>
            <http://www.example.org/end>    "587.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF223" ;
            <http://www.example.org/start>  "566.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Levine et al., 2005)" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Immune-mediated destruction of platelets is a relatively common cause of xenobiotic-induced decreases in blood platelet counts. Antiplatelet antibodies may be formed through various mechanisms. Penicillin and some cephalosporins cause platelet destruction through hapten-type or drug-dependent antibody production, while quinidine and some NSAIDS can cause immune-mediated platelet destruction through the formation of antibodies that only bind platelets when the soluble drug is present (Aster and Bougie, 2007) . Some drugs that inhibit the platelet glycoprotein a IIb b 3(GPIIb-IIIa) may lead to platelet expression of a new antigen due to conformation changes to the glycoprotein complexes that can then be bound by antibodies; such drugs include tirofiban, roxifiban, and eptifibatide (Aster and Bougie, 2007; Aster, 2005) . Abciximab has been reported to cause drugspecific antibodies that cause decreases in platelet counts (Aster, 2005) . Xenobiotic-induced production of autoantibodies that bind platelets, or drug-independent antibodies, has been attributed to procainamide and gold-based compound administration (Aster and Bougie, 2007) . In humans, immune-complex type antibodies are classically associated with heparin therapy, and are due to the interaction of heparin, a platelet granule component, and platelet factor 4 (PF4) (Aster and Bougie, 2007; Visentin and Liu, 2007; Arepally and Ortel, 2006) .\",\"cite_spans\":[{\"start\":488.0,\"end\":512.0,\"text\":\"(Aster and Bougie, 2007)\",\"ref_id\":\"BIBREF12\"},{\"start\":790.0,\"end\":814.0,\"text\":\"(Aster and Bougie, 2007;\",\"ref_id\":\"BIBREF12\"},{\"start\":815.0,\"end\":827.0,\"text\":\"Aster, 2005)\"},{\"start\":931.0,\"end\":944.0,\"text\":\"(Aster, 2005)\"},{\"start\":1123.0,\"end\":1147.0,\"text\":\"(Aster and Bougie, 2007)\",\"ref_id\":\"BIBREF12\"},{\"start\":1342.0,\"end\":1366.0,\"text\":\"(Aster and Bougie, 2007;\",\"ref_id\":\"BIBREF12\"},{\"start\":1367.0,\"end\":1390.0,\"text\":\"Visentin and Liu, 2007;\",\"ref_id\":\"BIBREF410\"},{\"start\":1391.0,\"end\":1416.0,\"text\":\"Arepally and Ortel, 2006)\",\"ref_id\":\"BIBREF6\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-931-944> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1391-1416> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-488-512> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-815-827> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1342-1366> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1367-1390> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-790-814> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1123-1147> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Immune-mediated destruction of platelets is a relatively common cause of xenobiotic-induced decreases in blood platelet counts. Antiplatelet antibodies may be formed through various mechanisms. Penicillin and some cephalosporins cause platelet destruction through hapten-type or drug-dependent antibody production, while quinidine and some NSAIDS can cause immune-mediated platelet destruction through the formation of antibodies that only bind platelets when the soluble drug is present (Aster and Bougie, 2007) . Some drugs that inhibit the platelet glycoprotein a IIb b 3(GPIIb-IIIa) may lead to platelet expression of a new antigen due to conformation changes to the glycoprotein complexes that can then be bound by antibodies; such drugs include tirofiban, roxifiban, and eptifibatide (Aster and Bougie, 2007; Aster, 2005) . Abciximab has been reported to cause drugspecific antibodies that cause decreases in platelet counts (Aster, 2005) . Xenobiotic-induced production of autoantibodies that bind platelets, or drug-independent antibodies, has been attributed to procainamide and gold-based compound administration (Aster and Bougie, 2007) . In humans, immune-complex type antibodies are classically associated with heparin therapy, and are due to the interaction of heparin, a platelet granule component, and platelet factor 4 (PF4) (Aster and Bougie, 2007; Visentin and Liu, 2007; Arepally and Ortel, 2006) ." ;
            <http://www.example.org/textHash>
                    "42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2" .
    
    <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-606-632>
            <http://www.example.org/end>    "632.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF67" ;
            <http://www.example.org/start>  "606.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Chinen and Shearer, 2010;" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-227-250>
            <http://www.example.org/end>    "250.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF219" ;
            <http://www.example.org/start>  "227.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Leder and Weller, 2000)" .
    
    <http://covid19.aksw.org/text-2252bb39c3ba663ece825638d176ed9cf503dec74ead8f47fa402a1e7de6e486>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Stimulation with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-6 promotes the differentiation of common myeloid progenitor cells to granulocyte/monocyte progenitor cells, and subsequent stimulation with granulocyte colony-stimulating factor (G-CSF) promotes differentiation, proliferation, and maturation of granulocytes from myeloblasts to mature segmented neutrophils (Radin and Wellman, 2010) . Granulocyte pools in the bone marrow can be divided into proliferating (mitotic) and maturing (postmitotic) pools. The proliferating pool encompasses the most immature myeloid precursors: myeloblasts, promyelocytes, and myelocytes. The maturing pool includes the later stages of metamyelocytes, band neutrophils, and mature segmented neutrophils. The mature segmented neutrophil population within the maturing pool is also considered the bone marrow storage pool, and acts as a reserve store of neutrophils that replenish blood stores following normal turnover and can be quickly mobilized to the blood in times of increased tissue demand. In health, mammalian blood neutrophils are mature, segmented neutrophils. They are distributed in two pools within the blood vessels, the circulating pool and the marginating pool. Circulating pool neutrophils flow freely through the vessel lumen and are sampled during blood collection. Marginating pool neutrophils are in contact with endothelial cells and temporarily adhere to or roll along the vessel wall. Neutrophils may shift between the circulating and marginating pools. The lifespan of a neutrophil in circulation is short (approximately 7 h half-life in blood), and ultimately neutrophils migrate into tissues where they survive for a few days (Smith, 2016) . Neutrophils are part of the innate immune system and primarily function as phagocytes to remove and destroy invading pathogens, but also can secrete proinflammatory and chemotactic mediators to enhance responses of both the innate and adaptive immune systems.\",\"cite_spans\":[{\"start\":412.0,\"end\":437.0,\"text\":\"(Radin and Wellman, 2010)\",\"ref_id\":\"BIBREF307\"},{\"start\":1736.0,\"end\":1749.0,\"text\":\"(Smith, 2016)\",\"ref_id\":\"BIBREF358\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2252bb39c3ba663ece825638d176ed9cf503dec74ead8f47fa402a1e7de6e486_citespan-412-437> , <http://covid19.aksw.org/text-2252bb39c3ba663ece825638d176ed9cf503dec74ead8f47fa402a1e7de6e486_citespan-1736-1749> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Stimulation with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-6 promotes the differentiation of common myeloid progenitor cells to granulocyte/monocyte progenitor cells, and subsequent stimulation with granulocyte colony-stimulating factor (G-CSF) promotes differentiation, proliferation, and maturation of granulocytes from myeloblasts to mature segmented neutrophils (Radin and Wellman, 2010) . Granulocyte pools in the bone marrow can be divided into proliferating (mitotic) and maturing (postmitotic) pools. The proliferating pool encompasses the most immature myeloid precursors: myeloblasts, promyelocytes, and myelocytes. The maturing pool includes the later stages of metamyelocytes, band neutrophils, and mature segmented neutrophils. The mature segmented neutrophil population within the maturing pool is also considered the bone marrow storage pool, and acts as a reserve store of neutrophils that replenish blood stores following normal turnover and can be quickly mobilized to the blood in times of increased tissue demand. In health, mammalian blood neutrophils are mature, segmented neutrophils. They are distributed in two pools within the blood vessels, the circulating pool and the marginating pool. Circulating pool neutrophils flow freely through the vessel lumen and are sampled during blood collection. Marginating pool neutrophils are in contact with endothelial cells and temporarily adhere to or roll along the vessel wall. Neutrophils may shift between the circulating and marginating pools. The lifespan of a neutrophil in circulation is short (approximately 7 h half-life in blood), and ultimately neutrophils migrate into tissues where they survive for a few days (Smith, 2016) . Neutrophils are part of the innate immune system and primarily function as phagocytes to remove and destroy invading pathogens, but also can secrete proinflammatory and chemotactic mediators to enhance responses of both the innate and adaptive immune systems." ;
            <http://www.example.org/textHash>
                    "2252bb39c3ba663ece825638d176ed9cf503dec74ead8f47fa402a1e7de6e486" .
    
    <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf_citespan-479-502>
            <http://www.example.org/end>    "502.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "479.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Benschop et al., 1996)" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-386-408>
            <http://www.example.org/end>    "408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Amundsen et al., 2012;" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-690-703>
            <http://www.example.org/end>    "703.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "690.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ameri, 2010)" .
    
    <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b_citespan-619-646>
            <http://www.example.org/end>    "646.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "619.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-870-891>
            <http://www.example.org/end>    "891.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Caldin et al., 2005)" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1342-1366>
            <http://www.example.org/end>    "1366.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Aster and Bougie, 2007;" .
    
    <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd_citespan-385-399>
            <http://www.example.org/end>    "399.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-335-356>
            <http://www.example.org/end>    "356.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF383" ;
            <http://www.example.org/start>  "335.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tefferi et al., 2006;" .
    
    <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in red cell mass associated with endocrinopathies are generally mild and do not result in overt clinical signs. Hyperthyroidism causes a sustained increase in tissue demand for oxygen, leading to hypoxia, increased EPO production, and consequent increases in red cell mass (Stockham and Scott, 2008b ). Acromegaly, caused by an increase in growth hormone concentrations, has also been associated with increases in red cell mass, particularly in cats (Randolph et al., 2010) . Hyperadrenocorticism or adrenal neoplasms that produce androgens or aldosterone may also be associated with increases in red cell mass (Prchal, 2016; Ghio et al., 1981; Mann et al., 1967) .\",\"cite_spans\":[{\"start\":283.0,\"end\":309.0,\"text\":\"(Stockham and Scott, 2008b\",\"ref_id\":\"BIBREF367\"},{\"start\":460.0,\"end\":483.0,\"text\":\"(Randolph et al., 2010)\",\"ref_id\":\"BIBREF313\"},{\"start\":621.0,\"end\":635.0,\"text\":\"(Prchal, 2016;\",\"ref_id\":\"BIBREF302\"},{\"start\":636.0,\"end\":654.0,\"text\":\"Ghio et al., 1981;\",\"ref_id\":\"BIBREF142\"},{\"start\":655.0,\"end\":673.0,\"text\":\"Mann et al., 1967)\",\"ref_id\":\"BIBREF241\"}],\"ref_spans\":[],\"section\":\"Endocrinopathies\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-283-309> , <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-460-483> , <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-621-635> , <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-636-654> , <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-655-673> ;
            <http://www.example.org/section>
                    "Endocrinopathies" ;
            <http://www.example.org/text>  "Increases in red cell mass associated with endocrinopathies are generally mild and do not result in overt clinical signs. Hyperthyroidism causes a sustained increase in tissue demand for oxygen, leading to hypoxia, increased EPO production, and consequent increases in red cell mass (Stockham and Scott, 2008b ). Acromegaly, caused by an increase in growth hormone concentrations, has also been associated with increases in red cell mass, particularly in cats (Randolph et al., 2010) . Hyperadrenocorticism or adrenal neoplasms that produce androgens or aldosterone may also be associated with increases in red cell mass (Prchal, 2016; Ghio et al., 1981; Mann et al., 1967) ." ;
            <http://www.example.org/textHash>
                    "40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a" .
    
    <http://covid19.aksw.org/text-d36f694c14f073282a61b380d6f3256e35435abc00cfe656741878bdbe5cc899>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Classic patterns of alterations in red blood cell parameters are summarized in Table 2 .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":79.0,\"end\":86.0,\"text\":\"Table 2\",\"ref_id\":\"TABREF1\"}],\"section\":\"Erythrocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-d36f694c14f073282a61b380d6f3256e35435abc00cfe656741878bdbe5cc899_refspan-79-86> ;
            <http://www.example.org/section>
                    "Erythrocytes" ;
            <http://www.example.org/text>  "Classic patterns of alterations in red blood cell parameters are summarized in Table 2 ." ;
            <http://www.example.org/textHash>
                    "d36f694c14f073282a61b380d6f3256e35435abc00cfe656741878bdbe5cc899" .
    
    <http://covid19.aksw.org/text-c5bacbfeb28ebc4ebfdc3b08969d9f17630cf2dfe9150b66d40999b0b04f26e7_citespan-574-598>
            <http://www.example.org/end>    "598.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF271" ;
            <http://www.example.org/start>  "574.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mutasim and Adams, 2000)" .
    
    <http://covid19.aksw.org/text-7618637eeccb25855a1c7ee52f9f959095f18ae5a2e4d9f9bea627d7777a9c39>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Anemia of chronic disease (ACD) is a relatively common cause of anemia, and anemia associated with inflammatory disease is included in ACD. The decreases in red cell mass observed with ACD are generally mild, and are generally normocytic, normochromic, indicating no changes in MCV or MCHC, respectively. ACD may occur through shortening of erythrocyte lifespans, alterations in iron metabolism, a blunted response of erythroid precursors to EPO, and decreased EPO production. Altered erythrocyte lifespans in patients with ACD may be related to increased macrophagic clearance of erythrocytes from circulation through unknown mechanisms (Ganz, 2016) . This type of mechanism has been associated with several chronic infections, including tuberculosis and endocarditis (Weiss, 2002) .\",\"cite_spans\":[{\"start\":638.0,\"end\":650.0,\"text\":\"(Ganz, 2016)\",\"ref_id\":\"BIBREF130\"},{\"start\":769.0,\"end\":782.0,\"text\":\"(Weiss, 2002)\",\"ref_id\":\"BIBREF426\"}],\"ref_spans\":[],\"section\":\"Chronic disease\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-7618637eeccb25855a1c7ee52f9f959095f18ae5a2e4d9f9bea627d7777a9c39_citespan-638-650> , <http://covid19.aksw.org/text-7618637eeccb25855a1c7ee52f9f959095f18ae5a2e4d9f9bea627d7777a9c39_citespan-769-782> ;
            <http://www.example.org/section>
                    "Chronic disease" ;
            <http://www.example.org/text>  "Anemia of chronic disease (ACD) is a relatively common cause of anemia, and anemia associated with inflammatory disease is included in ACD. The decreases in red cell mass observed with ACD are generally mild, and are generally normocytic, normochromic, indicating no changes in MCV or MCHC, respectively. ACD may occur through shortening of erythrocyte lifespans, alterations in iron metabolism, a blunted response of erythroid precursors to EPO, and decreased EPO production. Altered erythrocyte lifespans in patients with ACD may be related to increased macrophagic clearance of erythrocytes from circulation through unknown mechanisms (Ganz, 2016) . This type of mechanism has been associated with several chronic infections, including tuberculosis and endocarditis (Weiss, 2002) ." ;
            <http://www.example.org/textHash>
                    "7618637eeccb25855a1c7ee52f9f959095f18ae5a2e4d9f9bea627d7777a9c39" .
    
    <http://covid19.aksw.org/text-e449d4cc4436247430597c6799e77b64e4de0cbe16c25767f477a87d32b75b5e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Immune-mediated AIHA may be associated with erythrocyte morphologic changes that include agglutination and spherocytes. Agglutination may be observed grossly as red speckling along the inside of the specimen tube as blood is gently moved within the tube. If agglutination is present, blood smears may have a \\\"reverse smear\\\" appearance with the densest region of the smear observed at the feathered edge rather than the edge where the drop of blood was initially placed. Microscopically agglutination appears as grape-like clusters of erythrocytes. Spherocytes are erythrocytes that are spherical instead of having the normal biconcave disc shape. While spherocytes appear smaller and stain more intensely pink that unaffected mature erythrocytes, they have the same volume as unaffected erythrocytes. Loss of erythrocyte membrane occurs when macrophages begin to phagocytize antibody-bound erythrocytes, leading to decreased erythrocyte surface area without an appreciable change in volume, forcing erythrocytes to form spheres. Hence, spherocytosis alone will not result in an altered MCV. Of the most common laboratory species, dogs tend to have the most pronounced central pallor of normal mature erythrocytes, making microscopic identification of spherocytes easiest in the dog.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Immune-mediated AIHA may be associated with erythrocyte morphologic changes that include agglutination and spherocytes. Agglutination may be observed grossly as red speckling along the inside of the specimen tube as blood is gently moved within the tube. If agglutination is present, blood smears may have a \"reverse smear\" appearance with the densest region of the smear observed at the feathered edge rather than the edge where the drop of blood was initially placed. Microscopically agglutination appears as grape-like clusters of erythrocytes. Spherocytes are erythrocytes that are spherical instead of having the normal biconcave disc shape. While spherocytes appear smaller and stain more intensely pink that unaffected mature erythrocytes, they have the same volume as unaffected erythrocytes. Loss of erythrocyte membrane occurs when macrophages begin to phagocytize antibody-bound erythrocytes, leading to decreased erythrocyte surface area without an appreciable change in volume, forcing erythrocytes to form spheres. Hence, spherocytosis alone will not result in an altered MCV. Of the most common laboratory species, dogs tend to have the most pronounced central pallor of normal mature erythrocytes, making microscopic identification of spherocytes easiest in the dog." ;
            <http://www.example.org/textHash>
                    "e449d4cc4436247430597c6799e77b64e4de0cbe16c25767f477a87d32b75b5e" .
    
    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-787-812>
            <http://www.example.org/end>    "812.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF59" ;
            <http://www.example.org/start>  "787.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Casadevall et al., 2002)" .
    
    <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-307-322>
            <http://www.example.org/end>    "322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF122" ;
            <http://www.example.org/start>  "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Frazier, 2015)" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.3.1.4 Immune disorders Numerous immune disorders are associated with increases in blood monocyte counts. Immune-mediated destruction of erythrocytes or neutrophils often has concurrent increases in monocyte counts (Schultze, 2010; Stockham and Scott, 2008a) . The increase in monocyte count associated with immune-mediated neutropenia may be due to cytokine stimulation of the common precursor of both granulocytes and monocytes (Stockham and Scott, 2008a) . Rebound increases in neutrophil counts during recovery from agranulocytosis often have concurrent increases in monocyte counts (Lichtman, 2016a; Schultze, 2010) , which may also be due to stimulation of the common granulocyte and monocyte precursor. Systemic lupus erythematosus (Budman and Steinberg, 1977) , rheumatoid arthritis (Buchan et al., 1985) , sarcoidosis (Goodwin et al., 1979) , and other connective tissue diseases (Lichtman, 2016a ) may also cause increases in monocyte counts.\",\"cite_spans\":[{\"start\":222.0,\"end\":238.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":239.0,\"end\":265.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":437.0,\"end\":464.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":594.0,\"end\":611.0,\"text\":\"(Lichtman, 2016a;\",\"ref_id\":\"BIBREF225\"},{\"start\":612.0,\"end\":627.0,\"text\":\"Schultze, 2010)\",\"ref_id\":\"BIBREF342\"},{\"start\":746.0,\"end\":774.0,\"text\":\"(Budman and Steinberg, 1977)\",\"ref_id\":\"BIBREF47\"},{\"start\":798.0,\"end\":819.0,\"text\":\"(Buchan et al., 1985)\",\"ref_id\":\"BIBREF46\"},{\"start\":834.0,\"end\":856.0,\"text\":\"(Goodwin et al., 1979)\",\"ref_id\":\"BIBREF152\"},{\"start\":896.0,\"end\":912.0,\"text\":\"(Lichtman, 2016a\",\"ref_id\":\"BIBREF225\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-594-611> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-437-464> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-798-819> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-239-265> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-222-238> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-834-856> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-746-774> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-896-912> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-612-627> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "12.11.2.3.1.4 Immune disorders Numerous immune disorders are associated with increases in blood monocyte counts. Immune-mediated destruction of erythrocytes or neutrophils often has concurrent increases in monocyte counts (Schultze, 2010; Stockham and Scott, 2008a) . The increase in monocyte count associated with immune-mediated neutropenia may be due to cytokine stimulation of the common precursor of both granulocytes and monocytes (Stockham and Scott, 2008a) . Rebound increases in neutrophil counts during recovery from agranulocytosis often have concurrent increases in monocyte counts (Lichtman, 2016a; Schultze, 2010) , which may also be due to stimulation of the common granulocyte and monocyte precursor. Systemic lupus erythematosus (Budman and Steinberg, 1977) , rheumatoid arthritis (Buchan et al., 1985) , sarcoidosis (Goodwin et al., 1979) , and other connective tissue diseases (Lichtman, 2016a ) may also cause increases in monocyte counts." ;
            <http://www.example.org/textHash>
                    "192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb" .
    
    <http://covid19.aksw.org/text-0e49f86ebe42a035e301c530ebcbd55643657dc8672a42f82d962df46ea66136_citespan-326-352>
            <http://www.example.org/end>    "352.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF103" ;
            <http://www.example.org/start>  "326.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Edwards and Fuller, 1996)" .
    
    <http://covid19.aksw.org/text-f6a032c5737c6d45ad4c6b636bc6ceb2465afd3568393b4b1c32e6d291b1e188_citespan-294-315>
            <http://www.example.org/end>    "315.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF334" ;
            <http://www.example.org/start>  "294.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Salama et al., 1996)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-705-719>
            <http://www.example.org/end>    "719.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF121" ;
            <http://www.example.org/start>  "705.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fowler, 1998;" .
    
    <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.1.5 Inherited Some phenotypes of sickle cell disease are associated with hemolysis. The mechanism of hemolysis in sickle cell disease is likely multifactorial and not associated with a single pathogenesis. There is evidence for oxidative damage to erythrocytes (Lachant et al., 1983) , which may contribute to the hemolysis observed with sickle cell disease. However, hemoglobin polymerization leads to erythrocyte deformation and may lead to decreased flexibility of erythrocytes and veno-occlusive disorders (Bookchin and Lew, 1996) . Decreased flexibility or deformability of erythrocytes may contribute directly to increased cell fragility and rupture or promote clearance of deformed erythrocytes by splenic macrophages, while veno-occlusive disease has the potential to cause decreases in red cell mass through physical trauma and fragmentation. However, there is also evidence that in some severe cases of sickle cell disease there may be an increase in reticulocyte counts that are inappropriate for the magnitude of the decrease in red cell mass, suggesting a concurrent mechanism causing suppressed or ineffective erythropoiesis (Wu et al., 2005; Bookchin and Lew, 1996) . Oxidative stress on erythroid precursors may also contribute to ineffective erythropoiesis in some severe cases of sickle cell disease (Fibach and Rachmilewitz, 2008) .\",\"cite_spans\":[{\"start\":273.0,\"end\":295.0,\"text\":\"(Lachant et al., 1983)\",\"ref_id\":\"BIBREF211\"},{\"start\":522.0,\"end\":546.0,\"text\":\"(Bookchin and Lew, 1996)\",\"ref_id\":\"BIBREF37\"},{\"start\":1151.0,\"end\":1168.0,\"text\":\"(Wu et al., 2005;\",\"ref_id\":\"BIBREF434\"},{\"start\":1169.0,\"end\":1192.0,\"text\":\"Bookchin and Lew, 1996)\",\"ref_id\":\"BIBREF37\"},{\"start\":1330.0,\"end\":1361.0,\"text\":\"(Fibach and Rachmilewitz, 2008)\",\"ref_id\":\"BIBREF117\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-273-295> , <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-522-546> , <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-1151-1168> , <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-1169-1192> , <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-1330-1361> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.1.5 Inherited Some phenotypes of sickle cell disease are associated with hemolysis. The mechanism of hemolysis in sickle cell disease is likely multifactorial and not associated with a single pathogenesis. There is evidence for oxidative damage to erythrocytes (Lachant et al., 1983) , which may contribute to the hemolysis observed with sickle cell disease. However, hemoglobin polymerization leads to erythrocyte deformation and may lead to decreased flexibility of erythrocytes and veno-occlusive disorders (Bookchin and Lew, 1996) . Decreased flexibility or deformability of erythrocytes may contribute directly to increased cell fragility and rupture or promote clearance of deformed erythrocytes by splenic macrophages, while veno-occlusive disease has the potential to cause decreases in red cell mass through physical trauma and fragmentation. However, there is also evidence that in some severe cases of sickle cell disease there may be an increase in reticulocyte counts that are inappropriate for the magnitude of the decrease in red cell mass, suggesting a concurrent mechanism causing suppressed or ineffective erythropoiesis (Wu et al., 2005; Bookchin and Lew, 1996) . Oxidative stress on erythroid precursors may also contribute to ineffective erythropoiesis in some severe cases of sickle cell disease (Fibach and Rachmilewitz, 2008) ." ;
            <http://www.example.org/textHash>
                    "b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134" .
    
    <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-773-796>
            <http://www.example.org/end>    "796.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF169" ;
            <http://www.example.org/start>  "773.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hellmich et al., 2002)" .
    
    <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-460-483>
            <http://www.example.org/end>    "483.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF313" ;
            <http://www.example.org/start>  "460.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Randolph et al., 2010)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-97-112>
            <http://www.example.org/end>    "112.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "97.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016)" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-476-496>
            <http://www.example.org/end>    "496.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "476.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016;" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-1007-1023>
            <http://www.example.org/end>    "1023.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF394" ;
            <http://www.example.org/start>  "1007.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tristano, 2005)" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-187-204>
            <http://www.example.org/end>    "204.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF232" ;
            <http://www.example.org/start>  "187.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Liu et al., 2004)" .
    
    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The circulating blood volume is composed of about 40%-45% erythrocytes (Bloom and Brandt, 2008) , but there are usually many noncirculating erythrocytes present within the splenic red pulp. Automated hematology analyzers provide indications of blood erythrocyte counts, blood hemoglobin concentration, and hematocrit, which are collectively indicative of red cell mass. In health, the vast majority of blood erythrocytes are mature erythrocytes, with only a very small proportion of reticulocytes, except in rodents. Rodents normally have mildly greater reticulocyte counts relative to most other common laboratory species due to their higher erythrocyte turnover; gerbils tend to have the shortest erythrocyte lifespans and therefore the highest reticulocyte counts . Erythrocyte lifespan in circulation is species-dependent. Human erythrocytes have an average lifespan of about 120 days (Thiagarajan and Prchal, 2016) , while macaque erythrocytes have a lifespan of approximately 100 days (Provencher Bolliger et al., 2010) . Canine and feline erythrocyte lifespans are approximately 100 and 70 days, respectively (Stockham and Scott, 2008b) . In contrast, rat erythrocytes have an estimated lifespan of approximately 60 days (Van Putten and Croon, 1958) although there is some strain-related variability (Derelanko, 1987) , while mouse erythrocyte lifespans are even shorter, with an estimate of about 41 days (Van Putten and Croon, 1958) . Mongolian gerbil erythrocyte lifespans have an estimate of 9-10 days .\",\"cite_spans\":[{\"start\":71.0,\"end\":95.0,\"text\":\"(Bloom and Brandt, 2008)\",\"ref_id\":\"BIBREF35\"},{\"start\":889.0,\"end\":919.0,\"text\":\"(Thiagarajan and Prchal, 2016)\",\"ref_id\":\"BIBREF385\"},{\"start\":991.0,\"end\":1025.0,\"text\":\"(Provencher Bolliger et al., 2010)\",\"ref_id\":\"BIBREF305\"},{\"start\":1116.0,\"end\":1143.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":1307.0,\"end\":1324.0,\"text\":\"(Derelanko, 1987)\",\"ref_id\":\"BIBREF91\"},{\"start\":1413.0,\"end\":1441.0,\"text\":\"(Van Putten and Croon, 1958)\",\"ref_id\":\"BIBREF404\"}],\"ref_spans\":[],\"section\":\"Erythrocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-991-1025> , <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-1116-1143> , <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-71-95> , <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-1413-1441> , <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-1307-1324> , <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-889-919> ;
            <http://www.example.org/section>
                    "Erythrocytes" ;
            <http://www.example.org/text>  "The circulating blood volume is composed of about 40%-45% erythrocytes (Bloom and Brandt, 2008) , but there are usually many noncirculating erythrocytes present within the splenic red pulp. Automated hematology analyzers provide indications of blood erythrocyte counts, blood hemoglobin concentration, and hematocrit, which are collectively indicative of red cell mass. In health, the vast majority of blood erythrocytes are mature erythrocytes, with only a very small proportion of reticulocytes, except in rodents. Rodents normally have mildly greater reticulocyte counts relative to most other common laboratory species due to their higher erythrocyte turnover; gerbils tend to have the shortest erythrocyte lifespans and therefore the highest reticulocyte counts . Erythrocyte lifespan in circulation is species-dependent. Human erythrocytes have an average lifespan of about 120 days (Thiagarajan and Prchal, 2016) , while macaque erythrocytes have a lifespan of approximately 100 days (Provencher Bolliger et al., 2010) . Canine and feline erythrocyte lifespans are approximately 100 and 70 days, respectively (Stockham and Scott, 2008b) . In contrast, rat erythrocytes have an estimated lifespan of approximately 60 days (Van Putten and Croon, 1958) although there is some strain-related variability (Derelanko, 1987) , while mouse erythrocyte lifespans are even shorter, with an estimate of about 41 days (Van Putten and Croon, 1958) . Mongolian gerbil erythrocyte lifespans have an estimate of 9-10 days ." ;
            <http://www.example.org/textHash>
                    "a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25" .
    
    <http://covid19.aksw.org/text-4b3341a78d894bff5627a3a6590b134ad5e5d6333eb9c8098c2660a4c029cec0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The production of neutrophils, or granulopoiesis, occurs predominantly in the bone marrow, although extramedullary hematopoiesis may contribute, particularly in rats and mice, and if increased tissue demand for granulocytes or bone marrow disease is present. Table 1 Classic patterns of alterations in blood leukocyte components\",\"cite_spans\":[],\"ref_spans\":[{\"start\":259.0,\"end\":266.0,\"text\":\"Table 1\"}],\"section\":\"Neutrophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-4b3341a78d894bff5627a3a6590b134ad5e5d6333eb9c8098c2660a4c029cec0_refspan-259-266> ;
            <http://www.example.org/section>
                    "Neutrophils" ;
            <http://www.example.org/text>  "The production of neutrophils, or granulopoiesis, occurs predominantly in the bone marrow, although extramedullary hematopoiesis may contribute, particularly in rats and mice, and if increased tissue demand for granulocytes or bone marrow disease is present. Table 1 Classic patterns of alterations in blood leukocyte components" ;
            <http://www.example.org/textHash>
                    "4b3341a78d894bff5627a3a6590b134ad5e5d6333eb9c8098c2660a4c029cec0" .
    
    <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-846-870>
            <http://www.example.org/end>    "870.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF396" ;
            <http://www.example.org/start>  "846.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tuckermann et al., 2005)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1391-1412>
            <http://www.example.org/end>    "1412.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "1391.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bennett et al., 1998" .
    
    <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.2.1.2 Catecholamine-induced Similar to increases in neutrophil counts, increases in endogenous or exogenous catecholamines associated with excitement, fear, or exercise result in transient increases in lymphocyte counts. Catecholamine-induced increases in lymphocyte counts are associated with rapid shifts from the marginating to circulating lymphocyte pool, which is thought to be due to both decreased lymphocyte adhesion to endothelial cells and increased blood flow (Benschop et al., 1996) . Release of lymphocytes from the spleen in response to catecholamine stimulation likely also contributes to the increase in blood lymphocyte counts, but lymph nodes and bone marrow do not appear to be significant contributors (Benschop et al., 1996) . There are species differences in the response of lymphocytes to catecholamines, and the resultant increases in lymphocyte tend to be more common in monkeys and cats, while less common in adult dogs Schultze, 2010) .\",\"cite_spans\":[{\"start\":479.0,\"end\":502.0,\"text\":\"(Benschop et al., 1996)\",\"ref_id\":\"BIBREF25\"},{\"start\":730.0,\"end\":753.0,\"text\":\"(Benschop et al., 1996)\",\"ref_id\":\"BIBREF25\"},{\"start\":954.0,\"end\":969.0,\"text\":\"Schultze, 2010)\",\"ref_id\":\"BIBREF342\"}],\"ref_spans\":[],\"section\":\"Increases in lymphocyte counts (lymphocytosis)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf_citespan-479-502> , <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf_citespan-730-753> , <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf_citespan-954-969> ;
            <http://www.example.org/section>
                    "Increases in lymphocyte counts (lymphocytosis)" ;
            <http://www.example.org/text>  "12.11.2.2.1.2 Catecholamine-induced Similar to increases in neutrophil counts, increases in endogenous or exogenous catecholamines associated with excitement, fear, or exercise result in transient increases in lymphocyte counts. Catecholamine-induced increases in lymphocyte counts are associated with rapid shifts from the marginating to circulating lymphocyte pool, which is thought to be due to both decreased lymphocyte adhesion to endothelial cells and increased blood flow (Benschop et al., 1996) . Release of lymphocytes from the spleen in response to catecholamine stimulation likely also contributes to the increase in blood lymphocyte counts, but lymph nodes and bone marrow do not appear to be significant contributors (Benschop et al., 1996) . There are species differences in the response of lymphocytes to catecholamines, and the resultant increases in lymphocyte tend to be more common in monkeys and cats, while less common in adult dogs Schultze, 2010) ." ;
            <http://www.example.org/textHash>
                    "4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-541-561>
            <http://www.example.org/end>    "561.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "541.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Arock et al., 2002;" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-955-979>
            <http://www.example.org/end>    "979.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF196" ;
            <http://www.example.org/start>  "955.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Karttunen et al., 1996)" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-675-699>
            <http://www.example.org/end>    "699.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF349" ;
            <http://www.example.org/start>  "675.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sheafor and Couto, 1999)" .
    
    <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209_citespan-502-529>
            <http://www.example.org/end>    "529.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "502.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-763-775>
            <http://www.example.org/end>    "775.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF157" ;
            <http://www.example.org/start>  "763.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Green, 2016;" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-143-159>
            <http://www.example.org/end>    "159.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "143.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-285-307>
            <http://www.example.org/end>    "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF85" ;
            <http://www.example.org/start>  "285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dale and Welte, 2016;" .
    
    <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-1105-1119>
            <http://www.example.org/end>    "1119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF166" ;
            <http://www.example.org/start>  "1105.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Harvey, 2012;" .
    
    <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-144-165>
            <http://www.example.org/end>    "165.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "144.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Spiers et al., 1977)" .
    
    <http://covid19.aksw.org/text-aac8e0a7af1b85b1efee352e4b0f00e92ab89380289eec23e06045781c8cb633>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.1.3 Inflammation Inflammation is one of the most common causes of increased blood neutrophil counts. Inflammation is typically further characterized as acute or chronic, although these terms are often used inconsistently across disciplines and may refer to either the duration of the inflammation or the type of reaction to the inflammatory response. The latter definition is used here for alterations in blood leukocyte counts.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "12.11.2.1.1.3 Inflammation Inflammation is one of the most common causes of increased blood neutrophil counts. Inflammation is typically further characterized as acute or chronic, although these terms are often used inconsistently across disciplines and may refer to either the duration of the inflammation or the type of reaction to the inflammatory response. The latter definition is used here for alterations in blood leukocyte counts." ;
            <http://www.example.org/textHash>
                    "aac8e0a7af1b85b1efee352e4b0f00e92ab89380289eec23e06045781c8cb633" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-715-738>
            <http://www.example.org/end>    "738.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF127" ;
            <http://www.example.org/start>  "715.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gallagher et al., 1992;" .
    
    <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b_citespan-414-434>
            <http://www.example.org/end>    "434.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF111" ;
            <http://www.example.org/start>  "414.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Farid et al., 1969)" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.3.1.5 Neoplasia Hematopoietic malignancies involving the monocytic lineage are rare, but are commonly associated with increased blood monocyte counts. These hematopoietic neoplasms include myelodysplastic syndromes (e.g., chronic myelomonocytic leukemia), acute monocytic leukemia, acute myelomonocytic leukemia, dendritic cell leukemia, and malignant histiocytosis (Schultze, 2010; Tefferi and Vardiman, 2009; Villeneuve et al., 2008; Sun et al., 2007; Lichtman and Segel, 2005; Castoldi and Rigolin, 2001; Rigolin et al., 1997; Laurencet et al., 1994) . Blood monocytes associated with these hematopoietic neoplasms frequently have abnormal morphologic features and may be accompanied by monoblasts or promonocytes in circulation.\",\"cite_spans\":[{\"start\":374.0,\"end\":390.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":391.0,\"end\":418.0,\"text\":\"Tefferi and Vardiman, 2009;\",\"ref_id\":\"BIBREF382\"},{\"start\":419.0,\"end\":443.0,\"text\":\"Villeneuve et al., 2008;\",\"ref_id\":\"BIBREF408\"},{\"start\":444.0,\"end\":461.0,\"text\":\"Sun et al., 2007;\",\"ref_id\":\"BIBREF374\"},{\"start\":462.0,\"end\":487.0,\"text\":\"Lichtman and Segel, 2005;\",\"ref_id\":\"BIBREF227\"},{\"start\":488.0,\"end\":515.0,\"text\":\"Castoldi and Rigolin, 2001;\",\"ref_id\":\"BIBREF60\"},{\"start\":516.0,\"end\":537.0,\"text\":\"Rigolin et al., 1997;\",\"ref_id\":\"BIBREF319\"},{\"start\":538.0,\"end\":561.0,\"text\":\"Laurencet et al., 1994)\",\"ref_id\":\"BIBREF217\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-538-561> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-462-487> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-488-515> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-516-537> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-374-390> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-444-461> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-419-443> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-391-418> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "12.11.2.3.1.5 Neoplasia Hematopoietic malignancies involving the monocytic lineage are rare, but are commonly associated with increased blood monocyte counts. These hematopoietic neoplasms include myelodysplastic syndromes (e.g., chronic myelomonocytic leukemia), acute monocytic leukemia, acute myelomonocytic leukemia, dendritic cell leukemia, and malignant histiocytosis (Schultze, 2010; Tefferi and Vardiman, 2009; Villeneuve et al., 2008; Sun et al., 2007; Lichtman and Segel, 2005; Castoldi and Rigolin, 2001; Rigolin et al., 1997; Laurencet et al., 1994) . Blood monocytes associated with these hematopoietic neoplasms frequently have abnormal morphologic features and may be accompanied by monoblasts or promonocytes in circulation." ;
            <http://www.example.org/textHash>
                    "fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6" .
    
    <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-481-502>
            <http://www.example.org/end>    "502.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF299" ;
            <http://www.example.org/start>  "481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pisoni et al., 2001)" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-970-985>
            <http://www.example.org/end>    "985.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "970.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Russell, 2010;" .
    
    <http://covid19.aksw.org/text-7638c46ced28b43f8526452094bc66c63ae9064ea8c32529ce25e5d7dbdbd9a3_citespan-600-626>
            <http://www.example.org/end>    "626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF62" ;
            <http://www.example.org/start>  "600.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Chamberlain et al., 1990)" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-396-417>
            <http://www.example.org/end>    "417.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF224" ;
            <http://www.example.org/start>  "396.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Levine et al., 2006;" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-1035-1072>
            <http://www.example.org/end>    "1072.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF158" ;
            <http://www.example.org/start>  "1035.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gregg and Goldschmidt-Clermont, 2003)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-442-463>
            <http://www.example.org/end>    "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF109" ;
            <http://www.example.org/start>  "442.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Falcone et al., 2001;" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1255-1270>
            <http://www.example.org/end>    "1270.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF338" ;
            <http://www.example.org/start>  "1255.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sawyers, 1999)" .
    
    <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a_citespan-1247-1260>
            <http://www.example.org/end>    "1260.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF157" ;
            <http://www.example.org/start>  "1247.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Green, 2016)" .
    
    <http://covid19.aksw.org/text-14d4f54fbe70d0841956c98998b1a8984b4517f8d3811792b229e1fba07a164c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Once the inflammatory stimulus has persisted long enough to result in granulocytic hyperplasia of the bone marrow and at least partially replenished the neutrophil storage pool, increases in blood neutrophil counts are characterized by a diminishing left shift and a switch to predominant mature segmented neutrophils in circulation. Also, if the insult is effectively being resolved by the inflammatory response, tissue demand for neutrophils may decrease, resulting in release of fewer immature stages and the appearance of a chronic inflammatory pattern. In nonclinical toxicology studies, certain procedure-related effects, such as long-term catheterization, may cause an inflammatory leukogram (Hall, 2013) .\",\"cite_spans\":[{\"start\":699.0,\"end\":711.0,\"text\":\"(Hall, 2013)\",\"ref_id\":\"BIBREF162\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-14d4f54fbe70d0841956c98998b1a8984b4517f8d3811792b229e1fba07a164c_citespan-699-711> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Once the inflammatory stimulus has persisted long enough to result in granulocytic hyperplasia of the bone marrow and at least partially replenished the neutrophil storage pool, increases in blood neutrophil counts are characterized by a diminishing left shift and a switch to predominant mature segmented neutrophils in circulation. Also, if the insult is effectively being resolved by the inflammatory response, tissue demand for neutrophils may decrease, resulting in release of fewer immature stages and the appearance of a chronic inflammatory pattern. In nonclinical toxicology studies, certain procedure-related effects, such as long-term catheterization, may cause an inflammatory leukogram (Hall, 2013) ." ;
            <http://www.example.org/textHash>
                    "14d4f54fbe70d0841956c98998b1a8984b4517f8d3811792b229e1fba07a164c" .
    
    <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-339-352>
            <http://www.example.org/end>    "352.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF371" ;
            <http://www.example.org/start>  "339.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stone, 2005)" .
    
    <http://covid19.aksw.org/text-9f0e0005a91e30bf4f7b2aff2b3613e745dc5598152597f98fc91563184fa2c2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-induced marked decreases in platelet counts may also be associated with hemorrhage and are discussed in more detail later. However, chemotherapeutics that cause bone marrow suppression can be associated with spontaneous or postvenipuncture hemorrhage. Occasional idiopathic decreases in platelet counts have also been observed following xenobiotic administration and are most likely attributable to immune-mediated destruction; some examples of implicated xenobiotics are quinine, trimethoprim-sulfamethoxazole, anticonvulsants such as phenytoin and carbamazepine, unfractionated or low molecular weight heparin, and rituximab (Aster and Bougie, 2007) .\",\"cite_spans\":[{\"start\":638.0,\"end\":662.0,\"text\":\"(Aster and Bougie, 2007)\",\"ref_id\":\"BIBREF12\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-9f0e0005a91e30bf4f7b2aff2b3613e745dc5598152597f98fc91563184fa2c2_citespan-638-662> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Xenobiotic-induced marked decreases in platelet counts may also be associated with hemorrhage and are discussed in more detail later. However, chemotherapeutics that cause bone marrow suppression can be associated with spontaneous or postvenipuncture hemorrhage. Occasional idiopathic decreases in platelet counts have also been observed following xenobiotic administration and are most likely attributable to immune-mediated destruction; some examples of implicated xenobiotics are quinine, trimethoprim-sulfamethoxazole, anticonvulsants such as phenytoin and carbamazepine, unfractionated or low molecular weight heparin, and rituximab (Aster and Bougie, 2007) ." ;
            <http://www.example.org/textHash>
                    "9f0e0005a91e30bf4f7b2aff2b3613e745dc5598152597f98fc91563184fa2c2" .
    
    <http://covid19.aksw.org/text-b53c45de97c3cc1cf8b9363deec238fc77692ee62406b848905f438d0a261556>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although not truly hemorrhage, external blood loss can occur from repeated phlebotomy. Decreases in red cell mass may be acutely observed following collection of blood from donors for transfusion, and regular donors have a risk of developing iron deficiency from repeated external blood loss (Cable et al., 2011) . Repeated phlebotomy is a common occurrence in nonclinical toxicology studies, particularly in dogs and nonhuman primates, although rats may also occasionally undergo repeated blood collections. Blood is collected through the studies mainly for toxicokinetic or pharmacokinetic analysis, but also for analysis of hematology, coagulation, and clinical chemistry profiles. Decreases in red cell mass with increases in reticulocyte counts of similar magnitude relative to pretest values across all treatment groups, including controls, are a common procedure-related phenomenon in nonclinical toxicology studies and should be distinguished from a true test article-related effect.\",\"cite_spans\":[{\"start\":292.0,\"end\":312.0,\"text\":\"(Cable et al., 2011)\",\"ref_id\":\"BIBREF51\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b53c45de97c3cc1cf8b9363deec238fc77692ee62406b848905f438d0a261556_citespan-292-312> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Although not truly hemorrhage, external blood loss can occur from repeated phlebotomy. Decreases in red cell mass may be acutely observed following collection of blood from donors for transfusion, and regular donors have a risk of developing iron deficiency from repeated external blood loss (Cable et al., 2011) . Repeated phlebotomy is a common occurrence in nonclinical toxicology studies, particularly in dogs and nonhuman primates, although rats may also occasionally undergo repeated blood collections. Blood is collected through the studies mainly for toxicokinetic or pharmacokinetic analysis, but also for analysis of hematology, coagulation, and clinical chemistry profiles. Decreases in red cell mass with increases in reticulocyte counts of similar magnitude relative to pretest values across all treatment groups, including controls, are a common procedure-related phenomenon in nonclinical toxicology studies and should be distinguished from a true test article-related effect." ;
            <http://www.example.org/textHash>
                    "b53c45de97c3cc1cf8b9363deec238fc77692ee62406b848905f438d0a261556" .
    
    <http://covid19.aksw.org/text-5e4546534a5d189da5bd97fc69c0932066c5a7f9acb6b34bfa6224166ebe7bf7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Exogenous administration of glucocorticoids will result in decreases in blood basophil counts, similar to decreases caused by endogenous glucocorticoids. Also, administration of thyroid hormones or thyroid stimulating hormone to healthy individuals has been reported to cause decreases in blood basophil counts, consistent with the decreases in basophil counts observed with naturally occurring hyperthyroidism (Boseila, 1963) .\",\"cite_spans\":[{\"start\":411.0,\"end\":426.0,\"text\":\"(Boseila, 1963)\",\"ref_id\":\"BIBREF39\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5e4546534a5d189da5bd97fc69c0932066c5a7f9acb6b34bfa6224166ebe7bf7_citespan-411-426> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Exogenous administration of glucocorticoids will result in decreases in blood basophil counts, similar to decreases caused by endogenous glucocorticoids. Also, administration of thyroid hormones or thyroid stimulating hormone to healthy individuals has been reported to cause decreases in blood basophil counts, consistent with the decreases in basophil counts observed with naturally occurring hyperthyroidism (Boseila, 1963) ." ;
            <http://www.example.org/textHash>
                    "5e4546534a5d189da5bd97fc69c0932066c5a7f9acb6b34bfa6224166ebe7bf7" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-1191-1215>
            <http://www.example.org/end>    "1215.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF324" ;
            <http://www.example.org/start>  "1191.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rosenberg et al., 2013)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-730-743>
            <http://www.example.org/end>    "743.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF165" ;
            <http://www.example.org/start>  "730.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Harvey, 2006)" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Similar to primary immune-mediated decreases in neutrophil counts, xenobiotic-induced immune-mediated decreases in neutrophil counts are commonly associated with IgG or IgM antineutrophil antibodies, although some drugs may induce both (Salama et al., 1989) . Decreases in neutrophil counts by this mechanism tend to occur rapidly, within a few hours to 2 days after exposure (Schwartzberg, 2006) . Some xenobiotics mediate their effects by acting as haptens, which induce an antibody response targeting an antigen formed by the xenobiotic-neutrophil combination. Drugs reported to act as haptens include penicillin, gold-based compounds, aminopyrine, and propylthiouracil (Salama et al., 1989; Murphy et al., 1985) . These xenobiotics induce neutrophil destruction in a drug-dependent manner, and discontinuation of treatment generally results in resolution of blood neutrophil counts within 7 days (Schwartzberg, 2006) . Some xenobiotics, including propylthiouracil and quinidine sulfate, cause the formation of immune complexes that can subsequently bind and destroy neutrophils, even if the xenobiotic is no longer present (Schwartzberg, 2006; Bhatt and Saleem, 2004; Eisner et al., 1977) . In addition, some xenobiotics, such as propylthiouracil, may also cause the formation of antineutrophil antibodies resulting in complement-mediated neutrophil destruction (Akamizu et al., 2002) . Similar to idiopathic aplastic anemia, xenobiotic-induced aplastic anemia is most commonly associated with immune-mediated destruction of uncommitted or early hematopoietic stem cells, although direct cytotoxicity, such as with chemotherapeutic agents, may also lead to aplastic anemia. Several xenobiotics, including chloramphenicol, anticonvulsants such as phenytoin and carbamazepine, gold-based compounds, and phenylbutazone have been associated with aplastic anemia (Bloom and Brandt, 2008) .\",\"cite_spans\":[{\"start\":236.0,\"end\":257.0,\"text\":\"(Salama et al., 1989)\",\"ref_id\":\"BIBREF333\"},{\"start\":376.0,\"end\":396.0,\"text\":\"(Schwartzberg, 2006)\"},{\"start\":673.0,\"end\":694.0,\"text\":\"(Salama et al., 1989;\",\"ref_id\":\"BIBREF333\"},{\"start\":695.0,\"end\":715.0,\"text\":\"Murphy et al., 1985)\",\"ref_id\":\"BIBREF268\"},{\"start\":900.0,\"end\":920.0,\"text\":\"(Schwartzberg, 2006)\"},{\"start\":1127.0,\"end\":1147.0,\"text\":\"(Schwartzberg, 2006;\"},{\"start\":1148.0,\"end\":1171.0,\"text\":\"Bhatt and Saleem, 2004;\",\"ref_id\":\"BIBREF29\"},{\"start\":1172.0,\"end\":1192.0,\"text\":\"Eisner et al., 1977)\",\"ref_id\":\"BIBREF104\"},{\"start\":1366.0,\"end\":1388.0,\"text\":\"(Akamizu et al., 2002)\",\"ref_id\":\"BIBREF1\"},{\"start\":1862.0,\"end\":1886.0,\"text\":\"(Bloom and Brandt, 2008)\",\"ref_id\":\"BIBREF35\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1862-1886> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-236-257> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-673-694> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1148-1171> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-695-715> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1366-1388> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-376-396> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-900-920> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1127-1147> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1172-1192> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Similar to primary immune-mediated decreases in neutrophil counts, xenobiotic-induced immune-mediated decreases in neutrophil counts are commonly associated with IgG or IgM antineutrophil antibodies, although some drugs may induce both (Salama et al., 1989) . Decreases in neutrophil counts by this mechanism tend to occur rapidly, within a few hours to 2 days after exposure (Schwartzberg, 2006) . Some xenobiotics mediate their effects by acting as haptens, which induce an antibody response targeting an antigen formed by the xenobiotic-neutrophil combination. Drugs reported to act as haptens include penicillin, gold-based compounds, aminopyrine, and propylthiouracil (Salama et al., 1989; Murphy et al., 1985) . These xenobiotics induce neutrophil destruction in a drug-dependent manner, and discontinuation of treatment generally results in resolution of blood neutrophil counts within 7 days (Schwartzberg, 2006) . Some xenobiotics, including propylthiouracil and quinidine sulfate, cause the formation of immune complexes that can subsequently bind and destroy neutrophils, even if the xenobiotic is no longer present (Schwartzberg, 2006; Bhatt and Saleem, 2004; Eisner et al., 1977) . In addition, some xenobiotics, such as propylthiouracil, may also cause the formation of antineutrophil antibodies resulting in complement-mediated neutrophil destruction (Akamizu et al., 2002) . Similar to idiopathic aplastic anemia, xenobiotic-induced aplastic anemia is most commonly associated with immune-mediated destruction of uncommitted or early hematopoietic stem cells, although direct cytotoxicity, such as with chemotherapeutic agents, may also lead to aplastic anemia. Several xenobiotics, including chloramphenicol, anticonvulsants such as phenytoin and carbamazepine, gold-based compounds, and phenylbutazone have been associated with aplastic anemia (Bloom and Brandt, 2008) ." ;
            <http://www.example.org/textHash>
                    "118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c" .
    
    <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-419-434>
            <http://www.example.org/end>    "434.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF140" ;
            <http://www.example.org/start>  "419.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gergely, 1999)" .
    
    <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd_citespan-135-149>
            <http://www.example.org/end>    "149.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-1151-1168>
            <http://www.example.org/end>    "1168.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF434" ;
            <http://www.example.org/start>  "1151.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wu et al., 2005;" .
    
    <http://covid19.aksw.org/text-92c461c375482ace1b71ff6efb582798ba184ef012d9c7ad4bca5921eb14e96a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.1.6 Xenobiotic-induced There are numerous xenobiotics that can increase blood neutrophil counts, typically through similar mechanisms as described for naturally occurring increases in neutrophil counts. Several examples of these compounds are described later.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "12.11.2.1.1.6 Xenobiotic-induced There are numerous xenobiotics that can increase blood neutrophil counts, typically through similar mechanisms as described for naturally occurring increases in neutrophil counts. Several examples of these compounds are described later." ;
            <http://www.example.org/textHash>
                    "92c461c375482ace1b71ff6efb582798ba184ef012d9c7ad4bca5921eb14e96a" .
    
    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-609-629>
            <http://www.example.org/end>    "629.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF384" ;
            <http://www.example.org/start>  "609.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Telen et al., 1990)" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-142-155>
            <http://www.example.org/end>    "155.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF256" ;
            <http://www.example.org/start>  "142.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Means, 2000)" .
    
    <http://covid19.aksw.org/text-2a3827d5ce8ef2d06ea4cd316032a1af4c8ef3f615ba8cef9c3357b05957533f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in red cell mass, or anemia, are a relatively common finding in humans and common laboratory species. Decreases in red cell mass are further categorized by concurrent changes in reticulocyte counts, which provide an indication of bone marrow responsiveness and may help to differentiate among possible mechanisms. Decreases in red cell mass with concurrent increases in reticulocyte counts indicate a regenerative erythroid bone marrow response, where normal or low reticulocyte counts may represent a preregenerative, suppressed, or ineffective erythroid response.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Decreases in Red Cell Mass (Anemia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Decreases in Red Cell Mass (Anemia)" ;
            <http://www.example.org/text>  "Decreases in red cell mass, or anemia, are a relatively common finding in humans and common laboratory species. Decreases in red cell mass are further categorized by concurrent changes in reticulocyte counts, which provide an indication of bone marrow responsiveness and may help to differentiate among possible mechanisms. Decreases in red cell mass with concurrent increases in reticulocyte counts indicate a regenerative erythroid bone marrow response, where normal or low reticulocyte counts may represent a preregenerative, suppressed, or ineffective erythroid response." ;
            <http://www.example.org/textHash>
                    "2a3827d5ce8ef2d06ea4cd316032a1af4c8ef3f615ba8cef9c3357b05957533f" .
    
    <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b_citespan-504-526>
            <http://www.example.org/end>    "526.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF54" ;
            <http://www.example.org/start>  "504.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Camargo et al., 2013;" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-444-461>
            <http://www.example.org/end>    "461.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF374" ;
            <http://www.example.org/start>  "444.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sun et al., 2007;" .
    
    <http://covid19.aksw.org/text-d81e8754bc58cb98079215f382535974334e5d39476c34ea4e95210665de095c_citespan-504-525>
            <http://www.example.org/end>    "525.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "504.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Abella et al., 2002)" .
    
    <http://covid19.aksw.org/text-8ea81bf30129fd1375e74cf814628263adf7f1b1b44233480b7ee68eee39e56f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"AIHA has rarely been observed in association with lymphoproliferative neoplasia, such as chronic lymphocytic leukemia. Antierythrocyte antibodies in chronic lymphocytic leukemia are predominantly IgG with few cases of IgM reported (Mauro et al., 2000) .\",\"cite_spans\":[{\"start\":231.0,\"end\":251.0,\"text\":\"(Mauro et al., 2000)\",\"ref_id\":\"BIBREF252\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-8ea81bf30129fd1375e74cf814628263adf7f1b1b44233480b7ee68eee39e56f_citespan-231-251> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "AIHA has rarely been observed in association with lymphoproliferative neoplasia, such as chronic lymphocytic leukemia. Antierythrocyte antibodies in chronic lymphocytic leukemia are predominantly IgG with few cases of IgM reported (Mauro et al., 2000) ." ;
            <http://www.example.org/textHash>
                    "8ea81bf30129fd1375e74cf814628263adf7f1b1b44233480b7ee68eee39e56f" .
    
    <http://covid19.aksw.org/text-3f32cade925e042651afc56e04b509f2316269ed5c8809d0430af83259a01db8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-induced aplastic anemia is most commonly associated with immune-mediated destruction of uncommitted or early hematopoietic stem cells, although direct cytotoxicity, such as with chemotherapeutic agents, may also lead to aplastic anemia. Several xenobiotics, including chloramphenicol, anticonvulsants such as phenytoin and carbamazepine, gold-based compounds, and phenylbutazone have been associated with aplastic anemia (Bloom and Brandt, 2008) .\",\"cite_spans\":[{\"start\":432.0,\"end\":456.0,\"text\":\"(Bloom and Brandt, 2008)\",\"ref_id\":\"BIBREF35\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3f32cade925e042651afc56e04b509f2316269ed5c8809d0430af83259a01db8_citespan-432-456> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Xenobiotic-induced aplastic anemia is most commonly associated with immune-mediated destruction of uncommitted or early hematopoietic stem cells, although direct cytotoxicity, such as with chemotherapeutic agents, may also lead to aplastic anemia. Several xenobiotics, including chloramphenicol, anticonvulsants such as phenytoin and carbamazepine, gold-based compounds, and phenylbutazone have been associated with aplastic anemia (Bloom and Brandt, 2008) ." ;
            <http://www.example.org/textHash>
                    "3f32cade925e042651afc56e04b509f2316269ed5c8809d0430af83259a01db8" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-522-546>
            <http://www.example.org/end>    "546.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF381" ;
            <http://www.example.org/start>  "522.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tassinari et al., 1999)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1175-1198>
            <http://www.example.org/end>    "1198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "1175.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bexfield et al., 2007)" .
    
    <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A third mechanism by which xenobiotics may cause immune-mediated hemolysis is through a complex interaction of the drug, a drug binding site on erythrocytes, and an antibody. This mechanism is considered the ternary complex mechanism, but has previously, and perhaps less accurately, been called an immune complex or innocent bystander mechanism (Packman, 2016) . Quinidine is the prototypical drug that causes hemolysis via this mechanism. Quinidine may be associated with either IgM or IgG antibodies and predominantly causes complement-mediated lysis of erythrocytes or clearance of complement-coated erythrocytes by tissue macrophages (Packman, 2016) . Ceftriaxone has also been reported to cause hemolysis through this mechanism (Arndt and Garratty, 2005) .\",\"cite_spans\":[{\"start\":346.0,\"end\":361.0,\"text\":\"(Packman, 2016)\",\"ref_id\":\"BIBREF283\"},{\"start\":639.0,\"end\":654.0,\"text\":\"(Packman, 2016)\",\"ref_id\":\"BIBREF283\"},{\"start\":734.0,\"end\":760.0,\"text\":\"(Arndt and Garratty, 2005)\",\"ref_id\":\"BIBREF8\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b_citespan-346-361> , <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b_citespan-639-654> , <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b_citespan-734-760> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "A third mechanism by which xenobiotics may cause immune-mediated hemolysis is through a complex interaction of the drug, a drug binding site on erythrocytes, and an antibody. This mechanism is considered the ternary complex mechanism, but has previously, and perhaps less accurately, been called an immune complex or innocent bystander mechanism (Packman, 2016) . Quinidine is the prototypical drug that causes hemolysis via this mechanism. Quinidine may be associated with either IgM or IgG antibodies and predominantly causes complement-mediated lysis of erythrocytes or clearance of complement-coated erythrocytes by tissue macrophages (Packman, 2016) . Ceftriaxone has also been reported to cause hemolysis through this mechanism (Arndt and Garratty, 2005) ." ;
            <http://www.example.org/textHash>
                    "91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b" .
    
    <http://covid19.aksw.org/text-d6c5467de186713eaeeff06111e2cd5f0d0b688570bba87110dfd6d9f4905072_citespan-463-486>
            <http://www.example.org/end>    "486.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Benschop et al., 1996)" .
    
    <http://covid19.aksw.org/text-d281241fc64906aa25de49f69e81785af3ba0430e987b507ba327ffcbecf28d3_citespan-652-676>
            <http://www.example.org/end>    "676.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF288" ;
            <http://www.example.org/start>  "652.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Papa and Shelley, 1964)" .
    
    <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f_citespan-228-250>
            <http://www.example.org/end>    "250.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "228.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Athreya et al., 1975)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-472-496>
            <http://www.example.org/end>    "496.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF286" ;
            <http://www.example.org/start>  "472.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Palmisano et al., 1998)" .
    
    <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-679-698>
            <http://www.example.org/end>    "698.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF407" ;
            <http://www.example.org/start>  "679.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vial et al., 2002;" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-669-689>
            <http://www.example.org/end>    "689.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF346" ;
            <http://www.example.org/start>  "669.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Seldon et al., 1982;" .
    
    <http://covid19.aksw.org/text-16fb03654ef27bcdfa4524634bbba70daf47abd7f4915ec969ab2fc2bad90e92>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Blood loss associated with xenobiotics has been reported with coagulopathies due to abnormal vitamin K recycling and function of vitamin K-dependent coagulation factors. Drugs implicated in abnormal vitamin K synthesis include warfarin, rodenticides such as brodifacoum, and some broad-spectrum antibiotics (Bloom and Brandt, 2008) . With severe, acute loss of whole blood, all blood components, including platelets, will be decreased. If other mechanisms of xenobiotic-induced decreases in platelet counts, as discussed later, cause severe enough decreases in blood platelet counts (e.g., \\u003c 50,000 platelets mL À 1 ), then blood loss could be secondary to the decreases in platelets.\",\"cite_spans\":[{\"start\":307.0,\"end\":331.0,\"text\":\"(Bloom and Brandt, 2008)\",\"ref_id\":\"BIBREF35\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-16fb03654ef27bcdfa4524634bbba70daf47abd7f4915ec969ab2fc2bad90e92_citespan-307-331> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Blood loss associated with xenobiotics has been reported with coagulopathies due to abnormal vitamin K recycling and function of vitamin K-dependent coagulation factors. Drugs implicated in abnormal vitamin K synthesis include warfarin, rodenticides such as brodifacoum, and some broad-spectrum antibiotics (Bloom and Brandt, 2008) . With severe, acute loss of whole blood, all blood components, including platelets, will be decreased. If other mechanisms of xenobiotic-induced decreases in platelet counts, as discussed later, cause severe enough decreases in blood platelet counts (e.g., < 50,000 platelets mL À 1 ), then blood loss could be secondary to the decreases in platelets." ;
            <http://www.example.org/textHash>
                    "16fb03654ef27bcdfa4524634bbba70daf47abd7f4915ec969ab2fc2bad90e92" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-243-269>
            <http://www.example.org/end>    "269.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF361" ;
            <http://www.example.org/start>  "243.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Solanki and Sheikh, 1978)" .
    
    <http://covid19.aksw.org/text-5c13e5b358dba2e3bdfaba0cd2adbde14a42a90fcdf718971850a7bb3e25439d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"IMHA may occasionally be observed following blood transfusion (Garratty, 2004) . This may occur in response to alloantigens, and would not technically be considered autoimmune (Stockham and Scott, 2008b) . Posttransfusion immune-mediated hemolysis may also be observed when the host has autoantibodies that bind the donor erythrocytes and cause immune-mediated destruction. However, crossmatching of host and donor erythrocytes and plasma is able to prevent many cases with incompatible transfusionrelated AIHA.\",\"cite_spans\":[{\"start\":62.0,\"end\":78.0,\"text\":\"(Garratty, 2004)\",\"ref_id\":\"BIBREF133\"},{\"start\":176.0,\"end\":203.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5c13e5b358dba2e3bdfaba0cd2adbde14a42a90fcdf718971850a7bb3e25439d_citespan-62-78> , <http://covid19.aksw.org/text-5c13e5b358dba2e3bdfaba0cd2adbde14a42a90fcdf718971850a7bb3e25439d_citespan-176-203> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "IMHA may occasionally be observed following blood transfusion (Garratty, 2004) . This may occur in response to alloantigens, and would not technically be considered autoimmune (Stockham and Scott, 2008b) . Posttransfusion immune-mediated hemolysis may also be observed when the host has autoantibodies that bind the donor erythrocytes and cause immune-mediated destruction. However, crossmatching of host and donor erythrocytes and plasma is able to prevent many cases with incompatible transfusionrelated AIHA." ;
            <http://www.example.org/textHash>
                    "5c13e5b358dba2e3bdfaba0cd2adbde14a42a90fcdf718971850a7bb3e25439d" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1002-1016>
            <http://www.example.org/end>    "1016.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1002.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sawyer, 1999)" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Destruction of platelets is commonly associated with immune-mediated mechanisms, including immune-mediated thrombocytopenia (IMT) and immune-mediated thrombocytopenic purpura (ITP) in humans. Most autoantibodies that cause platelet destruction are of the IgG class, although cases with IgM or IgA antiplatelet antibodies have also been reported (Diz-Küçükkaya and López, 2016) . Antiplatelet antibodies may directly target platelet antigens, such as the glycoprotein integrin a IIb b 3(GPIIb-IIIa) that plays a major role in platelet aggregation (He et al., 1994) , antigens exposed or formed on platelet surfaces by infectious agents, or infectious agent-targeted antibodies that cross-react with normally expressed platelet surface antigens or membrane components such as phospholipid (Stockham and Scott, 2008c) . Antibody-bound platelets may be phagocytosed and destroyed by splenic, bone marrow, or hepatic macrophages, or may be associated with complement-mediated destruction or stimulation of phagocytosis (Diz-Küçükkaya and López, 2016; Russell, 2010) . Production of antiplatelet antibodies may be unassociated with an underlying disease condition (idiopathic or primary) and is usually presumed to be an autoimmune process, or may be secondary to infectious or neoplastic processes (Stockham and Scott, 2008c) . In sexually mature Göttingen minipigs, spontaneous thrombocytopenic purpura has been described and is believed to be caused immune-mediated platelet destruction (Carrasco et al., 2003) . ITP secondary to infectious disease has been reported to occur with various bacterial and viral etiologies, including Helicobacter pylori, many rickettsial diseases, HIV, cytomegalovirus, and hepatitis B and C viruses (Diz-Küçükkaya and López, 2016; Russell, 2010; Cines et al., 2009) . Lymphoproliferative neoplasia is a relatively common cause of ITP, and has been associated with chronic lymphocytic leukemia, Hodgkin lymphoma, and leukemia of large granular T-lymphocytes (Cines et al., 2009) . Connective tissue diseases such as SLE have also been associated with ITP (Cines et al., 2009) .\",\"cite_spans\":[{\"start\":345.0,\"end\":376.0,\"text\":\"(Diz-Küçükkaya and López, 2016)\",\"ref_id\":\"BIBREF94\"},{\"start\":546.0,\"end\":563.0,\"text\":\"(He et al., 1994)\",\"ref_id\":\"BIBREF168\"},{\"start\":787.0,\"end\":814.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":1014.0,\"end\":1045.0,\"text\":\"(Diz-Küçükkaya and López, 2016;\",\"ref_id\":\"BIBREF94\"},{\"start\":1046.0,\"end\":1060.0,\"text\":\"Russell, 2010)\",\"ref_id\":\"BIBREF329\"},{\"start\":1293.0,\"end\":1320.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":1484.0,\"end\":1507.0,\"text\":\"(Carrasco et al., 2003)\",\"ref_id\":\"BIBREF58\"},{\"start\":1728.0,\"end\":1759.0,\"text\":\"(Diz-Küçükkaya and López, 2016;\",\"ref_id\":\"BIBREF94\"},{\"start\":1760.0,\"end\":1774.0,\"text\":\"Russell, 2010;\",\"ref_id\":\"BIBREF329\"},{\"start\":1775.0,\"end\":1794.0,\"text\":\"Cines et al., 2009)\",\"ref_id\":\"BIBREF72\"},{\"start\":1986.0,\"end\":2006.0,\"text\":\"(Cines et al., 2009)\",\"ref_id\":\"BIBREF72\"},{\"start\":2083.0,\"end\":2103.0,\"text\":\"(Cines et al., 2009)\",\"ref_id\":\"BIBREF72\"}],\"ref_spans\":[],\"section\":\"Decreased survival\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1986-2006> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1046-1060> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1014-1045> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-345-376> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1728-1759> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-787-814> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1293-1320> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-2083-2103> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1484-1507> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1775-1794> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-546-563> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1760-1774> ;
            <http://www.example.org/section>
                    "Decreased survival" ;
            <http://www.example.org/text>  "Destruction of platelets is commonly associated with immune-mediated mechanisms, including immune-mediated thrombocytopenia (IMT) and immune-mediated thrombocytopenic purpura (ITP) in humans. Most autoantibodies that cause platelet destruction are of the IgG class, although cases with IgM or IgA antiplatelet antibodies have also been reported (Diz-Küçükkaya and López, 2016) . Antiplatelet antibodies may directly target platelet antigens, such as the glycoprotein integrin a IIb b 3(GPIIb-IIIa) that plays a major role in platelet aggregation (He et al., 1994) , antigens exposed or formed on platelet surfaces by infectious agents, or infectious agent-targeted antibodies that cross-react with normally expressed platelet surface antigens or membrane components such as phospholipid (Stockham and Scott, 2008c) . Antibody-bound platelets may be phagocytosed and destroyed by splenic, bone marrow, or hepatic macrophages, or may be associated with complement-mediated destruction or stimulation of phagocytosis (Diz-Küçükkaya and López, 2016; Russell, 2010) . Production of antiplatelet antibodies may be unassociated with an underlying disease condition (idiopathic or primary) and is usually presumed to be an autoimmune process, or may be secondary to infectious or neoplastic processes (Stockham and Scott, 2008c) . In sexually mature Göttingen minipigs, spontaneous thrombocytopenic purpura has been described and is believed to be caused immune-mediated platelet destruction (Carrasco et al., 2003) . ITP secondary to infectious disease has been reported to occur with various bacterial and viral etiologies, including Helicobacter pylori, many rickettsial diseases, HIV, cytomegalovirus, and hepatitis B and C viruses (Diz-Küçükkaya and López, 2016; Russell, 2010; Cines et al., 2009) . Lymphoproliferative neoplasia is a relatively common cause of ITP, and has been associated with chronic lymphocytic leukemia, Hodgkin lymphoma, and leukemia of large granular T-lymphocytes (Cines et al., 2009) . Connective tissue diseases such as SLE have also been associated with ITP (Cines et al., 2009) ." ;
            <http://www.example.org/textHash>
                    "40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-410-437>
            <http://www.example.org/end>    "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF87" ;
            <http://www.example.org/start>  "410.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Davis and Rothenberg, 2014;" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-255-276>
            <http://www.example.org/end>    "276.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF214" ;
            <http://www.example.org/start>  "255.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Langman et al., 1999;" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in platelet counts due to platelet activation and consumption are commonly associated with local or disseminated consumptive coagulopathies. Localized consumptive coagulopathy may be associated with sites of hemorrhage, microangiopathy or thrombosis, or vascular neoplasia such as hemangiosarcoma (Stockham and Scott, 2008c) . Thrombosis associated with chronic catheterization may be a cause of localized platelet consumption. DIC may be associated with infectious agents, particularly bacterial infections that cause septicemia or endotoxemia, hepatic disease, a variety of neoplastic diseases, and pancreatitis (Stockham and Scott, 2008c) . Activation and consumption of platelets associated with decreases in platelet counts has also been observed with vasculitis and conditions associated with turbulent blood flow such as endocarditis, cardiac valvular disease, following cardiac surgery, and with arterial disease that alter or damage endothelial cells (Russell, 2010; Selleng et al., 2010; Stockham and Scott, 2008c; Gregg and Goldschmidt-Clermont, 2003) . Hemolytic uremic syndrome (HUS) is a cause of thrombotic microangiopathy that may be associated with infection with Shigella dysenteriae or Escherichia coli (Russell, 2010) .\",\"cite_spans\":[{\"start\":307.0,\"end\":334.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":624.0,\"end\":651.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":970.0,\"end\":985.0,\"text\":\"(Russell, 2010;\",\"ref_id\":\"BIBREF329\"},{\"start\":986.0,\"end\":1007.0,\"text\":\"Selleng et al., 2010;\",\"ref_id\":\"BIBREF347\"},{\"start\":1008.0,\"end\":1034.0,\"text\":\"Stockham and Scott, 2008c;\",\"ref_id\":\"BIBREF368\"},{\"start\":1035.0,\"end\":1072.0,\"text\":\"Gregg and Goldschmidt-Clermont, 2003)\",\"ref_id\":\"BIBREF158\"},{\"start\":1232.0,\"end\":1247.0,\"text\":\"(Russell, 2010)\",\"ref_id\":\"BIBREF329\"}],\"ref_spans\":[],\"section\":\"Decreased survival\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-307-334> , <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-1008-1034> , <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-986-1007> , <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-624-651> , <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-1035-1072> , <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-970-985> , <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-1232-1247> ;
            <http://www.example.org/section>
                    "Decreased survival" ;
            <http://www.example.org/text>  "Decreases in platelet counts due to platelet activation and consumption are commonly associated with local or disseminated consumptive coagulopathies. Localized consumptive coagulopathy may be associated with sites of hemorrhage, microangiopathy or thrombosis, or vascular neoplasia such as hemangiosarcoma (Stockham and Scott, 2008c) . Thrombosis associated with chronic catheterization may be a cause of localized platelet consumption. DIC may be associated with infectious agents, particularly bacterial infections that cause septicemia or endotoxemia, hepatic disease, a variety of neoplastic diseases, and pancreatitis (Stockham and Scott, 2008c) . Activation and consumption of platelets associated with decreases in platelet counts has also been observed with vasculitis and conditions associated with turbulent blood flow such as endocarditis, cardiac valvular disease, following cardiac surgery, and with arterial disease that alter or damage endothelial cells (Russell, 2010; Selleng et al., 2010; Stockham and Scott, 2008c; Gregg and Goldschmidt-Clermont, 2003) . Hemolytic uremic syndrome (HUS) is a cause of thrombotic microangiopathy that may be associated with infection with Shigella dysenteriae or Escherichia coli (Russell, 2010) ." ;
            <http://www.example.org/textHash>
                    "f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958" .
    
    <http://covid19.aksw.org/text-7a88a621bbdc456272482052985a0ce35f94970e96830d4ba08da4046708a0d0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Lymphocytes are the most numerous blood leukocytes in rats and mice, and are typically present in greater numbers than neutrophils in young cynomolgus monkeys and dogs. Cynomolgus monkeys used in nonclinical toxicology studies are often young or peripubertal, with greater lymphocyte than neutrophil counts. However, in both cynomolgus monkeys and dogs, there is a shift of blood leukocyte populations to a predominance of neutrophils with maturation, and nonclinical toxicology studies may include animals having either hematologic pattern. In adults of species with neutrophils as the most numerous blood leukocyte, lymphocytes are typically the second most numerous.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Lymphocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Lymphocytes" ;
            <http://www.example.org/text>  "Lymphocytes are the most numerous blood leukocytes in rats and mice, and are typically present in greater numbers than neutrophils in young cynomolgus monkeys and dogs. Cynomolgus monkeys used in nonclinical toxicology studies are often young or peripubertal, with greater lymphocyte than neutrophil counts. However, in both cynomolgus monkeys and dogs, there is a shift of blood leukocyte populations to a predominance of neutrophils with maturation, and nonclinical toxicology studies may include animals having either hematologic pattern. In adults of species with neutrophils as the most numerous blood leukocyte, lymphocytes are typically the second most numerous." ;
            <http://www.example.org/textHash>
                    "7a88a621bbdc456272482052985a0ce35f94970e96830d4ba08da4046708a0d0" .
    
    <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in blood monocyte counts may occur secondary to hematologic malignancies or metastatic nonhematology malignancies that efface the bone marrow. Neoplastic myelophthisis results in decreased production of normal hematopoietic cells and therefore blood component counts, including monocytes. Examples of such reported conditions include hairy cell leukemia (den Ottolander et al., 1983; Ratain et al, 1985) and chronic lymphocytic leukemia (De Rossi et al., 1991) .\",\"cite_spans\":[{\"start\":364.0,\"end\":393.0,\"text\":\"(den Ottolander et al., 1983;\"},{\"start\":394.0,\"end\":413.0,\"text\":\"Ratain et al, 1985)\",\"ref_id\":\"BIBREF316\"},{\"start\":447.0,\"end\":470.0,\"text\":\"(De Rossi et al., 1991)\",\"ref_id\":\"BIBREF88\"}],\"ref_spans\":[],\"section\":\"Neoplastic\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e_citespan-364-393> , <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e_citespan-394-413> , <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e_citespan-447-470> ;
            <http://www.example.org/section>
                    "Neoplastic" ;
            <http://www.example.org/text>  "Decreases in blood monocyte counts may occur secondary to hematologic malignancies or metastatic nonhematology malignancies that efface the bone marrow. Neoplastic myelophthisis results in decreased production of normal hematopoietic cells and therefore blood component counts, including monocytes. Examples of such reported conditions include hairy cell leukemia (den Ottolander et al., 1983; Ratain et al, 1985) and chronic lymphocytic leukemia (De Rossi et al., 1991) ." ;
            <http://www.example.org/textHash>
                    "f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e" .
    
    <http://covid19.aksw.org/text-a7b72cb8b96d38f267c1d1546d21b9e85285123f33144f92dcf69596b96495a0_citespan-368-395>
            <http://www.example.org/end>    "395.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "368.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-dde22cd214cfadfb61478d4463b64027c1c7d27bd81cacb79e6c9b321f223308>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.2 Decreases in red cell mass with \\\"normal\\\" or low reticulocyte counts (nonregenerative anemia)\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.2 Decreases in red cell mass with \"normal\" or low reticulocyte counts (nonregenerative anemia)" ;
            <http://www.example.org/textHash>
                    "dde22cd214cfadfb61478d4463b64027c1c7d27bd81cacb79e6c9b321f223308" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-1626-1641>
            <http://www.example.org/end>    "1641.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF423" ;
            <http://www.example.org/start>  "1626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wegmann, 2011)" .
    
    <http://covid19.aksw.org/text-780b3f5806516e494a9bc4119787e67993dc1289d84934a9f3e97f9ae7236320>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.1.7 Xenobiotic-induced Many xenobiotics are capable of causing hemolysis, and may cause hemolysis through oxidative, fragmentation, or immune-mediated mechanisms. Examples of each are discussed here.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.1.7 Xenobiotic-induced Many xenobiotics are capable of causing hemolysis, and may cause hemolysis through oxidative, fragmentation, or immune-mediated mechanisms. Examples of each are discussed here." ;
            <http://www.example.org/textHash>
                    "780b3f5806516e494a9bc4119787e67993dc1289d84934a9f3e97f9ae7236320" .
    
    <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-973-995>
            <http://www.example.org/end>    "995.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "973.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Benschop et al., 1996;" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-986-1007>
            <http://www.example.org/end>    "1007.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF347" ;
            <http://www.example.org/start>  "986.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Selleng et al., 2010;" .
    
    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-323-344>
            <http://www.example.org/end>    "344.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF261" ;
            <http://www.example.org/start>  "323.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mintzer et al., 2009)" .
    
    <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-825-847>
            <http://www.example.org/end>    "847.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF96" ;
            <http://www.example.org/start>  "825.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Druilhe et al., 2003;" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-446-461>
            <http://www.example.org/end>    "461.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF338" ;
            <http://www.example.org/start>  "446.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sawyers, 1999)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-621-641>
            <http://www.example.org/end>    "641.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF299" ;
            <http://www.example.org/start>  "621.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pisoni et al, 2001)" .
    
    <http://covid19.aksw.org/text-14d4f54fbe70d0841956c98998b1a8984b4517f8d3811792b229e1fba07a164c_citespan-699-711>
            <http://www.example.org/end>    "711.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF162" ;
            <http://www.example.org/start>  "699.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hall, 2013)" .
    
    <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-502-523>
            <http://www.example.org/end>    "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "502.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1099-1123>
            <http://www.example.org/end>    "1123.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF219" ;
            <http://www.example.org/start>  "1099.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Leder and Weller, 2000)" .
    
    <http://covid19.aksw.org/text-7618637eeccb25855a1c7ee52f9f959095f18ae5a2e4d9f9bea627d7777a9c39_citespan-769-782>
            <http://www.example.org/end>    "782.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF426" ;
            <http://www.example.org/start>  "769.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Weiss, 2002)" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-739-759>
            <http://www.example.org/end>    "759.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF42" ;
            <http://www.example.org/start>  "739.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Branch et al., 1985;" .
    
    <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Uncommonly there are cases of inherited marked decreases in blood monocyte counts. In humans, an autosomal dominant inheritance pattern has been associated with decreased monocyte counts with a resulting increased susceptibility to mycobacteria and a variety of other infectious agents (Vinh et al., 2010) . Mutations in GATA2, a transcription factor that regulates hematopoietic cell gene expression and integrity, have been reported as a cause for autosomal dominant decreases in blood monocyte counts (Camargo et al., 2013; Hsu et al., 2011) .\",\"cite_spans\":[{\"start\":286.0,\"end\":305.0,\"text\":\"(Vinh et al., 2010)\",\"ref_id\":\"BIBREF409\"},{\"start\":504.0,\"end\":526.0,\"text\":\"(Camargo et al., 2013;\",\"ref_id\":\"BIBREF54\"},{\"start\":527.0,\"end\":544.0,\"text\":\"Hsu et al., 2011)\",\"ref_id\":\"BIBREF175\"}],\"ref_spans\":[],\"section\":\"Inherited causes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b_citespan-286-305> , <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b_citespan-504-526> , <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b_citespan-527-544> ;
            <http://www.example.org/section>
                    "Inherited causes" ;
            <http://www.example.org/text>  "Uncommonly there are cases of inherited marked decreases in blood monocyte counts. In humans, an autosomal dominant inheritance pattern has been associated with decreased monocyte counts with a resulting increased susceptibility to mycobacteria and a variety of other infectious agents (Vinh et al., 2010) . Mutations in GATA2, a transcription factor that regulates hematopoietic cell gene expression and integrity, have been reported as a cause for autosomal dominant decreases in blood monocyte counts (Camargo et al., 2013; Hsu et al., 2011) ." ;
            <http://www.example.org/textHash>
                    "3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b" .
    
    <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd_citespan-655-669>
            <http://www.example.org/end>    "669.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF350" ;
            <http://www.example.org/start>  "655.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Shelley, 1963)" .
    
    <http://covid19.aksw.org/text-c99e2327ae10204accb68af3ee1a5ca63c0ad5b73b9bbef2d5f58fede27c640e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.4.2.1 Catecholamine-induced In contrast to neutrophil, lymphocyte, and monocyte counts, blood eosinophil counts decrease in response to increased endogenous catecholamines. These effects may be inconsistent and difficult to detect due to timing of blood collection relative to the rapid changes in eosinophil counts and the normally low blood eosinophil counts. The b-adrenergic effects of epinephrine are believed to be the cause of the decreases in blood eosinophil counts (Koch-Weser, 1968) . Catecholamines may also cause decreased release of eosinophils from bone marrow (McEwen, 1992) .\",\"cite_spans\":[{\"start\":483.0,\"end\":501.0,\"text\":\"(Koch-Weser, 1968)\"},{\"start\":584.0,\"end\":598.0,\"text\":\"(McEwen, 1992)\",\"ref_id\":\"BIBREF255\"}],\"ref_spans\":[],\"section\":\"Decreases in eosinophil counts (eosinopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c99e2327ae10204accb68af3ee1a5ca63c0ad5b73b9bbef2d5f58fede27c640e_citespan-483-501> , <http://covid19.aksw.org/text-c99e2327ae10204accb68af3ee1a5ca63c0ad5b73b9bbef2d5f58fede27c640e_citespan-584-598> ;
            <http://www.example.org/section>
                    "Decreases in eosinophil counts (eosinopenia)" ;
            <http://www.example.org/text>  "12.11.2.4.2.1 Catecholamine-induced In contrast to neutrophil, lymphocyte, and monocyte counts, blood eosinophil counts decrease in response to increased endogenous catecholamines. These effects may be inconsistent and difficult to detect due to timing of blood collection relative to the rapid changes in eosinophil counts and the normally low blood eosinophil counts. The b-adrenergic effects of epinephrine are believed to be the cause of the decreases in blood eosinophil counts (Koch-Weser, 1968) . Catecholamines may also cause decreased release of eosinophils from bone marrow (McEwen, 1992) ." ;
            <http://www.example.org/textHash>
                    "c99e2327ae10204accb68af3ee1a5ca63c0ad5b73b9bbef2d5f58fede27c640e" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-637-657>
            <http://www.example.org/end>    "657.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF301" ;
            <http://www.example.org/start>  "637.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Prasse et al., 1975)" .
    
    <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-663-685>
            <http://www.example.org/end>    "685.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF184" ;
            <http://www.example.org/start>  "663.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Johnson et al., 1995;" .
    
    <http://covid19.aksw.org/text-e4132140be206c250a772e29ab0282ef8e1da49127040db47873205f52615e86>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Neoplastic processes that cause primary (nonreactive) increases in blood platelet counts are characterized by clonal expansions of megakaryocytes and therefore platelets. Hemic neoplasia that may result in clonal increases in platelet counts include acute megakaryoblastic leukemia and chronic myeloproliferative disease such as primary or essential thrombocythemia. However, clonal increases in platelet counts are associated with increases in TPO greater than increases in TPO observed with reactive thrombocytosis, so TPO-mediated thrombopoiesis may also play a role in clonal increases in platelet counts (Wang et al., 1998) .\",\"cite_spans\":[{\"start\":609.0,\"end\":628.0,\"text\":\"(Wang et al., 1998)\",\"ref_id\":\"BIBREF419\"}],\"ref_spans\":[],\"section\":\"Neoplastic\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e4132140be206c250a772e29ab0282ef8e1da49127040db47873205f52615e86_citespan-609-628> ;
            <http://www.example.org/section>
                    "Neoplastic" ;
            <http://www.example.org/text>  "Neoplastic processes that cause primary (nonreactive) increases in blood platelet counts are characterized by clonal expansions of megakaryocytes and therefore platelets. Hemic neoplasia that may result in clonal increases in platelet counts include acute megakaryoblastic leukemia and chronic myeloproliferative disease such as primary or essential thrombocythemia. However, clonal increases in platelet counts are associated with increases in TPO greater than increases in TPO observed with reactive thrombocytosis, so TPO-mediated thrombopoiesis may also play a role in clonal increases in platelet counts (Wang et al., 1998) ." ;
            <http://www.example.org/textHash>
                    "e4132140be206c250a772e29ab0282ef8e1da49127040db47873205f52615e86" .
    
    <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34_citespan-196-218>
            <http://www.example.org/end>    "218.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF76" ;
            <http://www.example.org/start>  "196.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Corsini et al., 2013)" .
    
    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-972-995>
            <http://www.example.org/end>    "995.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF312" ;
            <http://www.example.org/start>  "972.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Randolph et al., 2004)" .
    
    <http://covid19.aksw.org/text-e1658ee2b33276e9e49974c13439ca773d1fdb159e797793c40a7b5f7d09d8c3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Hemodilution may occur following administration of intravenous fluids or massive transfusion, and is expected to decrease all blood components to variable degrees, with the exception of any transfused blood components. Decreases in platelets from hemodilution are usually mild and may not be detected if platelet counts remain within reference intervals or historical control ranges. These changes are generally transient and resolve with redistribution of intravascular (extracellular) fluid into intracellular fluid compartments or elimination of excess fluid.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Relative\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Relative" ;
            <http://www.example.org/text>  "Hemodilution may occur following administration of intravenous fluids or massive transfusion, and is expected to decrease all blood components to variable degrees, with the exception of any transfused blood components. Decreases in platelets from hemodilution are usually mild and may not be detected if platelet counts remain within reference intervals or historical control ranges. These changes are generally transient and resolve with redistribution of intravascular (extracellular) fluid into intracellular fluid compartments or elimination of excess fluid." ;
            <http://www.example.org/textHash>
                    "e1658ee2b33276e9e49974c13439ca773d1fdb159e797793c40a7b5f7d09d8c3" .
    
    <http://covid19.aksw.org/text-c670f2de35ba9759a8a122d329789d668719649a30d3b1c14343e4ad704efd2a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.5.1 Increases in basophil counts (basophilia) 12.11.2.5.1.1 Inflammation Increases in blood basophil counts may be associated with inflammatory stimuli, although decreases in basophil counts are more commonly observed (Galli et al., 2016) . Increases in basophil counts have been associated with infectious, allergic, and paraneoplastic inflammatory conditions.\",\"cite_spans\":[{\"start\":226.0,\"end\":246.0,\"text\":\"(Galli et al., 2016)\",\"ref_id\":\"BIBREF128\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c670f2de35ba9759a8a122d329789d668719649a30d3b1c14343e4ad704efd2a_citespan-226-246> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "12.11.2.5.1 Increases in basophil counts (basophilia) 12.11.2.5.1.1 Inflammation Increases in blood basophil counts may be associated with inflammatory stimuli, although decreases in basophil counts are more commonly observed (Galli et al., 2016) . Increases in basophil counts have been associated with infectious, allergic, and paraneoplastic inflammatory conditions." ;
            <http://www.example.org/textHash>
                    "c670f2de35ba9759a8a122d329789d668719649a30d3b1c14343e4ad704efd2a" .
    
    <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.2.5 Nutritional deficiencies In addition to aplastic anemia associated with anorexia nervosa and severe food restriction, other nutritional deficiencies have been associated with ineffective erythropoiesis leading to decreases in red cell mass with decreases in reticulocyte counts. Iron deficiency and deficiencies of the B vitamins folate and cobalamin are examples of these nutritional deficiencies. Chronic iron deficiency results in impaired hematopoiesis due to the inability to synthesize sufficient hemoglobin, which may lead to a decrease in reticulocyte production. Deficiencies in folate and cobalamin also cause ineffective erythropoiesis due to defects in DNA synthesis, as discussed with folate and cobalamin deficiencies as a cause of deceases in neutrophil counts. In people, folate and cobalamin deficiencies result in megaloblastic anemia, characterized by larger than normal erythroid precursors in the bone marrow that have more cytoplasm with lower nuclear to cytoplasmic ratios than in normal erythroid precursors and asynchronous cytoplasmic and nuclear maturation (Green, 2016) . Megaloblastic erythrocytes may also be observed in circulation, and basophilic stippling or Howell-Jolly bodies may also be observed (Green, 2016) . In people, anemia attributable to a deficiency in cobalamin (vitamin B 12 ) may also be called pernicious anemia. In dogs and cats, megaloblastic erythroid cells may be observed in the bone marrow but may not be observed in blood (Stockham and Scott, 2008b) .\",\"cite_spans\":[{\"start\":1098.0,\"end\":1111.0,\"text\":\"(Green, 2016)\",\"ref_id\":\"BIBREF157\"},{\"start\":1247.0,\"end\":1260.0,\"text\":\"(Green, 2016)\",\"ref_id\":\"BIBREF157\"},{\"start\":1493.0,\"end\":1520.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Immune-mediated\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a_citespan-1098-1111> , <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a_citespan-1247-1260> , <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a_citespan-1493-1520> ;
            <http://www.example.org/section>
                    "Immune-mediated" ;
            <http://www.example.org/text>  "12.11.3.2.2.5 Nutritional deficiencies In addition to aplastic anemia associated with anorexia nervosa and severe food restriction, other nutritional deficiencies have been associated with ineffective erythropoiesis leading to decreases in red cell mass with decreases in reticulocyte counts. Iron deficiency and deficiencies of the B vitamins folate and cobalamin are examples of these nutritional deficiencies. Chronic iron deficiency results in impaired hematopoiesis due to the inability to synthesize sufficient hemoglobin, which may lead to a decrease in reticulocyte production. Deficiencies in folate and cobalamin also cause ineffective erythropoiesis due to defects in DNA synthesis, as discussed with folate and cobalamin deficiencies as a cause of deceases in neutrophil counts. In people, folate and cobalamin deficiencies result in megaloblastic anemia, characterized by larger than normal erythroid precursors in the bone marrow that have more cytoplasm with lower nuclear to cytoplasmic ratios than in normal erythroid precursors and asynchronous cytoplasmic and nuclear maturation (Green, 2016) . Megaloblastic erythrocytes may also be observed in circulation, and basophilic stippling or Howell-Jolly bodies may also be observed (Green, 2016) . In people, anemia attributable to a deficiency in cobalamin (vitamin B 12 ) may also be called pernicious anemia. In dogs and cats, megaloblastic erythroid cells may be observed in the bone marrow but may not be observed in blood (Stockham and Scott, 2008b) ." ;
            <http://www.example.org/textHash>
                    "7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a" .
    
    <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Acute inflammatory processes tend to cause decreases in lymphocyte counts, but some acute infectious processes, particularly several viral infections, may cause increases in lymphocyte counts. However, increases in lymphocyte counts are commonly observed with chronic inflammatory processes. Chronic stimulation of lymphocytes with antigens or cytokines results in the increased production of lymphocytes with release into the blood, causing the increases in blood lymphocyte counts. Reactive lymphocytes may be observed in blood accompanying inflammation-induced increases in lymphocytes counts. Reactive lymphocytes have a spectrum of morphologic changes that include increased cytoplasmic basophilia, large cells with mildly increased amounts of cytoplasm (lower nuclear to cytoplasmic ratios), variable patterns of chromatin clumping, and variable numbers of visible nucleoli. Occasionally, reactive lymphocytes may have paranuclear cytoplasmic clearing, giving a plasmacytoid appearance. Infectious mononucleosis syndromes in people are a relatively common cause of an inflammatory or reactive increase in lymphocyte counts that are usually acute (Vasu and Caligiuri, 2016) . Chronic infections leading to increase in blood lymphocyte counts may include visceral leishmaniasis, parasitic infections such as strongyloidiasis, and leprosy (Vasu and Caligiuri, 2016; Rai et al., 2008; Myers et al., 2000) . Several chronic infections, including ehrlichiosis, Rocky Mountain spotted fever, leishmaniasis, trypanosomiasis, and brucellosis, have been associated with increases in blood lymphocyte counts in dogs (Schultze, 2010) .\",\"cite_spans\":[{\"start\":1152.0,\"end\":1178.0,\"text\":\"(Vasu and Caligiuri, 2016)\",\"ref_id\":\"BIBREF406\"},{\"start\":1342.0,\"end\":1368.0,\"text\":\"(Vasu and Caligiuri, 2016;\",\"ref_id\":\"BIBREF406\"},{\"start\":1369.0,\"end\":1386.0,\"text\":\"Rai et al., 2008;\",\"ref_id\":\"BIBREF310\"},{\"start\":1387.0,\"end\":1406.0,\"text\":\"Myers et al., 2000)\",\"ref_id\":\"BIBREF272\"},{\"start\":1611.0,\"end\":1627.0,\"text\":\"(Schultze, 2010)\",\"ref_id\":\"BIBREF342\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1152-1178> , <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1342-1368> , <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1369-1386> , <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1387-1406> , <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1611-1627> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Acute inflammatory processes tend to cause decreases in lymphocyte counts, but some acute infectious processes, particularly several viral infections, may cause increases in lymphocyte counts. However, increases in lymphocyte counts are commonly observed with chronic inflammatory processes. Chronic stimulation of lymphocytes with antigens or cytokines results in the increased production of lymphocytes with release into the blood, causing the increases in blood lymphocyte counts. Reactive lymphocytes may be observed in blood accompanying inflammation-induced increases in lymphocytes counts. Reactive lymphocytes have a spectrum of morphologic changes that include increased cytoplasmic basophilia, large cells with mildly increased amounts of cytoplasm (lower nuclear to cytoplasmic ratios), variable patterns of chromatin clumping, and variable numbers of visible nucleoli. Occasionally, reactive lymphocytes may have paranuclear cytoplasmic clearing, giving a plasmacytoid appearance. Infectious mononucleosis syndromes in people are a relatively common cause of an inflammatory or reactive increase in lymphocyte counts that are usually acute (Vasu and Caligiuri, 2016) . Chronic infections leading to increase in blood lymphocyte counts may include visceral leishmaniasis, parasitic infections such as strongyloidiasis, and leprosy (Vasu and Caligiuri, 2016; Rai et al., 2008; Myers et al., 2000) . Several chronic infections, including ehrlichiosis, Rocky Mountain spotted fever, leishmaniasis, trypanosomiasis, and brucellosis, have been associated with increases in blood lymphocyte counts in dogs (Schultze, 2010) ." ;
            <http://www.example.org/textHash>
                    "db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-312-335>
            <http://www.example.org/end>    "335.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF65" ;
            <http://www.example.org/start>  "312.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Chernoff et al., 1995)" .
    
    <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-464-486>
            <http://www.example.org/end>    "486.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF261" ;
            <http://www.example.org/start>  "464.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Mintzer et al., 2009;" .
    
    <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b_citespan-734-760>
            <http://www.example.org/end>    "760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "734.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Arndt and Garratty, 2005)" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-365-384>
            <http://www.example.org/end>    "384.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Arock et al., 2002)" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-941-960>
            <http://www.example.org/end>    "960.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF390" ;
            <http://www.example.org/start>  "941.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tietz et al., 1997)" .
    
    <http://covid19.aksw.org/text-f023ed321326b573a95e1be1618f1ae74ee4531cc926bf8f2e03cb4cd97b8d15_citespan-261-281>
            <http://www.example.org/end>    "281.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF171" ;
            <http://www.example.org/start>  "261.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hirai et al., 1997;" .
    
    <http://covid19.aksw.org/text-d36f694c14f073282a61b380d6f3256e35435abc00cfe656741878bdbe5cc899_refspan-79-86>
            <http://www.example.org/end>    "86.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "79.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 2" .
    
    <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-686-700>
            <http://www.example.org/end>    "700.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF140" ;
            <http://www.example.org/start>  "686.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gergely, 1999)" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-562-581>
            <http://www.example.org/end>    "581.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF253" ;
            <http://www.example.org/start>  "562.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mayer et al., 1989)" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-544-562>
            <http://www.example.org/end>    "562.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF61" ;
            <http://www.example.org/start>  "544.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cave et al., 2004;" .
    
    <http://covid19.aksw.org/text-76d865d10df7e69d5efe4aba052c98cdf3b7530a48849e47a9639b4b7f492add_citespan-621-646>
            <http://www.example.org/end>    "646.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF125" ;
            <http://www.example.org/start>  "621.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Frye and Thompson, 1993)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-489-506>
            <http://www.example.org/end>    "506.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF226" ;
            <http://www.example.org/start>  "489.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016b)" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-931-944>
            <http://www.example.org/end>    "944.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "931.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Aster, 2005)" .
    
    <http://covid19.aksw.org/text-785b73145229f779ccc708abba95ba933ebe1586d9382ea1a94a5992de5d39f8_citespan-514-540>
            <http://www.example.org/end>    "540.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "514.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016)" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-345-376>
            <http://www.example.org/end>    "376.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF94" ;
            <http://www.example.org/start>  "345.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Diz-Küçükkaya and López, 2016)" .
    
    <http://covid19.aksw.org/text-c0d3fa2cc3ab5cb28628aa8dff473420c694a194a44c1c961fa8bcd62c5a2ca2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Heparin-induced increases in neutrophil counts are reported in a small percentage of patients receiving heparin therapy, and the mechanisms are likely multifactorial. Heparin may cause shifting of neutrophils to the circulating pool from the marginating pool due to decreased expression of selectins (Zhang et al., 2012) . Heparin-related release of CXCL12, a chemokine that is constitutively expressed by bone marrow stromal cells and plays a role in bone marrow neutrophil retention and leukocyte trafficking, may alter bone marrow and circulating CXCL12 gradients and promote release of neutrophils from the bone marrow storage pool, contributing to the increases in circulating neutrophil counts (Zhang et al., 2012) .\",\"cite_spans\":[{\"start\":300.0,\"end\":320.0,\"text\":\"(Zhang et al., 2012)\",\"ref_id\":\"BIBREF441\"},{\"start\":700.0,\"end\":720.0,\"text\":\"(Zhang et al., 2012)\",\"ref_id\":\"BIBREF441\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c0d3fa2cc3ab5cb28628aa8dff473420c694a194a44c1c961fa8bcd62c5a2ca2_citespan-300-320> , <http://covid19.aksw.org/text-c0d3fa2cc3ab5cb28628aa8dff473420c694a194a44c1c961fa8bcd62c5a2ca2_citespan-700-720> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Heparin-induced increases in neutrophil counts are reported in a small percentage of patients receiving heparin therapy, and the mechanisms are likely multifactorial. Heparin may cause shifting of neutrophils to the circulating pool from the marginating pool due to decreased expression of selectins (Zhang et al., 2012) . Heparin-related release of CXCL12, a chemokine that is constitutively expressed by bone marrow stromal cells and plays a role in bone marrow neutrophil retention and leukocyte trafficking, may alter bone marrow and circulating CXCL12 gradients and promote release of neutrophils from the bone marrow storage pool, contributing to the increases in circulating neutrophil counts (Zhang et al., 2012) ." ;
            <http://www.example.org/textHash>
                    "c0d3fa2cc3ab5cb28628aa8dff473420c694a194a44c1c961fa8bcd62c5a2ca2" .
    
    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-168-182>
            <http://www.example.org/end>    "182.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "168.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-307-334>
            <http://www.example.org/end>    "334.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-481-508>
            <http://www.example.org/end>    "508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Budman and Steinberg, 1977)" .
    
    <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97_citespan-570-591>
            <http://www.example.org/end>    "591.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "570.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Barker et al., 2012)" .
    
    <http://covid19.aksw.org/text-3f32cade925e042651afc56e04b509f2316269ed5c8809d0430af83259a01db8_citespan-432-456>
            <http://www.example.org/end>    "456.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008)" .
    
    <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef_citespan-276-290>
            <http://www.example.org/end>    "290.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "276.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-induced increases in neutrophil counts may be observed in conjunction with several cutaneous drug reactions that result in inflammatory stimuli. Acute generalized exanthematous pustulosis is a drug-related skin reaction that generally occurs within 2 days of drug administration but resolves spontaneously within 15 days (Roujeau, 2005) . Increases in eosinophil counts may or may not be observed along with the increases in neutrophil counts. Xenobiotics classically associated with this syndrome include diltiazem and antibiotics such as aminopenicillins and pristinamycine (Roujeau, 2005) . Acute febrile dermatosis (Sweet\\u0027s syndrome) has also been associated with elevations in circulating neutrophil counts, and drug-induced forms of this condition have been variably linked to a variety of compounds, including GM-CSF, trimethoprim-sulfamethoxazole, minocycline, celecoxib, furosemide, and azathioprine (Rochet et al., 2013; Saavedra et al., 2006) . 12.11.2.1.2 Decreases in neutrophil counts (neutropenia, granulocytopenia, agranulocytosis) 12.11.2.1.2.1 Overwhelming or severe acute inflammation Although inflammation often causes increases in neutrophil counts, an overwhelming or severe acute inflammatory stimulus may result in decreases in neutrophil counts. Such an inflammatory stimulus, sometimes also referred to as peracute inflammation, is commonly observed with bacterial sepsis. Decreases in neutrophil counts are a result of emigration to tissues that exceed the bone marrow capacity to release neutrophils. Proinflammatory mediators and chemoattractants stimulate increased neutrophil margination, firm adhesion to endothelial cells, and emigration into tissue, which shortens neutrophil circulating half-lives and depletes the circulating neutrophil pool. As neutrophils are released from the bone marrow and the storage pool is depleted, recruitment of immature neutrophils into circulation results in a left shift in which the number of immature forms exceeds the number of mature segmented neutrophils (degenerative left shift). If the stimulus persists long enough, granulocytic hyperplasia of the bone marrow will occur and the numbers of circulating neutrophils will increase and shift toward greater numbers of mature than immature neutrophils.\",\"cite_spans\":[{\"start\":332.0,\"end\":347.0,\"text\":\"(Roujeau, 2005)\",\"ref_id\":\"BIBREF327\"},{\"start\":587.0,\"end\":602.0,\"text\":\"(Roujeau, 2005)\",\"ref_id\":\"BIBREF327\"},{\"start\":920.0,\"end\":941.0,\"text\":\"(Rochet et al., 2013;\",\"ref_id\":\"BIBREF322\"},{\"start\":942.0,\"end\":964.0,\"text\":\"Saavedra et al., 2006)\",\"ref_id\":\"BIBREF330\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-332-347> , <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-587-602> , <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-920-941> , <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-942-964> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Xenobiotic-induced increases in neutrophil counts may be observed in conjunction with several cutaneous drug reactions that result in inflammatory stimuli. Acute generalized exanthematous pustulosis is a drug-related skin reaction that generally occurs within 2 days of drug administration but resolves spontaneously within 15 days (Roujeau, 2005) . Increases in eosinophil counts may or may not be observed along with the increases in neutrophil counts. Xenobiotics classically associated with this syndrome include diltiazem and antibiotics such as aminopenicillins and pristinamycine (Roujeau, 2005) . Acute febrile dermatosis (Sweet's syndrome) has also been associated with elevations in circulating neutrophil counts, and drug-induced forms of this condition have been variably linked to a variety of compounds, including GM-CSF, trimethoprim-sulfamethoxazole, minocycline, celecoxib, furosemide, and azathioprine (Rochet et al., 2013; Saavedra et al., 2006) . 12.11.2.1.2 Decreases in neutrophil counts (neutropenia, granulocytopenia, agranulocytosis) 12.11.2.1.2.1 Overwhelming or severe acute inflammation Although inflammation often causes increases in neutrophil counts, an overwhelming or severe acute inflammatory stimulus may result in decreases in neutrophil counts. Such an inflammatory stimulus, sometimes also referred to as peracute inflammation, is commonly observed with bacterial sepsis. Decreases in neutrophil counts are a result of emigration to tissues that exceed the bone marrow capacity to release neutrophils. Proinflammatory mediators and chemoattractants stimulate increased neutrophil margination, firm adhesion to endothelial cells, and emigration into tissue, which shortens neutrophil circulating half-lives and depletes the circulating neutrophil pool. As neutrophils are released from the bone marrow and the storage pool is depleted, recruitment of immature neutrophils into circulation results in a left shift in which the number of immature forms exceeds the number of mature segmented neutrophils (degenerative left shift). If the stimulus persists long enough, granulocytic hyperplasia of the bone marrow will occur and the numbers of circulating neutrophils will increase and shift toward greater numbers of mature than immature neutrophils." ;
            <http://www.example.org/textHash>
                    "4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f" .
    
    <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-413-439>
            <http://www.example.org/end>    "439.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "413.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008c;" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-484-506>
            <http://www.example.org/end>    "506.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF261" ;
            <http://www.example.org/start>  "484.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Mintzer et al., 2009)" .
    
    <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-1023-1044>
            <http://www.example.org/end>    "1044.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF107" ;
            <http://www.example.org/start>  "1023.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Everds et al., 2013a)" .
    
    <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-194-216>
            <http://www.example.org/end>    "216.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF436" ;
            <http://www.example.org/start>  "194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Yaramis et al., 2001)" .
    
    <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-635-657>
            <http://www.example.org/end>    "657.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF320" ;
            <http://www.example.org/start>  "635.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Rinehart et al., 1975)" .
    
    <http://covid19.aksw.org/text-88d5f1e89d130c7b951cf60cfd39f7ee8fc36d8a9880022cd78817537f471659>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.1.1.2 Catecholamine-induced Increases in circulating catecholamine levels in response to fright, excitement, or acute stress can result in increases in red cell mass due to splenic contraction. Noncirculating erythrocytes stored within the red pulp of the spleen are expelled, resulting in increased circulating red cell mass. Such increases in red cell mass are transient and resolve as splenic relaxation occurs following a decline in circulating catecholamine levels. Catecholamine-induced splenic contraction-associated relative increases in red cell mass are most commonly observed at pretest collections in nonclinical toxicology studies utilizing nonhuman primates, dogs, or cats, particularly the first pretest collection if multiple collections are performed. It is typically not observed at subsequent collections as the animal becomes acclimated to the housing, handling/restraint, phlebotomy, and other study-related procedures.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Relative increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Relative increases in red cell mass" ;
            <http://www.example.org/text>  "12.11.3.1.1.2 Catecholamine-induced Increases in circulating catecholamine levels in response to fright, excitement, or acute stress can result in increases in red cell mass due to splenic contraction. Noncirculating erythrocytes stored within the red pulp of the spleen are expelled, resulting in increased circulating red cell mass. Such increases in red cell mass are transient and resolve as splenic relaxation occurs following a decline in circulating catecholamine levels. Catecholamine-induced splenic contraction-associated relative increases in red cell mass are most commonly observed at pretest collections in nonclinical toxicology studies utilizing nonhuman primates, dogs, or cats, particularly the first pretest collection if multiple collections are performed. It is typically not observed at subsequent collections as the animal becomes acclimated to the housing, handling/restraint, phlebotomy, and other study-related procedures." ;
            <http://www.example.org/textHash>
                    "88d5f1e89d130c7b951cf60cfd39f7ee8fc36d8a9880022cd78817537f471659" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-239-259>
            <http://www.example.org/end>    "259.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF439" ;
            <http://www.example.org/start>  "239.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young et al., 2006)" .
    
    <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-424-444>
            <http://www.example.org/end>    "444.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "424.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-97437d25fdc1f555b92e0d94ecfe324afc8334e48c0dbf16441695695f9c14e1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are many xenobiotics that can cause decreases in red cell mass with concurrent decreases in reticulocyte counts. Bone marrow suppression that affects the erythroid lineage is commonly observed with chemotherapeutics in general. For example, agents that are directly cytotoxic to hematopoietic precursors, that inhibit mitotic spindle formation, and antimetabolites that alter folate metabolism may all result in suppression of erythropoiesis. However, development of parvovirus-induced PRCA has been reported as a consequence of chemotherapeutic administration (Song et al., 2002; Rao et al., 1994) .\",\"cite_spans\":[{\"start\":567.0,\"end\":586.0,\"text\":\"(Song et al., 2002;\",\"ref_id\":\"BIBREF362\"},{\"start\":587.0,\"end\":604.0,\"text\":\"Rao et al., 1994)\",\"ref_id\":\"BIBREF315\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-97437d25fdc1f555b92e0d94ecfe324afc8334e48c0dbf16441695695f9c14e1_citespan-567-586> , <http://covid19.aksw.org/text-97437d25fdc1f555b92e0d94ecfe324afc8334e48c0dbf16441695695f9c14e1_citespan-587-604> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "There are many xenobiotics that can cause decreases in red cell mass with concurrent decreases in reticulocyte counts. Bone marrow suppression that affects the erythroid lineage is commonly observed with chemotherapeutics in general. For example, agents that are directly cytotoxic to hematopoietic precursors, that inhibit mitotic spindle formation, and antimetabolites that alter folate metabolism may all result in suppression of erythropoiesis. However, development of parvovirus-induced PRCA has been reported as a consequence of chemotherapeutic administration (Song et al., 2002; Rao et al., 1994) ." ;
            <http://www.example.org/textHash>
                    "97437d25fdc1f555b92e0d94ecfe324afc8334e48c0dbf16441695695f9c14e1" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-446-466>
            <http://www.example.org/end>    "466.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "446.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Magden et al., 2015;" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1935-1954>
            <http://www.example.org/end>    "1954.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF332" ;
            <http://www.example.org/start>  "1935.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sakka et al., 2006)" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1288-1314>
            <http://www.example.org/end>    "1314.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF103" ;
            <http://www.example.org/start>  "1288.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Edwards and Fuller, 1996)" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1509-1535>
            <http://www.example.org/end>    "1535.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "1509.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016)" .
    
    <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-951-972>
            <http://www.example.org/end>    "972.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF120" ;
            <http://www.example.org/start>  "951.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Foster et al., 1986;" .
    
    <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are numerous reports of idiopathic increases in blood eosinophil counts. Such conditions include eosinophilic esophagitis, eosinophilic gastroenteritis, eosinophilic myositis, eosinophilic cellulitis, and eosinophilic pneumonitis in people, dogs, and/or cats (Wardlaw, 2016; Stockham and Scott, 2008a) . Hypereosinophilic syndrome (HES) in people is another condition that falls under the umbrella of idiopathic increases in eosinophil counts. In HES, chronic increases in eosinophil counts are observed without evidence of an underlying causative condition. This condition is associated with marked tissue infiltration and eventual organ damage and failure (Wardlaw, 2016; Rosenberg et al., 2013) . However, some patients with HES eventually develop either a lymphoid or myeloid neoplasm (Wardlaw, 2016) .\",\"cite_spans\":[{\"start\":265.0,\"end\":280.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":281.0,\"end\":307.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":664.0,\"end\":679.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":680.0,\"end\":703.0,\"text\":\"Rosenberg et al., 2013)\",\"ref_id\":\"BIBREF324\"},{\"start\":795.0,\"end\":810.0,\"text\":\"(Wardlaw, 2016)\",\"ref_id\":\"BIBREF420\"}],\"ref_spans\":[],\"section\":\"Idiopathic\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-265-280> , <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-281-307> , <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-664-679> , <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-680-703> , <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-795-810> ;
            <http://www.example.org/section>
                    "Idiopathic" ;
            <http://www.example.org/text>  "There are numerous reports of idiopathic increases in blood eosinophil counts. Such conditions include eosinophilic esophagitis, eosinophilic gastroenteritis, eosinophilic myositis, eosinophilic cellulitis, and eosinophilic pneumonitis in people, dogs, and/or cats (Wardlaw, 2016; Stockham and Scott, 2008a) . Hypereosinophilic syndrome (HES) in people is another condition that falls under the umbrella of idiopathic increases in eosinophil counts. In HES, chronic increases in eosinophil counts are observed without evidence of an underlying causative condition. This condition is associated with marked tissue infiltration and eventual organ damage and failure (Wardlaw, 2016; Rosenberg et al., 2013) . However, some patients with HES eventually develop either a lymphoid or myeloid neoplasm (Wardlaw, 2016) ." ;
            <http://www.example.org/textHash>
                    "1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777" .
    
    <http://covid19.aksw.org/text-a6352b6bc2547a312d7257486b51a2c87ccd7694aa98ea69b6323affa47c24fa>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Common patterns of alterations in blood leukocyte components are summarized in Table 1 .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":79.0,\"end\":86.0,\"text\":\"Table 1\"}],\"section\":\"Leukocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-a6352b6bc2547a312d7257486b51a2c87ccd7694aa98ea69b6323affa47c24fa_refspan-79-86> ;
            <http://www.example.org/section>
                    "Leukocytes" ;
            <http://www.example.org/text>  "Common patterns of alterations in blood leukocyte components are summarized in Table 1 ." ;
            <http://www.example.org/textHash>
                    "a6352b6bc2547a312d7257486b51a2c87ccd7694aa98ea69b6323affa47c24fa" .
    
    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"PRCA has occasionally been linked to xenobiotic treatment. A wide variety of xenobiotics from many different classes have been reported to cause PRCA. Examples of xenobiotics reportedly associated with PCRA include sulfonamides, allopurinol, procainamide, gold-containing compounds, rifampin, and chloroquine (Young, 2016; Mintzer et al., 2009) . However, causality is often difficult to prove, and most associations are limited to low numbers of case reports. One study evaluated reports of PRCA associated with administration of 30 different xenobiotics, but causality was only attributed to treatment with azathioprine, isoniazid, and phenytoin (Thompson and Gales, 1996) . PRCA due to the development of anti-EPO antibodies may follow the administration of recombinant EPO in humans (Casadevall et al., 2002) and EPO gene therapy in monkeys (Gao et al., 2004) . Administration of recombinant EPO to dogs has also led to the development of anti-EPO antibodies and PRCA (Randolph et al., 2004) .\",\"cite_spans\":[{\"start\":309.0,\"end\":322.0,\"text\":\"(Young, 2016;\",\"ref_id\":\"BIBREF437\"},{\"start\":323.0,\"end\":344.0,\"text\":\"Mintzer et al., 2009)\",\"ref_id\":\"BIBREF261\"},{\"start\":648.0,\"end\":674.0,\"text\":\"(Thompson and Gales, 1996)\",\"ref_id\":\"BIBREF386\"},{\"start\":787.0,\"end\":812.0,\"text\":\"(Casadevall et al., 2002)\",\"ref_id\":\"BIBREF59\"},{\"start\":845.0,\"end\":863.0,\"text\":\"(Gao et al., 2004)\",\"ref_id\":\"BIBREF131\"},{\"start\":972.0,\"end\":995.0,\"text\":\"(Randolph et al., 2004)\",\"ref_id\":\"BIBREF312\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-787-812> , <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-845-863> , <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-648-674> , <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-323-344> , <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-309-322> , <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-972-995> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "PRCA has occasionally been linked to xenobiotic treatment. A wide variety of xenobiotics from many different classes have been reported to cause PRCA. Examples of xenobiotics reportedly associated with PCRA include sulfonamides, allopurinol, procainamide, gold-containing compounds, rifampin, and chloroquine (Young, 2016; Mintzer et al., 2009) . However, causality is often difficult to prove, and most associations are limited to low numbers of case reports. One study evaluated reports of PRCA associated with administration of 30 different xenobiotics, but causality was only attributed to treatment with azathioprine, isoniazid, and phenytoin (Thompson and Gales, 1996) . PRCA due to the development of anti-EPO antibodies may follow the administration of recombinant EPO in humans (Casadevall et al., 2002) and EPO gene therapy in monkeys (Gao et al., 2004) . Administration of recombinant EPO to dogs has also led to the development of anti-EPO antibodies and PRCA (Randolph et al., 2004) ." ;
            <http://www.example.org/textHash>
                    "968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3" .
    
    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-386-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF204" ;
            <http://www.example.org/start>  "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Koduri et al., 2002)" .
    
    <http://covid19.aksw.org/text-8dbb32dd29a2a8f1dbff8134ae449f90f190d55cc97a4c05b320481151e5ea42>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in monocyte counts may be difficult to detect due to the relatively low blood monocyte counts in humans and most laboratory animal species, particularly if reference intervals or historical control ranges, rather than values from a concurrent control group, are being used for determining if changes in blood monocyte counts are present. In nonclinical toxicology studies, comparison to concurrent controls or pretest may enable detection of more subtle decreases in monocyte counts.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Decreases in monocyte counts (monocytopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Decreases in monocyte counts (monocytopenia)" ;
            <http://www.example.org/text>  "Decreases in monocyte counts may be difficult to detect due to the relatively low blood monocyte counts in humans and most laboratory animal species, particularly if reference intervals or historical control ranges, rather than values from a concurrent control group, are being used for determining if changes in blood monocyte counts are present. In nonclinical toxicology studies, comparison to concurrent controls or pretest may enable detection of more subtle decreases in monocyte counts." ;
            <http://www.example.org/textHash>
                    "8dbb32dd29a2a8f1dbff8134ae449f90f190d55cc97a4c05b320481151e5ea42" .
    
    <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Clostridium perfringens (formerly Clostridium welchii) infection in humans is an example of a bacterial cause of hemolysis. During intestinal overgrowth or septicemia, C. perfringens type A elaborates an a toxin that has lecithinase C activity, resulting in membrane phospholipid breakdown and release of lysolethicins, which have potent hemolytic capabilities (Lichtman, 2016b; Songer, 1996) . C. perfringens a toxin release is usually associated with severe intravascular hemolysis with both hemoglobinemia and hemoglobinuria. However, in veterinary species, C. perfringens-related hemolysis is typically limited to ruminants and horses (Stockham and Scott, 2008b) , and is unlikely to be observed in the common species used in nonclinical toxicology studies.\",\"cite_spans\":[{\"start\":361.0,\"end\":378.0,\"text\":\"(Lichtman, 2016b;\",\"ref_id\":\"BIBREF226\"},{\"start\":379.0,\"end\":392.0,\"text\":\"Songer, 1996)\",\"ref_id\":\"BIBREF363\"},{\"start\":639.0,\"end\":666.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3_citespan-361-378> , <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3_citespan-379-392> , <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3_citespan-639-666> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Clostridium perfringens (formerly Clostridium welchii) infection in humans is an example of a bacterial cause of hemolysis. During intestinal overgrowth or septicemia, C. perfringens type A elaborates an a toxin that has lecithinase C activity, resulting in membrane phospholipid breakdown and release of lysolethicins, which have potent hemolytic capabilities (Lichtman, 2016b; Songer, 1996) . C. perfringens a toxin release is usually associated with severe intravascular hemolysis with both hemoglobinemia and hemoglobinuria. However, in veterinary species, C. perfringens-related hemolysis is typically limited to ruminants and horses (Stockham and Scott, 2008b) , and is unlikely to be observed in the common species used in nonclinical toxicology studies." ;
            <http://www.example.org/textHash>
                    "a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-727-753>
            <http://www.example.org/end>    "753.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "727.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-321-337>
            <http://www.example.org/end>    "337.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "321.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-278a7692539e67a6b59f5e078344d33cd28efae2f6855def8a2903ee108c73a3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Acute Chronic\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Acute Chronic" ;
            <http://www.example.org/textHash>
                    "278a7692539e67a6b59f5e078344d33cd28efae2f6855def8a2903ee108c73a3" .
    
    <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-389-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF328" ;
            <http://www.example.org/start>  "389.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ruka et al., 2001)" .
    
    <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e_citespan-364-393>
            <http://www.example.org/end>    "393.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(den Ottolander et al., 1983;" .
    
    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-923-950>
            <http://www.example.org/end>    "950.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "923.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97_citespan-420-443>
            <http://www.example.org/end>    "443.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF320" ;
            <http://www.example.org/start>  "420.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rinehart et al., 1975;" .
    
    <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-788-810>
            <http://www.example.org/end>    "810.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF294" ;
            <http://www.example.org/start>  "788.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Penzhorn et al., 2004)" .
    
    <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-444-470>
            <http://www.example.org/end>    "470.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF202" ;
            <http://www.example.org/start>  "444.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kjemtrup and Conrad, 2000)" .
    
    <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c_citespan-299-311>
            <http://www.example.org/end>    "311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "299.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bass, 1975)" .
    
    <http://covid19.aksw.org/text-3811430106d3b33bdc10f9fe4a6c69213a615def0d58ae74df4c0a2047eb4f78_citespan-116-130>
            <http://www.example.org/end>    "130.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF189" ;
            <http://www.example.org/start>  "116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Juhlin, 1963c)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1274-1311>
            <http://www.example.org/end>    "1311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1274.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "), simvastatin (McCarthy et al., 1998" .
    
    <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Other compounds may cause hemolysis through mechanisms other than oxidative, microangiopathic, or immune-mediated. For example, although the primary effect of lead toxicity is impairment of heme synthesis, lead may also cause hemolysis. The mechanism of lead-induced hemolysis has not been fully determined, but interference with the erythrocyte membrane sodium/ potassium transporter may be involved (Bloom and Brandt, 2008) . Copper toxicity causes hemolysis as well, possibly through inhibition of many enzymes involved in glycolysis resulting in decreased intracellular ATP (Boulard et al., 1972) . Envenomation from multiple animals is reported to cause hemolysis. Envenomation by snakes, such as rattlesnakes and coral snakes, can cause hemolysis through phospholipase A2 activity, which may cause direct hemolysis or liberate hemolysins such as lysolethicin, or through complement-mediated hemolysis (Arce-Bejarano et al., 2014; Tambourgi and van den Berg, 2014; Walton et al., 1997) .\",\"cite_spans\":[{\"start\":401.0,\"end\":425.0,\"text\":\"(Bloom and Brandt, 2008)\",\"ref_id\":\"BIBREF35\"},{\"start\":578.0,\"end\":600.0,\"text\":\"(Boulard et al., 1972)\",\"ref_id\":\"BIBREF41\"},{\"start\":907.0,\"end\":935.0,\"text\":\"(Arce-Bejarano et al., 2014;\",\"ref_id\":\"BIBREF5\"},{\"start\":936.0,\"end\":969.0,\"text\":\"Tambourgi and van den Berg, 2014;\",\"ref_id\":\"BIBREF380\"},{\"start\":970.0,\"end\":990.0,\"text\":\"Walton et al., 1997)\",\"ref_id\":\"BIBREF418\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-401-425> , <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-578-600> , <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-907-935> , <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-936-969> , <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-970-990> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Other compounds may cause hemolysis through mechanisms other than oxidative, microangiopathic, or immune-mediated. For example, although the primary effect of lead toxicity is impairment of heme synthesis, lead may also cause hemolysis. The mechanism of lead-induced hemolysis has not been fully determined, but interference with the erythrocyte membrane sodium/ potassium transporter may be involved (Bloom and Brandt, 2008) . Copper toxicity causes hemolysis as well, possibly through inhibition of many enzymes involved in glycolysis resulting in decreased intracellular ATP (Boulard et al., 1972) . Envenomation from multiple animals is reported to cause hemolysis. Envenomation by snakes, such as rattlesnakes and coral snakes, can cause hemolysis through phospholipase A2 activity, which may cause direct hemolysis or liberate hemolysins such as lysolethicin, or through complement-mediated hemolysis (Arce-Bejarano et al., 2014; Tambourgi and van den Berg, 2014; Walton et al., 1997) ." ;
            <http://www.example.org/textHash>
                    "25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336" .
    
    <http://covid19.aksw.org/text-e277dd21a7e5f047e14c054f345417186c14db5ede6fe4166051863434455442>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Relative decreases in platelet counts occur when circulating platelet mass is not changed, but platelet clumping, redistribution, or hemodilution alter automated or estimated platelet counts. False decreases in platelet counts (pseudo-thrombocytopenia) due to platelet clumping are often present in rats, mice, and cats, although it may be observed in any species. MPV may be increased with the presence of platelet clumps, and microscopic blood smear review should be performed in all cases of decreased platelet counts to assess for the presence of platelet clumps; increases in MPV in instances of platelet clumping do not reflect a bone marrow response because a true decrease in platelet count is not present to stimulate thrombopoiesis. Resampling of blood with a clean venipuncture and use of sodium citrate as the anticoagulant may help reduce platelet clumps and result in a more accurate automated platelet count.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Relative\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Relative" ;
            <http://www.example.org/text>  "Relative decreases in platelet counts occur when circulating platelet mass is not changed, but platelet clumping, redistribution, or hemodilution alter automated or estimated platelet counts. False decreases in platelet counts (pseudo-thrombocytopenia) due to platelet clumping are often present in rats, mice, and cats, although it may be observed in any species. MPV may be increased with the presence of platelet clumps, and microscopic blood smear review should be performed in all cases of decreased platelet counts to assess for the presence of platelet clumps; increases in MPV in instances of platelet clumping do not reflect a bone marrow response because a true decrease in platelet count is not present to stimulate thrombopoiesis. Resampling of blood with a clean venipuncture and use of sodium citrate as the anticoagulant may help reduce platelet clumps and result in a more accurate automated platelet count." ;
            <http://www.example.org/textHash>
                    "e277dd21a7e5f047e14c054f345417186c14db5ede6fe4166051863434455442" .
    
    <http://covid19.aksw.org/text-7789f6b5b1c581691095b1b4ed7cea4928c189deef5986618312746b363f38d0_citespan-365-386>
            <http://www.example.org/end>    "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF304" ;
            <http://www.example.org/start>  "365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal et al., 1985)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1359-1377>
            <http://www.example.org/end>    "1377.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF56" ;
            <http://www.example.org/start>  "1359.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Car et al., 2006;" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Immune-mediated mechanisms of hemolysis have also been reported following exposure to numerous xenobiotics. Xenobiotics may induce antibodies by binding to the erythrocyte membrane and acting as haptens. These antibodies are considered drugdependent as they only mediate hemolysis when the drug is present. Penicillin is the prototypical xenobiotic that acts as a hapten to generate drug-dependent antibodies, and typically induces an IgG response (Ferner, 2012; Petz et al., 1966) . Semisynthetic penicillins, some cephalosporins, and tetracycline have also been reported to cause drug-dependent antibody-mediated hemolysis (Garratty, 2010; Tuffs and Manoharan, 1986; Seldon et al., 1982; Großjohann et al., 2004; Gallagher et al., 1992; Branch et al., 1985; Simpson et al., 1985) .\",\"cite_spans\":[{\"start\":448.0,\"end\":462.0,\"text\":\"(Ferner, 2012;\",\"ref_id\":\"BIBREF116\"},{\"start\":463.0,\"end\":481.0,\"text\":\"Petz et al., 1966)\",\"ref_id\":\"BIBREF296\"},{\"start\":625.0,\"end\":641.0,\"text\":\"(Garratty, 2010;\",\"ref_id\":\"BIBREF134\"},{\"start\":642.0,\"end\":668.0,\"text\":\"Tuffs and Manoharan, 1986;\",\"ref_id\":\"BIBREF397\"},{\"start\":669.0,\"end\":689.0,\"text\":\"Seldon et al., 1982;\",\"ref_id\":\"BIBREF346\"},{\"start\":690.0,\"end\":714.0,\"text\":\"Großjohann et al., 2004;\",\"ref_id\":\"BIBREF160\"},{\"start\":715.0,\"end\":738.0,\"text\":\"Gallagher et al., 1992;\",\"ref_id\":\"BIBREF127\"},{\"start\":739.0,\"end\":759.0,\"text\":\"Branch et al., 1985;\",\"ref_id\":\"BIBREF42\"},{\"start\":760.0,\"end\":781.0,\"text\":\"Simpson et al., 1985)\",\"ref_id\":\"BIBREF355\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-625-641> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-739-759> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-715-738> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-463-481> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-760-781> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-669-689> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-642-668> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-690-714> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-448-462> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Immune-mediated mechanisms of hemolysis have also been reported following exposure to numerous xenobiotics. Xenobiotics may induce antibodies by binding to the erythrocyte membrane and acting as haptens. These antibodies are considered drugdependent as they only mediate hemolysis when the drug is present. Penicillin is the prototypical xenobiotic that acts as a hapten to generate drug-dependent antibodies, and typically induces an IgG response (Ferner, 2012; Petz et al., 1966) . Semisynthetic penicillins, some cephalosporins, and tetracycline have also been reported to cause drug-dependent antibody-mediated hemolysis (Garratty, 2010; Tuffs and Manoharan, 1986; Seldon et al., 1982; Großjohann et al., 2004; Gallagher et al., 1992; Branch et al., 1985; Simpson et al., 1985) ." ;
            <http://www.example.org/textHash>
                    "d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f" .
    
    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-660-680>
            <http://www.example.org/end>    "680.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF258" ;
            <http://www.example.org/start>  "660.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mehmet et al., 2012)" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-297-321>
            <http://www.example.org/end>    "321.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF400" ;
            <http://www.example.org/start>  "297.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Valenciano et al., 2010;" .
    
    <http://covid19.aksw.org/text-23ae1ce221485560bd3e59a19208ab77a3a0963d9b5c14ed04c87ce9ca5b621d_citespan-244-261>
            <http://www.example.org/end>    "261.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF93" ;
            <http://www.example.org/start>  "244.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dinarello, 2000;" .
    
    <http://covid19.aksw.org/text-a1d3748d4858de2185ca589f0c4ab13bf30f27253f0634ddddba54401816fbef_citespan-405-425>
            <http://www.example.org/end>    "425.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF53" ;
            <http://www.example.org/start>  "405.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Callot et al., 1996)" .
    
    <http://covid19.aksw.org/text-ea2b8933d4899def7c648403d9eebd55102354ddcb399ecd31ccb2521283a73f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Redistribution or sequestration of circulating platelets may cause decreases in platelet counts, which may be transient. Platelet redistribution may be observed with splenomegaly, hypersplenism, or with severe hypothermia; total platelet mass is unaffected in these cases and typically does not result in increased TPO or platelet production (Stockham and Scott, 2008c) .\",\"cite_spans\":[{\"start\":342.0,\"end\":369.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"}],\"ref_spans\":[],\"section\":\"Relative\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ea2b8933d4899def7c648403d9eebd55102354ddcb399ecd31ccb2521283a73f_citespan-342-369> ;
            <http://www.example.org/section>
                    "Relative" ;
            <http://www.example.org/text>  "Redistribution or sequestration of circulating platelets may cause decreases in platelet counts, which may be transient. Platelet redistribution may be observed with splenomegaly, hypersplenism, or with severe hypothermia; total platelet mass is unaffected in these cases and typically does not result in increased TPO or platelet production (Stockham and Scott, 2008c) ." ;
            <http://www.example.org/textHash>
                    "ea2b8933d4899def7c648403d9eebd55102354ddcb399ecd31ccb2521283a73f" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-160-185>
            <http://www.example.org/end>    "185.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "160.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-340-360>
            <http://www.example.org/end>    "360.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "340.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schwartzberg, 2006;" .
    
    <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-145-165>
            <http://www.example.org/end>    "165.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF124" ;
            <http://www.example.org/start>  "145.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Frith et al., 1993)" .
    
    <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-746-768>
            <http://www.example.org/end>    "768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF143" ;
            <http://www.example.org/start>  "746.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ghislain et al., 2004)" .
    
    <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Many infectious agents may cause a decrease in lymphocyte counts due to inflammation. Infectious agents associated with decreases in lymphocyte counts include viruses such as coronavirus, parvovirus, West Nile virus, hepatitis viruses, and influenza (Vasu and Caligiuri, 2016; Schultze, 2010) ; acute systemic bacterial infections; as well as tuberculosis, typhoid fever, and bacterial pneumonias (Vasu and Caligiuri, 2016; Magden et al., 2015) . The acute phase of malaria may also be associated with decreases in lymphocyte counts (Vasu and Caligiuri, 2016) .\",\"cite_spans\":[{\"start\":250.0,\"end\":276.0,\"text\":\"(Vasu and Caligiuri, 2016;\",\"ref_id\":\"BIBREF406\"},{\"start\":277.0,\"end\":292.0,\"text\":\"Schultze, 2010)\",\"ref_id\":\"BIBREF342\"},{\"start\":397.0,\"end\":423.0,\"text\":\"(Vasu and Caligiuri, 2016;\",\"ref_id\":\"BIBREF406\"},{\"start\":424.0,\"end\":444.0,\"text\":\"Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"},{\"start\":533.0,\"end\":559.0,\"text\":\"(Vasu and Caligiuri, 2016)\",\"ref_id\":\"BIBREF406\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-250-276> , <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-277-292> , <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-397-423> , <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-424-444> , <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-533-559> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Many infectious agents may cause a decrease in lymphocyte counts due to inflammation. Infectious agents associated with decreases in lymphocyte counts include viruses such as coronavirus, parvovirus, West Nile virus, hepatitis viruses, and influenza (Vasu and Caligiuri, 2016; Schultze, 2010) ; acute systemic bacterial infections; as well as tuberculosis, typhoid fever, and bacterial pneumonias (Vasu and Caligiuri, 2016; Magden et al., 2015) . The acute phase of malaria may also be associated with decreases in lymphocyte counts (Vasu and Caligiuri, 2016) ." ;
            <http://www.example.org/textHash>
                    "fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1293-1320>
            <http://www.example.org/end>    "1320.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "1293.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-303-323>
            <http://www.example.org/end>    "323.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "303.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Other immunosuppressive agents that cause decreased blood lymphocyte counts include cyclophosphamide, methotrexate, purine nucleoside analogs, and azathioprine. Cyclophosphamide has been associated with profound decrease in blood lymphocyte counts through its effects on all lymphocyte subtypes (Gergely, 1999) . Methotrexate causes decreases in circulating CD4 þ and CD8 þ T-cells, while cladribine, a purine nucleoside analog, causes apoptosis of lymphocytes and has been reported to affect both CD4 þ and CD8 þ T-cells (Gergely, 1999) . Azothiaprine-induced decreases in blood lymphocyte counts appear to be due to long-term administration at high dose levels (Johnson et al., 1995; Gergely, 1999) .\",\"cite_spans\":[{\"start\":295.0,\"end\":310.0,\"text\":\"(Gergely, 1999)\",\"ref_id\":\"BIBREF140\"},{\"start\":522.0,\"end\":537.0,\"text\":\"(Gergely, 1999)\",\"ref_id\":\"BIBREF140\"},{\"start\":663.0,\"end\":685.0,\"text\":\"(Johnson et al., 1995;\",\"ref_id\":\"BIBREF184\"},{\"start\":686.0,\"end\":700.0,\"text\":\"Gergely, 1999)\",\"ref_id\":\"BIBREF140\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-295-310> , <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-522-537> , <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-663-685> , <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-686-700> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Other immunosuppressive agents that cause decreased blood lymphocyte counts include cyclophosphamide, methotrexate, purine nucleoside analogs, and azathioprine. Cyclophosphamide has been associated with profound decrease in blood lymphocyte counts through its effects on all lymphocyte subtypes (Gergely, 1999) . Methotrexate causes decreases in circulating CD4 þ and CD8 þ T-cells, while cladribine, a purine nucleoside analog, causes apoptosis of lymphocytes and has been reported to affect both CD4 þ and CD8 þ T-cells (Gergely, 1999) . Azothiaprine-induced decreases in blood lymphocyte counts appear to be due to long-term administration at high dose levels (Johnson et al., 1995; Gergely, 1999) ." ;
            <http://www.example.org/textHash>
                    "08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264" .
    
    <http://covid19.aksw.org/text-97437d25fdc1f555b92e0d94ecfe324afc8334e48c0dbf16441695695f9c14e1_citespan-567-586>
            <http://www.example.org/end>    "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF362" ;
            <http://www.example.org/start>  "567.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Song et al., 2002;" .
    
    <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-970-990>
            <http://www.example.org/end>    "990.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF418" ;
            <http://www.example.org/start>  "970.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Walton et al., 1997)" .
    
    <http://covid19.aksw.org/text-bda048633fce0c56cbf4fe713ee5ed0d8bf64bc5d145f476592e1b650ccec657_citespan-494-516>
            <http://www.example.org/end>    "516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF356" ;
            <http://www.example.org/start>  "494.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Skeldon et al., 2010)" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-573-602>
            <http://www.example.org/end>    "602.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF398" ;
            <http://www.example.org/start>  "573.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tvedten and Lilliehöök, 2011)" .
    
    <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd_citespan-638-654>
            <http://www.example.org/end>    "654.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "638.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1123-1147>
            <http://www.example.org/end>    "1147.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "1123.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Aster and Bougie, 2007)" .
    
    <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Chronic neutrophilic leukemia is also characterized by blood leukocyte counts ! 25,000 cells mL À 1 that are composed of \\u003e 80% segmented and band neutrophils (Uppal and Gong, 2015) . These neutrophils may or may not have cytoplasmic changes indicative of rapid neutropoiesis. Unlike CML, the increases in neutrophil counts associated with CNL are typically not associated with morphologic features of dysplasia, the presence of earlier stages of myeloid cells (i.e. myeloblasts, promyelocytes, myelocytes, and metamyelocytes), increases in monocyte, eosinophil, or basophil counts, or increases in nucleated erythroid precursors (Uppal and Gong, 2015) . Bone marrow changes associated with CNL include hypercellularity with increased myeloid to erythroid ratios, where the myelocyte through band neutrophil stages are increased without apparent increases in myeloblasts or promyelocytes (Uppal and Gong, 2015) . As such, differentiation of CNL from leukemoid reactions or extreme neutrophilia may be difficult, and affected patients should be carefully evaluated to exclude causes of neutrophilia not associated with hematopoietic malignancy.\",\"cite_spans\":[{\"start\":158.0,\"end\":180.0,\"text\":\"(Uppal and Gong, 2015)\",\"ref_id\":\"BIBREF399\"},{\"start\":629.0,\"end\":651.0,\"text\":\"(Uppal and Gong, 2015)\",\"ref_id\":\"BIBREF399\"},{\"start\":887.0,\"end\":909.0,\"text\":\"(Uppal and Gong, 2015)\",\"ref_id\":\"BIBREF399\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1_citespan-158-180> , <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1_citespan-629-651> , <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1_citespan-887-909> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Chronic neutrophilic leukemia is also characterized by blood leukocyte counts ! 25,000 cells mL À 1 that are composed of > 80% segmented and band neutrophils (Uppal and Gong, 2015) . These neutrophils may or may not have cytoplasmic changes indicative of rapid neutropoiesis. Unlike CML, the increases in neutrophil counts associated with CNL are typically not associated with morphologic features of dysplasia, the presence of earlier stages of myeloid cells (i.e. myeloblasts, promyelocytes, myelocytes, and metamyelocytes), increases in monocyte, eosinophil, or basophil counts, or increases in nucleated erythroid precursors (Uppal and Gong, 2015) . Bone marrow changes associated with CNL include hypercellularity with increased myeloid to erythroid ratios, where the myelocyte through band neutrophil stages are increased without apparent increases in myeloblasts or promyelocytes (Uppal and Gong, 2015) . As such, differentiation of CNL from leukemoid reactions or extreme neutrophilia may be difficult, and affected patients should be carefully evaluated to exclude causes of neutrophilia not associated with hematopoietic malignancy." ;
            <http://www.example.org/textHash>
                    "cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-946-969>
            <http://www.example.org/end>    "969.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF431" ;
            <http://www.example.org/start>  "946.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Williams et al., 2000)" .
    
    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-354-375>
            <http://www.example.org/end>    "375.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF269" ;
            <http://www.example.org/start>  "354.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Murray et al., 2001)" .
    
    <http://covid19.aksw.org/text-78314608b6253b19d35efaf82abe5c94e39d1a63dd2d7e6aa9fb00e98631ceb0_citespan-582-606>
            <http://www.example.org/end>    "606.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF271" ;
            <http://www.example.org/start>  "582.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mutasim and Adams, 2000)" .
    
    <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-366-388>
            <http://www.example.org/end>    "388.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF260" ;
            <http://www.example.org/start>  "366.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Melichar et al., 2001;" .
    
    <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-411-431>
            <http://www.example.org/end>    "431.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "411.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016;" .
    
    <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.2.2 Parasitism Both external and internal parasites may contribute to blood loss. Hookworms are a major internal parasite associated with chronic blood loss, and may lead to iron deficiency with prolonged infections (Stoltzfus et al., 1997) . However, whipworm infection and schistosomiasis may also be associated with blood loss, the latter being associated with blood loss through the urinary system (Farid et al., 1969) . Heavy infestation of animals with arthropods that take blood meals, such as ticks, some lice, and fleas, may also cause sufficient blood loss to result in decreases in red cell mass (Stockham and Scott, 2008b) .\",\"cite_spans\":[{\"start\":228.0,\"end\":252.0,\"text\":\"(Stoltzfus et al., 1997)\",\"ref_id\":\"BIBREF370\"},{\"start\":414.0,\"end\":434.0,\"text\":\"(Farid et al., 1969)\",\"ref_id\":\"BIBREF111\"},{\"start\":619.0,\"end\":646.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b_citespan-228-252> , <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b_citespan-414-434> , <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b_citespan-619-646> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.2.2 Parasitism Both external and internal parasites may contribute to blood loss. Hookworms are a major internal parasite associated with chronic blood loss, and may lead to iron deficiency with prolonged infections (Stoltzfus et al., 1997) . However, whipworm infection and schistosomiasis may also be associated with blood loss, the latter being associated with blood loss through the urinary system (Farid et al., 1969) . Heavy infestation of animals with arthropods that take blood meals, such as ticks, some lice, and fleas, may also cause sufficient blood loss to result in decreases in red cell mass (Stockham and Scott, 2008b) ." ;
            <http://www.example.org/textHash>
                    "f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-404-430>
            <http://www.example.org/end>    "430.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF185" ;
            <http://www.example.org/start>  "404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Jongwutiwes et al., 2002;" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Many xenobiotics may also cause hemolysis through their association with microangiopathy, most commonly as part of the thrombotic microangiopathy syndrome, which is associated with fragmentation hemolysis and decreases in platelet counts. Drug-induced endothelial injury, including from direct and antibody or immune complex-mediated mechanisms, plays a major role in the pathogenesis of thrombotic microangiopathy (Pisoni et al., 2001) . Endothelial damage may be propagated by leukocyte adhesion and release of granule contents or reactive oxygen species, platelet activation and aggregation, and complement activation (Pisoni et al, 2001) . Drugs implicated in thrombotic microangiopathy include chemotherapeutic agents include xenobiotics from a wide variety of chemotherapeutic classes. Examples of chemotherapeutics associated with thrombotic microangiopathy include mitomycin C (Cantrell et al., 1985) , cisplatin (Palmisano et al., 1998) , estramustine phosphate (Tassinari et al., 1999 ), gemcitabine (Nackaerts et al., 1998 , and daunorubicin (Byrnes et al., 1986) . Nonchemotherapeutic agents that have been reported to cause thrombotic microangiopathy include immunomodulators such as cyclosporine and tacrolimus (Katznelson et al., 1994; Trimarchi et al., 1999 ), simvastatin (McCarthy et al., 1998 , and inhibitors of platelet aggregation including ticlopidine and clopidogrel (Bennett et al., 1998 .\",\"cite_spans\":[{\"start\":415.0,\"end\":436.0,\"text\":\"(Pisoni et al., 2001)\",\"ref_id\":\"BIBREF299\"},{\"start\":621.0,\"end\":641.0,\"text\":\"(Pisoni et al, 2001)\",\"ref_id\":\"BIBREF299\"},{\"start\":885.0,\"end\":908.0,\"text\":\"(Cantrell et al., 1985)\",\"ref_id\":\"BIBREF55\"},{\"start\":921.0,\"end\":945.0,\"text\":\"(Palmisano et al., 1998)\",\"ref_id\":\"BIBREF286\"},{\"start\":971.0,\"end\":994.0,\"text\":\"(Tassinari et al., 1999\",\"ref_id\":\"BIBREF381\"},{\"start\":995.0,\"end\":1033.0,\"text\":\"), gemcitabine (Nackaerts et al., 1998\"},{\"start\":1053.0,\"end\":1074.0,\"text\":\"(Byrnes et al., 1986)\",\"ref_id\":\"BIBREF50\"},{\"start\":1225.0,\"end\":1250.0,\"text\":\"(Katznelson et al., 1994;\",\"ref_id\":\"BIBREF199\"},{\"start\":1251.0,\"end\":1273.0,\"text\":\"Trimarchi et al., 1999\",\"ref_id\":\"BIBREF393\"},{\"start\":1274.0,\"end\":1311.0,\"text\":\"), simvastatin (McCarthy et al., 1998\"},{\"start\":1391.0,\"end\":1412.0,\"text\":\"(Bennett et al., 1998\",\"ref_id\":\"BIBREF23\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-921-945> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-995-1033> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-415-436> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1053-1074> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-621-641> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1251-1273> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1274-1311> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1225-1250> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-885-908> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-971-994> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1391-1412> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Many xenobiotics may also cause hemolysis through their association with microangiopathy, most commonly as part of the thrombotic microangiopathy syndrome, which is associated with fragmentation hemolysis and decreases in platelet counts. Drug-induced endothelial injury, including from direct and antibody or immune complex-mediated mechanisms, plays a major role in the pathogenesis of thrombotic microangiopathy (Pisoni et al., 2001) . Endothelial damage may be propagated by leukocyte adhesion and release of granule contents or reactive oxygen species, platelet activation and aggregation, and complement activation (Pisoni et al, 2001) . Drugs implicated in thrombotic microangiopathy include chemotherapeutic agents include xenobiotics from a wide variety of chemotherapeutic classes. Examples of chemotherapeutics associated with thrombotic microangiopathy include mitomycin C (Cantrell et al., 1985) , cisplatin (Palmisano et al., 1998) , estramustine phosphate (Tassinari et al., 1999 ), gemcitabine (Nackaerts et al., 1998 , and daunorubicin (Byrnes et al., 1986) . Nonchemotherapeutic agents that have been reported to cause thrombotic microangiopathy include immunomodulators such as cyclosporine and tacrolimus (Katznelson et al., 1994; Trimarchi et al., 1999 ), simvastatin (McCarthy et al., 1998 , and inhibitors of platelet aggregation including ticlopidine and clopidogrel (Bennett et al., 1998 ." ;
            <http://www.example.org/textHash>
                    "47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-318-330>
            <http://www.example.org/end>    "330.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF129" ;
            <http://www.example.org/start>  "318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ganz, 2003)" .
    
    <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-560-585>
            <http://www.example.org/end>    "585.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF307" ;
            <http://www.example.org/start>  "560.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Radin and Wellman, 2010)" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Infection with nonhelminth parasites may also cause increases in blood eosinophil counts. Ectoparasites, including fleas and ticks, have been associated with increase in eosinophil counts in dogs and cats and may be due to arthropod-related allergic or hypersensitivity reactions (Schultze, 2010; Valenciano et al., 2010; Stockham and Scott, 2008a) . Several protozoal infections, including isosporiasis (Jongwutiwes et al., 2002; Junod, 1987) and toxoplasmosis (Grant and Klein, 1987) , may result in increases in blood eosinophil counts. However, protozoal agents that infect erythrocytes, such as Plasmodium and Babesia species, are generally not expected to result in altered blood eosinophil counts (Tefferi et al., 2006; Stockham and Scott, 2008a) . Some bacterial infections, including borreliosis (Granter et al., 1996) and rickettsiosis (Wardlaw, 2016) , and several viral infections, including herpes virus and HIV (Wardlaw, 2016; Tietz et al., 1997) , have also been associated with increases in blood eosinophil counts. Fungal infections that cause allergic inflammation, such as coccidiomycosis, candidiasis, and aspergillosis (Wardlaw, 2016) , may also cause increases in blood eosinophil counts.\",\"cite_spans\":[{\"start\":280.0,\"end\":296.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":297.0,\"end\":321.0,\"text\":\"Valenciano et al., 2010;\",\"ref_id\":\"BIBREF400\"},{\"start\":322.0,\"end\":348.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":404.0,\"end\":430.0,\"text\":\"(Jongwutiwes et al., 2002;\",\"ref_id\":\"BIBREF185\"},{\"start\":431.0,\"end\":443.0,\"text\":\"Junod, 1987)\",\"ref_id\":\"BIBREF190\"},{\"start\":462.0,\"end\":485.0,\"text\":\"(Grant and Klein, 1987)\",\"ref_id\":\"BIBREF153\"},{\"start\":704.0,\"end\":726.0,\"text\":\"(Tefferi et al., 2006;\",\"ref_id\":\"BIBREF383\"},{\"start\":727.0,\"end\":753.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":805.0,\"end\":827.0,\"text\":\"(Granter et al., 1996)\",\"ref_id\":\"BIBREF154\"},{\"start\":846.0,\"end\":861.0,\"text\":\"(Wardlaw, 2016)\",\"ref_id\":\"BIBREF420\"},{\"start\":925.0,\"end\":940.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":941.0,\"end\":960.0,\"text\":\"Tietz et al., 1997)\",\"ref_id\":\"BIBREF390\"},{\"start\":1140.0,\"end\":1155.0,\"text\":\"(Wardlaw, 2016)\",\"ref_id\":\"BIBREF420\"}],\"ref_spans\":[],\"section\":\"Inflammation and Hypersensitivity\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-297-321> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-846-861> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-1140-1155> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-727-753> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-280-296> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-805-827> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-462-485> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-941-960> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-322-348> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-431-443> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-704-726> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-925-940> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-404-430> ;
            <http://www.example.org/section>
                    "Inflammation and Hypersensitivity" ;
            <http://www.example.org/text>  "Infection with nonhelminth parasites may also cause increases in blood eosinophil counts. Ectoparasites, including fleas and ticks, have been associated with increase in eosinophil counts in dogs and cats and may be due to arthropod-related allergic or hypersensitivity reactions (Schultze, 2010; Valenciano et al., 2010; Stockham and Scott, 2008a) . Several protozoal infections, including isosporiasis (Jongwutiwes et al., 2002; Junod, 1987) and toxoplasmosis (Grant and Klein, 1987) , may result in increases in blood eosinophil counts. However, protozoal agents that infect erythrocytes, such as Plasmodium and Babesia species, are generally not expected to result in altered blood eosinophil counts (Tefferi et al., 2006; Stockham and Scott, 2008a) . Some bacterial infections, including borreliosis (Granter et al., 1996) and rickettsiosis (Wardlaw, 2016) , and several viral infections, including herpes virus and HIV (Wardlaw, 2016; Tietz et al., 1997) , have also been associated with increases in blood eosinophil counts. Fungal infections that cause allergic inflammation, such as coccidiomycosis, candidiasis, and aspergillosis (Wardlaw, 2016) , may also cause increases in blood eosinophil counts." ;
            <http://www.example.org/textHash>
                    "ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8" .
    
    <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Bone marrow suppression that involves the megakaryocytic lineage causes decreases in platelet production and therefore decreases in platelet counts. Bone marrow suppression may occur in association with infectious agents that can directly infect hematopoietic precursors such as immunodeficiency viruses in various species, parvoviruses, distemper virus in dogs, and feline leukemia virus in cats (Russell, 2010; Stockham and Scott, 2008c; Scaradavou, 2002) . Chronic ehrlichiosis in dogs has also been reported to cause bone marrow hypoplasia, although the mechanism remains unclear (Stockham and Scott, 2008c) . However, decreases in platelet counts attributable to infectious agents may have contributions from mechanisms other than bone marrow suppression, such as peripheral consumption or immune-mediated destruction. Hyperestrogenism associated with testicular or ovarian neoplasia may also cause general bone marrow suppression, and dogs appear to be particularly sensitive to this effect (Sontas et al., 2009) .\",\"cite_spans\":[{\"start\":397.0,\"end\":412.0,\"text\":\"(Russell, 2010;\",\"ref_id\":\"BIBREF329\"},{\"start\":413.0,\"end\":439.0,\"text\":\"Stockham and Scott, 2008c;\",\"ref_id\":\"BIBREF368\"},{\"start\":440.0,\"end\":457.0,\"text\":\"Scaradavou, 2002)\",\"ref_id\":\"BIBREF340\"},{\"start\":584.0,\"end\":611.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":997.0,\"end\":1018.0,\"text\":\"(Sontas et al., 2009)\",\"ref_id\":\"BIBREF364\"}],\"ref_spans\":[],\"section\":\"Decreased production\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-397-412> , <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-413-439> , <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-440-457> , <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-584-611> , <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-997-1018> ;
            <http://www.example.org/section>
                    "Decreased production" ;
            <http://www.example.org/text>  "Bone marrow suppression that involves the megakaryocytic lineage causes decreases in platelet production and therefore decreases in platelet counts. Bone marrow suppression may occur in association with infectious agents that can directly infect hematopoietic precursors such as immunodeficiency viruses in various species, parvoviruses, distemper virus in dogs, and feline leukemia virus in cats (Russell, 2010; Stockham and Scott, 2008c; Scaradavou, 2002) . Chronic ehrlichiosis in dogs has also been reported to cause bone marrow hypoplasia, although the mechanism remains unclear (Stockham and Scott, 2008c) . However, decreases in platelet counts attributable to infectious agents may have contributions from mechanisms other than bone marrow suppression, such as peripheral consumption or immune-mediated destruction. Hyperestrogenism associated with testicular or ovarian neoplasia may also cause general bone marrow suppression, and dogs appear to be particularly sensitive to this effect (Sontas et al., 2009) ." ;
            <http://www.example.org/textHash>
                    "0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814" .
    
    <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-797-817>
            <http://www.example.org/end>    "817.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "797.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016)" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-770-784>
            <http://www.example.org/end>    "784.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "770.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-493f1545be540d3d12b0266ca8ee354b7ce1849df49ad8a817bc889f6f06c8c1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Both acute and chronic inflammatory stimulation may result in increases in blood eosinophil counts along with increases in neutrophil, lymphocyte, and/or monocyte counts. However, inflammatory processes that stimulate primarily an eosinophil response may also occur. IL-5, eotaxin, and RANTES are cytokines and chemokines that selectively stimulate eosinophil responses (Sampson, 2000) . Some of the most common inflammatory processes involving eosinophils include parasite and allergy-induced inflammation.\",\"cite_spans\":[{\"start\":370.0,\"end\":385.0,\"text\":\"(Sampson, 2000)\",\"ref_id\":\"BIBREF335\"}],\"ref_spans\":[],\"section\":\"Inflammation and Hypersensitivity\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-493f1545be540d3d12b0266ca8ee354b7ce1849df49ad8a817bc889f6f06c8c1_citespan-370-385> ;
            <http://www.example.org/section>
                    "Inflammation and Hypersensitivity" ;
            <http://www.example.org/text>  "Both acute and chronic inflammatory stimulation may result in increases in blood eosinophil counts along with increases in neutrophil, lymphocyte, and/or monocyte counts. However, inflammatory processes that stimulate primarily an eosinophil response may also occur. IL-5, eotaxin, and RANTES are cytokines and chemokines that selectively stimulate eosinophil responses (Sampson, 2000) . Some of the most common inflammatory processes involving eosinophils include parasite and allergy-induced inflammation." ;
            <http://www.example.org/textHash>
                    "493f1545be540d3d12b0266ca8ee354b7ce1849df49ad8a817bc889f6f06c8c1" .
    
    <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-828-850>
            <http://www.example.org/end>    "850.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF272" ;
            <http://www.example.org/start>  "828.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Nakagawa et al., 1998)" .
    
    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-518-537>
            <http://www.example.org/end>    "537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF414" ;
            <http://www.example.org/start>  "518.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wald et al., 1991)" .
    
    <http://covid19.aksw.org/text-a9e3de87a343d2d7bbc238095e20193fb4ff0f3b9bbbfcefc7ae59563d97aa41>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Blood monocytes are distributed in both circulating and marginating pools, and marginating pool monocytes can emigrate into tissues. Circulating half-life of monocytes in mice has been reported to range from 24 to 60 h (Provencher Bolliger et al., 2010) . Macrophages and dendritic cells can arise from monocytes or monocyte precursors depending on the local tissue microenvironment and cytokine stimulation (Papenfuss, 2010) , forming the mononuclear phagocytic system.\",\"cite_spans\":[{\"start\":219.0,\"end\":253.0,\"text\":\"(Provencher Bolliger et al., 2010)\",\"ref_id\":\"BIBREF305\"},{\"start\":408.0,\"end\":425.0,\"text\":\"(Papenfuss, 2010)\",\"ref_id\":\"BIBREF289\"}],\"ref_spans\":[],\"section\":\"Monocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a9e3de87a343d2d7bbc238095e20193fb4ff0f3b9bbbfcefc7ae59563d97aa41_citespan-219-253> , <http://covid19.aksw.org/text-a9e3de87a343d2d7bbc238095e20193fb4ff0f3b9bbbfcefc7ae59563d97aa41_citespan-408-425> ;
            <http://www.example.org/section>
                    "Monocytes" ;
            <http://www.example.org/text>  "Blood monocytes are distributed in both circulating and marginating pools, and marginating pool monocytes can emigrate into tissues. Circulating half-life of monocytes in mice has been reported to range from 24 to 60 h (Provencher Bolliger et al., 2010) . Macrophages and dendritic cells can arise from monocytes or monocyte precursors depending on the local tissue microenvironment and cytokine stimulation (Papenfuss, 2010) , forming the mononuclear phagocytic system." ;
            <http://www.example.org/textHash>
                    "a9e3de87a343d2d7bbc238095e20193fb4ff0f3b9bbbfcefc7ae59563d97aa41" .
    
    <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-273-295>
            <http://www.example.org/end>    "295.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF211" ;
            <http://www.example.org/start>  "273.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lachant et al., 1983)" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1862-1886>
            <http://www.example.org/end>    "1886.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "1862.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008)" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-418-445>
            <http://www.example.org/end>    "445.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF178" ;
            <http://www.example.org/start>  "418.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Israel and Plaisance, 1991;" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-930-951>
            <http://www.example.org/end>    "951.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF182" ;
            <http://www.example.org/start>  "930.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Johnson et al., 1989" .
    
    <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-295-310>
            <http://www.example.org/end>    "310.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF140" ;
            <http://www.example.org/start>  "295.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gergely, 1999)" .
    
    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-278-305>
            <http://www.example.org/end>    "305.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF382" ;
            <http://www.example.org/start>  "278.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tefferi and Vardiman, 2009" .
    
    <http://covid19.aksw.org/text-8f8fd942e21b7a8cf047857798609b05ee05a9526878a93062221b93ea2918f6_citespan-316-331>
            <http://www.example.org/end>    "331.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Russell, 2010)" .
    
    <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-593-616>
            <http://www.example.org/end>    "616.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF98" ;
            <http://www.example.org/start>  "593.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Duchayne et al., 2003;" .
    
    <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-137-164>
            <http://www.example.org/end>    "164.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "137.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf_citespan-954-969>
            <http://www.example.org/end>    "969.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "954.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-991-1025>
            <http://www.example.org/end>    "1025.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF305" ;
            <http://www.example.org/start>  "991.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Provencher Bolliger et al., 2010)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-436-459>
            <http://www.example.org/end>    "459.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF55" ;
            <http://www.example.org/start>  "436.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cantrell et al., 1985)" .
    
    <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-250-276>
            <http://www.example.org/end>    "276.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "250.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016;" .
    
    <http://covid19.aksw.org/text-3d4d5e15aa12ec2e4bcf2359b511e1c7fb2c78e730c13ee45fc0f353aadd5ec1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Coagulation disorders may also be associated with either internal or external hemorrhage. Primary deficiencies in coagulation factors or von Willebrand factor may be inherited causes of hemorrhage. Deficiencies in coagulation factors that lead to hemorrhage sufficient to cause decreases in red cell mass include hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency); deficiencies in factor XI and von Willebrand factor are usually mild and are often not associated with notable hemorrhage (Bolton-Maggs and Pasi, 2003) . Hemorrhage may be secondary to marked decreases in platelet counts from consumptive coagulopathies secondary to infectious or neoplastic processes.\",\"cite_spans\":[{\"start\":514.0,\"end\":543.0,\"text\":\"(Bolton-Maggs and Pasi, 2003)\",\"ref_id\":\"BIBREF36\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3d4d5e15aa12ec2e4bcf2359b511e1c7fb2c78e730c13ee45fc0f353aadd5ec1_citespan-514-543> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Coagulation disorders may also be associated with either internal or external hemorrhage. Primary deficiencies in coagulation factors or von Willebrand factor may be inherited causes of hemorrhage. Deficiencies in coagulation factors that lead to hemorrhage sufficient to cause decreases in red cell mass include hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency); deficiencies in factor XI and von Willebrand factor are usually mild and are often not associated with notable hemorrhage (Bolton-Maggs and Pasi, 2003) . Hemorrhage may be secondary to marked decreases in platelet counts from consumptive coagulopathies secondary to infectious or neoplastic processes." ;
            <http://www.example.org/textHash>
                    "3d4d5e15aa12ec2e4bcf2359b511e1c7fb2c78e730c13ee45fc0f353aadd5ec1" .
    
    <http://covid19.aksw.org/text-c0d3fa2cc3ab5cb28628aa8dff473420c694a194a44c1c961fa8bcd62c5a2ca2_citespan-300-320>
            <http://www.example.org/end>    "320.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF441" ;
            <http://www.example.org/start>  "300.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Zhang et al., 2012)" .
    
    <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1152-1178>
            <http://www.example.org/end>    "1178.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "1152.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016)" .
    
    <http://covid19.aksw.org/text-23cf0d97732233f9cb434db3bca976b852c11b5dd4f9ac7fc8ac626246477ef8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Hemolysis in AIHA is largely attributable to extravascular hemolysis due to phagocytosis of antibody-bound erythrocytes by tissue macrophages. Macrophages or monocytes containing phagocytized erythrocytes may be rarely observed in blood smears of laboratory species with immune-mediated hemolysis. However, antibody-mediated complement activation or increased fragility of spherocytes may result in direct intravascular lysis or rupture of erythrocytes (Packman, 2016) . Evaluation of patients for the presence of antierythrocyte antibodies may be performed using the direct antiglobulin test (DAT; also called the Coombs\\u0027 test) or by flow cytometry.\",\"cite_spans\":[{\"start\":453.0,\"end\":468.0,\"text\":\"(Packman, 2016)\",\"ref_id\":\"BIBREF283\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-23cf0d97732233f9cb434db3bca976b852c11b5dd4f9ac7fc8ac626246477ef8_citespan-453-468> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Hemolysis in AIHA is largely attributable to extravascular hemolysis due to phagocytosis of antibody-bound erythrocytes by tissue macrophages. Macrophages or monocytes containing phagocytized erythrocytes may be rarely observed in blood smears of laboratory species with immune-mediated hemolysis. However, antibody-mediated complement activation or increased fragility of spherocytes may result in direct intravascular lysis or rupture of erythrocytes (Packman, 2016) . Evaluation of patients for the presence of antierythrocyte antibodies may be performed using the direct antiglobulin test (DAT; also called the Coombs' test) or by flow cytometry." ;
            <http://www.example.org/textHash>
                    "23cf0d97732233f9cb434db3bca976b852c11b5dd4f9ac7fc8ac626246477ef8" .
    
    <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-295-316>
            <http://www.example.org/end>    "316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF107" ;
            <http://www.example.org/start>  "295.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Everds et al., 2013a)" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-963-983>
            <http://www.example.org/end>    "983.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF287" ;
            <http://www.example.org/start>  "963.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Pandit et al., 2007;" .
    
    <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-629-651>
            <http://www.example.org/end>    "651.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF383" ;
            <http://www.example.org/start>  "629.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tefferi et al., 2006)" .
    
    <http://covid19.aksw.org/1c2ec5f7aa7133b58659aa5403e03f14da7ba1a1>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "1c2ec5f7aa7133b58659aa5403e03f14da7ba1a1" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-f023ed321326b573a95e1be1618f1ae74ee4531cc926bf8f2e03cb4cd97b8d15> , <http://covid19.aksw.org/text-98dd5c2311e47e22cc13fdd34d8a3c214499006634453f8deee2c2fb6de2dd0a> , <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9> , <http://covid19.aksw.org/text-56a0f2e8df0b15b9ab1fdb7042da21859a72d2664093d2ce78e85cdd7e657c3a> , <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752> , <http://covid19.aksw.org/text-9f0e0005a91e30bf4f7b2aff2b3613e745dc5598152597f98fc91563184fa2c2> , <http://covid19.aksw.org/text-1cee1201d51cee2d66f0e07a971d33bab94882ade852c0c1df1cfa734070aac2> , <http://covid19.aksw.org/text-751d89daa26136b44e24435ac5a8c5fd8c9cf08a3f6e3a627813fbd8c4b87395> , <http://covid19.aksw.org/text-c5bacbfeb28ebc4ebfdc3b08969d9f17630cf2dfe9150b66d40999b0b04f26e7> , <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8> , <http://covid19.aksw.org/text-d36f694c14f073282a61b380d6f3256e35435abc00cfe656741878bdbe5cc899> , <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327> , <http://covid19.aksw.org/text-780b3f5806516e494a9bc4119787e67993dc1289d84934a9f3e97f9ae7236320> , <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56> , <http://covid19.aksw.org/text-7620e8d701f01ae2e750c8591ccaab7792df89fbefbf4cbb8e616767325c120d> , <http://covid19.aksw.org/text-7789f6b5b1c581691095b1b4ed7cea4928c189deef5986618312746b363f38d0> , <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27> , <http://covid19.aksw.org/text-aec94e745e315f20a1a60e2301c5f7f3a05a9c7bbb45d68f464838ff3bb70fd1> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391> , <http://covid19.aksw.org/text-578bb563f947f04aba36cf955897ebe919ef4a1fb3cff88b984c5b2aea466a2d> , <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f> , <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d> , <http://covid19.aksw.org/text-bca6486c44a5db03fcc770e97f5e2cfefc89fc77474295dfa6532428d158c668> , <http://covid19.aksw.org/text-bfebf21d3ce3f1e4f5e1b69d4088520d4c887ba32ea1117478e403a83f6172b9> , <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134> , <http://covid19.aksw.org/text-60c02907d89fda325b632248d63349e3fb28fc19bf13553f740235beb86efd61> , <http://covid19.aksw.org/text-1976c7b56c655f36b2aafff6bee09c4b64676bd69a64375671e3f9152196f113> , <http://covid19.aksw.org/text-78314608b6253b19d35efaf82abe5c94e39d1a63dd2d7e6aa9fb00e98631ceb0> , <http://covid19.aksw.org/text-d76683337213c44f43b98a160d3d52137e06a3dfed9b8759d8b7dc67c7560610> , <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d> , <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85> , <http://covid19.aksw.org/text-3036ff66cb0166fbf5c444b5bf1490b2c1f19f403425cc4425fdfe69db0a9207> , <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6> , <http://covid19.aksw.org/text-3811430106d3b33bdc10f9fe4a6c69213a615def0d58ae74df4c0a2047eb4f78> , <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26> , <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8> , <http://covid19.aksw.org/text-be7daa4ac38811cdb3542af168715650f68fa8c4300243745b2e3a76126c3e1c> , <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742> , <http://covid19.aksw.org/text-0e49f86ebe42a035e301c530ebcbd55643657dc8672a42f82d962df46ea66136> , <http://covid19.aksw.org/text-7a88a621bbdc456272482052985a0ce35f94970e96830d4ba08da4046708a0d0> , <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524> , <http://covid19.aksw.org/text-72cdd5f94494b2a9146ad2ed2793e599c748523abfad265e2a0a6c42abddf0c1> , <http://covid19.aksw.org/text-f6a032c5737c6d45ad4c6b636bc6ceb2465afd3568393b4b1c32e6d291b1e188> , <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a> , <http://covid19.aksw.org/text-bc5ee5d2be8cfdc89d4ff440d22aa596ad61641b67bce05c8c8dfba0b001d918> , <http://covid19.aksw.org/text-eea77246941ec41158fc31c1e8da0e727784adb3f4088df6ac0341deae0afec3> , <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665> , <http://covid19.aksw.org/text-eb67ed6d92a5dc594599d4d70e71f77d4266e98ed832c9cb4b58d799cb77d0d8> , <http://covid19.aksw.org/text-7ce91b5d88a952a93486bc590d8c2a609f8ca2dff061dc46c947488babf003db> , <http://covid19.aksw.org/text-3d4d5e15aa12ec2e4bcf2359b511e1c7fb2c78e730c13ee45fc0f353aadd5ec1> , <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb> , <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1> , <http://covid19.aksw.org/text-c0d3fa2cc3ab5cb28628aa8dff473420c694a194a44c1c961fa8bcd62c5a2ca2> , <http://covid19.aksw.org/text-0b708d860d23383562843f1ea6ff8dd0f6b9b8eba2fe7038b0d010967b009254> , <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac> , <http://covid19.aksw.org/text-0454039d5f7a9b1e880a4cb7e700a8efebdf3c913a68373e3338db32fe3e38fd> , <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0> , <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3> , <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8> , <http://covid19.aksw.org/text-23cf0d97732233f9cb434db3bca976b852c11b5dd4f9ac7fc8ac626246477ef8> , <http://covid19.aksw.org/text-97437d25fdc1f555b92e0d94ecfe324afc8334e48c0dbf16441695695f9c14e1> , <http://covid19.aksw.org/text-9ea5c9661a1c734f64c55c3bcfa8bb5f955002f60fc9834f926d2e2725abe9dd> , <http://covid19.aksw.org/text-278a7692539e67a6b59f5e078344d33cd28efae2f6855def8a2903ee108c73a3> , <http://covid19.aksw.org/text-3258a0d9e14436c75440e6c79714da9317db0dfa08bd7bfb81e6a197b691839c> , <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca> , <http://covid19.aksw.org/text-76ae2d6ca8ab514658fa40f52f143a6617c592a7222c70174c4eadbb87bc83d0> , <http://covid19.aksw.org/text-7618637eeccb25855a1c7ee52f9f959095f18ae5a2e4d9f9bea627d7777a9c39> , <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef> , <http://covid19.aksw.org/text-bda048633fce0c56cbf4fe713ee5ed0d8bf64bc5d145f476592e1b650ccec657> , <http://covid19.aksw.org/text-e00276642f98e38aaf9181b63151df55bf2ba44f53c344836578f081ef7b09b0> , <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64> , <http://covid19.aksw.org/text-7638c46ced28b43f8526452094bc66c63ae9064ea8c32529ce25e5d7dbdbd9a3> , <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554> , <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b> , <http://covid19.aksw.org/text-c7bace5d441d31937758320dba311320591bcce623f8782c5276211fc1e86ba8> , <http://covid19.aksw.org/text-743a792f7630acee9819c0a354a3214d5ae436ce038edd0aeda874ceaebf3e4b> , <http://covid19.aksw.org/text-f93d23cc1a6f34d35e3d9cf585b6e04a601d6efc9c2f5f0d659375671f3e2d85> , <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d> , <http://covid19.aksw.org/text-2a908d0d4623487ba40e2414d65ee9f35edac83c6e0ed481c79ebd0a8d8be52c> , <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2> , <http://covid19.aksw.org/text-2a3827d5ce8ef2d06ea4cd316032a1af4c8ef3f615ba8cef9c3357b05957533f> , <http://covid19.aksw.org/text-e0ad55de38a56e69df45a6f909c6c65f5f4b6e1648ba0bc8f951b521fcda41a4> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0> , <http://covid19.aksw.org/text-d81e8754bc58cb98079215f382535974334e5d39476c34ea4e95210665de095c> , <http://covid19.aksw.org/text-637cc8e7dab553f631863f3d8bd0974754c2cedecd28416fb0376c44a3d3ad0c> , <http://covid19.aksw.org/text-4b3341a78d894bff5627a3a6590b134ad5e5d6333eb9c8098c2660a4c029cec0> , <http://covid19.aksw.org/text-e449d4cc4436247430597c6799e77b64e4de0cbe16c25767f477a87d32b75b5e> , <http://covid19.aksw.org/text-54b088a38add774b695a530442ee730df63239c7224176518f4b94ca1ee21cb8> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288> , <http://covid19.aksw.org/text-902e2456e15608fa100a9e4923efb472be38b7e4e71711e0098f8ed31af9e65c> , <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814> , <http://covid19.aksw.org/text-3f32cade925e042651afc56e04b509f2316269ed5c8809d0430af83259a01db8> , <http://covid19.aksw.org/text-c670f2de35ba9759a8a122d329789d668719649a30d3b1c14343e4ad704efd2a> , <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f> , <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6> , <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2> , <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6> , <http://covid19.aksw.org/text-85d317d9adb88c5e2078cc794f8a40830c8d6f6f93d1e406a652af2800fd9d04> , <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009> , <http://covid19.aksw.org/text-b0b0914e794177ac9a2bf2c2393376fc604f3e797e9173978923b4fafa399b03> , <http://covid19.aksw.org/text-139543a0beb5bc7e2148653faf8edfe56734a6e4b6f6ab9f95cf4d93abd2d865> , <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406> , <http://covid19.aksw.org/text-5e4546534a5d189da5bd97fc69c0932066c5a7f9acb6b34bfa6224166ebe7bf7> , <http://covid19.aksw.org/text-23ae1ce221485560bd3e59a19208ab77a3a0963d9b5c14ed04c87ce9ca5b621d> , <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812> , <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a> , <http://covid19.aksw.org/text-cbe52974c1390ba965e9d546ee5be42f2f4810f69074746a13c9e7489d48f9a7> , <http://covid19.aksw.org/text-aac8e0a7af1b85b1efee352e4b0f00e92ab89380289eec23e06045781c8cb633> , <http://covid19.aksw.org/text-a1d3748d4858de2185ca589f0c4ab13bf30f27253f0634ddddba54401816fbef> , <http://covid19.aksw.org/text-967d2eb15c9e1d06b64697f52167174ec1a820f577e8b1605468514104f006e0> , <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3> , <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0> , <http://covid19.aksw.org/text-dde22cd214cfadfb61478d4463b64027c1c7d27bd81cacb79e6c9b321f223308> , <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6> , <http://covid19.aksw.org/text-d3bdd73863d7f4816bb77573a61ef70c66182608850c44703f41e05118198faa> , <http://covid19.aksw.org/text-88d5f1e89d130c7b951cf60cfd39f7ee8fc36d8a9880022cd78817537f471659> , <http://covid19.aksw.org/text-2bc22939fa9c83241c94ce75de8823815c263a5f365c49370a8c4eda656aa8d1> , <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d> , <http://covid19.aksw.org/text-5fbc1cd80b0aa20f4f8a16f775bdc97ebbddbbcbb413367c7f8c00cd2985ed9c> , <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526> , <http://covid19.aksw.org/text-e1658ee2b33276e9e49974c13439ca773d1fdb159e797793c40a7b5f7d09d8c3> , <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4> , <http://covid19.aksw.org/text-a6352b6bc2547a312d7257486b51a2c87ccd7694aa98ea69b6323affa47c24fa> , <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877> , <http://covid19.aksw.org/text-8c3262e1180356c69c49cf70efd69d4d08d29082804a03fc27e1c319954608d0> , <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958> , <http://covid19.aksw.org/text-d72313bfa628dbe99402abd17f6bc00942b142ab812f7a6d73ea2b33ed39a462> , <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd> , <http://covid19.aksw.org/text-c7727161c8174f11cfe6fe81738511813b4fe33eb1406f470c1812b71354f584> , <http://covid19.aksw.org/text-c6bea817b877dd7041815289e97330a98c5a59ead3508298824c5ba1054d54fd> , <http://covid19.aksw.org/text-886a10703ee186646c1fcef132a95376cda2fd0abf66e04049f8c8a7ccc1629f> , <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf> , <http://covid19.aksw.org/text-3afe5b856a4c8a03b0602286440a7f242a6f04b3d42aadf8f7a2c7246e27d680> , <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21> , <http://covid19.aksw.org/text-76d865d10df7e69d5efe4aba052c98cdf3b7530a48849e47a9639b4b7f492add> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209> , <http://covid19.aksw.org/text-8dbb32dd29a2a8f1dbff8134ae449f90f190d55cc97a4c05b320481151e5ea42> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470> , <http://covid19.aksw.org/text-c99e2327ae10204accb68af3ee1a5ca63c0ad5b73b9bbef2d5f58fede27c640e> , <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93> , <http://covid19.aksw.org/text-909c9c5eaff4e7acc700f5066a9caba8f528de86e4af74de7e0298e4a74666ca> , <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa> , <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264> , <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97> , <http://covid19.aksw.org/text-0391ba59f3f7d1614586fbe4d2286f2eab685a2438ab645a91bd604e72e604eb> , <http://covid19.aksw.org/text-44e5305a92acd0b2f8c470d071bc3b59ca64a12d13ca4aeb540f61059fc63239> , <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf> , <http://covid19.aksw.org/text-9ec8d3a6972b4586c31358667004b68ef3d9b87327385a8c7b00e7bbc8398f9f> , <http://covid19.aksw.org/text-4049be250cd9beb5d7a7373e3292efb1091b70412e16d78b4ef1b106f11ef50c> , <http://covid19.aksw.org/text-ea2b8933d4899def7c648403d9eebd55102354ddcb399ecd31ccb2521283a73f> , <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14> , <http://covid19.aksw.org/text-5c13e5b358dba2e3bdfaba0cd2adbde14a42a90fcdf718971850a7bb3e25439d> , <http://covid19.aksw.org/text-a7b72cb8b96d38f267c1d1546d21b9e85285123f33144f92dcf69596b96495a0> , <http://covid19.aksw.org/text-e4132140be206c250a772e29ab0282ef8e1da49127040db47873205f52615e86> , <http://covid19.aksw.org/text-73c0aead69c5ef6509f5402451b25224c5f4d577caefe7c77c73d4d9c480f4ef> , <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93> , <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14> , <http://covid19.aksw.org/text-51c0ab88385306e0f244df7660c7398263eafffd1178eb05ed2bbf9e5764bbc6> , <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777> , <http://covid19.aksw.org/text-71290b1bed9714f92a3d63866c4bd78006f87156d56c3ce8d35a4fa5a3b18075> , <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd> , <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209> , <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b> , <http://covid19.aksw.org/text-8ea81bf30129fd1375e74cf814628263adf7f1b1b44233480b7ee68eee39e56f> , <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b> , <http://covid19.aksw.org/text-8f8fd942e21b7a8cf047857798609b05ee05a9526878a93062221b93ea2918f6> , <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0> , <http://covid19.aksw.org/text-9032a3b671b9e8104171a5f76864960d55d8efd5c8fd99334756484cfb25992c> , <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3> , <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b> , <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb> , <http://covid19.aksw.org/text-e15d44d7bd31a3608f2d13172db9fa5994484d66adb5800b9b6320a5abf351cc> , <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34> , <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f> , <http://covid19.aksw.org/text-ed051e9f6774e0d5381f7678308045e772eabafe6558f59d86a9b70ba18060b2> , <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356> , <http://covid19.aksw.org/text-e277dd21a7e5f047e14c054f345417186c14db5ede6fe4166051863434455442> , <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08> , <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe> , <http://covid19.aksw.org/text-da02dd2d4020683e33331a78209d8ac3a590970addef3219c2a74f17b759624d> , <http://covid19.aksw.org/text-ad18adb1056860822e1b6893452b36cd128be85185e11bf75e451770e39a83ef> , <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe> , <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c> , <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f> , <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336> , <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3> , <http://covid19.aksw.org/text-b124d38870179659c047325ddb815425ab0807ba7d7dba5e5c1223d88cf41739> , <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1> , <http://covid19.aksw.org/text-b83e8da7e6c671ee51c7a848fc934132e9d4529e199bc1521f9bdf967d815125> , <http://covid19.aksw.org/text-40b8fd1bfe0a01b9ed22c817d599d2719ae9858789b58c2898ec32bd3f007a96> , <http://covid19.aksw.org/text-b53c45de97c3cc1cf8b9363deec238fc77692ee62406b848905f438d0a261556> , <http://covid19.aksw.org/text-92c461c375482ace1b71ff6efb582798ba184ef012d9c7ad4bca5921eb14e96a> , <http://covid19.aksw.org/text-493f1545be540d3d12b0266ca8ee354b7ce1849df49ad8a817bc889f6f06c8c1> , <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb> , <http://covid19.aksw.org/text-40543c581215d7f87d33a4c7dd8405ccc84f1bb5781ac6e73da8b536ed809c7a> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9> , <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea> , <http://covid19.aksw.org/text-67c3b9afb16f69513b2fcce7c0299a2a50443437bd449ba58c1790075143280e> , <http://covid19.aksw.org/text-14d4f54fbe70d0841956c98998b1a8984b4517f8d3811792b229e1fba07a164c> , <http://covid19.aksw.org/text-87d6d638388562b95fbc55da7ce6df6bd68f432a8460cfeaa74c532cab4f720f> , <http://covid19.aksw.org/text-16fb03654ef27bcdfa4524634bbba70daf47abd7f4915ec969ab2fc2bad90e92> , <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e> , <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0> , <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506> , <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2> , <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac> , <http://covid19.aksw.org/text-785b73145229f779ccc708abba95ba933ebe1586d9382ea1a94a5992de5d39f8> , <http://covid19.aksw.org/text-a9e3de87a343d2d7bbc238095e20193fb4ff0f3b9bbbfcefc7ae59563d97aa41> , <http://covid19.aksw.org/text-663afa110a1b6f3e53d05e97ed483ebb68a3d70eb7aeb52cb3b58f8d3f1f6f38> , <http://covid19.aksw.org/text-2252bb39c3ba663ece825638d176ed9cf503dec74ead8f47fa402a1e7de6e486> , <http://covid19.aksw.org/text-92b5a29b064c99b374b26a0994786b872453b383774723a554d534b6030cc521> , <http://covid19.aksw.org/text-d281241fc64906aa25de49f69e81785af3ba0430e987b507ba327ffcbecf28d3> , <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080> , <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3> , <http://covid19.aksw.org/text-aa1e25105c9cb7851d59cc0c1f83acdc572de8ad6a5c21e403ef2524dd55f7cc> , <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888> , <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e> , <http://covid19.aksw.org/text-6b427ca71ed891381eb50cbc3831b102c8bb85bbad384aedcbd5d00312ebecba> , <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f> , <http://covid19.aksw.org/text-d6c5467de186713eaeeff06111e2cd5f0d0b688570bba87110dfd6d9f4905072> , <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3> , <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf> , <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c> , <http://covid19.aksw.org/text-853414940fd98336894a4fdef7c1a88d828e59a87b6dedb2ece77adf00fb37ae> , <http://covid19.aksw.org/text-79d5674a824b477e14e92262ee9f36603a7ca26d9f5a9af77cb5523f1178518a> , <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c> , <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6> , <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181> , <http://covid19.aksw.org/text-31f0029b5072968918d01e306f6809738749b5340f5bfdc82de3a3ead0a60d4f> , <http://covid19.aksw.org/text-d0db80cae51c5a85eaf17c20b4fa36a06b7bbe6588f5a332563688880f336be1> , <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f> .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-520-543>
            <http://www.example.org/end>    "543.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF243" ;
            <http://www.example.org/start>  "520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Marchetti et al., 2005;" .
    
    <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1387-1406>
            <http://www.example.org/end>    "1406.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF272" ;
            <http://www.example.org/start>  "1387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Myers et al., 2000)" .
    
    <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.1 Increases in neutrophil counts (neutrophilia, granulocytosis) 12.11.2.1.1.1 Catecholamine-induced Acute, transient increases (typically \\u003c 1 h) in neutrophil counts that are mild (typically increases of twofold or less) can occur in response to endogenous catecholamine stimulation (e.g., epinephrine), and are accompanied by increases in other blood leukocyte counts (physiologic leukocytosis). Increases in circulating catecholamines are commonly associated with excitement, fear, or exercise, and at times are referred to as acute stress. Increases in neutrophil counts secondary to catecholamine stimulation are mostly attributable to a shift in neutrophils from the marginating pool to the circulating pool, resulting in increased numbers of freely flowing neutrophils captured during blood sampling, and may occur through decreased expression of leukocyte adhesion molecules and potentially from increased blood flow and shear forces (Foster et al., 1986; Benschop et al., 1996; Stockham and Scott, 2008a; Everds et al., 2013a) . Splenic contraction resulting in redistribution of sequestered neutrophils to circulation also contributes. Mechanisms by which exogenous catecholamines and adrenergic agents cause increases in blood neutrophil counts are the same as those described for endogenous catecholamine stimulation.\",\"cite_spans\":[{\"start\":951.0,\"end\":972.0,\"text\":\"(Foster et al., 1986;\",\"ref_id\":\"BIBREF120\"},{\"start\":973.0,\"end\":995.0,\"text\":\"Benschop et al., 1996;\",\"ref_id\":\"BIBREF25\"},{\"start\":996.0,\"end\":1022.0,\"text\":\"Stockham and Scott, 2008a;\",\"ref_id\":\"BIBREF366\"},{\"start\":1023.0,\"end\":1044.0,\"text\":\"Everds et al., 2013a)\",\"ref_id\":\"BIBREF107\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-951-972> , <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-973-995> , <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-996-1022> , <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-1023-1044> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "12.11.2.1.1 Increases in neutrophil counts (neutrophilia, granulocytosis) 12.11.2.1.1.1 Catecholamine-induced Acute, transient increases (typically < 1 h) in neutrophil counts that are mild (typically increases of twofold or less) can occur in response to endogenous catecholamine stimulation (e.g., epinephrine), and are accompanied by increases in other blood leukocyte counts (physiologic leukocytosis). Increases in circulating catecholamines are commonly associated with excitement, fear, or exercise, and at times are referred to as acute stress. Increases in neutrophil counts secondary to catecholamine stimulation are mostly attributable to a shift in neutrophils from the marginating pool to the circulating pool, resulting in increased numbers of freely flowing neutrophils captured during blood sampling, and may occur through decreased expression of leukocyte adhesion molecules and potentially from increased blood flow and shear forces (Foster et al., 1986; Benschop et al., 1996; Stockham and Scott, 2008a; Everds et al., 2013a) . Splenic contraction resulting in redistribution of sequestered neutrophils to circulation also contributes. Mechanisms by which exogenous catecholamines and adrenergic agents cause increases in blood neutrophil counts are the same as those described for endogenous catecholamine stimulation." ;
            <http://www.example.org/textHash>
                    "97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf" .
    
    <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-265-280>
            <http://www.example.org/end>    "280.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "265.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-4049be250cd9beb5d7a7373e3292efb1091b70412e16d78b4ef1b106f11ef50c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Infection of humans with Mycoplasma pneumoniae has also been associated with hemolytic decreases in red cell mass, although most cases of M. pneumoniae infection are asymptomatic. Hemolysis with this organism is attributable to stimulation of autoimmune erythrocyte destruction with agglutination of erythrocytes (Khan and Yassin, 2009) .\",\"cite_spans\":[{\"start\":313.0,\"end\":336.0,\"text\":\"(Khan and Yassin, 2009)\",\"ref_id\":\"BIBREF201\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4049be250cd9beb5d7a7373e3292efb1091b70412e16d78b4ef1b106f11ef50c_citespan-313-336> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Infection of humans with Mycoplasma pneumoniae has also been associated with hemolytic decreases in red cell mass, although most cases of M. pneumoniae infection are asymptomatic. Hemolysis with this organism is attributable to stimulation of autoimmune erythrocyte destruction with agglutination of erythrocytes (Khan and Yassin, 2009) ." ;
            <http://www.example.org/textHash>
                    "4049be250cd9beb5d7a7373e3292efb1091b70412e16d78b4ef1b106f11ef50c" .
    
    <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Other miscellaneous causes of inflammatory increases in blood basophil counts include ulcerative colitis (Juhlin, 1963a) , the systemic mast cell disorder urticaria pigmentosa (Asboe-Hansen, 1960), juvenile rheumatoid arthritis (Athreya et al., 1975) , and immunological responses causing acute rejection of some tissue grafts (Tikkanen et al., 2001) .\",\"cite_spans\":[{\"start\":105.0,\"end\":120.0,\"text\":\"(Juhlin, 1963a)\",\"ref_id\":\"BIBREF187\"},{\"start\":228.0,\"end\":250.0,\"text\":\"(Athreya et al., 1975)\",\"ref_id\":\"BIBREF13\"},{\"start\":327.0,\"end\":350.0,\"text\":\"(Tikkanen et al., 2001)\",\"ref_id\":\"BIBREF391\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f_citespan-105-120> , <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f_citespan-228-250> , <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f_citespan-327-350> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "Other miscellaneous causes of inflammatory increases in blood basophil counts include ulcerative colitis (Juhlin, 1963a) , the systemic mast cell disorder urticaria pigmentosa (Asboe-Hansen, 1960), juvenile rheumatoid arthritis (Athreya et al., 1975) , and immunological responses causing acute rejection of some tissue grafts (Tikkanen et al., 2001) ." ;
            <http://www.example.org/textHash>
                    "044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-627-648>
            <http://www.example.org/end>    "648.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF164" ;
            <http://www.example.org/start>  "627.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Handa and Sato, 1975;" .
    
    <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-492-504>
            <http://www.example.org/end>    "504.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF162" ;
            <http://www.example.org/start>  "492.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hall, 2013)" .
    
    <http://covid19.aksw.org/text-0391ba59f3f7d1614586fbe4d2286f2eab685a2438ab645a91bd604e72e604eb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.1.2 Oxidative Another major cause of decreases in red cell mass due to hemolysis is oxidative damage to erythrocytes. Under normal conditions, ferrous iron (Fe 2 þ ) in hemoglobin binds to and dissociates from oxygen as it delivers oxygen from the lungs to the tissues. At times, this binding and dissociation results in the formation of ferric iron (Fe 3 þ ) in hemoglobin (methemoglobin) as well as superoxide (O 2 À ). Superoxide is a free radical with potent oxidative capacity that may cause cellular damage. Cytochrome b 5 -reductase is an intraerythrocytic enzyme that converts methemoglobin back to hemoglobin. Superoxide dismutase converts superoxide to hydrogen peroxide (H 2 O 2 ), which also may produce oxidative damage to cells. Further metabolism of hydrogen peroxide by catalase or glutathione peroxidase protects cells from oxidative damage. These pathways are usually sufficient to address the normal low-level formation of methemoglobin and superoxide, but methemoglobin can increase and impair delivery of oxygen to tissues and superoxide can accumulate and cause oxidative damage if these pathways are overwhelmed or defective. Oxidative damage to erythrocytes may affect the lipid membranes, cytoskeleton, or hemoglobin. Peroxidation of internal membrane lipids or cytoskeletal components of erythrocytes results in the fusion of portions of the membrane with consequent shifting of the cytoplasm and hemoglobin to one side of the cells. Erythrocytes with this morphologic change are called eccentrocytes. Oxidative damage that causes the formation of eccentrocytes may result in hemolysis due to increased clearance of eccentrocytes by splenic macrophages due to trapping of rigid erythrocytes in splenic sinusoids or spontaneous rupture in blood due to the increased fragility of eccentrocytes (Stockham and Scott, 2008b) .\",\"cite_spans\":[{\"start\":1830.0,\"end\":1857.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0391ba59f3f7d1614586fbe4d2286f2eab685a2438ab645a91bd604e72e604eb_citespan-1830-1857> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.1.2 Oxidative Another major cause of decreases in red cell mass due to hemolysis is oxidative damage to erythrocytes. Under normal conditions, ferrous iron (Fe 2 þ ) in hemoglobin binds to and dissociates from oxygen as it delivers oxygen from the lungs to the tissues. At times, this binding and dissociation results in the formation of ferric iron (Fe 3 þ ) in hemoglobin (methemoglobin) as well as superoxide (O 2 À ). Superoxide is a free radical with potent oxidative capacity that may cause cellular damage. Cytochrome b 5 -reductase is an intraerythrocytic enzyme that converts methemoglobin back to hemoglobin. Superoxide dismutase converts superoxide to hydrogen peroxide (H 2 O 2 ), which also may produce oxidative damage to cells. Further metabolism of hydrogen peroxide by catalase or glutathione peroxidase protects cells from oxidative damage. These pathways are usually sufficient to address the normal low-level formation of methemoglobin and superoxide, but methemoglobin can increase and impair delivery of oxygen to tissues and superoxide can accumulate and cause oxidative damage if these pathways are overwhelmed or defective. Oxidative damage to erythrocytes may affect the lipid membranes, cytoskeleton, or hemoglobin. Peroxidation of internal membrane lipids or cytoskeletal components of erythrocytes results in the fusion of portions of the membrane with consequent shifting of the cytoplasm and hemoglobin to one side of the cells. Erythrocytes with this morphologic change are called eccentrocytes. Oxidative damage that causes the formation of eccentrocytes may result in hemolysis due to increased clearance of eccentrocytes by splenic macrophages due to trapping of rigid erythrocytes in splenic sinusoids or spontaneous rupture in blood due to the increased fragility of eccentrocytes (Stockham and Scott, 2008b) ." ;
            <http://www.example.org/textHash>
                    "0391ba59f3f7d1614586fbe4d2286f2eab685a2438ab645a91bd604e72e604eb" .
    
    <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-281-307>
            <http://www.example.org/end>    "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "281.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-ea2b8933d4899def7c648403d9eebd55102354ddcb399ecd31ccb2521283a73f_citespan-342-369>
            <http://www.example.org/end>    "369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-c7bace5d441d31937758320dba311320591bcce623f8782c5276211fc1e86ba8_citespan-280-306>
            <http://www.example.org/end>    "306.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "280.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1102-1122>
            <http://www.example.org/end>    "1122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF435" ;
            <http://www.example.org/start>  "1102.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Yamato et al., 2005;" .
    
    <http://covid19.aksw.org/text-85d317d9adb88c5e2078cc794f8a40830c8d6f6f93d1e406a652af2800fd9d04_citespan-463-490>
            <http://www.example.org/end>    "490.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1019-1035>
            <http://www.example.org/end>    "1035.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "1019.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1775-1794>
            <http://www.example.org/end>    "1794.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF72" ;
            <http://www.example.org/start>  "1775.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cines et al., 2009)" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1093-1118>
            <http://www.example.org/end>    "1118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF245" ;
            <http://www.example.org/start>  "1093.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mariani and Fulton, 2001;" .
    
    <http://covid19.aksw.org/text-60c02907d89fda325b632248d63349e3fb28fc19bf13553f740235beb86efd61_citespan-194-211>
            <http://www.example.org/end>    "211.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF289" ;
            <http://www.example.org/start>  "194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Papenfuss, 2010)" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-486-511>
            <http://www.example.org/end>    "511.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF147" ;
            <http://www.example.org/start>  "486.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gleich and Hartmann, 2009" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Paraneoplastic increases in basophil counts have been associated with several neoplastic processes, including disseminated mast cell neoplasia (Schultze, 2010; Stockham and Scott, 2008a ) and carcinomas (Galli et al., 2016) . Increases in blood basophil counts may also be observed with lymphomatoid granulomatosis (Schultze, 2010; Stockham and Scott, 2008a) , and myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (Galli et al., 2016; Stockham and Scott, 2008a) .\",\"cite_spans\":[{\"start\":143.0,\"end\":159.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":160.0,\"end\":185.0,\"text\":\"Stockham and Scott, 2008a\",\"ref_id\":\"BIBREF366\"},{\"start\":203.0,\"end\":223.0,\"text\":\"(Galli et al., 2016)\",\"ref_id\":\"BIBREF128\"},{\"start\":315.0,\"end\":331.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":332.0,\"end\":358.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":476.0,\"end\":496.0,\"text\":\"(Galli et al., 2016;\",\"ref_id\":\"BIBREF128\"},{\"start\":497.0,\"end\":523.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-203-223> , <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-332-358> , <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-143-159> , <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-315-331> , <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-476-496> , <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-497-523> , <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-160-185> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "Paraneoplastic increases in basophil counts have been associated with several neoplastic processes, including disseminated mast cell neoplasia (Schultze, 2010; Stockham and Scott, 2008a ) and carcinomas (Galli et al., 2016) . Increases in blood basophil counts may also be observed with lymphomatoid granulomatosis (Schultze, 2010; Stockham and Scott, 2008a) , and myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (Galli et al., 2016; Stockham and Scott, 2008a) ." ;
            <http://www.example.org/textHash>
                    "0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-224-242>
            <http://www.example.org/end>    "242.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF275" ;
            <http://www.example.org/start>  "224.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Notarangelo, 2010;" .
    
    <http://covid19.aksw.org/text-1cee1201d51cee2d66f0e07a971d33bab94882ade852c0c1df1cfa734070aac2_citespan-353-368>
            <http://www.example.org/end>    "368.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "353.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Russell, 2010;" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-357-370>
            <http://www.example.org/end>    "370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF401" ;
            <http://www.example.org/start>  "357.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Valent, 2009" .
    
    <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-681-697>
            <http://www.example.org/end>    "697.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF134" ;
            <http://www.example.org/start>  "681.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Garratty, 2010;" .
    
    <http://covid19.aksw.org/text-7620e8d701f01ae2e750c8591ccaab7792df89fbefbf4cbb8e616767325c120d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Clinically, increases in neutrophil counts above expected values in health (usually conveyed in a reference interval) may be referred to as neutrophilia or granulocytosis, while decreases in neutrophil counts may be called neutropenia, granulocytopenia, or, if severe, agranulocytosis. However, in nonclinical toxicology studies, the convention is to not use such clinical terminology to describe alterations caused by a test article. Referring to changes as increases or decreases in neutrophil counts is the standard for nonclinical toxicology studies, and this terminology is used throughout this article. However, clinical terms are also provided for reference.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Clinically, increases in neutrophil counts above expected values in health (usually conveyed in a reference interval) may be referred to as neutrophilia or granulocytosis, while decreases in neutrophil counts may be called neutropenia, granulocytopenia, or, if severe, agranulocytosis. However, in nonclinical toxicology studies, the convention is to not use such clinical terminology to describe alterations caused by a test article. Referring to changes as increases or decreases in neutrophil counts is the standard for nonclinical toxicology studies, and this terminology is used throughout this article. However, clinical terms are also provided for reference." ;
            <http://www.example.org/textHash>
                    "7620e8d701f01ae2e750c8591ccaab7792df89fbefbf4cbb8e616767325c120d" .
    
    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.1.3.1 Polycythemia vera Polycythemia vera is categorized as a chronic myeloproliferative disorder. Neoplastic transformation, from an acquired somatic mutation (Prchal, 2016) , of a hematopoietic progenitor cell results in clonal and autonomous expansion of hematopoietic cells, including erythrocytes. Eventually the clonal expansion is sufficient to suppress normal hematopoiesis . Increases in red cell mass are the prototypical findings, but concurrent increases in leukocyte and platelet counts that arise from the neoplastic clone are often also be observed in people (Pearson, 2001) , although these findings are typically not observed in dogs or cats (Randolph et al., 2010) . The most common causative somatic mutation of polycythemia vera in humans is a mutation of JAK2, a kinase that plays a role in intracellular proliferative signaling (Prchal, 2016) . However, forms of polycythemia vera or \\\"idiopathic erythrocytosis\\\" without JAK2 mutations have been observed and associated with mutations in lymphocyte-specific adaptor protein (LNK) that inhibits JAK2 phosphorylation (Lasho et al., 2010) . Serum EPO concentrations are expected to be low in patients with polycythemia vera. In domestic dogs and cats, middle-aged female dogs and male cats tend to be most commonly affected (Randolph et al., 2010) .\",\"cite_spans\":[{\"start\":168.0,\"end\":182.0,\"text\":\"(Prchal, 2016)\",\"ref_id\":\"BIBREF302\"},{\"start\":582.0,\"end\":597.0,\"text\":\"(Pearson, 2001)\",\"ref_id\":\"BIBREF293\"},{\"start\":667.0,\"end\":690.0,\"text\":\"(Randolph et al., 2010)\",\"ref_id\":\"BIBREF313\"},{\"start\":858.0,\"end\":872.0,\"text\":\"(Prchal, 2016)\",\"ref_id\":\"BIBREF302\"},{\"start\":1094.0,\"end\":1114.0,\"text\":\"(Lasho et al., 2010)\",\"ref_id\":\"BIBREF216\"},{\"start\":1300.0,\"end\":1323.0,\"text\":\"(Randolph et al., 2010)\",\"ref_id\":\"BIBREF313\"}],\"ref_spans\":[],\"section\":\"Primary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-1094-1114> , <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-858-872> , <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-168-182> , <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-1300-1323> , <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-582-597> , <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-667-690> ;
            <http://www.example.org/section>
                    "Primary increases in red cell mass" ;
            <http://www.example.org/text>  "12.11.3.1.3.1 Polycythemia vera Polycythemia vera is categorized as a chronic myeloproliferative disorder. Neoplastic transformation, from an acquired somatic mutation (Prchal, 2016) , of a hematopoietic progenitor cell results in clonal and autonomous expansion of hematopoietic cells, including erythrocytes. Eventually the clonal expansion is sufficient to suppress normal hematopoiesis . Increases in red cell mass are the prototypical findings, but concurrent increases in leukocyte and platelet counts that arise from the neoplastic clone are often also be observed in people (Pearson, 2001) , although these findings are typically not observed in dogs or cats (Randolph et al., 2010) . The most common causative somatic mutation of polycythemia vera in humans is a mutation of JAK2, a kinase that plays a role in intracellular proliferative signaling (Prchal, 2016) . However, forms of polycythemia vera or \"idiopathic erythrocytosis\" without JAK2 mutations have been observed and associated with mutations in lymphocyte-specific adaptor protein (LNK) that inhibits JAK2 phosphorylation (Lasho et al., 2010) . Serum EPO concentrations are expected to be low in patients with polycythemia vera. In domestic dogs and cats, middle-aged female dogs and male cats tend to be most commonly affected (Randolph et al., 2010) ." ;
            <http://www.example.org/textHash>
                    "69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c" .
    
    <http://covid19.aksw.org/text-743a792f7630acee9819c0a354a3214d5ae436ce038edd0aeda874ceaebf3e4b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-induced increases in red cell mass are uncommon. Administration of recombinant erythropoietin and anabolic steroids has been reported to cause increases in red cell mass (Mintzer et al., 2009) . For example, increases in red cell mass have been associated with testosterone administration (Gardner et al., 1968) . Theoretically, excess administration of thyroid hormones could also cause increases in red cell mass.\",\"cite_spans\":[{\"start\":181.0,\"end\":203.0,\"text\":\"(Mintzer et al., 2009)\",\"ref_id\":\"BIBREF261\"},{\"start\":300.0,\"end\":322.0,\"text\":\"(Gardner et al., 1968)\",\"ref_id\":\"BIBREF132\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-743a792f7630acee9819c0a354a3214d5ae436ce038edd0aeda874ceaebf3e4b_citespan-181-203> , <http://covid19.aksw.org/text-743a792f7630acee9819c0a354a3214d5ae436ce038edd0aeda874ceaebf3e4b_citespan-300-322> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Xenobiotic-induced increases in red cell mass are uncommon. Administration of recombinant erythropoietin and anabolic steroids has been reported to cause increases in red cell mass (Mintzer et al., 2009) . For example, increases in red cell mass have been associated with testosterone administration (Gardner et al., 1968) . Theoretically, excess administration of thyroid hormones could also cause increases in red cell mass." ;
            <http://www.example.org/textHash>
                    "743a792f7630acee9819c0a354a3214d5ae436ce038edd0aeda874ceaebf3e4b" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-183-208>
            <http://www.example.org/end>    "208.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF103" ;
            <http://www.example.org/start>  "183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Edwards and Fuller, 1996)" .
    
    <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Bone marrow suppression is caused by numerous xenobiotics, most notably chemotherapeutic agents. Chemotherapeutic agents associated with bone marrow suppression include compounds from many classes, including alkylating agents such as busulfan, antimetabolites that impair DNA synthesis such as methotrexate and mercaptopurine, antibiotics such as doxorubicin, and mitotic spindle inhibitors such as the vinca alkaloids vinblastine and vincristine (Carey, 2003; Weiss, 2010; Stockham and Scott, 2008c) . Idiosyncratic myelosuppression may also occur with numerous nonchemotherapeutic xenobiotics, and has been reported with antithyroid drugs such as methimazole, anticonvulsants including felbamate and carbamazepine, antipsychotic agents such as clozapine, cardiovascular drugs such as methyldopa and captopril, antibiotics including trimethoprimsulfamethoxazole and chloroquine, and other xenobiotic agents including gold-based compounds, diclofenac, and allopurinol (Carey, 2003) .\",\"cite_spans\":[{\"start\":447.0,\"end\":460.0,\"text\":\"(Carey, 2003;\",\"ref_id\":\"BIBREF57\"},{\"start\":461.0,\"end\":473.0,\"text\":\"Weiss, 2010;\",\"ref_id\":\"BIBREF428\"},{\"start\":474.0,\"end\":500.0,\"text\":\"Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":968.0,\"end\":981.0,\"text\":\"(Carey, 2003)\",\"ref_id\":\"BIBREF57\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-447-460> , <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-461-473> , <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-474-500> , <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-968-981> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Bone marrow suppression is caused by numerous xenobiotics, most notably chemotherapeutic agents. Chemotherapeutic agents associated with bone marrow suppression include compounds from many classes, including alkylating agents such as busulfan, antimetabolites that impair DNA synthesis such as methotrexate and mercaptopurine, antibiotics such as doxorubicin, and mitotic spindle inhibitors such as the vinca alkaloids vinblastine and vincristine (Carey, 2003; Weiss, 2010; Stockham and Scott, 2008c) . Idiosyncratic myelosuppression may also occur with numerous nonchemotherapeutic xenobiotics, and has been reported with antithyroid drugs such as methimazole, anticonvulsants including felbamate and carbamazepine, antipsychotic agents such as clozapine, cardiovascular drugs such as methyldopa and captopril, antibiotics including trimethoprimsulfamethoxazole and chloroquine, and other xenobiotic agents including gold-based compounds, diclofenac, and allopurinol (Carey, 2003) ." ;
            <http://www.example.org/textHash>
                    "10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742" .
    
    <http://covid19.aksw.org/text-d72313bfa628dbe99402abd17f6bc00942b142ab812f7a6d73ea2b33ed39a462>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Lymphoid suppression is a common finding with many xenobiotics and may be associated with decreases in blood lymphocyte counts. Mechanisms through which these decreases occur may either be part of the expected pharmacology of these compounds or may represent an off-target effect. Several examples of xenobiotic-induced decreases in lymphocyte counts are described here.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Lymphoid suppression is a common finding with many xenobiotics and may be associated with decreases in blood lymphocyte counts. Mechanisms through which these decreases occur may either be part of the expected pharmacology of these compounds or may represent an off-target effect. Several examples of xenobiotic-induced decreases in lymphocyte counts are described here." ;
            <http://www.example.org/textHash>
                    "d72313bfa628dbe99402abd17f6bc00942b142ab812f7a6d73ea2b33ed39a462" .
    
    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-1116-1143>
            <http://www.example.org/end>    "1143.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "1116.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-350-365>
            <http://www.example.org/end>    "365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "350.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-921-941>
            <http://www.example.org/end>    "941.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "921.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Balian et al., 2001;" .
    
    <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-396-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF77" ;
            <http://www.example.org/start>  "396.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cox, 1995)" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-382-401>
            <http://www.example.org/end>    "401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF421" ;
            <http://www.example.org/start>  "382.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Watts et al., 1990;" .
    
    <http://covid19.aksw.org/text-8f8fd942e21b7a8cf047857798609b05ee05a9526878a93062221b93ea2918f6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Marked decreases in platelet counts are a clinical concern because they may be associated with spontaneous bleeding. Animals are typically considered at risk for spontaneous bleeding when platelet counts are \\u003c 50,000 mL À 1 and at a significantly greater risk for spontaneous bleeding with \\u003c 10,000 platelets mL À 1 (Russell, 2010) , although hemorrhage with platelet counts \\u003c 50,000 mL À 1 may also occur following surgery or trauma, including venipuncture routinely performed during nonclinical toxicology studies. Minimal to moderate decreases in platelet counts are typically not associated with hemorrhage, and are not a major clinical concern unless there is a concurrent platelet functional defect. Increased MPV is an indicator of increased average platelet size, and may be associated with rapid or increased thrombopoiesis and indicative of a bone marrow response to decreases in platelet counts.\",\"cite_spans\":[{\"start\":316.0,\"end\":331.0,\"text\":\"(Russell, 2010)\",\"ref_id\":\"BIBREF329\"}],\"ref_spans\":[],\"section\":\"Decreases in Platelet Counts (Thrombocytopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-8f8fd942e21b7a8cf047857798609b05ee05a9526878a93062221b93ea2918f6_citespan-316-331> ;
            <http://www.example.org/section>
                    "Decreases in Platelet Counts (Thrombocytopenia)" ;
            <http://www.example.org/text>  "Marked decreases in platelet counts are a clinical concern because they may be associated with spontaneous bleeding. Animals are typically considered at risk for spontaneous bleeding when platelet counts are < 50,000 mL À 1 and at a significantly greater risk for spontaneous bleeding with < 10,000 platelets mL À 1 (Russell, 2010) , although hemorrhage with platelet counts < 50,000 mL À 1 may also occur following surgery or trauma, including venipuncture routinely performed during nonclinical toxicology studies. Minimal to moderate decreases in platelet counts are typically not associated with hemorrhage, and are not a major clinical concern unless there is a concurrent platelet functional defect. Increased MPV is an indicator of increased average platelet size, and may be associated with rapid or increased thrombopoiesis and indicative of a bone marrow response to decreases in platelet counts." ;
            <http://www.example.org/textHash>
                    "8f8fd942e21b7a8cf047857798609b05ee05a9526878a93062221b93ea2918f6" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1071-1092>
            <http://www.example.org/end>    "1092.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF415" ;
            <http://www.example.org/start>  "1071.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Wallace et al., 2002;" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-805-827>
            <http://www.example.org/end>    "827.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF154" ;
            <http://www.example.org/start>  "805.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Granter et al., 1996)" .
    
    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-366-383>
            <http://www.example.org/end>    "383.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF225" ;
            <http://www.example.org/start>  "366.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016a)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-658-671>
            <http://www.example.org/end>    "671.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF255" ;
            <http://www.example.org/start>  "658.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "McEwen, 1992)" .
    
    <http://covid19.aksw.org/text-87d6d638388562b95fbc55da7ce6df6bd68f432a8460cfeaa74c532cab4f720f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"G-CSF and GM-CSF-based xenobiotic administration has been associated with increases in blood platelet counts from general bone marrow stimulation. These changes may be due to proliferation of myeloid precursors including common precursors that may then differentiate into megakaryocytes.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "G-CSF and GM-CSF-based xenobiotic administration has been associated with increases in blood platelet counts from general bone marrow stimulation. These changes may be due to proliferation of myeloid precursors including common precursors that may then differentiate into megakaryocytes." ;
            <http://www.example.org/textHash>
                    "87d6d638388562b95fbc55da7ce6df6bd68f432a8460cfeaa74c532cab4f720f" .
    
    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-648-674>
            <http://www.example.org/end>    "674.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF386" ;
            <http://www.example.org/start>  "648.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Thompson and Gales, 1996)" .
    
    <http://covid19.aksw.org/text-76ae2d6ca8ab514658fa40f52f143a6617c592a7222c70174c4eadbb87bc83d0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in monocyte counts have also been reported in a few patients associated with pseudolymphoma syndrome caused by therapy with several anticonvulsants, including phenytoin, phenobarbital, and valproic acid (Choi et al., 2003) .\",\"cite_spans\":[{\"start\":213.0,\"end\":232.0,\"text\":\"(Choi et al., 2003)\",\"ref_id\":\"BIBREF68\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-76ae2d6ca8ab514658fa40f52f143a6617c592a7222c70174c4eadbb87bc83d0_citespan-213-232> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Increases in monocyte counts have also been reported in a few patients associated with pseudolymphoma syndrome caused by therapy with several anticonvulsants, including phenytoin, phenobarbital, and valproic acid (Choi et al., 2003) ." ;
            <http://www.example.org/textHash>
                    "76ae2d6ca8ab514658fa40f52f143a6617c592a7222c70174c4eadbb87bc83d0" .
    
    <http://covid19.aksw.org/text-0454039d5f7a9b1e880a4cb7e700a8efebdf3c913a68373e3338db32fe3e38fd_citespan-422-436>
            <http://www.example.org/end>    "436.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF166" ;
            <http://www.example.org/start>  "422.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Harvey, 2012;" .
    
    <http://covid19.aksw.org/text-c7727161c8174f11cfe6fe81738511813b4fe33eb1406f470c1812b71354f584>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Neoplasia may result in suppressed erythropoiesis. This may be due to neoplasia-related inflammation and cytokine release leading to ACD. However, granulocytic leukemia or lymphoproliferative neoplasia involving the bone marrow may result in crowding or effacement of the bone marrow cavities with impaired erythropoiesis that results in decreases in red cell mass with concurrent decreases in reticulocyte counts. Hematopoietic neoplasia involving the erythroid lineage usually results in atypical erythrocyte production that can lead to decreases in red cell mass and reticulocyte counts; however, nucleated erythrocytes with evidence of dysplasia may be observed in blood. Similar to hematopoietic neoplasms that efface the bone marrow, metastatic neoplasia, often carcinomas, may also cause myelophthisis and result in decreased erythropoiesis.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Neoplasia\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Neoplasia" ;
            <http://www.example.org/text>  "Neoplasia may result in suppressed erythropoiesis. This may be due to neoplasia-related inflammation and cytokine release leading to ACD. However, granulocytic leukemia or lymphoproliferative neoplasia involving the bone marrow may result in crowding or effacement of the bone marrow cavities with impaired erythropoiesis that results in decreases in red cell mass with concurrent decreases in reticulocyte counts. Hematopoietic neoplasia involving the erythroid lineage usually results in atypical erythrocyte production that can lead to decreases in red cell mass and reticulocyte counts; however, nucleated erythrocytes with evidence of dysplasia may be observed in blood. Similar to hematopoietic neoplasms that efface the bone marrow, metastatic neoplasia, often carcinomas, may also cause myelophthisis and result in decreased erythropoiesis." ;
            <http://www.example.org/textHash>
                    "c7727161c8174f11cfe6fe81738511813b4fe33eb1406f470c1812b71354f584" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-448-462>
            <http://www.example.org/end>    "462.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF116" ;
            <http://www.example.org/start>  "448.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ferner, 2012;" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Administration of exogenous cytokines may also result in increases in blood monocyte counts. Such increases in blood monocyte counts have been observed with G-CSF (Ranaghan et al., 1998; Liu et al., 2004) , GM-CSF (Schmitz et al., 1994) , M-CSF (Weiner et al., 1994; Cole et al., 1994) , or IL-10 administration (Chernoff et al., 1995) . M-CSF administration-related increases in monocyte counts have been associated with concurrent, dose-limiting decreases in platelet counts (Weiner et al., 1994; Cole et al., 1994) .\",\"cite_spans\":[{\"start\":163.0,\"end\":186.0,\"text\":\"(Ranaghan et al., 1998;\",\"ref_id\":\"BIBREF311\"},{\"start\":187.0,\"end\":204.0,\"text\":\"Liu et al., 2004)\",\"ref_id\":\"BIBREF232\"},{\"start\":214.0,\"end\":236.0,\"text\":\"(Schmitz et al., 1994)\",\"ref_id\":\"BIBREF341\"},{\"start\":245.0,\"end\":266.0,\"text\":\"(Weiner et al., 1994;\",\"ref_id\":\"BIBREF424\"},{\"start\":267.0,\"end\":285.0,\"text\":\"Cole et al., 1994)\",\"ref_id\":\"BIBREF74\"},{\"start\":312.0,\"end\":335.0,\"text\":\"(Chernoff et al., 1995)\",\"ref_id\":\"BIBREF65\"},{\"start\":477.0,\"end\":498.0,\"text\":\"(Weiner et al., 1994;\",\"ref_id\":\"BIBREF424\"},{\"start\":499.0,\"end\":517.0,\"text\":\"Cole et al., 1994)\",\"ref_id\":\"BIBREF74\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-312-335> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-187-204> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-245-266> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-477-498> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-214-236> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-267-285> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-499-517> , <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-163-186> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Administration of exogenous cytokines may also result in increases in blood monocyte counts. Such increases in blood monocyte counts have been observed with G-CSF (Ranaghan et al., 1998; Liu et al., 2004) , GM-CSF (Schmitz et al., 1994) , M-CSF (Weiner et al., 1994; Cole et al., 1994) , or IL-10 administration (Chernoff et al., 1995) . M-CSF administration-related increases in monocyte counts have been associated with concurrent, dose-limiting decreases in platelet counts (Weiner et al., 1994; Cole et al., 1994) ." ;
            <http://www.example.org/textHash>
                    "76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1127-1147>
            <http://www.example.org/end>    "1147.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "1127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schwartzberg, 2006;" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-343-363>
            <http://www.example.org/end>    "363.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "343.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Caldin et al., 2005;" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-527-542>
            <http://www.example.org/end>    "542.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF300" ;
            <http://www.example.org/start>  "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pohlman, 2010;" .
    
    <http://covid19.aksw.org/text-67c3b9afb16f69513b2fcce7c0299a2a50443437bd449ba58c1790075143280e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The presence of immature neutrophils in blood is called a left shift. These immature neutrophils are most commonly band neutrophils, but a sufficient stimulus can result in the release of lower numbers of more immature stages, including metamyelocytes, myelocytes, or even earlier stages. A left shift may be categorized as degenerative, indicating a greater number of immature neutrophils than mature neutrophils, or regenerative, where mature neutrophils are present in greater numbers than the immature neutrophils. Degenerative left shifts are typically observed in the face of decreased or low-normal blood neutrophil counts when the tissue demand exceeds bone marrow neutrophil production, while regenerative left shifts tend to occur with increased blood neutrophil counts when bone marrow production is starting to meet the tissue demand.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "The presence of immature neutrophils in blood is called a left shift. These immature neutrophils are most commonly band neutrophils, but a sufficient stimulus can result in the release of lower numbers of more immature stages, including metamyelocytes, myelocytes, or even earlier stages. A left shift may be categorized as degenerative, indicating a greater number of immature neutrophils than mature neutrophils, or regenerative, where mature neutrophils are present in greater numbers than the immature neutrophils. Degenerative left shifts are typically observed in the face of decreased or low-normal blood neutrophil counts when the tissue demand exceeds bone marrow neutrophil production, while regenerative left shifts tend to occur with increased blood neutrophil counts when bone marrow production is starting to meet the tissue demand." ;
            <http://www.example.org/textHash>
                    "67c3b9afb16f69513b2fcce7c0299a2a50443437bd449ba58c1790075143280e" .
    
    <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-1568-1594>
            <http://www.example.org/end>    "1594.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "1568.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-409-430>
            <http://www.example.org/end>    "430.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF100" ;
            <http://www.example.org/start>  "409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ducrest et al., 2005)" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Causes of decreased bone marrow megakaryocytes with decreases in blood platelet counts have also been associated with mechanisms that are likely immune-mediated. Aplastic anemia, which is most commonly caused by immune-mediated mechanisms (Young et al., 2006) , is associated with generalized bone marrow hypoplasia involving all hematopoietic lineages, including megakaryocytes. Amegakaryocytic thrombocytopenic purpura in humans may be inherited or acquired, and acquired forms commonly occur through immune-mediated mechanisms (Diz-Küçükkaya and López, 2016) . Inherited or congenital forms cause marked decreases in blood platelet counts with an absence of megakaryocytes in the bone marrow. This form is frequently associated with mutations in the TPO receptor gene, MPL, and may progress to aplastic anemia (Germeshausen et al., 2006; Van Den Oudenrijn et al., 2000) . Acquired amegakaryocytic thrombocytopenic purpura is likely associated with immune-mediated decreases in bone marrow megakaryocytes (Tristano, 2005) , and antibodies that bind TPO or the TPO receptor have also been reported to cause acquired amegakaryocytic thrombocytopenic purpura (Shiozaki et al., 2000; Katsumata et al., 2003) .\",\"cite_spans\":[{\"start\":239.0,\"end\":259.0,\"text\":\"(Young et al., 2006)\",\"ref_id\":\"BIBREF439\"},{\"start\":530.0,\"end\":561.0,\"text\":\"(Diz-Küçükkaya and López, 2016)\",\"ref_id\":\"BIBREF94\"},{\"start\":813.0,\"end\":840.0,\"text\":\"(Germeshausen et al., 2006;\",\"ref_id\":\"BIBREF141\"},{\"start\":841.0,\"end\":872.0,\"text\":\"Van Den Oudenrijn et al., 2000)\",\"ref_id\":\"BIBREF402\"},{\"start\":1007.0,\"end\":1023.0,\"text\":\"(Tristano, 2005)\",\"ref_id\":\"BIBREF394\"},{\"start\":1158.0,\"end\":1181.0,\"text\":\"(Shiozaki et al., 2000;\",\"ref_id\":\"BIBREF353\"},{\"start\":1182.0,\"end\":1205.0,\"text\":\"Katsumata et al., 2003)\",\"ref_id\":\"BIBREF198\"}],\"ref_spans\":[],\"section\":\"Decreased production\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-813-840> , <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-841-872> , <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-239-259> , <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-530-561> , <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-1182-1205> , <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-1007-1023> , <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-1158-1181> ;
            <http://www.example.org/section>
                    "Decreased production" ;
            <http://www.example.org/text>  "Causes of decreased bone marrow megakaryocytes with decreases in blood platelet counts have also been associated with mechanisms that are likely immune-mediated. Aplastic anemia, which is most commonly caused by immune-mediated mechanisms (Young et al., 2006) , is associated with generalized bone marrow hypoplasia involving all hematopoietic lineages, including megakaryocytes. Amegakaryocytic thrombocytopenic purpura in humans may be inherited or acquired, and acquired forms commonly occur through immune-mediated mechanisms (Diz-Küçükkaya and López, 2016) . Inherited or congenital forms cause marked decreases in blood platelet counts with an absence of megakaryocytes in the bone marrow. This form is frequently associated with mutations in the TPO receptor gene, MPL, and may progress to aplastic anemia (Germeshausen et al., 2006; Van Den Oudenrijn et al., 2000) . Acquired amegakaryocytic thrombocytopenic purpura is likely associated with immune-mediated decreases in bone marrow megakaryocytes (Tristano, 2005) , and antibodies that bind TPO or the TPO receptor have also been reported to cause acquired amegakaryocytic thrombocytopenic purpura (Shiozaki et al., 2000; Katsumata et al., 2003) ." ;
            <http://www.example.org/textHash>
                    "e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93" .
    
    <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Oxidative damage to exposed cysteine sulfhydryl groups on hemoglobin results in hemoglobin denaturation and decreased solubility (Bloom and Brandt, 2008) . Denatured hemoglobin may then precipitate and aggregate within the erythrocyte, forming small, pale-staining round structures that bind to the erythrocyte membrane and tend to protrude from the surface of the erythrocyte. These aggregates of denatured hemoglobin are called Heinz bodies. Cats appear to be particularly sensitive to the formation of Heinz bodies because of an increased number of reactive sulfhydryl groups in hemoglobin relative to other species (Christopher et al., 1990) , and may be more rapidly observed on blood smear evaluation due to the nonsinusoidal architecture of the feline spleen that results in decreased clearance of Heinz bodies from circulation. Similar to eccentrocytes, erythrocytes with Heinz bodies may undergo hemolysis due to increased clearance by splenic macrophages following trapping in splenic sinusoids due to decreased erythrocyte deformability and spontaneous rupture due to increased fragility from membrane damage; immune-mediated clearance may also occur and is believed to result from binding of hemochromes to and subsequent redistribution of band 3, an erythrocyte membrane structural protein, which may then be recognized by autologous antibodies (Winterbourn, 1990) .\",\"cite_spans\":[{\"start\":129.0,\"end\":153.0,\"text\":\"(Bloom and Brandt, 2008)\",\"ref_id\":\"BIBREF35\"},{\"start\":619.0,\"end\":645.0,\"text\":\"(Christopher et al., 1990)\",\"ref_id\":\"BIBREF70\"},{\"start\":1358.0,\"end\":1377.0,\"text\":\"(Winterbourn, 1990)\",\"ref_id\":\"BIBREF433\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9_citespan-129-153> , <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9_citespan-619-645> , <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9_citespan-1358-1377> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Oxidative damage to exposed cysteine sulfhydryl groups on hemoglobin results in hemoglobin denaturation and decreased solubility (Bloom and Brandt, 2008) . Denatured hemoglobin may then precipitate and aggregate within the erythrocyte, forming small, pale-staining round structures that bind to the erythrocyte membrane and tend to protrude from the surface of the erythrocyte. These aggregates of denatured hemoglobin are called Heinz bodies. Cats appear to be particularly sensitive to the formation of Heinz bodies because of an increased number of reactive sulfhydryl groups in hemoglobin relative to other species (Christopher et al., 1990) , and may be more rapidly observed on blood smear evaluation due to the nonsinusoidal architecture of the feline spleen that results in decreased clearance of Heinz bodies from circulation. Similar to eccentrocytes, erythrocytes with Heinz bodies may undergo hemolysis due to increased clearance by splenic macrophages following trapping in splenic sinusoids due to decreased erythrocyte deformability and spontaneous rupture due to increased fragility from membrane damage; immune-mediated clearance may also occur and is believed to result from binding of hemochromes to and subsequent redistribution of band 3, an erythrocyte membrane structural protein, which may then be recognized by autologous antibodies (Winterbourn, 1990) ." ;
            <http://www.example.org/textHash>
                    "c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-2659-2664>
            <http://www.example.org/end>    "2664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "2659.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[LAD]" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although rare, some inherited immunodeficiency syndromes cause blood lymphocyte counts to be decreased. One example, severe combined immunodeficiency (SCID), has been reported in humans, dogs, mice, and horses (Suter, 2010; Notarangelo, 2010; Meek et al., 2001; Felsberg et al., 1992; Custer et al., 1985) . SCID may be inherited through autosomal recessive or X-linked recessive patterns, and causes consistent decreases in T-cells, with concurrent decreases in B-cells or NK-cells in some forms of the disease. SCID in humans is caused by a variety of mechanisms, including: adenosine deaminase deficiency resulting in early cell death due to metabolite accumulation; common gamma chain or janus kinase 3 (JAK3) mutations that cause decreased survival of T-cell precursors due to defective cytokine signaling; recombinase-activating gene 1 (RAG1) or RAG2 mutations that cause defective V(D)J rearrangement of B-cell and T-cell receptors; and mutations in CD3 or CD45 that cause defects in T-cell receptor signaling (Suter, 2010; Notarangelo, 2010) . SCID in Jack Russell terriers, Arabian foals, and mice has been demonstrated to be caused by defective V(D)J recombination due to loss of DNA-dependent protein kinase (Meek et al., 2001 ). X-linked SCID has been described in both Bassett Hounds and Welsh Corgi dogs (Suter, 2010) . Other inherited immunodeficiency syndromes resulting in decreases in blood lymphocyte counts include reticular dysgenesis, ataxia-telangiectasia, and Wiskott-Aldrich syndrome (Vasu and Caligiuri, 2016) .\",\"cite_spans\":[{\"start\":210.0,\"end\":223.0,\"text\":\"(Suter, 2010;\",\"ref_id\":\"BIBREF376\"},{\"start\":224.0,\"end\":242.0,\"text\":\"Notarangelo, 2010;\",\"ref_id\":\"BIBREF275\"},{\"start\":243.0,\"end\":261.0,\"text\":\"Meek et al., 2001;\",\"ref_id\":\"BIBREF257\"},{\"start\":262.0,\"end\":284.0,\"text\":\"Felsberg et al., 1992;\",\"ref_id\":\"BIBREF114\"},{\"start\":285.0,\"end\":305.0,\"text\":\"Custer et al., 1985)\",\"ref_id\":\"BIBREF83\"},{\"start\":1017.0,\"end\":1030.0,\"text\":\"(Suter, 2010;\",\"ref_id\":\"BIBREF376\"},{\"start\":1031.0,\"end\":1049.0,\"text\":\"Notarangelo, 2010)\",\"ref_id\":\"BIBREF275\"},{\"start\":1219.0,\"end\":1237.0,\"text\":\"(Meek et al., 2001\",\"ref_id\":\"BIBREF257\"},{\"start\":1318.0,\"end\":1331.0,\"text\":\"(Suter, 2010)\",\"ref_id\":\"BIBREF376\"},{\"start\":1509.0,\"end\":1535.0,\"text\":\"(Vasu and Caligiuri, 2016)\",\"ref_id\":\"BIBREF406\"}],\"ref_spans\":[],\"section\":\"Inherited causes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1318-1331> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1509-1535> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-224-242> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-285-305> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-262-284> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-243-261> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1017-1030> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1219-1237> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-210-223> , <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1031-1049> ;
            <http://www.example.org/section>
                    "Inherited causes" ;
            <http://www.example.org/text>  "Although rare, some inherited immunodeficiency syndromes cause blood lymphocyte counts to be decreased. One example, severe combined immunodeficiency (SCID), has been reported in humans, dogs, mice, and horses (Suter, 2010; Notarangelo, 2010; Meek et al., 2001; Felsberg et al., 1992; Custer et al., 1985) . SCID may be inherited through autosomal recessive or X-linked recessive patterns, and causes consistent decreases in T-cells, with concurrent decreases in B-cells or NK-cells in some forms of the disease. SCID in humans is caused by a variety of mechanisms, including: adenosine deaminase deficiency resulting in early cell death due to metabolite accumulation; common gamma chain or janus kinase 3 (JAK3) mutations that cause decreased survival of T-cell precursors due to defective cytokine signaling; recombinase-activating gene 1 (RAG1) or RAG2 mutations that cause defective V(D)J rearrangement of B-cell and T-cell receptors; and mutations in CD3 or CD45 that cause defects in T-cell receptor signaling (Suter, 2010; Notarangelo, 2010) . SCID in Jack Russell terriers, Arabian foals, and mice has been demonstrated to be caused by defective V(D)J recombination due to loss of DNA-dependent protein kinase (Meek et al., 2001 ). X-linked SCID has been described in both Bassett Hounds and Welsh Corgi dogs (Suter, 2010) . Other inherited immunodeficiency syndromes resulting in decreases in blood lymphocyte counts include reticular dysgenesis, ataxia-telangiectasia, and Wiskott-Aldrich syndrome (Vasu and Caligiuri, 2016) ." ;
            <http://www.example.org/textHash>
                    "f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-834-856>
            <http://www.example.org/end>    "856.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF152" ;
            <http://www.example.org/start>  "834.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Goodwin et al., 1979)" .
    
    <http://covid19.aksw.org/text-aec94e745e315f20a1a60e2301c5f7f3a05a9c7bbb45d68f464838ff3bb70fd1_citespan-440-455>
            <http://www.example.org/end>    "455.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "440.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Russell, 2010)" .
    
    <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-600-623>
            <http://www.example.org/end>    "623.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "600.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloemena et al., 1990)" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-277-300>
            <http://www.example.org/end>    "300.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "277.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Bjarnason et al., 1987)" .
    
    <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Infection with immunodeficiency viruses, including human, simian, and feline immunodeficiency viruses, may result in destruction of both infected and noninfected lymphocytes. HIV directly infects CD4 þ T-cells via the CD4 molecule; infected cells then migrate to lymphoid tissues where the virus replicates and infects more CD4 þ T-cells (Chinen and Shearer, 2010) . HIV-mediated lymphocyte destruction is likely multifactorial; HIV may be cytotoxic, directly induce T-cell apoptosis, induce T-cell death through a nonspecific immune response, and cause T-cell death by stimulating autophagocytic pathways (Chinen and Shearer, 2010; Stump and VandeWoude, 2007) . SIV and FIV tropism for T-cells is also mediated by receptors expressed by CD4 þ T-cells (Stump and VandeWoude, 2007) . Simian betaretrovirus also causes decreases in blood lymphocyte counts due to infection and eventual depletion of both B-cells and T-cells, although infection of nonlymphoid cells also occurs (Montiel, 2010) .\",\"cite_spans\":[{\"start\":338.0,\"end\":364.0,\"text\":\"(Chinen and Shearer, 2010)\",\"ref_id\":\"BIBREF67\"},{\"start\":606.0,\"end\":632.0,\"text\":\"(Chinen and Shearer, 2010;\",\"ref_id\":\"BIBREF67\"},{\"start\":633.0,\"end\":660.0,\"text\":\"Stump and VandeWoude, 2007)\"},{\"start\":752.0,\"end\":780.0,\"text\":\"(Stump and VandeWoude, 2007)\"},{\"start\":975.0,\"end\":990.0,\"text\":\"(Montiel, 2010)\",\"ref_id\":\"BIBREF264\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-338-364> , <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-606-632> , <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-633-660> , <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-752-780> , <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-975-990> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Infection with immunodeficiency viruses, including human, simian, and feline immunodeficiency viruses, may result in destruction of both infected and noninfected lymphocytes. HIV directly infects CD4 þ T-cells via the CD4 molecule; infected cells then migrate to lymphoid tissues where the virus replicates and infects more CD4 þ T-cells (Chinen and Shearer, 2010) . HIV-mediated lymphocyte destruction is likely multifactorial; HIV may be cytotoxic, directly induce T-cell apoptosis, induce T-cell death through a nonspecific immune response, and cause T-cell death by stimulating autophagocytic pathways (Chinen and Shearer, 2010; Stump and VandeWoude, 2007) . SIV and FIV tropism for T-cells is also mediated by receptors expressed by CD4 þ T-cells (Stump and VandeWoude, 2007) . Simian betaretrovirus also causes decreases in blood lymphocyte counts due to infection and eventual depletion of both B-cells and T-cells, although infection of nonlymphoid cells also occurs (Montiel, 2010) ." ;
            <http://www.example.org/textHash>
                    "d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-882-902>
            <http://www.example.org/end>    "902.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF144" ;
            <http://www.example.org/start>  "882.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Giger et al., 1985)" .
    
    <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-386-407>
            <http://www.example.org/end>    "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF274" ;
            <http://www.example.org/start>  "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Noguchi et al., 1992;" .
    
    <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-338-364>
            <http://www.example.org/end>    "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF67" ;
            <http://www.example.org/start>  "338.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Chinen and Shearer, 2010)" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-571-584>
            <http://www.example.org/end>    "584.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF256" ;
            <http://www.example.org/start>  "571.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Means, 2000)" .
    
    <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-936-969>
            <http://www.example.org/end>    "969.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF380" ;
            <http://www.example.org/start>  "936.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tambourgi and van den Berg, 2014;" .
    
    <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-800-827>
            <http://www.example.org/end>    "827.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "800.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a;" .
    
    <http://covid19.aksw.org/text-0454039d5f7a9b1e880a4cb7e700a8efebdf3c913a68373e3338db32fe3e38fd_citespan-437-463>
            <http://www.example.org/end>    "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb_citespan-345-360>
            <http://www.example.org/end>    "360.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "345.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1611-1627>
            <http://www.example.org/end>    "1627.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "1611.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-54b088a38add774b695a530442ee730df63239c7224176518f4b94ca1ee21cb8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Bartonella bacilliformis in people and the hemotrophic mycoplasmas (hemoplasmas) in dogs and cats (formerly Haemobartonella species) and swine (formerly Eperythrozoon species) are organisms that parasitize erythrocytes, but these organisms remain extracellular in shallow depressions of the erythrocyte membrane. These organisms are typically round-, rod-, or ring-shaped and may be observed individually or in chains on erythrocyte surfaces. Hemolysis with these organisms may be immune-mediate and associated either with binding of antibodies to parasite antigens or antigens exposed on the erythrocyte secondary to parasite-induced membrane changes (Stockham and Scott, 2008b) .\",\"cite_spans\":[{\"start\":652.0,\"end\":679.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-54b088a38add774b695a530442ee730df63239c7224176518f4b94ca1ee21cb8_citespan-652-679> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Bartonella bacilliformis in people and the hemotrophic mycoplasmas (hemoplasmas) in dogs and cats (formerly Haemobartonella species) and swine (formerly Eperythrozoon species) are organisms that parasitize erythrocytes, but these organisms remain extracellular in shallow depressions of the erythrocyte membrane. These organisms are typically round-, rod-, or ring-shaped and may be observed individually or in chains on erythrocyte surfaces. Hemolysis with these organisms may be immune-mediate and associated either with binding of antibodies to parasite antigens or antigens exposed on the erythrocyte secondary to parasite-induced membrane changes (Stockham and Scott, 2008b) ." ;
            <http://www.example.org/textHash>
                    "54b088a38add774b695a530442ee730df63239c7224176518f4b94ca1ee21cb8" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-605-626>
            <http://www.example.org/end>    "626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF75" ;
            <http://www.example.org/start>  "605.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Coleman et al., 1991;" .
    
    <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.2 Blood loss 12.11.3.2.1.2.1 Hemorrhage Hemorrhage may cause internal or external blood loss. Due to the loss of whole blood during hemorrhage, decreases in red cell mass are usually accompanied by proportionate decreases in albumin and globulin concentrations. The decreases in plasma proteins tend to be less pronounced with internal hemorrhage because the lost proteins may be resorbed in lymph and returned to blood (Stockham and Scott, 2008b) . Cases of internal hemorrhage are typically not associated with iron deficiency. However, prolonged external blood loss may cause depletion of total body iron. Iron deficiency anemia is characterized by small erythrocytes with a decrease in MCV and erythrocytes that contain less hemoglobin with a decrease in MCHC, and may be classified as a microcytic, hypochromic anemia. Hemoglobin synthesis plays a role in inhibiting erythrocyte division, and when sufficient iron is not available for heme production, there is loss of the inhibitory effect resulting in more cell divisions and microcytes (Stohlman et al., 1963) . Hypochromasia of the erythrocytes is due to the lower than normal hemoglobin content due to decreased production of heme. Morphologic erythrocyte changes that accompany iron deficiency anemia include visual microcytosis and hypochromasia, keratocytes and schistocytes from physical damage to the more fragile erythrocytes, and sometimes codocytes (also called target cells) that have a thin rim of pink-staining hemoglobin and a small central area of hemoglobin with a ring of pallor in between, typical of erythrocytes with less hemoglobin present relative to the amount of membrane. In chronic iron deficiency, increases in reticulocyte counts and microscopic polychromasia may be lower than expected for a regenerative anemia due to loss of RNA during the extended maturation phase of erythrocyte production caused by decreased hemoglobin content (Burkhard et al., 2001) .\",\"cite_spans\":[{\"start\":432.0,\"end\":459.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":1056.0,\"end\":1079.0,\"text\":\"(Stohlman et al., 1963)\",\"ref_id\":\"BIBREF369\"},{\"start\":1932.0,\"end\":1955.0,\"text\":\"(Burkhard et al., 2001)\",\"ref_id\":\"BIBREF49\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d_citespan-432-459> , <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d_citespan-1056-1079> , <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d_citespan-1932-1955> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.2 Blood loss 12.11.3.2.1.2.1 Hemorrhage Hemorrhage may cause internal or external blood loss. Due to the loss of whole blood during hemorrhage, decreases in red cell mass are usually accompanied by proportionate decreases in albumin and globulin concentrations. The decreases in plasma proteins tend to be less pronounced with internal hemorrhage because the lost proteins may be resorbed in lymph and returned to blood (Stockham and Scott, 2008b) . Cases of internal hemorrhage are typically not associated with iron deficiency. However, prolonged external blood loss may cause depletion of total body iron. Iron deficiency anemia is characterized by small erythrocytes with a decrease in MCV and erythrocytes that contain less hemoglobin with a decrease in MCHC, and may be classified as a microcytic, hypochromic anemia. Hemoglobin synthesis plays a role in inhibiting erythrocyte division, and when sufficient iron is not available for heme production, there is loss of the inhibitory effect resulting in more cell divisions and microcytes (Stohlman et al., 1963) . Hypochromasia of the erythrocytes is due to the lower than normal hemoglobin content due to decreased production of heme. Morphologic erythrocyte changes that accompany iron deficiency anemia include visual microcytosis and hypochromasia, keratocytes and schistocytes from physical damage to the more fragile erythrocytes, and sometimes codocytes (also called target cells) that have a thin rim of pink-staining hemoglobin and a small central area of hemoglobin with a ring of pallor in between, typical of erythrocytes with less hemoglobin present relative to the amount of membrane. In chronic iron deficiency, increases in reticulocyte counts and microscopic polychromasia may be lower than expected for a regenerative anemia due to loss of RNA during the extended maturation phase of erythrocyte production caused by decreased hemoglobin content (Burkhard et al., 2001) ." ;
            <http://www.example.org/textHash>
                    "03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d" .
    
    <http://covid19.aksw.org/text-92b5a29b064c99b374b26a0994786b872453b383774723a554d534b6030cc521>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Collectively, the porphyrias are a group of enzymatic defects in the heme synthesis pathway. Porphyrias may be congenital or, more commonly, acquired. In these conditions, the accumulation of porphyrins, the precursors of heme, within erythrocytes leads to hemolysis. The mechanism of hemolysis may be related to lysis of erythrocytes following exposure to light (photolysis) in superficial vasculature, or by direct erythrocyte membrane damage due to the lipid soluble nature of porphyrins or following porphyrin absorption of ultraviolet light and excitation (Phillips and Anderson, 2016; Kaneko, 2008) .\",\"cite_spans\":[{\"start\":561.0,\"end\":590.0,\"text\":\"(Phillips and Anderson, 2016;\",\"ref_id\":\"BIBREF297\"},{\"start\":591.0,\"end\":604.0,\"text\":\"Kaneko, 2008)\",\"ref_id\":\"BIBREF193\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-92b5a29b064c99b374b26a0994786b872453b383774723a554d534b6030cc521_citespan-561-590> , <http://covid19.aksw.org/text-92b5a29b064c99b374b26a0994786b872453b383774723a554d534b6030cc521_citespan-591-604> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Collectively, the porphyrias are a group of enzymatic defects in the heme synthesis pathway. Porphyrias may be congenital or, more commonly, acquired. In these conditions, the accumulation of porphyrins, the precursors of heme, within erythrocytes leads to hemolysis. The mechanism of hemolysis may be related to lysis of erythrocytes following exposure to light (photolysis) in superficial vasculature, or by direct erythrocyte membrane damage due to the lipid soluble nature of porphyrins or following porphyrin absorption of ultraviolet light and excitation (Phillips and Anderson, 2016; Kaneko, 2008) ." ;
            <http://www.example.org/textHash>
                    "92b5a29b064c99b374b26a0994786b872453b383774723a554d534b6030cc521" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-546-563>
            <http://www.example.org/end>    "563.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF168" ;
            <http://www.example.org/start>  "546.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(He et al., 1994)" .
    
    <http://covid19.aksw.org/text-7618637eeccb25855a1c7ee52f9f959095f18ae5a2e4d9f9bea627d7777a9c39_citespan-638-650>
            <http://www.example.org/end>    "650.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF130" ;
            <http://www.example.org/start>  "638.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ganz, 2016)" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-565-586>
            <http://www.example.org/end>    "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF186" ;
            <http://www.example.org/start>  "565.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Josephs et al., 1961)" .
    
    <http://covid19.aksw.org/text-76d865d10df7e69d5efe4aba052c98cdf3b7530a48849e47a9639b4b7f492add>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-induced increases in platelet counts have also been attributed to treatment with vinca alkaloids or miconazole, and are believed to be attributable to the ability of these xenobiotics to stimulate increased megakaryocyte production within the bone marrow (Frye and Thompson, 1993) . While increases in platelet counts have been reported with treatment with several antibiotic classes, including some cephalosporins, b-lactams, and penicillin, causality is difficult to prove in these cases and a reactive thrombocytosis from inflammation associated with the infectious process being treated must be considered (Frye and Thompson, 1993) .\",\"cite_spans\":[{\"start\":266.0,\"end\":291.0,\"text\":\"(Frye and Thompson, 1993)\",\"ref_id\":\"BIBREF125\"},{\"start\":621.0,\"end\":646.0,\"text\":\"(Frye and Thompson, 1993)\",\"ref_id\":\"BIBREF125\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-76d865d10df7e69d5efe4aba052c98cdf3b7530a48849e47a9639b4b7f492add_citespan-266-291> , <http://covid19.aksw.org/text-76d865d10df7e69d5efe4aba052c98cdf3b7530a48849e47a9639b4b7f492add_citespan-621-646> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Xenobiotic-induced increases in platelet counts have also been attributed to treatment with vinca alkaloids or miconazole, and are believed to be attributable to the ability of these xenobiotics to stimulate increased megakaryocyte production within the bone marrow (Frye and Thompson, 1993) . While increases in platelet counts have been reported with treatment with several antibiotic classes, including some cephalosporins, b-lactams, and penicillin, causality is difficult to prove in these cases and a reactive thrombocytosis from inflammation associated with the infectious process being treated must be considered (Frye and Thompson, 1993) ." ;
            <http://www.example.org/textHash>
                    "76d865d10df7e69d5efe4aba052c98cdf3b7530a48849e47a9639b4b7f492add" .
    
    <http://covid19.aksw.org/text-68059463768aed0ce4bc41ebf5a7ac986c926c7eaef8c923bb8bd34439a7d8cd_citespan-393-416>
            <http://www.example.org/end>    "416.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF79" ;
            <http://www.example.org/start>  "393.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Criswell et al., 2000)" .
    
    <http://covid19.aksw.org/text-ed051e9f6774e0d5381f7678308045e772eabafe6558f59d86a9b70ba18060b2_citespan-705-720>
            <http://www.example.org/end>    "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF377" ;
            <http://www.example.org/start>  "705.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Szebeni, 2005)" .
    
    <http://covid19.aksw.org/text-c5bacbfeb28ebc4ebfdc3b08969d9f17630cf2dfe9150b66d40999b0b04f26e7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Numerous xenobiotics have also been linked to SLE, with decreases in blood neutrophil counts in some cases. In xenobioticinduced SLE, decreased neutrophil counts reflect production of autoantibodies and subsequent neutrophil destruction, similar to nonxenobiotic-induced SLE. Xenobiotics associated with SLE include anticonvulsants such as phenothiazines, chlorpromazine, and valproate, antibiotics such as penicillin, streptomycin, tetracycline, griseofulvin, and sulphonamides, and miscellaneous xenobiotics such as captopril, phenylbutazone, and lovastatin (Stone, 2005; Mutasim and Adams, 2000) .\",\"cite_spans\":[{\"start\":560.0,\"end\":573.0,\"text\":\"(Stone, 2005;\",\"ref_id\":\"BIBREF371\"},{\"start\":574.0,\"end\":598.0,\"text\":\"Mutasim and Adams, 2000)\",\"ref_id\":\"BIBREF271\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c5bacbfeb28ebc4ebfdc3b08969d9f17630cf2dfe9150b66d40999b0b04f26e7_citespan-560-573> , <http://covid19.aksw.org/text-c5bacbfeb28ebc4ebfdc3b08969d9f17630cf2dfe9150b66d40999b0b04f26e7_citespan-574-598> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Numerous xenobiotics have also been linked to SLE, with decreases in blood neutrophil counts in some cases. In xenobioticinduced SLE, decreased neutrophil counts reflect production of autoantibodies and subsequent neutrophil destruction, similar to nonxenobiotic-induced SLE. Xenobiotics associated with SLE include anticonvulsants such as phenothiazines, chlorpromazine, and valproate, antibiotics such as penicillin, streptomycin, tetracycline, griseofulvin, and sulphonamides, and miscellaneous xenobiotics such as captopril, phenylbutazone, and lovastatin (Stone, 2005; Mutasim and Adams, 2000) ." ;
            <http://www.example.org/textHash>
                    "c5bacbfeb28ebc4ebfdc3b08969d9f17630cf2dfe9150b66d40999b0b04f26e7" .
    
    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-858-872>
            <http://www.example.org/end>    "872.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "858.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-d281241fc64906aa25de49f69e81785af3ba0430e987b507ba327ffcbecf28d3_citespan-311-326>
            <http://www.example.org/end>    "326.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF327" ;
            <http://www.example.org/start>  "311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Roujeau, 2005)" .
    
    <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-565-586>
            <http://www.example.org/end>    "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "565.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-332-349>
            <http://www.example.org/end>    "349.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF225" ;
            <http://www.example.org/start>  "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016a;" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-438-451>
            <http://www.example.org/end>    "451.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF401" ;
            <http://www.example.org/start>  "438.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Valent, 2009;" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-488-512>
            <http://www.example.org/end>    "512.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "488.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Aster and Bougie, 2007)" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-649-673>
            <http://www.example.org/end>    "673.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF102" ;
            <http://www.example.org/start>  "649.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Easley and Condon, 1974)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1251-1273>
            <http://www.example.org/end>    "1273.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF393" ;
            <http://www.example.org/start>  "1251.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Trimarchi et al., 1999" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1387-1407>
            <http://www.example.org/end>    "1407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF82" ;
            <http://www.example.org/start>  "1387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Culver et al., 2013)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-720-745>
            <http://www.example.org/end>    "745.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF199" ;
            <http://www.example.org/start>  "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Katznelson et al., 1994;" .
    
    <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-1014-1037>
            <http://www.example.org/end>    "1037.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF266" ;
            <http://www.example.org/start>  "1014.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moriyama et al., 2008)" .
    
    <http://covid19.aksw.org/text-d81e8754bc58cb98079215f382535974334e5d39476c34ea4e95210665de095c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.3.2.1 Immune-mediated Immune-mediated decreases in monocyte counts are typically not observed in isolation and are associated with causes of pancytopenia, such as aplastic anemia. With aplastic anemia, destruction of early hematopoietic precursors results in loss of production of most or all hematopoietic cell lineages and subsequent development of severe decreases in multiple blood component counts. Aplastic anemia can also occur with nonimmune-mediated conditions, such as anorexia nervosa (Abella et al., 2002) .\",\"cite_spans\":[{\"start\":504.0,\"end\":525.0,\"text\":\"(Abella et al., 2002)\",\"ref_id\":\"BIBREF0\"}],\"ref_spans\":[],\"section\":\"Decreases in monocyte counts (monocytopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d81e8754bc58cb98079215f382535974334e5d39476c34ea4e95210665de095c_citespan-504-525> ;
            <http://www.example.org/section>
                    "Decreases in monocyte counts (monocytopenia)" ;
            <http://www.example.org/text>  "12.11.2.3.2.1 Immune-mediated Immune-mediated decreases in monocyte counts are typically not observed in isolation and are associated with causes of pancytopenia, such as aplastic anemia. With aplastic anemia, destruction of early hematopoietic precursors results in loss of production of most or all hematopoietic cell lineages and subsequent development of severe decreases in multiple blood component counts. Aplastic anemia can also occur with nonimmune-mediated conditions, such as anorexia nervosa (Abella et al., 2002) ." ;
            <http://www.example.org/textHash>
                    "d81e8754bc58cb98079215f382535974334e5d39476c34ea4e95210665de095c" .
    
    <http://covid19.aksw.org/text-8ea81bf30129fd1375e74cf814628263adf7f1b1b44233480b7ee68eee39e56f_citespan-231-251>
            <http://www.example.org/end>    "251.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF252" ;
            <http://www.example.org/start>  "231.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Mauro et al., 2000)" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-236-257>
            <http://www.example.org/end>    "257.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF333" ;
            <http://www.example.org/start>  "236.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Salama et al., 1989)" .
    
    <http://covid19.aksw.org/text-23ae1ce221485560bd3e59a19208ab77a3a0963d9b5c14ed04c87ce9ca5b621d_citespan-262-291>
            <http://www.example.org/end>    "291.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "262.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kolackzowska and Kubes, 2013)" .
    
    <http://covid19.aksw.org/text-0e49f86ebe42a035e301c530ebcbd55643657dc8672a42f82d962df46ea66136_citespan-455-479>
            <http://www.example.org/end>    "479.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF115" ;
            <http://www.example.org/start>  "455.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fernandez et al., 1984)" .
    
    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-455-479>
            <http://www.example.org/end>    "479.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF240" ;
            <http://www.example.org/start>  "455.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Makoni and Laber, 2004)" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-952-975>
            <http://www.example.org/end>    "975.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF183" ;
            <http://www.example.org/start>  "952.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Johnson et al., , 1990" .
    
    <http://covid19.aksw.org/text-5c13e5b358dba2e3bdfaba0cd2adbde14a42a90fcdf718971850a7bb3e25439d_citespan-176-203>
            <http://www.example.org/end>    "203.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "176.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1053-1070>
            <http://www.example.org/end>    "1070.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF92" ;
            <http://www.example.org/start>  "1053.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Desnoyers, 2010;" .
    
    <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Myeloid neoplasms can result in clonal eosinophil expansion and increases in blood eosinophil counts expansion (Tefferi et al., 2006) . Neoplastic increases in eosinophil counts have been associated with acute eosinophilic leukemia, chronic eosinophilic leukemia, chronic myeloid leukemia, and myelodysplastic syndrome (Wardlaw, 2016; Tefferi et al., 2006; Schultze, 2010) . Clonal increases in eosinophil counts may be difficult to distinguish from idiopathic hypereosinophilic syndrome, and cytogenetic analysis may be necessary; numerous cytogenetic abnormalities have been reported with clonal increases in eosinophil counts (Tefferi et al., 2006) .\",\"cite_spans\":[{\"start\":111.0,\"end\":133.0,\"text\":\"(Tefferi et al., 2006)\",\"ref_id\":\"BIBREF383\"},{\"start\":319.0,\"end\":334.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":335.0,\"end\":356.0,\"text\":\"Tefferi et al., 2006;\",\"ref_id\":\"BIBREF383\"},{\"start\":357.0,\"end\":372.0,\"text\":\"Schultze, 2010)\",\"ref_id\":\"BIBREF342\"},{\"start\":629.0,\"end\":651.0,\"text\":\"(Tefferi et al., 2006)\",\"ref_id\":\"BIBREF383\"}],\"ref_spans\":[],\"section\":\"Neoplastic\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-111-133> , <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-319-334> , <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-335-356> , <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-357-372> , <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-629-651> ;
            <http://www.example.org/section>
                    "Neoplastic" ;
            <http://www.example.org/text>  "Myeloid neoplasms can result in clonal eosinophil expansion and increases in blood eosinophil counts expansion (Tefferi et al., 2006) . Neoplastic increases in eosinophil counts have been associated with acute eosinophilic leukemia, chronic eosinophilic leukemia, chronic myeloid leukemia, and myelodysplastic syndrome (Wardlaw, 2016; Tefferi et al., 2006; Schultze, 2010) . Clonal increases in eosinophil counts may be difficult to distinguish from idiopathic hypereosinophilic syndrome, and cytogenetic analysis may be necessary; numerous cytogenetic abnormalities have been reported with clonal increases in eosinophil counts (Tefferi et al., 2006) ." ;
            <http://www.example.org/textHash>
                    "fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6" .
    
    <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-813-838>
            <http://www.example.org/end>    "838.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF438" ;
            <http://www.example.org/start>  "813.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young and Meadows, 2010)" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-760-781>
            <http://www.example.org/end>    "781.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF355" ;
            <http://www.example.org/start>  "760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Simpson et al., 1985)" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-497-523>
            <http://www.example.org/end>    "523.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "497.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1520-1531>
            <http://www.example.org/end>    "1531.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF318" ;
            <http://www.example.org/start>  "1520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ren, 2005)" .
    
    <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.1.6 Neoplastic Various neoplastic conditions may be associated with hemolysis. Malignant metastatic neoplasms or primary vascular neoplasms may result in fragmentation hemolysis by physical trauma to erythrocytes, as previously discussed. However, neoplastic conditions may also rarely be associated with phagocytosis and destruction of erythrocytes, or hemophagocytic syndrome. Hemophagocytic syndromes have been associated with T-cell lymphoma (Gonzalez et al., 1991) , NK-cell leukemia (Kobayashi et al., 1996) , hemophagocytic histiocytic sarcoma (Moore et al., 2006) , and various hematological neoplasias (Majluf-Cruz et al., 1998) .\",\"cite_spans\":[{\"start\":458.0,\"end\":481.0,\"text\":\"(Gonzalez et al., 1991)\",\"ref_id\":\"BIBREF151\"},{\"start\":501.0,\"end\":525.0,\"text\":\"(Kobayashi et al., 1996)\",\"ref_id\":\"BIBREF203\"},{\"start\":563.0,\"end\":583.0,\"text\":\"(Moore et al., 2006)\",\"ref_id\":\"BIBREF265\"},{\"start\":623.0,\"end\":649.0,\"text\":\"(Majluf-Cruz et al., 1998)\",\"ref_id\":\"BIBREF239\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-458-481> , <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-501-525> , <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-563-583> , <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-623-649> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.1.6 Neoplastic Various neoplastic conditions may be associated with hemolysis. Malignant metastatic neoplasms or primary vascular neoplasms may result in fragmentation hemolysis by physical trauma to erythrocytes, as previously discussed. However, neoplastic conditions may also rarely be associated with phagocytosis and destruction of erythrocytes, or hemophagocytic syndrome. Hemophagocytic syndromes have been associated with T-cell lymphoma (Gonzalez et al., 1991) , NK-cell leukemia (Kobayashi et al., 1996) , hemophagocytic histiocytic sarcoma (Moore et al., 2006) , and various hematological neoplasias (Majluf-Cruz et al., 1998) ." ;
            <http://www.example.org/textHash>
                    "428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554" .
    
    <http://covid19.aksw.org/text-40b8fd1bfe0a01b9ed22c817d599d2719ae9858789b58c2898ec32bd3f007a96>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.1.2 Glucocorticoid-induced The pattern of glucocorticoid-related alterations in leukocyte counts is commonly referred to as a stress leukogram. The predominant endogenous steroids are cortisone in most species or corticosterone in the rat. Classically, endogenous steroids cause increases in neutrophil counts that are accompanied by decreases in lymphocyte counts, increases in monocyte counts, and decreases in eosinophil counts. However, these effects may be variable depending on the species, and increases in neutrophil counts may be less prominent or absent in rats and mice. Interpretation of a stress or endogenous glucocorticoid effect in a nonclinical toxicity study should be made conservatively using a weight of evidence approach. It should also be noted that hyperadrenocorticism (Cushing syndrome or hypercortisolism) is associated with excess production of endogenous glucocorticoids, and will also cause increases in blood neutrophil counts through glucocorticoid-mediated mechanisms.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "12.11.2.1.1.2 Glucocorticoid-induced The pattern of glucocorticoid-related alterations in leukocyte counts is commonly referred to as a stress leukogram. The predominant endogenous steroids are cortisone in most species or corticosterone in the rat. Classically, endogenous steroids cause increases in neutrophil counts that are accompanied by decreases in lymphocyte counts, increases in monocyte counts, and decreases in eosinophil counts. However, these effects may be variable depending on the species, and increases in neutrophil counts may be less prominent or absent in rats and mice. Interpretation of a stress or endogenous glucocorticoid effect in a nonclinical toxicity study should be made conservatively using a weight of evidence approach. It should also be noted that hyperadrenocorticism (Cushing syndrome or hypercortisolism) is associated with excess production of endogenous glucocorticoids, and will also cause increases in blood neutrophil counts through glucocorticoid-mediated mechanisms." ;
            <http://www.example.org/textHash>
                    "40b8fd1bfe0a01b9ed22c817d599d2719ae9858789b58c2898ec32bd3f007a96" .
    
    <http://covid19.aksw.org/text-9032a3b671b9e8104171a5f76864960d55d8efd5c8fd99334756484cfb25992c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Relative increases in red cell mass, or hemoconcentration, most commonly occur due to dehydration and splenic contraction. In contrast to the absolute or \\\"true\\\" increases in red cell mass that result from proliferation of erythroid precursors in the bone marrow and/or spleen, relative increases are transient and consist of changes to total blood volume or shifting or noncirculating erythrocytes into circulation resulting in increases in red cell mass, which can rapidly resolve.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Relative increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Relative increases in red cell mass" ;
            <http://www.example.org/text>  "Relative increases in red cell mass, or hemoconcentration, most commonly occur due to dehydration and splenic contraction. In contrast to the absolute or \"true\" increases in red cell mass that result from proliferation of erythroid precursors in the bone marrow and/or spleen, relative increases are transient and consist of changes to total blood volume or shifting or noncirculating erythrocytes into circulation resulting in increases in red cell mass, which can rapidly resolve." ;
            <http://www.example.org/textHash>
                    "9032a3b671b9e8104171a5f76864960d55d8efd5c8fd99334756484cfb25992c" .
    
    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-516-536>
            <http://www.example.org/end>    "536.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF197" ;
            <http://www.example.org/start>  "516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kaser et al., 2001)" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-488-515>
            <http://www.example.org/end>    "515.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF60" ;
            <http://www.example.org/start>  "488.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Castoldi and Rigolin, 2001;" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-2001-2021>
            <http://www.example.org/end>    "2021.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF159" ;
            <http://www.example.org/start>  "2001.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Grewe et al., 1998)" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-2310-2333>
            <http://www.example.org/end>    "2333.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF266" ;
            <http://www.example.org/start>  "2310.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moriyama et al., 2008)" .
    
    <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d_citespan-1932-1955>
            <http://www.example.org/end>    "1955.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF49" ;
            <http://www.example.org/start>  "1932.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Burkhard et al., 2001)" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-896-916>
            <http://www.example.org/end>    "916.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF215" ;
            <http://www.example.org/start>  "896.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lantz et al., 1998)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-1028-1051>
            <http://www.example.org/end>    "1051.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF388" ;
            <http://www.example.org/start>  "1028.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Thompson et al., 1989)" .
    
    <http://covid19.aksw.org/text-e0ad55de38a56e69df45a6f909c6c65f5f4b6e1648ba0bc8f951b521fcda41a4_citespan-286-299>
            <http://www.example.org/end>    "299.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF280" ;
            <http://www.example.org/start>  "286.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Olver, 2010)" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1760-1774>
            <http://www.example.org/end>    "1774.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "1760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Russell, 2010;" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1129-1156>
            <http://www.example.org/end>    "1156.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF279" ;
            <http://www.example.org/start>  "1129.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ohene-Abuakwa et al., 2005)" .
    
    <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6_citespan-379-394>
            <http://www.example.org/end>    "394.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "379.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-3afe5b856a4c8a03b0602286440a7f242a6f04b3d42aadf8f7a2c7246e27d680>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Administration of exogenous catecholamines, such as epinephrine, or some adrenergic agonists has similar effects as those mediated by endogenous catecholamines. Shifting of neutrophils from the marginating to the circulating pools is responsible for the increases in blood neutrophil counts, potentially from altered adhesion molecule expression or hemodynamic forces. Leukocyte subtypes have different receptors modulating their adrenergic effects, and neutrophils appear to be primarily affected by a-adrenergic receptors (Benschop et al., 1996) .\",\"cite_spans\":[{\"start\":524.0,\"end\":547.0,\"text\":\"(Benschop et al., 1996)\",\"ref_id\":\"BIBREF25\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3afe5b856a4c8a03b0602286440a7f242a6f04b3d42aadf8f7a2c7246e27d680_citespan-524-547> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Administration of exogenous catecholamines, such as epinephrine, or some adrenergic agonists has similar effects as those mediated by endogenous catecholamines. Shifting of neutrophils from the marginating to the circulating pools is responsible for the increases in blood neutrophil counts, potentially from altered adhesion molecule expression or hemodynamic forces. Leukocyte subtypes have different receptors modulating their adrenergic effects, and neutrophils appear to be primarily affected by a-adrenergic receptors (Benschop et al., 1996) ." ;
            <http://www.example.org/textHash>
                    "3afe5b856a4c8a03b0602286440a7f242a6f04b3d42aadf8f7a2c7246e27d680" .
    
    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Several viral organisms in humans have also been reported to cause decreases in red cell mass due to hemolysis. Viral causes of hemolysis are commonly associated with autoimmune mechanisms, and include infection with Epstein-Barr virus (Palanduz et al., 2002) , hepatitis A, B, and C viruses (Kanematsu et al., 1996; Chao et al., 2001) , cytomegalovirus (Murray et al., 2001) , and HIV (Koduri et al., 2002) , although HIV infection is also commonly associated with decreases in reticulocyte counts rather than the expected increases secondary to hemolysis, indicative of concurrent suppressed erythropoiesis (Telen et al., 1990) .\",\"cite_spans\":[{\"start\":236.0,\"end\":259.0,\"text\":\"(Palanduz et al., 2002)\",\"ref_id\":\"BIBREF284\"},{\"start\":292.0,\"end\":316.0,\"text\":\"(Kanematsu et al., 1996;\"},{\"start\":317.0,\"end\":335.0,\"text\":\"Chao et al., 2001)\",\"ref_id\":\"BIBREF64\"},{\"start\":354.0,\"end\":375.0,\"text\":\"(Murray et al., 2001)\",\"ref_id\":\"BIBREF269\"},{\"start\":386.0,\"end\":407.0,\"text\":\"(Koduri et al., 2002)\",\"ref_id\":\"BIBREF204\"},{\"start\":609.0,\"end\":629.0,\"text\":\"(Telen et al., 1990)\",\"ref_id\":\"BIBREF384\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-609-629> , <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-354-375> , <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-386-407> , <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-317-335> , <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-236-259> , <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-292-316> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Several viral organisms in humans have also been reported to cause decreases in red cell mass due to hemolysis. Viral causes of hemolysis are commonly associated with autoimmune mechanisms, and include infection with Epstein-Barr virus (Palanduz et al., 2002) , hepatitis A, B, and C viruses (Kanematsu et al., 1996; Chao et al., 2001) , cytomegalovirus (Murray et al., 2001) , and HIV (Koduri et al., 2002) , although HIV infection is also commonly associated with decreases in reticulocyte counts rather than the expected increases secondary to hemolysis, indicative of concurrent suppressed erythropoiesis (Telen et al., 1990) ." ;
            <http://www.example.org/textHash>
                    "c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532" .
    
    <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-453-475>
            <http://www.example.org/end>    "475.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF156" ;
            <http://www.example.org/start>  "453.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Grattan et al., , 2003" .
    
    <http://covid19.aksw.org/text-f6a032c5737c6d45ad4c6b636bc6ceb2465afd3568393b4b1c32e6d291b1e188>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-induced immune-mediated hemolysis may not be limited to one of the three mechanisms described earlier, and a combination of these mechanisms may occur in some patients. For example, the NSAID diclofenac may cause hemolysis through both drug-dependent and drug-independent mechanisms (Salama et al., 1996) . Carboplatin has been reported to cause hemolysis through all three immune-mediated mechanisms (Marani et al., 1996) .\",\"cite_spans\":[{\"start\":294.0,\"end\":315.0,\"text\":\"(Salama et al., 1996)\",\"ref_id\":\"BIBREF334\"},{\"start\":412.0,\"end\":433.0,\"text\":\"(Marani et al., 1996)\",\"ref_id\":\"BIBREF242\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f6a032c5737c6d45ad4c6b636bc6ceb2465afd3568393b4b1c32e6d291b1e188_citespan-294-315> , <http://covid19.aksw.org/text-f6a032c5737c6d45ad4c6b636bc6ceb2465afd3568393b4b1c32e6d291b1e188_citespan-412-433> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Xenobiotic-induced immune-mediated hemolysis may not be limited to one of the three mechanisms described earlier, and a combination of these mechanisms may occur in some patients. For example, the NSAID diclofenac may cause hemolysis through both drug-dependent and drug-independent mechanisms (Salama et al., 1996) . Carboplatin has been reported to cause hemolysis through all three immune-mediated mechanisms (Marani et al., 1996) ." ;
            <http://www.example.org/textHash>
                    "f6a032c5737c6d45ad4c6b636bc6ceb2465afd3568393b4b1c32e6d291b1e188" .
    
    <http://covid19.aksw.org/text-97c0f2f115bf87a0a38d5bcaad2063d686b7a0b9c0a2f242e0a577ea7969c2bf_citespan-996-1022>
            <http://www.example.org/end>    "1022.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "996.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a;" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-262-284>
            <http://www.example.org/end>    "284.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF114" ;
            <http://www.example.org/start>  "262.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Felsberg et al., 1992;" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-348-361>
            <http://www.example.org/end>    "361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF437" ;
            <http://www.example.org/start>  "348.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young, 2016)" .
    
    <http://covid19.aksw.org/text-f305e8243806de65b25cf58ad20c82c108231c8cb5122712ee65c49221f8f40e_citespan-394-413>
            <http://www.example.org/end>    "413.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF316" ;
            <http://www.example.org/start>  "394.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ratain et al, 1985)" .
    
    <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-578-600>
            <http://www.example.org/end>    "600.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF41" ;
            <http://www.example.org/start>  "578.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Boulard et al., 1972)" .
    
    <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-284-308>
            <http://www.example.org/end>    "308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF149" ;
            <http://www.example.org/start>  "284.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Goh and Anderson, 1979)" .
    
    <http://covid19.aksw.org/text-3afe5b856a4c8a03b0602286440a7f242a6f04b3d42aadf8f7a2c7246e27d680_citespan-524-547>
            <http://www.example.org/end>    "547.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "524.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Benschop et al., 1996)" .
    
    <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.1.2.1 Hypoxia-dependent (appropriate) Increases in EPO production occur in response to hypoxia primarily from the kidney, although there is also some evidence that hypoxia may also stimulate production of EPO by the liver (Rankin et al., 2007) . Under normal oxygenation states, hypoxia-inducible factor (HIF) subunits are polyubiquitinated by a von Hipple-Lindau (VHL) tumor suppressor E3 ligase complex, which results in proteosomal degradation of HIF (Jaakkola et al., 2001) . Binding of the VHL E3 ligase complex to HIF requires hydroxylation of a proline residue in the VHL protein, a process that requires both oxygen and iron (Ivan et al., 2001) . In hypoxic states, HIF is not ubiquitinated and HIF subunits translocate to the nucleus, forming a transcription factor for genes, including the erythropoietin gene. Increases in circulating EPO concentrations as a result of hypoxia cause an \",\"cite_spans\":[{\"start\":230.0,\"end\":251.0,\"text\":\"(Rankin et al., 2007)\",\"ref_id\":\"BIBREF314\"},{\"start\":462.0,\"end\":485.0,\"text\":\"(Jaakkola et al., 2001)\",\"ref_id\":\"BIBREF180\"},{\"start\":641.0,\"end\":660.0,\"text\":\"(Ivan et al., 2001)\",\"ref_id\":\"BIBREF179\"}],\"ref_spans\":[],\"section\":\"Secondary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652_citespan-230-251> , <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652_citespan-462-485> , <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652_citespan-641-660> ;
            <http://www.example.org/section>
                    "Secondary increases in red cell mass" ;
            <http://www.example.org/text>  "12.11.3.1.2.1 Hypoxia-dependent (appropriate) Increases in EPO production occur in response to hypoxia primarily from the kidney, although there is also some evidence that hypoxia may also stimulate production of EPO by the liver (Rankin et al., 2007) . Under normal oxygenation states, hypoxia-inducible factor (HIF) subunits are polyubiquitinated by a von Hipple-Lindau (VHL) tumor suppressor E3 ligase complex, which results in proteosomal degradation of HIF (Jaakkola et al., 2001) . Binding of the VHL E3 ligase complex to HIF requires hydroxylation of a proline residue in the VHL protein, a process that requires both oxygen and iron (Ivan et al., 2001) . In hypoxic states, HIF is not ubiquitinated and HIF subunits translocate to the nucleus, forming a transcription factor for genes, including the erythropoietin gene. Increases in circulating EPO concentrations as a result of hypoxia cause an " ;
            <http://www.example.org/textHash>
                    "1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652" .
    
    <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-563-583>
            <http://www.example.org/end>    "583.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF265" ;
            <http://www.example.org/start>  "563.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore et al., 2006)" .
    
    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Allergic inflammation that involves IgE and/or causes increases in eosinophil counts typically also causes increases in blood basophil counts. Immediate or delayed hypersensitivity may cause increases in basophil counts, although immediate hypersensitivity has also been associated with decreases in basophil counts in some cases; whether basophil counts increase or decrease may represent a distinction between allergic sensitization and an immediate allergic reaction (Shelley and Parnes, 1965) . Food or inhalant allergies, such as ragweed pollen (Otsuka et al., 1986) , can frequently cause increases in blood basophil counts (Galli et al., 2016; Pohlman, 2010) . Allergic inflammation also occurs with insect stings or bites (Stockham and Scott, 2008a) and probably H. pylori infection (Karttunen et al., 1996) .\",\"cite_spans\":[{\"start\":470.0,\"end\":496.0,\"text\":\"(Shelley and Parnes, 1965)\",\"ref_id\":\"BIBREF352\"},{\"start\":550.0,\"end\":571.0,\"text\":\"(Otsuka et al., 1986)\",\"ref_id\":\"BIBREF281\"},{\"start\":630.0,\"end\":650.0,\"text\":\"(Galli et al., 2016;\",\"ref_id\":\"BIBREF128\"},{\"start\":651.0,\"end\":665.0,\"text\":\"Pohlman, 2010)\",\"ref_id\":\"BIBREF300\"},{\"start\":730.0,\"end\":757.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":791.0,\"end\":815.0,\"text\":\"(Karttunen et al., 1996)\",\"ref_id\":\"BIBREF196\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-791-815> , <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-651-665> , <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-730-757> , <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-470-496> , <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-630-650> , <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-550-571> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "Allergic inflammation that involves IgE and/or causes increases in eosinophil counts typically also causes increases in blood basophil counts. Immediate or delayed hypersensitivity may cause increases in basophil counts, although immediate hypersensitivity has also been associated with decreases in basophil counts in some cases; whether basophil counts increase or decrease may represent a distinction between allergic sensitization and an immediate allergic reaction (Shelley and Parnes, 1965) . Food or inhalant allergies, such as ragweed pollen (Otsuka et al., 1986) , can frequently cause increases in blood basophil counts (Galli et al., 2016; Pohlman, 2010) . Allergic inflammation also occurs with insect stings or bites (Stockham and Scott, 2008a) and probably H. pylori infection (Karttunen et al., 1996) ." ;
            <http://www.example.org/textHash>
                    "32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Autonomous production of EPO by neoplasms has been associated with both benign and malignant tumors. Renal adenoma, renal carcinoma, and sarcoma of the kidney have been reported to cause increases in red cell mass (Ways et al., 1961) . Renal lymphoma has also been associated with increases in red cell mass (Durno et al., 2011) . Nonrenal tumors with inappropriate EPO production include hepatoma, hamartoma of the liver, leiomyosarcoma, schwannoma, and pheochromocytoma (Stockham and Scott, 2008b; LevGur and Levie, 1995; Muta et al., 1994; Shulkin et al., 1987; Josephs et al., 1961) . VHL syndrome, which follows an autosomal dominant pattern of inheritance, may predispose affected people to developing renal or nonrenal neoplasms that can autonomously produce EPO (Prchal, 2016) .\",\"cite_spans\":[{\"start\":214.0,\"end\":233.0,\"text\":\"(Ways et al., 1961)\",\"ref_id\":\"BIBREF422\"},{\"start\":308.0,\"end\":328.0,\"text\":\"(Durno et al., 2011)\",\"ref_id\":\"BIBREF101\"},{\"start\":472.0,\"end\":499.0,\"text\":\"(Stockham and Scott, 2008b;\",\"ref_id\":\"BIBREF367\"},{\"start\":500.0,\"end\":523.0,\"text\":\"LevGur and Levie, 1995;\",\"ref_id\":\"BIBREF220\"},{\"start\":524.0,\"end\":542.0,\"text\":\"Muta et al., 1994;\",\"ref_id\":\"BIBREF270\"},{\"start\":543.0,\"end\":564.0,\"text\":\"Shulkin et al., 1987;\",\"ref_id\":\"BIBREF354\"},{\"start\":565.0,\"end\":586.0,\"text\":\"Josephs et al., 1961)\",\"ref_id\":\"BIBREF186\"},{\"start\":770.0,\"end\":784.0,\"text\":\"(Prchal, 2016)\",\"ref_id\":\"BIBREF302\"}],\"ref_spans\":[],\"section\":\"Secondary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-565-586> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-524-542> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-308-328> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-214-233> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-770-784> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-543-564> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-472-499> , <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-500-523> ;
            <http://www.example.org/section>
                    "Secondary increases in red cell mass" ;
            <http://www.example.org/text>  "Autonomous production of EPO by neoplasms has been associated with both benign and malignant tumors. Renal adenoma, renal carcinoma, and sarcoma of the kidney have been reported to cause increases in red cell mass (Ways et al., 1961) . Renal lymphoma has also been associated with increases in red cell mass (Durno et al., 2011) . Nonrenal tumors with inappropriate EPO production include hepatoma, hamartoma of the liver, leiomyosarcoma, schwannoma, and pheochromocytoma (Stockham and Scott, 2008b; LevGur and Levie, 1995; Muta et al., 1994; Shulkin et al., 1987; Josephs et al., 1961) . VHL syndrome, which follows an autosomal dominant pattern of inheritance, may predispose affected people to developing renal or nonrenal neoplasms that can autonomously produce EPO (Prchal, 2016) ." ;
            <http://www.example.org/textHash>
                    "6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14" .
    
    <http://covid19.aksw.org/text-c0d3fa2cc3ab5cb28628aa8dff473420c694a194a44c1c961fa8bcd62c5a2ca2_citespan-700-720>
            <http://www.example.org/end>    "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF441" ;
            <http://www.example.org/start>  "700.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Zhang et al., 2012)" .
    
    <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Miscellaneous causes of xenobiotic-induced decreases in blood platelet counts include nonimmune-mediated destruction reported to occur with desmopressin (Bloom and Brandt, 2008) and idiosyncratic reactions associated with CARPA (Patkó and Szebeni, 2015) or administration of some antisense oligonucleotides (Frazier, 2015) . Idiosyncratic decreases in platelet counts have also been reported as an off-target effect of human monoclonal antibodies during nonclinical toxicology studies (Everds et al., 2013b) .\",\"cite_spans\":[{\"start\":153.0,\"end\":177.0,\"text\":\"(Bloom and Brandt, 2008)\",\"ref_id\":\"BIBREF35\"},{\"start\":228.0,\"end\":253.0,\"text\":\"(Patkó and Szebeni, 2015)\",\"ref_id\":\"BIBREF292\"},{\"start\":307.0,\"end\":322.0,\"text\":\"(Frazier, 2015)\",\"ref_id\":\"BIBREF122\"},{\"start\":485.0,\"end\":507.0,\"text\":\"(Everds et al., 2013b)\",\"ref_id\":\"BIBREF108\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-153-177> , <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-228-253> , <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-307-322> , <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-485-507> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Miscellaneous causes of xenobiotic-induced decreases in blood platelet counts include nonimmune-mediated destruction reported to occur with desmopressin (Bloom and Brandt, 2008) and idiosyncratic reactions associated with CARPA (Patkó and Szebeni, 2015) or administration of some antisense oligonucleotides (Frazier, 2015) . Idiosyncratic decreases in platelet counts have also been reported as an off-target effect of human monoclonal antibodies during nonclinical toxicology studies (Everds et al., 2013b) ." ;
            <http://www.example.org/textHash>
                    "2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f" .
    
    <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-447-460>
            <http://www.example.org/end>    "460.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF57" ;
            <http://www.example.org/start>  "447.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Carey, 2003;" .
    
    <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-680-703>
            <http://www.example.org/end>    "703.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF324" ;
            <http://www.example.org/start>  "680.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Rosenberg et al., 2013)" .
    
    <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-703-723>
            <http://www.example.org/end>    "723.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF53" ;
            <http://www.example.org/start>  "703.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Callot et al., 1996;" .
    
    <http://covid19.aksw.org/text-79d5674a824b477e14e92262ee9f36603a7ca26d9f5a9af77cb5523f1178518a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"An increasing number of xenobiotics are associated with alterations in the hematopoietic system. These alterations encompass a variety of direct and indirect effects, many of which are associated with the intended pharmacology of the compound but may also be related to off-target effects. Alterations in the hematopoietic system are commonly reflected by changes in the peripheral blood components. Blood components include leukocytes, erythrocytes, and platelets. Leukocyte subtypes in humans and common laboratory species include neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts. The erythrocyte component includes both total erythrocyte and reticulocyte counts. The complete blood count (CBC) is the standard method for analyzing blood leukocyte, erythrocyte, and platelet components. Absolute concentrations (cells mL À 1 ), conventionally referred to as absolute counts in nonclinical toxicity studies, should be used to evaluate and interpret changes in blood components because relative percentages do not account for the total numbers of cells present and may be misleading. Interpretation of xenobiotic-related alterations in blood components should be made with the consideration of the inherent biological variation in CBC endpoints observed in common laboratory species, and an understanding of the various mechanisms underlying increased or decreased blood component counts. There is considerable overlap in the mechanisms of blood cell alterations in both naturally occurring and xenobiotic-induced changes. The focus of this article is to review more commonly observed alterations in blood leukocyte, erythrocyte, and platelet components.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "An increasing number of xenobiotics are associated with alterations in the hematopoietic system. These alterations encompass a variety of direct and indirect effects, many of which are associated with the intended pharmacology of the compound but may also be related to off-target effects. Alterations in the hematopoietic system are commonly reflected by changes in the peripheral blood components. Blood components include leukocytes, erythrocytes, and platelets. Leukocyte subtypes in humans and common laboratory species include neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts. The erythrocyte component includes both total erythrocyte and reticulocyte counts. The complete blood count (CBC) is the standard method for analyzing blood leukocyte, erythrocyte, and platelet components. Absolute concentrations (cells mL À 1 ), conventionally referred to as absolute counts in nonclinical toxicity studies, should be used to evaluate and interpret changes in blood components because relative percentages do not account for the total numbers of cells present and may be misleading. Interpretation of xenobiotic-related alterations in blood components should be made with the consideration of the inherent biological variation in CBC endpoints observed in common laboratory species, and an understanding of the various mechanisms underlying increased or decreased blood component counts. There is considerable overlap in the mechanisms of blood cell alterations in both naturally occurring and xenobiotic-induced changes. The focus of this article is to review more commonly observed alterations in blood leukocyte, erythrocyte, and platelet components." ;
            <http://www.example.org/textHash>
                    "79d5674a824b477e14e92262ee9f36603a7ca26d9f5a9af77cb5523f1178518a" .
    
    <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c_citespan-775-791>
            <http://www.example.org/end>    "791.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF48" ;
            <http://www.example.org/start>  "775.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Burkhard, 2010)" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-543-564>
            <http://www.example.org/end>    "564.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF354" ;
            <http://www.example.org/start>  "543.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Shulkin et al., 1987;" .
    
    <http://covid19.aksw.org/text-73c0aead69c5ef6509f5402451b25224c5f4d577caefe7c77c73d4d9c480f4ef_citespan-298-312>
            <http://www.example.org/end>    "312.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF166" ;
            <http://www.example.org/start>  "298.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Harvey, 2012)" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-1182-1205>
            <http://www.example.org/end>    "1205.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF198" ;
            <http://www.example.org/start>  "1182.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Katsumata et al., 2003)" .
    
    <http://covid19.aksw.org/text-40543c581215d7f87d33a4c7dd8405ccc84f1bb5781ac6e73da8b536ed809c7a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"May be slightly increased in some cases. b Due to low eosinophil and basophil counts in health, decreases may be difficult to identify. c Morphologic changes indicative of rapid neutropoiesis (Döhle bodies, cytoplasmic vacuolation, and cytoplasmic basophilia) may be observed.\",\"cite_spans\":[{\"start\":41.0,\"end\":42.0,\"text\":\"b\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-40543c581215d7f87d33a4c7dd8405ccc84f1bb5781ac6e73da8b536ed809c7a_citespan-41-42> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "May be slightly increased in some cases. b Due to low eosinophil and basophil counts in health, decreases may be difficult to identify. c Morphologic changes indicative of rapid neutropoiesis (Döhle bodies, cytoplasmic vacuolation, and cytoplasmic basophilia) may be observed." ;
            <http://www.example.org/textHash>
                    "40543c581215d7f87d33a4c7dd8405ccc84f1bb5781ac6e73da8b536ed809c7a" .
    
    <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-572-595>
            <http://www.example.org/end>    "595.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF295" ;
            <http://www.example.org/start>  "572.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Perigard et al., 2016)" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-594-611>
            <http://www.example.org/end>    "611.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF225" ;
            <http://www.example.org/start>  "594.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016a;" .
    
    <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-762-782>
            <http://www.example.org/end>    "782.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF209" ;
            <http://www.example.org/start>  "762.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kupers et al., 1975;" .
    
    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-582-597>
            <http://www.example.org/end>    "597.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF293" ;
            <http://www.example.org/start>  "582.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pearson, 2001)" .
    
    <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.3.1.6 Xenobiotic-induced Administration of exogenous glucocorticoids classically causes increases in monocyte counts, although this effect may be inconsistently observed and no change in blood monocyte counts may occur. Some studies have demonstrated that transient decreases in monocyte counts occur immediately following administration of exogenous glucocorticoids with subsequent increases in monocyte counts (Rinehart et al., 1975; Steer et al., 1997) , but others have only reported increases in monocyte counts with exogenous glucocorticoid administration (Barker et al., 2012) .\",\"cite_spans\":[{\"start\":420.0,\"end\":443.0,\"text\":\"(Rinehart et al., 1975;\",\"ref_id\":\"BIBREF320\"},{\"start\":444.0,\"end\":463.0,\"text\":\"Steer et al., 1997)\",\"ref_id\":\"BIBREF365\"},{\"start\":570.0,\"end\":591.0,\"text\":\"(Barker et al., 2012)\",\"ref_id\":\"BIBREF17\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97_citespan-420-443> , <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97_citespan-444-463> , <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97_citespan-570-591> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "12.11.2.3.1.6 Xenobiotic-induced Administration of exogenous glucocorticoids classically causes increases in monocyte counts, although this effect may be inconsistently observed and no change in blood monocyte counts may occur. Some studies have demonstrated that transient decreases in monocyte counts occur immediately following administration of exogenous glucocorticoids with subsequent increases in monocyte counts (Rinehart et al., 1975; Steer et al., 1997) , but others have only reported increases in monocyte counts with exogenous glucocorticoid administration (Barker et al., 2012) ." ;
            <http://www.example.org/textHash>
                    "c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97" .
    
    <http://covid19.aksw.org/text-d3bdd73863d7f4816bb77573a61ef70c66182608850c44703f41e05118198faa>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Immune-mediated destruction of erythroid precursors in the bone marrow results in decreases in red cell mass with concurrent decreases in reticulocyte counts. The immune-mediated conditions discussed here may represent a spectrum of disease associated with immune destruction of various stages of erythroid precursors rather than unrelated entities. 12.11.3.2.2.4.1 Autoimmune hemolytic anemia with decreases in reticulocyte counts Autoimmune hemolytic anemia with antibodies that target antigens on mid-to late-stage erythroid precursors ranging from rubricytes to metarubricytes results in AIHA with a decrease in reticulocyte count, which may also be called immune-mediated nonregenerative anemia or precursor-targeted immune-mediated anemia (PIMA). AIHA with reticulocytopenia is generally a normocytic, normochromic anemia. Bone marrow examination may reveal erythroid hyperplasia or maturation arrest (Weiss, 2008) with pyramidal expansion of erythroid precursors at stages earlier than the targeted stage, indicative of ineffective erythropoiesis. This may be less apparent with autoantibodies that recognize more immature stages of erythroid precursors. Bone marrow evaluation may also reveal rubriphagocytosis, or erythroid precursors phagocytized by macrophages. The stage of phagocytized precursor depends on the stage or stages expressing the targeted antigen.\",\"cite_spans\":[{\"start\":907.0,\"end\":920.0,\"text\":\"(Weiss, 2008)\",\"ref_id\":\"BIBREF427\"}],\"ref_spans\":[],\"section\":\"Immune-mediated\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d3bdd73863d7f4816bb77573a61ef70c66182608850c44703f41e05118198faa_citespan-907-920> ;
            <http://www.example.org/section>
                    "Immune-mediated" ;
            <http://www.example.org/text>  "Immune-mediated destruction of erythroid precursors in the bone marrow results in decreases in red cell mass with concurrent decreases in reticulocyte counts. The immune-mediated conditions discussed here may represent a spectrum of disease associated with immune destruction of various stages of erythroid precursors rather than unrelated entities. 12.11.3.2.2.4.1 Autoimmune hemolytic anemia with decreases in reticulocyte counts Autoimmune hemolytic anemia with antibodies that target antigens on mid-to late-stage erythroid precursors ranging from rubricytes to metarubricytes results in AIHA with a decrease in reticulocyte count, which may also be called immune-mediated nonregenerative anemia or precursor-targeted immune-mediated anemia (PIMA). AIHA with reticulocytopenia is generally a normocytic, normochromic anemia. Bone marrow examination may reveal erythroid hyperplasia or maturation arrest (Weiss, 2008) with pyramidal expansion of erythroid precursors at stages earlier than the targeted stage, indicative of ineffective erythropoiesis. This may be less apparent with autoantibodies that recognize more immature stages of erythroid precursors. Bone marrow evaluation may also reveal rubriphagocytosis, or erythroid precursors phagocytized by macrophages. The stage of phagocytized precursor depends on the stage or stages expressing the targeted antigen." ;
            <http://www.example.org/textHash>
                    "d3bdd73863d7f4816bb77573a61ef70c66182608850c44703f41e05118198faa" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-673-694>
            <http://www.example.org/end>    "694.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF333" ;
            <http://www.example.org/start>  "673.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Salama et al., 1989;" .
    
    <http://covid19.aksw.org/text-9ea5c9661a1c734f64c55c3bcfa8bb5f955002f60fc9834f926d2e2725abe9dd_citespan-403-425>
            <http://www.example.org/end>    "425.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF261" ;
            <http://www.example.org/start>  "403.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Mintzer et al., 2009)" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1115-1128>
            <http://www.example.org/end>    "1128.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF437" ;
            <http://www.example.org/start>  "1115.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young, 2016;" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-618-633>
            <http://www.example.org/end>    "633.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "618.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-2bc22939fa9c83241c94ce75de8823815c263a5f365c49370a8c4eda656aa8d1_citespan-336-358>
            <http://www.example.org/end>    "358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF107" ;
            <http://www.example.org/start>  "336.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Everds et al., 2013a)" .
    
    <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.2.1.1 Age-related Lymphocytes are common as the predominant blood leukocyte of neonate and juvenile animals, even in species with predominant neutrophils in the circulation of adults. Recognition of this apparent \\\"lymphocytosis\\\" of young animals is important, as comparison of lymphocyte counts in young animals with adult historical control data may give the appearance of increased lymphocyte counts. Species in which \\\"lymphocytosis\\\" in young animals has been described include dogs and cats (Stockham and Scott, 2008a) and cynomolgus monkeys (Sugimoto et al., 1986) . As the shift from predominantly lymphocytes to predominantly neutrophils in circulation occurs around 4 to 5 years old in cynomolgus monkeys (Sugimoto et al., 1986) , it is not uncommon for nonclinical toxicology studies to include individuals with both lymphocyte and neutrophil-predominant leukograms.\",\"cite_spans\":[{\"start\":502.0,\"end\":529.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":553.0,\"end\":576.0,\"text\":\"(Sugimoto et al., 1986)\",\"ref_id\":\"BIBREF373\"},{\"start\":720.0,\"end\":743.0,\"text\":\"(Sugimoto et al., 1986)\",\"ref_id\":\"BIBREF373\"}],\"ref_spans\":[],\"section\":\"Increases in lymphocyte counts (lymphocytosis)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209_citespan-502-529> , <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209_citespan-553-576> , <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209_citespan-720-743> ;
            <http://www.example.org/section>
                    "Increases in lymphocyte counts (lymphocytosis)" ;
            <http://www.example.org/text>  "12.11.2.2.1.1 Age-related Lymphocytes are common as the predominant blood leukocyte of neonate and juvenile animals, even in species with predominant neutrophils in the circulation of adults. Recognition of this apparent \"lymphocytosis\" of young animals is important, as comparison of lymphocyte counts in young animals with adult historical control data may give the appearance of increased lymphocyte counts. Species in which \"lymphocytosis\" in young animals has been described include dogs and cats (Stockham and Scott, 2008a) and cynomolgus monkeys (Sugimoto et al., 1986) . As the shift from predominantly lymphocytes to predominantly neutrophils in circulation occurs around 4 to 5 years old in cynomolgus monkeys (Sugimoto et al., 1986) , it is not uncommon for nonclinical toxicology studies to include individuals with both lymphocyte and neutrophil-predominant leukograms." ;
            <http://www.example.org/textHash>
                    "fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3179-3194>
            <http://www.example.org/end>    "3194.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "3179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Arnaout, 1990;" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-597-624>
            <http://www.example.org/end>    "624.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "597.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-be7daa4ac38811cdb3542af168715650f68fa8c4300243745b2e3a76126c3e1c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in platelet counts associated with xenobiotic administration are most commonly reactive, and associated with increases in IL-6 and/or TPO. Any xenobiotic that can result in an inflammatory stimulus may result in reactive increases in platelet counts, and examples of such xenobiotics are discussed in more detail in previous sections. Resolution of xenobiotic-induced bone marrow suppression may cause a transient rebound increase in platelet counts due to increased TPO and thrombopoiesis secondary to the xenobiotic-induced decreases in platelet counts.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Increases in platelet counts associated with xenobiotic administration are most commonly reactive, and associated with increases in IL-6 and/or TPO. Any xenobiotic that can result in an inflammatory stimulus may result in reactive increases in platelet counts, and examples of such xenobiotics are discussed in more detail in previous sections. Resolution of xenobiotic-induced bone marrow suppression may cause a transient rebound increase in platelet counts due to increased TPO and thrombopoiesis secondary to the xenobiotic-induced decreases in platelet counts." ;
            <http://www.example.org/textHash>
                    "be7daa4ac38811cdb3542af168715650f68fa8c4300243745b2e3a76126c3e1c" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-338-357>
            <http://www.example.org/end>    "357.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF332" ;
            <http://www.example.org/start>  "338.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sakka et al., 2006)" .
    
    <http://covid19.aksw.org/text-2a908d0d4623487ba40e2414d65ee9f35edac83c6e0ed481c79ebd0a8d8be52c_citespan-430-457>
            <http://www.example.org/end>    "457.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "430.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c_citespan-526-564>
            <http://www.example.org/end>    "564.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "526.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "IL-11, INFg, and TGFb (Burkhard, 2010)" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-210-223>
            <http://www.example.org/end>    "223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF376" ;
            <http://www.example.org/start>  "210.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Suter, 2010;" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-595-616>
            <http://www.example.org/end>    "616.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF167" ;
            <http://www.example.org/start>  "595.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Harvey et al., 1977;" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1367-1390>
            <http://www.example.org/end>    "1390.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF410" ;
            <http://www.example.org/start>  "1367.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Visentin and Liu, 2007;" .
    
    <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652_citespan-641-660>
            <http://www.example.org/end>    "660.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF179" ;
            <http://www.example.org/start>  "641.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ivan et al., 2001)" .
    
    <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Iron deficiency with decreases in red cell mass has been associated with reactive increases in platelet counts in many, but not all, cases (Stockham and Scott, 2008c) . The mechanism of the increases in platelet counts is unclear (Dan, 2005) . Some studies have demonstrated that there are no detectable increases in TPO or IL-6 in iron deficiency anemia (Akan et al., 2000) , and that although EPO is increased with iron deficiency anemia, cross-reactivity of TPO and EPO does not explain the reactive thrombocytosis (Geddis and Kaushansky, 2003) .\",\"cite_spans\":[{\"start\":139.0,\"end\":166.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":230.0,\"end\":241.0,\"text\":\"(Dan, 2005)\",\"ref_id\":\"BIBREF86\"},{\"start\":355.0,\"end\":374.0,\"text\":\"(Akan et al., 2000)\",\"ref_id\":\"BIBREF2\"},{\"start\":518.0,\"end\":547.0,\"text\":\"(Geddis and Kaushansky, 2003)\",\"ref_id\":\"BIBREF138\"}],\"ref_spans\":[],\"section\":\"Inflammation or reactive\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-139-166> , <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-230-241> , <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-355-374> , <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-518-547> ;
            <http://www.example.org/section>
                    "Inflammation or reactive" ;
            <http://www.example.org/text>  "Iron deficiency with decreases in red cell mass has been associated with reactive increases in platelet counts in many, but not all, cases (Stockham and Scott, 2008c) . The mechanism of the increases in platelet counts is unclear (Dan, 2005) . Some studies have demonstrated that there are no detectable increases in TPO or IL-6 in iron deficiency anemia (Akan et al., 2000) , and that although EPO is increased with iron deficiency anemia, cross-reactivity of TPO and EPO does not explain the reactive thrombocytosis (Geddis and Kaushansky, 2003) ." ;
            <http://www.example.org/textHash>
                    "6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009" .
    
    <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.2.2.1 Glucocorticoid-induced Endogenous glucocorticoids may be increased with chronic stress or hyperadrenocorticism, and decreases in lymphocyte counts tend to be the most prominent and consistent glucocorticoid-mediated leukocyte change across species. Glucocorticoids induce decreases in blood lymphocyte counts through several mechanisms. In addition to a rapid shift of lymphocytes from the circulating to marginating and tissue pools, there is evidence for both lymphocyte redistribution from blood to bone marrow (Fauci, 1975) and decreased efflux of lymphocytes from lymphoid tissues (Bloemena et al., 1990) contributing to the shift of lymphocytes to tissue pools. With long-term increases in glucocorticoid concentrations, lymphotoxicity may be observed due to an increased activation of apoptotic pathways (Garvy et al., 1993; Tuckermann et al., 2005) . In rats, feed restriction has been associated with decreases in blood lymphocyte counts and lymphocyte depletion in various lymphoid tissues (Moriyama et al., 2008) , possibly associated with prolonged stress and therefore a glucocorticoid-mediated effect. Indirect test article-related effects mediated by altered food consumption are important to consider in nonclinical toxicology studies, in which test articles may cause direct or indirect hematologic effects. Interpretation of these changes, including stress-associated effects, must be made cautiously and thoughtfully, using a weight of evidence approach.\",\"cite_spans\":[{\"start\":528.0,\"end\":541.0,\"text\":\"(Fauci, 1975)\",\"ref_id\":\"BIBREF112\"},{\"start\":600.0,\"end\":623.0,\"text\":\"(Bloemena et al., 1990)\",\"ref_id\":\"BIBREF34\"},{\"start\":825.0,\"end\":845.0,\"text\":\"(Garvy et al., 1993;\",\"ref_id\":\"BIBREF135\"},{\"start\":846.0,\"end\":870.0,\"text\":\"Tuckermann et al., 2005)\",\"ref_id\":\"BIBREF396\"},{\"start\":1014.0,\"end\":1037.0,\"text\":\"(Moriyama et al., 2008)\",\"ref_id\":\"BIBREF266\"}],\"ref_spans\":[],\"section\":\"Decreases in lymphocyte counts (lymphopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-528-541> , <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-600-623> , <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-825-845> , <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-846-870> , <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-1014-1037> ;
            <http://www.example.org/section>
                    "Decreases in lymphocyte counts (lymphopenia)" ;
            <http://www.example.org/text>  "12.11.2.2.2.1 Glucocorticoid-induced Endogenous glucocorticoids may be increased with chronic stress or hyperadrenocorticism, and decreases in lymphocyte counts tend to be the most prominent and consistent glucocorticoid-mediated leukocyte change across species. Glucocorticoids induce decreases in blood lymphocyte counts through several mechanisms. In addition to a rapid shift of lymphocytes from the circulating to marginating and tissue pools, there is evidence for both lymphocyte redistribution from blood to bone marrow (Fauci, 1975) and decreased efflux of lymphocytes from lymphoid tissues (Bloemena et al., 1990) contributing to the shift of lymphocytes to tissue pools. With long-term increases in glucocorticoid concentrations, lymphotoxicity may be observed due to an increased activation of apoptotic pathways (Garvy et al., 1993; Tuckermann et al., 2005) . In rats, feed restriction has been associated with decreases in blood lymphocyte counts and lymphocyte depletion in various lymphoid tissues (Moriyama et al., 2008) , possibly associated with prolonged stress and therefore a glucocorticoid-mediated effect. Indirect test article-related effects mediated by altered food consumption are important to consider in nonclinical toxicology studies, in which test articles may cause direct or indirect hematologic effects. Interpretation of these changes, including stress-associated effects, must be made cautiously and thoughtfully, using a weight of evidence approach." ;
            <http://www.example.org/textHash>
                    "99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3" .
    
    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-1133-1154>
            <http://www.example.org/end>    "1154.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF364" ;
            <http://www.example.org/start>  "1133.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sontas et al., 2009)" .
    
    <http://covid19.aksw.org/text-785b73145229f779ccc708abba95ba933ebe1586d9382ea1a94a5992de5d39f8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Treatment of CML and chronic lymphocytic leukemia with dasatinib and ibrutinib, respectively, has been associated with increases in blood lymphocytes counts (Vasu and Caligiuri, 2016) . Dasatinib-related increases in lymphocyte counts may be related to expansion of T-cell or NK-cell populations and increases in IL-2R, INF-g, and IL-6, with reported favorable outcome to treatment, while ibrutinib-related increases in lymphocyte counts may be related to and increased efflux of lymphocytes from lymphoid tissues (Vasu and Caligiuri, 2016) .\",\"cite_spans\":[{\"start\":157.0,\"end\":183.0,\"text\":\"(Vasu and Caligiuri, 2016)\",\"ref_id\":\"BIBREF406\"},{\"start\":514.0,\"end\":540.0,\"text\":\"(Vasu and Caligiuri, 2016)\",\"ref_id\":\"BIBREF406\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-785b73145229f779ccc708abba95ba933ebe1586d9382ea1a94a5992de5d39f8_citespan-157-183> , <http://covid19.aksw.org/text-785b73145229f779ccc708abba95ba933ebe1586d9382ea1a94a5992de5d39f8_citespan-514-540> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Treatment of CML and chronic lymphocytic leukemia with dasatinib and ibrutinib, respectively, has been associated with increases in blood lymphocytes counts (Vasu and Caligiuri, 2016) . Dasatinib-related increases in lymphocyte counts may be related to expansion of T-cell or NK-cell populations and increases in IL-2R, INF-g, and IL-6, with reported favorable outcome to treatment, while ibrutinib-related increases in lymphocyte counts may be related to and increased efflux of lymphocytes from lymphoid tissues (Vasu and Caligiuri, 2016) ." ;
            <http://www.example.org/textHash>
                    "785b73145229f779ccc708abba95ba933ebe1586d9382ea1a94a5992de5d39f8" .
    
    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-71-95>
            <http://www.example.org/end>    "95.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "71.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008)" .
    
    <http://covid19.aksw.org/text-31f0029b5072968918d01e306f6809738749b5340f5bfdc82de3a3ead0a60d4f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Eosinophils share a common early myeloid precursor with neutrophils. Early proliferation of the eosinophil lineage appears to be largely due to stimulation of myeloid precursors with GM-CSF and IL-3, while IL-5 plays a critical role in terminal eosinophil differentiation and maturation (Sanderson, 1992) .\",\"cite_spans\":[{\"start\":287.0,\"end\":304.0,\"text\":\"(Sanderson, 1992)\",\"ref_id\":\"BIBREF336\"}],\"ref_spans\":[],\"section\":\"Eosinophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-31f0029b5072968918d01e306f6809738749b5340f5bfdc82de3a3ead0a60d4f_citespan-287-304> ;
            <http://www.example.org/section>
                    "Eosinophils" ;
            <http://www.example.org/text>  "Eosinophils share a common early myeloid precursor with neutrophils. Early proliferation of the eosinophil lineage appears to be largely due to stimulation of myeloid precursors with GM-CSF and IL-3, while IL-5 plays a critical role in terminal eosinophil differentiation and maturation (Sanderson, 1992) ." ;
            <http://www.example.org/textHash>
                    "31f0029b5072968918d01e306f6809738749b5340f5bfdc82de3a3ead0a60d4f" .
    
    <http://covid19.aksw.org/text-7ce91b5d88a952a93486bc590d8c2a609f8ca2dff061dc46c947488babf003db>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Inflammatory patterns\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Epinephrine Glucocorticoid\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Epinephrine Glucocorticoid" ;
            <http://www.example.org/text>  "Inflammatory patterns" ;
            <http://www.example.org/textHash>
                    "7ce91b5d88a952a93486bc590d8c2a609f8ca2dff061dc46c947488babf003db" .
    
    <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812_citespan-1179-1196>
            <http://www.example.org/end>    "1196.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF40" ;
            <http://www.example.org/start>  "1179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Boudreaux, 2010)" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-841-872>
            <http://www.example.org/end>    "872.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF402" ;
            <http://www.example.org/start>  "841.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Van Den Oudenrijn et al., 2000)" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1929-1951>
            <http://www.example.org/end>    "1951.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF210" ;
            <http://www.example.org/start>  "1929.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Russa and Innis, 1995)" .
    
    <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-451-474>
            <http://www.example.org/end>    "474.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "451.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Baker and Moake, 2016;" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1219-1237>
            <http://www.example.org/end>    "1237.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF257" ;
            <http://www.example.org/start>  "1219.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Meek et al., 2001" .
    
    <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9_citespan-1358-1377>
            <http://www.example.org/end>    "1377.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF433" ;
            <http://www.example.org/start>  "1358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Winterbourn, 1990)" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-976-997>
            <http://www.example.org/end>    "997.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF308" ;
            <http://www.example.org/start>  "976.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Raefsky et al., 1985)" .
    
    <http://covid19.aksw.org/text-b124d38870179659c047325ddb815425ab0807ba7d7dba5e5c1223d88cf41739_citespan-500-519>
            <http://www.example.org/end>    "519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF84" ;
            <http://www.example.org/start>  "500.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dahl et al., 1994)" .
    
    <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-313-338>
            <http://www.example.org/end>    "338.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF438" ;
            <http://www.example.org/start>  "313.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young and Meadows, 2010)" .
    
    <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812_citespan-957-975>
            <http://www.example.org/end>    "975.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF191" ;
            <http://www.example.org/start>  "957.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Junt et al., 2007)" .
    
    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-364-386>
            <http://www.example.org/end>    "386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF436" ;
            <http://www.example.org/start>  "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Yanagawa et al., 1995;" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1441-1463>
            <http://www.example.org/end>    "1463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF207" ;
            <http://www.example.org/start>  "1441.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Korenaga et al., 1991;" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-2010-2036>
            <http://www.example.org/end>    "2036.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF345" ;
            <http://www.example.org/start>  "2010.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Segel and Lichtman, 2016)" .
    
    <http://covid19.aksw.org/text-c99e2327ae10204accb68af3ee1a5ca63c0ad5b73b9bbef2d5f58fede27c640e_citespan-584-598>
            <http://www.example.org/end>    "598.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF255" ;
            <http://www.example.org/start>  "584.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(McEwen, 1992)" .
    
    <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-636-654>
            <http://www.example.org/end>    "654.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF142" ;
            <http://www.example.org/start>  "636.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ghio et al., 1981;" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-204-226>
            <http://www.example.org/end>    "226.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF383" ;
            <http://www.example.org/start>  "204.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tefferi et al., 2006;" .
    
    <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf_citespan-864-888>
            <http://www.example.org/end>    "888.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "864.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bhatt and Saleem, 2004;" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-688-703>
            <http://www.example.org/end>    "703.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF300" ;
            <http://www.example.org/start>  "688.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pohlman, 2010;" .
    
    <http://covid19.aksw.org/text-c99e2327ae10204accb68af3ee1a5ca63c0ad5b73b9bbef2d5f58fede27c640e_citespan-483-501>
            <http://www.example.org/end>    "501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "483.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Koch-Weser, 1968)" .
    
    <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-861-888>
            <http://www.example.org/end>    "888.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "861.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-853-868>
            <http://www.example.org/end>    "868.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF189" ;
            <http://www.example.org/start>  "853.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Juhlin, 1963c)" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1031-1049>
            <http://www.example.org/end>    "1049.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF275" ;
            <http://www.example.org/start>  "1031.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Notarangelo, 2010)" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-625-641>
            <http://www.example.org/end>    "641.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF134" ;
            <http://www.example.org/start>  "625.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Garratty, 2010;" .
    
    <http://covid19.aksw.org/text-bfebf21d3ce3f1e4f5e1b69d4088520d4c887ba32ea1117478e403a83f6172b9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Inflammatory or reactive increases in platelet counts are typically secondary to a process that causes general bone marrow stimulation, resulting in increased circulating TPO and therefore increased thrombopoiesis. These increases in platelets are not clonal.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Inflammation or reactive\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Inflammation or reactive" ;
            <http://www.example.org/text>  "Inflammatory or reactive increases in platelet counts are typically secondary to a process that causes general bone marrow stimulation, resulting in increased circulating TPO and therefore increased thrombopoiesis. These increases in platelets are not clonal." ;
            <http://www.example.org/textHash>
                    "bfebf21d3ce3f1e4f5e1b69d4088520d4c887ba32ea1117478e403a83f6172b9" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Basophils are the least numerous leukocyte in blood, and in health usually compose approximately 0.5% or less of the blood leukocyte differential (Pohlman, 2010; Galli et al., 2016) . Automated hematology analyzer differentials may provide low estimates of actual blood basophil counts in humans, and flow cytometric methods may provide a more accurate estimate (Meintker et al., 2013; Amundsen et al., 2012; Ducrest et al., 2005) . Automated hematology analyzer counts in dogs and cats have been demonstrated to be inaccurate (Pohlman, 2010; Lilliehöök and Tvedten, 2011; Tvedten and Lilliehöök, 2011) . However, basophils in rabbits appear to be detected with automated methods . Due to the evidence for low or inaccurate basophil counts in humans, dogs, and cats, it is unclear how accurate automated basophil counts are in nonhuman primates and rodents used in nonclinical toxicology studies.\",\"cite_spans\":[{\"start\":146.0,\"end\":161.0,\"text\":\"(Pohlman, 2010;\",\"ref_id\":\"BIBREF300\"},{\"start\":162.0,\"end\":181.0,\"text\":\"Galli et al., 2016)\",\"ref_id\":\"BIBREF128\"},{\"start\":362.0,\"end\":385.0,\"text\":\"(Meintker et al., 2013;\",\"ref_id\":\"BIBREF259\"},{\"start\":386.0,\"end\":408.0,\"text\":\"Amundsen et al., 2012;\",\"ref_id\":\"BIBREF4\"},{\"start\":409.0,\"end\":430.0,\"text\":\"Ducrest et al., 2005)\",\"ref_id\":\"BIBREF100\"},{\"start\":527.0,\"end\":542.0,\"text\":\"(Pohlman, 2010;\",\"ref_id\":\"BIBREF300\"},{\"start\":543.0,\"end\":572.0,\"text\":\"Lilliehöök and Tvedten, 2011;\",\"ref_id\":\"BIBREF228\"},{\"start\":573.0,\"end\":602.0,\"text\":\"Tvedten and Lilliehöök, 2011)\",\"ref_id\":\"BIBREF398\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-527-542> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-573-602> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-162-181> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-386-408> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-543-572> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-362-385> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-409-430> , <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-146-161> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "Basophils are the least numerous leukocyte in blood, and in health usually compose approximately 0.5% or less of the blood leukocyte differential (Pohlman, 2010; Galli et al., 2016) . Automated hematology analyzer differentials may provide low estimates of actual blood basophil counts in humans, and flow cytometric methods may provide a more accurate estimate (Meintker et al., 2013; Amundsen et al., 2012; Ducrest et al., 2005) . Automated hematology analyzer counts in dogs and cats have been demonstrated to be inaccurate (Pohlman, 2010; Lilliehöök and Tvedten, 2011; Tvedten and Lilliehöök, 2011) . However, basophils in rabbits appear to be detected with automated methods . Due to the evidence for low or inaccurate basophil counts in humans, dogs, and cats, it is unclear how accurate automated basophil counts are in nonhuman primates and rodents used in nonclinical toxicology studies." ;
            <http://www.example.org/textHash>
                    "5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356" .
    
    <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752_citespan-679-701>
            <http://www.example.org/end>    "701.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF85" ;
            <http://www.example.org/start>  "679.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dale and Welte, 2016;" .
    
    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-668-683>
            <http://www.example.org/end>    "683.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "668.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Boseila, 1963)" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1172-1192>
            <http://www.example.org/end>    "1192.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF104" ;
            <http://www.example.org/start>  "1172.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Eisner et al., 1977)" .
    
    <http://covid19.aksw.org/text-98dd5c2311e47e22cc13fdd34d8a3c214499006634453f8deee2c2fb6de2dd0a_citespan-750-773>
            <http://www.example.org/end>    "773.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF412" ;
            <http://www.example.org/start>  "750.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wagner and Roth, 1999)" .
    
    <http://covid19.aksw.org/text-3258a0d9e14436c75440e6c79714da9317db0dfa08bd7bfb81e6a197b691839c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Exogenous glucocorticoids, such as prednisolone, dexamethasone, and betamethasone, will mediate increases in neutrophil counts through similar mechanisms as endogenous glucocorticoids. In brief, these increases in neutrophil counts are due to shifting of neutrophils from the marginating to circulating pool, release of neutrophils from the bone marrow storage pool, and expansion of granulopoiesis in the bone marrow. The dose and duration of the glucocorticoid therapy may alter the proportional contribution of each of these effects to the increases in neutrophil counts.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Exogenous glucocorticoids, such as prednisolone, dexamethasone, and betamethasone, will mediate increases in neutrophil counts through similar mechanisms as endogenous glucocorticoids. In brief, these increases in neutrophil counts are due to shifting of neutrophils from the marginating to circulating pool, release of neutrophils from the bone marrow storage pool, and expansion of granulopoiesis in the bone marrow. The dose and duration of the glucocorticoid therapy may alter the proportional contribution of each of these effects to the increases in neutrophil counts." ;
            <http://www.example.org/textHash>
                    "3258a0d9e14436c75440e6c79714da9317db0dfa08bd7bfb81e6a197b691839c" .
    
    <http://covid19.aksw.org/text-54b088a38add774b695a530442ee730df63239c7224176518f4b94ca1ee21cb8_citespan-652-679>
            <http://www.example.org/end>    "679.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "652.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-247-266>
            <http://www.example.org/end>    "266.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF317" ;
            <http://www.example.org/start>  "247.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Reed et al., 1970;" .
    
    <http://covid19.aksw.org/text-98dd5c2311e47e22cc13fdd34d8a3c214499006634453f8deee2c2fb6de2dd0a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.2.2 Endotoxemia Decreases in neutrophil counts may be observed as a result of Gram-negative bacterial infections that release endotoxin. Endotoxemia has been demonstrated to increase expression of the integrin CD11b/CD18 and decreased expression of L-selectin on neutrophils (Wagner and Roth, 1999) , mediating a shift from circulating to marginating pools with firm adhesion to endothelial cells. There is evidence that this upregulation of CD18 contributes to neutrophil vascular sequestration in the lungs and liver, but there is also evidence for other mechanisms, such as cytoskeletal changes that alter neutrophil deformability, causing the initial vascular sequestration of neutrophils that is consistently observed with endotoxemia (Wagner and Roth, 1999) . The decreases in neutrophil counts associated with endotoxemia tend to be rapid but transient, and detection of these decreases in neutrophil counts will depend on timing of the blood collection in relation to endotoxemic and other concurrent or subsequent proinflammatory stimuli.\",\"cite_spans\":[{\"start\":285.0,\"end\":308.0,\"text\":\"(Wagner and Roth, 1999)\",\"ref_id\":\"BIBREF412\"},{\"start\":750.0,\"end\":773.0,\"text\":\"(Wagner and Roth, 1999)\",\"ref_id\":\"BIBREF412\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-98dd5c2311e47e22cc13fdd34d8a3c214499006634453f8deee2c2fb6de2dd0a_citespan-285-308> , <http://covid19.aksw.org/text-98dd5c2311e47e22cc13fdd34d8a3c214499006634453f8deee2c2fb6de2dd0a_citespan-750-773> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "12.11.2.1.2.2 Endotoxemia Decreases in neutrophil counts may be observed as a result of Gram-negative bacterial infections that release endotoxin. Endotoxemia has been demonstrated to increase expression of the integrin CD11b/CD18 and decreased expression of L-selectin on neutrophils (Wagner and Roth, 1999) , mediating a shift from circulating to marginating pools with firm adhesion to endothelial cells. There is evidence that this upregulation of CD18 contributes to neutrophil vascular sequestration in the lungs and liver, but there is also evidence for other mechanisms, such as cytoskeletal changes that alter neutrophil deformability, causing the initial vascular sequestration of neutrophils that is consistently observed with endotoxemia (Wagner and Roth, 1999) . The decreases in neutrophil counts associated with endotoxemia tend to be rapid but transient, and detection of these decreases in neutrophil counts will depend on timing of the blood collection in relation to endotoxemic and other concurrent or subsequent proinflammatory stimuli." ;
            <http://www.example.org/textHash>
                    "98dd5c2311e47e22cc13fdd34d8a3c214499006634453f8deee2c2fb6de2dd0a" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1046-1060>
            <http://www.example.org/end>    "1060.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "1046.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Russell, 2010)" .
    
    <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-485-507>
            <http://www.example.org/end>    "507.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF108" ;
            <http://www.example.org/start>  "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Everds et al., 2013b)" .
    
    <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-355-374>
            <http://www.example.org/end>    "374.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "355.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Akan et al., 2000)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-392-408>
            <http://www.example.org/end>    "408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "392.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-886a10703ee186646c1fcef132a95376cda2fd0abf66e04049f8c8a7ccc1629f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Administration of exogenous catecholamines has been reported to cause increases in blood platelet counts, and the mechanism is primarily from splenic contraction and a transient increased in platelet counts. However, platelet pools from pulmonary circulation may also contribute. For example, administration of epinephrine to dogs resulted in dose-responsive increases in blood platelet counts that were believed to be the result of adrenaline-induced mobilization of platelets from pulmonary circulation into peripheral blood (Bierman et al., 1952) .\",\"cite_spans\":[{\"start\":527.0,\"end\":549.0,\"text\":\"(Bierman et al., 1952)\",\"ref_id\":\"BIBREF30\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-886a10703ee186646c1fcef132a95376cda2fd0abf66e04049f8c8a7ccc1629f_citespan-527-549> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Administration of exogenous catecholamines has been reported to cause increases in blood platelet counts, and the mechanism is primarily from splenic contraction and a transient increased in platelet counts. However, platelet pools from pulmonary circulation may also contribute. For example, administration of epinephrine to dogs resulted in dose-responsive increases in blood platelet counts that were believed to be the result of adrenaline-induced mobilization of platelets from pulmonary circulation into peripheral blood (Bierman et al., 1952) ." ;
            <http://www.example.org/textHash>
                    "886a10703ee186646c1fcef132a95376cda2fd0abf66e04049f8c8a7ccc1629f" .
    
    <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-157-185>
            <http://www.example.org/end>    "185.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF136" ;
            <http://www.example.org/start>  "157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gassmann and Löffler, 1995)" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-904-920>
            <http://www.example.org/end>    "920.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "904.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-617-635>
            <http://www.example.org/end>    "635.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF231" ;
            <http://www.example.org/start>  "617.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lion et al., 1992)" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-695-715>
            <http://www.example.org/end>    "715.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF268" ;
            <http://www.example.org/start>  "695.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Murphy et al., 1985)" .
    
    <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-231-244>
            <http://www.example.org/end>    "244.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF371" ;
            <http://www.example.org/start>  "231.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stone, 2005)" .
    
    <http://covid19.aksw.org/text-76ae2d6ca8ab514658fa40f52f143a6617c592a7222c70174c4eadbb87bc83d0_citespan-213-232>
            <http://www.example.org/end>    "232.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF68" ;
            <http://www.example.org/start>  "213.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Choi et al., 2003)" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-846-861>
            <http://www.example.org/end>    "861.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "846.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016)" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-374-390>
            <http://www.example.org/end>    "390.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "374.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Infectious agents may also lead to fragmentation of erythrocytes, and some Leptospirosis interrogans serovars associated with vasculitis (Stockham and Scott, 2008b) , Brucella species infection (Yaramis et al., 2001) , and cutaneous anthrax (Freedman et al., 2002) have been reported to cause microangiopathic hemolysis. In children, fragmentation hemolysis associated with thrombotic microangiopathy may occur with Shigella dysenteriae type 1 and some Escherichia coli infections (Pisoni et al., 2001) . Hemolysis from erythrocyte fragmentation may also occur with HIV infection (Maslo et al., 1997) .\",\"cite_spans\":[{\"start\":137.0,\"end\":164.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":194.0,\"end\":216.0,\"text\":\"(Yaramis et al., 2001)\",\"ref_id\":\"BIBREF436\"},{\"start\":241.0,\"end\":264.0,\"text\":\"(Freedman et al., 2002)\",\"ref_id\":\"BIBREF123\"},{\"start\":481.0,\"end\":502.0,\"text\":\"(Pisoni et al., 2001)\",\"ref_id\":\"BIBREF299\"},{\"start\":580.0,\"end\":600.0,\"text\":\"(Maslo et al., 1997)\",\"ref_id\":\"BIBREF250\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-137-164> , <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-194-216> , <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-241-264> , <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-481-502> , <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-580-600> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Infectious agents may also lead to fragmentation of erythrocytes, and some Leptospirosis interrogans serovars associated with vasculitis (Stockham and Scott, 2008b) , Brucella species infection (Yaramis et al., 2001) , and cutaneous anthrax (Freedman et al., 2002) have been reported to cause microangiopathic hemolysis. In children, fragmentation hemolysis associated with thrombotic microangiopathy may occur with Shigella dysenteriae type 1 and some Escherichia coli infections (Pisoni et al., 2001) . Hemolysis from erythrocyte fragmentation may also occur with HIV infection (Maslo et al., 1997) ." ;
            <http://www.example.org/textHash>
                    "d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-849-872>
            <http://www.example.org/end>    "872.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF105" ;
            <http://www.example.org/start>  "849.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Etiemble et al., 1976)" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-1079-1108>
            <http://www.example.org/end>    "1108.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF298" ;
            <http://www.example.org/start>  "1079.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pisciotta and Kaldahl, 1962)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-776-790>
            <http://www.example.org/end>    "790.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF306" ;
            <http://www.example.org/start>  "776.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Quadros, 2010)" .
    
    <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In humans and nonhuman primate species with true menstrual cycles, including Old World monkeys and great apes (Provencher Bolliger et al., 2010) , decreases in red cell mass are uncommon but may be observed from menses-related blood loss. In women, heavy blood loss, abnormal cycling, or uterine neoplasms may lead to sufficient blood loss to cause decreases in red cell mass and potentially even iron deficiency (Van Voorhis, 2009; Goel and Gupta, 2007) . In cynomolgus monkeys, decreases in red cell mass have been occasionally observed in females with prolonged menses (Perigard et al., 2016) .\",\"cite_spans\":[{\"start\":110.0,\"end\":144.0,\"text\":\"(Provencher Bolliger et al., 2010)\",\"ref_id\":\"BIBREF305\"},{\"start\":413.0,\"end\":432.0,\"text\":\"(Van Voorhis, 2009;\",\"ref_id\":\"BIBREF405\"},{\"start\":433.0,\"end\":454.0,\"text\":\"Goel and Gupta, 2007)\",\"ref_id\":\"BIBREF148\"},{\"start\":572.0,\"end\":595.0,\"text\":\"(Perigard et al., 2016)\",\"ref_id\":\"BIBREF295\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-110-144> , <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-413-432> , <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-433-454> , <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-572-595> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "In humans and nonhuman primate species with true menstrual cycles, including Old World monkeys and great apes (Provencher Bolliger et al., 2010) , decreases in red cell mass are uncommon but may be observed from menses-related blood loss. In women, heavy blood loss, abnormal cycling, or uterine neoplasms may lead to sufficient blood loss to cause decreases in red cell mass and potentially even iron deficiency (Van Voorhis, 2009; Goel and Gupta, 2007) . In cynomolgus monkeys, decreases in red cell mass have been occasionally observed in females with prolonged menses (Perigard et al., 2016) ." ;
            <http://www.example.org/textHash>
                    "ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac" .
    
    <http://covid19.aksw.org/text-98dd5c2311e47e22cc13fdd34d8a3c214499006634453f8deee2c2fb6de2dd0a_citespan-285-308>
            <http://www.example.org/end>    "308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF412" ;
            <http://www.example.org/start>  "285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wagner and Roth, 1999)" .
    
    <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34_citespan-336-359>
            <http://www.example.org/end>    "359.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF249" ;
            <http://www.example.org/start>  "336.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Maseneni et al., 2013)" .
    
    <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef_citespan-434-456>
            <http://www.example.org/end>    "456.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF343" ;
            <http://www.example.org/start>  "434.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schuster et al., 1989)" .
    
    <http://covid19.aksw.org/text-51c0ab88385306e0f244df7660c7398263eafffd1178eb05ed2bbf9e5764bbc6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Eosinophil counts are normally low in most species, which can make detection of decreases in eosinophil counts difficult. Similar to detecting decreases in monocyte counts, comparison of treated groups with concurrent controls or pretest values in nonclinical toxicology studies will aid in the identification of changes in eosinophil counts. Eosinophils are morphologically distinct from other leukocytes due to their large, pink-staining cytoplasmic granules; however, species differences in granule size, shape, and staining properties exist. Blood eosinophil counts in health generally only exceed basophil counts.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Eosinophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Eosinophils" ;
            <http://www.example.org/text>  "Eosinophil counts are normally low in most species, which can make detection of decreases in eosinophil counts difficult. Similar to detecting decreases in monocyte counts, comparison of treated groups with concurrent controls or pretest values in nonclinical toxicology studies will aid in the identification of changes in eosinophil counts. Eosinophils are morphologically distinct from other leukocytes due to their large, pink-staining cytoplasmic granules; however, species differences in granule size, shape, and staining properties exist. Blood eosinophil counts in health generally only exceed basophil counts." ;
            <http://www.example.org/textHash>
                    "51c0ab88385306e0f244df7660c7398263eafffd1178eb05ed2bbf9e5764bbc6" .
    
    <http://covid19.aksw.org/text-f93d23cc1a6f34d35e3d9cf585b6e04a601d6efc9c2f5f0d659375671f3e2d85>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.5.2.2 Inflammation and hypersensitivity Severe acute or overwhelming inflammation can lead to a decrease in basophil counts along with decreases in other blood leukocyte counts. A relationship between endotoxemia and decreases in basophil counts has been supported by reductions in blood basophil counts in rabbits administered endotoxin from Salmonella typhi (Goncharova and Krylova, 1967) . Also, inflammatory leukocytosis not associated with overwhelming inflammation is often associated with decreases in basophil counts (Galli et al., 2016) .\",\"cite_spans\":[{\"start\":368.0,\"end\":398.0,\"text\":\"(Goncharova and Krylova, 1967)\",\"ref_id\":\"BIBREF150\"},{\"start\":533.0,\"end\":553.0,\"text\":\"(Galli et al., 2016)\",\"ref_id\":\"BIBREF128\"}],\"ref_spans\":[],\"section\":\"Decreases in basophil counts (basopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f93d23cc1a6f34d35e3d9cf585b6e04a601d6efc9c2f5f0d659375671f3e2d85_citespan-368-398> , <http://covid19.aksw.org/text-f93d23cc1a6f34d35e3d9cf585b6e04a601d6efc9c2f5f0d659375671f3e2d85_citespan-533-553> ;
            <http://www.example.org/section>
                    "Decreases in basophil counts (basopenia)" ;
            <http://www.example.org/text>  "12.11.2.5.2.2 Inflammation and hypersensitivity Severe acute or overwhelming inflammation can lead to a decrease in basophil counts along with decreases in other blood leukocyte counts. A relationship between endotoxemia and decreases in basophil counts has been supported by reductions in blood basophil counts in rabbits administered endotoxin from Salmonella typhi (Goncharova and Krylova, 1967) . Also, inflammatory leukocytosis not associated with overwhelming inflammation is often associated with decreases in basophil counts (Galli et al., 2016) ." ;
            <http://www.example.org/textHash>
                    "f93d23cc1a6f34d35e3d9cf585b6e04a601d6efc9c2f5f0d659375671f3e2d85" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In some cases, a leukemoid response or extreme neutrophilia may occur. A leukemoid response is characterized by a persistent leukocytosis of \\u003e50,000 cells mL À 1 , typically due to a marked neutrophilia with a left shift that remains orderly and may or may not have morphologic changes indicative of rapid granulopoiesis (Schultze, 2010; Sakka et al., 2006) . Extreme neutrophilia typically has \\u003e 100,000 cells mL À 1 and evidence of a left shift. The terms leukemoid reaction and extreme neutrophilia are most appropriately applied retrospectively, after the possibility for hematopoietic neoplasia has been excluded. Differentiation of a leukemoid response or extreme neutrophilia from chronic myelogenous leukemia or chronic neutrophilic leukemia includes CBC, blood smear, and bone marrow evaluations in most species, and may also include leukocyte alkaline phosphatase activity, immunophenotyping, cytogenetic analysis (e.g., evaluation for bcr-abl translocation), serum G-CSF, and clonality evaluations in humans (Schultze, 2010; Sakka et al., 2006) . Leukemoid reactions have been associated with carcinomas of various origins, including renal and pulmonary carcinomas, Hodgkin\\u0027s lymphoma, melanoma, and sarcomas, and may be attributable to aberrant production of proinflammatory mediators by the neoplasm, such as G-CSF, GM-CSF, or IL-6 (Sakka et al., 2006) . Leukemoid reactions have also been reported in F334/N rats affected by large granular cell leukemia (Car et al., 2006) . However, leukemoid reactions may also be associated with infectious processes, including disseminated tuberculosis, Clostridium difficile colitis, severe shigellosis (Sakka et al., 2006) , chronic localized suppurative lesions such as pyometra, pleuritis, and internal abscesses (Schultze, 2010; Stockham and Scott, 2008a) . Leukemoid reactions may also be seen secondary to severe hemorrhage or immune-mediated hemolytic anemia (Schultze, 2010; Sakka et al., 2006) . 12.11.2.1.1.4 Inherited leukocyte adhesion deficiencies Increases in neutrophil counts associated with deficiencies in leukocyte adhesion molecules may manifest as a leukemoid response or extreme neutrophilia. Adhesion molecules expressed on neutrophils are responsible for neutrophil margination, rolling along vessel walls, and emigration into tissues. L-selectin (CD62L) mediates low-affinity initial binding of leukocyte to endothelial cells, while integrins, including CD11b/CD18 (Mac-1), mediate firm adhesion to endothelial cells and ligands in the extracellular matrix (Muller, 2012) . Neutrophils constitutively express CD11b/CD18. A deficiency of this integrin (leukocyte adhesion deficiency [LAD] type 1) results in the failure of neutrophils to emigrate to tissues, and may result in severe, recurrent bacterial infections (Arnaout, 1990) . LAD type 2 is due to an inherited disorder of fucose metabolism, resulting in the lack of selectin ligands expressed on neutrophils and therefore results in immunodeficiency from a failure of selectin-mediated neutrophil rolling along vessel walls (Marquardt et al., 1999) . Leukocyte adhesion deficiencies have been reported in humans, dogs, mice, and Holstein cattle (Arnaout, 1990; Marquardt et al., 1999; Gu et al., 2004) .\",\"cite_spans\":[{\"start\":321.0,\"end\":337.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":338.0,\"end\":357.0,\"text\":\"Sakka et al., 2006)\",\"ref_id\":\"BIBREF332\"},{\"start\":1019.0,\"end\":1035.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":1036.0,\"end\":1055.0,\"text\":\"Sakka et al., 2006)\",\"ref_id\":\"BIBREF332\"},{\"start\":1345.0,\"end\":1365.0,\"text\":\"(Sakka et al., 2006)\",\"ref_id\":\"BIBREF332\"},{\"start\":1468.0,\"end\":1486.0,\"text\":\"(Car et al., 2006)\",\"ref_id\":\"BIBREF56\"},{\"start\":1655.0,\"end\":1675.0,\"text\":\"(Sakka et al., 2006)\",\"ref_id\":\"BIBREF332\"},{\"start\":1768.0,\"end\":1784.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":1785.0,\"end\":1811.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":1918.0,\"end\":1934.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":1935.0,\"end\":1954.0,\"text\":\"Sakka et al., 2006)\",\"ref_id\":\"BIBREF332\"},{\"start\":2534.0,\"end\":2548.0,\"text\":\"(Muller, 2012)\",\"ref_id\":\"BIBREF267\"},{\"start\":2659.0,\"end\":2664.0,\"text\":\"[LAD]\"},{\"start\":2792.0,\"end\":2807.0,\"text\":\"(Arnaout, 1990)\",\"ref_id\":\"BIBREF7\"},{\"start\":3058.0,\"end\":3082.0,\"text\":\"(Marquardt et al., 1999)\",\"ref_id\":\"BIBREF246\"},{\"start\":3179.0,\"end\":3194.0,\"text\":\"(Arnaout, 1990;\",\"ref_id\":\"BIBREF7\"},{\"start\":3195.0,\"end\":3218.0,\"text\":\"Marquardt et al., 1999;\",\"ref_id\":\"BIBREF246\"},{\"start\":3219.0,\"end\":3235.0,\"text\":\"Gu et al., 2004)\",\"ref_id\":\"BIBREF161\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3195-3218> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-2792-2807> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1768-1784> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1918-1934> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1345-1365> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3058-3082> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1019-1035> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1468-1486> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-2534-2548> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1935-1954> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-338-357> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3179-3194> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1655-1675> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1785-1811> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-321-337> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1036-1055> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3219-3235> , <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-2659-2664> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "In some cases, a leukemoid response or extreme neutrophilia may occur. A leukemoid response is characterized by a persistent leukocytosis of >50,000 cells mL À 1 , typically due to a marked neutrophilia with a left shift that remains orderly and may or may not have morphologic changes indicative of rapid granulopoiesis (Schultze, 2010; Sakka et al., 2006) . Extreme neutrophilia typically has > 100,000 cells mL À 1 and evidence of a left shift. The terms leukemoid reaction and extreme neutrophilia are most appropriately applied retrospectively, after the possibility for hematopoietic neoplasia has been excluded. Differentiation of a leukemoid response or extreme neutrophilia from chronic myelogenous leukemia or chronic neutrophilic leukemia includes CBC, blood smear, and bone marrow evaluations in most species, and may also include leukocyte alkaline phosphatase activity, immunophenotyping, cytogenetic analysis (e.g., evaluation for bcr-abl translocation), serum G-CSF, and clonality evaluations in humans (Schultze, 2010; Sakka et al., 2006) . Leukemoid reactions have been associated with carcinomas of various origins, including renal and pulmonary carcinomas, Hodgkin's lymphoma, melanoma, and sarcomas, and may be attributable to aberrant production of proinflammatory mediators by the neoplasm, such as G-CSF, GM-CSF, or IL-6 (Sakka et al., 2006) . Leukemoid reactions have also been reported in F334/N rats affected by large granular cell leukemia (Car et al., 2006) . However, leukemoid reactions may also be associated with infectious processes, including disseminated tuberculosis, Clostridium difficile colitis, severe shigellosis (Sakka et al., 2006) , chronic localized suppurative lesions such as pyometra, pleuritis, and internal abscesses (Schultze, 2010; Stockham and Scott, 2008a) . Leukemoid reactions may also be seen secondary to severe hemorrhage or immune-mediated hemolytic anemia (Schultze, 2010; Sakka et al., 2006) . 12.11.2.1.1.4 Inherited leukocyte adhesion deficiencies Increases in neutrophil counts associated with deficiencies in leukocyte adhesion molecules may manifest as a leukemoid response or extreme neutrophilia. Adhesion molecules expressed on neutrophils are responsible for neutrophil margination, rolling along vessel walls, and emigration into tissues. L-selectin (CD62L) mediates low-affinity initial binding of leukocyte to endothelial cells, while integrins, including CD11b/CD18 (Mac-1), mediate firm adhesion to endothelial cells and ligands in the extracellular matrix (Muller, 2012) . Neutrophils constitutively express CD11b/CD18. A deficiency of this integrin (leukocyte adhesion deficiency [LAD] type 1) results in the failure of neutrophils to emigrate to tissues, and may result in severe, recurrent bacterial infections (Arnaout, 1990) . LAD type 2 is due to an inherited disorder of fucose metabolism, resulting in the lack of selectin ligands expressed on neutrophils and therefore results in immunodeficiency from a failure of selectin-mediated neutrophil rolling along vessel walls (Marquardt et al., 1999) . Leukocyte adhesion deficiencies have been reported in humans, dogs, mice, and Holstein cattle (Arnaout, 1990; Marquardt et al., 1999; Gu et al., 2004) ." ;
            <http://www.example.org/textHash>
                    "295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Parasitism is considered the most common cause of increases in blood eosinophil counts worldwide (Wardlaw, 2016) , of which helminth (e.g., nematode, trematode, or cestode) infections are the major cause (Tefferi et al., 2006; Leder and Weller, 2000) . Inflammatory increases in eosinophil counts in response to helminths are cytokine (e.g., IL-5) mediated (Valent, 2009 ), but IgE and histamine release from mast cells, anaphylatoxin (e.g., C5a) production from complement activation, helper T-cell activation, and direct stimulation of eosinophils with helminthic antigens also play a role in eosinophil recruitment (Wardlaw, 2016; Leder and Weller, 2000; McEwen, 1992) . Helminth migration through host tissues is a key factor in stimulating increases in blood eosinophils and tissue eosinophilic inflammation, and helminths that remain confined to the intestinal lumen may not result in an eosinophil response (Leder and Weller, 2000) . The degree of the eosinophil response and increases in blood eosinophil counts are also dependent on parasite burden, maturation, and distribution in tissues (Leder and Weller, 2000) . Ascariasis, strongyloidiasis, trichinosis, filariasis, and ancylosomiasis have all been associated with increases in eosinophil counts in humans (Wardlaw, 2016; Tefferi et al., 2006; Leder and Weller, 2000) , and many of these may also be observed in common laboratory species (Schultze, 2010; Magden et al., 2015; Korenaga et al., 1991; Ogilvie et al., 1980) . Helminth infection in most purpose-bred laboratory animals is uncommonly observed during nonclinical toxicology studies due to breeding and housing facility biosecurity measures, but several less commonly used large animal species from other sources, such as farm pigs, calves, and sheep, have helminth infections more frequently observed.\",\"cite_spans\":[{\"start\":97.0,\"end\":112.0,\"text\":\"(Wardlaw, 2016)\",\"ref_id\":\"BIBREF420\"},{\"start\":204.0,\"end\":226.0,\"text\":\"(Tefferi et al., 2006;\",\"ref_id\":\"BIBREF383\"},{\"start\":227.0,\"end\":250.0,\"text\":\"Leder and Weller, 2000)\",\"ref_id\":\"BIBREF219\"},{\"start\":357.0,\"end\":370.0,\"text\":\"(Valent, 2009\",\"ref_id\":\"BIBREF401\"},{\"start\":618.0,\"end\":633.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":634.0,\"end\":657.0,\"text\":\"Leder and Weller, 2000;\",\"ref_id\":\"BIBREF219\"},{\"start\":658.0,\"end\":671.0,\"text\":\"McEwen, 1992)\",\"ref_id\":\"BIBREF255\"},{\"start\":914.0,\"end\":938.0,\"text\":\"(Leder and Weller, 2000)\",\"ref_id\":\"BIBREF219\"},{\"start\":1099.0,\"end\":1123.0,\"text\":\"(Leder and Weller, 2000)\",\"ref_id\":\"BIBREF219\"},{\"start\":1271.0,\"end\":1286.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":1287.0,\"end\":1308.0,\"text\":\"Tefferi et al., 2006;\",\"ref_id\":\"BIBREF383\"},{\"start\":1309.0,\"end\":1332.0,\"text\":\"Leder and Weller, 2000)\",\"ref_id\":\"BIBREF219\"},{\"start\":1403.0,\"end\":1419.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":1420.0,\"end\":1440.0,\"text\":\"Magden et al., 2015;\",\"ref_id\":\"BIBREF238\"},{\"start\":1441.0,\"end\":1463.0,\"text\":\"Korenaga et al., 1991;\",\"ref_id\":\"BIBREF207\"},{\"start\":1464.0,\"end\":1485.0,\"text\":\"Ogilvie et al., 1980)\",\"ref_id\":\"BIBREF278\"}],\"ref_spans\":[],\"section\":\"Inflammation and Hypersensitivity\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1309-1332> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1099-1123> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1441-1463> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1420-1440> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-618-633> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1403-1419> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-634-657> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-227-250> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-357-370> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-658-671> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1287-1308> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-914-938> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-97-112> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1464-1485> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1271-1286> , <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-204-226> ;
            <http://www.example.org/section>
                    "Inflammation and Hypersensitivity" ;
            <http://www.example.org/text>  "Parasitism is considered the most common cause of increases in blood eosinophil counts worldwide (Wardlaw, 2016) , of which helminth (e.g., nematode, trematode, or cestode) infections are the major cause (Tefferi et al., 2006; Leder and Weller, 2000) . Inflammatory increases in eosinophil counts in response to helminths are cytokine (e.g., IL-5) mediated (Valent, 2009 ), but IgE and histamine release from mast cells, anaphylatoxin (e.g., C5a) production from complement activation, helper T-cell activation, and direct stimulation of eosinophils with helminthic antigens also play a role in eosinophil recruitment (Wardlaw, 2016; Leder and Weller, 2000; McEwen, 1992) . Helminth migration through host tissues is a key factor in stimulating increases in blood eosinophils and tissue eosinophilic inflammation, and helminths that remain confined to the intestinal lumen may not result in an eosinophil response (Leder and Weller, 2000) . The degree of the eosinophil response and increases in blood eosinophil counts are also dependent on parasite burden, maturation, and distribution in tissues (Leder and Weller, 2000) . Ascariasis, strongyloidiasis, trichinosis, filariasis, and ancylosomiasis have all been associated with increases in eosinophil counts in humans (Wardlaw, 2016; Tefferi et al., 2006; Leder and Weller, 2000) , and many of these may also be observed in common laboratory species (Schultze, 2010; Magden et al., 2015; Korenaga et al., 1991; Ogilvie et al., 1980) . Helminth infection in most purpose-bred laboratory animals is uncommonly observed during nonclinical toxicology studies due to breeding and housing facility biosecurity measures, but several less commonly used large animal species from other sources, such as farm pigs, calves, and sheep, have helminth infections more frequently observed." ;
            <http://www.example.org/textHash>
                    "47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0" .
    
    <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-1553-1567>
            <http://www.example.org/end>    "1567.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "1553.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016;" .
    
    <http://covid19.aksw.org/text-5fbc1cd80b0aa20f4f8a16f775bdc97ebbddbbcbb413367c7f8c00cd2985ed9c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in blood basophil counts may also occur along with decreases in other leukocyte counts associated with xenobioticinduced bone marrow suppression and aplastic anemia. As a class, chemotherapeutic agents may cause bone marrow suppression resulting in decreases in multiple leukocyte lineages in blood, including basophils. Xenobiotics implicated in causing aplastic anemia include chloramphenicol, anticonvulsants such as phenytoin and carbamazepine, gold-based compounds, penicillamine, and phenylbutazone (Bloom and Brandt, 2008; Kaufman et al., 1996) .\",\"cite_spans\":[{\"start\":515.0,\"end\":539.0,\"text\":\"(Bloom and Brandt, 2008;\",\"ref_id\":\"BIBREF35\"},{\"start\":540.0,\"end\":561.0,\"text\":\"Kaufman et al., 1996)\",\"ref_id\":\"BIBREF200\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5fbc1cd80b0aa20f4f8a16f775bdc97ebbddbbcbb413367c7f8c00cd2985ed9c_citespan-515-539> , <http://covid19.aksw.org/text-5fbc1cd80b0aa20f4f8a16f775bdc97ebbddbbcbb413367c7f8c00cd2985ed9c_citespan-540-561> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Decreases in blood basophil counts may also occur along with decreases in other leukocyte counts associated with xenobioticinduced bone marrow suppression and aplastic anemia. As a class, chemotherapeutic agents may cause bone marrow suppression resulting in decreases in multiple leukocyte lineages in blood, including basophils. Xenobiotics implicated in causing aplastic anemia include chloramphenicol, anticonvulsants such as phenytoin and carbamazepine, gold-based compounds, penicillamine, and phenylbutazone (Bloom and Brandt, 2008; Kaufman et al., 1996) ." ;
            <http://www.example.org/textHash>
                    "5fbc1cd80b0aa20f4f8a16f775bdc97ebbddbbcbb413367c7f8c00cd2985ed9c" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-1296-1316>
            <http://www.example.org/end>    "1316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF234" ;
            <http://www.example.org/start>  "1296.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Logue et al., 1978)" .
    
    <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.5.1.3 Neoplasia Although relatively rare, chronic myelogenous leukemia is frequently associated with increases in blood basophil counts (Spiers et al., 1977) , in which the blood basophils have been demonstrated through cytogenetic analysis to arise from the neoplastic clone (Goh and Anderson, 1979) . However, there is some suggestion that chronic basophilic leukemia may be a separate process than basophilic chronic myeloid or granulocytic leukemia (Pardanani et al., 2003) . Chronic leukemia associated with clonal increases in blood basophil counts also has the potential to undergo blast transformation. Acute basophilic leukemia may also occur but is rare (Duchayne et al., 1999) . Other forms of acute myelogenous leukemia may also be associated with increases in basophil counts (Galli et al., 2016) .\",\"cite_spans\":[{\"start\":144.0,\"end\":165.0,\"text\":\"(Spiers et al., 1977)\"},{\"start\":284.0,\"end\":308.0,\"text\":\"(Goh and Anderson, 1979)\",\"ref_id\":\"BIBREF149\"},{\"start\":461.0,\"end\":485.0,\"text\":\"(Pardanani et al., 2003)\",\"ref_id\":\"BIBREF290\"},{\"start\":672.0,\"end\":695.0,\"text\":\"(Duchayne et al., 1999)\",\"ref_id\":\"BIBREF97\"},{\"start\":797.0,\"end\":817.0,\"text\":\"(Galli et al., 2016)\",\"ref_id\":\"BIBREF128\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-144-165> , <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-284-308> , <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-461-485> , <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-672-695> , <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-797-817> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "12.11.2.5.1.3 Neoplasia Although relatively rare, chronic myelogenous leukemia is frequently associated with increases in blood basophil counts (Spiers et al., 1977) , in which the blood basophils have been demonstrated through cytogenetic analysis to arise from the neoplastic clone (Goh and Anderson, 1979) . However, there is some suggestion that chronic basophilic leukemia may be a separate process than basophilic chronic myeloid or granulocytic leukemia (Pardanani et al., 2003) . Chronic leukemia associated with clonal increases in blood basophil counts also has the potential to undergo blast transformation. Acute basophilic leukemia may also occur but is rare (Duchayne et al., 1999) . Other forms of acute myelogenous leukemia may also be associated with increases in basophil counts (Galli et al., 2016) ." ;
            <http://www.example.org/textHash>
                    "5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe" .
    
    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-1136-1153>
            <http://www.example.org/end>    "1153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF225" ;
            <http://www.example.org/start>  "1136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016a)" .
    
    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-236-259>
            <http://www.example.org/end>    "259.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF284" ;
            <http://www.example.org/start>  "236.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Palanduz et al., 2002)" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1418-1441>
            <http://www.example.org/end>    "1441.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF360" ;
            <http://www.example.org/start>  "1418.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Socinski et al., 1984)" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-896-912>
            <http://www.example.org/end>    "912.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF225" ;
            <http://www.example.org/start>  "896.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016a" .
    
    <http://covid19.aksw.org/text-d281241fc64906aa25de49f69e81785af3ba0430e987b507ba327ffcbecf28d3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Acute hypersensitivity reactions to xenobiotics may cause decreases in blood basophil counts. Xenobiotic-induced urticaria, angioedema, and anaphylactic reactions are IgE-mediated type I hypersensitivity reactions, and have been associated with angiotensin-converting enzyme (ACE) inhibitors and various NSAIDs (Roujeau, 2005) . Due to the IgE-mediated nature of these reactions, these xenobiotics would have the potential to cause concurrent decreases in blood basophil counts, although IgE-related increases in basophil counts could also occur as described previously. Menthol has also been associated with urticaria and decreases in basophil counts (Papa and Shelley, 1964) .\",\"cite_spans\":[{\"start\":311.0,\"end\":326.0,\"text\":\"(Roujeau, 2005)\",\"ref_id\":\"BIBREF327\"},{\"start\":652.0,\"end\":676.0,\"text\":\"(Papa and Shelley, 1964)\",\"ref_id\":\"BIBREF288\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d281241fc64906aa25de49f69e81785af3ba0430e987b507ba327ffcbecf28d3_citespan-311-326> , <http://covid19.aksw.org/text-d281241fc64906aa25de49f69e81785af3ba0430e987b507ba327ffcbecf28d3_citespan-652-676> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Acute hypersensitivity reactions to xenobiotics may cause decreases in blood basophil counts. Xenobiotic-induced urticaria, angioedema, and anaphylactic reactions are IgE-mediated type I hypersensitivity reactions, and have been associated with angiotensin-converting enzyme (ACE) inhibitors and various NSAIDs (Roujeau, 2005) . Due to the IgE-mediated nature of these reactions, these xenobiotics would have the potential to cause concurrent decreases in blood basophil counts, although IgE-related increases in basophil counts could also occur as described previously. Menthol has also been associated with urticaria and decreases in basophil counts (Papa and Shelley, 1964) ." ;
            <http://www.example.org/textHash>
                    "d281241fc64906aa25de49f69e81785af3ba0430e987b507ba327ffcbecf28d3" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-1199-1221>
            <http://www.example.org/end>    "1221.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF181" ;
            <http://www.example.org/start>  "1199.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Jelkmann et al., 1992)" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-1404-1428>
            <http://www.example.org/end>    "1428.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF249" ;
            <http://www.example.org/start>  "1404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Maseneni et al., , 2013" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-349-376>
            <http://www.example.org/end>    "376.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "349.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-960-977>
            <http://www.example.org/end>    "977.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF225" ;
            <http://www.example.org/start>  "960.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016a)" .
    
    <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-401-425>
            <http://www.example.org/end>    "425.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008)" .
    
    <http://covid19.aksw.org/text-eea77246941ec41158fc31c1e8da0e727784adb3f4088df6ac0341deae0afec3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in red cell mass with concurrent decreases in reticulocyte counts have occurred with prolonged or repeated high dose administration of G-CSF or GM-CSF-based xenobiotics in nonclinical toxicology studies, particularly in rodents. Impaired erythropoiesis in these cases occurs due to the massive expansion of myeloid precursors within the bone marrow. Extreme myeloid hyperplasia with continued stimulation results in overcrowding of the marrow cavities with less physical space available for erythroid production.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Decreases in red cell mass with concurrent decreases in reticulocyte counts have occurred with prolonged or repeated high dose administration of G-CSF or GM-CSF-based xenobiotics in nonclinical toxicology studies, particularly in rodents. Impaired erythropoiesis in these cases occurs due to the massive expansion of myeloid precursors within the bone marrow. Extreme myeloid hyperplasia with continued stimulation results in overcrowding of the marrow cavities with less physical space available for erythroid production." ;
            <http://www.example.org/textHash>
                    "eea77246941ec41158fc31c1e8da0e727784adb3f4088df6ac0341deae0afec3" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-885-908>
            <http://www.example.org/end>    "908.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF55" ;
            <http://www.example.org/start>  "885.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cantrell et al., 1985)" .
    
    <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in monocyte counts related to neoplasia are not limited to hematopoietic neoplasms of the monocytic lineage. Increases in monocyte counts have also been described in association with a wide spectrum of lymphoproliferative neoplasms, soft tissue sarcomas, hemangiosarcomas, chondrosarcomas, rectal polyps, and colon cancer (Lichtman, 2016a; Schultze, 2010; Melichar et al., 2001; Ruka et al., 2001) . In one study, over half of the patients with solid tumor malignancies were reported to have concurrent increases in monocyte counts, which were independent of tumor metastasis (Barrett, 1970) .\",\"cite_spans\":[{\"start\":332.0,\"end\":349.0,\"text\":\"(Lichtman, 2016a;\",\"ref_id\":\"BIBREF225\"},{\"start\":350.0,\"end\":365.0,\"text\":\"Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":366.0,\"end\":388.0,\"text\":\"Melichar et al., 2001;\",\"ref_id\":\"BIBREF260\"},{\"start\":389.0,\"end\":407.0,\"text\":\"Ruka et al., 2001)\",\"ref_id\":\"BIBREF328\"},{\"start\":586.0,\"end\":601.0,\"text\":\"(Barrett, 1970)\",\"ref_id\":\"BIBREF19\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-332-349> , <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-350-365> , <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-366-388> , <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-389-407> , <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-586-601> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Increases in monocyte counts related to neoplasia are not limited to hematopoietic neoplasms of the monocytic lineage. Increases in monocyte counts have also been described in association with a wide spectrum of lymphoproliferative neoplasms, soft tissue sarcomas, hemangiosarcomas, chondrosarcomas, rectal polyps, and colon cancer (Lichtman, 2016a; Schultze, 2010; Melichar et al., 2001; Ruka et al., 2001) . In one study, over half of the patients with solid tumor malignancies were reported to have concurrent increases in monocyte counts, which were independent of tumor metastasis (Barrett, 1970) ." ;
            <http://www.example.org/textHash>
                    "efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb" .
    
    <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-408-435>
            <http://www.example.org/end>    "435.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Budman and Steinberg, 1977)" .
    
    <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-598-619>
            <http://www.example.org/end>    "619.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "598.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Abella et al., 2002)" .
    
    <http://covid19.aksw.org/text-e15d44d7bd31a3608f2d13172db9fa5994484d66adb5800b9b6320a5abf351cc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Administration of exogenous glucocorticoids, for antiinflammatory or immunosuppressive purposes, will result in decreases in blood lymphocyte counts. The mechanisms for this are the same as those for endogenous glucocorticoids, and include altered blood and tissue pool distribution, decreased efflux of lymphocytes from lymphoid tissues, and increased lymphocyte apoptosis with prolonged glucocorticoid exposure.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Administration of exogenous glucocorticoids, for antiinflammatory or immunosuppressive purposes, will result in decreases in blood lymphocyte counts. The mechanisms for this are the same as those for endogenous glucocorticoids, and include altered blood and tissue pool distribution, decreased efflux of lymphocytes from lymphoid tissues, and increased lymphocyte apoptosis with prolonged glucocorticoid exposure." ;
            <http://www.example.org/textHash>
                    "e15d44d7bd31a3608f2d13172db9fa5994484d66adb5800b9b6320a5abf351cc" .
    
    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-1094-1114>
            <http://www.example.org/end>    "1114.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF216" ;
            <http://www.example.org/start>  "1094.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lasho et al., 2010)" .
    
    <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652_citespan-230-251>
            <http://www.example.org/end>    "251.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF314" ;
            <http://www.example.org/start>  "230.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rankin et al., 2007)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-2224-2244>
            <http://www.example.org/end>    "2244.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF80" ;
            <http://www.example.org/start>  "2224.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cromer et al., 2006)" .
    
    <http://covid19.aksw.org/text-e00276642f98e38aaf9181b63151df55bf2ba44f53c344836578f081ef7b09b0_citespan-435-462>
            <http://www.example.org/end>    "462.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "435.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1309-1332>
            <http://www.example.org/end>    "1332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF219" ;
            <http://www.example.org/start>  "1309.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Leder and Weller, 2000)" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-245-266>
            <http://www.example.org/end>    "266.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF424" ;
            <http://www.example.org/start>  "245.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Weiner et al., 1994;" .
    
    <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-432-452>
            <http://www.example.org/end>    "452.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF155" ;
            <http://www.example.org/start>  "432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Grattan et al., 1997" .
    
    <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are also rare inherited conditions that cause defects in oxygen sensing pathways described in humans. These include Chuvash polycythemia, which follows an autosomal recessive inheritance pattern, and EGLN1 gene mutations, which cause a deficiency in proline hydroxylase (Prchal, 2016) . High cobalt concentrations may also inhibit the oxygen sensing pathway by preventing binding of the VHL E3 ligase to HIF (Yuan et al., 2003; Schuster et al., 1989) .\",\"cite_spans\":[{\"start\":276.0,\"end\":290.0,\"text\":\"(Prchal, 2016)\",\"ref_id\":\"BIBREF302\"},{\"start\":414.0,\"end\":433.0,\"text\":\"(Yuan et al., 2003;\",\"ref_id\":\"BIBREF440\"},{\"start\":434.0,\"end\":456.0,\"text\":\"Schuster et al., 1989)\",\"ref_id\":\"BIBREF343\"}],\"ref_spans\":[],\"section\":\"Secondary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef_citespan-276-290> , <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef_citespan-414-433> , <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef_citespan-434-456> ;
            <http://www.example.org/section>
                    "Secondary increases in red cell mass" ;
            <http://www.example.org/text>  "There are also rare inherited conditions that cause defects in oxygen sensing pathways described in humans. These include Chuvash polycythemia, which follows an autosomal recessive inheritance pattern, and EGLN1 gene mutations, which cause a deficiency in proline hydroxylase (Prchal, 2016) . High cobalt concentrations may also inhibit the oxygen sensing pathway by preventing binding of the VHL E3 ligase to HIF (Yuan et al., 2003; Schuster et al., 1989) ." ;
            <http://www.example.org/textHash>
                    "385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef" .
    
    <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c_citespan-442-454>
            <http://www.example.org/end>    "454.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "442.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bass, 1977)" .
    
    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-309-322>
            <http://www.example.org/end>    "322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF437" ;
            <http://www.example.org/start>  "309.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young, 2016;" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Direct infection of erythrocytes with protozoal Plasmodium species, the causative agent of malaria that is transmitted by mosquitoes, is a relatively common cause of hemolysis in humans, but may also be observed in nonhuman primates used in nonclinical toxicology studies. Humans are infected by one of five different Plasmodium species: P. falciparum, P. vivax, P. knowlesi, P. malariae, or P. ovale, although only P. falciparum and P. vivax are commonly associated with severe hemolysis (Lichtman, 2016b) . Macaques are most commonly infected with P. inui or P. knowlesi, although the cynomolgus monkey appears to be more resistant to disease from these infections than the rhesus monkey (Ameri, 2010) . Infection with P. cynomolgi, P. fieldi, or P. fragile may also occur in macaques (Magden et al., 2015) . Although it is uncommon to include macaques infected with Plasmodium species during a nonclinical toxicity study due to current screening practices and pretest evaluations, rare animals with decreases in red cell mass and increases in reticulocyte counts and intraerythrocytic Plasmodium organisms have been observed. Rats and mice may be infected with Plasmodium berghei (Holloway et al., 1995; Sadun et al., 1965) . Plasmodium berghei has a specific tropism for reticulocytes rather than mature erythrocytes Plasmodium species that infect humans (Car et al., 2006; Cromer et al., 2006) . Concurrent increases in reticulocyte counts may occur in early stages or disease or with recrudescence of parasitemia and hemolysis. Hemolysis is associated with clearance of parasitized erythrocytes from circulation predominantly by splenic macrophages (Lichtman, 2016b) , although accumulation of hemin, an iron-containing porphyrin, which can directly stimulate apoptotic erythrocyte death (eryptosis) (Gatidis et al., 2009) , oxidative damage to erythrocyte membranes (Clark and Hunt, 1983) , and increased osmotic fragility (George et al., 1967) may all contribute to hemolysis. However, late-stage infections in humans and rodents have also been associated with inappropriate or decreased reticulocyte counts indicative of suppressed erythropoiesis despite decreases in red cell mass from hemolysis (Lichtman, 2016b; Cromer et al., 2006) .\",\"cite_spans\":[{\"start\":489.0,\"end\":506.0,\"text\":\"(Lichtman, 2016b)\",\"ref_id\":\"BIBREF226\"},{\"start\":690.0,\"end\":703.0,\"text\":\"(Ameri, 2010)\",\"ref_id\":\"BIBREF3\"},{\"start\":787.0,\"end\":808.0,\"text\":\"(Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"},{\"start\":1183.0,\"end\":1206.0,\"text\":\"(Holloway et al., 1995;\",\"ref_id\":\"BIBREF173\"},{\"start\":1207.0,\"end\":1226.0,\"text\":\"Sadun et al., 1965)\",\"ref_id\":\"BIBREF331\"},{\"start\":1359.0,\"end\":1377.0,\"text\":\"(Car et al., 2006;\",\"ref_id\":\"BIBREF56\"},{\"start\":1378.0,\"end\":1398.0,\"text\":\"Cromer et al., 2006)\",\"ref_id\":\"BIBREF80\"},{\"start\":1655.0,\"end\":1672.0,\"text\":\"(Lichtman, 2016b)\",\"ref_id\":\"BIBREF226\"},{\"start\":1806.0,\"end\":1828.0,\"text\":\"(Gatidis et al., 2009)\",\"ref_id\":\"BIBREF137\"},{\"start\":1873.0,\"end\":1895.0,\"text\":\"(Clark and Hunt, 1983)\",\"ref_id\":\"BIBREF73\"},{\"start\":1930.0,\"end\":1951.0,\"text\":\"(George et al., 1967)\",\"ref_id\":\"BIBREF139\"},{\"start\":2206.0,\"end\":2223.0,\"text\":\"(Lichtman, 2016b;\",\"ref_id\":\"BIBREF226\"},{\"start\":2224.0,\"end\":2244.0,\"text\":\"Cromer et al., 2006)\",\"ref_id\":\"BIBREF80\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1806-1828> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-2224-2244> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1378-1398> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-787-808> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1183-1206> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1359-1377> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1207-1226> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-489-506> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1873-1895> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1930-1951> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1655-1672> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-690-703> , <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-2206-2223> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Direct infection of erythrocytes with protozoal Plasmodium species, the causative agent of malaria that is transmitted by mosquitoes, is a relatively common cause of hemolysis in humans, but may also be observed in nonhuman primates used in nonclinical toxicology studies. Humans are infected by one of five different Plasmodium species: P. falciparum, P. vivax, P. knowlesi, P. malariae, or P. ovale, although only P. falciparum and P. vivax are commonly associated with severe hemolysis (Lichtman, 2016b) . Macaques are most commonly infected with P. inui or P. knowlesi, although the cynomolgus monkey appears to be more resistant to disease from these infections than the rhesus monkey (Ameri, 2010) . Infection with P. cynomolgi, P. fieldi, or P. fragile may also occur in macaques (Magden et al., 2015) . Although it is uncommon to include macaques infected with Plasmodium species during a nonclinical toxicity study due to current screening practices and pretest evaluations, rare animals with decreases in red cell mass and increases in reticulocyte counts and intraerythrocytic Plasmodium organisms have been observed. Rats and mice may be infected with Plasmodium berghei (Holloway et al., 1995; Sadun et al., 1965) . Plasmodium berghei has a specific tropism for reticulocytes rather than mature erythrocytes Plasmodium species that infect humans (Car et al., 2006; Cromer et al., 2006) . Concurrent increases in reticulocyte counts may occur in early stages or disease or with recrudescence of parasitemia and hemolysis. Hemolysis is associated with clearance of parasitized erythrocytes from circulation predominantly by splenic macrophages (Lichtman, 2016b) , although accumulation of hemin, an iron-containing porphyrin, which can directly stimulate apoptotic erythrocyte death (eryptosis) (Gatidis et al., 2009) , oxidative damage to erythrocyte membranes (Clark and Hunt, 1983) , and increased osmotic fragility (George et al., 1967) may all contribute to hemolysis. However, late-stage infections in humans and rodents have also been associated with inappropriate or decreased reticulocyte counts indicative of suppressed erythropoiesis despite decreases in red cell mass from hemolysis (Lichtman, 2016b; Cromer et al., 2006) ." ;
            <http://www.example.org/textHash>
                    "eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524" .
    
    <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-587-602>
            <http://www.example.org/end>    "602.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF327" ;
            <http://www.example.org/start>  "587.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Roujeau, 2005)" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-203-223>
            <http://www.example.org/end>    "223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "203.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016)" .
    
    <http://covid19.aksw.org/text-f023ed321326b573a95e1be1618f1ae74ee4531cc926bf8f2e03cb4cd97b8d15_citespan-282-296>
            <http://www.example.org/end>    "296.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF300" ;
            <http://www.example.org/start>  "282.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Pohlman, 2010)" .
    
    <http://covid19.aksw.org/text-e0ad55de38a56e69df45a6f909c6c65f5f4b6e1648ba0bc8f951b521fcda41a4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Erythropoiesis is largely under the control of stimulation with erythropoietin (EPO), although stem cell factor (SCF), IL-3, and thrombopoietin (TPO) may also play a role in early erythrocyte differentiation and insulin-like growth factor (IGF)-1 may contribute to later erythropoiesis (Olver, 2010) . Erythrocyte differentiation begins with pluripotent hematopoietic stem cells that differentiate into common myeloid progenitor cells, which further differentiate into megakaryocyte-erythrocyte progenitor cells. Under stimulation with EPO, megakaryocyte-erythrocyte progenitors differentiate into the first committed erythroid progenitor, the burst-forming unit erythrocyte (BFU-E), which then differentiates into colony-forming unit erythrocyte (CFU-E) precursors. The next stage in erythroid development is the rubriblast, which is the earliest erythroid progenitor that may be identified with light microscopy. Erythroid cell maturation then progresses through prorubricyte, basophilic rubricyte, polychromatophilic rubricyte, and metarubricyte stages. As these stages progress, the nuclear chromatin becomes more condensed and the nucleus becomes pyknotic, coinciding with increased hemoglobin production and accumulation within the cytoplasm and simultaneously decreased RNA production. At this point, pyknotic nuclei are extruded from the cell to form reticulocytes, which are released from the bone marrow. Proliferative bone marrow erythrocyte pools include rubriblasts through basophilic rubricytes, while maturing bone marrow erythrocyte pools include polychromatophilic rubricytes and reticulocytes.\",\"cite_spans\":[{\"start\":286.0,\"end\":299.0,\"text\":\"(Olver, 2010)\",\"ref_id\":\"BIBREF280\"}],\"ref_spans\":[],\"section\":\"Erythrocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e0ad55de38a56e69df45a6f909c6c65f5f4b6e1648ba0bc8f951b521fcda41a4_citespan-286-299> ;
            <http://www.example.org/section>
                    "Erythrocytes" ;
            <http://www.example.org/text>  "Erythropoiesis is largely under the control of stimulation with erythropoietin (EPO), although stem cell factor (SCF), IL-3, and thrombopoietin (TPO) may also play a role in early erythrocyte differentiation and insulin-like growth factor (IGF)-1 may contribute to later erythropoiesis (Olver, 2010) . Erythrocyte differentiation begins with pluripotent hematopoietic stem cells that differentiate into common myeloid progenitor cells, which further differentiate into megakaryocyte-erythrocyte progenitor cells. Under stimulation with EPO, megakaryocyte-erythrocyte progenitors differentiate into the first committed erythroid progenitor, the burst-forming unit erythrocyte (BFU-E), which then differentiates into colony-forming unit erythrocyte (CFU-E) precursors. The next stage in erythroid development is the rubriblast, which is the earliest erythroid progenitor that may be identified with light microscopy. Erythroid cell maturation then progresses through prorubricyte, basophilic rubricyte, polychromatophilic rubricyte, and metarubricyte stages. As these stages progress, the nuclear chromatin becomes more condensed and the nucleus becomes pyknotic, coinciding with increased hemoglobin production and accumulation within the cytoplasm and simultaneously decreased RNA production. At this point, pyknotic nuclei are extruded from the cell to form reticulocytes, which are released from the bone marrow. Proliferative bone marrow erythrocyte pools include rubriblasts through basophilic rubricytes, while maturing bone marrow erythrocyte pools include polychromatophilic rubricytes and reticulocytes." ;
            <http://www.example.org/textHash>
                    "e0ad55de38a56e69df45a6f909c6c65f5f4b6e1648ba0bc8f951b521fcda41a4" .
    
    <http://covid19.aksw.org/text-1cee1201d51cee2d66f0e07a971d33bab94882ade852c0c1df1cfa734070aac2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Generalized bone marrow disease, such as replacement of normal bone marrow hematopoietic tissue with hemic or nonhemic neoplasia, severe granulomatous inflammation effacing normal bone marrow tissue, myelofibrosis, or bone marrow necrosis, will result in decreases in megakaryocytes and thrombopoiesis with subsequent decreases in blood platelet counts (Russell, 2010; Stockham and Scott, 2008c) .\",\"cite_spans\":[{\"start\":353.0,\"end\":368.0,\"text\":\"(Russell, 2010;\",\"ref_id\":\"BIBREF329\"},{\"start\":369.0,\"end\":395.0,\"text\":\"Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"}],\"ref_spans\":[],\"section\":\"Decreased production\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-1cee1201d51cee2d66f0e07a971d33bab94882ade852c0c1df1cfa734070aac2_citespan-353-368> , <http://covid19.aksw.org/text-1cee1201d51cee2d66f0e07a971d33bab94882ade852c0c1df1cfa734070aac2_citespan-369-395> ;
            <http://www.example.org/section>
                    "Decreased production" ;
            <http://www.example.org/text>  "Generalized bone marrow disease, such as replacement of normal bone marrow hematopoietic tissue with hemic or nonhemic neoplasia, severe granulomatous inflammation effacing normal bone marrow tissue, myelofibrosis, or bone marrow necrosis, will result in decreases in megakaryocytes and thrombopoiesis with subsequent decreases in blood platelet counts (Russell, 2010; Stockham and Scott, 2008c) ." ;
            <http://www.example.org/textHash>
                    "1cee1201d51cee2d66f0e07a971d33bab94882ade852c0c1df1cfa734070aac2" .
    
    <http://covid19.aksw.org/text-bca6486c44a5db03fcc770e97f5e2cfefc89fc77474295dfa6532428d158c668>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"AIHA and IMHA commonly have concurrent inflammatory increases in leukocyte subtype counts, characterized mainly by neutrophilia that may or may not have a left shift with cytoplasmic changes indicative of rapid neutropoiesis.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "AIHA and IMHA commonly have concurrent inflammatory increases in leukocyte subtype counts, characterized mainly by neutrophilia that may or may not have a left shift with cytoplasmic changes indicative of rapid neutropoiesis." ;
            <http://www.example.org/textHash>
                    "bca6486c44a5db03fcc770e97f5e2cfefc89fc77474295dfa6532428d158c668" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-617-636>
            <http://www.example.org/end>    "636.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF145" ;
            <http://www.example.org/start>  "617.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Giger et al., 1991;" .
    
    <http://covid19.aksw.org/text-0454039d5f7a9b1e880a4cb7e700a8efebdf3c913a68373e3338db32fe3e38fd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Bone marrow neutrophil production increases as the inflammatory stimulus depletes the neutrophil storage pool and recruits immature cells into circulation. The process of proliferation and maturation from the myelocyte stage to release of mature segmented neutrophils from the bone marrow takes approximately 6 to 9 days in health, although transit time can be decreased to 2 to 4 days with an acute inflammatory stimulus (Harvey, 2012; Stockham and Scott, 2008a) . Due to acceleration of granulopoiesis, morphologic changes may occur in the cytoplasm of neutrophils. These changes include Döhle bodies (remnants of rough endoplasmic reticulum that contain RNA), foamy cytoplasmic vacuolation, increased cytoplasmic basophilia, and evidence of asynchronous cytoplasmic and nuclear maturation (e.g., large neutrophils, lobes of immature nuclear chromatin with filamentous segmentation, or presence of primary granules in more mature stages). These changes are often referred to as \\\"toxic\\\" changes, but they are more accurately cellular morphologic alterations that are considered an indicator of rapid/accelerated neutrophil production.\",\"cite_spans\":[{\"start\":422.0,\"end\":436.0,\"text\":\"(Harvey, 2012;\",\"ref_id\":\"BIBREF166\"},{\"start\":437.0,\"end\":463.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0454039d5f7a9b1e880a4cb7e700a8efebdf3c913a68373e3338db32fe3e38fd_citespan-422-436> , <http://covid19.aksw.org/text-0454039d5f7a9b1e880a4cb7e700a8efebdf3c913a68373e3338db32fe3e38fd_citespan-437-463> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Bone marrow neutrophil production increases as the inflammatory stimulus depletes the neutrophil storage pool and recruits immature cells into circulation. The process of proliferation and maturation from the myelocyte stage to release of mature segmented neutrophils from the bone marrow takes approximately 6 to 9 days in health, although transit time can be decreased to 2 to 4 days with an acute inflammatory stimulus (Harvey, 2012; Stockham and Scott, 2008a) . Due to acceleration of granulopoiesis, morphologic changes may occur in the cytoplasm of neutrophils. These changes include Döhle bodies (remnants of rough endoplasmic reticulum that contain RNA), foamy cytoplasmic vacuolation, increased cytoplasmic basophilia, and evidence of asynchronous cytoplasmic and nuclear maturation (e.g., large neutrophils, lobes of immature nuclear chromatin with filamentous segmentation, or presence of primary granules in more mature stages). These changes are often referred to as \"toxic\" changes, but they are more accurately cellular morphologic alterations that are considered an indicator of rapid/accelerated neutrophil production." ;
            <http://www.example.org/textHash>
                    "0454039d5f7a9b1e880a4cb7e700a8efebdf3c913a68373e3338db32fe3e38fd" .
    
    <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-230-252>
            <http://www.example.org/end>    "252.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF379" ;
            <http://www.example.org/start>  "230.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tallman et al., 2000)" .
    
    <http://covid19.aksw.org/text-f87639415cd3e0ff539dc21ae8a8f1e174611851936c8bf344df13c2467de812_citespan-942-956>
            <http://www.example.org/end>    "956.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF166" ;
            <http://www.example.org/start>  "942.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Harvey, 2012;" .
    
    <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-475-496>
            <http://www.example.org/end>    "496.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF392" ;
            <http://www.example.org/start>  "475.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Toh and Dennis, 2003)" .
    
    <http://covid19.aksw.org/text-1976c7b56c655f36b2aafff6bee09c4b64676bd69a64375671e3f9152196f113>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.1.2.2 Hypoxia-independent (inappropriate) Secondary but hypoxia-independent increases in red cell mass are associated with increases in circulating EPO levels. However, increased EPO in these cases are attributable to autonomous production of EPO rather than hypoxia response. Reported associations include renal diseases, renal or nonrenal neoplasms, or rare dysfunctions of the oxygen sensing pathway.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Secondary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Secondary increases in red cell mass" ;
            <http://www.example.org/text>  "12.11.3.1.2.2 Hypoxia-independent (inappropriate) Secondary but hypoxia-independent increases in red cell mass are associated with increases in circulating EPO levels. However, increased EPO in these cases are attributable to autonomous production of EPO rather than hypoxia response. Reported associations include renal diseases, renal or nonrenal neoplasms, or rare dysfunctions of the oxygen sensing pathway." ;
            <http://www.example.org/textHash>
                    "1976c7b56c655f36b2aafff6bee09c4b64676bd69a64375671e3f9152196f113" .
    
    <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although uncommon, disorders causing chronic loss of lymphocyte-rich lymph fluid lead to body depletion of lymphocytes and decrease in blood lymphocyte counts. Examples of such conditions include protein-losing enteropathy, lymphangiectasia, ulcerative enteritis, or repeated iatrogenic removal of chylothoracic fluid (Vasu and Caligiuri, 2016; Schultze, 2010; Stockham and Scott, 2008a) .\",\"cite_spans\":[{\"start\":318.0,\"end\":344.0,\"text\":\"(Vasu and Caligiuri, 2016;\",\"ref_id\":\"BIBREF406\"},{\"start\":345.0,\"end\":360.0,\"text\":\"Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":361.0,\"end\":387.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Loss of lymph fluid\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb_citespan-318-344> , <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb_citespan-345-360> , <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb_citespan-361-387> ;
            <http://www.example.org/section>
                    "Loss of lymph fluid" ;
            <http://www.example.org/text>  "Although uncommon, disorders causing chronic loss of lymphocyte-rich lymph fluid lead to body depletion of lymphocytes and decrease in blood lymphocyte counts. Examples of such conditions include protein-losing enteropathy, lymphangiectasia, ulcerative enteritis, or repeated iatrogenic removal of chylothoracic fluid (Vasu and Caligiuri, 2016; Schultze, 2010; Stockham and Scott, 2008a) ." ;
            <http://www.example.org/textHash>
                    "292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb" .
    
    <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-376-397>
            <http://www.example.org/end>    "397.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF95" ;
            <http://www.example.org/start>  "376.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Domina et al., 1997)" .
    
    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-667-690>
            <http://www.example.org/end>    "690.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF313" ;
            <http://www.example.org/start>  "667.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Randolph et al., 2010)" .
    
    <http://covid19.aksw.org/text-4226723a381b4cb1ca81dc7980f23d181290868ab5e8d1c743e1338efd26dfbf_citespan-730-753>
            <http://www.example.org/end>    "753.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "730.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Benschop et al., 1996)" .
    
    <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-621-635>
            <http://www.example.org/end>    "635.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "621.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016;" .
    
    <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-942-964>
            <http://www.example.org/end>    "964.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF330" ;
            <http://www.example.org/start>  "942.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Saavedra et al., 2006)" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in neutrophil counts may be observed as part of the neoplastic processes of chronic myeloid leukemia (CML) or chronic neutrophilic leukemia (CNL). Leukocytosis in CML is ! 25,000 cells mL À 1 with increases in all stages of neutrophilic myeloid cells in blood, which are typically accompanied by increases in monocyte counts, eosinophil counts, basophil counts, platelet counts, and possibly increases in nucleated erythroid precursors (Sawyers, 1999) . In contrast to a leukemoid response, the left shift associated with CML tends to be less orderly, with greater numbers of earlier stages of myeloid cells in circulation along with the band and segmented neutrophils. Morphologic features indicative of dysplasia may be seen, and cytoplasmic features indicative of rapid granulopoiesis may be observed in neutrophils associated with CML. Bone marrow findings include hypercellularity with increased myeloid to erythroid ratios where myeloblasts and promyelocytes make up \\u003c 10% of all cells (Sawyer, 1999) . Most human cases of chronic myeloid leukemia have been associated with a translocation of chromosomes 9 and 22 (Philadelphia chromosome) resulting in the constitutively active BCR-ABL tyrosine kinase, an oncogene that induces leukemias (Sawyers, 1999) . A comparable bcr-abl translocation has been observed in dogs (Breen and Modiano, 2008; Cruz Cardona et al., 2011; Culver et al., 2013) , and transgenic and knock-in mouse models for bcr-abl translocation-induced CML have been utilized in research (Ren, 2005) .\",\"cite_spans\":[{\"start\":446.0,\"end\":461.0,\"text\":\"(Sawyers, 1999)\",\"ref_id\":\"BIBREF338\"},{\"start\":1002.0,\"end\":1016.0,\"text\":\"(Sawyer, 1999)\"},{\"start\":1255.0,\"end\":1270.0,\"text\":\"(Sawyers, 1999)\",\"ref_id\":\"BIBREF338\"},{\"start\":1334.0,\"end\":1359.0,\"text\":\"(Breen and Modiano, 2008;\",\"ref_id\":\"BIBREF44\"},{\"start\":1360.0,\"end\":1386.0,\"text\":\"Cruz Cardona et al., 2011;\",\"ref_id\":\"BIBREF81\"},{\"start\":1387.0,\"end\":1407.0,\"text\":\"Culver et al., 2013)\",\"ref_id\":\"BIBREF82\"},{\"start\":1520.0,\"end\":1531.0,\"text\":\"(Ren, 2005)\",\"ref_id\":\"BIBREF318\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1360-1386> , <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1334-1359> , <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1520-1531> , <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1387-1407> , <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1002-1016> , <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1255-1270> , <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-446-461> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Increases in neutrophil counts may be observed as part of the neoplastic processes of chronic myeloid leukemia (CML) or chronic neutrophilic leukemia (CNL). Leukocytosis in CML is ! 25,000 cells mL À 1 with increases in all stages of neutrophilic myeloid cells in blood, which are typically accompanied by increases in monocyte counts, eosinophil counts, basophil counts, platelet counts, and possibly increases in nucleated erythroid precursors (Sawyers, 1999) . In contrast to a leukemoid response, the left shift associated with CML tends to be less orderly, with greater numbers of earlier stages of myeloid cells in circulation along with the band and segmented neutrophils. Morphologic features indicative of dysplasia may be seen, and cytoplasmic features indicative of rapid granulopoiesis may be observed in neutrophils associated with CML. Bone marrow findings include hypercellularity with increased myeloid to erythroid ratios where myeloblasts and promyelocytes make up < 10% of all cells (Sawyer, 1999) . Most human cases of chronic myeloid leukemia have been associated with a translocation of chromosomes 9 and 22 (Philadelphia chromosome) resulting in the constitutively active BCR-ABL tyrosine kinase, an oncogene that induces leukemias (Sawyers, 1999) . A comparable bcr-abl translocation has been observed in dogs (Breen and Modiano, 2008; Cruz Cardona et al., 2011; Culver et al., 2013) , and transgenic and knock-in mouse models for bcr-abl translocation-induced CML have been utilized in research (Ren, 2005) ." ;
            <http://www.example.org/textHash>
                    "4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1" .
    
    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-768-788>
            <http://www.example.org/end>    "788.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Magden et al., 2015;" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-539-569>
            <http://www.example.org/end>    "569.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "539.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Baronciani and Beutler, 1993)" .
    
    <http://covid19.aksw.org/text-d0db80cae51c5a85eaf17c20b4fa36a06b7bbe6588f5a332563688880f336be1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.2.1.6 Xenobiotic-induced Xenobiotic-induced increases in blood lymphocyte counts are relatively uncommon, with most reports associated with an administration of catecholamines or rare idiosyncratic hypersensitivity-type reactions.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "12.11.2.2.1.6 Xenobiotic-induced Xenobiotic-induced increases in blood lymphocyte counts are relatively uncommon, with most reports associated with an administration of catecholamines or rare idiosyncratic hypersensitivity-type reactions." ;
            <http://www.example.org/textHash>
                    "d0db80cae51c5a85eaf17c20b4fa36a06b7bbe6588f5a332563688880f336be1" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-704-723>
            <http://www.example.org/end>    "723.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF113" ;
            <http://www.example.org/start>  "704.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Favre et al., 1990)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1226-1247>
            <http://www.example.org/end>    "1247.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF118" ;
            <http://www.example.org/start>  "1226.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fierro et al., 2013)" .
    
    <http://covid19.aksw.org/text-578bb563f947f04aba36cf955897ebe919ef4a1fb3cff88b984c5b2aea466a2d_citespan-766-793>
            <http://www.example.org/end>    "793.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "766.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-2084-2110>
            <http://www.example.org/end>    "2110.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "2084.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1366-1388>
            <http://www.example.org/end>    "1388.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "1366.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Akamizu et al., 2002)" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-339-364>
            <http://www.example.org/end>    "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF307" ;
            <http://www.example.org/start>  "339.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Radin and Wellman, 2010;" .
    
    <http://covid19.aksw.org/text-2252bb39c3ba663ece825638d176ed9cf503dec74ead8f47fa402a1e7de6e486_citespan-412-437>
            <http://www.example.org/end>    "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF307" ;
            <http://www.example.org/start>  "412.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Radin and Wellman, 2010)" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-142-169>
            <http://www.example.org/end>    "169.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF89" ;
            <http://www.example.org/start>  "142.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(de Titto and Araujo, 1988;" .
    
    <http://covid19.aksw.org/text-aec94e745e315f20a1a60e2301c5f7f3a05a9c7bbb45d68f464838ff3bb70fd1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are large species-based variations in platelet counts in health; rodents generally have the highest platelet counts of the common laboratory species, which may exceed 1,000,000 platelets mL À 1 , while nonhuman primates and dogs generally have lower but highly variable platelet counts. The circulating lifespan of platelets is approximately 5-9 days, and up to 30% of circulating platelets may be transiently contained by the spleen (Russell, 2010) . Clearance of senescent platelets from circulation is mainly due to phagocytosis by splenic macrophages.\",\"cite_spans\":[{\"start\":440.0,\"end\":455.0,\"text\":\"(Russell, 2010)\",\"ref_id\":\"BIBREF329\"}],\"ref_spans\":[],\"section\":\"Platelets\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-aec94e745e315f20a1a60e2301c5f7f3a05a9c7bbb45d68f464838ff3bb70fd1_citespan-440-455> ;
            <http://www.example.org/section>
                    "Platelets" ;
            <http://www.example.org/text>  "There are large species-based variations in platelet counts in health; rodents generally have the highest platelet counts of the common laboratory species, which may exceed 1,000,000 platelets mL À 1 , while nonhuman primates and dogs generally have lower but highly variable platelet counts. The circulating lifespan of platelets is approximately 5-9 days, and up to 30% of circulating platelets may be transiently contained by the spleen (Russell, 2010) . Clearance of senescent platelets from circulation is mainly due to phagocytosis by splenic macrophages." ;
            <http://www.example.org/textHash>
                    "aec94e745e315f20a1a60e2301c5f7f3a05a9c7bbb45d68f464838ff3bb70fd1" .
    
    <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-681-712>
            <http://www.example.org/end>    "712.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF389" ;
            <http://www.example.org/start>  "681.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Thorley-Lawson and Gross, 2004)" .
    
    <http://covid19.aksw.org/text-4b3341a78d894bff5627a3a6590b134ad5e5d6333eb9c8098c2660a4c029cec0_refspan-259-266>
            <http://www.example.org/end>    "266.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "259.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-a1d3748d4858de2185ca589f0c4ab13bf30f27253f0634ddddba54401816fbef_citespan-389-404>
            <http://www.example.org/end>    "404.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF327" ;
            <http://www.example.org/start>  "389.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Roujeau, 2005;" .
    
    <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-752-780>
            <http://www.example.org/end>    "780.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "752.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stump and VandeWoude, 2007)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1183-1206>
            <http://www.example.org/end>    "1206.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF173" ;
            <http://www.example.org/start>  "1183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Holloway et al., 1995;" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-468-492>
            <http://www.example.org/end>    "492.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF400" ;
            <http://www.example.org/start>  "468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Valenciano et al., 2010;" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1655-1672>
            <http://www.example.org/end>    "1672.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF226" ;
            <http://www.example.org/start>  "1655.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016b)" .
    
    <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-848-868>
            <http://www.example.org/end>    "868.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF416" ;
            <http://www.example.org/start>  "848.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Wallen et al., 1991)" .
    
    <http://covid19.aksw.org/text-08c5385d53cbe4116f7e94aa710b0f5400a9156ec043a47224d48737b8a5a264_citespan-522-537>
            <http://www.example.org/end>    "537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF140" ;
            <http://www.example.org/start>  "522.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gergely, 1999)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1225-1250>
            <http://www.example.org/end>    "1250.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF199" ;
            <http://www.example.org/start>  "1225.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Katznelson et al., 1994;" .
    
    <http://covid19.aksw.org/text-78314608b6253b19d35efaf82abe5c94e39d1a63dd2d7e6aa9fb00e98631ceb0_citespan-568-581>
            <http://www.example.org/end>    "581.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF371" ;
            <http://www.example.org/start>  "568.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stone, 2005;" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-146-161>
            <http://www.example.org/end>    "161.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF300" ;
            <http://www.example.org/start>  "146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pohlman, 2010;" .
    
    <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-283-309>
            <http://www.example.org/end>    "309.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "283.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b" .
    
    <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-513-543>
            <http://www.example.org/end>    "543.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF387" ;
            <http://www.example.org/start>  "513.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Thompson and van Furth, 1973)" .
    
    <http://covid19.aksw.org/text-e4132140be206c250a772e29ab0282ef8e1da49127040db47873205f52615e86_citespan-609-628>
            <http://www.example.org/end>    "628.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF419" ;
            <http://www.example.org/start>  "609.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wang et al., 1998)" .
    
    <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-720-734>
            <http://www.example.org/end>    "734.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF163" ;
            <http://www.example.org/start>  "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Hamblin, 2006)" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-578-604>
            <http://www.example.org/end>    "604.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF103" ;
            <http://www.example.org/start>  "578.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Edwards and Fuller, 1996;" .
    
    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Several endocrinopathies have also been associated with decreases in red cell mass with decreases in reticulocyte counts, including hypothyroidism, hypoadrenocorticism, and hyperestrogenism. In cases of hypothyroidism, several mechanisms may be contributing to the decreases in red cell mass. Decreased folate or cobalamin concentrations secondary to the hypothyroidism leading to ineffective erythropoiesis, decreased tissue oxygen demand leading to decreased EPO and lower baseline red cell mass, and ACD may contribute to the mild decreases in red cell mass observed with hypothyroidism (Ottesen et al., 1995; Hines et al., 1968; Stockham and Scott, 2008b; Mehmet et al., 2012) . Mild decreases in red cell mass without apparent changes in reticulocyte counts have been associated with hypoadrenocorticism. This may be due to a decrease in glucocorticoids, and the loss of the apparent proerythropoietic stimulation of glucocorticoids (Stockham and Scott, 2008b) . Hyperestrogenism, which occurs with some ovarian or testicular neoplasms, may result in bone marrow toxicity and suppression of erythropoiesis, particularly in dogs (Sontas et al., 2009) .\",\"cite_spans\":[{\"start\":590.0,\"end\":612.0,\"text\":\"(Ottesen et al., 1995;\",\"ref_id\":\"BIBREF282\"},{\"start\":613.0,\"end\":632.0,\"text\":\"Hines et al., 1968;\",\"ref_id\":\"BIBREF170\"},{\"start\":633.0,\"end\":659.0,\"text\":\"Stockham and Scott, 2008b;\",\"ref_id\":\"BIBREF367\"},{\"start\":660.0,\"end\":680.0,\"text\":\"Mehmet et al., 2012)\",\"ref_id\":\"BIBREF258\"},{\"start\":938.0,\"end\":965.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":1133.0,\"end\":1154.0,\"text\":\"(Sontas et al., 2009)\",\"ref_id\":\"BIBREF364\"}],\"ref_spans\":[],\"section\":\"Endocrinopathy\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-938-965> , <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-633-659> , <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-613-632> , <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-1133-1154> , <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-660-680> , <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-590-612> ;
            <http://www.example.org/section>
                    "Endocrinopathy" ;
            <http://www.example.org/text>  "Several endocrinopathies have also been associated with decreases in red cell mass with decreases in reticulocyte counts, including hypothyroidism, hypoadrenocorticism, and hyperestrogenism. In cases of hypothyroidism, several mechanisms may be contributing to the decreases in red cell mass. Decreased folate or cobalamin concentrations secondary to the hypothyroidism leading to ineffective erythropoiesis, decreased tissue oxygen demand leading to decreased EPO and lower baseline red cell mass, and ACD may contribute to the mild decreases in red cell mass observed with hypothyroidism (Ottesen et al., 1995; Hines et al., 1968; Stockham and Scott, 2008b; Mehmet et al., 2012) . Mild decreases in red cell mass without apparent changes in reticulocyte counts have been associated with hypoadrenocorticism. This may be due to a decrease in glucocorticoids, and the loss of the apparent proerythropoietic stimulation of glucocorticoids (Stockham and Scott, 2008b) . Hyperestrogenism, which occurs with some ovarian or testicular neoplasms, may result in bone marrow toxicity and suppression of erythropoiesis, particularly in dogs (Sontas et al., 2009) ." ;
            <http://www.example.org/textHash>
                    "e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1231-1254>
            <http://www.example.org/end>    "1254.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF403" ;
            <http://www.example.org/start>  "1231.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Van Horn et al., 1986)" .
    
    <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Nonneoplasic renal diseases associated with increased EPO production include hydronephrosis, renal cysts, and polycystic renal disease (Prchal, 2016) . These renal diseases may be associated with local tissue hypoxia (Randolph et al., 2010) , but are not associated with systemic hypoxia. Similarly, increases in red cell mass may be observed in humans following renal transplantation (Prchal, 2016) .\",\"cite_spans\":[{\"start\":135.0,\"end\":149.0,\"text\":\"(Prchal, 2016)\",\"ref_id\":\"BIBREF302\"},{\"start\":217.0,\"end\":240.0,\"text\":\"(Randolph et al., 2010)\",\"ref_id\":\"BIBREF313\"},{\"start\":385.0,\"end\":399.0,\"text\":\"(Prchal, 2016)\",\"ref_id\":\"BIBREF302\"}],\"ref_spans\":[],\"section\":\"Secondary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd_citespan-135-149> , <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd_citespan-217-240> , <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd_citespan-385-399> ;
            <http://www.example.org/section>
                    "Secondary increases in red cell mass" ;
            <http://www.example.org/text>  "Nonneoplasic renal diseases associated with increased EPO production include hydronephrosis, renal cysts, and polycystic renal disease (Prchal, 2016) . These renal diseases may be associated with local tissue hypoxia (Randolph et al., 2010) , but are not associated with systemic hypoxia. Similarly, increases in red cell mass may be observed in humans following renal transplantation (Prchal, 2016) ." ;
            <http://www.example.org/textHash>
                    "5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-798-819>
            <http://www.example.org/end>    "819.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF46" ;
            <http://www.example.org/start>  "798.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Buchan et al., 1985)" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1986-2006>
            <http://www.example.org/end>    "2006.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF72" ;
            <http://www.example.org/start>  "1986.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cines et al., 2009)" .
    
    <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-533-559>
            <http://www.example.org/end>    "559.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "533.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016)" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-315-331>
            <http://www.example.org/end>    "331.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "315.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-b53c45de97c3cc1cf8b9363deec238fc77692ee62406b848905f438d0a261556_citespan-292-312>
            <http://www.example.org/end>    "312.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF51" ;
            <http://www.example.org/start>  "292.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Cable et al., 2011)" .
    
    <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c_citespan-936-952>
            <http://www.example.org/end>    "952.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF48" ;
            <http://www.example.org/start>  "936.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Burkhard, 2010)" .
    
    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-789-804>
            <http://www.example.org/end>    "804.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "789.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-942-962>
            <http://www.example.org/end>    "962.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF417" ;
            <http://www.example.org/start>  "942.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Walter et al., 2002;" .
    
    <http://covid19.aksw.org/text-72cdd5f94494b2a9146ad2ed2793e599c748523abfad265e2a0a6c42abddf0c1_citespan-295-314>
            <http://www.example.org/end>    "314.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF309" ;
            <http://www.example.org/start>  "295.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rael et al., 2000)" .
    
    <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Other classes of drugs reported to cause decrease lymphocyte counts are varied: pesticides including organochloride pesticides such as pentachlorophenol, organotin compounds, and organophosphates (Corsini et al., 2013) ; thienopyridines, such as clopidogrel and ticlopidine, which can cause direct lymphotoxicity at high concentrations (Maseneni et al., 2013) ; the histamine H2 receptor antagonist cimetidine; the anticonvulsant carbamazepine; imidazoles used to treat fungal infections; and opioids such as morphine (Gergely, 1999) .\",\"cite_spans\":[{\"start\":196.0,\"end\":218.0,\"text\":\"(Corsini et al., 2013)\",\"ref_id\":\"BIBREF76\"},{\"start\":336.0,\"end\":359.0,\"text\":\"(Maseneni et al., 2013)\",\"ref_id\":\"BIBREF249\"},{\"start\":518.0,\"end\":533.0,\"text\":\"(Gergely, 1999)\",\"ref_id\":\"BIBREF140\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34_citespan-196-218> , <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34_citespan-336-359> , <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34_citespan-518-533> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Other classes of drugs reported to cause decrease lymphocyte counts are varied: pesticides including organochloride pesticides such as pentachlorophenol, organotin compounds, and organophosphates (Corsini et al., 2013) ; thienopyridines, such as clopidogrel and ticlopidine, which can cause direct lymphotoxicity at high concentrations (Maseneni et al., 2013) ; the histamine H2 receptor antagonist cimetidine; the anticonvulsant carbamazepine; imidazoles used to treat fungal infections; and opioids such as morphine (Gergely, 1999) ." ;
            <http://www.example.org/textHash>
                    "3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34" .
    
    <http://covid19.aksw.org/text-aa1e25105c9cb7851d59cc0c1f83acdc572de8ad6a5c21e403ef2524dd55f7cc_citespan-758-785>
            <http://www.example.org/end>    "785.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "758.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-282-294>
            <http://www.example.org/end>    "294.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF162" ;
            <http://www.example.org/start>  "282.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hall, 2013;" .
    
    <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-783-805>
            <http://www.example.org/end>    "805.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF235" ;
            <http://www.example.org/start>  "783.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lohrmann et al., 1973)" .
    
    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-355-379>
            <http://www.example.org/end>    "379.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF213" ;
            <http://www.example.org/start>  "355.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lamy and Loughran, 1999)" .
    
    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-791-815>
            <http://www.example.org/end>    "815.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF196" ;
            <http://www.example.org/start>  "791.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Karttunen et al., 1996)" .
    
    <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-170-190>
            <http://www.example.org/end>    "190.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF439" ;
            <http://www.example.org/start>  "170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young et al., 2006)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Parasitism is a relatively frequent cause of inflammatory increases in basophil counts, which are almost always observed in conjunction with increases in blood eosinophil counts. Many endoparasites, predominantly helminths with tissue exposure or migration, and ectoparasites, including a variety of arthropods, have been associated with concurrent increase in eosinophil and basophil counts (Schultze, 2010; Pohlman, 2010; Voehringer, 2009; Falcone et al., 2001; Brown and Rosalsky, 1984; Roth and Levy, 1980; Ogilvie et al., 1980) . Infectious agents other than parasites have also been reported to cause increases in basophil counts. Several viral etiologies associated with increases in basophil counts in humans include influenza, chickenpox, and smallpox viruses (Galli et al., 2016) . Several bacterial infections may also cause increases in blood basophil counts, including tuberculosis (Galli et al., 2016) and infection with Helicobacter pylori (Karttunen et al., 1996) .\",\"cite_spans\":[{\"start\":392.0,\"end\":408.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":409.0,\"end\":423.0,\"text\":\"Pohlman, 2010;\",\"ref_id\":\"BIBREF300\"},{\"start\":424.0,\"end\":441.0,\"text\":\"Voehringer, 2009;\",\"ref_id\":\"BIBREF411\"},{\"start\":442.0,\"end\":463.0,\"text\":\"Falcone et al., 2001;\",\"ref_id\":\"BIBREF109\"},{\"start\":464.0,\"end\":489.0,\"text\":\"Brown and Rosalsky, 1984;\",\"ref_id\":\"BIBREF45\"},{\"start\":490.0,\"end\":510.0,\"text\":\"Roth and Levy, 1980;\",\"ref_id\":\"BIBREF326\"},{\"start\":511.0,\"end\":532.0,\"text\":\"Ogilvie et al., 1980)\",\"ref_id\":\"BIBREF278\"},{\"start\":769.0,\"end\":789.0,\"text\":\"(Galli et al., 2016)\",\"ref_id\":\"BIBREF128\"},{\"start\":895.0,\"end\":915.0,\"text\":\"(Galli et al., 2016)\",\"ref_id\":\"BIBREF128\"},{\"start\":955.0,\"end\":979.0,\"text\":\"(Karttunen et al., 1996)\",\"ref_id\":\"BIBREF196\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-955-979> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-464-489> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-511-532> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-442-463> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-895-915> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-392-408> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-424-441> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-769-789> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-490-510> , <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-409-423> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "Parasitism is a relatively frequent cause of inflammatory increases in basophil counts, which are almost always observed in conjunction with increases in blood eosinophil counts. Many endoparasites, predominantly helminths with tissue exposure or migration, and ectoparasites, including a variety of arthropods, have been associated with concurrent increase in eosinophil and basophil counts (Schultze, 2010; Pohlman, 2010; Voehringer, 2009; Falcone et al., 2001; Brown and Rosalsky, 1984; Roth and Levy, 1980; Ogilvie et al., 1980) . Infectious agents other than parasites have also been reported to cause increases in basophil counts. Several viral etiologies associated with increases in basophil counts in humans include influenza, chickenpox, and smallpox viruses (Galli et al., 2016) . Several bacterial infections may also cause increases in blood basophil counts, including tuberculosis (Galli et al., 2016) and infection with Helicobacter pylori (Karttunen et al., 1996) ." ;
            <http://www.example.org/textHash>
                    "e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-697-710>
            <http://www.example.org/end>    "710.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF425" ;
            <http://www.example.org/start>  "697.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Weiss, 1986)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-982-995>
            <http://www.example.org/end>    "995.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF157" ;
            <http://www.example.org/start>  "982.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Green, 2016)" .
    
    <http://covid19.aksw.org/text-eb67ed6d92a5dc594599d4d70e71f77d4266e98ed832c9cb4b58d799cb77d0d8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although decreases in eosinophil counts are relatively uncommon with the exception of the administration of exogenous glucocorticoid-based xenobiotics, they may also be observed in cases of xenobiotic-induced bone marrow suppression and aplastic anemia. In these situations, the decreases in eosinophil counts do not occur in isolation but are generally observed with concurrent decreases in neutrophil, lymphocyte, and/or monocyte counts. Xenobiotic causes of bone marrow suppression classically include chemotherapeutic agents, while xenobiotics that can sporadically be associated with aplastic anemia include chloramphenicol and anticonvulsants such as phenytoin. Other xenobiotics associated with bone marrow suppression or aplastic anemia are described in more detail in the previous leukocyte subtype sections.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Although decreases in eosinophil counts are relatively uncommon with the exception of the administration of exogenous glucocorticoid-based xenobiotics, they may also be observed in cases of xenobiotic-induced bone marrow suppression and aplastic anemia. In these situations, the decreases in eosinophil counts do not occur in isolation but are generally observed with concurrent decreases in neutrophil, lymphocyte, and/or monocyte counts. Xenobiotic causes of bone marrow suppression classically include chemotherapeutic agents, while xenobiotics that can sporadically be associated with aplastic anemia include chloramphenicol and anticonvulsants such as phenytoin. Other xenobiotics associated with bone marrow suppression or aplastic anemia are described in more detail in the previous leukocyte subtype sections." ;
            <http://www.example.org/textHash>
                    "eb67ed6d92a5dc594599d4d70e71f77d4266e98ed832c9cb4b58d799cb77d0d8" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-1348-1373>
            <http://www.example.org/end>    "1373.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF337" ;
            <http://www.example.org/start>  "1348.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sato and Yanagita, 2013)" .
    
    <http://covid19.aksw.org/text-16fb03654ef27bcdfa4524634bbba70daf47abd7f4915ec969ab2fc2bad90e92_citespan-307-331>
            <http://www.example.org/end>    "331.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Thrombotic microangiopathy syndrome, which may include thrombotic thrombocytopenic purpura (TTP) and HUS, may cause peripheral consumption and/or destruction of platelets with the development of decreases in platelet counts. Xenobiotic-induced endothelial injury leads to platelet activation and aggregation (Pisoni et al., 2001) . Several chemotherapeutic agents associated with thrombotic microangiopathy syndrome include mitomycin C (Cantrell et al., 1985) , cisplatin (Palmisano et al., 1998) , estramustine phosphate (Tassinari et al., 1999) , gemcitabine (Nackaerts et al., 1998) , and daunorubicin (Byrnes et al., 1986) . Nonchemotherapeutic agents, including immunomodulators such as cyclosporine and tacrolimus (Katznelson et al., 1994; Trimarchi et al., 1999 ), simvastatin (McCarthy et al., 1998 , and inhibitors of platelet aggregation including ticlopidine and clopidogrel (Bennett et al., 1998 , have also been associated with thrombotic microangiopathy syndrome.\",\"cite_spans\":[{\"start\":308.0,\"end\":329.0,\"text\":\"(Pisoni et al., 2001)\",\"ref_id\":\"BIBREF299\"},{\"start\":436.0,\"end\":459.0,\"text\":\"(Cantrell et al., 1985)\",\"ref_id\":\"BIBREF55\"},{\"start\":472.0,\"end\":496.0,\"text\":\"(Palmisano et al., 1998)\",\"ref_id\":\"BIBREF286\"},{\"start\":522.0,\"end\":546.0,\"text\":\"(Tassinari et al., 1999)\",\"ref_id\":\"BIBREF381\"},{\"start\":561.0,\"end\":585.0,\"text\":\"(Nackaerts et al., 1998)\",\"ref_id\":\"BIBREF272\"},{\"start\":605.0,\"end\":626.0,\"text\":\"(Byrnes et al., 1986)\",\"ref_id\":\"BIBREF50\"},{\"start\":720.0,\"end\":745.0,\"text\":\"(Katznelson et al., 1994;\",\"ref_id\":\"BIBREF199\"},{\"start\":746.0,\"end\":768.0,\"text\":\"Trimarchi et al., 1999\",\"ref_id\":\"BIBREF393\"},{\"start\":769.0,\"end\":806.0,\"text\":\"), simvastatin (McCarthy et al., 1998\"},{\"start\":886.0,\"end\":907.0,\"text\":\"(Bennett et al., 1998\",\"ref_id\":\"BIBREF23\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-472-496> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-886-907> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-561-585> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-720-745> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-769-806> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-436-459> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-308-329> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-522-546> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-746-768> , <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-605-626> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Thrombotic microangiopathy syndrome, which may include thrombotic thrombocytopenic purpura (TTP) and HUS, may cause peripheral consumption and/or destruction of platelets with the development of decreases in platelet counts. Xenobiotic-induced endothelial injury leads to platelet activation and aggregation (Pisoni et al., 2001) . Several chemotherapeutic agents associated with thrombotic microangiopathy syndrome include mitomycin C (Cantrell et al., 1985) , cisplatin (Palmisano et al., 1998) , estramustine phosphate (Tassinari et al., 1999) , gemcitabine (Nackaerts et al., 1998) , and daunorubicin (Byrnes et al., 1986) . Nonchemotherapeutic agents, including immunomodulators such as cyclosporine and tacrolimus (Katznelson et al., 1994; Trimarchi et al., 1999 ), simvastatin (McCarthy et al., 1998 , and inhibitors of platelet aggregation including ticlopidine and clopidogrel (Bennett et al., 1998 , have also been associated with thrombotic microangiopathy syndrome." ;
            <http://www.example.org/textHash>
                    "24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-710-729>
            <http://www.example.org/end>    "729.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF63" ;
            <http://www.example.org/start>  "710.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Chan et al., 1982;" .
    
    <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f_citespan-478-493>
            <http://www.example.org/end>    "493.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "478.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327_citespan-425-440>
            <http://www.example.org/end>    "440.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF277" ;
            <http://www.example.org/start>  "425.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Oelkers, 1996;" .
    
    <http://covid19.aksw.org/text-637cc8e7dab553f631863f3d8bd0974754c2cedecd28416fb0376c44a3d3ad0c_citespan-1726-1743>
            <http://www.example.org/end>    "1743.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "1726.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Berkowitz, 1991)" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-2247-2268>
            <http://www.example.org/end>    "2268.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "2247.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Abella et al., 2002)" .
    
    <http://covid19.aksw.org/text-e00276642f98e38aaf9181b63151df55bf2ba44f53c344836578f081ef7b09b0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in TPO also occur during instances of decreases in platelet counts, such as observed with immune-mediated platelet destruction, bone marrow suppression, or blood loss, as discussed later. Following resolution of the cause of decreased blood platelet counts, TPO stimulation of increased production may cause a transient increases in blood platelet counts, or rebound thrombocytosis, prior to normalization of platelet counts (Stockham and Scott, 2008c) .\",\"cite_spans\":[{\"start\":435.0,\"end\":462.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"}],\"ref_spans\":[],\"section\":\"Inflammation or reactive\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e00276642f98e38aaf9181b63151df55bf2ba44f53c344836578f081ef7b09b0_citespan-435-462> ;
            <http://www.example.org/section>
                    "Inflammation or reactive" ;
            <http://www.example.org/text>  "Increases in TPO also occur during instances of decreases in platelet counts, such as observed with immune-mediated platelet destruction, bone marrow suppression, or blood loss, as discussed later. Following resolution of the cause of decreased blood platelet counts, TPO stimulation of increased production may cause a transient increases in blood platelet counts, or rebound thrombocytosis, prior to normalization of platelet counts (Stockham and Scott, 2008c) ." ;
            <http://www.example.org/textHash>
                    "e00276642f98e38aaf9181b63151df55bf2ba44f53c344836578f081ef7b09b0" .
    
    <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.5.1.2 Endocrinopathy Several endocrinopathies have been associated with increases in blood basophil counts. These endocrinopathies include hypothyroidism (myxedema) and diabetes mellitus (Galli et al., 2016; Shelley and Parnes, 1965) . It has been suggested that the increases in basophil counts are secondary to hyperlipidemia associated with the endocrinopathies, but supporting mechanistic evidence is scant (Pohlman, 2010; Schultze, 2010) .\",\"cite_spans\":[{\"start\":195.0,\"end\":215.0,\"text\":\"(Galli et al., 2016;\",\"ref_id\":\"BIBREF128\"},{\"start\":216.0,\"end\":241.0,\"text\":\"Shelley and Parnes, 1965)\",\"ref_id\":\"BIBREF352\"},{\"start\":419.0,\"end\":434.0,\"text\":\"(Pohlman, 2010;\",\"ref_id\":\"BIBREF300\"},{\"start\":435.0,\"end\":450.0,\"text\":\"Schultze, 2010)\",\"ref_id\":\"BIBREF342\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-195-215> , <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-216-241> , <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-419-434> , <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-435-450> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "12.11.2.5.1.2 Endocrinopathy Several endocrinopathies have been associated with increases in blood basophil counts. These endocrinopathies include hypothyroidism (myxedema) and diabetes mellitus (Galli et al., 2016; Shelley and Parnes, 1965) . It has been suggested that the increases in basophil counts are secondary to hyperlipidemia associated with the endocrinopathies, but supporting mechanistic evidence is scant (Pohlman, 2010; Schultze, 2010) ." ;
            <http://www.example.org/textHash>
                    "c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08" .
    
    <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3_citespan-379-392>
            <http://www.example.org/end>    "392.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF363" ;
            <http://www.example.org/start>  "379.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Songer, 1996)" .
    
    <http://covid19.aksw.org/text-4e1c536929b0417c6b104c62e3be54e2e4b8498bb26238e5c8cd085a3c47692f_citespan-332-347>
            <http://www.example.org/end>    "347.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF327" ;
            <http://www.example.org/start>  "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Roujeau, 2005)" .
    
    <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf_citespan-889-901>
            <http://www.example.org/end>    "901.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF428" ;
            <http://www.example.org/start>  "889.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Weiss, 2010;" .
    
    <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f_citespan-450-477>
            <http://www.example.org/end>    "477.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "450.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a;" .
    
    <http://covid19.aksw.org/text-f93d23cc1a6f34d35e3d9cf585b6e04a601d6efc9c2f5f0d659375671f3e2d85_citespan-368-398>
            <http://www.example.org/end>    "398.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF150" ;
            <http://www.example.org/start>  "368.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Goncharova and Krylova, 1967)" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-790-814>
            <http://www.example.org/end>    "814.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "790.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Aster and Bougie, 2007;" .
    
    <http://covid19.aksw.org/text-fff20fe4f9837d8a6e817f8e9c8ae445066e69ea42ad8287726da2e4fb2a02ea_citespan-277-292>
            <http://www.example.org/end>    "292.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "277.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Acute Chagas disease, caused by infection with Trypanosoma cruzi, has been reported to cause decreases in red cell mass in humans and monkeys (de Titto and Araujo, 1988; Rosner et al., 1988; Seah et al., 1974) . In experimentally infected Cebus paella monkeys, the acute phase of Chagas disease was reported to cause normocytic, normochromic anemia (Rosner et al., 1988) , typical of a nonregenerative anemia. Experimentally infected mice demonstrated bone marrow suppression with decreases in red cell mass as well as decreases in leukocyte and platelet counts (Marcondes et al., 2000) . Although rarely encountered in nonclinical toxicology studies, monkeys held in the southwestern United States may become infected with T. cruzi prior to distribution (Magden et al., 2015) . During parasitemia, trypomastigotes may be observed in peripheral blood smears. Viral infections may also cause decreases in red cell mass without concurrent increases in reticulocyte counts. Parvoviruses may cause decreases in red cell mass from direct infection of erythroid precursor resulting in decreased erythrocyte production, as well as decreased erythrocyte lifespans. Parvovirus may result in transient pure red cell aplasia (PRCA) in humans (Van Horn et al., 1986) . Cell-mediated suppression of erythropoiesis resulting in PRCA has also been reported with viral hepatitis (Wilson et al., 1980) and Epstein-Barr virus infection (Socinski et al., 1984) . Although HIV infection can result in decreases in red cell mass through various mechanisms, direct infection of erythroid precursors appears to contribute to suppressed erythropoiesis (Evans and Scadden, 2000) . In cats, a membrane protein of feline leukemia virus has been associated with decreased growth of CFU-E (Wellman et al., 1984) . Flavivirus infection, such as dengue, may also result in decreases in red cell mass and reticulocyte counts through bone marrow suppression (La Russa and Innis, 1995) .\",\"cite_spans\":[{\"start\":142.0,\"end\":169.0,\"text\":\"(de Titto and Araujo, 1988;\",\"ref_id\":\"BIBREF89\"},{\"start\":170.0,\"end\":190.0,\"text\":\"Rosner et al., 1988;\",\"ref_id\":\"BIBREF325\"},{\"start\":191.0,\"end\":209.0,\"text\":\"Seah et al., 1974)\",\"ref_id\":\"BIBREF344\"},{\"start\":349.0,\"end\":370.0,\"text\":\"(Rosner et al., 1988)\",\"ref_id\":\"BIBREF325\"},{\"start\":562.0,\"end\":586.0,\"text\":\"(Marcondes et al., 2000)\",\"ref_id\":\"BIBREF244\"},{\"start\":755.0,\"end\":776.0,\"text\":\"(Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"},{\"start\":1231.0,\"end\":1254.0,\"text\":\"(Van Horn et al., 1986)\",\"ref_id\":\"BIBREF403\"},{\"start\":1363.0,\"end\":1384.0,\"text\":\"(Wilson et al., 1980)\",\"ref_id\":\"BIBREF432\"},{\"start\":1418.0,\"end\":1441.0,\"text\":\"(Socinski et al., 1984)\",\"ref_id\":\"BIBREF360\"},{\"start\":1628.0,\"end\":1653.0,\"text\":\"(Evans and Scadden, 2000)\",\"ref_id\":\"BIBREF106\"},{\"start\":1760.0,\"end\":1782.0,\"text\":\"(Wellman et al., 1984)\",\"ref_id\":\"BIBREF429\"},{\"start\":1929.0,\"end\":1951.0,\"text\":\"Russa and Innis, 1995)\",\"ref_id\":\"BIBREF210\"}],\"ref_spans\":[],\"section\":\"Infectious\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-191-209> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1418-1441> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-562-586> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-755-776> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1628-1653> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-170-190> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-349-370> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1760-1782> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1363-1384> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1929-1951> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1231-1254> , <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-142-169> ;
            <http://www.example.org/section>
                    "Infectious" ;
            <http://www.example.org/text>  "Acute Chagas disease, caused by infection with Trypanosoma cruzi, has been reported to cause decreases in red cell mass in humans and monkeys (de Titto and Araujo, 1988; Rosner et al., 1988; Seah et al., 1974) . In experimentally infected Cebus paella monkeys, the acute phase of Chagas disease was reported to cause normocytic, normochromic anemia (Rosner et al., 1988) , typical of a nonregenerative anemia. Experimentally infected mice demonstrated bone marrow suppression with decreases in red cell mass as well as decreases in leukocyte and platelet counts (Marcondes et al., 2000) . Although rarely encountered in nonclinical toxicology studies, monkeys held in the southwestern United States may become infected with T. cruzi prior to distribution (Magden et al., 2015) . During parasitemia, trypomastigotes may be observed in peripheral blood smears. Viral infections may also cause decreases in red cell mass without concurrent increases in reticulocyte counts. Parvoviruses may cause decreases in red cell mass from direct infection of erythroid precursor resulting in decreased erythrocyte production, as well as decreased erythrocyte lifespans. Parvovirus may result in transient pure red cell aplasia (PRCA) in humans (Van Horn et al., 1986) . Cell-mediated suppression of erythropoiesis resulting in PRCA has also been reported with viral hepatitis (Wilson et al., 1980) and Epstein-Barr virus infection (Socinski et al., 1984) . Although HIV infection can result in decreases in red cell mass through various mechanisms, direct infection of erythroid precursors appears to contribute to suppressed erythropoiesis (Evans and Scadden, 2000) . In cats, a membrane protein of feline leukemia virus has been associated with decreased growth of CFU-E (Wellman et al., 1984) . Flavivirus infection, such as dengue, may also result in decreases in red cell mass and reticulocyte counts through bone marrow suppression (La Russa and Innis, 1995) ." ;
            <http://www.example.org/textHash>
                    "0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3" .
    
    <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-580-600>
            <http://www.example.org/end>    "600.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF250" ;
            <http://www.example.org/start>  "580.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Maslo et al., 1997)" .
    
    <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-605-618>
            <http://www.example.org/end>    "618.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF357" ;
            <http://www.example.org/start>  "605.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Smith, 1996)" .
    
    <http://covid19.aksw.org/text-631f130b3f7c34fc5e5286bcf6a8d6b33a58fa77aad0e15acbed90762738d752_citespan-702-720>
            <http://www.example.org/end>    "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF229" ;
            <http://www.example.org/start>  "702.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lima et al., 2006)" .
    
    <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-363-385>
            <http://www.example.org/end>    "385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF251" ;
            <http://www.example.org/start>  "363.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Massardo et al., 2009;" .
    
    <http://covid19.aksw.org/text-aa1e25105c9cb7851d59cc0c1f83acdc572de8ad6a5c21e403ef2524dd55f7cc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In health, blood lymphocytes are predominantly T-cells. Similar to neutrophils, blood lymphocytes are divided into circulating and marginating pools, with cells frequently shifting between these pools. Lymphocytes in the blood travel to lymph nodes, where they exit the blood through high endothelial venules and enter the lymph node cortices. Lymphocytes that migrate through the lymph nodes leave through efferent lymphatic vessels, from which they return to the blood. Blood lymphocytes may also emigrate to other tissues if chemotactic stimuli are present. In tissues, lymphocytes may proliferate, die, or migrate back into blood. Lymphocyte life spans are highly variable depending on the cell type and function, and some lymphocytes may live for years (Stockham and Scott, 2008a) .\",\"cite_spans\":[{\"start\":758.0,\"end\":785.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Lymphocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-aa1e25105c9cb7851d59cc0c1f83acdc572de8ad6a5c21e403ef2524dd55f7cc_citespan-758-785> ;
            <http://www.example.org/section>
                    "Lymphocytes" ;
            <http://www.example.org/text>  "In health, blood lymphocytes are predominantly T-cells. Similar to neutrophils, blood lymphocytes are divided into circulating and marginating pools, with cells frequently shifting between these pools. Lymphocytes in the blood travel to lymph nodes, where they exit the blood through high endothelial venules and enter the lymph node cortices. Lymphocytes that migrate through the lymph nodes leave through efferent lymphatic vessels, from which they return to the blood. Blood lymphocytes may also emigrate to other tissues if chemotactic stimuli are present. In tissues, lymphocytes may proliferate, die, or migrate back into blood. Lymphocyte life spans are highly variable depending on the cell type and function, and some lymphocytes may live for years (Stockham and Scott, 2008a) ." ;
            <http://www.example.org/textHash>
                    "aa1e25105c9cb7851d59cc0c1f83acdc572de8ad6a5c21e403ef2524dd55f7cc" .
    
    <http://covid19.aksw.org/text-a9e3de87a343d2d7bbc238095e20193fb4ff0f3b9bbbfcefc7ae59563d97aa41_citespan-408-425>
            <http://www.example.org/end>    "425.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF289" ;
            <http://www.example.org/start>  "408.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Papenfuss, 2010)" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1659-1679>
            <http://www.example.org/end>    "1679.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF439" ;
            <http://www.example.org/start>  "1659.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young et al., 2006)" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-1054-1074>
            <http://www.example.org/end>    "1074.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF144" ;
            <http://www.example.org/start>  "1054.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Giger et al., 1985)" .
    
    <http://covid19.aksw.org/text-7789f6b5b1c581691095b1b4ed7cea4928c189deef5986618312746b363f38d0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.1.3.2 Primary familial and congenital polycythemia Similar to polycythemia vera, primary familial and congenital polycythemia (PFCP) is also caused by autonomous erythroid proliferation despite low serum EPO. However, PFCP is associated with nonclonal erythroid proliferation from an inherited mutation that has an autosomal dominant pattern of inheritance (Prchal et al., 1985) . Identified mutations definitively associated with PFCP result in the truncation of the EPO receptor with a loss of the negative regulatory domain, causing constitutive activity of the signaling pathway promoting erythrocyte proliferation .\",\"cite_spans\":[{\"start\":365.0,\"end\":386.0,\"text\":\"(Prchal et al., 1985)\",\"ref_id\":\"BIBREF304\"}],\"ref_spans\":[],\"section\":\"Primary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-7789f6b5b1c581691095b1b4ed7cea4928c189deef5986618312746b363f38d0_citespan-365-386> ;
            <http://www.example.org/section>
                    "Primary increases in red cell mass" ;
            <http://www.example.org/text>  "12.11.3.1.3.2 Primary familial and congenital polycythemia Similar to polycythemia vera, primary familial and congenital polycythemia (PFCP) is also caused by autonomous erythroid proliferation despite low serum EPO. However, PFCP is associated with nonclonal erythroid proliferation from an inherited mutation that has an autosomal dominant pattern of inheritance (Prchal et al., 1985) . Identified mutations definitively associated with PFCP result in the truncation of the EPO receptor with a loss of the negative regulatory domain, causing constitutive activity of the signaling pathway promoting erythrocyte proliferation ." ;
            <http://www.example.org/textHash>
                    "7789f6b5b1c581691095b1b4ed7cea4928c189deef5986618312746b363f38d0" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1806-1828>
            <http://www.example.org/end>    "1828.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF137" ;
            <http://www.example.org/start>  "1806.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gatidis et al., 2009)" .
    
    <http://covid19.aksw.org/text-5e4546534a5d189da5bd97fc69c0932066c5a7f9acb6b34bfa6224166ebe7bf7_citespan-411-426>
            <http://www.example.org/end>    "426.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "411.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Boseila, 1963)" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-163-186>
            <http://www.example.org/end>    "186.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF311" ;
            <http://www.example.org/start>  "163.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ranaghan et al., 1998;" .
    
    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-149-175>
            <http://www.example.org/end>    "175.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF352" ;
            <http://www.example.org/start>  "149.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Shelley and Parnes, 1965;" .
    
    <http://covid19.aksw.org/text-139543a0beb5bc7e2148653faf8edfe56734a6e4b6f6ab9f95cf4d93abd2d865_citespan-224-249>
            <http://www.example.org/end>    "249.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "224.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a" .
    
    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-324-343>
            <http://www.example.org/end>    "343.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "324.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Blay et al., 1993;" .
    
    <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-509-524>
            <http://www.example.org/end>    "524.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF283" ;
            <http://www.example.org/start>  "509.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Packman, 2016)" .
    
    <http://covid19.aksw.org/text-5fbc1cd80b0aa20f4f8a16f775bdc97ebbddbbcbb413367c7f8c00cd2985ed9c_citespan-515-539>
            <http://www.example.org/end>    "539.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "515.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008;" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-376-396>
            <http://www.example.org/end>    "396.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "376.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schwartzberg, 2006)" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-499-517>
            <http://www.example.org/end>    "517.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF74" ;
            <http://www.example.org/start>  "499.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cole et al., 1994)" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-787-814>
            <http://www.example.org/end>    "814.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "787.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-419-434>
            <http://www.example.org/end>    "434.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF300" ;
            <http://www.example.org/start>  "419.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pohlman, 2010;" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-971-994>
            <http://www.example.org/end>    "994.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF381" ;
            <http://www.example.org/start>  "971.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tassinari et al., 1999" .
    
    <http://covid19.aksw.org/text-292a21e46ec5ae95cd61e7d9a475224811f2f693dd82e3905a925699a148bbcb_citespan-361-387>
            <http://www.example.org/end>    "387.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-825-845>
            <http://www.example.org/end>    "845.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF135" ;
            <http://www.example.org/start>  "825.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Garvy et al., 1993;" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-1381-1403>
            <http://www.example.org/end>    "1403.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF248" ;
            <http://www.example.org/start>  "1381.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Maseneni et al., 2012" .
    
    <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-433-454>
            <http://www.example.org/end>    "454.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF148" ;
            <http://www.example.org/start>  "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Goel and Gupta, 2007)" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-1140-1155>
            <http://www.example.org/end>    "1155.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "1140.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016)" .
    
    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-1307-1324>
            <http://www.example.org/end>    "1324.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF91" ;
            <http://www.example.org/start>  "1307.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Derelanko, 1987)" .
    
    <http://covid19.aksw.org/text-909c9c5eaff4e7acc700f5066a9caba8f528de86e4af74de7e0298e4a74666ca>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The association of inherited G6PD and FAD deficiencies with hemolysis resulting from oxidative damage is discussed earlier. In brief, G6PD and FAD play a role in the antioxidant pathways of erythrocytes. Deficiencies of G6PD and FAD may result in increased oxidative damage to erythrocytes and subsequent hemolysis.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "The association of inherited G6PD and FAD deficiencies with hemolysis resulting from oxidative damage is discussed earlier. In brief, G6PD and FAD play a role in the antioxidant pathways of erythrocytes. Deficiencies of G6PD and FAD may result in increased oxidative damage to erythrocytes and subsequent hemolysis." ;
            <http://www.example.org/textHash>
                    "909c9c5eaff4e7acc700f5066a9caba8f528de86e4af74de7e0298e4a74666ca" .
    
    <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-150-176>
            <http://www.example.org/end>    "176.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF345" ;
            <http://www.example.org/start>  "150.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Segel and Lichtman, 2016)" .
    
    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-750-767>
            <http://www.example.org/end>    "767.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF225" ;
            <http://www.example.org/start>  "750.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016a;" .
    
    <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-659-680>
            <http://www.example.org/end>    "680.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "659.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Magden et al., 2015;" .
    
    <http://covid19.aksw.org/text-493f1545be540d3d12b0266ca8ee354b7ce1849df49ad8a817bc889f6f06c8c1_citespan-370-385>
            <http://www.example.org/end>    "385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF335" ;
            <http://www.example.org/start>  "370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sampson, 2000)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1271-1286>
            <http://www.example.org/end>    "1286.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "1271.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-f023ed321326b573a95e1be1618f1ae74ee4531cc926bf8f2e03cb4cd97b8d15>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In blood, basophils are distributed into circulating and marginating pools, similar to other granulocytes. The circulating half-life of basophils is short (about 6 h), and they rapidly migrate into tissues where they have a much longer survival (up to 2 weeks) (Hirai et al., 1997; Pohlman, 2010) .\",\"cite_spans\":[{\"start\":261.0,\"end\":281.0,\"text\":\"(Hirai et al., 1997;\",\"ref_id\":\"BIBREF171\"},{\"start\":282.0,\"end\":296.0,\"text\":\"Pohlman, 2010)\",\"ref_id\":\"BIBREF300\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f023ed321326b573a95e1be1618f1ae74ee4531cc926bf8f2e03cb4cd97b8d15_citespan-261-281> , <http://covid19.aksw.org/text-f023ed321326b573a95e1be1618f1ae74ee4531cc926bf8f2e03cb4cd97b8d15_citespan-282-296> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "In blood, basophils are distributed into circulating and marginating pools, similar to other granulocytes. The circulating half-life of basophils is short (about 6 h), and they rapidly migrate into tissues where they have a much longer survival (up to 2 weeks) (Hirai et al., 1997; Pohlman, 2010) ." ;
            <http://www.example.org/textHash>
                    "f023ed321326b573a95e1be1618f1ae74ee4531cc926bf8f2e03cb4cd97b8d15" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in blood neutrophil counts may also result from decreased neutrophil production, as in acquired viral immunodeficiency. Immunodeficiency syndromes with decreased neutrophil counts have been reported with infections by HIV in people, simian immunodeficiency virus (SIV) or simian betaretrovirus in monkeys, or feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) in cats (Levine et al., 2006; Israel and Plaisance, 1991; Magden et al., 2015; Gill et al., 2012; Gleich and Hartmann, 2009 ). 12.11.2.1.2.4 Immune-mediated Primary or idiopathic immune-mediated destruction of mature neutrophils or neutrophil precursors will result in decreases in neutrophil counts, and has been reported in humans and most laboratory species. Antineutrophil antibodies are most commonly IgG and less commonly IgM class. Opsonization of neutrophil membranes may lead to leukoagglutination and neutrophil sequestration in sites including the spleen, liver, and lymph nodes, with phagocytosis by macrophages. Some antineutrophil antibodies may cause direct cytotoxicity through either complement-mediated or complement-independent mechanisms (Chickering and Prasse, 1981) . In humans, immune-mediated neutrophil destruction due to antibody-dependent lymphocyte cytotoxicity has been reported (Logue et al., 1978) .\",\"cite_spans\":[{\"start\":396.0,\"end\":417.0,\"text\":\"(Levine et al., 2006;\",\"ref_id\":\"BIBREF224\"},{\"start\":418.0,\"end\":445.0,\"text\":\"Israel and Plaisance, 1991;\",\"ref_id\":\"BIBREF178\"},{\"start\":446.0,\"end\":466.0,\"text\":\"Magden et al., 2015;\",\"ref_id\":\"BIBREF238\"},{\"start\":467.0,\"end\":485.0,\"text\":\"Gill et al., 2012;\",\"ref_id\":\"BIBREF146\"},{\"start\":486.0,\"end\":511.0,\"text\":\"Gleich and Hartmann, 2009\",\"ref_id\":\"BIBREF147\"},{\"start\":1146.0,\"end\":1175.0,\"text\":\"(Chickering and Prasse, 1981)\",\"ref_id\":\"BIBREF66\"},{\"start\":1296.0,\"end\":1316.0,\"text\":\"(Logue et al., 1978)\",\"ref_id\":\"BIBREF234\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-396-417> , <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-486-511> , <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-1296-1316> , <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-1146-1175> , <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-418-445> , <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-446-466> , <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-467-485> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Decreases in blood neutrophil counts may also result from decreased neutrophil production, as in acquired viral immunodeficiency. Immunodeficiency syndromes with decreased neutrophil counts have been reported with infections by HIV in people, simian immunodeficiency virus (SIV) or simian betaretrovirus in monkeys, or feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) in cats (Levine et al., 2006; Israel and Plaisance, 1991; Magden et al., 2015; Gill et al., 2012; Gleich and Hartmann, 2009 ). 12.11.2.1.2.4 Immune-mediated Primary or idiopathic immune-mediated destruction of mature neutrophils or neutrophil precursors will result in decreases in neutrophil counts, and has been reported in humans and most laboratory species. Antineutrophil antibodies are most commonly IgG and less commonly IgM class. Opsonization of neutrophil membranes may lead to leukoagglutination and neutrophil sequestration in sites including the spleen, liver, and lymph nodes, with phagocytosis by macrophages. Some antineutrophil antibodies may cause direct cytotoxicity through either complement-mediated or complement-independent mechanisms (Chickering and Prasse, 1981) . In humans, immune-mediated neutrophil destruction due to antibody-dependent lymphocyte cytotoxicity has been reported (Logue et al., 1978) ." ;
            <http://www.example.org/textHash>
                    "a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-452-467>
            <http://www.example.org/end>    "467.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "452.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-75b0dfaea5c1c94a3521f56df1cb238ef9b990cc3c94c3ef8511c3093e1e3dfe_citespan-460-480>
            <http://www.example.org/end>    "480.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF174" ;
            <http://www.example.org/start>  "460.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Hsieh et al., 2003;" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-563-590>
            <http://www.example.org/end>    "590.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF99" ;
            <http://www.example.org/start>  "563.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Duckett and Matthews, 1997)" .
    
    <http://covid19.aksw.org/text-3989a2796e1a8a37c6de69e6c09bbf1588ed6ef8f7423926b20dc34081288a34_citespan-518-533>
            <http://www.example.org/end>    "533.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF140" ;
            <http://www.example.org/start>  "518.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gergely, 1999)" .
    
    <http://covid19.aksw.org/text-b83e8da7e6c671ee51c7a848fc934132e9d4529e199bc1521f9bdf967d815125>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Transient increases in blood platelet counts have been reported following splenectomy. Splenectomy has been associated with increases in circulating TPO levels (Ichikawa et al., 1998) , resulting in increased platelet product ion and the observed increases in platelet counts.\",\"cite_spans\":[{\"start\":160.0,\"end\":183.0,\"text\":\"(Ichikawa et al., 1998)\",\"ref_id\":\"BIBREF176\"}],\"ref_spans\":[],\"section\":\"Inflammation or reactive\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b83e8da7e6c671ee51c7a848fc934132e9d4529e199bc1521f9bdf967d815125_citespan-160-183> ;
            <http://www.example.org/section>
                    "Inflammation or reactive" ;
            <http://www.example.org/text>  "Transient increases in blood platelet counts have been reported following splenectomy. Splenectomy has been associated with increases in circulating TPO levels (Ichikawa et al., 1998) , resulting in increased platelet product ion and the observed increases in platelet counts." ;
            <http://www.example.org/textHash>
                    "b83e8da7e6c671ee51c7a848fc934132e9d4529e199bc1521f9bdf967d815125" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-731-754>
            <http://www.example.org/end>    "754.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "731.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Baker and Moake, 2016)" .
    
    <http://covid19.aksw.org/text-c5bacbfeb28ebc4ebfdc3b08969d9f17630cf2dfe9150b66d40999b0b04f26e7_citespan-560-573>
            <http://www.example.org/end>    "573.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF371" ;
            <http://www.example.org/start>  "560.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stone, 2005;" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-1008-1034>
            <http://www.example.org/end>    "1034.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "1008.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008c;" .
    
    <http://covid19.aksw.org/text-968b38d8ba7721534e023e943307c4be3b206c14224a945ddb1ce94b2883fce3_citespan-845-863>
            <http://www.example.org/end>    "863.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF131" ;
            <http://www.example.org/start>  "845.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gao et al., 2004)" .
    
    <http://covid19.aksw.org/text-6b427ca71ed891381eb50cbc3831b102c8bb85bbad384aedcbd5d00312ebecba>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.1.5 Neoplasia Neoplasms involving hematopoietic cells naturally occur with relatively low frequency. In general, such neoplastic processes may be observed as background findings in rats and mice during longer toxicity studies (e.g., carcinogenicity studies), but are uncommon in nonrodent species during toxicity studies .\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "12.11.2.1.1.5 Neoplasia Neoplasms involving hematopoietic cells naturally occur with relatively low frequency. In general, such neoplastic processes may be observed as background findings in rats and mice during longer toxicity studies (e.g., carcinogenicity studies), but are uncommon in nonrodent species during toxicity studies ." ;
            <http://www.example.org/textHash>
                    "6b427ca71ed891381eb50cbc3831b102c8bb85bbad384aedcbd5d00312ebecba" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-362-385>
            <http://www.example.org/end>    "385.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF259" ;
            <http://www.example.org/start>  "362.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Meintker et al., 2013;" .
    
    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-412-428>
            <http://www.example.org/end>    "428.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "412.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-4049be250cd9beb5d7a7373e3292efb1091b70412e16d78b4ef1b106f11ef50c_citespan-313-336>
            <http://www.example.org/end>    "336.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF201" ;
            <http://www.example.org/start>  "313.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Khan and Yassin, 2009)" .
    
    <http://covid19.aksw.org/text-ad18adb1056860822e1b6893452b36cd128be85185e11bf75e451770e39a83ef>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Hemolysis and blood loss are the two main categories of decreases in red cell mass with appropriate increases in reticulocyte counts.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)" ;
            <http://www.example.org/text>  "Hemolysis and blood loss are the two main categories of decreases in red cell mass with appropriate increases in reticulocyte counts." ;
            <http://www.example.org/textHash>
                    "ad18adb1056860822e1b6893452b36cd128be85185e11bf75e451770e39a83ef" .
    
    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-344-363>
            <http://www.example.org/end>    "363.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF372" ;
            <http://www.example.org/start>  "344.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stone et al., 2012;" .
    
    <http://covid19.aksw.org/text-0e49f86ebe42a035e301c530ebcbd55643657dc8672a42f82d962df46ea66136>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In some cases, oxygenated hemoglobin may act as a peroxidase and cause the metabolism of a xenobiotic to a reactive compound that causes erythrocyte oxidative damage and conversion of oxyhemoglobin to methemoglobin. Examples of xenobiotics that cause oxidative damage through this mechanism are phenylhydrazine and primaquine (Edwards and Fuller, 1996) . Vitamin K administration in dogs can also cause oxidative erythrocyte damage through this mechanism (Fernandez et al., 1984) .\",\"cite_spans\":[{\"start\":326.0,\"end\":352.0,\"text\":\"(Edwards and Fuller, 1996)\",\"ref_id\":\"BIBREF103\"},{\"start\":455.0,\"end\":479.0,\"text\":\"(Fernandez et al., 1984)\",\"ref_id\":\"BIBREF115\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0e49f86ebe42a035e301c530ebcbd55643657dc8672a42f82d962df46ea66136_citespan-326-352> , <http://covid19.aksw.org/text-0e49f86ebe42a035e301c530ebcbd55643657dc8672a42f82d962df46ea66136_citespan-455-479> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "In some cases, oxygenated hemoglobin may act as a peroxidase and cause the metabolism of a xenobiotic to a reactive compound that causes erythrocyte oxidative damage and conversion of oxyhemoglobin to methemoglobin. Examples of xenobiotics that cause oxidative damage through this mechanism are phenylhydrazine and primaquine (Edwards and Fuller, 1996) . Vitamin K administration in dogs can also cause oxidative erythrocyte damage through this mechanism (Fernandez et al., 1984) ." ;
            <http://www.example.org/textHash>
                    "0e49f86ebe42a035e301c530ebcbd55643657dc8672a42f82d962df46ea66136" .
    
    <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1_citespan-887-909>
            <http://www.example.org/end>    "909.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF399" ;
            <http://www.example.org/start>  "887.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Uppal and Gong, 2015)" .
    
    <http://covid19.aksw.org/text-72cdd5f94494b2a9146ad2ed2793e599c748523abfad265e2a0a6c42abddf0c1_citespan-414-434>
            <http://www.example.org/end>    "434.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "414.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Blair et al., 1990)" .
    
    <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-740-761>
            <http://www.example.org/end>    "761.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF375" ;
            <http://www.example.org/start>  "740.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Susano et al., 1994;" .
    
    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-590-612>
            <http://www.example.org/end>    "612.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF282" ;
            <http://www.example.org/start>  "590.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ottesen et al., 1995;" .
    
    <http://covid19.aksw.org/text-5b636b3bb6950cd7a2c38cafae010e9a976a947beef635ad203a0331640770fe_citespan-461-485>
            <http://www.example.org/end>    "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF290" ;
            <http://www.example.org/start>  "461.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pardanani et al., 2003)" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-813-840>
            <http://www.example.org/end>    "840.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF141" ;
            <http://www.example.org/start>  "813.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Germeshausen et al., 2006;" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-1017-1030>
            <http://www.example.org/end>    "1030.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF376" ;
            <http://www.example.org/start>  "1017.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Suter, 2010;" .
    
    <http://covid19.aksw.org/text-23cf0d97732233f9cb434db3bca976b852c11b5dd4f9ac7fc8ac626246477ef8_citespan-453-468>
            <http://www.example.org/end>    "468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF283" ;
            <http://www.example.org/start>  "453.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Packman, 2016)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-605-626>
            <http://www.example.org/end>    "626.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF50" ;
            <http://www.example.org/start>  "605.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Byrnes et al., 1986)" .
    
    <http://covid19.aksw.org/text-785b73145229f779ccc708abba95ba933ebe1586d9382ea1a94a5992de5d39f8_citespan-157-183>
            <http://www.example.org/end>    "183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016)" .
    
    <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-623-649>
            <http://www.example.org/end>    "649.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF239" ;
            <http://www.example.org/start>  "623.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Majluf-Cruz et al., 1998)" .
    
    <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-950-975>
            <http://www.example.org/end>    "975.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF438" ;
            <http://www.example.org/start>  "950.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Young and Meadows, 2010)" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-308-328>
            <http://www.example.org/end>    "328.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF101" ;
            <http://www.example.org/start>  "308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Durno et al., 2011)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-415-436>
            <http://www.example.org/end>    "436.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF299" ;
            <http://www.example.org/start>  "415.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pisoni et al., 2001)" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-222-238>
            <http://www.example.org/end>    "238.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "222.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-5c13e5b358dba2e3bdfaba0cd2adbde14a42a90fcdf718971850a7bb3e25439d_citespan-62-78>
            <http://www.example.org/end>    "78.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF133" ;
            <http://www.example.org/start>  "62.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Garratty, 2004)" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-437-464>
            <http://www.example.org/end>    "464.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "437.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-1119-1145>
            <http://www.example.org/end>    "1145.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "1119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Aronson and Drobatz, 1996)" .
    
    <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in lymphocyte counts are typically observed with acute inflammation. These decreases are likely due to increased margination and emigration of lymphocytes to the site of inflammation, increased migration of lymphocytes to lymphoid tissues, and decreased efflux of lymphocytes out of lymphoid tissues (Stockham and Scott, 2008a) . Stress associated with illness or acute inflammation may also contribute by glucocorticoid-induced mechanisms (Stockham and Scott, 2008a; Schultze, 2010) .\",\"cite_spans\":[{\"start\":310.0,\"end\":337.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":450.0,\"end\":477.0,\"text\":\"(Stockham and Scott, 2008a;\",\"ref_id\":\"BIBREF366\"},{\"start\":478.0,\"end\":493.0,\"text\":\"Schultze, 2010)\",\"ref_id\":\"BIBREF342\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f_citespan-310-337> , <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f_citespan-450-477> , <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f_citespan-478-493> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Decreases in lymphocyte counts are typically observed with acute inflammation. These decreases are likely due to increased margination and emigration of lymphocytes to the site of inflammation, increased migration of lymphocytes to lymphoid tissues, and decreased efflux of lymphocytes out of lymphoid tissues (Stockham and Scott, 2008a) . Stress associated with illness or acute inflammation may also contribute by glucocorticoid-induced mechanisms (Stockham and Scott, 2008a; Schultze, 2010) ." ;
            <http://www.example.org/textHash>
                    "aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-769-806>
            <http://www.example.org/end>    "806.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "769.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "), simvastatin (McCarthy et al., 1998" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-243-261>
            <http://www.example.org/end>    "261.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF257" ;
            <http://www.example.org/start>  "243.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Meek et al., 2001;" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1760-1782>
            <http://www.example.org/end>    "1782.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF429" ;
            <http://www.example.org/start>  "1760.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wellman et al., 1984)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-769-789>
            <http://www.example.org/end>    "789.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "769.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016)" .
    
    <http://covid19.aksw.org/text-92b5a29b064c99b374b26a0994786b872453b383774723a554d534b6030cc521_citespan-561-590>
            <http://www.example.org/end>    "590.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF297" ;
            <http://www.example.org/start>  "561.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Phillips and Anderson, 2016;" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"More commonly, ACD is associated with impaired iron mobilization with low iron concentrations in serum or plasma despite adequate iron stores (Means, 2000) . Impaired mobilization of iron results from IL-6 induction of hepcidin that results in sequestration of iron in macrophages and decreased intestinal iron update (Ganz, 2003) , IL-1 stimulation of increased synthesis of ferritin which may bind to iron and impair delivery of iron to erythroid precursors (Rogers et al., 1994) , and with decreased expression and impaired internalization of the transferrin receptor (Means, 2000) . ACD from impaired iron metabolism is associated with numerous inflammatory, infectious, and even neoplastic conditions. ACD may also cause altered EPO responsiveness or decreased EPO production. Decreased responsiveness of erythroid precursors to EPO is cytokine-mediated, and has been associated with increases in TNFa, IL-1, and interferons (Johnson et al., 1989 (Johnson et al., , 1990 Raefsky et al., 1985) that may commonly be associated with inflammatory conditions. Decreased EPO production may also be cytokine-mediated, and has been reported with increases in TGFb, TNFa, and IL-1 (Faquin et al., 1992; Jelkmann et al., 1992) . However, chronic renal disease may also result directly in impaired EPO production and decreased production of erythrocytes (Sato and Yanagita, 2013) .\",\"cite_spans\":[{\"start\":142.0,\"end\":155.0,\"text\":\"(Means, 2000)\",\"ref_id\":\"BIBREF256\"},{\"start\":318.0,\"end\":330.0,\"text\":\"(Ganz, 2003)\",\"ref_id\":\"BIBREF129\"},{\"start\":460.0,\"end\":481.0,\"text\":\"(Rogers et al., 1994)\",\"ref_id\":\"BIBREF323\"},{\"start\":571.0,\"end\":584.0,\"text\":\"(Means, 2000)\",\"ref_id\":\"BIBREF256\"},{\"start\":930.0,\"end\":951.0,\"text\":\"(Johnson et al., 1989\",\"ref_id\":\"BIBREF182\"},{\"start\":952.0,\"end\":975.0,\"text\":\"(Johnson et al., , 1990\",\"ref_id\":\"BIBREF183\"},{\"start\":976.0,\"end\":997.0,\"text\":\"Raefsky et al., 1985)\",\"ref_id\":\"BIBREF308\"},{\"start\":1177.0,\"end\":1198.0,\"text\":\"(Faquin et al., 1992;\",\"ref_id\":\"BIBREF110\"},{\"start\":1199.0,\"end\":1221.0,\"text\":\"Jelkmann et al., 1992)\",\"ref_id\":\"BIBREF181\"},{\"start\":1348.0,\"end\":1373.0,\"text\":\"(Sato and Yanagita, 2013)\",\"ref_id\":\"BIBREF337\"}],\"ref_spans\":[],\"section\":\"Chronic disease\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-571-584> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-1348-1373> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-460-481> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-142-155> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-976-997> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-318-330> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-952-975> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-930-951> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-1177-1198> , <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-1199-1221> ;
            <http://www.example.org/section>
                    "Chronic disease" ;
            <http://www.example.org/text>  "More commonly, ACD is associated with impaired iron mobilization with low iron concentrations in serum or plasma despite adequate iron stores (Means, 2000) . Impaired mobilization of iron results from IL-6 induction of hepcidin that results in sequestration of iron in macrophages and decreased intestinal iron update (Ganz, 2003) , IL-1 stimulation of increased synthesis of ferritin which may bind to iron and impair delivery of iron to erythroid precursors (Rogers et al., 1994) , and with decreased expression and impaired internalization of the transferrin receptor (Means, 2000) . ACD from impaired iron metabolism is associated with numerous inflammatory, infectious, and even neoplastic conditions. ACD may also cause altered EPO responsiveness or decreased EPO production. Decreased responsiveness of erythroid precursors to EPO is cytokine-mediated, and has been associated with increases in TNFa, IL-1, and interferons (Johnson et al., 1989 (Johnson et al., , 1990 Raefsky et al., 1985) that may commonly be associated with inflammatory conditions. Decreased EPO production may also be cytokine-mediated, and has been reported with increases in TGFb, TNFa, and IL-1 (Faquin et al., 1992; Jelkmann et al., 1992) . However, chronic renal disease may also result directly in impaired EPO production and decreased production of erythrocytes (Sato and Yanagita, 2013) ." ;
            <http://www.example.org/textHash>
                    "3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-746-774>
            <http://www.example.org/end>    "774.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF47" ;
            <http://www.example.org/start>  "746.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Budman and Steinberg, 1977)" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1484-1507>
            <http://www.example.org/end>    "1507.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF58" ;
            <http://www.example.org/start>  "1484.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Carrasco et al., 2003)" .
    
    <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-795-810>
            <http://www.example.org/end>    "810.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "795.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-490-510>
            <http://www.example.org/end>    "510.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF326" ;
            <http://www.example.org/start>  "490.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Roth and Levy, 1980;" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-460-481>
            <http://www.example.org/end>    "481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF323" ;
            <http://www.example.org/start>  "460.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rogers et al., 1994)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-308-320>
            <http://www.example.org/end>    "320.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF157" ;
            <http://www.example.org/start>  "308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Green, 2016)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1873-1895>
            <http://www.example.org/end>    "1895.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF73" ;
            <http://www.example.org/start>  "1873.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Clark and Hunt, 1983)" .
    
    <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-1169-1192>
            <http://www.example.org/end>    "1192.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "1169.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Bookchin and Lew, 1996)" .
    
    <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-975-990>
            <http://www.example.org/end>    "990.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF264" ;
            <http://www.example.org/start>  "975.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Montiel, 2010)" .
    
    <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Lymphoproliferative neoplasia is observed as a relatively common background finding in older rats and mice during nonclinical toxicology studies (Frith et al., 1993) . Although less common, it may also be observed in low frequencies in older monkeys. Monkeys with concurrent infection with species-specific lymphocryptoviruses and immunosuppression have been reported to have virus-related lymphoproliferative neoplasias (Magden et al., 2015) . Lymphocryptoviruses are in the Gammaherpesvirinae subfamily and are related to Epstein-Barr virus, which has been associated with lymphoproliferative neoplasia in people but may aberrantly infect New World monkeys (Magden et al., 2015; Thorley-Lawson and Gross, 2004) .\",\"cite_spans\":[{\"start\":145.0,\"end\":165.0,\"text\":\"(Frith et al., 1993)\",\"ref_id\":\"BIBREF124\"},{\"start\":421.0,\"end\":442.0,\"text\":\"(Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"},{\"start\":659.0,\"end\":680.0,\"text\":\"(Magden et al., 2015;\",\"ref_id\":\"BIBREF238\"},{\"start\":681.0,\"end\":712.0,\"text\":\"Thorley-Lawson and Gross, 2004)\",\"ref_id\":\"BIBREF389\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-145-165> , <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-421-442> , <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-659-680> , <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-681-712> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Lymphoproliferative neoplasia is observed as a relatively common background finding in older rats and mice during nonclinical toxicology studies (Frith et al., 1993) . Although less common, it may also be observed in low frequencies in older monkeys. Monkeys with concurrent infection with species-specific lymphocryptoviruses and immunosuppression have been reported to have virus-related lymphoproliferative neoplasias (Magden et al., 2015) . Lymphocryptoviruses are in the Gammaherpesvirinae subfamily and are related to Epstein-Barr virus, which has been associated with lymphoproliferative neoplasia in people but may aberrantly infect New World monkeys (Magden et al., 2015; Thorley-Lawson and Gross, 2004) ." ;
            <http://www.example.org/textHash>
                    "13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85" .
    
    <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-997-1018>
            <http://www.example.org/end>    "1018.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF364" ;
            <http://www.example.org/start>  "997.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sontas et al., 2009)" .
    
    <http://covid19.aksw.org/text-c2cb35b92dad94d0c8092f5fca357aa180145ff269f0db14b078cc0632642532_citespan-292-316>
            <http://www.example.org/end>    "316.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "292.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kanematsu et al., 1996;" .
    
    <http://covid19.aksw.org/text-f93d23cc1a6f34d35e3d9cf585b6e04a601d6efc9c2f5f0d659375671f3e2d85_citespan-533-553>
            <http://www.example.org/end>    "553.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "533.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016)" .
    
    <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-230-241>
            <http://www.example.org/end>    "241.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF86" ;
            <http://www.example.org/start>  "230.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Dan, 2005)" .
    
    <http://covid19.aksw.org/text-c0568d4373733e5156e932bec27f94b48d2dc03600f697f65b401a11c76b0e97_citespan-444-463>
            <http://www.example.org/end>    "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF365" ;
            <http://www.example.org/start>  "444.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Steer et al., 1997)" .
    
    <http://covid19.aksw.org/text-637cc8e7dab553f631863f3d8bd0974754c2cedecd28416fb0376c44a3d3ad0c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Destruction of mature erythrocytes is called hemolysis. Hemolysis may occur either intravascularly or extravascularly. With intravascular hemolysis, erythrocyte destruction occurs within the blood and results in hemoglobinemia, or free hemoglobin within plasma. Ghost erythrocytes, or the remnant membranes of erythrocytes that no longer contain cytoplasm or hemoglobin, may be observed with intravascular hemolysis. Consequent hemoglobinuria, or free hemoglobin in the urine, is rare and only occurs in cases of massive intravascular hemolysis that overwhelm the normal pathways that clear free hemoglobin from the blood. In contrast, extravascular hemolysis does not occur within the blood, but rather occurs in the spleen, liver, or bone marrow, where resident macrophages phagocytose erythrocytes and destroy them intracellularly. Extravascular hemolysis does not result in free plasma hemoglobin or hemoglobinuria. Both types of hemolysis may be associated with increases in total bilirubin concentrations where unconjugated (indirect) bilirubin usually exceeds conjugated (direct) bilirubin, and may result in plasma or serum icterus (yellow discoloration) or bilirubinuria (bilirubin present in urine). However, not all cases of hemolysis are clearly either intravascular or extravascular, and both forms of hemolysis may contribute in some conditions. 12.11.3.2.1.1.1 Infectious There are numerous protozoal, bacterial, and viral diseases that can be associated with hemolysis. Mechanisms by which infectious agents cause erythrocyte destruction are varied, and may include direct infection of erythrocytes, elaboration of toxins such as hemolysin, or stimulation of an immune-mediated response against infected cells (Berkowitz, 1991) . Several examples of infectious agents that cause hemolytic anemia are discussed later.\",\"cite_spans\":[{\"start\":1726.0,\"end\":1743.0,\"text\":\"(Berkowitz, 1991)\",\"ref_id\":\"BIBREF26\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-637cc8e7dab553f631863f3d8bd0974754c2cedecd28416fb0376c44a3d3ad0c_citespan-1726-1743> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Destruction of mature erythrocytes is called hemolysis. Hemolysis may occur either intravascularly or extravascularly. With intravascular hemolysis, erythrocyte destruction occurs within the blood and results in hemoglobinemia, or free hemoglobin within plasma. Ghost erythrocytes, or the remnant membranes of erythrocytes that no longer contain cytoplasm or hemoglobin, may be observed with intravascular hemolysis. Consequent hemoglobinuria, or free hemoglobin in the urine, is rare and only occurs in cases of massive intravascular hemolysis that overwhelm the normal pathways that clear free hemoglobin from the blood. In contrast, extravascular hemolysis does not occur within the blood, but rather occurs in the spleen, liver, or bone marrow, where resident macrophages phagocytose erythrocytes and destroy them intracellularly. Extravascular hemolysis does not result in free plasma hemoglobin or hemoglobinuria. Both types of hemolysis may be associated with increases in total bilirubin concentrations where unconjugated (indirect) bilirubin usually exceeds conjugated (direct) bilirubin, and may result in plasma or serum icterus (yellow discoloration) or bilirubinuria (bilirubin present in urine). However, not all cases of hemolysis are clearly either intravascular or extravascular, and both forms of hemolysis may contribute in some conditions. 12.11.3.2.1.1.1 Infectious There are numerous protozoal, bacterial, and viral diseases that can be associated with hemolysis. Mechanisms by which infectious agents cause erythrocyte destruction are varied, and may include direct infection of erythrocytes, elaboration of toxins such as hemolysin, or stimulation of an immune-mediated response against infected cells (Berkowitz, 1991) . Several examples of infectious agents that cause hemolytic anemia are discussed later." ;
            <http://www.example.org/textHash>
                    "637cc8e7dab553f631863f3d8bd0974754c2cedecd28416fb0376c44a3d3ad0c" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-409-423>
            <http://www.example.org/end>    "423.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF300" ;
            <http://www.example.org/start>  "409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Pohlman, 2010;" .
    
    <http://covid19.aksw.org/text-a7b72cb8b96d38f267c1d1546d21b9e85285123f33144f92dcf69596b96495a0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Depending on the timing of the insult causing the decreases in red cell mass, reticulocyte counts within reference interval may represent a preregenerative anemia rather than suppressed erythropoiesis. Production of erythrocytes by the bone marrow requires at least 3-4 days, and a peak increase in blood reticulocyte count occurs about 7-14 days following the insult (Stockham and Scott, 2008b) . If it an individual with decreased red cell mass and reticulocyte counts that are within the reference interval and it is unclear if the individual has a preregenerative anemia or suppressed erythropoiesis, repeating a CBC several days later may help clarify which process is occurring.\",\"cite_spans\":[{\"start\":368.0,\"end\":395.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Preregenerative\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a7b72cb8b96d38f267c1d1546d21b9e85285123f33144f92dcf69596b96495a0_citespan-368-395> ;
            <http://www.example.org/section>
                    "Preregenerative" ;
            <http://www.example.org/text>  "Depending on the timing of the insult causing the decreases in red cell mass, reticulocyte counts within reference interval may represent a preregenerative anemia rather than suppressed erythropoiesis. Production of erythrocytes by the bone marrow requires at least 3-4 days, and a peak increase in blood reticulocyte count occurs about 7-14 days following the insult (Stockham and Scott, 2008b) . If it an individual with decreased red cell mass and reticulocyte counts that are within the reference interval and it is unclear if the individual has a preregenerative anemia or suppressed erythropoiesis, repeating a CBC several days later may help clarify which process is occurring." ;
            <http://www.example.org/textHash>
                    "a7b72cb8b96d38f267c1d1546d21b9e85285123f33144f92dcf69596b96495a0" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-267-285>
            <http://www.example.org/end>    "285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF74" ;
            <http://www.example.org/start>  "267.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cole et al., 1994)" .
    
    <http://covid19.aksw.org/text-0391ba59f3f7d1614586fbe4d2286f2eab685a2438ab645a91bd604e72e604eb_citespan-1830-1857>
            <http://www.example.org/end>    "1857.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "1830.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-296-311>
            <http://www.example.org/end>    "311.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "296.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016)" .
    
    <http://covid19.aksw.org/text-78314608b6253b19d35efaf82abe5c94e39d1a63dd2d7e6aa9fb00e98631ceb0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"As discussed previously, numerous xenobiotics have been associated with drug-induced SLE in people. Decreases in lymphocytes in these cases are likely due to the production of autoantibodies with subsequent lymphocyte destruction, similar to nonxenobioticinduced SLE. Xenobiotics associated with SLE include several anticonvulsants such as phenothiazines, chlorpromazine, and valproate, several antibiotics such as penicillin, streptomycin, tetracycline, griseofulvin, and sulphonamides, and miscellaneous xenobiotics such as captopril, phenylbutazone, and lovastatin (Stone, 2005; Mutasim and Adams, 2000) .\",\"cite_spans\":[{\"start\":568.0,\"end\":581.0,\"text\":\"(Stone, 2005;\",\"ref_id\":\"BIBREF371\"},{\"start\":582.0,\"end\":606.0,\"text\":\"Mutasim and Adams, 2000)\",\"ref_id\":\"BIBREF271\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-78314608b6253b19d35efaf82abe5c94e39d1a63dd2d7e6aa9fb00e98631ceb0_citespan-568-581> , <http://covid19.aksw.org/text-78314608b6253b19d35efaf82abe5c94e39d1a63dd2d7e6aa9fb00e98631ceb0_citespan-582-606> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "As discussed previously, numerous xenobiotics have been associated with drug-induced SLE in people. Decreases in lymphocytes in these cases are likely due to the production of autoantibodies with subsequent lymphocyte destruction, similar to nonxenobioticinduced SLE. Xenobiotics associated with SLE include several anticonvulsants such as phenothiazines, chlorpromazine, and valproate, several antibiotics such as penicillin, streptomycin, tetracycline, griseofulvin, and sulphonamides, and miscellaneous xenobiotics such as captopril, phenylbutazone, and lovastatin (Stone, 2005; Mutasim and Adams, 2000) ." ;
            <http://www.example.org/textHash>
                    "78314608b6253b19d35efaf82abe5c94e39d1a63dd2d7e6aa9fb00e98631ceb0" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-214-236>
            <http://www.example.org/end>    "236.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF341" ;
            <http://www.example.org/start>  "214.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schmitz et al., 1994)" .
    
    <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-724-745>
            <http://www.example.org/end>    "745.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF383" ;
            <http://www.example.org/start>  "724.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tefferi et al., 2006;" .
    
    <http://covid19.aksw.org/text-3036ff66cb0166fbf5c444b5bf1490b2c1f19f403425cc4425fdfe69db0a9207>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreased platelet survival may be due to increased platelet destruction and/or consumption, and is a relatively common cause of decreases in blood platelet counts.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Decreased survival\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Decreased survival" ;
            <http://www.example.org/text>  "Decreased platelet survival may be due to increased platelet destruction and/or consumption, and is a relatively common cause of decreases in blood platelet counts." ;
            <http://www.example.org/textHash>
                    "3036ff66cb0166fbf5c444b5bf1490b2c1f19f403425cc4425fdfe69db0a9207" .
    
    <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-319-334>
            <http://www.example.org/end>    "334.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "319.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-440-457>
            <http://www.example.org/end>    "457.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF340" ;
            <http://www.example.org/start>  "440.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Scaradavou, 2002)" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-455-476>
            <http://www.example.org/end>    "476.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF222" ;
            <http://www.example.org/start>  "455.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Levine et al., 2001)" .
    
    <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-283-302>
            <http://www.example.org/end>    "302.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF236" ;
            <http://www.example.org/start>  "283.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lowe et al., 2013;" .
    
    <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-741-767>
            <http://www.example.org/end>    "767.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF43" ;
            <http://www.example.org/start>  "741.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Brazzell and Weiss, 2006)" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.2.4.2 Pure red cell aplasia In patients affected by PRCA, there are marked decreases in reticulocyte counts along with variable decreases in red cell mass. Bone marrow examination typically reveals an absence of erythroid precursors (erythroid aplasia) or low numbers of the earliest stages of erythroid precursors (erythroid hypoplasia) (Young, 2016) . PRCA in people may be caused by antibodies that bind antigens on the earliest erythroid precursors or even antibodies that bind EPO and prevent EPO-dependent erythropoiesis, but it has also been attributed to clonal T-cell disorders (Stockham and Scott, 2008b) . PRCA in dogs has been associated with IgG that inhibit erythropoiesis (Weiss, 1986) . PRCA may also be caused by inherited genetic defect in people. Inherited PRCA in people is called Diamond-Blackfan anemia, and often has an autosomal dominant inheritance pattern with defects in genes encoding ribosomal proteins (Young, 2016) . Macrocytosis, or increased numbers of large erythrocytes with increases in MCV, may be observed and is consistent with impaired EPO-dependent erythropoiesis (Young, 2016; Ohene-Abuakwa et al., 2005) . 12.11.3.2.2.4.3 Aplastic anemia Aplastic anemia is a condition associated with decreases in all cellular blood components (pancytopenia), including decreases in red cell mass with concurrent decreases in reticulocyte counts. Upon examination, the bone marrow classically had severe hypocellularity of hematopoietic cells or an absence of hematopoietic precursors the marrow cavities filled by mostly adipocytes and some stromal elements. Aplastic anemia is thought to be most commonly immunemediated (Young et al., 2006) , and may be frequently associated with cytotoxic T-cells that become autoreactive (Segel and Lichtman, 2016) . However, there are also cases of inherited aplastic anemia, most commonly Fanconi anemia associated with genetic mutations that impair DNA repair resulting in pancytopenia developing around 5-10 years of age in people (Segel and Lichtman, 2016) . A form of aplastic anemia associated with bone marrow depletion or hypocellularity of hematopoietic tissue and gelatinous transformation of marrow cavity fat has been reported with anorexia nervosa in people (Abella et al., 2002) and with severe food restriction in rats (Moriyama et al., 2008) .\",\"cite_spans\":[{\"start\":348.0,\"end\":361.0,\"text\":\"(Young, 2016)\",\"ref_id\":\"BIBREF437\"},{\"start\":597.0,\"end\":624.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":697.0,\"end\":710.0,\"text\":\"(Weiss, 1986)\",\"ref_id\":\"BIBREF425\"},{\"start\":942.0,\"end\":955.0,\"text\":\"(Young, 2016)\",\"ref_id\":\"BIBREF437\"},{\"start\":1115.0,\"end\":1128.0,\"text\":\"(Young, 2016;\",\"ref_id\":\"BIBREF437\"},{\"start\":1129.0,\"end\":1156.0,\"text\":\"Ohene-Abuakwa et al., 2005)\",\"ref_id\":\"BIBREF279\"},{\"start\":1659.0,\"end\":1679.0,\"text\":\"(Young et al., 2006)\",\"ref_id\":\"BIBREF439\"},{\"start\":1763.0,\"end\":1789.0,\"text\":\"(Segel and Lichtman, 2016)\",\"ref_id\":\"BIBREF345\"},{\"start\":2010.0,\"end\":2036.0,\"text\":\"(Segel and Lichtman, 2016)\",\"ref_id\":\"BIBREF345\"},{\"start\":2247.0,\"end\":2268.0,\"text\":\"(Abella et al., 2002)\",\"ref_id\":\"BIBREF0\"},{\"start\":2310.0,\"end\":2333.0,\"text\":\"(Moriyama et al., 2008)\",\"ref_id\":\"BIBREF266\"}],\"ref_spans\":[],\"section\":\"Immune-mediated\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-2010-2036> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-942-955> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1129-1156> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1659-1679> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1763-1789> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1115-1128> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-348-361> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-2247-2268> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-2310-2333> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-597-624> , <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-697-710> ;
            <http://www.example.org/section>
                    "Immune-mediated" ;
            <http://www.example.org/text>  "12.11.3.2.2.4.2 Pure red cell aplasia In patients affected by PRCA, there are marked decreases in reticulocyte counts along with variable decreases in red cell mass. Bone marrow examination typically reveals an absence of erythroid precursors (erythroid aplasia) or low numbers of the earliest stages of erythroid precursors (erythroid hypoplasia) (Young, 2016) . PRCA in people may be caused by antibodies that bind antigens on the earliest erythroid precursors or even antibodies that bind EPO and prevent EPO-dependent erythropoiesis, but it has also been attributed to clonal T-cell disorders (Stockham and Scott, 2008b) . PRCA in dogs has been associated with IgG that inhibit erythropoiesis (Weiss, 1986) . PRCA may also be caused by inherited genetic defect in people. Inherited PRCA in people is called Diamond-Blackfan anemia, and often has an autosomal dominant inheritance pattern with defects in genes encoding ribosomal proteins (Young, 2016) . Macrocytosis, or increased numbers of large erythrocytes with increases in MCV, may be observed and is consistent with impaired EPO-dependent erythropoiesis (Young, 2016; Ohene-Abuakwa et al., 2005) . 12.11.3.2.2.4.3 Aplastic anemia Aplastic anemia is a condition associated with decreases in all cellular blood components (pancytopenia), including decreases in red cell mass with concurrent decreases in reticulocyte counts. Upon examination, the bone marrow classically had severe hypocellularity of hematopoietic cells or an absence of hematopoietic precursors the marrow cavities filled by mostly adipocytes and some stromal elements. Aplastic anemia is thought to be most commonly immunemediated (Young et al., 2006) , and may be frequently associated with cytotoxic T-cells that become autoreactive (Segel and Lichtman, 2016) . However, there are also cases of inherited aplastic anemia, most commonly Fanconi anemia associated with genetic mutations that impair DNA repair resulting in pancytopenia developing around 5-10 years of age in people (Segel and Lichtman, 2016) . A form of aplastic anemia associated with bone marrow depletion or hypocellularity of hematopoietic tissue and gelatinous transformation of marrow cavity fat has been reported with anorexia nervosa in people (Abella et al., 2002) and with severe food restriction in rats (Moriyama et al., 2008) ." ;
            <http://www.example.org/textHash>
                    "70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac" .
    
    <http://covid19.aksw.org/text-385c47634e37c9ae4a27569219665cea693624db2b83fbf4784f019c80e02cef_citespan-414-433>
            <http://www.example.org/end>    "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF440" ;
            <http://www.example.org/start>  "414.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Yuan et al., 2003;" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-895-915>
            <http://www.example.org/end>    "915.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "895.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016)" .
    
    <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The production of lymphocytes, or lymphopoiesis, progresses from pluripotent hematopoietic stem cells that differentiate into common lymphoid progenitor cells, and further differentiate into B-cells, T-cells, and natural killer (NK) cells. B-cell development begins in the fetal liver and transitions to bone marrow postnatally, where the cells undergo proliferation and differentiation, followed by migration to the peripheral lymphoid tissues. B-cell development requires a variety of soluble factors, including IL-3, IL-4, IL-11, INFg, and TGFb (Burkhard, 2010) . T-cell precursors migrate to the thymus during embryonic development, where they undergo proliferation, differentiation, and both positive and negative selection. T-cell development requires IL-7 stimulation (Burkhard, 2010) . NK-cell development, which requires IL-15 stimulation, occurs mostly in the fetal liver and thymus, as well as in the bone marrow after birth (Burkhard, 2010) .\",\"cite_spans\":[{\"start\":526.0,\"end\":564.0,\"text\":\"IL-11, INFg, and TGFb (Burkhard, 2010)\"},{\"start\":775.0,\"end\":791.0,\"text\":\"(Burkhard, 2010)\",\"ref_id\":\"BIBREF48\"},{\"start\":936.0,\"end\":952.0,\"text\":\"(Burkhard, 2010)\",\"ref_id\":\"BIBREF48\"}],\"ref_spans\":[],\"section\":\"Lymphocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c_citespan-526-564> , <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c_citespan-775-791> , <http://covid19.aksw.org/text-2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c_citespan-936-952> ;
            <http://www.example.org/section>
                    "Lymphocytes" ;
            <http://www.example.org/text>  "The production of lymphocytes, or lymphopoiesis, progresses from pluripotent hematopoietic stem cells that differentiate into common lymphoid progenitor cells, and further differentiate into B-cells, T-cells, and natural killer (NK) cells. B-cell development begins in the fetal liver and transitions to bone marrow postnatally, where the cells undergo proliferation and differentiation, followed by migration to the peripheral lymphoid tissues. B-cell development requires a variety of soluble factors, including IL-3, IL-4, IL-11, INFg, and TGFb (Burkhard, 2010) . T-cell precursors migrate to the thymus during embryonic development, where they undergo proliferation, differentiation, and both positive and negative selection. T-cell development requires IL-7 stimulation (Burkhard, 2010) . NK-cell development, which requires IL-15 stimulation, occurs mostly in the fetal liver and thymus, as well as in the bone marrow after birth (Burkhard, 2010) ." ;
            <http://www.example.org/textHash>
                    "2f1e1a572c6555cbc49b185f62ef0a779a4a51d2be164c96b565aaf013e05b8c" .
    
    <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-409-426>
            <http://www.example.org/end>    "426.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF172" ;
            <http://www.example.org/start>  "409.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ho et al., 1979)" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-191-209>
            <http://www.example.org/end>    "209.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF344" ;
            <http://www.example.org/start>  "191.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Seah et al., 1974)" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-467-485>
            <http://www.example.org/end>    "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF146" ;
            <http://www.example.org/start>  "467.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gill et al., 2012;" .
    
    <http://covid19.aksw.org/text-ed80fb52f4732cc7caf74e456c58f82d9de7330b51ac7f02411990d9c6e29888_citespan-400-427>
            <http://www.example.org/end>    "427.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "400.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in blood monocyte counts occur with both acute and chronic inflammation, and such inflammatory increases in monocytes may be associated with both infectious and noninfectious etiologies. Tuberculosis and other mycobacterial infections are commonly associated with increases in monocyte counts which may represent an increased tissue demand for macrophages (Lichtman, 2016a) . Increases in monocyte counts have also been associated with bacterial endocarditis and sepsis, osteomyelitis, various pyogranulomatous diseases, candidiasis, viral infections including cytomegalovirus and influenza, and several parasitic diseases including pneumocystosis, Entopolypoides macacai infection in old world monkeys and apes, and dirofilariasis in dogs (Lichtman, 2016a; Magden et al., 2015; Schultze, 2010) . However, increases in monocyte counts may be less commonly related to malaria, leishmaniasis, and rickettsial diseases in people than previously thought (Lichtman, 2016a) . Noninfectious causes of increases in blood monocyte counts include inflammatory bowel disease, ulcerative gastritis, myocardial infarction, and parturition (Lichtman, 2016a) .\",\"cite_spans\":[{\"start\":366.0,\"end\":383.0,\"text\":\"(Lichtman, 2016a)\",\"ref_id\":\"BIBREF225\"},{\"start\":750.0,\"end\":767.0,\"text\":\"(Lichtman, 2016a;\",\"ref_id\":\"BIBREF225\"},{\"start\":768.0,\"end\":788.0,\"text\":\"Magden et al., 2015;\",\"ref_id\":\"BIBREF238\"},{\"start\":789.0,\"end\":804.0,\"text\":\"Schultze, 2010)\",\"ref_id\":\"BIBREF342\"},{\"start\":960.0,\"end\":977.0,\"text\":\"(Lichtman, 2016a)\",\"ref_id\":\"BIBREF225\"},{\"start\":1136.0,\"end\":1153.0,\"text\":\"(Lichtman, 2016a)\",\"ref_id\":\"BIBREF225\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-768-788> , <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-750-767> , <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-960-977> , <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-366-383> , <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-789-804> , <http://covid19.aksw.org/text-298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6_citespan-1136-1153> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Increases in blood monocyte counts occur with both acute and chronic inflammation, and such inflammatory increases in monocytes may be associated with both infectious and noninfectious etiologies. Tuberculosis and other mycobacterial infections are commonly associated with increases in monocyte counts which may represent an increased tissue demand for macrophages (Lichtman, 2016a) . Increases in monocyte counts have also been associated with bacterial endocarditis and sepsis, osteomyelitis, various pyogranulomatous diseases, candidiasis, viral infections including cytomegalovirus and influenza, and several parasitic diseases including pneumocystosis, Entopolypoides macacai infection in old world monkeys and apes, and dirofilariasis in dogs (Lichtman, 2016a; Magden et al., 2015; Schultze, 2010) . However, increases in monocyte counts may be less commonly related to malaria, leishmaniasis, and rickettsial diseases in people than previously thought (Lichtman, 2016a) . Noninfectious causes of increases in blood monocyte counts include inflammatory bowel disease, ulcerative gastritis, myocardial infarction, and parturition (Lichtman, 2016a) ." ;
            <http://www.example.org/textHash>
                    "298640230ac61832d9780a22b65457ca1085bdfd1bc00dc73640c253415b4ea6" .
    
    <http://covid19.aksw.org/text-9ec8d3a6972b4586c31358667004b68ef3d9b87327385a8c7b00e7bbc8398f9f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.1.3 Fragmentation Physical trauma to erythrocytes results in hemolysis due to erythrocyte fragmentation and lysis. Sometimes this type of hemolysis is referred to as microangiopathic hemolytic anemia. Morphologic changes to erythrocytes occur as a result of physical trauma. Schistocytes (also called schizocytes or erythrocyte fragments), keratocytes (also called helmet cells), prekeratocytes (also called blister cells), or even spherocytes or microspherocytes may be observed. Schistocytes are very small, usually irregularly shaped fragments that can break off erythrocytes when physical trauma occurs. Keratocytes have one to two variably sized projections or horns adjacent to a small flattened region of the erythrocyte surface, while prekeratocytes appear to be precursors that have small loops of erythrocyte cytoplasm extending from the surface and surrounding a small hole in the cell. Spherocytes and microspherocytes are spherical cells that appear smaller and have more intensely pink-staining cytoplasm than normal mature erythrocytes. Spherocytes and microspherocytes may be formed during physical trauma as fragments are broken off, resulting in less membrane surface area in the parent erythrocyte surrounding a similar volume (spherocytes) or smaller volume (microspherocytes) as the parent erythrocyte.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.1.3 Fragmentation Physical trauma to erythrocytes results in hemolysis due to erythrocyte fragmentation and lysis. Sometimes this type of hemolysis is referred to as microangiopathic hemolytic anemia. Morphologic changes to erythrocytes occur as a result of physical trauma. Schistocytes (also called schizocytes or erythrocyte fragments), keratocytes (also called helmet cells), prekeratocytes (also called blister cells), or even spherocytes or microspherocytes may be observed. Schistocytes are very small, usually irregularly shaped fragments that can break off erythrocytes when physical trauma occurs. Keratocytes have one to two variably sized projections or horns adjacent to a small flattened region of the erythrocyte surface, while prekeratocytes appear to be precursors that have small loops of erythrocyte cytoplasm extending from the surface and surrounding a small hole in the cell. Spherocytes and microspherocytes are spherical cells that appear smaller and have more intensely pink-staining cytoplasm than normal mature erythrocytes. Spherocytes and microspherocytes may be formed during physical trauma as fragments are broken off, resulting in less membrane surface area in the parent erythrocyte surrounding a similar volume (spherocytes) or smaller volume (microspherocytes) as the parent erythrocyte." ;
            <http://www.example.org/textHash>
                    "9ec8d3a6972b4586c31358667004b68ef3d9b87327385a8c7b00e7bbc8398f9f" .
    
    <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-296-323>
            <http://www.example.org/end>    "323.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "296.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-2a908d0d4623487ba40e2414d65ee9f35edac83c6e0ed481c79ebd0a8d8be52c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Direct damage to blood vessels from trauma is a relatively common cause of acute external or internal blood loss. Traumatic rupture of the spleen may also cause significant acute internal blood loss. Decreases in red cell mass due to acute hemorrhage are typically due to dilution of remaining blood from shifting of intracellular fluid to extracellular fluid in an attempt to preserve blood volume and therefore tissue perfusion (Stockham and Scott, 2008b) . Dilution of red cell mass may also be observed following administration of intravenous fluids to replace blood volume. A detectable increase in reticulocyte count is expected 3-4 days following the acute event in a patient with normally functioning bone marrow. Damage to blood vessels that results in hemorrhage also may occur secondary to ulcerative or neoplastic conditions. In dogs, rupture of splenic hemangiosarcoma is a common cause of internal blood loss into the abdomen (hemoabdomen). Ulceration of the gastrointestinal system may lead to blood loss into feces, which can be observed as black, tarry feces (melena) if the ulceration occurs in the small intestines or as frank blood if the ulceration occurs in the large intestines.\",\"cite_spans\":[{\"start\":430.0,\"end\":457.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2a908d0d4623487ba40e2414d65ee9f35edac83c6e0ed481c79ebd0a8d8be52c_citespan-430-457> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Direct damage to blood vessels from trauma is a relatively common cause of acute external or internal blood loss. Traumatic rupture of the spleen may also cause significant acute internal blood loss. Decreases in red cell mass due to acute hemorrhage are typically due to dilution of remaining blood from shifting of intracellular fluid to extracellular fluid in an attempt to preserve blood volume and therefore tissue perfusion (Stockham and Scott, 2008b) . Dilution of red cell mass may also be observed following administration of intravenous fluids to replace blood volume. A detectable increase in reticulocyte count is expected 3-4 days following the acute event in a patient with normally functioning bone marrow. Damage to blood vessels that results in hemorrhage also may occur secondary to ulcerative or neoplastic conditions. In dogs, rupture of splenic hemangiosarcoma is a common cause of internal blood loss into the abdomen (hemoabdomen). Ulceration of the gastrointestinal system may lead to blood loss into feces, which can be observed as black, tarry feces (melena) if the ulceration occurs in the small intestines or as frank blood if the ulceration occurs in the large intestines." ;
            <http://www.example.org/textHash>
                    "2a908d0d4623487ba40e2414d65ee9f35edac83c6e0ed481c79ebd0a8d8be52c" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-530-561>
            <http://www.example.org/end>    "561.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF94" ;
            <http://www.example.org/start>  "530.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Diz-Küçükkaya and López, 2016)" .
    
    <http://covid19.aksw.org/text-0c6ef520dbff4dabacd4ae2a5609d84e11334097231bc250f7f475264da70814_citespan-584-611>
            <http://www.example.org/end>    "611.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "584.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Allergic inflammation is another common cause of increases in blood eosinophil counts. Allergic conditions associated with increases in blood eosinophil counts include asthma, atopic dermatitis, and allergic rhinitis although increases in eosinophil counts with these conditions are usually mild (Wardlaw, 2016) . Allergic inflammation associated with immediate release of IgE is considered a type I hypersensitivity reaction. Some allergen-induced inflammation may be attributable to type IV (delayed-type or cell-mediated) hypersensitivity following T H activation with subsequent eosinophil recruitment. However, some differences have been observed between atopic dermatitis and classic type IV hypersensitivity (Gaga et al., 1991) , so not all T H -mediated allergic inflammation may represent a true type IV hypersensitivity reaction. As with most forms of inflammatory increases in blood eosinophil counts, production of cytokines and chemokines, such as IL-5 and eotaxin, appear to play a major role. In allergic asthma, activated T-helper type 2 (T H 2) cells release or stimulate the release of these cytokines and chemokines, resulting in recruitment and activation of eosinophils (Rosenberg et al., 2013) . Sensitization of the airways to ovalbumin with subsequent challenge in mice has mimicked many of the clinical and pathological features of allergic asthma, including the interaction of T H 2 cells and eosinophils (Rosenberg et al., 2013) . However, asthma encompasses a heterogeneous set of phenotypes and not all forms demonstrate clinical improvement in response to therapies targeting IL-5 or eosinophils (Wegmann, 2011) . While asthma is uncommon in most laboratory animal species, it can be experimentally induced in mice and may occur naturally in cats. Activation of T H 2 and T H 1 cells have been proposed to contribute to the pathology of atopic dermatitis, with the T H 2 activation being of particular relevance to the development of increases in blood eosinophil counts (Grewe et al., 1998) , similar to allergic asthma. Activation of T H 2 cells also plays a role in cytokine and chemokine elaboration with eosinophil recruitment in allergic rhinitis, although effects on eosinophils in allergic rhinitis are also mediated by histamine and IgE release from mast cells and histamine release from basophils (Borish, 2003) .\",\"cite_spans\":[{\"start\":296.0,\"end\":311.0,\"text\":\"(Wardlaw, 2016)\",\"ref_id\":\"BIBREF420\"},{\"start\":715.0,\"end\":734.0,\"text\":\"(Gaga et al., 1991)\",\"ref_id\":\"BIBREF126\"},{\"start\":1191.0,\"end\":1215.0,\"text\":\"(Rosenberg et al., 2013)\",\"ref_id\":\"BIBREF324\"},{\"start\":1431.0,\"end\":1455.0,\"text\":\"(Rosenberg et al., 2013)\",\"ref_id\":\"BIBREF324\"},{\"start\":1626.0,\"end\":1641.0,\"text\":\"(Wegmann, 2011)\",\"ref_id\":\"BIBREF423\"},{\"start\":2001.0,\"end\":2021.0,\"text\":\"(Grewe et al., 1998)\",\"ref_id\":\"BIBREF159\"},{\"start\":2337.0,\"end\":2351.0,\"text\":\"(Borish, 2003)\",\"ref_id\":\"BIBREF38\"}],\"ref_spans\":[],\"section\":\"Inflammation and Hypersensitivity\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-2337-2351> , <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-1431-1455> , <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-715-734> , <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-1626-1641> , <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-2001-2021> , <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-1191-1215> , <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-296-311> ;
            <http://www.example.org/section>
                    "Inflammation and Hypersensitivity" ;
            <http://www.example.org/text>  "Allergic inflammation is another common cause of increases in blood eosinophil counts. Allergic conditions associated with increases in blood eosinophil counts include asthma, atopic dermatitis, and allergic rhinitis although increases in eosinophil counts with these conditions are usually mild (Wardlaw, 2016) . Allergic inflammation associated with immediate release of IgE is considered a type I hypersensitivity reaction. Some allergen-induced inflammation may be attributable to type IV (delayed-type or cell-mediated) hypersensitivity following T H activation with subsequent eosinophil recruitment. However, some differences have been observed between atopic dermatitis and classic type IV hypersensitivity (Gaga et al., 1991) , so not all T H -mediated allergic inflammation may represent a true type IV hypersensitivity reaction. As with most forms of inflammatory increases in blood eosinophil counts, production of cytokines and chemokines, such as IL-5 and eotaxin, appear to play a major role. In allergic asthma, activated T-helper type 2 (T H 2) cells release or stimulate the release of these cytokines and chemokines, resulting in recruitment and activation of eosinophils (Rosenberg et al., 2013) . Sensitization of the airways to ovalbumin with subsequent challenge in mice has mimicked many of the clinical and pathological features of allergic asthma, including the interaction of T H 2 cells and eosinophils (Rosenberg et al., 2013) . However, asthma encompasses a heterogeneous set of phenotypes and not all forms demonstrate clinical improvement in response to therapies targeting IL-5 or eosinophils (Wegmann, 2011) . While asthma is uncommon in most laboratory animal species, it can be experimentally induced in mice and may occur naturally in cats. Activation of T H 2 and T H 1 cells have been proposed to contribute to the pathology of atopic dermatitis, with the T H 2 activation being of particular relevance to the development of increases in blood eosinophil counts (Grewe et al., 1998) , similar to allergic asthma. Activation of T H 2 cells also plays a role in cytokine and chemokine elaboration with eosinophil recruitment in allergic rhinitis, although effects on eosinophils in allergic rhinitis are also mediated by histamine and IgE release from mast cells and histamine release from basophils (Borish, 2003) ." ;
            <http://www.example.org/textHash>
                    "db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526" .
    
    <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d_citespan-432-459>
            <http://www.example.org/end>    "459.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-677-696>
            <http://www.example.org/end>    "696.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF221" ;
            <http://www.example.org/start>  "677.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Levin et al., 1993)" .
    
    <http://covid19.aksw.org/text-25957fb1e35df3b0f20c1146e28dd540b26f9f77f078af613889791ae7a10336_citespan-907-935>
            <http://www.example.org/end>    "935.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "907.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Arce-Bejarano et al., 2014;" .
    
    <http://covid19.aksw.org/text-743a792f7630acee9819c0a354a3214d5ae436ce038edd0aeda874ceaebf3e4b_citespan-181-203>
            <http://www.example.org/end>    "203.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF261" ;
            <http://www.example.org/start>  "181.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Mintzer et al., 2009)" .
    
    <http://covid19.aksw.org/text-99c0cccd237589fa11226ec71581a8030a886f0a7178296a36780531178488a3_citespan-528-541>
            <http://www.example.org/end>    "541.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF112" ;
            <http://www.example.org/start>  "528.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Fauci, 1975)" .
    
    <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Aplastic anemia has also been linked to administration of xenobiotics. Classically, chloramphenicol is reported to sporadically cause aplastic anemia (Segel and Lichtman, 2016) . However, antithyroid compounds, sulfonamides including trimethoprim sulfamethoxazole, beta-lactams, the diuretic furosemide, gold-containing compounds, penicillamine, and anticonvulsants including carbamazepine and phenacetin have all been reported in association with aplastic anemia (Mintzer et al., 2009; Kaufman et al., 1996) . Aplastic anemia has also been attributed to environmental or occupational exposure to benzene (Smith, 1996) . In a case of aplastic anemia in a dog, griseofulvin administration was suspected to be the cause of the aplastic anemia (Brazzell and Weiss, 2006) .\",\"cite_spans\":[{\"start\":150.0,\"end\":176.0,\"text\":\"(Segel and Lichtman, 2016)\",\"ref_id\":\"BIBREF345\"},{\"start\":464.0,\"end\":486.0,\"text\":\"(Mintzer et al., 2009;\",\"ref_id\":\"BIBREF261\"},{\"start\":487.0,\"end\":508.0,\"text\":\"Kaufman et al., 1996)\",\"ref_id\":\"BIBREF200\"},{\"start\":605.0,\"end\":618.0,\"text\":\"(Smith, 1996)\",\"ref_id\":\"BIBREF357\"},{\"start\":741.0,\"end\":767.0,\"text\":\"(Brazzell and Weiss, 2006)\",\"ref_id\":\"BIBREF43\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-150-176> , <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-464-486> , <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-487-508> , <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-605-618> , <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-741-767> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Aplastic anemia has also been linked to administration of xenobiotics. Classically, chloramphenicol is reported to sporadically cause aplastic anemia (Segel and Lichtman, 2016) . However, antithyroid compounds, sulfonamides including trimethoprim sulfamethoxazole, beta-lactams, the diuretic furosemide, gold-containing compounds, penicillamine, and anticonvulsants including carbamazepine and phenacetin have all been reported in association with aplastic anemia (Mintzer et al., 2009; Kaufman et al., 1996) . Aplastic anemia has also been attributed to environmental or occupational exposure to benzene (Smith, 1996) . In a case of aplastic anemia in a dog, griseofulvin administration was suspected to be the cause of the aplastic anemia (Brazzell and Weiss, 2006) ." ;
            <http://www.example.org/textHash>
                    "afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-162-181>
            <http://www.example.org/end>    "181.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "162.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Galli et al., 2016)" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-538-561>
            <http://www.example.org/end>    "561.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF217" ;
            <http://www.example.org/start>  "538.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Laurencet et al., 1994)" .
    
    <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-110-144>
            <http://www.example.org/end>    "144.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF305" ;
            <http://www.example.org/start>  "110.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Provencher Bolliger et al., 2010)" .
    
    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.2.6 Myelophthisis, myelofibrosis, and myelonecrosis Conditions that efface the bone marrow cavities or displace hematopoietic cells (myelophthisis) may result in decreased production of all hematopoietic cell lines, including neutrophils. Myeloproliferative syndromes (Tefferi and Vardiman, 2009 ), many leukemic diseases (Talcott et al., 1992; Lamy and Loughran, 1999) , lymphoproliferative neoplasia (Schultze, 2010) , or metastatic carcinoma (Makoni and Laber, 2004) can cause sufficient bone marrow overcrowding to decrease the production of neutrophils. Fungal infections resulting in granulomatous inflammation of the bone marrow, such as can be observed with disseminated histoplasmosis, may also result in decreased neutrophil production. Disruption of the bone marrow cavities and hematopoietic stem cells from myelofibrosis or myelonecrosis may also be associated with decreased blood neutrophil counts (Stockham and Scott, 2008a) .\",\"cite_spans\":[{\"start\":278.0,\"end\":305.0,\"text\":\"(Tefferi and Vardiman, 2009\",\"ref_id\":\"BIBREF382\"},{\"start\":332.0,\"end\":354.0,\"text\":\"(Talcott et al., 1992;\",\"ref_id\":\"BIBREF378\"},{\"start\":355.0,\"end\":379.0,\"text\":\"Lamy and Loughran, 1999)\",\"ref_id\":\"BIBREF213\"},{\"start\":412.0,\"end\":428.0,\"text\":\"(Schultze, 2010)\",\"ref_id\":\"BIBREF342\"},{\"start\":455.0,\"end\":479.0,\"text\":\"(Makoni and Laber, 2004)\",\"ref_id\":\"BIBREF240\"},{\"start\":923.0,\"end\":950.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-278-305> , <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-412-428> , <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-332-354> , <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-923-950> , <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-355-379> , <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-455-479> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "12.11.2.1.2.6 Myelophthisis, myelofibrosis, and myelonecrosis Conditions that efface the bone marrow cavities or displace hematopoietic cells (myelophthisis) may result in decreased production of all hematopoietic cell lines, including neutrophils. Myeloproliferative syndromes (Tefferi and Vardiman, 2009 ), many leukemic diseases (Talcott et al., 1992; Lamy and Loughran, 1999) , lymphoproliferative neoplasia (Schultze, 2010) , or metastatic carcinoma (Makoni and Laber, 2004) can cause sufficient bone marrow overcrowding to decrease the production of neutrophils. Fungal infections resulting in granulomatous inflammation of the bone marrow, such as can be observed with disseminated histoplasmosis, may also result in decreased neutrophil production. Disruption of the bone marrow cavities and hematopoietic stem cells from myelofibrosis or myelonecrosis may also be associated with decreased blood neutrophil counts (Stockham and Scott, 2008a) ." ;
            <http://www.example.org/textHash>
                    "7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1468-1486>
            <http://www.example.org/end>    "1486.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF56" ;
            <http://www.example.org/start>  "1468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Car et al., 2006)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1403-1419>
            <http://www.example.org/end>    "1419.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "1403.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-578bb563f947f04aba36cf955897ebe919ef4a1fb3cff88b984c5b2aea466a2d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.1.4 Immune-mediated Autoimmune hemolytic anemia (AIHA or AHA) described in humans or immune-mediated hemolytic anemia (IMHA) described in most common laboratory species is a cause of hemolysis, and may be primary or idiopathic, but may also be secondary to conditions such as infections as discussed previously. Primary or idiopathic AIHA/ IMHA is discussed here. Primary AIHA has no underlying detectable cause and is an immune-mediated condition that produces antibodies targeting erythrocyte antigens. These antierythrocyte antibodies tend to be very specific for a single erythrocyte antigen in a given case (Packman, 2016) . These autoantibodies may be classified as warm antibodies, which are usually IgG, or cold antibodies, which are usually IgM (Stockham and Scott, 2008b) .\",\"cite_spans\":[{\"start\":624.0,\"end\":639.0,\"text\":\"(Packman, 2016)\",\"ref_id\":\"BIBREF283\"},{\"start\":766.0,\"end\":793.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-578bb563f947f04aba36cf955897ebe919ef4a1fb3cff88b984c5b2aea466a2d_citespan-624-639> , <http://covid19.aksw.org/text-578bb563f947f04aba36cf955897ebe919ef4a1fb3cff88b984c5b2aea466a2d_citespan-766-793> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.1.4 Immune-mediated Autoimmune hemolytic anemia (AIHA or AHA) described in humans or immune-mediated hemolytic anemia (IMHA) described in most common laboratory species is a cause of hemolysis, and may be primary or idiopathic, but may also be secondary to conditions such as infections as discussed previously. Primary or idiopathic AIHA/ IMHA is discussed here. Primary AIHA has no underlying detectable cause and is an immune-mediated condition that produces antibodies targeting erythrocyte antigens. These antierythrocyte antibodies tend to be very specific for a single erythrocyte antigen in a given case (Packman, 2016) . These autoantibodies may be classified as warm antibodies, which are usually IgG, or cold antibodies, which are usually IgM (Stockham and Scott, 2008b) ." ;
            <http://www.example.org/textHash>
                    "578bb563f947f04aba36cf955897ebe919ef4a1fb3cff88b984c5b2aea466a2d" .
    
    <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b_citespan-286-305>
            <http://www.example.org/end>    "305.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF409" ;
            <http://www.example.org/start>  "286.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vinh et al., 2010)" .
    
    <http://covid19.aksw.org/text-ebf62c5255866323a601ef0e03fd613d44972e92cf3006d9412b21b115ab9f6c_citespan-904-928>
            <http://www.example.org/end>    "928.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF219" ;
            <http://www.example.org/start>  "904.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Leder and Weller, 2000)" .
    
    <http://covid19.aksw.org/text-03840eb951b436c6f80fe142374c580d28425579cd6ab97e6bb6575af804d38d_citespan-1056-1079>
            <http://www.example.org/end>    "1079.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF369" ;
            <http://www.example.org/start>  "1056.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stohlman et al., 1963)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-886-907>
            <http://www.example.org/end>    "907.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "886.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bennett et al., 1998" .
    
    <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327_citespan-468-490>
            <http://www.example.org/end>    "490.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF14" ;
            <http://www.example.org/start>  "468.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Avery and Avery, 2007)" .
    
    <http://covid19.aksw.org/text-5fbc1cd80b0aa20f4f8a16f775bdc97ebbddbbcbb413367c7f8c00cd2985ed9c_citespan-540-561>
            <http://www.example.org/end>    "561.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF200" ;
            <http://www.example.org/start>  "540.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kaufman et al., 1996)" .
    
    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-889-919>
            <http://www.example.org/end>    "919.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF385" ;
            <http://www.example.org/start>  "889.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Thiagarajan and Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-267-283>
            <http://www.example.org/end>    "283.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "267.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Koch-Weser, 1968" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-391-418>
            <http://www.example.org/end>    "418.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF382" ;
            <http://www.example.org/start>  "391.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tefferi and Vardiman, 2009;" .
    
    <http://covid19.aksw.org/text-cc7311cce7d5f3297ecfc34b9bb4393bd0f0b004453845f6b007410a19648ac1_citespan-158-180>
            <http://www.example.org/end>    "180.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF399" ;
            <http://www.example.org/start>  "158.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Uppal and Gong, 2015)" .
    
    <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Glucocorticoids increase blood neutrophil counts through several mechanisms. They downregulate neutrophil expression of adhesion molecules, leading to both a shift from marginating to circulating pools, and by prolongation of neutrophil lifespan in circulation due to decreased tissue emigration (Stockham and Scott, 2008a) . Neutrophil half-life may also be prolonged due to decreased apoptosis (Cox, 1995) . These increases in neutrophil lifespan may be associated with hypersegmentation of neutrophil nuclei that can be observed during blood smear evaluation. Glucocorticoids also increase the release of segmented and occasionally band neutrophils from the bone marrow storage pool, although this mechanism contributes to the neutrophilia to a lesser degree than shifting to the circulating pool (Stockham and Scott, 2008a; Nakagawa et al., 1998) . Bone marrow expansion of all stages of myeloid cells may also be increased by glucocorticoid stimulation (Trottier et al., 2008) . Administration of exogenous glucocorticoids, such as prednisolone and dexamethasone, will result in similar effects on blood leukocyte counts.\",\"cite_spans\":[{\"start\":296.0,\"end\":323.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"},{\"start\":396.0,\"end\":407.0,\"text\":\"(Cox, 1995)\",\"ref_id\":\"BIBREF77\"},{\"start\":800.0,\"end\":827.0,\"text\":\"(Stockham and Scott, 2008a;\",\"ref_id\":\"BIBREF366\"},{\"start\":828.0,\"end\":850.0,\"text\":\"Nakagawa et al., 1998)\",\"ref_id\":\"BIBREF272\"},{\"start\":958.0,\"end\":981.0,\"text\":\"(Trottier et al., 2008)\",\"ref_id\":\"BIBREF395\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-296-323> , <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-396-407> , <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-800-827> , <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-828-850> , <http://covid19.aksw.org/text-ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52_citespan-958-981> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Glucocorticoids increase blood neutrophil counts through several mechanisms. They downregulate neutrophil expression of adhesion molecules, leading to both a shift from marginating to circulating pools, and by prolongation of neutrophil lifespan in circulation due to decreased tissue emigration (Stockham and Scott, 2008a) . Neutrophil half-life may also be prolonged due to decreased apoptosis (Cox, 1995) . These increases in neutrophil lifespan may be associated with hypersegmentation of neutrophil nuclei that can be observed during blood smear evaluation. Glucocorticoids also increase the release of segmented and occasionally band neutrophils from the bone marrow storage pool, although this mechanism contributes to the neutrophilia to a lesser degree than shifting to the circulating pool (Stockham and Scott, 2008a; Nakagawa et al., 1998) . Bone marrow expansion of all stages of myeloid cells may also be increased by glucocorticoid stimulation (Trottier et al., 2008) . Administration of exogenous glucocorticoids, such as prednisolone and dexamethasone, will result in similar effects on blood leukocyte counts." ;
            <http://www.example.org/textHash>
                    "ae2fcf660832d35b4cde234eba163cf7ef19f69f5a8815ecd7789750c8b4fe52" .
    
    <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-614-634>
            <http://www.example.org/end>    "634.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF365" ;
            <http://www.example.org/start>  "614.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Steer et al., 1997;" .
    
    <http://covid19.aksw.org/text-fca9c90cc45efec65e55da20f3af378247db0cee8e1b7822e5458118a81c7209_citespan-553-576>
            <http://www.example.org/end>    "576.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF373" ;
            <http://www.example.org/start>  "553.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sugimoto et al., 1986)" .
    
    <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Causes of acute inflammation are many and varied. Bacterial and fungal infections are commonly associated with increases in neutrophil counts. Tuberculosis has been associated with increased neutrophil counts in humans and in macaques commonly used in nonclinical toxicology studies (Lowe et al., 2013; Magden et al., 2015) . In macaques commonly used in nonclinical toxicology studies, shigellosis may cause neutrophilia with or without a left shift even in the absence of clinical signs and diarrhea (Magden et al., 2015) . Macaques may also have increases in neutrophil counts with enteric infection by Yersinia species and respiratory tract infection by Streptococcus pneumoniae or Klebsiella pneumoniae (Magden et al., 2015) . Increases in neutrophil counts can also be observed as a direct response to viral infections or secondary to viral-induced tissue damage, tissue damage from trauma, or as a paraneoplastic effect.\",\"cite_spans\":[{\"start\":283.0,\"end\":302.0,\"text\":\"(Lowe et al., 2013;\",\"ref_id\":\"BIBREF236\"},{\"start\":303.0,\"end\":323.0,\"text\":\"Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"},{\"start\":502.0,\"end\":523.0,\"text\":\"(Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"},{\"start\":708.0,\"end\":729.0,\"text\":\"(Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-283-302> , <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-303-323> , <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-502-523> , <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-708-729> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Causes of acute inflammation are many and varied. Bacterial and fungal infections are commonly associated with increases in neutrophil counts. Tuberculosis has been associated with increased neutrophil counts in humans and in macaques commonly used in nonclinical toxicology studies (Lowe et al., 2013; Magden et al., 2015) . In macaques commonly used in nonclinical toxicology studies, shigellosis may cause neutrophilia with or without a left shift even in the absence of clinical signs and diarrhea (Magden et al., 2015) . Macaques may also have increases in neutrophil counts with enteric infection by Yersinia species and respiratory tract infection by Streptococcus pneumoniae or Klebsiella pneumoniae (Magden et al., 2015) . Increases in neutrophil counts can also be observed as a direct response to viral infections or secondary to viral-induced tissue damage, tissue damage from trauma, or as a paraneoplastic effect." ;
            <http://www.example.org/textHash>
                    "be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-633-653>
            <http://www.example.org/end>    "653.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "633.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Berny et al., 2010;" .
    
    <http://covid19.aksw.org/text-d76683337213c44f43b98a160d3d52137e06a3dfed9b8759d8b7dc67c7560610_citespan-415-438>
            <http://www.example.org/end>    "438.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF373" ;
            <http://www.example.org/start>  "415.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sugimoto et al., 1986)" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-419-443>
            <http://www.example.org/end>    "443.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF408" ;
            <http://www.example.org/start>  "419.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Villeneuve et al., 2008;" .
    
    <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Regenerative erythroid responses with increases in blood reticulocyte counts may be associated with several morphologic findings observed during blood smear evaluation. Most commonly, increases in polychromatophils (polychromasia) are observed with Wright-Giemsa or modified Wright stains. Polychromatophils are erythrocytes that stain blue-purple in color due to the combined effects of blue-staining RNA content typical of reticulocytes and pink-staining hemoglobin. As reticulocytes mature and lose RNA, a visual difference in staining cannot longer be detected between late reticulocytes and mature erythrocytes. However, staining of blood with a vital dye such as New Methylene Blue permits differentiation between aggregate and punctatetype reticulocytes. Polychromasia usually correlates well with increases in reticulocytes in most species, except cats (Stockham and Scott, 2008b) . In cats, aggregate-type but not punctate-type reticulocytes correlate with polychromasia and are considered clinically relevant, and differentiation of these two with manual reticulocyte counts should be performed (Harvey, 2012; Stockham and Scott, 2008b) . Reticulocytes or erythrocytes with few small, punctate dark blue-gray inclusions may be observed during a regenerative erythroid response. These inclusions contain iron and may be called Pappenheimer bodies or siderotic inclusions. Due to the rapid production and release of erythrocytes during a regenerative erythroid response, there may also be increase in nucleated red blood cells or erythrocytes with Howell-Jolly bodies. Nucleated red blood cells are usually present in low numbers, but if 10 or more are observed per 100 leukocytes, the automated total leukocyte count will be falsely increased and should be corrected using published equations (Stockham and Scott, 2008a) . In some species, particularly cows and sheep, erythrocytes with basophilic stippling may also be observed in circulation during a regenerative erythroid response.\",\"cite_spans\":[{\"start\":861.0,\"end\":888.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":1105.0,\"end\":1119.0,\"text\":\"(Harvey, 2012;\",\"ref_id\":\"BIBREF166\"},{\"start\":1120.0,\"end\":1146.0,\"text\":\"Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":1802.0,\"end\":1829.0,\"text\":\"(Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-861-888> , <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-1105-1119> , <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-1120-1146> , <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-1802-1829> ;
            <http://www.example.org/section>
                    "Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)" ;
            <http://www.example.org/text>  "Regenerative erythroid responses with increases in blood reticulocyte counts may be associated with several morphologic findings observed during blood smear evaluation. Most commonly, increases in polychromatophils (polychromasia) are observed with Wright-Giemsa or modified Wright stains. Polychromatophils are erythrocytes that stain blue-purple in color due to the combined effects of blue-staining RNA content typical of reticulocytes and pink-staining hemoglobin. As reticulocytes mature and lose RNA, a visual difference in staining cannot longer be detected between late reticulocytes and mature erythrocytes. However, staining of blood with a vital dye such as New Methylene Blue permits differentiation between aggregate and punctatetype reticulocytes. Polychromasia usually correlates well with increases in reticulocytes in most species, except cats (Stockham and Scott, 2008b) . In cats, aggregate-type but not punctate-type reticulocytes correlate with polychromasia and are considered clinically relevant, and differentiation of these two with manual reticulocyte counts should be performed (Harvey, 2012; Stockham and Scott, 2008b) . Reticulocytes or erythrocytes with few small, punctate dark blue-gray inclusions may be observed during a regenerative erythroid response. These inclusions contain iron and may be called Pappenheimer bodies or siderotic inclusions. Due to the rapid production and release of erythrocytes during a regenerative erythroid response, there may also be increase in nucleated red blood cells or erythrocytes with Howell-Jolly bodies. Nucleated red blood cells are usually present in low numbers, but if 10 or more are observed per 100 leukocytes, the automated total leukocyte count will be falsely increased and should be corrected using published equations (Stockham and Scott, 2008a) . In some species, particularly cows and sheep, erythrocytes with basophilic stippling may also be observed in circulation during a regenerative erythroid response." ;
            <http://www.example.org/textHash>
                    "29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e" .
    
    <http://covid19.aksw.org/text-c6bea817b877dd7041815289e97330a98c5a59ead3508298824c5ba1054d54fd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.2.7 Xenobiotic-induced Xenobiotic-induced decreases in neutrophil counts may be caused by immune-mediated or nonimmune-mediated mechanisms. The incidences of these events tend to be low with most implicated xenobiotics, with the exception of chemotherapeutic agents. Examples of both immune-mediated and nonimmune-mediated mechanisms are described later.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "12.11.2.1.2.7 Xenobiotic-induced Xenobiotic-induced decreases in neutrophil counts may be caused by immune-mediated or nonimmune-mediated mechanisms. The incidences of these events tend to be low with most implicated xenobiotics, with the exception of chemotherapeutic agents. Examples of both immune-mediated and nonimmune-mediated mechanisms are described later." ;
            <http://www.example.org/textHash>
                    "c6bea817b877dd7041815289e97330a98c5a59ead3508298824c5ba1054d54fd" .
    
    <http://covid19.aksw.org/text-2bc22939fa9c83241c94ce75de8823815c263a5f365c49370a8c4eda656aa8d1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.3.1.1 Catecholamine-induced Although less commonly observed than increases in neutrophil or lymphocyte counts, blood monocyte counts may be modestly increased under the stimulation of endogenous catecholamines. This effect is most likely mediated by rapid shifting of monocytes from the marginating pool to the circulating pool (Everds et al., 2013a) .\",\"cite_spans\":[{\"start\":336.0,\"end\":358.0,\"text\":\"(Everds et al., 2013a)\",\"ref_id\":\"BIBREF107\"}],\"ref_spans\":[],\"section\":\"Increases in monocyte counts (monocytosis)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2bc22939fa9c83241c94ce75de8823815c263a5f365c49370a8c4eda656aa8d1_citespan-336-358> ;
            <http://www.example.org/section>
                    "Increases in monocyte counts (monocytosis)" ;
            <http://www.example.org/text>  "12.11.2.3.1.1 Catecholamine-induced Although less commonly observed than increases in neutrophil or lymphocyte counts, blood monocyte counts may be modestly increased under the stimulation of endogenous catecholamines. This effect is most likely mediated by rapid shifting of monocytes from the marginating pool to the circulating pool (Everds et al., 2013a) ." ;
            <http://www.example.org/textHash>
                    "2bc22939fa9c83241c94ce75de8823815c263a5f365c49370a8c4eda656aa8d1" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3058-3082>
            <http://www.example.org/end>    "3082.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF246" ;
            <http://www.example.org/start>  "3058.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Marquardt et al., 1999)" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-165-182>
            <http://www.example.org/end>    "182.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "165.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bradberry, 2003;" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-349-370>
            <http://www.example.org/end>    "370.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF325" ;
            <http://www.example.org/start>  "349.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rosner et al., 1988)" .
    
    <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The physical trauma to erythrocytes that causes fragmentation or microangiopathic hemolysis may result from consumptive coagulopathies, either local or disseminated (DIC), with fibrin or thrombus formation in the vasculature that impedes the passage of erythrocytes through the vessel lumen, creating both turbulence and physical obstruction of blood flow. Local coagulopathy or DIC may occur secondary to trauma, infections with sepsis, or neoplasia (Baker and Moake, 2016; Toh and Dennis, 2003) . Microangiopathic hemolysis due to neoplasia is most commonly associated with malignant rather than benign neoplasms and with metastatic disease or neoplasic emboli rather than primary tumors, with the exception of primary vascular neoplasms (Susano et al., 1994; Kupers et al., 1975; Lohrmann et al., 1973) .\",\"cite_spans\":[{\"start\":451.0,\"end\":474.0,\"text\":\"(Baker and Moake, 2016;\",\"ref_id\":\"BIBREF15\"},{\"start\":475.0,\"end\":496.0,\"text\":\"Toh and Dennis, 2003)\",\"ref_id\":\"BIBREF392\"},{\"start\":740.0,\"end\":761.0,\"text\":\"(Susano et al., 1994;\",\"ref_id\":\"BIBREF375\"},{\"start\":762.0,\"end\":782.0,\"text\":\"Kupers et al., 1975;\",\"ref_id\":\"BIBREF209\"},{\"start\":783.0,\"end\":805.0,\"text\":\"Lohrmann et al., 1973)\",\"ref_id\":\"BIBREF235\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-451-474> , <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-475-496> , <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-740-761> , <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-762-782> , <http://covid19.aksw.org/text-3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93_citespan-783-805> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "The physical trauma to erythrocytes that causes fragmentation or microangiopathic hemolysis may result from consumptive coagulopathies, either local or disseminated (DIC), with fibrin or thrombus formation in the vasculature that impedes the passage of erythrocytes through the vessel lumen, creating both turbulence and physical obstruction of blood flow. Local coagulopathy or DIC may occur secondary to trauma, infections with sepsis, or neoplasia (Baker and Moake, 2016; Toh and Dennis, 2003) . Microangiopathic hemolysis due to neoplasia is most commonly associated with malignant rather than benign neoplasms and with metastatic disease or neoplasic emboli rather than primary tumors, with the exception of primary vascular neoplasms (Susano et al., 1994; Kupers et al., 1975; Lohrmann et al., 1973) ." ;
            <http://www.example.org/textHash>
                    "3211ea3003294cb8d7a9303120b397ac065d01ff23ff4582d74ba25905e88a93" .
    
    <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-687-702>
            <http://www.example.org/end>    "702.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF327" ;
            <http://www.example.org/start>  "687.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Roujeau, 2005;" .
    
    <http://covid19.aksw.org/text-76f97fdcbb4efa0acd91d6cddb0af75071a8dc8b6e0b755916fa0b39244581a8_citespan-477-498>
            <http://www.example.org/end>    "498.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF424" ;
            <http://www.example.org/start>  "477.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Weiner et al., 1994;" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-1304-1322>
            <http://www.example.org/end>    "1322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF218" ;
            <http://www.example.org/start>  "1304.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lazarchick, 2012)" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1655-1675>
            <http://www.example.org/end>    "1675.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF332" ;
            <http://www.example.org/start>  "1655.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sakka et al., 2006)" .
    
    <http://covid19.aksw.org/text-3ba2a60bdf55ade2147de2900dd8907613bec0c1810971890791b0f2cb82267b_citespan-527-544>
            <http://www.example.org/end>    "544.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF175" ;
            <http://www.example.org/start>  "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Hsu et al., 2011)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-2206-2223>
            <http://www.example.org/end>    "2223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF226" ;
            <http://www.example.org/start>  "2206.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016b;" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1785-1811>
            <http://www.example.org/end>    "1811.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "1785.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-651-665>
            <http://www.example.org/end>    "665.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF300" ;
            <http://www.example.org/start>  "651.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Pohlman, 2010)" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-1148-1171>
            <http://www.example.org/end>    "1171.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "1148.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Bhatt and Saleem, 2004;" .
    
    <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-2234-2257>
            <http://www.example.org/end>    "2257.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF313" ;
            <http://www.example.org/start>  "2234.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Randolph et al., 2010)" .
    
    <http://covid19.aksw.org/text-b058dd64e30ce83823cca56b014252db88835f11159f8cffe241111ae37fe134_citespan-522-546>
            <http://www.example.org/end>    "546.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "522.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bookchin and Lew, 1996)" .
    
    <http://covid19.aksw.org/text-31f0029b5072968918d01e306f6809738749b5340f5bfdc82de3a3ead0a60d4f_citespan-287-304>
            <http://www.example.org/end>    "304.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF336" ;
            <http://www.example.org/start>  "287.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sanderson, 1992)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-746-768>
            <http://www.example.org/end>    "768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF393" ;
            <http://www.example.org/start>  "746.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Trimarchi et al., 1999" .
    
    <http://covid19.aksw.org/text-c44f184b5236cf15ab64e4b997ceb9af9b93332e94cd319e79f4d031e7d8aee9_citespan-619-645>
            <http://www.example.org/end>    "645.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF70" ;
            <http://www.example.org/start>  "619.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Christopher et al., 1990)" .
    
    <http://covid19.aksw.org/text-cbe52974c1390ba965e9d546ee5be42f2f4810f69074746a13c9e7489d48f9a7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Acute, severe loss of whole blood may result in decrease in all blood components, including platelets. Blood loss of significant magnitude to cause decreases in blood platelet counts may occur following trauma, splenic rupture from trauma or neoplasia, or from uncontrolled bleeding associated with coagulopathies, such as hemophilia A or B. However, consumption of platelets at the site(s) of hemorrhage may also contribute to the decreases in platelet counts observed with blood loss.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Loss\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Loss" ;
            <http://www.example.org/text>  "Acute, severe loss of whole blood may result in decrease in all blood components, including platelets. Blood loss of significant magnitude to cause decreases in blood platelet counts may occur following trauma, splenic rupture from trauma or neoplasia, or from uncontrolled bleeding associated with coagulopathies, such as hemophilia A or B. However, consumption of platelets at the site(s) of hemorrhage may also contribute to the decreases in platelet counts observed with blood loss." ;
            <http://www.example.org/textHash>
                    "cbe52974c1390ba965e9d546ee5be42f2f4810f69074746a13c9e7489d48f9a7" .
    
    <http://covid19.aksw.org/text-71290b1bed9714f92a3d63866c4bd78006f87156d56c3ce8d35a4fa5a3b18075>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.2.1.5 Neoplasia Increases in blood lymphocyte counts associated with lymphoproliferative neoplasia may represent either lymphocytic leukemia or the leukemic phase of lymphoma. A normal circulating lymphocyte population should be heterogeneous, with predominantly small lymphocytes and fewer intermediate to large lymphocytes. Increased blood lymphocyte counts with a loss of heterogeneity in the blood lymphocyte population or predominantly a monomorphic intermediate to large lymphocyte population are key features for diagnosing lymphoproliferative neoplasia. With the exception of chronic lymphocytic leukemia, which is characterized by increased numbers of small lymphocytes with few or subtle morphologic alterations, circulating lymphocytes often have abnormal morphologic features that may be observed microscopically. Abnormal morphologic features of the leukemic lymphocyte population may include increased cytoplasmic basophilia, increased amounts of cytoplasm with altered nuclear to cytoplasmic ratios, irregular clumping of nuclear chromatin, indentation or lobulation of nuclei, variably sized but typically prominent nucleoli, or multiple nucleoli. Some of these morphologic features are similar to those observed in reactive lymphocytes, but these two processes may be distinguished by the overall heterogeneity of the lymphocyte population and proportion of the lymphocyte population with these morphologic alterations. Additional testing, such as flow cytometry for phenotyping or PCR for antigen receptor rearrangement (PARR), also aids in the diagnosis or characterization of lymphoproliferative neoplasia.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "12.11.2.2.1.5 Neoplasia Increases in blood lymphocyte counts associated with lymphoproliferative neoplasia may represent either lymphocytic leukemia or the leukemic phase of lymphoma. A normal circulating lymphocyte population should be heterogeneous, with predominantly small lymphocytes and fewer intermediate to large lymphocytes. Increased blood lymphocyte counts with a loss of heterogeneity in the blood lymphocyte population or predominantly a monomorphic intermediate to large lymphocyte population are key features for diagnosing lymphoproliferative neoplasia. With the exception of chronic lymphocytic leukemia, which is characterized by increased numbers of small lymphocytes with few or subtle morphologic alterations, circulating lymphocytes often have abnormal morphologic features that may be observed microscopically. Abnormal morphologic features of the leukemic lymphocyte population may include increased cytoplasmic basophilia, increased amounts of cytoplasm with altered nuclear to cytoplasmic ratios, irregular clumping of nuclear chromatin, indentation or lobulation of nuclei, variably sized but typically prominent nucleoli, or multiple nucleoli. Some of these morphologic features are similar to those observed in reactive lymphocytes, but these two processes may be distinguished by the overall heterogeneity of the lymphocyte population and proportion of the lymphocyte population with these morphologic alterations. Additional testing, such as flow cytometry for phenotyping or PCR for antigen receptor rearrangement (PARR), also aids in the diagnosis or characterization of lymphoproliferative neoplasia." ;
            <http://www.example.org/textHash>
                    "71290b1bed9714f92a3d63866c4bd78006f87156d56c3ce8d35a4fa5a3b18075" .
    
    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-938-965>
            <http://www.example.org/end>    "965.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "938.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-aa6e36e73c2f72054f0bdb55b0e8c4685415aa794f7a0fe4e00a030233e9289f_citespan-310-337>
            <http://www.example.org/end>    "337.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "310.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-902e2456e15608fa100a9e4923efb472be38b7e4e71711e0098f8ed31af9e65c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although present in low numbers, monocytes represent the third most numerous blood leukocytes in health, after neutrophils and lymphocytes. They are typically the largest of the leukocytes in routine blood films. Monocytes play a major role in resolution of infectious processes, particularly those involving larger or more complex organisms, such as fungi and protozoa, and in the clearance of other foreign material from the body. Following cardiac blood collection in mice, tissue macrophages may be inadvertently collected and may rarely be observed during blood smear evaluation.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Monocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Monocytes" ;
            <http://www.example.org/text>  "Although present in low numbers, monocytes represent the third most numerous blood leukocytes in health, after neutrophils and lymphocytes. They are typically the largest of the leukocytes in routine blood films. Monocytes play a major role in resolution of infectious processes, particularly those involving larger or more complex organisms, such as fungi and protozoa, and in the clearance of other foreign material from the body. Following cardiac blood collection in mice, tissue macrophages may be inadvertently collected and may rarely be observed during blood smear evaluation." ;
            <http://www.example.org/textHash>
                    "902e2456e15608fa100a9e4923efb472be38b7e4e71711e0098f8ed31af9e65c" .
    
    <http://covid19.aksw.org/text-751d89daa26136b44e24435ac5a8c5fd8c9cf08a3f6e3a627813fbd8c4b87395>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Some automated hematology analyzers, such as the Siemens Healthcare ADVIA systems, include a \\\"large unclassified cell\\\" (LUC) or \\\"other\\\" cell category in the leukocyte differential. These cells are generally large with no or minimal myeloperoxidase activity, and do not fall within the predefined species\\u0027 gating parameters for typically identified leukocyte subtypes. These cells do not represent a distinct cell type, but are most commonly large and/or reactive lymphocytes or monocytes, and increases in LUC counts may be observed with any conditions resulting in increases in blood lymphocyte or monocyte counts. In species where automated basophil counts are not reliable, increases in blood basophil counts may also appear as an increase in LUC counts . Acute leukemia, typified by increases in hematopoietic blast cells in bone marrow and circulation, almost always results in increases in LUC counts. In the presence of high LUC counts, blood smear evaluation should be performed to assess the leukocyte differential and morphologic appearance of the blood leukocytes.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Large Unclassified or Other Cells\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Large Unclassified or Other Cells" ;
            <http://www.example.org/text>  "Some automated hematology analyzers, such as the Siemens Healthcare ADVIA systems, include a \"large unclassified cell\" (LUC) or \"other\" cell category in the leukocyte differential. These cells are generally large with no or minimal myeloperoxidase activity, and do not fall within the predefined species' gating parameters for typically identified leukocyte subtypes. These cells do not represent a distinct cell type, but are most commonly large and/or reactive lymphocytes or monocytes, and increases in LUC counts may be observed with any conditions resulting in increases in blood lymphocyte or monocyte counts. In species where automated basophil counts are not reliable, increases in blood basophil counts may also appear as an increase in LUC counts . Acute leukemia, typified by increases in hematopoietic blast cells in bone marrow and circulation, almost always results in increases in LUC counts. In the presence of high LUC counts, blood smear evaluation should be performed to assess the leukocyte differential and morphologic appearance of the blood leukocytes." ;
            <http://www.example.org/textHash>
                    "751d89daa26136b44e24435ac5a8c5fd8c9cf08a3f6e3a627813fbd8c4b87395" .
    
    <http://covid19.aksw.org/text-5332347dfedc9b08a33178b67700792c70f47a9edc921c098d37aeecc534d356_citespan-543-572>
            <http://www.example.org/end>    "572.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF228" ;
            <http://www.example.org/start>  "543.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lilliehöök and Tvedten, 2011;" .
    
    <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-501-525>
            <http://www.example.org/end>    "525.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF203" ;
            <http://www.example.org/start>  "501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kobayashi et al., 1996)" .
    
    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-407-424>
            <http://www.example.org/end>    "424.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF230" ;
            <http://www.example.org/start>  "407.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lin et al., 2014)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-995-1033>
            <http://www.example.org/end>    "1033.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "995.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "), gemcitabine (Nackaerts et al., 1998" .
    
    <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a_citespan-1098-1111>
            <http://www.example.org/end>    "1111.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF157" ;
            <http://www.example.org/start>  "1098.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Green, 2016)" .
    
    <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-216-241>
            <http://www.example.org/end>    "241.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF352" ;
            <http://www.example.org/start>  "216.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Shelley and Parnes, 1965)" .
    
    <http://covid19.aksw.org/text-85d317d9adb88c5e2078cc794f8a40830c8d6f6f93d1e406a652af2800fd9d04>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in red cell mass with concurrent increases in reticulocyte counts (reticulocytosis) indicate a regenerative erythroid response by the bone marrow, or by extramedullary hematopoiesis in the spleen of rodents. An increase in reticulocyte count is typically first observed 3-4 days after an acute drop in red cell mass due to bone marrow erythrocyte production and transit time, and peak responses generally occur around 7-14 days depending on the species (Stockham and Scott, 2008b) . The regenerative erythroid response is considered appropriate if the increases in reticulocyte counts reflect the magnitude of the decreases in red cell mass; in other words, a mild decrease in red cell mass is expected to result in a mild increase in reticulocyte count, while a moderate to marked decrease in red cell mass should have a concurrent moderate to marked increase in reticulocyte count. The regenerative erythroid response is considered inappropriate if there is an inconsistency between the magnitude of the decrease in red cell mass and the magnitude of the increase in reticulocyte count. For example, a marked decrease in red cell mass with only a mild increase in reticulocyte count a week after the insult would be considered an inappropriate regenerative erythroid response.\",\"cite_spans\":[{\"start\":463.0,\"end\":490.0,\"text\":\"(Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"}],\"ref_spans\":[],\"section\":\"Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-85d317d9adb88c5e2078cc794f8a40830c8d6f6f93d1e406a652af2800fd9d04_citespan-463-490> ;
            <http://www.example.org/section>
                    "Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)" ;
            <http://www.example.org/text>  "Decreases in red cell mass with concurrent increases in reticulocyte counts (reticulocytosis) indicate a regenerative erythroid response by the bone marrow, or by extramedullary hematopoiesis in the spleen of rodents. An increase in reticulocyte count is typically first observed 3-4 days after an acute drop in red cell mass due to bone marrow erythrocyte production and transit time, and peak responses generally occur around 7-14 days depending on the species (Stockham and Scott, 2008b) . The regenerative erythroid response is considered appropriate if the increases in reticulocyte counts reflect the magnitude of the decreases in red cell mass; in other words, a mild decrease in red cell mass is expected to result in a mild increase in reticulocyte count, while a moderate to marked decrease in red cell mass should have a concurrent moderate to marked increase in reticulocyte count. The regenerative erythroid response is considered inappropriate if there is an inconsistency between the magnitude of the decrease in red cell mass and the magnitude of the increase in reticulocyte count. For example, a marked decrease in red cell mass with only a mild increase in reticulocyte count a week after the insult would be considered an inappropriate regenerative erythroid response." ;
            <http://www.example.org/textHash>
                    "85d317d9adb88c5e2078cc794f8a40830c8d6f6f93d1e406a652af2800fd9d04" .
    
    <http://covid19.aksw.org/text-c670f2de35ba9759a8a122d329789d668719649a30d3b1c14343e4ad704efd2a_citespan-226-246>
            <http://www.example.org/end>    "246.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "226.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016)" .
    
    <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6_citespan-395-421>
            <http://www.example.org/end>    "421.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "395.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-72cdd5f94494b2a9146ad2ed2793e599c748523abfad265e2a0a6c42abddf0c1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Some chemical agents may cause oxidative damage by directly oxidizing hemoglobin sulfhydryl groups or through direct oxidation of erythrocyte cytoskeletal proteins. Arsine gas, predominantly an environmental toxin, appears to mediate its hemolytic effects through erythrocyte membrane oxidation (Rael et al., 2000) , although studies in mice have also demonstrated the formation of Heinz bodies following exposure (Blair et al., 1990) , suggesting an oxidative effect on hemoglobin as well.\",\"cite_spans\":[{\"start\":295.0,\"end\":314.0,\"text\":\"(Rael et al., 2000)\",\"ref_id\":\"BIBREF309\"},{\"start\":414.0,\"end\":434.0,\"text\":\"(Blair et al., 1990)\",\"ref_id\":\"BIBREF32\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-72cdd5f94494b2a9146ad2ed2793e599c748523abfad265e2a0a6c42abddf0c1_citespan-295-314> , <http://covid19.aksw.org/text-72cdd5f94494b2a9146ad2ed2793e599c748523abfad265e2a0a6c42abddf0c1_citespan-414-434> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Some chemical agents may cause oxidative damage by directly oxidizing hemoglobin sulfhydryl groups or through direct oxidation of erythrocyte cytoskeletal proteins. Arsine gas, predominantly an environmental toxin, appears to mediate its hemolytic effects through erythrocyte membrane oxidation (Rael et al., 2000) , although studies in mice have also demonstrated the formation of Heinz bodies following exposure (Blair et al., 1990) , suggesting an oxidative effect on hemoglobin as well." ;
            <http://www.example.org/textHash>
                    "72cdd5f94494b2a9146ad2ed2793e599c748523abfad265e2a0a6c42abddf0c1" .
    
    <http://covid19.aksw.org/text-d6c5467de186713eaeeff06111e2cd5f0d0b688570bba87110dfd6d9f4905072>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Administration of exogenous catecholamines, such as epinephrine, or adrenergic agonists has similar effects on blood lymphocyte counts as those mediated by endogenous catecholamines. Rapid shifting of lymphocytes from marginating to circulating blood pools as well as mobilization of lymphocytes from the spleen contributes to the increases in lymphocyte counts. Lymphocytes appear to have their adrenergic effects primarily mediated by b 2 -adrenergic receptors (Benschop et al., 1996) .\",\"cite_spans\":[{\"start\":463.0,\"end\":486.0,\"text\":\"(Benschop et al., 1996)\",\"ref_id\":\"BIBREF25\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d6c5467de186713eaeeff06111e2cd5f0d0b688570bba87110dfd6d9f4905072_citespan-463-486> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Administration of exogenous catecholamines, such as epinephrine, or adrenergic agonists has similar effects on blood lymphocyte counts as those mediated by endogenous catecholamines. Rapid shifting of lymphocytes from marginating to circulating blood pools as well as mobilization of lymphocytes from the spleen contributes to the increases in lymphocyte counts. Lymphocytes appear to have their adrenergic effects primarily mediated by b 2 -adrenergic receptors (Benschop et al., 1996) ." ;
            <http://www.example.org/textHash>
                    "d6c5467de186713eaeeff06111e2cd5f0d0b688570bba87110dfd6d9f4905072" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-3195-3218>
            <http://www.example.org/end>    "3218.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF246" ;
            <http://www.example.org/start>  "3195.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Marquardt et al., 1999;" .
    
    <http://covid19.aksw.org/text-f23698ecbd95281fa1e771d4eaf843a3543fc8fb9ff291e1b0919dfca098e98b_citespan-228-252>
            <http://www.example.org/end>    "252.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF370" ;
            <http://www.example.org/start>  "228.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stoltzfus et al., 1997)" .
    
    <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-139-166>
            <http://www.example.org/end>    "166.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "139.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Decreases in red cell mass with increases in reticulocyte counts from erythrocyte fragmentation may also occur secondary to cardiac or other conditions that alter hemodynamics and increase turbulent blood flow. For example, subaortic stenosis (Solanki and Sheikh, 1978) , intraluminal aortic grafts (Sayar et al., 2006) , uncorrected cardiac valvular disease (Marsh and Lewis, 1969) , prosthetic valves (Crexells et al., 1972) , and hypertrophic obstructive cardiomyopathy (Kubo et al., 2010) have all been reported to cause hemolysis from erythrocyte fragmentation. Increased turbulence associated with hypertension may also cause decreases in red cell mass from fragmentation, and has been associated with pulmonary hypertension (Baker and Moake, 2016) and malignant systemic hypertension (Capelli et al., 1966) .\",\"cite_spans\":[{\"start\":243.0,\"end\":269.0,\"text\":\"(Solanki and Sheikh, 1978)\",\"ref_id\":\"BIBREF361\"},{\"start\":299.0,\"end\":319.0,\"text\":\"(Sayar et al., 2006)\",\"ref_id\":\"BIBREF339\"},{\"start\":359.0,\"end\":382.0,\"text\":\"(Marsh and Lewis, 1969)\",\"ref_id\":\"BIBREF247\"},{\"start\":403.0,\"end\":426.0,\"text\":\"(Crexells et al., 1972)\",\"ref_id\":\"BIBREF78\"},{\"start\":473.0,\"end\":492.0,\"text\":\"(Kubo et al., 2010)\",\"ref_id\":\"BIBREF208\"},{\"start\":731.0,\"end\":754.0,\"text\":\"(Baker and Moake, 2016)\",\"ref_id\":\"BIBREF15\"},{\"start\":791.0,\"end\":813.0,\"text\":\"(Capelli et al., 1966)\",\"ref_id\":\"BIBREF56\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-473-492> , <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-731-754> , <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-791-813> , <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-243-269> , <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-403-426> , <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-359-382> , <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-299-319> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Decreases in red cell mass with increases in reticulocyte counts from erythrocyte fragmentation may also occur secondary to cardiac or other conditions that alter hemodynamics and increase turbulent blood flow. For example, subaortic stenosis (Solanki and Sheikh, 1978) , intraluminal aortic grafts (Sayar et al., 2006) , uncorrected cardiac valvular disease (Marsh and Lewis, 1969) , prosthetic valves (Crexells et al., 1972) , and hypertrophic obstructive cardiomyopathy (Kubo et al., 2010) have all been reported to cause hemolysis from erythrocyte fragmentation. Increased turbulence associated with hypertension may also cause decreases in red cell mass from fragmentation, and has been associated with pulmonary hypertension (Baker and Moake, 2016) and malignant systemic hypertension (Capelli et al., 1966) ." ;
            <http://www.example.org/textHash>
                    "31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca" .
    
    <http://covid19.aksw.org/text-743a792f7630acee9819c0a354a3214d5ae436ce038edd0aeda874ceaebf3e4b_citespan-300-322>
            <http://www.example.org/end>    "322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF132" ;
            <http://www.example.org/start>  "300.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gardner et al., 1968)" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1334-1359>
            <http://www.example.org/end>    "1359.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF44" ;
            <http://www.example.org/start>  "1334.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Breen and Modiano, 2008;" .
    
    <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Similar to other granulocytes, eosinophils are distributed into proliferating and maturing pools in the bone marrow, and into circulating and marginating pools in the blood. The bone marrow is the primary site of eosinophil production, although rat eosinophils migrate and complete their maturation in the spleen (Young and Meadows, 2010) . Early proliferating bone marrow eosinophils are usually indistinguishable microscopically from other early myeloid precursors because their characteristic granules do not begin to form until the late promyelocyte stage (Radin and Wellman, 2010) . The time for production of mature eosinophils from the myeloblast stage is 2-6 days and the half-life of mature eosinophils in circulation ranges from less than 1 to 24 h, although both of these transit times vary by species (Young and Meadows, 2010) . Eosinophils migrate into tissue from circulation, where they live for about 2 days unless stimulation occurs (Young and Meadows, 2010) .\",\"cite_spans\":[{\"start\":313.0,\"end\":338.0,\"text\":\"(Young and Meadows, 2010)\",\"ref_id\":\"BIBREF438\"},{\"start\":560.0,\"end\":585.0,\"text\":\"(Radin and Wellman, 2010)\",\"ref_id\":\"BIBREF307\"},{\"start\":813.0,\"end\":838.0,\"text\":\"(Young and Meadows, 2010)\",\"ref_id\":\"BIBREF438\"},{\"start\":950.0,\"end\":975.0,\"text\":\"(Young and Meadows, 2010)\",\"ref_id\":\"BIBREF438\"}],\"ref_spans\":[],\"section\":\"Eosinophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-313-338> , <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-560-585> , <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-813-838> , <http://covid19.aksw.org/text-23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29_citespan-950-975> ;
            <http://www.example.org/section>
                    "Eosinophils" ;
            <http://www.example.org/text>  "Similar to other granulocytes, eosinophils are distributed into proliferating and maturing pools in the bone marrow, and into circulating and marginating pools in the blood. The bone marrow is the primary site of eosinophil production, although rat eosinophils migrate and complete their maturation in the spleen (Young and Meadows, 2010) . Early proliferating bone marrow eosinophils are usually indistinguishable microscopically from other early myeloid precursors because their characteristic granules do not begin to form until the late promyelocyte stage (Radin and Wellman, 2010) . The time for production of mature eosinophils from the myeloblast stage is 2-6 days and the half-life of mature eosinophils in circulation ranges from less than 1 to 24 h, although both of these transit times vary by species (Young and Meadows, 2010) . Eosinophils migrate into tissue from circulation, where they live for about 2 days unless stimulation occurs (Young and Meadows, 2010) ." ;
            <http://www.example.org/textHash>
                    "23b877199cefef48e3dfbb474d4b7d4dc22470168d4c7c599518358bb0491f29" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-214-233>
            <http://www.example.org/end>    "233.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF422" ;
            <http://www.example.org/start>  "214.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ways et al., 1961)" .
    
    <http://covid19.aksw.org/text-a9e3de87a343d2d7bbc238095e20193fb4ff0f3b9bbbfcefc7ae59563d97aa41_citespan-219-253>
            <http://www.example.org/end>    "253.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF305" ;
            <http://www.example.org/start>  "219.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Provencher Bolliger et al., 2010)" .
    
    <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The magnitude of reticulocyte count increases generally reflects the magnitude of red cell mass decreases; all decreases in red cell mass are initially preregenerative without apparent increases in reticulocyte counts. b When overwhelming intravascular hemolysis causes increases in plasma or serum free hemoglobin, MCHC may be artifactually increased, but MCHC is more commonly decreased due to increases in reticulocyte counts. c Increases in plasma or serum free hemoglobin are only expected to occur with overwhelming intravascular hemolysis. d Chronic iron deficiency anemia is typically nonregenerative with decreases in reticulocyte counts, but increases in reticulocyte counts may be observed following transfusion or iron supplementation. Patterns described in this table indicate classic or expected changes in red blood cell components and associated endpoints due to these processes. However, duration of these processes, variations in the underlying causes of these conditions, and superimposition of multiple processes may result in differences between expected patterns of leukocyte changes and actual changes observed in an individual. appropriate increase in erythropoiesis and subsequent increase in red cell mass, which should improve delivery of oxygen to tissues. Sustained tissue hypoxia can result from high altitude residence, cardiac disease causing poor tissue or lung perfusion, or prolonged or chronic pulmonary diseases that impair oxygenation, such as COPD secondary to chronic smoking or obstructive sleep apnea in humans (Prchal, 2016; Stockham and Scott, 2008b) . Other conditions that may cause hypoxia-induced increases in red cell mass include mutations leading to hemoglobin with high affinity for oxygen, carboxyhemoglobin formation with heavy smoking, and erythrocyte enzyme deficiencies leading to methemoglobinemia, such as cytochrome b 5 reductase deficiency may also result in hypoxia-induced increases in red cell mass (Prchal, 2016) . Erythrocyte enzyme deficiencies resulting in methemoglobinemia have been reported in veterinary species (Stockham and Scott, 2008b ), but hemoglobinopathies, conditions characterized by abnormal hemoglobin, have not yet been reported in domestic animals (Randolph et al., 2010) .\",\"cite_spans\":[{\"start\":1553.0,\"end\":1567.0,\"text\":\"(Prchal, 2016;\",\"ref_id\":\"BIBREF302\"},{\"start\":1568.0,\"end\":1594.0,\"text\":\"Stockham and Scott, 2008b)\",\"ref_id\":\"BIBREF367\"},{\"start\":1963.0,\"end\":1977.0,\"text\":\"(Prchal, 2016)\",\"ref_id\":\"BIBREF302\"},{\"start\":2084.0,\"end\":2110.0,\"text\":\"(Stockham and Scott, 2008b\",\"ref_id\":\"BIBREF367\"},{\"start\":2234.0,\"end\":2257.0,\"text\":\"(Randolph et al., 2010)\",\"ref_id\":\"BIBREF313\"}],\"ref_spans\":[],\"section\":\"Secondary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-1553-1567> , <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-1568-1594> , <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-1963-1977> , <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-2084-2110> , <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-2234-2257> ;
            <http://www.example.org/section>
                    "Secondary increases in red cell mass" ;
            <http://www.example.org/text>  "The magnitude of reticulocyte count increases generally reflects the magnitude of red cell mass decreases; all decreases in red cell mass are initially preregenerative without apparent increases in reticulocyte counts. b When overwhelming intravascular hemolysis causes increases in plasma or serum free hemoglobin, MCHC may be artifactually increased, but MCHC is more commonly decreased due to increases in reticulocyte counts. c Increases in plasma or serum free hemoglobin are only expected to occur with overwhelming intravascular hemolysis. d Chronic iron deficiency anemia is typically nonregenerative with decreases in reticulocyte counts, but increases in reticulocyte counts may be observed following transfusion or iron supplementation. Patterns described in this table indicate classic or expected changes in red blood cell components and associated endpoints due to these processes. However, duration of these processes, variations in the underlying causes of these conditions, and superimposition of multiple processes may result in differences between expected patterns of leukocyte changes and actual changes observed in an individual. appropriate increase in erythropoiesis and subsequent increase in red cell mass, which should improve delivery of oxygen to tissues. Sustained tissue hypoxia can result from high altitude residence, cardiac disease causing poor tissue or lung perfusion, or prolonged or chronic pulmonary diseases that impair oxygenation, such as COPD secondary to chronic smoking or obstructive sleep apnea in humans (Prchal, 2016; Stockham and Scott, 2008b) . Other conditions that may cause hypoxia-induced increases in red cell mass include mutations leading to hemoglobin with high affinity for oxygen, carboxyhemoglobin formation with heavy smoking, and erythrocyte enzyme deficiencies leading to methemoglobinemia, such as cytochrome b 5 reductase deficiency may also result in hypoxia-induced increases in red cell mass (Prchal, 2016) . Erythrocyte enzyme deficiencies resulting in methemoglobinemia have been reported in veterinary species (Stockham and Scott, 2008b ), but hemoglobinopathies, conditions characterized by abnormal hemoglobin, have not yet been reported in domestic animals (Randolph et al., 2010) ." ;
            <http://www.example.org/textHash>
                    "bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a" .
    
    <http://covid19.aksw.org/text-91f8b095c96b32185d2a13c5a1a90c9604caf1ea299cb41f8ee9c638edc8d64b_citespan-346-361>
            <http://www.example.org/end>    "361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF283" ;
            <http://www.example.org/start>  "346.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Packman, 2016)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-720-736>
            <http://www.example.org/end>    "736.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF430" ;
            <http://www.example.org/start>  "720.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Whitehead, 2006;" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-322-348>
            <http://www.example.org/end>    "348.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "322.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-464-489>
            <http://www.example.org/end>    "489.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF45" ;
            <http://www.example.org/start>  "464.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Brown and Rosalsky, 1984;" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-299-319>
            <http://www.example.org/end>    "319.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF339" ;
            <http://www.example.org/start>  "299.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sayar et al., 2006)" .
    
    <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265_citespan-724-746>
            <http://www.example.org/end>    "746.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "724.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Beer and Green, 2016)" .
    
    <http://covid19.aksw.org/text-97437d25fdc1f555b92e0d94ecfe324afc8334e48c0dbf16441695695f9c14e1_citespan-587-604>
            <http://www.example.org/end>    "604.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF315" ;
            <http://www.example.org/start>  "587.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Rao et al., 1994)" .
    
    <http://covid19.aksw.org/text-1e01bf37db763eb9e0a053203524850784e461670740d9429ebdd1c979a19777_citespan-664-679>
            <http://www.example.org/end>    "679.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-e9653eb1397ad6bb4a3c171715d607aa7fad463f3c5fbc78856b1824376a2a93_citespan-1158-1181>
            <http://www.example.org/end>    "1181.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF353" ;
            <http://www.example.org/start>  "1158.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Shiozaki et al., 2000;" .
    
    <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-111-133>
            <http://www.example.org/end>    "133.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF383" ;
            <http://www.example.org/start>  "111.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tefferi et al., 2006)" .
    
    <http://covid19.aksw.org/text-7c9a2ad374b583524a0e192fb16a836d4b53ccb3f296fca8afdfe90c126f659a_citespan-1493-1520>
            <http://www.example.org/end>    "1520.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "1493.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1080-1101>
            <http://www.example.org/end>    "1101.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF52" ;
            <http://www.example.org/start>  "1080.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Caldin et al., 2005;" .
    
    <http://covid19.aksw.org/text-118e7235e832c7d436341e19161d1246d6d10634a8d900af5c6ada580cbd116c_citespan-900-920>
            <http://www.example.org/end>    "920.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "900.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schwartzberg, 2006)" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.3.2.1.2.3 Xenobiotic-induced Xenobiotic-induced blood loss is relatively uncommon but can occur. Classically, hemorrhage into the intestinal tract can result from ulceration associated with chronic NSAID or coxib administration (Laine et al., 2003; Langman et al., 1999; Bjarnason et al., 1987) . Also, prolonged or high dose administration of anticoagulants, such as warfarin or heparin, can result in hemorrhage-related decreases in red cell mass (Levine et al., 2001) . Ingestion of rodenticides, including brodifacoum chlorophacinone, has been reported to cause marked hemorrhage in humans and many other nonrodent species (Berny et al., 2010; Palmer et al., 1999; Sheafor and Couto, 1999) .\",\"cite_spans\":[{\"start\":234.0,\"end\":254.0,\"text\":\"(Laine et al., 2003;\",\"ref_id\":\"BIBREF212\"},{\"start\":255.0,\"end\":276.0,\"text\":\"Langman et al., 1999;\",\"ref_id\":\"BIBREF214\"},{\"start\":277.0,\"end\":300.0,\"text\":\"Bjarnason et al., 1987)\",\"ref_id\":\"BIBREF31\"},{\"start\":455.0,\"end\":476.0,\"text\":\"(Levine et al., 2001)\",\"ref_id\":\"BIBREF222\"},{\"start\":633.0,\"end\":653.0,\"text\":\"(Berny et al., 2010;\",\"ref_id\":\"BIBREF27\"},{\"start\":654.0,\"end\":674.0,\"text\":\"Palmer et al., 1999;\",\"ref_id\":\"BIBREF285\"},{\"start\":675.0,\"end\":699.0,\"text\":\"Sheafor and Couto, 1999)\",\"ref_id\":\"BIBREF349\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-234-254> , <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-633-653> , <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-654-674> , <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-277-300> , <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-255-276> , <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-455-476> , <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-675-699> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "12.11.3.2.1.2.3 Xenobiotic-induced Xenobiotic-induced blood loss is relatively uncommon but can occur. Classically, hemorrhage into the intestinal tract can result from ulceration associated with chronic NSAID or coxib administration (Laine et al., 2003; Langman et al., 1999; Bjarnason et al., 1987) . Also, prolonged or high dose administration of anticoagulants, such as warfarin or heparin, can result in hemorrhage-related decreases in red cell mass (Levine et al., 2001) . Ingestion of rodenticides, including brodifacoum chlorophacinone, has been reported to cause marked hemorrhage in humans and many other nonrodent species (Berny et al., 2010; Palmer et al., 1999; Sheafor and Couto, 1999) ." ;
            <http://www.example.org/textHash>
                    "91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d" .
    
    <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-1120-1146>
            <http://www.example.org/end>    "1146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "1120.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Immune-mediated destruction of lymphocytes is uncommon. When occurring in the autoimmune disease SLE, such immunemediated decreases in lymphocyte counts typically occur with concurrent cutaneous, arthritic, or neurologic disorders (Stone, 2005) , and may be the result of autoantibodies causing lymphocyte destruction or death through apoptosis (Lu et al., 2012; Massardo et al., 2009; Noguchi et al., 1992; Budman and Steinberg, 1977) .\",\"cite_spans\":[{\"start\":231.0,\"end\":244.0,\"text\":\"(Stone, 2005)\",\"ref_id\":\"BIBREF371\"},{\"start\":345.0,\"end\":362.0,\"text\":\"(Lu et al., 2012;\",\"ref_id\":\"BIBREF237\"},{\"start\":363.0,\"end\":385.0,\"text\":\"Massardo et al., 2009;\",\"ref_id\":\"BIBREF251\"},{\"start\":386.0,\"end\":407.0,\"text\":\"Noguchi et al., 1992;\",\"ref_id\":\"BIBREF274\"},{\"start\":408.0,\"end\":435.0,\"text\":\"Budman and Steinberg, 1977)\",\"ref_id\":\"BIBREF47\"}],\"ref_spans\":[],\"section\":\"Immune-mediated\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-231-244> , <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-345-362> , <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-363-385> , <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-386-407> , <http://covid19.aksw.org/text-8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56_citespan-408-435> ;
            <http://www.example.org/section>
                    "Immune-mediated" ;
            <http://www.example.org/text>  "Immune-mediated destruction of lymphocytes is uncommon. When occurring in the autoimmune disease SLE, such immunemediated decreases in lymphocyte counts typically occur with concurrent cutaneous, arthritic, or neurologic disorders (Stone, 2005) , and may be the result of autoantibodies causing lymphocyte destruction or death through apoptosis (Lu et al., 2012; Massardo et al., 2009; Noguchi et al., 1992; Budman and Steinberg, 1977) ." ;
            <http://www.example.org/textHash>
                    "8c51e017d6eec0ad48279ee8f621264694a192aa382120da1a83b266408f7d56" .
    
    <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-228-253>
            <http://www.example.org/end>    "253.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF292" ;
            <http://www.example.org/start>  "228.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Patkó and Szebeni, 2015)" .
    
    <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Primary thrombocythemia has been associated with marked increases in platelet counts, but bone marrow megakaryoblasts are \\u003c 30% in contrast to acute megakaryoblastic leukemia. Evidence of platelet dysplasia may be observed on microscopic evaluation of blood smears; these morphologic changes may include hypogranular platelets, large platelets associated with an increase in mean platelet volume (MPV), or pleomorphic platelets (Stockham and Scott, 2008c) . Similar to polycythemia vera, primary thrombocythemia has been associated with activating mutations in JAK2 (Levine et al., 2005) . However, primary thrombocythemia may also be associated with mutations in the TPO receptor gene, MPL, and the calreticulin gene, CALR (Beer and Green, 2016) .\",\"cite_spans\":[{\"start\":428.0,\"end\":455.0,\"text\":\"(Stockham and Scott, 2008c)\",\"ref_id\":\"BIBREF368\"},{\"start\":566.0,\"end\":587.0,\"text\":\"(Levine et al., 2005)\",\"ref_id\":\"BIBREF223\"},{\"start\":724.0,\"end\":746.0,\"text\":\"(Beer and Green, 2016)\",\"ref_id\":\"BIBREF22\"}],\"ref_spans\":[],\"section\":\"Neoplastic\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265_citespan-428-455> , <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265_citespan-566-587> , <http://covid19.aksw.org/text-a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265_citespan-724-746> ;
            <http://www.example.org/section>
                    "Neoplastic" ;
            <http://www.example.org/text>  "Primary thrombocythemia has been associated with marked increases in platelet counts, but bone marrow megakaryoblasts are < 30% in contrast to acute megakaryoblastic leukemia. Evidence of platelet dysplasia may be observed on microscopic evaluation of blood smears; these morphologic changes may include hypogranular platelets, large platelets associated with an increase in mean platelet volume (MPV), or pleomorphic platelets (Stockham and Scott, 2008c) . Similar to polycythemia vera, primary thrombocythemia has been associated with activating mutations in JAK2 (Levine et al., 2005) . However, primary thrombocythemia may also be associated with mutations in the TPO receptor gene, MPL, and the calreticulin gene, CALR (Beer and Green, 2016) ." ;
            <http://www.example.org/textHash>
                    "a2c52ac897a5b9abd15940aedde047f3a5fcf9bc9edc84da7934b32171718265" .
    
    <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f_citespan-105-120>
            <http://www.example.org/end>    "120.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF187" ;
            <http://www.example.org/start>  "105.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Juhlin, 1963a)" .
    
    <http://covid19.aksw.org/text-d69ac5545f3ae53077f5ea9def1e59a90a072ac98609f272d6c236dc8f38d877_citespan-633-660>
            <http://www.example.org/end>    "660.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "633.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stump and VandeWoude, 2007)" .
    
    <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1369-1386>
            <http://www.example.org/end>    "1386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF310" ;
            <http://www.example.org/start>  "1369.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Rai et al., 2008;" .
    
    <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-426-443>
            <http://www.example.org/end>    "443.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF226" ;
            <http://www.example.org/start>  "426.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016b;" .
    
    <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-653-676>
            <http://www.example.org/end>    "676.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF266" ;
            <http://www.example.org/start>  "653.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moriyama et al., 2008;" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-516-537>
            <http://www.example.org/end>    "537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF319" ;
            <http://www.example.org/start>  "516.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Rigolin et al., 1997;" .
    
    <http://covid19.aksw.org/text-5237224400cd2ce54fc24f9080b902cf1695da1768a2bc1d60729297c56a74dd_citespan-217-240>
            <http://www.example.org/end>    "240.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF313" ;
            <http://www.example.org/start>  "217.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Randolph et al., 2010)" .
    
    <http://covid19.aksw.org/text-7e4245889eca7d2305014b6f72e9ad42294667943908f43220188eb83d61f5f0_citespan-332-354>
            <http://www.example.org/end>    "354.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF378" ;
            <http://www.example.org/start>  "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Talcott et al., 1992;" .
    
    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-550-571>
            <http://www.example.org/end>    "571.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF281" ;
            <http://www.example.org/start>  "550.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Otsuka et al., 1986)" .
    
    <http://covid19.aksw.org/text-e3a112bdb49047db7a86986a36f992726d939059c9a0b906de643daca538bd0a_citespan-613-632>
            <http://www.example.org/end>    "632.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF170" ;
            <http://www.example.org/start>  "613.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Hines et al., 1968;" .
    
    <http://covid19.aksw.org/text-6dd5537069b8854c335ec3440a29c10041c325c7abdd9377cc118bf6718f9009_citespan-518-547>
            <http://www.example.org/end>    "547.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF138" ;
            <http://www.example.org/start>  "518.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Geddis and Kaushansky, 2003)" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1768-1784>
            <http://www.example.org/end>    "1784.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "1768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Nonimmune-mediated decreases in neutrophil counts may be observed with bone marrow suppression, which is associated with many xenobiotics, particularly chemotherapeutic agents. Chemotherapeutic-related decreases in neutrophil counts are often a result of direct cytotoxicity or suppressed proliferation of the rapidly dividing granulocytic precursors in the bone marrow. Examples of chemotherapeutic classes associated with decreased blood neutrophil counts include agents that cause direct DNA damage, such as platinum-containing agents (e.g., cisplatin, carboplatin) and classical alkylating agents (e.g., cyclophosphamide, melphalan, busulfan); mitotic spindle inhibitors (e.g., paclitaxel, docetaxel, vinblastine, vincristine); topoisomerase inhibitors (e.g., etoposide, doxorubicin); and antimetabolites (e.g., methotrexate, 6-mercaptopurine, 5-fluorouracil) (Bhatt and Saleem, 2004; Weiss, 2010; Wailoo et al., 2009) . Decreases in neutrophil counts are expected with chemotherapeutic treatment, and can be easily monitored through serial CBCs. If severe enough to increase the risk of life-threatening infections clinically, treatment with empiric antibiotics or G-CSF-like compounds may be considered.\",\"cite_spans\":[{\"start\":864.0,\"end\":888.0,\"text\":\"(Bhatt and Saleem, 2004;\",\"ref_id\":\"BIBREF29\"},{\"start\":889.0,\"end\":901.0,\"text\":\"Weiss, 2010;\",\"ref_id\":\"BIBREF428\"},{\"start\":902.0,\"end\":922.0,\"text\":\"Wailoo et al., 2009)\",\"ref_id\":\"BIBREF413\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf_citespan-864-888> , <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf_citespan-889-901> , <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf_citespan-902-922> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Nonimmune-mediated decreases in neutrophil counts may be observed with bone marrow suppression, which is associated with many xenobiotics, particularly chemotherapeutic agents. Chemotherapeutic-related decreases in neutrophil counts are often a result of direct cytotoxicity or suppressed proliferation of the rapidly dividing granulocytic precursors in the bone marrow. Examples of chemotherapeutic classes associated with decreased blood neutrophil counts include agents that cause direct DNA damage, such as platinum-containing agents (e.g., cisplatin, carboplatin) and classical alkylating agents (e.g., cyclophosphamide, melphalan, busulfan); mitotic spindle inhibitors (e.g., paclitaxel, docetaxel, vinblastine, vincristine); topoisomerase inhibitors (e.g., etoposide, doxorubicin); and antimetabolites (e.g., methotrexate, 6-mercaptopurine, 5-fluorouracil) (Bhatt and Saleem, 2004; Weiss, 2010; Wailoo et al., 2009) . Decreases in neutrophil counts are expected with chemotherapeutic treatment, and can be easily monitored through serial CBCs. If severe enough to increase the risk of life-threatening infections clinically, treatment with empiric antibiotics or G-CSF-like compounds may be considered." ;
            <http://www.example.org/textHash>
                    "5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf" .
    
    <http://covid19.aksw.org/text-d3bdd73863d7f4816bb77573a61ef70c66182608850c44703f41e05118198faa_citespan-907-920>
            <http://www.example.org/end>    "920.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF427" ;
            <http://www.example.org/start>  "907.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Weiss, 2008)" .
    
    <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-667-681>
            <http://www.example.org/end>    "681.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF255" ;
            <http://www.example.org/start>  "667.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(McEwen, 1992)" .
    
    <http://covid19.aksw.org/text-44e5305a92acd0b2f8c470d071bc3b59ca64a12d13ca4aeb540f61059fc63239_citespan-1557-1578>
            <http://www.example.org/end>    "1578.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF119" ;
            <http://www.example.org/start>  "1557.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Focosi et al., 2009)" .
    
    <http://covid19.aksw.org/text-42a0fe35af7c1006430f3aa4bbdf5dbcbf20be5c0c63a5f60001f23a214a38c2_citespan-1391-1416>
            <http://www.example.org/end>    "1416.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "1391.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Arepally and Ortel, 2006)" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-463-481>
            <http://www.example.org/end>    "481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF296" ;
            <http://www.example.org/start>  "463.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Petz et al., 1966)" .
    
    <http://covid19.aksw.org/text-9f0e0005a91e30bf4f7b2aff2b3613e745dc5598152597f98fc91563184fa2c2_citespan-638-662>
            <http://www.example.org/end>    "662.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "638.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Aster and Bougie, 2007)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1464-1485>
            <http://www.example.org/end>    "1485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF278" ;
            <http://www.example.org/start>  "1464.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ogilvie et al., 1980)" .
    
    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in IL-6 may occur as the result of inflammatory or immune stimulation of myriad etiologies, but may also increase as part of a paraneoplastic syndrome in association with malignant neoplasia of nonhemic origin, including renal cell carcinoma, ovarian neoplasia, primary lung cancer, and gastrointestinal neoplasia (Blay et al., 1993; Stone et al., 2012; Yanagawa et al., 1995; Kabir et al., 1995; Lin et al., 2014) . Increased IL-6 concentrations have been demonstrated to increase liver production of TPO (Kaser et al., 2001) , which stimulates thrombopoiesis with consequent increases in blood platelet counts.\",\"cite_spans\":[{\"start\":324.0,\"end\":343.0,\"text\":\"(Blay et al., 1993;\",\"ref_id\":\"BIBREF33\"},{\"start\":344.0,\"end\":363.0,\"text\":\"Stone et al., 2012;\",\"ref_id\":\"BIBREF372\"},{\"start\":364.0,\"end\":386.0,\"text\":\"Yanagawa et al., 1995;\",\"ref_id\":\"BIBREF436\"},{\"start\":387.0,\"end\":406.0,\"text\":\"Kabir et al., 1995;\",\"ref_id\":\"BIBREF192\"},{\"start\":407.0,\"end\":424.0,\"text\":\"Lin et al., 2014)\",\"ref_id\":\"BIBREF230\"},{\"start\":516.0,\"end\":536.0,\"text\":\"(Kaser et al., 2001)\",\"ref_id\":\"BIBREF197\"}],\"ref_spans\":[],\"section\":\"Inflammation or reactive\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-344-363> , <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-387-406> , <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-324-343> , <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-516-536> , <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-364-386> , <http://covid19.aksw.org/text-c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26_citespan-407-424> ;
            <http://www.example.org/section>
                    "Inflammation or reactive" ;
            <http://www.example.org/text>  "Increases in IL-6 may occur as the result of inflammatory or immune stimulation of myriad etiologies, but may also increase as part of a paraneoplastic syndrome in association with malignant neoplasia of nonhemic origin, including renal cell carcinoma, ovarian neoplasia, primary lung cancer, and gastrointestinal neoplasia (Blay et al., 1993; Stone et al., 2012; Yanagawa et al., 1995; Kabir et al., 1995; Lin et al., 2014) . Increased IL-6 concentrations have been demonstrated to increase liver production of TPO (Kaser et al., 2001) , which stimulates thrombopoiesis with consequent increases in blood platelet counts." ;
            <http://www.example.org/textHash>
                    "c6bca05cc934062c179bd3a9982bb2e4a7e584360776b72860f53c7d5bcf8b26" .
    
    <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3_citespan-361-378>
            <http://www.example.org/end>    "378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF226" ;
            <http://www.example.org/start>  "361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Lichtman, 2016b;" .
    
    <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Numerous reactions to xenobiotics can also cause increases in blood eosinophil counts. Acute generalized exanthematous pustulosis due to drugs such as aminopenicillins and diltiazem, as discussed with xenobiotic-induced increases in neutrophil counts, may be associated with concurrent increases in eosinophil counts (Roujeau, 2005) . Drug reaction with eosinophilia and systemic syndromes (DRESS) is a predominantly cutaneous manifestation of a drug hypersensitivity reaction. Numerous compounds have been associated with DRESS, including several anticonvulsant drugs, such as phenobarbital and phenytoin, allopurinol, minocycline, sulfonamides, gold salts, dapsone, and spironolactone (Roujeau, 2005; Callot et al., 1996; Tefferi et al., 2006; Ghislain et al., 2004) .\",\"cite_spans\":[{\"start\":317.0,\"end\":332.0,\"text\":\"(Roujeau, 2005)\",\"ref_id\":\"BIBREF327\"},{\"start\":687.0,\"end\":702.0,\"text\":\"(Roujeau, 2005;\",\"ref_id\":\"BIBREF327\"},{\"start\":703.0,\"end\":723.0,\"text\":\"Callot et al., 1996;\",\"ref_id\":\"BIBREF53\"},{\"start\":724.0,\"end\":745.0,\"text\":\"Tefferi et al., 2006;\",\"ref_id\":\"BIBREF383\"},{\"start\":746.0,\"end\":768.0,\"text\":\"Ghislain et al., 2004)\",\"ref_id\":\"BIBREF143\"}],\"ref_spans\":[],\"section\":\"Spurious\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-317-332> , <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-687-702> , <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-703-723> , <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-724-745> , <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-746-768> ;
            <http://www.example.org/section>
                    "Spurious" ;
            <http://www.example.org/text>  "Numerous reactions to xenobiotics can also cause increases in blood eosinophil counts. Acute generalized exanthematous pustulosis due to drugs such as aminopenicillins and diltiazem, as discussed with xenobiotic-induced increases in neutrophil counts, may be associated with concurrent increases in eosinophil counts (Roujeau, 2005) . Drug reaction with eosinophilia and systemic syndromes (DRESS) is a predominantly cutaneous manifestation of a drug hypersensitivity reaction. Numerous compounds have been associated with DRESS, including several anticonvulsant drugs, such as phenobarbital and phenytoin, allopurinol, minocycline, sulfonamides, gold salts, dapsone, and spironolactone (Roujeau, 2005; Callot et al., 1996; Tefferi et al., 2006; Ghislain et al., 2004) ." ;
            <http://www.example.org/textHash>
                    "bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406" .
    
    <http://covid19.aksw.org/text-044ca5469cea26fd5c916c080e25704818b7c59650da5e77687ba71e3e36c70f_citespan-327-350>
            <http://www.example.org/end>    "350.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF391" ;
            <http://www.example.org/start>  "327.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tikkanen et al., 2001)" .
    
    <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.4.2.2 Glucocorticoid-induced Decreases in blood eosinophil counts are a classic feature of a glucocorticoid leukogram occurring in conjunction with decreases in lymphocyte counts and usually with increases in neutrophil counts. Blood eosinophils appear to be particularly responsive to the effects of glucocorticoids, and concurrent decreases in blood lymphocyte and eosinophil counts in common laboratory species used in nonclinical toxicology studies are a good indicator of stress (Hall, 2013) . Glucocorticoids cause shifts in blood eosinophils from the circulating to the marginating pool as well as decreased release of eosinophils from the bone marrow (McEwen, 1992) , and may also contribute to decreases in blood eosinophil counts from inhibition of prosurvival stimulation and direct induction of apoptosis (Druilhe et al., 2003; Wallen et al., 1991) .\",\"cite_spans\":[{\"start\":492.0,\"end\":504.0,\"text\":\"(Hall, 2013)\",\"ref_id\":\"BIBREF162\"},{\"start\":667.0,\"end\":681.0,\"text\":\"(McEwen, 1992)\",\"ref_id\":\"BIBREF255\"},{\"start\":825.0,\"end\":847.0,\"text\":\"(Druilhe et al., 2003;\",\"ref_id\":\"BIBREF96\"},{\"start\":848.0,\"end\":868.0,\"text\":\"Wallen et al., 1991)\",\"ref_id\":\"BIBREF416\"}],\"ref_spans\":[],\"section\":\"Decreases in eosinophil counts (eosinopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-492-504> , <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-667-681> , <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-825-847> , <http://covid19.aksw.org/text-0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2_citespan-848-868> ;
            <http://www.example.org/section>
                    "Decreases in eosinophil counts (eosinopenia)" ;
            <http://www.example.org/text>  "12.11.2.4.2.2 Glucocorticoid-induced Decreases in blood eosinophil counts are a classic feature of a glucocorticoid leukogram occurring in conjunction with decreases in lymphocyte counts and usually with increases in neutrophil counts. Blood eosinophils appear to be particularly responsive to the effects of glucocorticoids, and concurrent decreases in blood lymphocyte and eosinophil counts in common laboratory species used in nonclinical toxicology studies are a good indicator of stress (Hall, 2013) . Glucocorticoids cause shifts in blood eosinophils from the circulating to the marginating pool as well as decreased release of eosinophils from the bone marrow (McEwen, 1992) , and may also contribute to decreases in blood eosinophil counts from inhibition of prosurvival stimulation and direct induction of apoptosis (Druilhe et al., 2003; Wallen et al., 1991) ." ;
            <http://www.example.org/textHash>
                    "0d364765ea3e8811c7bd540ab09bd0cd4f2a99c16f3a25dfcf910194fe43e5a2" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-239-265>
            <http://www.example.org/end>    "265.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "239.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-db0018d084a412109046976e762d8bd72d3b15827baef1b606db381f6cd10665_citespan-1342-1368>
            <http://www.example.org/end>    "1368.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF406" ;
            <http://www.example.org/start>  "1342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Vasu and Caligiuri, 2016;" .
    
    <http://covid19.aksw.org/text-7638c46ced28b43f8526452094bc66c63ae9064ea8c32529ce25e5d7dbdbd9a3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.4.1.1 Catecholamine-induced Increases in circulating catecholamine concentrations, such as epinephrine, from fright or excitement can result in mobilization of platelets from the spleen into circulation, usually through splenic contraction. The increases in platelet counts from catecholamineinduced redistribution are generally transient and resolve with splenic relaxation and decreases in catecholamine concentrations back to basal levels. Strenuous exercise may also cause redistribution of splenic platelets due to a-adrenergic stimulation, resulting in increases in blood platelet counts (Chamberlain et al., 1990) .\",\"cite_spans\":[{\"start\":600.0,\"end\":626.0,\"text\":\"(Chamberlain et al., 1990)\",\"ref_id\":\"BIBREF62\"}],\"ref_spans\":[],\"section\":\"Increases in Platelet Counts (Thrombocytosis)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-7638c46ced28b43f8526452094bc66c63ae9064ea8c32529ce25e5d7dbdbd9a3_citespan-600-626> ;
            <http://www.example.org/section>
                    "Increases in Platelet Counts (Thrombocytosis)" ;
            <http://www.example.org/text>  "12.11.4.1.1 Catecholamine-induced Increases in circulating catecholamine concentrations, such as epinephrine, from fright or excitement can result in mobilization of platelets from the spleen into circulation, usually through splenic contraction. The increases in platelet counts from catecholamineinduced redistribution are generally transient and resolve with splenic relaxation and decreases in catecholamine concentrations back to basal levels. Strenuous exercise may also cause redistribution of splenic platelets due to a-adrenergic stimulation, resulting in increases in blood platelet counts (Chamberlain et al., 1990) ." ;
            <http://www.example.org/textHash>
                    "7638c46ced28b43f8526452094bc66c63ae9064ea8c32529ce25e5d7dbdbd9a3" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-642-668>
            <http://www.example.org/end>    "668.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF397" ;
            <http://www.example.org/start>  "642.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tuffs and Manoharan, 1986;" .
    
    <http://covid19.aksw.org/text-90ac45f860f25a15dbf58fed68779b8042742eacc9adc2acd017f5557abc7b4f_citespan-747-772>
            <http://www.example.org/end>    "772.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "747.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Boelsterli et al., 1983)" .
    
    <http://covid19.aksw.org/text-3811430106d3b33bdc10f9fe4a6c69213a615def0d58ae74df4c0a2047eb4f78>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Hyperthyroidism (thyrotoxicosis) is reported to cause decreases in blood basophil counts (Shelley and Parnes, 1965; Juhlin, 1963c) . However, the mechanism of this decrease has not been clearly demonstrated.\",\"cite_spans\":[{\"start\":89.0,\"end\":115.0,\"text\":\"(Shelley and Parnes, 1965;\",\"ref_id\":\"BIBREF352\"},{\"start\":116.0,\"end\":130.0,\"text\":\"Juhlin, 1963c)\",\"ref_id\":\"BIBREF189\"}],\"ref_spans\":[],\"section\":\"Endocrinopathy\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-3811430106d3b33bdc10f9fe4a6c69213a615def0d58ae74df4c0a2047eb4f78_citespan-89-115> , <http://covid19.aksw.org/text-3811430106d3b33bdc10f9fe4a6c69213a615def0d58ae74df4c0a2047eb4f78_citespan-116-130> ;
            <http://www.example.org/section>
                    "Endocrinopathy" ;
            <http://www.example.org/text>  "Hyperthyroidism (thyrotoxicosis) is reported to cause decreases in blood basophil counts (Shelley and Parnes, 1965; Juhlin, 1963c) . However, the mechanism of this decrease has not been clearly demonstrated." ;
            <http://www.example.org/textHash>
                    "3811430106d3b33bdc10f9fe4a6c69213a615def0d58ae74df4c0a2047eb4f78" .
    
    <http://covid19.aksw.org/text-d663c4e74974e66b04210f6551d9d93a2525eee880d9d79f850a368f4a402a6f_citespan-690-714>
            <http://www.example.org/end>    "714.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF160" ;
            <http://www.example.org/start>  "690.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Großjohann et al., 2004;" .
    
    <http://covid19.aksw.org/text-40e4efa3c23ba3c6d25e671f06bda8c2cf840952bc2a92995e1e5addef8c627a_citespan-655-673>
            <http://www.example.org/end>    "673.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF241" ;
            <http://www.example.org/start>  "655.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mann et al., 1967)" .
    
    <http://covid19.aksw.org/text-3d4d5e15aa12ec2e4bcf2359b511e1c7fb2c78e730c13ee45fc0f353aadd5ec1_citespan-514-543>
            <http://www.example.org/end>    "543.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "514.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bolton-Maggs and Pasi, 2003)" .
    
    <http://covid19.aksw.org/text-23ae1ce221485560bd3e59a19208ab77a3a0963d9b5c14ed04c87ce9ca5b621d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Acute inflammatory stimulation results from a tissue insult or invading pathogen that causes the release of proinflammatory mediators. Proinflammatory mediators in the stimulation of acute inflammatory neutrophilia include IL-1, IL-8, and TNFa (Dinarello, 2000; Kolackzowska and Kubes, 2013) . These changes cause a rapid initial release from the bone marrow storage pool into circulation that generally occurs within 8 h. Increased neutrophil counts are observed when bone marrow release exceeds emigration of neutrophils to the site of the inflammatory insult. With persistence of the inflammatory stimulus, the bone marrow storage pool becomes depleted and more immature neutrophil stages are released into circulation.\",\"cite_spans\":[{\"start\":244.0,\"end\":261.0,\"text\":\"(Dinarello, 2000;\",\"ref_id\":\"BIBREF93\"},{\"start\":262.0,\"end\":291.0,\"text\":\"Kolackzowska and Kubes, 2013)\"}],\"ref_spans\":[],\"section\":\"Bone marrow suppression Overwhelming\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-23ae1ce221485560bd3e59a19208ab77a3a0963d9b5c14ed04c87ce9ca5b621d_citespan-244-261> , <http://covid19.aksw.org/text-23ae1ce221485560bd3e59a19208ab77a3a0963d9b5c14ed04c87ce9ca5b621d_citespan-262-291> ;
            <http://www.example.org/section>
                    "Bone marrow suppression Overwhelming" ;
            <http://www.example.org/text>  "Acute inflammatory stimulation results from a tissue insult or invading pathogen that causes the release of proinflammatory mediators. Proinflammatory mediators in the stimulation of acute inflammatory neutrophilia include IL-1, IL-8, and TNFa (Dinarello, 2000; Kolackzowska and Kubes, 2013) . These changes cause a rapid initial release from the bone marrow storage pool into circulation that generally occurs within 8 h. Increased neutrophil counts are observed when bone marrow release exceeds emigration of neutrophils to the site of the inflammatory insult. With persistence of the inflammatory stimulus, the bone marrow storage pool becomes depleted and more immature neutrophil stages are released into circulation." ;
            <http://www.example.org/textHash>
                    "23ae1ce221485560bd3e59a19208ab77a3a0963d9b5c14ed04c87ce9ca5b621d" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-402-422>
            <http://www.example.org/end>    "422.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF273" ;
            <http://www.example.org/start>  "402.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Neftel et al., 1985)" .
    
    <http://covid19.aksw.org/text-be6866be15e1a545211c20194ed64e4d0b5d7baf0d97254155c04e251d2491fa_citespan-708-729>
            <http://www.example.org/end>    "729.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "708.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-195-215>
            <http://www.example.org/end>    "215.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF128" ;
            <http://www.example.org/start>  "195.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Galli et al., 2016;" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-1053-1074>
            <http://www.example.org/end>    "1074.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF50" ;
            <http://www.example.org/start>  "1053.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Byrnes et al., 1986)" .
    
    <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotics may also induce the production of antierythrocyte antibodies that mediate hemolysis even when the drug is no longer present, also called drug-independent antibodies or autoantibodies. In this type of hemolysis, xenobiotic exposure stimulates production of an antibody that can bind to native erythrocyte antigens even in the absence of the drug. This type of immune-mediated xenobiotic-induced hemolysis is classically caused by a-methyldopa, and is characterized by predominantly an IgG response (Packman, 2016) . However, nucleoside purine analogs such as cladribine and fludarabine have also been associated with hemolysis due to production of autoimmune antibodies (Garratty, 2010; Mintzer et al., 2009; Hamblin, 2006) .\",\"cite_spans\":[{\"start\":509.0,\"end\":524.0,\"text\":\"(Packman, 2016)\",\"ref_id\":\"BIBREF283\"},{\"start\":681.0,\"end\":697.0,\"text\":\"(Garratty, 2010;\",\"ref_id\":\"BIBREF134\"},{\"start\":698.0,\"end\":719.0,\"text\":\"Mintzer et al., 2009;\",\"ref_id\":\"BIBREF261\"},{\"start\":720.0,\"end\":734.0,\"text\":\"Hamblin, 2006)\",\"ref_id\":\"BIBREF163\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-509-524> , <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-681-697> , <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-698-719> , <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-720-734> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Xenobiotics may also induce the production of antierythrocyte antibodies that mediate hemolysis even when the drug is no longer present, also called drug-independent antibodies or autoantibodies. In this type of hemolysis, xenobiotic exposure stimulates production of an antibody that can bind to native erythrocyte antigens even in the absence of the drug. This type of immune-mediated xenobiotic-induced hemolysis is classically caused by a-methyldopa, and is characterized by predominantly an IgG response (Packman, 2016) . However, nucleoside purine analogs such as cladribine and fludarabine have also been associated with hemolysis due to production of autoimmune antibodies (Garratty, 2010; Mintzer et al., 2009; Hamblin, 2006) ." ;
            <http://www.example.org/textHash>
                    "13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6" .
    
    <http://covid19.aksw.org/text-91633b3470e5192a028ec34695350f9b831f2144a10df3c22c18513943a02d7d_citespan-234-254>
            <http://www.example.org/end>    "254.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF212" ;
            <http://www.example.org/start>  "234.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Laine et al., 2003;" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-472-499>
            <http://www.example.org/end>    "499.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "472.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b;" .
    
    <http://covid19.aksw.org/text-bda048633fce0c56cbf4fe713ee5ed0d8bf64bc5d145f476592e1b650ccec657>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Occasionally there may be mast cells observed in the blood smears of dogs, cats, or laboratory rodents. Mast cells in blood (mastocytemia) typically occur in low in numbers that do not significantly affect the automated leukocyte differential. Such mastocytemia may occur along with an inflammatory response. However, systemic mastocytosis or mast cell leukemia may cause notable increases in blood mast cells, and mast cell neoplasia is the most common cause of circulating mast cells in cats (Skeldon et al., 2010) . Blood smear evaluation is required for enumerating mast cells as part of a leukocyte differentiation.\",\"cite_spans\":[{\"start\":494.0,\"end\":516.0,\"text\":\"(Skeldon et al., 2010)\",\"ref_id\":\"BIBREF356\"}],\"ref_spans\":[],\"section\":\"Large Unclassified or Other Cells\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-bda048633fce0c56cbf4fe713ee5ed0d8bf64bc5d145f476592e1b650ccec657_citespan-494-516> ;
            <http://www.example.org/section>
                    "Large Unclassified or Other Cells" ;
            <http://www.example.org/text>  "Occasionally there may be mast cells observed in the blood smears of dogs, cats, or laboratory rodents. Mast cells in blood (mastocytemia) typically occur in low in numbers that do not significantly affect the automated leukocyte differential. Such mastocytemia may occur along with an inflammatory response. However, systemic mastocytosis or mast cell leukemia may cause notable increases in blood mast cells, and mast cell neoplasia is the most common cause of circulating mast cells in cats (Skeldon et al., 2010) . Blood smear evaluation is required for enumerating mast cells as part of a leukocyte differentiation." ;
            <http://www.example.org/textHash>
                    "bda048633fce0c56cbf4fe713ee5ed0d8bf64bc5d145f476592e1b650ccec657" .
    
    <http://covid19.aksw.org/text-ef832640a4512f87b9dad64191ce7e9c21aee1df40b85195ac470de7143ba0ac_citespan-413-432>
            <http://www.example.org/end>    "432.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF405" ;
            <http://www.example.org/start>  "413.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Van Voorhis, 2009;" .
    
    <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although lymphoproliferative neoplasia may be associated with increases in lymphocyte counts as previously discussed, lymphoma and lymphocytic leukemia may also be associated with decreases in lymphocyte counts including from altered lymphocyte recirculation patterns or decreased production of nonneoplasic lymphocytes secondary to lymphoid organ damage (Mitrovic et al., 2012; Schultze, 2010; Stockham and Scott, 2008a) .\",\"cite_spans\":[{\"start\":355.0,\"end\":378.0,\"text\":\"(Mitrovic et al., 2012;\",\"ref_id\":\"BIBREF262\"},{\"start\":379.0,\"end\":394.0,\"text\":\"Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":395.0,\"end\":421.0,\"text\":\"Stockham and Scott, 2008a)\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Neoplasia\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6_citespan-355-378> , <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6_citespan-379-394> , <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6_citespan-395-421> ;
            <http://www.example.org/section>
                    "Neoplasia" ;
            <http://www.example.org/text>  "Although lymphoproliferative neoplasia may be associated with increases in lymphocyte counts as previously discussed, lymphoma and lymphocytic leukemia may also be associated with decreases in lymphocyte counts including from altered lymphocyte recirculation patterns or decreased production of nonneoplasic lymphocytes secondary to lymphoid organ damage (Mitrovic et al., 2012; Schultze, 2010; Stockham and Scott, 2008a) ." ;
            <http://www.example.org/textHash>
                    "20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6" .
    
    <http://covid19.aksw.org/text-967d2eb15c9e1d06b64697f52167174ec1a820f577e8b1605468514104f006e0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Reticulocytes may mature into erythrocytes either in the spleen or the blood. Sometimes reticulocytes or mature erythrocytes may contain small remnants or fragments of their nuclei, called Howell-Jolly bodies. These may be observed in low numbers in circulation, but passage blood through the spleen typically results in their removal. Most species have a sinusoidal splenic architecture, but cats have nonsinusoidal splenic architecture and are less efficient at removal of Howell-Jolly bodies, so more circulating erythrocytes with Howell-Jolly bodies may be observed in healthy cats than in other species. Occasionally metarubricytes may also be released from the bone marrow and observed in circulation, although nucleus extrusion typically occurs during splenic passage of these cells. Also, the splenic reticuloendothelial system has a major role in removing damages or senescent erythrocytes from circulation.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Erythrocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Erythrocytes" ;
            <http://www.example.org/text>  "Reticulocytes may mature into erythrocytes either in the spleen or the blood. Sometimes reticulocytes or mature erythrocytes may contain small remnants or fragments of their nuclei, called Howell-Jolly bodies. These may be observed in low numbers in circulation, but passage blood through the spleen typically results in their removal. Most species have a sinusoidal splenic architecture, but cats have nonsinusoidal splenic architecture and are less efficient at removal of Howell-Jolly bodies, so more circulating erythrocytes with Howell-Jolly bodies may be observed in healthy cats than in other species. Occasionally metarubricytes may also be released from the bone marrow and observed in circulation, although nucleus extrusion typically occurs during splenic passage of these cells. Also, the splenic reticuloendothelial system has a major role in removing damages or senescent erythrocytes from circulation." ;
            <http://www.example.org/textHash>
                    "967d2eb15c9e1d06b64697f52167174ec1a820f577e8b1605468514104f006e0" .
    
    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-191-205>
            <http://www.example.org/end>    "205.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF39" ;
            <http://www.example.org/start>  "191.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Boseila, 1963)" .
    
    <http://covid19.aksw.org/text-20af4e930cfdfec5a77e7cdc9c481bafce4c1a7c7a38c907ddc9889fe9c3b9b6_citespan-355-378>
            <http://www.example.org/end>    "378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF262" ;
            <http://www.example.org/start>  "355.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Mitrovic et al., 2012;" .
    
    <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-476-501>
            <http://www.example.org/end>    "501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF351" ;
            <http://www.example.org/start>  "476.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Shelley and Juhlin, 1961)" .
    
    <http://covid19.aksw.org/text-47f2a40799322c8c02c2516c98b5949382c3b79243233109efa128c4601e325d_citespan-921-945>
            <http://www.example.org/end>    "945.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF286" ;
            <http://www.example.org/start>  "921.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Palmisano et al., 1998)" .
    
    <http://covid19.aksw.org/text-fbd4dbf34f80116109df9a34f7535b0a92472ebf2cc58e3a0424a88157ba70c6_citespan-357-372>
            <http://www.example.org/end>    "372.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "357.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-efb8a9d63be68d914ca6870f4a6d2a84a306f743257c50f39efe870c8c3e4adb_citespan-586-601>
            <http://www.example.org/end>    "601.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Barrett, 1970)" .
    
    <http://covid19.aksw.org/text-13f70dd9bf9937ca24689c07d39a6ac91129cef6c5e78adde7bc89811876d7d6_citespan-698-719>
            <http://www.example.org/end>    "719.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF261" ;
            <http://www.example.org/start>  "698.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Mintzer et al., 2009;" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-170-190>
            <http://www.example.org/end>    "190.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF325" ;
            <http://www.example.org/start>  "170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Rosner et al., 1988;" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-325-342>
            <http://www.example.org/end>    "342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF92" ;
            <http://www.example.org/start>  "325.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Desnoyers, 2010;" .
    
    <http://covid19.aksw.org/text-c11dd45ff4d44a57609415d2f53e97ce78158640c45eb845caecedf2f3121d08_citespan-435-450>
            <http://www.example.org/end>    "450.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "435.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-403-426>
            <http://www.example.org/end>    "426.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF78" ;
            <http://www.example.org/start>  "403.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Crexells et al., 1972)" .
    
    <http://covid19.aksw.org/text-6ab9799cf39726680b7c7a9877366fd4b1325afd7450f389313ad12bc43a4e14_citespan-524-542>
            <http://www.example.org/end>    "542.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF270" ;
            <http://www.example.org/start>  "524.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Muta et al., 1994;" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-914-938>
            <http://www.example.org/end>    "938.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF219" ;
            <http://www.example.org/start>  "914.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Leder and Weller, 2000)" .
    
    <http://covid19.aksw.org/text-a9eedbfe01990a74a1000e7979a2da145bc6f7f87475debd2281aaeab5f10dc4_citespan-1146-1175>
            <http://www.example.org/end>    "1175.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF66" ;
            <http://www.example.org/start>  "1146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Chickering and Prasse, 1981)" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.1.2.5 Cobalamin (B 12 ) and folate (B 9 ) Deficiencies in cobalamin and folate cause disruption of DNA synthesis that results in megaloblastic hematopoiesis, commonly associated with megaloblastic anemia and occasionally with decreases in neutrophil counts and/or pancytopenia (Dale and Welte, 2016; Green, 2016) . Cobalamin or folate deficiencies may be due to malnutrition, malabsorption from gastrointestinal disease or dysfunction, or genetic deficiencies of transport proteins, such as intrinsic factor, transcobalamin, or R-factor for cobalamin, receptors for intestinal absorption, such as the CUBAM receptor, or metabolizing enzymes, such as methylenetetrahydrofolate reductase for folate (Fowler, 1998; Whitehead, 2006; Montagle and Tauro, 1995; Green, 2016; Quadros, 2010) . During megaloblastic hematopoiesis, asynchronous cytoplasmic and nuclear maturation may result in giant granulocytes with irregular nuclear chromatin patterns, such as giant metamyelocytes (Green, 2016) , or hypersegmented neutrophils (Thompson et al., 1989) . These conditions can often be managed with supplementation of the deficient vitamin. A differential for cobalamin or folate deficiency-induced decreases in blood neutrophil counts is copper deficiency, which can have a similar clinical manifestation (Lazarchick, 2012) .\",\"cite_spans\":[{\"start\":285.0,\"end\":307.0,\"text\":\"(Dale and Welte, 2016;\",\"ref_id\":\"BIBREF85\"},{\"start\":308.0,\"end\":320.0,\"text\":\"Green, 2016)\",\"ref_id\":\"BIBREF157\"},{\"start\":705.0,\"end\":719.0,\"text\":\"(Fowler, 1998;\",\"ref_id\":\"BIBREF121\"},{\"start\":720.0,\"end\":736.0,\"text\":\"Whitehead, 2006;\",\"ref_id\":\"BIBREF430\"},{\"start\":737.0,\"end\":762.0,\"text\":\"Montagle and Tauro, 1995;\",\"ref_id\":\"BIBREF263\"},{\"start\":763.0,\"end\":775.0,\"text\":\"Green, 2016;\",\"ref_id\":\"BIBREF157\"},{\"start\":776.0,\"end\":790.0,\"text\":\"Quadros, 2010)\",\"ref_id\":\"BIBREF306\"},{\"start\":982.0,\"end\":995.0,\"text\":\"(Green, 2016)\",\"ref_id\":\"BIBREF157\"},{\"start\":1028.0,\"end\":1051.0,\"text\":\"(Thompson et al., 1989)\",\"ref_id\":\"BIBREF388\"},{\"start\":1304.0,\"end\":1322.0,\"text\":\"(Lazarchick, 2012)\",\"ref_id\":\"BIBREF218\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-982-995> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-763-775> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-1028-1051> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-308-320> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-285-307> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-1304-1322> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-737-762> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-776-790> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-720-736> , <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-705-719> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "12.11.2.1.2.5 Cobalamin (B 12 ) and folate (B 9 ) Deficiencies in cobalamin and folate cause disruption of DNA synthesis that results in megaloblastic hematopoiesis, commonly associated with megaloblastic anemia and occasionally with decreases in neutrophil counts and/or pancytopenia (Dale and Welte, 2016; Green, 2016) . Cobalamin or folate deficiencies may be due to malnutrition, malabsorption from gastrointestinal disease or dysfunction, or genetic deficiencies of transport proteins, such as intrinsic factor, transcobalamin, or R-factor for cobalamin, receptors for intestinal absorption, such as the CUBAM receptor, or metabolizing enzymes, such as methylenetetrahydrofolate reductase for folate (Fowler, 1998; Whitehead, 2006; Montagle and Tauro, 1995; Green, 2016; Quadros, 2010) . During megaloblastic hematopoiesis, asynchronous cytoplasmic and nuclear maturation may result in giant granulocytes with irregular nuclear chromatin patterns, such as giant metamyelocytes (Green, 2016) , or hypersegmented neutrophils (Thompson et al., 1989) . These conditions can often be managed with supplementation of the deficient vitamin. A differential for cobalamin or folate deficiency-induced decreases in blood neutrophil counts is copper deficiency, which can have a similar clinical manifestation (Lazarchick, 2012) ." ;
            <http://www.example.org/textHash>
                    "460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9" .
    
    <http://covid19.aksw.org/text-bdeab784a61dfbcbba4b4a21893d6cae016f458b5df776716663d2ba692b1406_citespan-317-332>
            <http://www.example.org/end>    "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF327" ;
            <http://www.example.org/start>  "317.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Roujeau, 2005)" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-791-813>
            <http://www.example.org/end>    "813.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF56" ;
            <http://www.example.org/start>  "791.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Capelli et al., 1966)" .
    
    <http://covid19.aksw.org/text-70e51a282165d1f865788a02f8fef0d4d377ac4eb6c78b04fa00dfceebd2f2ac_citespan-1763-1789>
            <http://www.example.org/end>    "1789.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF345" ;
            <http://www.example.org/start>  "1763.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Segel and Lichtman, 2016)" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-704-726>
            <http://www.example.org/end>    "726.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF383" ;
            <http://www.example.org/start>  "704.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Tefferi et al., 2006;" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1345-1365>
            <http://www.example.org/end>    "1365.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF332" ;
            <http://www.example.org/start>  "1345.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sakka et al., 2006)" .
    
    <http://covid19.aksw.org/text-29c51d9b79f635976dba69ff319776470fef96db5d321ce35a5f9551baa9862e_citespan-1802-1829>
            <http://www.example.org/end>    "1829.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "1802.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-e94f71490b3290ea9ecd03aae51022d32e28b3301287079bb1001c5f30123c21_citespan-511-532>
            <http://www.example.org/end>    "532.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF278" ;
            <http://www.example.org/start>  "511.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Ogilvie et al., 1980)" .
    
    <http://covid19.aksw.org/text-f1068bf078a810ee6e2b11014161ca4264c366fc0d9f7759ef39919b8c30e958_citespan-1232-1247>
            <http://www.example.org/end>    "1247.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF329" ;
            <http://www.example.org/start>  "1232.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Russell, 2010)" .
    
    <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-555-570>
            <http://www.example.org/end>    "570.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "555.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016)" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-308-329>
            <http://www.example.org/end>    "329.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF299" ;
            <http://www.example.org/start>  "308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Pisoni et al., 2001)" .
    
    <http://covid19.aksw.org/text-a95f753295254845256e3a5680bb7dc214b565e596debd1c170df2a0c4150e25_citespan-1413-1441>
            <http://www.example.org/end>    "1441.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF404" ;
            <http://www.example.org/start>  "1413.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Van Putten and Croon, 1958)" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-984-996>
            <http://www.example.org/end>    "996.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF401" ;
            <http://www.example.org/start>  "984.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Valent, 2009" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-462-485>
            <http://www.example.org/end>    "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF153" ;
            <http://www.example.org/start>  "462.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Grant and Klein, 1987)" .
    
    <http://covid19.aksw.org/text-853414940fd98336894a4fdef7c1a88d828e59a87b6dedb2ece77adf00fb37ae>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in blood reticulocyte counts may be associated with concurrent changes in mean corpuscular volume (MCV; an indicator of erythrocyte size) and mean corpuscular hemoglobin concentration (MCHC; an indicator of erythrocyte hemoglobin content), two red blood cell indices provided by most automated hematology analyzers. Due to the reticulocyte\\u0027s increased volume relative to mature erythrocytes, increases in blood reticulocyte counts may cause increases in MCV (macrocytosis) and decreases in MCHC (hypochromasia). Regenerative anemias with increases in MCV and decreases in MCHC and/or CHCM may also be classified by these indices as macrocytic, hypochromic anemias. The decrease in MCHC does not necessarily reflect less hemoglobin content per cell, but is a consequence of reduced concentration of hemoglobin due to the larger cytoplasmic volume of reticulocytes. MCHC, which is a calculated endpoint, may be artificially increased when free plasma hemoglobin is present due to intravascular hemolysis. Some automated hematology analyzers also provide the corpuscular mean hemoglobin content (CHCM) which provides a mean of direct measurements of cellular hemoglobin concentration and is therefore resistant to interference from free plasma hemoglobin.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Decreases in red cell mass with increases in reticulocyte counts (regenerative anemia)" ;
            <http://www.example.org/text>  "Increases in blood reticulocyte counts may be associated with concurrent changes in mean corpuscular volume (MCV; an indicator of erythrocyte size) and mean corpuscular hemoglobin concentration (MCHC; an indicator of erythrocyte hemoglobin content), two red blood cell indices provided by most automated hematology analyzers. Due to the reticulocyte's increased volume relative to mature erythrocytes, increases in blood reticulocyte counts may cause increases in MCV (macrocytosis) and decreases in MCHC (hypochromasia). Regenerative anemias with increases in MCV and decreases in MCHC and/or CHCM may also be classified by these indices as macrocytic, hypochromic anemias. The decrease in MCHC does not necessarily reflect less hemoglobin content per cell, but is a consequence of reduced concentration of hemoglobin due to the larger cytoplasmic volume of reticulocytes. MCHC, which is a calculated endpoint, may be artificially increased when free plasma hemoglobin is present due to intravascular hemolysis. Some automated hematology analyzers also provide the corpuscular mean hemoglobin content (CHCM) which provides a mean of direct measurements of cellular hemoglobin concentration and is therefore resistant to interference from free plasma hemoglobin." ;
            <http://www.example.org/textHash>
                    "853414940fd98336894a4fdef7c1a88d828e59a87b6dedb2ece77adf00fb37ae" .
    
    <http://covid19.aksw.org/text-f6a032c5737c6d45ad4c6b636bc6ceb2465afd3568393b4b1c32e6d291b1e188_citespan-412-433>
            <http://www.example.org/end>    "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF242" ;
            <http://www.example.org/start>  "412.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Marani et al., 1996)" .
    
    <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.4.1.6 Xenobiotic-induced Beta adrenergic blocking agents may be associated with modest increases in eosinophil counts, and administration of propranolol has been demonstrated to prevent catecholamine-induced decreases in eosinophil counts (Reed et al., 1970; Koch-Weser, 1968 ). The antibiotic tetracycline has been associated with increased eosinophil counts in dogs (Domina et al., 1997) and humans (Ho et al., 1979) . Therapeutic administration of IL-2 for renal cell carcinoma has also been reported to cause increased blood eosinophil counts (Wardlaw, 2016) . Administration of G-CSF and GM-CSF will also cause increases in blood eosinophil counts due to stimulation of common myeloid precursor proliferation. However, increases in eosinophil counts with these compounds will be small in comparison with the increases in blood neutrophil counts.\",\"cite_spans\":[{\"start\":247.0,\"end\":266.0,\"text\":\"(Reed et al., 1970;\",\"ref_id\":\"BIBREF317\"},{\"start\":267.0,\"end\":283.0,\"text\":\"Koch-Weser, 1968\"},{\"start\":376.0,\"end\":397.0,\"text\":\"(Domina et al., 1997)\",\"ref_id\":\"BIBREF95\"},{\"start\":409.0,\"end\":426.0,\"text\":\"(Ho et al., 1979)\",\"ref_id\":\"BIBREF172\"},{\"start\":555.0,\"end\":570.0,\"text\":\"(Wardlaw, 2016)\",\"ref_id\":\"BIBREF420\"}],\"ref_spans\":[],\"section\":\"Spurious\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-247-266> , <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-267-283> , <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-376-397> , <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-409-426> , <http://covid19.aksw.org/text-b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2_citespan-555-570> ;
            <http://www.example.org/section>
                    "Spurious" ;
            <http://www.example.org/text>  "12.11.2.4.1.6 Xenobiotic-induced Beta adrenergic blocking agents may be associated with modest increases in eosinophil counts, and administration of propranolol has been demonstrated to prevent catecholamine-induced decreases in eosinophil counts (Reed et al., 1970; Koch-Weser, 1968 ). The antibiotic tetracycline has been associated with increased eosinophil counts in dogs (Domina et al., 1997) and humans (Ho et al., 1979) . Therapeutic administration of IL-2 for renal cell carcinoma has also been reported to cause increased blood eosinophil counts (Wardlaw, 2016) . Administration of G-CSF and GM-CSF will also cause increases in blood eosinophil counts due to stimulation of common myeloid precursor proliferation. However, increases in eosinophil counts with these compounds will be small in comparison with the increases in blood neutrophil counts." ;
            <http://www.example.org/textHash>
                    "b7d67b6b91983718a42efdfed27c047bc6589151ed3fb94035b990a2144c74c2" .
    
    <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Most cases of primary or idiopathic aplastic anemia result from underlying immune-mediated destruction of uncommitted or early lineage-committed hematopoietic stem cells (Young et al., 2006) . Aplastic anemia is characterized by pancytopenia (marked decreases in all blood component counts) and hematopoietic cell hypocellularity in bone marrow. Although most commonly associated with immune-mediated destruction of hematopoietic precursors, marked depletion of bone marrow hematopoietic cells or aplastic anemia may also occur with severe nutritional deficiencies associated with anorexia nervosa (Abella et al., 2002) and 75% feed restriction in rats (Moriyama et al., 2008; Levin et al., 1993) .\",\"cite_spans\":[{\"start\":170.0,\"end\":190.0,\"text\":\"(Young et al., 2006)\",\"ref_id\":\"BIBREF439\"},{\"start\":598.0,\"end\":619.0,\"text\":\"(Abella et al., 2002)\",\"ref_id\":\"BIBREF0\"},{\"start\":653.0,\"end\":676.0,\"text\":\"(Moriyama et al., 2008;\",\"ref_id\":\"BIBREF266\"},{\"start\":677.0,\"end\":696.0,\"text\":\"Levin et al., 1993)\",\"ref_id\":\"BIBREF221\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-170-190> , <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-598-619> , <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-653-676> , <http://covid19.aksw.org/text-4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0_citespan-677-696> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Most cases of primary or idiopathic aplastic anemia result from underlying immune-mediated destruction of uncommitted or early lineage-committed hematopoietic stem cells (Young et al., 2006) . Aplastic anemia is characterized by pancytopenia (marked decreases in all blood component counts) and hematopoietic cell hypocellularity in bone marrow. Although most commonly associated with immune-mediated destruction of hematopoietic precursors, marked depletion of bone marrow hematopoietic cells or aplastic anemia may also occur with severe nutritional deficiencies associated with anorexia nervosa (Abella et al., 2002) and 75% feed restriction in rats (Moriyama et al., 2008; Levin et al., 1993) ." ;
            <http://www.example.org/textHash>
                    "4f20e800e0cbefa344bc38e2e671379fd4502b97266cb7be987f3639d23c11b0" .
    
    <http://covid19.aksw.org/text-afba272ab48e2ad1d694b3db14b82a60b29c00e4731c5672f08d393c888b18c3_citespan-487-508>
            <http://www.example.org/end>    "508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF200" ;
            <http://www.example.org/start>  "487.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Kaufman et al., 1996)" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-715-734>
            <http://www.example.org/end>    "734.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF126" ;
            <http://www.example.org/start>  "715.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gaga et al., 1991)" .
    
    <http://covid19.aksw.org/text-b0b0914e794177ac9a2bf2c2393376fc604f3e797e9173978923b4fafa399b03>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Primary, or erythropoietin-independent, increases in red cell mass are associated with myelodysplastic conditions with autonomous production of erythrocytes. Due to the autonomous nature of the proliferations, primary increases in red cell mass are also termed inappropriate as they are not dependent on EPO stimulation. Causes of the more common secondary increases in red cell mass should be excluded prior to the diagnosis of a primary increase in red cell mass. Measurement of EPO concentrations may be useful clinically in people, but assays that quantify EPO are not readily available for most veterinary species. Primary increases in red cell mass are uncommon, and are typically not observed in common laboratory species during nonclinical toxicology studies.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Primary increases in red cell mass\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Primary increases in red cell mass" ;
            <http://www.example.org/text>  "Primary, or erythropoietin-independent, increases in red cell mass are associated with myelodysplastic conditions with autonomous production of erythrocytes. Due to the autonomous nature of the proliferations, primary increases in red cell mass are also termed inappropriate as they are not dependent on EPO stimulation. Causes of the more common secondary increases in red cell mass should be excluded prior to the diagnosis of a primary increase in red cell mass. Measurement of EPO concentrations may be useful clinically in people, but assays that quantify EPO are not readily available for most veterinary species. Primary increases in red cell mass are uncommon, and are typically not observed in common laboratory species during nonclinical toxicology studies." ;
            <http://www.example.org/textHash>
                    "b0b0914e794177ac9a2bf2c2393376fc604f3e797e9173978923b4fafa399b03" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-2792-2807>
            <http://www.example.org/end>    "2807.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "2792.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Arnaout, 1990)" .
    
    <http://covid19.aksw.org/text-32ebe3f6f3f8c235a3c94152d2efd5043a0d882783f62e999fc8b7ceccdbe506_citespan-730-757>
            <http://www.example.org/end>    "757.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "730.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-1287-1308>
            <http://www.example.org/end>    "1308.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF383" ;
            <http://www.example.org/start>  "1287.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Tefferi et al., 2006;" .
    
    <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327_citespan-441-467>
            <http://www.example.org/end>    "467.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "441.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a;" .
    
    <http://covid19.aksw.org/text-c7bace5d441d31937758320dba311320591bcce623f8782c5276211fc1e86ba8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Increases in blood lymphocyte counts may also occur secondary to nonlymphoproliferative neoplasms. Increases in polyclonal T-cells have been reported in patients with malignant thymoma, while increases in reactive lymphocytes have been reported with AML and systemic mastocytosis (Vasu and Caligiuri, 2016) .\",\"cite_spans\":[{\"start\":280.0,\"end\":306.0,\"text\":\"(Vasu and Caligiuri, 2016)\",\"ref_id\":\"BIBREF406\"}],\"ref_spans\":[],\"section\":\"Inflammation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c7bace5d441d31937758320dba311320591bcce623f8782c5276211fc1e86ba8_citespan-280-306> ;
            <http://www.example.org/section>
                    "Inflammation" ;
            <http://www.example.org/text>  "Increases in blood lymphocyte counts may also occur secondary to nonlymphoproliferative neoplasms. Increases in polyclonal T-cells have been reported in patients with malignant thymoma, while increases in reactive lymphocytes have been reported with AML and systemic mastocytosis (Vasu and Caligiuri, 2016) ." ;
            <http://www.example.org/textHash>
                    "c7bace5d441d31937758320dba311320591bcce623f8782c5276211fc1e86ba8" .
    
    <http://covid19.aksw.org/text-ed051e9f6774e0d5381f7678308045e772eabafe6558f59d86a9b70ba18060b2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In laboratory species used in nonclinical toxicology studies, transient xenobiotic-induced decreases in blood neutrophil counts have been associated with anaphylactoid reactions termed complement activation-related pseudoallergy (CARPA). These nonhypersensitive reactions are mediated instead by activation of the complement cascade, leading to the production of the anaphylatoxins C3a and C5a. CARPA typically occurs after the first dose of xenobiotic with decreasing severity or resolution following additional doses. Xenobiotics implicated in CARPA reactions include radiocontrast media, drug-carrying liposomes and lipid complexes, and some solvents with amphiphilic emulsifiers, such as Cremophor EL (Szebeni, 2005) .\",\"cite_spans\":[{\"start\":705.0,\"end\":720.0,\"text\":\"(Szebeni, 2005)\",\"ref_id\":\"BIBREF377\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ed051e9f6774e0d5381f7678308045e772eabafe6558f59d86a9b70ba18060b2_citespan-705-720> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "In laboratory species used in nonclinical toxicology studies, transient xenobiotic-induced decreases in blood neutrophil counts have been associated with anaphylactoid reactions termed complement activation-related pseudoallergy (CARPA). These nonhypersensitive reactions are mediated instead by activation of the complement cascade, leading to the production of the anaphylatoxins C3a and C5a. CARPA typically occurs after the first dose of xenobiotic with decreasing severity or resolution following additional doses. Xenobiotics implicated in CARPA reactions include radiocontrast media, drug-carrying liposomes and lipid complexes, and some solvents with amphiphilic emulsifiers, such as Cremophor EL (Szebeni, 2005) ." ;
            <http://www.example.org/textHash>
                    "ed051e9f6774e0d5381f7678308045e772eabafe6558f59d86a9b70ba18060b2" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-1918-1934>
            <http://www.example.org/end>    "1934.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "1918.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-5c1381f5160d1332a4b938c7cc280b07a68b131f24403cf0fc860ec6a161a7bf_citespan-902-922>
            <http://www.example.org/end>    "922.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF413" ;
            <http://www.example.org/start>  "902.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Wailoo et al., 2009)" .
    
    <http://covid19.aksw.org/text-bc5ee5d2be8cfdc89d4ff440d22aa596ad61641b67bce05c8c8dfba0b001d918>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are numerous causes of direct alterations in blood components, including an increasing number of xenobiotics. Alterations in the bone marrow hematopoietic systemic either independent of xenobiotics or induced by xenobiotics may also result in changes in peripheral blood cell counts. Many of the mechanisms of alterations in blood cell counts that are not related to xenobiotic administration have considerable overlap with the mechanisms through which xenobiotics cause changes, and understanding these mechanisms and their association with individual compounds or drug classes may help elucidate potential pathways through which novel xenobiotics cause alterations in blood components.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Conclusions" ;
            <http://www.example.org/text>  "There are numerous causes of direct alterations in blood components, including an increasing number of xenobiotics. Alterations in the bone marrow hematopoietic systemic either independent of xenobiotics or induced by xenobiotics may also result in changes in peripheral blood cell counts. Many of the mechanisms of alterations in blood cell counts that are not related to xenobiotic administration have considerable overlap with the mechanisms through which xenobiotics cause changes, and understanding these mechanisms and their association with individual compounds or drug classes may help elucidate potential pathways through which novel xenobiotics cause alterations in blood components." ;
            <http://www.example.org/textHash>
                    "bc5ee5d2be8cfdc89d4ff440d22aa596ad61641b67bce05c8c8dfba0b001d918" .
    
    <http://covid19.aksw.org/text-56a0f2e8df0b15b9ab1fdb7042da21859a72d2664093d2ce78e85cdd7e657c3a_citespan-146-170>
            <http://www.example.org/end>    "170.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF276" ;
            <http://www.example.org/start>  "146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(O'Connell et al., 2015)" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-473-492>
            <http://www.example.org/end>    "492.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF208" ;
            <http://www.example.org/start>  "473.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kubo et al., 2010)" .
    
    <http://covid19.aksw.org/text-13187f2b6884adc61cfec122bd36560ec1b72c4dd38aaf208dde28ba1d9d6e85_citespan-421-442>
            <http://www.example.org/end>    "442.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF238" ;
            <http://www.example.org/start>  "421.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Magden et al., 2015)" .
    
    <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Type I hypersensitivity reactions, which are mediated by rapid IgE release, are commonly associated with decreases in both eosinophil and basophil counts. However, type IV hypersensitivity (cell-mediated) causing histamine release from mast cells may also be associated with decreases in basophil counts. Such hypersensitivity-related decreases in basophil counts can be observed with anaphylaxis and urticaria (Galli et al., 2016; Grattan et al., 1997 Grattan et al., , 2003 Shelley and Juhlin, 1961) .\",\"cite_spans\":[{\"start\":411.0,\"end\":431.0,\"text\":\"(Galli et al., 2016;\",\"ref_id\":\"BIBREF128\"},{\"start\":432.0,\"end\":452.0,\"text\":\"Grattan et al., 1997\",\"ref_id\":\"BIBREF155\"},{\"start\":453.0,\"end\":475.0,\"text\":\"Grattan et al., , 2003\",\"ref_id\":\"BIBREF156\"},{\"start\":476.0,\"end\":501.0,\"text\":\"Shelley and Juhlin, 1961)\",\"ref_id\":\"BIBREF351\"}],\"ref_spans\":[],\"section\":\"Decreases in basophil counts (basopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-411-431> , <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-432-452> , <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-453-475> , <http://covid19.aksw.org/text-e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d_citespan-476-501> ;
            <http://www.example.org/section>
                    "Decreases in basophil counts (basopenia)" ;
            <http://www.example.org/text>  "Type I hypersensitivity reactions, which are mediated by rapid IgE release, are commonly associated with decreases in both eosinophil and basophil counts. However, type IV hypersensitivity (cell-mediated) causing histamine release from mast cells may also be associated with decreases in basophil counts. Such hypersensitivity-related decreases in basophil counts can be observed with anaphylaxis and urticaria (Galli et al., 2016; Grattan et al., 1997 Grattan et al., , 2003 Shelley and Juhlin, 1961) ." ;
            <http://www.example.org/textHash>
                    "e8efdc87749578c09972650257fcd74cfead0a6c8742458f7ab3dea1e71bbf2d" .
    
    <http://covid19.aksw.org/text-a6352b6bc2547a312d7257486b51a2c87ccd7694aa98ea69b6323affa47c24fa_refspan-79-86>
            <http://www.example.org/end>    "86.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "79.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-4ea599e9dd08bdca4d655ccc1896fb41b7bde951ee47806dde5f48032a6a32e1_citespan-1360-1386>
            <http://www.example.org/end>    "1386.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF81" ;
            <http://www.example.org/start>  "1360.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cruz Cardona et al., 2011;" .
    
    <http://covid19.aksw.org/text-bdc96126ead88324e579f987b9425621f6e8d4bd9f0f0ded896765341079105a_citespan-1963-1977>
            <http://www.example.org/end>    "1977.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF302" ;
            <http://www.example.org/start>  "1963.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Prchal, 2016)" .
    
    <http://covid19.aksw.org/text-192c6b03226897083d61b845f418483a6b8973e52b6edd2dfd90af7f508f35eb_citespan-612-627>
            <http://www.example.org/end>    "627.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "612.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Schultze, 2010)" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-1628-1653>
            <http://www.example.org/end>    "1653.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF106" ;
            <http://www.example.org/start>  "1628.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Evans and Scadden, 2000)" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-361-381>
            <http://www.example.org/end>    "381.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF177" ;
            <http://www.example.org/start>  "361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Irvine et al., 1994;" .
    
    <http://covid19.aksw.org/text-d7116a9f44411a2876e5240605c500963997909f0da78cfb04a0acb9adc8ea64_citespan-241-264>
            <http://www.example.org/end>    "264.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF123" ;
            <http://www.example.org/start>  "241.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Freedman et al., 2002)" .
    
    <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-142-157>
            <http://www.example.org/end>    "157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF140" ;
            <http://www.example.org/start>  "142.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gergely, 1999)" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Basophils develop in the bone marrow from uncommitted myeloid progenitor cells that differentiate into committed basophil progenitors. However, intermediate stages in basophil production have not been definitively identified, and there is evidence that basophils may share a common precursor with eosinophil, mast cells, or megakaryocytes (Radin and Wellman, 2010; Arock et al., 2002) . Stimulation with IL-3 plays a major role in the terminal differentiation of basophils, while GM-CSF and IL-5 also play a role in basophil differentiation (Arock et al., 2002; Mayer et al., 1989) . There is also some evidence for stem cell factor (SCF) and IL-4 stimulation in basophil differentiation (Pohlman, 2010; Favre et al., 1990) . As studies in mice have shown that normal blood basophil counts may be maintained in the absence of IL-3, a required role for IL-3 in basophil production is not apparent (Lantz et al., 1998) . Specific factors leading to terminal differentiation have not been identified for the basophil lineage, and basophil differentiation may in fact represent a default leukocyte differentiation pathway (Arock et al., 2002) .\",\"cite_spans\":[{\"start\":339.0,\"end\":364.0,\"text\":\"(Radin and Wellman, 2010;\",\"ref_id\":\"BIBREF307\"},{\"start\":365.0,\"end\":384.0,\"text\":\"Arock et al., 2002)\",\"ref_id\":\"BIBREF9\"},{\"start\":541.0,\"end\":561.0,\"text\":\"(Arock et al., 2002;\",\"ref_id\":\"BIBREF9\"},{\"start\":562.0,\"end\":581.0,\"text\":\"Mayer et al., 1989)\",\"ref_id\":\"BIBREF253\"},{\"start\":688.0,\"end\":703.0,\"text\":\"(Pohlman, 2010;\",\"ref_id\":\"BIBREF300\"},{\"start\":704.0,\"end\":723.0,\"text\":\"Favre et al., 1990)\",\"ref_id\":\"BIBREF113\"},{\"start\":896.0,\"end\":916.0,\"text\":\"(Lantz et al., 1998)\",\"ref_id\":\"BIBREF215\"},{\"start\":1118.0,\"end\":1138.0,\"text\":\"(Arock et al., 2002)\",\"ref_id\":\"BIBREF9\"}],\"ref_spans\":[],\"section\":\"Basophils\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-896-916> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-365-384> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-562-581> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-339-364> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-541-561> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-1118-1138> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-688-703> , <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-704-723> ;
            <http://www.example.org/section>
                    "Basophils" ;
            <http://www.example.org/text>  "Basophils develop in the bone marrow from uncommitted myeloid progenitor cells that differentiate into committed basophil progenitors. However, intermediate stages in basophil production have not been definitively identified, and there is evidence that basophils may share a common precursor with eosinophil, mast cells, or megakaryocytes (Radin and Wellman, 2010; Arock et al., 2002) . Stimulation with IL-3 plays a major role in the terminal differentiation of basophils, while GM-CSF and IL-5 also play a role in basophil differentiation (Arock et al., 2002; Mayer et al., 1989) . There is also some evidence for stem cell factor (SCF) and IL-4 stimulation in basophil differentiation (Pohlman, 2010; Favre et al., 1990) . As studies in mice have shown that normal blood basophil counts may be maintained in the absence of IL-3, a required role for IL-3 in basophil production is not apparent (Lantz et al., 1998) . Specific factors leading to terminal differentiation have not been identified for the basophil lineage, and basophil differentiation may in fact represent a default leukocyte differentiation pathway (Arock et al., 2002) ." ;
            <http://www.example.org/textHash>
                    "f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288" .
    
    <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Endogenous glucocorticoids classically cause increases in blood monocyte counts. However, these increases in monocyte counts are less consistently observed than decreases in lymphocyte counts or increases in neutrophil counts, and no perceptible change in monocyte counts may occur (Hall, 2013; Everds et al., 2013a) . There have also been reports of decreases in monocyte counts attributable to endogenous glucocorticoids, which may be associated with decreased production with prolonged glucocorticoid exposure (Thompson and van Furth, 1973) , or may be transient and followed by an increased in monocyte counts (Steer et al., 1997; Rinehart et al., 1975) .\",\"cite_spans\":[{\"start\":282.0,\"end\":294.0,\"text\":\"(Hall, 2013;\",\"ref_id\":\"BIBREF162\"},{\"start\":295.0,\"end\":316.0,\"text\":\"Everds et al., 2013a)\",\"ref_id\":\"BIBREF107\"},{\"start\":513.0,\"end\":543.0,\"text\":\"(Thompson and van Furth, 1973)\",\"ref_id\":\"BIBREF387\"},{\"start\":614.0,\"end\":634.0,\"text\":\"(Steer et al., 1997;\",\"ref_id\":\"BIBREF365\"},{\"start\":635.0,\"end\":657.0,\"text\":\"Rinehart et al., 1975)\",\"ref_id\":\"BIBREF320\"}],\"ref_spans\":[],\"section\":\"Glucocorticoid-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-282-294> , <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-295-316> , <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-513-543> , <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-614-634> , <http://covid19.aksw.org/text-c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b_citespan-635-657> ;
            <http://www.example.org/section>
                    "Glucocorticoid-induced" ;
            <http://www.example.org/text>  "Endogenous glucocorticoids classically cause increases in blood monocyte counts. However, these increases in monocyte counts are less consistently observed than decreases in lymphocyte counts or increases in neutrophil counts, and no perceptible change in monocyte counts may occur (Hall, 2013; Everds et al., 2013a) . There have also been reports of decreases in monocyte counts attributable to endogenous glucocorticoids, which may be associated with decreased production with prolonged glucocorticoid exposure (Thompson and van Furth, 1973) , or may be transient and followed by an increased in monocyte counts (Steer et al., 1997; Rinehart et al., 1975) ." ;
            <http://www.example.org/textHash>
                    "c7b4bb948b21c4a38c049f43331a4eb3007baa6d92e9275a8f83407c6280f23b" .
    
    <http://covid19.aksw.org/text-9ea5c9661a1c734f64c55c3bcfa8bb5f955002f60fc9834f926d2e2725abe9dd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-related causes of relative increases in red cell mass are relatively uncommon, with the exception of dehydration associated with decreased food consumption in rodents utilized in nonclinical toxicology studies, as described earlier. Diuretics, such as furosemide or spironolactone, which result in increased elimination of water into urine, may result in hemoconcentration due to dehydration (Mintzer et al., 2009) .\",\"cite_spans\":[{\"start\":403.0,\"end\":425.0,\"text\":\"(Mintzer et al., 2009)\",\"ref_id\":\"BIBREF261\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-9ea5c9661a1c734f64c55c3bcfa8bb5f955002f60fc9834f926d2e2725abe9dd_citespan-403-425> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Xenobiotic-related causes of relative increases in red cell mass are relatively uncommon, with the exception of dehydration associated with decreased food consumption in rodents utilized in nonclinical toxicology studies, as described earlier. Diuretics, such as furosemide or spironolactone, which result in increased elimination of water into urine, may result in hemoconcentration due to dehydration (Mintzer et al., 2009) ." ;
            <http://www.example.org/textHash>
                    "9ea5c9661a1c734f64c55c3bcfa8bb5f955002f60fc9834f926d2e2725abe9dd" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are many conditions that may cause oxidative damage and result in eccentrocytosis, Heinz body formation, or even both simultaneously. Diabetes mellitus may cause either morphologic change, and diabetic ketoacidosis appears to be associated with an increased susceptibility and incidence of oxidative erythrocyte damage (Desnoyers, 2010; Caldin et al., 2005; Christopher et al., 1995) . Inherited deficiencies in erythrocyte glucose-6-phosphate dehydrogenase (G6PD) and flavin adenine dinucleotide (FAD) have also been associated with erythrocyte oxidative damage, eccentrocyte or Heinz body formation, and hemolysis or a predisposition for these events due to the loss of protective antioxidant pathways (Chan et al., 1982; Harvey, 2006) . Lymphoma has also been associated with Heinz body formation in cats (Christopher, 1989) and eccentrocytes formation in dogs (Caldin et al., 2005) . In dogs and cats, ingestion of Allium species, particularly onions, garlic, and Chinese chive, may cause erythrocyte oxidative damage with formation of eccentrocytes and/or Heinz bodies (Caldin et al., 2005; Yamato et al., 2005; Robertson et al., 1998) . Ingestion of zinc in dogs (Bexfield et al., 2007) and exposure to skunk musk (Fierro et al., 2013) have also been reported to cause hemolysis due to Heinz body formation.\",\"cite_spans\":[{\"start\":325.0,\"end\":342.0,\"text\":\"(Desnoyers, 2010;\",\"ref_id\":\"BIBREF92\"},{\"start\":343.0,\"end\":363.0,\"text\":\"Caldin et al., 2005;\",\"ref_id\":\"BIBREF52\"},{\"start\":364.0,\"end\":389.0,\"text\":\"Christopher et al., 1995)\",\"ref_id\":\"BIBREF71\"},{\"start\":710.0,\"end\":729.0,\"text\":\"(Chan et al., 1982;\",\"ref_id\":\"BIBREF63\"},{\"start\":730.0,\"end\":743.0,\"text\":\"Harvey, 2006)\",\"ref_id\":\"BIBREF165\"},{\"start\":814.0,\"end\":833.0,\"text\":\"(Christopher, 1989)\",\"ref_id\":\"BIBREF69\"},{\"start\":870.0,\"end\":891.0,\"text\":\"(Caldin et al., 2005)\",\"ref_id\":\"BIBREF52\"},{\"start\":1080.0,\"end\":1101.0,\"text\":\"(Caldin et al., 2005;\",\"ref_id\":\"BIBREF52\"},{\"start\":1102.0,\"end\":1122.0,\"text\":\"Yamato et al., 2005;\",\"ref_id\":\"BIBREF435\"},{\"start\":1123.0,\"end\":1146.0,\"text\":\"Robertson et al., 1998)\",\"ref_id\":\"BIBREF321\"},{\"start\":1175.0,\"end\":1198.0,\"text\":\"(Bexfield et al., 2007)\",\"ref_id\":\"BIBREF28\"},{\"start\":1226.0,\"end\":1247.0,\"text\":\"(Fierro et al., 2013)\",\"ref_id\":\"BIBREF118\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1226-1247> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1175-1198> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-364-389> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-710-729> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-814-833> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-325-342> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-870-891> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1080-1101> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-343-363> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1102-1122> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1123-1146> , <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-730-743> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "There are many conditions that may cause oxidative damage and result in eccentrocytosis, Heinz body formation, or even both simultaneously. Diabetes mellitus may cause either morphologic change, and diabetic ketoacidosis appears to be associated with an increased susceptibility and incidence of oxidative erythrocyte damage (Desnoyers, 2010; Caldin et al., 2005; Christopher et al., 1995) . Inherited deficiencies in erythrocyte glucose-6-phosphate dehydrogenase (G6PD) and flavin adenine dinucleotide (FAD) have also been associated with erythrocyte oxidative damage, eccentrocyte or Heinz body formation, and hemolysis or a predisposition for these events due to the loss of protective antioxidant pathways (Chan et al., 1982; Harvey, 2006) . Lymphoma has also been associated with Heinz body formation in cats (Christopher, 1989) and eccentrocytes formation in dogs (Caldin et al., 2005) . In dogs and cats, ingestion of Allium species, particularly onions, garlic, and Chinese chive, may cause erythrocyte oxidative damage with formation of eccentrocytes and/or Heinz bodies (Caldin et al., 2005; Yamato et al., 2005; Robertson et al., 1998) . Ingestion of zinc in dogs (Bexfield et al., 2007) and exposure to skunk musk (Fierro et al., 2013) have also been reported to cause hemolysis due to Heinz body formation." ;
            <http://www.example.org/textHash>
                    "6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080" .
    
    <http://covid19.aksw.org/text-bff38a4d3e845937e91b1d52d80ad8c5d481eef00c5d069359a60124bed426f3_citespan-699-713>
            <http://www.example.org/end>    "713.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF140" ;
            <http://www.example.org/start>  "699.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Gergely, 1999)" .
    
    <http://covid19.aksw.org/text-b124d38870179659c047325ddb815425ab0807ba7d7dba5e5c1223d88cf41739>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Xenobiotic-induced bone marrow suppression can often cause decreases in blood monocyte counts in combination with decreases in other blood component counts. Causes include chemotherapeutic agents, such as discussed in xenobiotic-induced decreases in neutrophil counts, due to direct hematopoietic precursor cell toxicity and xenobiotics associated with aplastic anemia, such as chloramphenicol. Monocyte cytotoxicity has been reported with methylmetacrylate monomer used in joint replacement surgery (Dahl et al., 1994) . Lindane, a pesticide, has been reported to cause CFU-GM cytotoxicity (Parent-Massin and Thouvenot, 1993).\",\"cite_spans\":[{\"start\":500.0,\"end\":519.0,\"text\":\"(Dahl et al., 1994)\",\"ref_id\":\"BIBREF84\"}],\"ref_spans\":[],\"section\":\"Xenobiotic-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b124d38870179659c047325ddb815425ab0807ba7d7dba5e5c1223d88cf41739_citespan-500-519> ;
            <http://www.example.org/section>
                    "Xenobiotic-induced" ;
            <http://www.example.org/text>  "Xenobiotic-induced bone marrow suppression can often cause decreases in blood monocyte counts in combination with decreases in other blood component counts. Causes include chemotherapeutic agents, such as discussed in xenobiotic-induced decreases in neutrophil counts, due to direct hematopoietic precursor cell toxicity and xenobiotics associated with aplastic anemia, such as chloramphenicol. Monocyte cytotoxicity has been reported with methylmetacrylate monomer used in joint replacement surgery (Dahl et al., 1994) . Lindane, a pesticide, has been reported to cause CFU-GM cytotoxicity (Parent-Massin and Thouvenot, 1993)." ;
            <http://www.example.org/textHash>
                    "b124d38870179659c047325ddb815425ab0807ba7d7dba5e5c1223d88cf41739" .
    
    <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Babesia species are tick-borne protozoal organisms that directly infect erythrocytes in most species, including humans, nonhuman primates, dogs, and cats. Babesia species appear as intracellular oval to pyriform organisms. Babesia microti and Babesia divergens may infect humans in North America and Europe, respectively, and cause moderate hemolytic anemia from intraerythrocytic replication and subsequent erythrocyte lysis (Lichtman, 2016b; Kjemtrup and Conrad, 2000) . Babesia pitheci has been reported to infect both old and new world monkeys and cause anemia (Magden et al., 2015) . B. canis, a large babesial species, and B. gibsoni, a small babesial species, infect dogs, while cats may be infected by the small babesial organisms B. felis and B. cati (Stockham and Scott, 2008b; Penzhorn et al., 2004) . These organisms are generally not of concern in purpose-bred animals used in nonclinical toxicology studies.\",\"cite_spans\":[{\"start\":426.0,\"end\":443.0,\"text\":\"(Lichtman, 2016b;\",\"ref_id\":\"BIBREF226\"},{\"start\":444.0,\"end\":470.0,\"text\":\"Kjemtrup and Conrad, 2000)\",\"ref_id\":\"BIBREF202\"},{\"start\":565.0,\"end\":586.0,\"text\":\"(Magden et al., 2015)\",\"ref_id\":\"BIBREF238\"},{\"start\":760.0,\"end\":787.0,\"text\":\"(Stockham and Scott, 2008b;\",\"ref_id\":\"BIBREF367\"},{\"start\":788.0,\"end\":810.0,\"text\":\"Penzhorn et al., 2004)\",\"ref_id\":\"BIBREF294\"}],\"ref_spans\":[],\"section\":\"Hemolysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-426-443> , <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-444-470> , <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-565-586> , <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-760-787> , <http://covid19.aksw.org/text-e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3_citespan-788-810> ;
            <http://www.example.org/section>
                    "Hemolysis" ;
            <http://www.example.org/text>  "Babesia species are tick-borne protozoal organisms that directly infect erythrocytes in most species, including humans, nonhuman primates, dogs, and cats. Babesia species appear as intracellular oval to pyriform organisms. Babesia microti and Babesia divergens may infect humans in North America and Europe, respectively, and cause moderate hemolytic anemia from intraerythrocytic replication and subsequent erythrocyte lysis (Lichtman, 2016b; Kjemtrup and Conrad, 2000) . Babesia pitheci has been reported to infect both old and new world monkeys and cause anemia (Magden et al., 2015) . B. canis, a large babesial species, and B. gibsoni, a small babesial species, infect dogs, while cats may be infected by the small babesial organisms B. felis and B. cati (Stockham and Scott, 2008b; Penzhorn et al., 2004) . These organisms are generally not of concern in purpose-bred animals used in nonclinical toxicology studies." ;
            <http://www.example.org/textHash>
                    "e717d34d0770acfa29cf62eefd59ff8cb0f429859f6d3af6c1298084fa5714c3" .
    
    <http://covid19.aksw.org/text-ab6f782396df99676e7e61c3ad36885945fe800d8214fb6307b48d11ea46e181_citespan-685-706>
            <http://www.example.org/end>    "706.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF205" ;
            <http://www.example.org/start>  "685.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kohn and Fumi, 2008)" .
    
    <http://covid19.aksw.org/text-3a9094be98b4c9fa7ebda77444be6043364adf206c55e3c5fa9da0e3550d3209_citespan-1177-1198>
            <http://www.example.org/end>    "1198.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF110" ;
            <http://www.example.org/start>  "1177.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Faquin et al., 1992;" .
    
    <http://covid19.aksw.org/text-2252bb39c3ba663ece825638d176ed9cf503dec74ead8f47fa402a1e7de6e486_citespan-1736-1749>
            <http://www.example.org/end>    "1749.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF358" ;
            <http://www.example.org/start>  "1736.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Smith, 2016)" .
    
    <http://covid19.aksw.org/text-6c1f9868c597e731bf0c78ba95ee91238672dc119ca1002b14fe3a1fbb0e0080_citespan-1123-1146>
            <http://www.example.org/end>    "1146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF321" ;
            <http://www.example.org/start>  "1123.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Robertson et al., 1998)" .
    
    <http://covid19.aksw.org/text-db8e6269aebb878f58ed6d5f1b171bf5d87035f3d7e5dc19369b7b4d49a9d526_citespan-1431-1455>
            <http://www.example.org/end>    "1455.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF324" ;
            <http://www.example.org/start>  "1431.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Rosenberg et al., 2013)" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1014-1045>
            <http://www.example.org/end>    "1045.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF94" ;
            <http://www.example.org/start>  "1014.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Diz-Küçükkaya and López, 2016;" .
    
    <http://covid19.aksw.org/text-69fe9736d186d78134763bcde7f7a90ace7161f691160023865e092fe1be944c_citespan-1300-1323>
            <http://www.example.org/end>    "1323.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF313" ;
            <http://www.example.org/start>  "1300.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Randolph et al., 2010)" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Suppression of granulopoiesis or direct granulocyte toxicity is also reported with some nonchemotherapeutic agents. Dosedependent inhibition of colony-forming units of granulocytes and macrophages in the bone marrow has been reported with several anticonvulsant drugs, including valproic acid and carbamazepine, and beta-lactam antibiotics (Schwartzberg, 2006; Irvine et al., 1994; Watts et al., 1990; Neftel et al., 1985) . Several other anticonvulsant drugs, including ethosuximide (Mintzer et al., 2009) and phenytoin (Sharafuddin et al., 1991) , have been reported to cause direct toxic effects on granulocyte precursors. Antipsychotic agents, including clozapine and chlorpromazine, may also cause direct cytotoxic effects: neutrophil metabolism of clozapine has been demonstrated to form an unstable intracellular metabolite, nitrenium ion, which depletes glutathione and makes the neutrophils susceptible to oxidative damage and apoptosis (Williams et al., 2000) ; chlorpromazine may cause cytotoxicity through the inhibition of thymidine and uracil uptake by neutrophils (Pisciotta and Kaldahl, 1962) . Thienopyridine inhibitors of platelet aggregation, including clopidogrel and ticlopidine, have also been associated with direct neutrophil toxicity resulting from mitochondrial toxicity by metabolites generated through myeloperoxidase metabolism of the parent compounds (Maseneni et al., 2012 (Maseneni et al., , 2013 .\",\"cite_spans\":[{\"start\":340.0,\"end\":360.0,\"text\":\"(Schwartzberg, 2006;\"},{\"start\":361.0,\"end\":381.0,\"text\":\"Irvine et al., 1994;\",\"ref_id\":\"BIBREF177\"},{\"start\":382.0,\"end\":401.0,\"text\":\"Watts et al., 1990;\",\"ref_id\":\"BIBREF421\"},{\"start\":402.0,\"end\":422.0,\"text\":\"Neftel et al., 1985)\",\"ref_id\":\"BIBREF273\"},{\"start\":484.0,\"end\":506.0,\"text\":\"(Mintzer et al., 2009)\",\"ref_id\":\"BIBREF261\"},{\"start\":521.0,\"end\":547.0,\"text\":\"(Sharafuddin et al., 1991)\",\"ref_id\":\"BIBREF348\"},{\"start\":946.0,\"end\":969.0,\"text\":\"(Williams et al., 2000)\",\"ref_id\":\"BIBREF431\"},{\"start\":1079.0,\"end\":1108.0,\"text\":\"(Pisciotta and Kaldahl, 1962)\",\"ref_id\":\"BIBREF298\"},{\"start\":1381.0,\"end\":1403.0,\"text\":\"(Maseneni et al., 2012\",\"ref_id\":\"BIBREF248\"},{\"start\":1404.0,\"end\":1428.0,\"text\":\"(Maseneni et al., , 2013\",\"ref_id\":\"BIBREF249\"}],\"ref_spans\":[],\"section\":\"Viral-induced\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-521-547> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-1079-1108> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-484-506> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-382-401> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-340-360> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-402-422> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-946-969> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-1404-1428> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-1381-1403> , <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-361-381> ;
            <http://www.example.org/section>
                    "Viral-induced" ;
            <http://www.example.org/text>  "Suppression of granulopoiesis or direct granulocyte toxicity is also reported with some nonchemotherapeutic agents. Dosedependent inhibition of colony-forming units of granulocytes and macrophages in the bone marrow has been reported with several anticonvulsant drugs, including valproic acid and carbamazepine, and beta-lactam antibiotics (Schwartzberg, 2006; Irvine et al., 1994; Watts et al., 1990; Neftel et al., 1985) . Several other anticonvulsant drugs, including ethosuximide (Mintzer et al., 2009) and phenytoin (Sharafuddin et al., 1991) , have been reported to cause direct toxic effects on granulocyte precursors. Antipsychotic agents, including clozapine and chlorpromazine, may also cause direct cytotoxic effects: neutrophil metabolism of clozapine has been demonstrated to form an unstable intracellular metabolite, nitrenium ion, which depletes glutathione and makes the neutrophils susceptible to oxidative damage and apoptosis (Williams et al., 2000) ; chlorpromazine may cause cytotoxicity through the inhibition of thymidine and uracil uptake by neutrophils (Pisciotta and Kaldahl, 1962) . Thienopyridine inhibitors of platelet aggregation, including clopidogrel and ticlopidine, have also been associated with direct neutrophil toxicity resulting from mitochondrial toxicity by metabolites generated through myeloperoxidase metabolism of the parent compounds (Maseneni et al., 2012 (Maseneni et al., , 2013 ." ;
            <http://www.example.org/textHash>
                    "b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27" .
    
    <http://covid19.aksw.org/text-139543a0beb5bc7e2148653faf8edfe56734a6e4b6f6ab9f95cf4d93abd2d865_citespan-208-223>
            <http://www.example.org/end>    "223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF420" ;
            <http://www.example.org/start>  "208.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Wardlaw, 2016;" .
    
    <http://covid19.aksw.org/text-40557015ff8a4eadf9c6bd3d20e69ee12535abc61685d298233aa2ef8224e0e8_citespan-1728-1759>
            <http://www.example.org/end>    "1759.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF94" ;
            <http://www.example.org/start>  "1728.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Diz-Küçükkaya and López, 2016;" .
    
    <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-461-473>
            <http://www.example.org/end>    "473.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF428" ;
            <http://www.example.org/start>  "461.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Weiss, 2010;" .
    
    <http://covid19.aksw.org/text-295a630b070bc108a76195976ebfa9e5cd9bbf4399a24bbac211ce06c276e470_citespan-2534-2548>
            <http://www.example.org/end>    "2548.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF267" ;
            <http://www.example.org/start>  "2534.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Muller, 2012)" .
    
    <http://covid19.aksw.org/text-1656ae5b2cf3f1d919719bc09fb19d8b7fcfb2bc90d090f27244be87e0ed3652_citespan-462-485>
            <http://www.example.org/end>    "485.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF180" ;
            <http://www.example.org/start>  "462.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Jaakkola et al., 2001)" .
    
    <http://covid19.aksw.org/text-428a7fb3173a28f29ce777c3cf0df58efb56e0b15d2a1a1bd051088f011a2554_citespan-458-481>
            <http://www.example.org/end>    "481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF151" ;
            <http://www.example.org/start>  "458.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Gonzalez et al., 1991)" .
    
    <http://covid19.aksw.org/text-2f7f591c2df65564c5c3d71e30be629a6f11aec40d221372faab22279946d05f_citespan-153-177>
            <http://www.example.org/end>    "177.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bloom and Brandt, 2008)" .
    
    <http://covid19.aksw.org/text-b83e8da7e6c671ee51c7a848fc934132e9d4529e199bc1521f9bdf967d815125_citespan-160-183>
            <http://www.example.org/end>    "183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF176" ;
            <http://www.example.org/start>  "160.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Ichikawa et al., 1998)" .
    
    <http://covid19.aksw.org/text-ae0c718ce406b87a50b7e46fc296afe92034a867f7b1ae0e64ba318ac35a13a8_citespan-280-296>
            <http://www.example.org/end>    "296.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF342" ;
            <http://www.example.org/start>  "280.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Schultze, 2010;" .
    
    <http://covid19.aksw.org/text-f4140d7cf7fca25e7ba042cc66fffc98428a6f7571a102867edf26fb35dba288_citespan-1118-1138>
            <http://www.example.org/end>    "1138.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "1118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Arock et al., 2002)" .
    
    <http://covid19.aksw.org/text-60c02907d89fda325b632248d63349e3fb28fc19bf13553f740235beb86efd61>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Bone marrow common myeloid progenitors differentiate into the monocytic lineage under stimulation by stem cell factor, GM-CSF, macrophage-colony-stimulating factor (M-CSF), IL-6, IL-1, and IL-3 (Papenfuss, 2010) . Monoblasts further differentiate to promonocytes and then to monocytes.\",\"cite_spans\":[{\"start\":194.0,\"end\":211.0,\"text\":\"(Papenfuss, 2010)\",\"ref_id\":\"BIBREF289\"}],\"ref_spans\":[],\"section\":\"Monocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-60c02907d89fda325b632248d63349e3fb28fc19bf13553f740235beb86efd61_citespan-194-211> ;
            <http://www.example.org/section>
                    "Monocytes" ;
            <http://www.example.org/text>  "Bone marrow common myeloid progenitors differentiate into the monocytic lineage under stimulation by stem cell factor, GM-CSF, macrophage-colony-stimulating factor (M-CSF), IL-6, IL-1, and IL-3 (Papenfuss, 2010) . Monoblasts further differentiate to promonocytes and then to monocytes." ;
            <http://www.example.org/textHash>
                    "60c02907d89fda325b632248d63349e3fb28fc19bf13553f740235beb86efd61" .
    
    <http://covid19.aksw.org/text-24698c59654c31d5ab904c8e1ea7541fa90001095220145f8f9e5fad700b6391_citespan-561-585>
            <http://www.example.org/end>    "585.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF272" ;
            <http://www.example.org/start>  "561.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Nackaerts et al., 1998)" .
    
    <http://covid19.aksw.org/text-886a10703ee186646c1fcef132a95376cda2fd0abf66e04049f8c8a7ccc1629f_citespan-527-549>
            <http://www.example.org/end>    "549.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "527.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Bierman et al., 1952)" .
    
    <http://covid19.aksw.org/text-10d70c28a9feb5ae521fa2abfc09051618162699cf7e4ecb73bd0843e3493742_citespan-474-500>
            <http://www.example.org/end>    "500.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF368" ;
            <http://www.example.org/start>  "474.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008c)" .
    
    <http://covid19.aksw.org/text-eaca621e2520803ad64efefc084bc34193ea644dfaee50d10d2673b3f62b0524_citespan-1207-1226>
            <http://www.example.org/end>    "1226.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF331" ;
            <http://www.example.org/start>  "1207.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Sadun et al., 1965)" .
    
    <http://covid19.aksw.org/text-0cb8b2ba3532554b4a991a2bc9dd521148af21888a273c9ee622c5dbcde96db0_citespan-332-358>
            <http://www.example.org/end>    "358.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a)" .
    
    <http://covid19.aksw.org/text-76d865d10df7e69d5efe4aba052c98cdf3b7530a48849e47a9639b4b7f492add_citespan-266-291>
            <http://www.example.org/end>    "291.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF125" ;
            <http://www.example.org/start>  "266.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Frye and Thompson, 1993)" .
    
    <http://covid19.aksw.org/text-a20deba2adb2945956a65150d1c0004f0697886dd96905f6af91893db4c5a4b3_citespan-639-666>
            <http://www.example.org/end>    "666.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF367" ;
            <http://www.example.org/start>  "639.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Stockham and Scott, 2008b)" .
    
    <http://covid19.aksw.org/text-8c3262e1180356c69c49cf70efd69d4d08d29082804a03fc27e1c319954608d0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The major role of erythrocytes is to carry oxygen, which binds to hemoglobin, from the lungs to tissues. Altered tissue demands for oxygen can increase or decrease the production of EPO and therefore erythropoiesis. In the adult, EPO is produced by the kidney in response to hypoxia.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Erythrocytes\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Erythrocytes" ;
            <http://www.example.org/text>  "The major role of erythrocytes is to carry oxygen, which binds to hemoglobin, from the lungs to tissues. Altered tissue demands for oxygen can increase or decrease the production of EPO and therefore erythropoiesis. In the adult, EPO is produced by the kidney in response to hypoxia." ;
            <http://www.example.org/textHash>
                    "8c3262e1180356c69c49cf70efd69d4d08d29082804a03fc27e1c319954608d0" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-493-519>
            <http://www.example.org/end>    "519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF366" ;
            <http://www.example.org/start>  "493.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Stockham and Scott, 2008a;" .
    
    <http://covid19.aksw.org/text-139543a0beb5bc7e2148653faf8edfe56734a6e4b6f6ab9f95cf4d93abd2d865>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.4.1.1 Decreased glucocorticoids Although uncommon, decreases in endogenous glucocorticoid concentrations due to hypoadrenocorticism have been associated with mild increases in blood eosinophil counts (Wardlaw, 2016; Stockham and Scott, 2008a ). This effect is most likely due to the loss of glucocorticoid-associated shifting of blood eosinophils to the marginating pool as well as the lack of proapoptotic stimulation of glucocorticoids on eosinophil precursors.\",\"cite_spans\":[{\"start\":208.0,\"end\":223.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":224.0,\"end\":249.0,\"text\":\"Stockham and Scott, 2008a\",\"ref_id\":\"BIBREF366\"}],\"ref_spans\":[],\"section\":\"Increases in eosinophil counts (eosinophilia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-139543a0beb5bc7e2148653faf8edfe56734a6e4b6f6ab9f95cf4d93abd2d865_citespan-208-223> , <http://covid19.aksw.org/text-139543a0beb5bc7e2148653faf8edfe56734a6e4b6f6ab9f95cf4d93abd2d865_citespan-224-249> ;
            <http://www.example.org/section>
                    "Increases in eosinophil counts (eosinophilia)" ;
            <http://www.example.org/text>  "12.11.2.4.1.1 Decreased glucocorticoids Although uncommon, decreases in endogenous glucocorticoid concentrations due to hypoadrenocorticism have been associated with mild increases in blood eosinophil counts (Wardlaw, 2016; Stockham and Scott, 2008a ). This effect is most likely due to the loss of glucocorticoid-associated shifting of blood eosinophils to the marginating pool as well as the lack of proapoptotic stimulation of glucocorticoids on eosinophil precursors." ;
            <http://www.example.org/textHash>
                    "139543a0beb5bc7e2148653faf8edfe56734a6e4b6f6ab9f95cf4d93abd2d865" .
    
    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Inflammatory increases in blood eosinophil counts can also be associated with paraneoplastic syndromes, likely related to increases in IL-5, which may be liberated by activated T H cells or directly by the neoplasm. Lymphoma, including both T-and B-cell lymphomas, is a common cause of paraneoplastic increases in eosinophil counts in multiple species, including humans, dogs, cats, and horses (Wardlaw, 2016; Davis and Rothenberg, 2014; Valent, 2009; Schultze, 2010; Valenciano et al., 2010; Stockham and Scott, 2008a; Marchetti et al., 2005; Cave et al., 2004; Duckett and Matthews, 1997) . However, many nonlymphoid tumors have also been associated with paraneoplastic increases in blood eosinophil counts, including mammary carcinoma, hepatocellular carcinoma, squamous cell carcinoma, thymoma, nonsmall-cell lung cancer, and mast cell diseases including systemic mastocytosis and mast cell leukemia (Schultze, 2010; Balian et al., 2001; Walter et al., 2002; Pandit et al., 2007; Valent, 2009 ).\",\"cite_spans\":[{\"start\":394.0,\"end\":409.0,\"text\":\"(Wardlaw, 2016;\",\"ref_id\":\"BIBREF420\"},{\"start\":410.0,\"end\":437.0,\"text\":\"Davis and Rothenberg, 2014;\",\"ref_id\":\"BIBREF87\"},{\"start\":438.0,\"end\":451.0,\"text\":\"Valent, 2009;\",\"ref_id\":\"BIBREF401\"},{\"start\":452.0,\"end\":467.0,\"text\":\"Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":468.0,\"end\":492.0,\"text\":\"Valenciano et al., 2010;\",\"ref_id\":\"BIBREF400\"},{\"start\":493.0,\"end\":519.0,\"text\":\"Stockham and Scott, 2008a;\",\"ref_id\":\"BIBREF366\"},{\"start\":520.0,\"end\":543.0,\"text\":\"Marchetti et al., 2005;\",\"ref_id\":\"BIBREF243\"},{\"start\":544.0,\"end\":562.0,\"text\":\"Cave et al., 2004;\",\"ref_id\":\"BIBREF61\"},{\"start\":563.0,\"end\":590.0,\"text\":\"Duckett and Matthews, 1997)\",\"ref_id\":\"BIBREF99\"},{\"start\":904.0,\"end\":920.0,\"text\":\"(Schultze, 2010;\",\"ref_id\":\"BIBREF342\"},{\"start\":921.0,\"end\":941.0,\"text\":\"Balian et al., 2001;\",\"ref_id\":\"BIBREF16\"},{\"start\":942.0,\"end\":962.0,\"text\":\"Walter et al., 2002;\",\"ref_id\":\"BIBREF417\"},{\"start\":963.0,\"end\":983.0,\"text\":\"Pandit et al., 2007;\",\"ref_id\":\"BIBREF287\"},{\"start\":984.0,\"end\":996.0,\"text\":\"Valent, 2009\",\"ref_id\":\"BIBREF401\"}],\"ref_spans\":[],\"section\":\"Inflammation and Hypersensitivity\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-493-519> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-984-996> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-468-492> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-544-562> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-410-437> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-452-467> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-563-590> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-921-941> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-963-983> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-942-962> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-520-543> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-904-920> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-438-451> , <http://covid19.aksw.org/text-9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b_citespan-394-409> ;
            <http://www.example.org/section>
                    "Inflammation and Hypersensitivity" ;
            <http://www.example.org/text>  "Inflammatory increases in blood eosinophil counts can also be associated with paraneoplastic syndromes, likely related to increases in IL-5, which may be liberated by activated T H cells or directly by the neoplasm. Lymphoma, including both T-and B-cell lymphomas, is a common cause of paraneoplastic increases in eosinophil counts in multiple species, including humans, dogs, cats, and horses (Wardlaw, 2016; Davis and Rothenberg, 2014; Valent, 2009; Schultze, 2010; Valenciano et al., 2010; Stockham and Scott, 2008a; Marchetti et al., 2005; Cave et al., 2004; Duckett and Matthews, 1997) . However, many nonlymphoid tumors have also been associated with paraneoplastic increases in blood eosinophil counts, including mammary carcinoma, hepatocellular carcinoma, squamous cell carcinoma, thymoma, nonsmall-cell lung cancer, and mast cell diseases including systemic mastocytosis and mast cell leukemia (Schultze, 2010; Balian et al., 2001; Walter et al., 2002; Pandit et al., 2007; Valent, 2009 )." ;
            <http://www.example.org/textHash>
                    "9a28fc6b8e9f7e287a107c4602aac16df96cb83965f91b8a9be29cc1579a8f6b" .
    
    <http://covid19.aksw.org/text-0b573f4dae5ca133641060b9e3b8cf8b4a1de12f39095934a728b8501b58deb3_citespan-562-586>
            <http://www.example.org/end>    "586.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF244" ;
            <http://www.example.org/start>  "562.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Marcondes et al., 2000)" .
    
    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-176-190>
            <http://www.example.org/end>    "190.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF188" ;
            <http://www.example.org/start>  "176.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Juhlin, 1963b;" .
    
    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"12.11.2.5.2.1 Glucocorticoid-induced Increases in glucocorticoid concentrations, particularly if prolonged, cause decreases in blood basophil counts (Shelley and Parnes, 1965; Juhlin, 1963b; Boseila, 1963) . Similar to glucocorticoid-induced decreases in eosinophil counts, there is likely shifting of blood basophils from the circulating to marginating pool. There is also evidence that glucocorticoids cause migration of basophils from circulation into tissues and decrease recirculation from tissue back into blood (Wald et al., 1991) . Direct lytic effects on blood or tissue basophils and suppression of basophil production in the bone marrow may also contribute (Boseila, 1963) . Myocardial infarction, which has been associated with decreases in blood basophil counts, may be mediated by effects of chronic stress secondary to the ischemic event (Juhlin, 1963c) .\",\"cite_spans\":[{\"start\":149.0,\"end\":175.0,\"text\":\"(Shelley and Parnes, 1965;\",\"ref_id\":\"BIBREF352\"},{\"start\":176.0,\"end\":190.0,\"text\":\"Juhlin, 1963b;\",\"ref_id\":\"BIBREF188\"},{\"start\":191.0,\"end\":205.0,\"text\":\"Boseila, 1963)\",\"ref_id\":\"BIBREF39\"},{\"start\":518.0,\"end\":537.0,\"text\":\"(Wald et al., 1991)\",\"ref_id\":\"BIBREF414\"},{\"start\":668.0,\"end\":683.0,\"text\":\"(Boseila, 1963)\",\"ref_id\":\"BIBREF39\"},{\"start\":853.0,\"end\":868.0,\"text\":\"(Juhlin, 1963c)\",\"ref_id\":\"BIBREF189\"}],\"ref_spans\":[],\"section\":\"Decreases in basophil counts (basopenia)\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-518-537> , <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-176-190> , <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-149-175> , <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-853-868> , <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-668-683> , <http://covid19.aksw.org/text-2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14_citespan-191-205> ;
            <http://www.example.org/section>
                    "Decreases in basophil counts (basopenia)" ;
            <http://www.example.org/text>  "12.11.2.5.2.1 Glucocorticoid-induced Increases in glucocorticoid concentrations, particularly if prolonged, cause decreases in blood basophil counts (Shelley and Parnes, 1965; Juhlin, 1963b; Boseila, 1963) . Similar to glucocorticoid-induced decreases in eosinophil counts, there is likely shifting of blood basophils from the circulating to marginating pool. There is also evidence that glucocorticoids cause migration of basophils from circulation into tissues and decrease recirculation from tissue back into blood (Wald et al., 1991) . Direct lytic effects on blood or tissue basophils and suppression of basophil production in the bone marrow may also contribute (Boseila, 1963) . Myocardial infarction, which has been associated with decreases in blood basophil counts, may be mediated by effects of chronic stress secondary to the ischemic event (Juhlin, 1963c) ." ;
            <http://www.example.org/textHash>
                    "2e5a98c1843c43d2c1ff74d183fa3bf49447d248452730fad49e711bac576e14" .
    
    <http://covid19.aksw.org/text-f7fddc45a41b0a3fd88ccda0689fe426b0c1202b1989d85659228bf7a5991ff0_citespan-285-305>
            <http://www.example.org/end>    "305.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF83" ;
            <http://www.example.org/start>  "285.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Custer et al., 1985)" .
    
    <http://covid19.aksw.org/text-31aa2ecbcfef9bb7cc3c6cfd5b5b6f038f198c92fa3205805f497c1ef9cf25ca_citespan-359-382>
            <http://www.example.org/end>    "382.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF247" ;
            <http://www.example.org/start>  "359.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Marsh and Lewis, 1969)" .
    
    <http://covid19.aksw.org/text-47a6a77e71c7d637b58dfb27c5e65047f6f55526f62b2d2b3ae06eca563090a0_citespan-634-657>
            <http://www.example.org/end>    "657.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF219" ;
            <http://www.example.org/start>  "634.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Leder and Weller, 2000;" .
    
    <http://covid19.aksw.org/text-460615260d595b6c5ee43899c9040a3d270e67351155e20e02624a5dedf229a9_citespan-737-762>
            <http://www.example.org/end>    "762.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF263" ;
            <http://www.example.org/start>  "737.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Montagle and Tauro, 1995;" .
    
    <http://covid19.aksw.org/text-fbcc465ad9b6337558e3b283e773758ed277fa345848fe25feba167077e83bb6_citespan-462-487>
            <http://www.example.org/end>    "487.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF227" ;
            <http://www.example.org/start>  "462.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Lichtman and Segel, 2005;" .
    
    <http://covid19.aksw.org/text-b9b2dac567abb46806a9ef8eb59191aadd929c3ff968ec6b5d7f5a2660a06e27_citespan-521-547>
            <http://www.example.org/end>    "547.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF348" ;
            <http://www.example.org/start>  "521.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Sharafuddin et al., 1991)" .
    
    <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Glucocorticoids have a negative effect on blood lymphocyte counts due to their effects on lymphocyte distribution in the body and suppression of lymphopoieis. Hypoadrenocorticism (Addison\\u0027s disease), in which the adrenal glands are unable to maintain normal concentrations of glucocorticoids, may be associated with increases in blood lymphocyte counts due to the loss of the inhibitory effects of endogenous glucocorticoids (Oelkers, 1996; Stockham and Scott, 2008a; Avery and Avery, 2007) .\",\"cite_spans\":[{\"start\":425.0,\"end\":440.0,\"text\":\"(Oelkers, 1996;\",\"ref_id\":\"BIBREF277\"},{\"start\":441.0,\"end\":467.0,\"text\":\"Stockham and Scott, 2008a;\",\"ref_id\":\"BIBREF366\"},{\"start\":468.0,\"end\":490.0,\"text\":\"Avery and Avery, 2007)\",\"ref_id\":\"BIBREF14\"}],\"ref_spans\":[],\"section\":\"Decreased Glucocorticoids\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327_citespan-425-440> , <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327_citespan-441-467> , <http://covid19.aksw.org/text-e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327_citespan-468-490> ;
            <http://www.example.org/section>
                    "Decreased Glucocorticoids" ;
            <http://www.example.org/text>  "Glucocorticoids have a negative effect on blood lymphocyte counts due to their effects on lymphocyte distribution in the body and suppression of lymphopoieis. Hypoadrenocorticism (Addison's disease), in which the adrenal glands are unable to maintain normal concentrations of glucocorticoids, may be associated with increases in blood lymphocyte counts due to the loss of the inhibitory effects of endogenous glucocorticoids (Oelkers, 1996; Stockham and Scott, 2008a; Avery and Avery, 2007) ." ;
            <http://www.example.org/textHash>
                    "e39cacffe95bb3266777ac7e423f99b3805ea0baa2c664ce8a91b351ca665327" .
    
    <http://covid19.aksw.org/text-3811430106d3b33bdc10f9fe4a6c69213a615def0d58ae74df4c0a2047eb4f78_citespan-89-115>
            <http://www.example.org/end>    "115.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF352" ;
            <http://www.example.org/start>  "89.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Shelley and Parnes, 1965;" .
}
<http://covid19.aksw.org/d34c5f3a5f439702d5c04a9c11b8b5c18d869151> {
    <http://covid19.aksw.org/text-1f6da04f0dd8ce2f4baac7cd3d00d2cd71650e6567f961b36cb48f1e2fea547c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where I is the set of inputs, D is the set of documents and R is the set of related document sets.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Preliminaries\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Preliminaries" ;
            <http://www.example.org/text>  "where I is the set of inputs, D is the set of documents and R is the set of related document sets." ;
            <http://www.example.org/textHash>
                    "1f6da04f0dd8ce2f4baac7cd3d00d2cd71650e6567f961b36cb48f1e2fea547c" .
    
    <http://covid19.aksw.org/text-91bd359b1d5d20d4aae19684fd74ddda3ecf0732cb79a824d699f03c2c9830d9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"If users are only interested in the event reference relationships between events, we can conduct a π r projection on of a TEM and obtain a reference TEM as shown in Fig. 10 , which is a sub-graph of the whole TEM. Such a sub-graph only shows the event reference relationships between events. Notationally, we represent the projection based on reference dependency relationship for TEM i as π r (TEM i ).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":165.0,\"end\":172.0,\"text\":\"Fig. 10\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Projection based on reference relation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-91bd359b1d5d20d4aae19684fd74ddda3ecf0732cb79a824d699f03c2c9830d9_refspan-165-172> ;
            <http://www.example.org/section>
                    "Projection based on reference relation" ;
            <http://www.example.org/text>  "If users are only interested in the event reference relationships between events, we can conduct a π r projection on of a TEM and obtain a reference TEM as shown in Fig. 10 , which is a sub-graph of the whole TEM. Such a sub-graph only shows the event reference relationships between events. Notationally, we represent the projection based on reference dependency relationship for TEM i as π r (TEM i )." ;
            <http://www.example.org/textHash>
                    "91bd359b1d5d20d4aae19684fd74ddda3ecf0732cb79a824d699f03c2c9830d9" .
    
    <http://covid19.aksw.org/text-a4d1b9fdb6626753ae297a7d39f129c783686b097c7784c724c20512fee50c22>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In TEM construction, there is a parameter α which is used to prune the \\u0027\\u0027weak\\u0027\\u0027 event dependency relationships. First, we test different values of α to evaluate the effect of α on Precision,\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "In TEM construction, there is a parameter α which is used to prune the ''weak'' event dependency relationships. First, we test different values of α to evaluate the effect of α on Precision," ;
            <http://www.example.org/textHash>
                    "a4d1b9fdb6626753ae297a7d39f129c783686b097c7784c724c20512fee50c22" .
    
    <http://covid19.aksw.org/text-e195586f477664448fa032125f9b7cb75cc8e4e077583f0dfa5d2057c23ec41e_citespan-13-17>
            <http://www.example.org/end>    "17.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "13.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[30]" .
    
    <http://covid19.aksw.org/text-0212f53c85aac94843f53e3448c684bbe37957b618e3b5126cc384170b9fee90>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• To evaluate the performance of our proposed approach, we conduct experiments on a real data set by comparing a number of baseline methods. Experimental results show that our method outperforms baseline methods in discovering event dependence relationships, as well as in ranking events based on event importance. Furthermore, a case study selected from our experiments shows that our method can discover new relationships that cannot be discovered by previous methods and are even missed/ignored by annotators. Finally, we show the use of these operators on a TEM via select examples.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "• To evaluate the performance of our proposed approach, we conduct experiments on a real data set by comparing a number of baseline methods. Experimental results show that our method outperforms baseline methods in discovering event dependence relationships, as well as in ranking events based on event importance. Furthermore, a case study selected from our experiments shows that our method can discover new relationships that cannot be discovered by previous methods and are even missed/ignored by annotators. Finally, we show the use of these operators on a TEM via select examples." ;
            <http://www.example.org/textHash>
                    "0212f53c85aac94843f53e3448c684bbe37957b618e3b5126cc384170b9fee90" .
    
    <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-76-79>
            <http://www.example.org/end>    "79.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "76.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[4," .
    
    <http://covid19.aksw.org/text-29fd6786379b5aa4a94d32025ad178e1cf5e81c32e6c0d4e60856e7f2cc20edf>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are negative reports and rumors in different countries 8\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "There are negative reports and rumors in different countries 8" ;
            <http://www.example.org/textHash>
                    "29fd6786379b5aa4a94d32025ad178e1cf5e81c32e6c0d4e60856e7f2cc20edf" .
    
    <http://covid19.aksw.org/text-b2bea5f712ce86b543eedfb38907e9389775078ede9af2e9ab6ccdfee955c7ae>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To measure the event importance synthetically, we combine CRank ′ (a) and RRank ′ (a) using an aggregation function Rank(a), as follows:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "To measure the event importance synthetically, we combine CRank ′ (a) and RRank ′ (a) using an aggregation function Rank(a), as follows:" ;
            <http://www.example.org/textHash>
                    "b2bea5f712ce86b543eedfb38907e9389775078ede9af2e9ab6ccdfee955c7ae" .
    
    <http://covid19.aksw.org/text-0f7d89b1a09bc4627a5322f9fdeea1157416a6c7bfbf0e5e1633015915482e74_refspan-97-103>
            <http://www.example.org/end>    "103.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "97.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 1" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-86-89>
            <http://www.example.org/end>    "89.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "86.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[2]" .
    
    <http://covid19.aksw.org/text-85d2631070d181b18fe5ea841549c007515e4c71a6781d12665fd11a12c2c6a1_citespan-704-707>
            <http://www.example.org/end>    "707.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "704.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[1]" .
    
    <http://covid19.aksw.org/text-d6b13aa2cf6d856df470a0804eb1f79ffe8c169773ac5980909e5d7d7e19cb09>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where N b is the number of related documents of b, M a b,i is the number of core features of a existing in the document d b i , and |F c a | is the cardinality of F c a . Note that there is a restriction for M a b,i in Cr (a,b) where M a b,i \\u003e 1, highlighting that a reference relationship from b to a should refer to more than one core feature of a.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":219.0,\"end\":227.0,\"text\":\"Cr (a,b)\"}],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-d6b13aa2cf6d856df470a0804eb1f79ffe8c169773ac5980909e5d7d7e19cb09_refspan-219-227> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "where N b is the number of related documents of b, M a b,i is the number of core features of a existing in the document d b i , and |F c a | is the cardinality of F c a . Note that there is a restriction for M a b,i in Cr (a,b) where M a b,i > 1, highlighting that a reference relationship from b to a should refer to more than one core feature of a." ;
            <http://www.example.org/textHash>
                    "d6b13aa2cf6d856df470a0804eb1f79ffe8c169773ac5980909e5d7d7e19cb09" .
    
    <http://covid19.aksw.org/text-44e9bcf0c640bea3b15799c6cf8d94089c501f5b963df22788a5f94f163756b6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where I is the set of inputs, D is the set of documents and T ′ is the set of temporal event maps. For the example of Fig. 1 , we may have the following query input:\",\"cite_spans\":[],\"ref_spans\":[{\"start\":118.0,\"end\":124.0,\"text\":\"Fig. 1\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Definition 5. A Temporal Event Map is a weighted directed\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-44e9bcf0c640bea3b15799c6cf8d94089c501f5b963df22788a5f94f163756b6_refspan-118-124> ;
            <http://www.example.org/section>
                    "Definition 5. A Temporal Event Map is a weighted directed" ;
            <http://www.example.org/text>  "where I is the set of inputs, D is the set of documents and T ′ is the set of temporal event maps. For the example of Fig. 1 , we may have the following query input:" ;
            <http://www.example.org/textHash>
                    "44e9bcf0c640bea3b15799c6cf8d94089c501f5b963df22788a5f94f163756b6" .
    
    <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-154-158>
            <http://www.example.org/end>    "158.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "154.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[31]" .
    
    <http://covid19.aksw.org/text-0912a8518d83434cbc93d7c72bff31eff461d136574be84b4d42d98784e5db21_refspan-173-179>
            <http://www.example.org/end>    "179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF12" ;
            <http://www.example.org/start>  "173.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 9" .
    
    <http://covid19.aksw.org/text-0912a8518d83434cbc93d7c72bff31eff461d136574be84b4d42d98784e5db21>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"If users are only interested in the content dependency relationships between events, we can conduct a π c projection of a TEM and obtain a content dependent TEM as shown in Fig. 9 . Such a sub-graph only shows the CD relationships between events. Notationally, we denote the projection based on the CD relationship for a TEM i as π c (TEM i ).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":173.0,\"end\":179.0,\"text\":\"Fig. 9\",\"ref_id\":\"FIGREF12\"}],\"section\":\"Projection based on content dependency relation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-0912a8518d83434cbc93d7c72bff31eff461d136574be84b4d42d98784e5db21_refspan-173-179> ;
            <http://www.example.org/section>
                    "Projection based on content dependency relation" ;
            <http://www.example.org/text>  "If users are only interested in the content dependency relationships between events, we can conduct a π c projection of a TEM and obtain a content dependent TEM as shown in Fig. 9 . Such a sub-graph only shows the CD relationships between events. Notationally, we denote the projection based on the CD relationship for a TEM i as π c (TEM i )." ;
            <http://www.example.org/textHash>
                    "0912a8518d83434cbc93d7c72bff31eff461d136574be84b4d42d98784e5db21" .
    
    <http://covid19.aksw.org/text-6201111b83a0cb5b0922cb37cc442b9a40e24e3b1ce100a4bb204f4c63fd2ac0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"and\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"− →\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "− →" ;
            <http://www.example.org/text>  "and" ;
            <http://www.example.org/textHash>
                    "6201111b83a0cb5b0922cb37cc442b9a40e24e3b1ce100a4bb204f4c63fd2ac0" .
    
    <http://covid19.aksw.org/text-ea76ebfe6b6ef32448ba0c317869d7abc0d63cede1682b3ee1b0f0ca9107b422>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The earthquake and tsunami caused a number of nuclear accidents 5\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "The earthquake and tsunami caused a number of nuclear accidents 5" ;
            <http://www.example.org/textHash>
                    "ea76ebfe6b6ef32448ba0c317869d7abc0d63cede1682b3ee1b0f0ca9107b422" .
    
    <http://covid19.aksw.org/text-a4c3a1c1ae0899e54efc49a5d96f0cfc1fbaafe3b4e4ed8b18ed884fdf8dd4c8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To satisfy a user\\u0027s need to find and understand the whole picture of an event effectively and efficiently, in this paper we formalize the problem of temporal event searches and propose a framework of event relationship analysis for search events based on user queries. We define three kinds of event relationships: temporal, content dependence, and event reference, that can be used to identify to what extent a component event is dependent on another in the evolution of a target event (i.e., the query event). The search results are organized as a temporal event map (TEM) that serves as the whole picture about an event\\u0027s evolution or development by showing the dependence relationships among events. Based on the event relationships in the TEM, we further propose a method to measure the degrees of importance of events, so as to discover the important component events for a query, as well as the several algebraic operators involved in the TEM, that allow users to view the target event. Experiments conducted on a real data set show that our method outperforms the baseline method Event Evolution Graph (EEG), and it can help discover certain new relationships missed by previous methods and even by human annotators. ✩ This article is an extension version of a conference proceeding published in Cai et al. (2013) [1], and some notations, definitions, formulations, descriptions, figures, tables and so on are reused to make new contributions smoothly in this article. The new contributions of this article are (1) new methods of event ranking and temporal event map construction; (2) algebraic operations of the event map; (3) more examples, case studies, and metrics in experiments; and (4) more comprehensive literature review and descriptions.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Abstract\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Abstract" ;
            <http://www.example.org/text>  "To satisfy a user's need to find and understand the whole picture of an event effectively and efficiently, in this paper we formalize the problem of temporal event searches and propose a framework of event relationship analysis for search events based on user queries. We define three kinds of event relationships: temporal, content dependence, and event reference, that can be used to identify to what extent a component event is dependent on another in the evolution of a target event (i.e., the query event). The search results are organized as a temporal event map (TEM) that serves as the whole picture about an event's evolution or development by showing the dependence relationships among events. Based on the event relationships in the TEM, we further propose a method to measure the degrees of importance of events, so as to discover the important component events for a query, as well as the several algebraic operators involved in the TEM, that allow users to view the target event. Experiments conducted on a real data set show that our method outperforms the baseline method Event Evolution Graph (EEG), and it can help discover certain new relationships missed by previous methods and even by human annotators. ✩ This article is an extension version of a conference proceeding published in Cai et al. (2013) [1], and some notations, definitions, formulations, descriptions, figures, tables and so on are reused to make new contributions smoothly in this article. The new contributions of this article are (1) new methods of event ranking and temporal event map construction; (2) algebraic operations of the event map; (3) more examples, case studies, and metrics in experiments; and (4) more comprehensive literature review and descriptions." ;
            <http://www.example.org/textHash>
                    "a4c3a1c1ae0899e54efc49a5d96f0cfc1fbaafe3b4e4ed8b18ed884fdf8dd4c8" .
    
    <http://covid19.aksw.org/text-9835da118ea109d104bd9e790258efa25799d7d6b2a0a66395469937684878d7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• Previous attempts to discover dependence relationships between two events measure the similarity of content by matching keywords (terms) related to the events. However, there may be some keywords (in the two events) that are related/dependent but not identical. For example, \\u0027\\u0027hospital\\u0027\\u0027 and \\u0027\\u0027doctor\\u0027\\u0027 are dependent, but previous methods have treated them as having no relationship. To avoid this limitation, we adopt mutual information criteria to measure the dependence between two terms (features), and we then aggregate all mutual information among features in events to measure the degree of content dependence between the events. This process is called content dependence (CD) analysis, and the dependence relationship that is discovered based on the dependence features of two events is called the content dependence relationship.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "• Previous attempts to discover dependence relationships between two events measure the similarity of content by matching keywords (terms) related to the events. However, there may be some keywords (in the two events) that are related/dependent but not identical. For example, ''hospital'' and ''doctor'' are dependent, but previous methods have treated them as having no relationship. To avoid this limitation, we adopt mutual information criteria to measure the dependence between two terms (features), and we then aggregate all mutual information among features in events to measure the degree of content dependence between the events. This process is called content dependence (CD) analysis, and the dependence relationship that is discovered based on the dependence features of two events is called the content dependence relationship." ;
            <http://www.example.org/textHash>
                    "9835da118ea109d104bd9e790258efa25799d7d6b2a0a66395469937684878d7" .
    
    <http://covid19.aksw.org/text-bdd2a1035cbafdfcd7f9959f4c7eeab9a85b40206835604bfa9ca0615c2ae097>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Comparing Our Result and Annotated Result. The search results of our method as a temporal event map (TEM) are shown in Fig. 7. In Fig. 7 , the size of each node represents the importance of an event, and width of each line represents the strength degree of a dependence relationship between events. According to the result, our method misses only 7 relationships, while the EEG method misses 17 relationships. Table 5 shows the statistics of the event relationships discovered by our method and EEG, vis-a-vis the results of the human annotators for this case. As shown, our method finds more, and miss less, correct inter-event relationships. In addition, our method discovers not only the inter-event relationships but also the strength degrees of such relationships. Comparing the relationships missed by our method and EEG, we find that most missing relationships (6 out of 7) are also missing in EEG, and these relationships are: from event 5 to event 1, from event 5 to event 12, from event 2 to event 12, from event 4 to event 6, from event 6 to event 1, and from event 10 to event 8. Only one relationship missed by our method was found by EEG, which is from event 8 to event 11. In contrast, most relationships missed by EEG were discovered by our method. For instance, EEG did not find any relationships for events 1, 4, 5 and 10, while our method found their dependence relationships with other events. We find that most of the relationships missed by EEG were discovered by our method due to event reference analysis rather than content dependence analysis. This means that content dependence analysis and event reference analysis should work together in identifying event dependence relationships. More interestingly, our method found some new relationships that were not found by EEG or by the human annotators. Such new relationships are confirmed and approved later by the annotators as meaningful ones (e.g., the relationship from event 5 to event 2 and the relationship from event 3 to event 2). For the relationship between events 5 and 2, note that event 5 is about the outbreak of SARS and infections that can cause more new SARS cases to appear and make the disease more serious. For the relationship between events 3 and 2, note that event 2 is about the number of SARS cases reported by hospitals, and when SARS cases increased and the disease spread, more and more patients contracted the disease and called for hospital care. According to the annotators, the main reason they missed these relationships was that there were just too many relationships among the events in the data set, which inevitably caused them to miss some during their annotation processes.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":119.0,\"end\":136.0,\"text\":\"Fig. 7. In Fig. 7\"},{\"start\":410.0,\"end\":417.0,\"text\":\"Table 5\"}],\"section\":\"Case study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-bdd2a1035cbafdfcd7f9959f4c7eeab9a85b40206835604bfa9ca0615c2ae097_refspan-119-136> , <http://covid19.aksw.org/text-bdd2a1035cbafdfcd7f9959f4c7eeab9a85b40206835604bfa9ca0615c2ae097_refspan-410-417> ;
            <http://www.example.org/section>
                    "Case study" ;
            <http://www.example.org/text>  "Comparing Our Result and Annotated Result. The search results of our method as a temporal event map (TEM) are shown in Fig. 7. In Fig. 7 , the size of each node represents the importance of an event, and width of each line represents the strength degree of a dependence relationship between events. According to the result, our method misses only 7 relationships, while the EEG method misses 17 relationships. Table 5 shows the statistics of the event relationships discovered by our method and EEG, vis-a-vis the results of the human annotators for this case. As shown, our method finds more, and miss less, correct inter-event relationships. In addition, our method discovers not only the inter-event relationships but also the strength degrees of such relationships. Comparing the relationships missed by our method and EEG, we find that most missing relationships (6 out of 7) are also missing in EEG, and these relationships are: from event 5 to event 1, from event 5 to event 12, from event 2 to event 12, from event 4 to event 6, from event 6 to event 1, and from event 10 to event 8. Only one relationship missed by our method was found by EEG, which is from event 8 to event 11. In contrast, most relationships missed by EEG were discovered by our method. For instance, EEG did not find any relationships for events 1, 4, 5 and 10, while our method found their dependence relationships with other events. We find that most of the relationships missed by EEG were discovered by our method due to event reference analysis rather than content dependence analysis. This means that content dependence analysis and event reference analysis should work together in identifying event dependence relationships. More interestingly, our method found some new relationships that were not found by EEG or by the human annotators. Such new relationships are confirmed and approved later by the annotators as meaningful ones (e.g., the relationship from event 5 to event 2 and the relationship from event 3 to event 2). For the relationship between events 5 and 2, note that event 5 is about the outbreak of SARS and infections that can cause more new SARS cases to appear and make the disease more serious. For the relationship between events 3 and 2, note that event 2 is about the number of SARS cases reported by hospitals, and when SARS cases increased and the disease spread, more and more patients contracted the disease and called for hospital care. According to the annotators, the main reason they missed these relationships was that there were just too many relationships among the events in the data set, which inevitably caused them to miss some during their annotation processes." ;
            <http://www.example.org/textHash>
                    "bdd2a1035cbafdfcd7f9959f4c7eeab9a85b40206835604bfa9ca0615c2ae097" .
    
    <http://covid19.aksw.org/text-558b79cf842219499dadcceb790fe651ffd5dcd0853c0c0298456be9d0957f06>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To the best of our knowledge, there is no previous exploration of analyzing the event reference (ER) relationships for event searches in existing works. In contrast to comparing the contents between events, ER relationship analysis aims to discover and leverage human viewpoints and thoughts on inter-event relationships to support the identification of event dependence relationships.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "To the best of our knowledge, there is no previous exploration of analyzing the event reference (ER) relationships for event searches in existing works. In contrast to comparing the contents between events, ER relationship analysis aims to discover and leverage human viewpoints and thoughts on inter-event relationships to support the identification of event dependence relationships." ;
            <http://www.example.org/textHash>
                    "558b79cf842219499dadcceb790fe651ffd5dcd0853c0c0298456be9d0957f06" .
    
    <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"After setting the value of α, we conduct all test queries and average the results of them on different metrics. The best value of α for each method is also identified. Fig. 4 and Table 2 show the comparison of our method with one baseline method (i.e., EEG) and two variations (i.e., ERM and CDM) on Precision, Recall and F − measure. According to Fig. 4 , it is clear that our method outperforms other three methods on Precision, Recall and F −measure.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":168.0,\"end\":174.0,\"text\":\"Fig. 4\",\"ref_id\":\"FIGREF8\"},{\"start\":179.0,\"end\":186.0,\"text\":\"Table 2\",\"ref_id\":\"TABREF1\"},{\"start\":348.0,\"end\":354.0,\"text\":\"Fig. 4\",\"ref_id\":\"FIGREF8\"}],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8_refspan-168-174> , <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8_refspan-179-186> , <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8_refspan-348-354> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "After setting the value of α, we conduct all test queries and average the results of them on different metrics. The best value of α for each method is also identified. Fig. 4 and Table 2 show the comparison of our method with one baseline method (i.e., EEG) and two variations (i.e., ERM and CDM) on Precision, Recall and F − measure. According to Fig. 4 , it is clear that our method outperforms other three methods on Precision, Recall and F −measure." ;
            <http://www.example.org/textHash>
                    "0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8" .
    
    <http://covid19.aksw.org/text-bb80acb167836463c447b1943ea57cfd674586243cabd121a13ab10e9ff6c6d3_refspan-374-381>
            <http://www.example.org/end>    "381.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF6" ;
            <http://www.example.org/start>  "374.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 7" .
    
    <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Comparison on Ranking Component Events. Our method provides a mechanism to rank events based on their inter-event relationships. To evaluate the ranking mechanism, we also ask annotators to rank the component events for the query Q SARS according to their importance. Table 6 shows the rankings of the component events obtained by our method and those given by annotators. The two sets of event rankings are similar. 5 For events 2, 9 and 10, our method regards these as important because they have many relationships with (much effect on) others, while events 1, 4, 6, 7 and 12 are not so important because they have fewer relationships with (less effect on) others. This shows that ranking events by event relationships is a reasonable and effective approach. Such an event ranking facility can help users find the \\u0027\\u0027milestone\\u0027\\u0027 component events easily. Exceptions, such as event 8 and event 7, have lower ranks because our method also missed 7 relationships (such as the one from event 8 to event 11 and so on.) This further confirms the necessity and importance to find out 5 The seminal event 5 and ending event 11 are ranked with the highest score in our method for all target events, and this is also in line with the human annotators. more dependence relationships in order to facilitate better event search and ranking. Event 8 is an example of an exception, and as mentioned earlier, our method misses 7 relationships, including the one from event 8 to event 11 and the one from event 10 to event 8. If we take these missed relationships into account, the ranking of event 8 will rise. Another exception is that our method views event 7 as less important than event 4. We believe that these errors in the orders of importance are due to the missing relationships.\",\"cite_spans\":[{\"start\":417.0,\"end\":418.0,\"text\":\"5\",\"ref_id\":\"BIBREF4\"},{\"start\":1078.0,\"end\":1079.0,\"text\":\"5\",\"ref_id\":\"BIBREF4\"}],\"ref_spans\":[{\"start\":268.0,\"end\":275.0,\"text\":\"Table 6\",\"ref_id\":\"TABREF5\"}],\"section\":\"Case study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c_citespan-417-418> , <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c_citespan-1078-1079> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c_refspan-268-275> ;
            <http://www.example.org/section>
                    "Case study" ;
            <http://www.example.org/text>  "Comparison on Ranking Component Events. Our method provides a mechanism to rank events based on their inter-event relationships. To evaluate the ranking mechanism, we also ask annotators to rank the component events for the query Q SARS according to their importance. Table 6 shows the rankings of the component events obtained by our method and those given by annotators. The two sets of event rankings are similar. 5 For events 2, 9 and 10, our method regards these as important because they have many relationships with (much effect on) others, while events 1, 4, 6, 7 and 12 are not so important because they have fewer relationships with (less effect on) others. This shows that ranking events by event relationships is a reasonable and effective approach. Such an event ranking facility can help users find the ''milestone'' component events easily. Exceptions, such as event 8 and event 7, have lower ranks because our method also missed 7 relationships (such as the one from event 8 to event 11 and so on.) This further confirms the necessity and importance to find out 5 The seminal event 5 and ending event 11 are ranked with the highest score in our method for all target events, and this is also in line with the human annotators. more dependence relationships in order to facilitate better event search and ranking. Event 8 is an example of an exception, and as mentioned earlier, our method misses 7 relationships, including the one from event 8 to event 11 and the one from event 10 to event 8. If we take these missed relationships into account, the ranking of event 8 will rise. Another exception is that our method views event 7 as less important than event 4. We believe that these errors in the orders of importance are due to the missing relationships." ;
            <http://www.example.org/textHash>
                    "0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c" .
    
    <http://covid19.aksw.org/text-e195586f477664448fa032125f9b7cb75cc8e4e077583f0dfa5d2057c23ec41e_citespan-22-25>
            <http://www.example.org/end>    "25.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "22.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[6]" .
    
    <http://covid19.aksw.org/text-e195586f477664448fa032125f9b7cb75cc8e4e077583f0dfa5d2057c23ec41e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"According to [30] and [6] , an event is something that happens at a specific time and place. Real world events often are reported by documents, such as news articles on web pages. More specifically, for an event a, there is a set of documents talking about a, and such a set of documents, denoted as R a \\u003d {d a 1 , d a 2 , . . . , d a n }, is named as the related document set of a. An event could be described (reported) by several documents. Although a news document may be related to more than one event (e.g., it may refer to other events), there is a main event that is the focus of the news document that discusses it. A document introducing an event includes the start time, place(s) and content of the event.\",\"cite_spans\":[{\"start\":13.0,\"end\":17.0,\"text\":\"[30]\",\"ref_id\":\"BIBREF29\"},{\"start\":22.0,\"end\":25.0,\"text\":\"[6]\",\"ref_id\":\"BIBREF5\"}],\"ref_spans\":[],\"section\":\"Problem formulation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-e195586f477664448fa032125f9b7cb75cc8e4e077583f0dfa5d2057c23ec41e_citespan-13-17> , <http://covid19.aksw.org/text-e195586f477664448fa032125f9b7cb75cc8e4e077583f0dfa5d2057c23ec41e_citespan-22-25> ;
            <http://www.example.org/section>
                    "Problem formulation" ;
            <http://www.example.org/text>  "According to [30] and [6] , an event is something that happens at a specific time and place. Real world events often are reported by documents, such as news articles on web pages. More specifically, for an event a, there is a set of documents talking about a, and such a set of documents, denoted as R a = {d a 1 , d a 2 , . . . , d a n }, is named as the related document set of a. An event could be described (reported) by several documents. Although a news document may be related to more than one event (e.g., it may refer to other events), there is a main event that is the focus of the news document that discusses it. A document introducing an event includes the start time, place(s) and content of the event." ;
            <http://www.example.org/textHash>
                    "e195586f477664448fa032125f9b7cb75cc8e4e077583f0dfa5d2057c23ec41e" .
    
    <http://covid19.aksw.org/text-adf0fb9606dfe5dc3d53ee6c6f6a0f99fc17e6745b9b1b9648e944a2b948a2f0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In analyzing content dependence (CD) relationships for a temporal event search, we notice that the features of event a may have various degrees of importance in representing a. Some features are more salient than others for the event. An event can be represented by a feature vector, denoted by − → F a , which is a set of feature:value pairs.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Content dependence analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Content dependence analysis" ;
            <http://www.example.org/text>  "In analyzing content dependence (CD) relationships for a temporal event search, we notice that the features of event a may have various degrees of importance in representing a. Some features are more salient than others for the event. An event can be represented by a feature vector, denoted by − → F a , which is a set of feature:value pairs." ;
            <http://www.example.org/textHash>
                    "adf0fb9606dfe5dc3d53ee6c6f6a0f99fc17e6745b9b1b9648e944a2b948a2f0" .
    
    <http://covid19.aksw.org/text-aebaac6f91b823c1cc4aec21ddd331e19b43dc11a2349945a159e5ae0dec3c07_refspan-95-101>
            <http://www.example.org/end>    "101.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF9" ;
            <http://www.example.org/start>  "95.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 5" .
    
    <http://covid19.aksw.org/text-a7ef78724573aa88a09927247cc68fcb40a438d4024d1fc00dd175a7cedb0e9f_citespan-361-364>
            <http://www.example.org/end>    "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "361.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[2]" .
    
    <http://covid19.aksw.org/text-e730f6c262370b2a00449ebe14dd247cc7917d561399574a2680551d2123a750_refspan-188-196>
            <http://www.example.org/end>    "196.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "188.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cr(1, 2)" .
    
    <http://covid19.aksw.org/text-3db8d80872f4e842d1b7a1fff9261eb9b38cfe616b66d4074033d06a065140fe>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"With the development of the Internet, news events are reported by many news articles in the form of web pages. People have become more and more used to reading news articles online to learn about current events, including stories about emergencies. Events may consist of several component events, i.e., episodes, and people are often interested in the whole picture related events, because it affects and causes the occurrence of the other component events.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "With the development of the Internet, news events are reported by many news articles in the form of web pages. People have become more and more used to reading news articles online to learn about current events, including stories about emergencies. Events may consist of several component events, i.e., episodes, and people are often interested in the whole picture related events, because it affects and causes the occurrence of the other component events." ;
            <http://www.example.org/textHash>
                    "3db8d80872f4e842d1b7a1fff9261eb9b38cfe616b66d4074033d06a065140fe" .
    
    <http://covid19.aksw.org/text-c93eb6ed6958dbe514101cd120d016315068da556bd820e2f55e69d1fbcf602b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The higher value Rank(a) has, the more important event a is. Example 3. For example, the event \\u0027\\u0027Toyota recall due to safety problems\\u0027\\u0027 denoted by a is an important event. It is clear that there are four other events dependent on it. In other words, we first calculate the content-based Event Rank Function CRank ′ (a) and calculate the reference-based Event Rank Function RRank ′ (a). Because event a has a high CRank ′ (a) value and also a high RRank ′ (a) value, according to Eq. (9), we can obtain a high Rank(a) value for a.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "The higher value Rank(a) has, the more important event a is. Example 3. For example, the event ''Toyota recall due to safety problems'' denoted by a is an important event. It is clear that there are four other events dependent on it. In other words, we first calculate the content-based Event Rank Function CRank ′ (a) and calculate the reference-based Event Rank Function RRank ′ (a). Because event a has a high CRank ′ (a) value and also a high RRank ′ (a) value, according to Eq. (9), we can obtain a high Rank(a) value for a." ;
            <http://www.example.org/textHash>
                    "c93eb6ed6958dbe514101cd120d016315068da556bd820e2f55e69d1fbcf602b" .
    
    <http://covid19.aksw.org/text-f52336f23d9639a2d35f82f51bdd4d41c37ddd7ab0f0e42a5617126bb3518559>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Because the strength of the CD relationship between events is different, i.e., the dependence degrees are different, we take the dependence degrees into consideration and propose a weighed content-based Event Rank Function as follows:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "Because the strength of the CD relationship between events is different, i.e., the dependence degrees are different, we take the dependence degrees into consideration and propose a weighed content-based Event Rank Function as follows:" ;
            <http://www.example.org/textHash>
                    "f52336f23d9639a2d35f82f51bdd4d41c37ddd7ab0f0e42a5617126bb3518559" .
    
    <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although some work has been done to find and link incidents in news stories [4, 5] or discover event evolution graphs [6, 7] , this scholarship has only focused on time sequences and content similarity between two component events to identify the dependence relationships. Using two factors alone is inadequate for identifying dependence relationships among component events for the purpose of forming an overall picture of a major event\\u0027s evolution. For example, the event \\u0027\\u0027Toyota recall due to safety problems from 2009 to 2010\\u0027\\u0027 shares little similar content with the events \\u0027\\u0027NHTSA conducts investigations for Toyota recall\\u0027\\u0027 and \\u0027\\u0027US congressional hearings hold for Toyota recall\\u0027\\u0027. It is obvious that the first event has a strong affect on the latter two events, as it actually caused them to happen. Unfortunately, previous work in this field has not analyzed event relationships and cannot discover the dependence relationships between any two events that do not share enough similar content. As a result, the main picture of a \\u0027\\u0027big event\\u0027\\u0027 that has been discovered by previous scholarship is often incomplete, and significant relationships are missing. Furthermore, as there is no facility in this work for measuring event importance, it does not identify milestone events that are significant for most users to know.\",\"cite_spans\":[{\"start\":76.0,\"end\":79.0,\"text\":\"[4,\",\"ref_id\":\"BIBREF3\"},{\"start\":80.0,\"end\":82.0,\"text\":\"5]\",\"ref_id\":\"BIBREF4\"},{\"start\":118.0,\"end\":121.0,\"text\":\"[6,\",\"ref_id\":\"BIBREF5\"},{\"start\":122.0,\"end\":124.0,\"text\":\"7]\",\"ref_id\":\"BIBREF6\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-76-79> , <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-80-82> , <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-118-121> , <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-122-124> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "Although some work has been done to find and link incidents in news stories [4, 5] or discover event evolution graphs [6, 7] , this scholarship has only focused on time sequences and content similarity between two component events to identify the dependence relationships. Using two factors alone is inadequate for identifying dependence relationships among component events for the purpose of forming an overall picture of a major event's evolution. For example, the event ''Toyota recall due to safety problems from 2009 to 2010'' shares little similar content with the events ''NHTSA conducts investigations for Toyota recall'' and ''US congressional hearings hold for Toyota recall''. It is obvious that the first event has a strong affect on the latter two events, as it actually caused them to happen. Unfortunately, previous work in this field has not analyzed event relationships and cannot discover the dependence relationships between any two events that do not share enough similar content. As a result, the main picture of a ''big event'' that has been discovered by previous scholarship is often incomplete, and significant relationships are missing. Furthermore, as there is no facility in this work for measuring event importance, it does not identify milestone events that are significant for most users to know." ;
            <http://www.example.org/textHash>
                    "612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07" .
    
    <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-95-98>
            <http://www.example.org/end>    "98.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "95.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "31]" .
    
    <http://covid19.aksw.org/text-759eaae1a6a1382d201861b25e7d8a3240c5f5c33549ea70e97813acb180beda>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For all the component events of a target event, some component events are more important than others, including the seminal component event and ending component event, which are interesting and important for most people. Thus, in our method, we consider the seminal component event and ending component event as \\u0027\\u0027definitely important\\u0027\\u0027 and give the highest ranking score to them. For the other component events (excluding seminal and ending events), intuitively, an event that is more important means that it has more significant impact on other events. Such an effect in the TEM can be reflected by a relationship between events. If more events refer to or depend on an event a, then a should be more important.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "For all the component events of a target event, some component events are more important than others, including the seminal component event and ending component event, which are interesting and important for most people. Thus, in our method, we consider the seminal component event and ending component event as ''definitely important'' and give the highest ranking score to them. For the other component events (excluding seminal and ending events), intuitively, an event that is more important means that it has more significant impact on other events. Such an effect in the TEM can be reflected by a relationship between events. If more events refer to or depend on an event a, then a should be more important." ;
            <http://www.example.org/textHash>
                    "759eaae1a6a1382d201861b25e7d8a3240c5f5c33549ea70e97813acb180beda" .
    
    <http://covid19.aksw.org/text-c6da05d838902e02dc48c83ea0fff0525e19eb3d612ca98a58909180d2b46582>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Admittedly, several possible extensions may be made to our work. In our current method, only top-5 core features are selected for event reference analysis of the collected data set. How to automatically choose the \\u0027\\u0027right\\u0027\\u0027 number of core features for event reference analysis of different data sets is an open issue for further study. Another potential extension is to implement a visualization tool with a sophisticated user interface based on our current method. Also, we plan to investigate personalized temporal event searches, as different users may have their own preferences and interests about different kinds of component events. This sort of event search may be used to recommend news articles to a user based on his/her current knowledge of his/her interested event. Furthermore, it is also possible to exploit the temporal event map in some domain-specific applications, including first story detection [37] and financial news analysis [38] . \",\"cite_spans\":[{\"start\":916.0,\"end\":920.0,\"text\":\"[37]\",\"ref_id\":\"BIBREF36\"},{\"start\":949.0,\"end\":953.0,\"text\":\"[38]\",\"ref_id\":\"BIBREF37\"}],\"ref_spans\":[],\"section\":\"Discussion and conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-c6da05d838902e02dc48c83ea0fff0525e19eb3d612ca98a58909180d2b46582_citespan-916-920> , <http://covid19.aksw.org/text-c6da05d838902e02dc48c83ea0fff0525e19eb3d612ca98a58909180d2b46582_citespan-949-953> ;
            <http://www.example.org/section>
                    "Discussion and conclusions" ;
            <http://www.example.org/text>  "Admittedly, several possible extensions may be made to our work. In our current method, only top-5 core features are selected for event reference analysis of the collected data set. How to automatically choose the ''right'' number of core features for event reference analysis of different data sets is an open issue for further study. Another potential extension is to implement a visualization tool with a sophisticated user interface based on our current method. Also, we plan to investigate personalized temporal event searches, as different users may have their own preferences and interests about different kinds of component events. This sort of event search may be used to recommend news articles to a user based on his/her current knowledge of his/her interested event. Furthermore, it is also possible to exploit the temporal event map in some domain-specific applications, including first story detection [37] and financial news analysis [38] . " ;
            <http://www.example.org/textHash>
                    "c6da05d838902e02dc48c83ea0fff0525e19eb3d612ca98a58909180d2b46582" .
    
    <http://covid19.aksw.org/text-f6f4659dc4fc897a4dafbbb6fb4d4e1c58c268ca7edd514dfab2a71ed9aba961>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Scientists find coronavirus and conduct animal test for vaccine 9\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "Scientists find coronavirus and conduct animal test for vaccine 9" ;
            <http://www.example.org/textHash>
                    "f6f4659dc4fc897a4dafbbb6fb4d4e1c58c268ca7edd514dfab2a71ed9aba961" .
    
    <http://covid19.aksw.org/text-bb80acb167836463c447b1943ea57cfd674586243cabd121a13ab10e9ff6c6d3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• Projection based on content dependence relation, denoted by π c • Projection based on reference relation, denoted by π r • Projection of a time period, denoted by π t • Projection of locations, denoted by π p Specifically, we illustrate how to use these operations on the TEM of \\u0027\\u00272011 Japan Earthquake\\u0027\\u0027 which are shown in Fig. 8 , and the competent events are listed in Table 7 .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":326.0,\"end\":332.0,\"text\":\"Fig. 8\",\"ref_id\":\"FIGREF11\"},{\"start\":374.0,\"end\":381.0,\"text\":\"Table 7\",\"ref_id\":\"TABREF6\"}],\"section\":\"Algebraic operations\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-bb80acb167836463c447b1943ea57cfd674586243cabd121a13ab10e9ff6c6d3_refspan-326-332> , <http://covid19.aksw.org/text-bb80acb167836463c447b1943ea57cfd674586243cabd121a13ab10e9ff6c6d3_refspan-374-381> ;
            <http://www.example.org/section>
                    "Algebraic operations" ;
            <http://www.example.org/text>  "• Projection based on content dependence relation, denoted by π c • Projection based on reference relation, denoted by π r • Projection of a time period, denoted by π t • Projection of locations, denoted by π p Specifically, we illustrate how to use these operations on the TEM of ''2011 Japan Earthquake'' which are shown in Fig. 8 , and the competent events are listed in Table 7 ." ;
            <http://www.example.org/textHash>
                    "bb80acb167836463c447b1943ea57cfd674586243cabd121a13ab10e9ff6c6d3" .
    
    <http://covid19.aksw.org/text-d0ba00ce7ded319287d328da5d6c35bc6994400ccfe5ca133357cd48a24077d8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In this paper, to satisfy the aforementioned user needs of finding and understanding the entire picture of a complex event, we conduct an in-depth event relationship analysis for event searches and propose a framework to search events based on user queries. The new characteristics of the proposed framework and the contributions of our work are as follows:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "In this paper, to satisfy the aforementioned user needs of finding and understanding the entire picture of a complex event, we conduct an in-depth event relationship analysis for event searches and propose a framework to search events based on user queries. The new characteristics of the proposed framework and the contributions of our work are as follows:" ;
            <http://www.example.org/textHash>
                    "d0ba00ce7ded319287d328da5d6c35bc6994400ccfe5ca133357cd48a24077d8" .
    
    <http://covid19.aksw.org/text-d7641de052c31498106b7420eeeff31dbf051ca94ace521fc002a8527cb877d5>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In general, we consider (I t , I p , I f ) as three kinds of user search requirements (though not all are compulsory). In some cases, 1 We use the size of a node to indicate the event importance (i.e., the bigger of a node, the more important) and the width of a line to indicate the strength of a dependence relationship. 2 In the rest of the paper, we use the term \\u0027\\u0027event\\u0027\\u0027 to denote \\u0027\\u0027component event\\u0027\\u0027 for convenience wherever there is no ambiguity.\",\"cite_spans\":[{\"start\":134.0,\"end\":135.0,\"text\":\"1\",\"ref_id\":\"BIBREF0\"},{\"start\":323.0,\"end\":324.0,\"text\":\"2\",\"ref_id\":\"BIBREF1\"}],\"ref_spans\":[],\"section\":\"Preliminaries\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d7641de052c31498106b7420eeeff31dbf051ca94ace521fc002a8527cb877d5_citespan-134-135> , <http://covid19.aksw.org/text-d7641de052c31498106b7420eeeff31dbf051ca94ace521fc002a8527cb877d5_citespan-323-324> ;
            <http://www.example.org/section>
                    "Preliminaries" ;
            <http://www.example.org/text>  "In general, we consider (I t , I p , I f ) as three kinds of user search requirements (though not all are compulsory). In some cases, 1 We use the size of a node to indicate the event importance (i.e., the bigger of a node, the more important) and the width of a line to indicate the strength of a dependence relationship. 2 In the rest of the paper, we use the term ''event'' to denote ''component event'' for convenience wherever there is no ambiguity." ;
            <http://www.example.org/textHash>
                    "d7641de052c31498106b7420eeeff31dbf051ca94ace521fc002a8527cb877d5" .
    
    <http://covid19.aksw.org/text-1ac35a1e3b11dbb5713fa57ce8530f88a7c2e7715c4aa38b9594cd8210a12432>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where p(f i |a) is the probability of feature f i to exist in the related documents of event a, and p(a|f i ) is the probability of a document (in which f i is a feature) being about event a. A higher value of p(f i |a) means that feature f i is more frequently appearing (i.e., is more likely to appear) in the related documents of event a, and thus we consider that feature f i is more salient for event a. p(f i |a)\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "where p(f i |a) is the probability of feature f i to exist in the related documents of event a, and p(a|f i ) is the probability of a document (in which f i is a feature) being about event a. A higher value of p(f i |a) means that feature f i is more frequently appearing (i.e., is more likely to appear) in the related documents of event a, and thus we consider that feature f i is more salient for event a. p(f i |a)" ;
            <http://www.example.org/textHash>
                    "1ac35a1e3b11dbb5713fa57ce8530f88a7c2e7715c4aa38b9594cd8210a12432" .
    
    <http://covid19.aksw.org/text-316a9c158a8199f17710a4ee2b76edc670b49e5ab7eff6c70a7e8fab1b3cbd1f_citespan-645-649>
            <http://www.example.org/end>    "649.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "645.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[33]" .
    
    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_refspan-564-571>
            <http://www.example.org/end>    "571.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF3" ;
            <http://www.example.org/start>  "564.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 4" .
    
    <http://covid19.aksw.org/text-e3c8b4102af10848c5e7599c170f05f71dfcf9692daf9b1fd48f5c2e4b20c845_refspan-594-602>
            <http://www.example.org/end>    "602.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "594.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cr(a, b)" .
    
    <http://covid19.aksw.org/text-633d5965835fc8599542627dd5cd534f02c789a2c01cd9e2c12a18c9a6aa0dd9>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"An event a is a tuple (L a , P a , F a ) where L a is the life cycle of a, P a is the set of places where a happens, and F a is the set of features (keywords) describing a.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Definition 1.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Definition 1." ;
            <http://www.example.org/text>  "An event a is a tuple (L a , P a , F a ) where L a is the life cycle of a, P a is the set of places where a happens, and F a is the set of features (keywords) describing a." ;
            <http://www.example.org/textHash>
                    "633d5965835fc8599542627dd5cd534f02c789a2c01cd9e2c12a18c9a6aa0dd9" .
    
    <http://covid19.aksw.org/text-e91aa93ddad2c608423f1b076c7d3dbb17cacc92d05fea907900ab7eff65a455>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"is considered as a measurement to measure the salience of a feature for an event. Thus, we consider it can reflect Property 1. A higher value of p(a|f i ) means relates to a feature f i , and there is a high probability to identify that f i is related to event a. p(f i |a)\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "is considered as a measurement to measure the salience of a feature for an event. Thus, we consider it can reflect Property 1. A higher value of p(a|f i ) means relates to a feature f i , and there is a high probability to identify that f i is related to event a. p(f i |a)" ;
            <http://www.example.org/textHash>
                    "e91aa93ddad2c608423f1b076c7d3dbb17cacc92d05fea907900ab7eff65a455" .
    
    <http://covid19.aksw.org/text-1078dda99cc4fd07bd56e77801579e99b52fe883922be8d1990ca43267f3b346>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where where each entry is a content dependence degree between two component events.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"− →\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "− →" ;
            <http://www.example.org/text>  "where where each entry is a content dependence degree between two component events." ;
            <http://www.example.org/textHash>
                    "1078dda99cc4fd07bd56e77801579e99b52fe883922be8d1990ca43267f3b346" .
    
    <http://covid19.aksw.org/text-0d7256456cb05d0b0e49248440968a446ea638fc3d090fbb51ccf468c1fb0694>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where Cd(a, v) is the content dependence degree (cf. Eq. (2)) between events a and v.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "where Cd(a, v) is the content dependence degree (cf. Eq. (2)) between events a and v." ;
            <http://www.example.org/textHash>
                    "0d7256456cb05d0b0e49248440968a446ea638fc3d090fbb51ccf468c1fb0694" .
    
    <http://covid19.aksw.org/text-b28581a369dd714d11c417d3f3f44b8e3631e1242c1270d6fccb184540feada0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"No author associated with this paper has disclosed any potential or pertinent conflicts which may be perceived to have impending conflict with this work. For full disclosure statements refer to https://doi.org/10.1016/j.asoc.2019.105750.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Declaration of competing interest\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Declaration of competing interest" ;
            <http://www.example.org/text>  "No author associated with this paper has disclosed any potential or pertinent conflicts which may be perceived to have impending conflict with this work. For full disclosure statements refer to https://doi.org/10.1016/j.asoc.2019.105750." ;
            <http://www.example.org/textHash>
                    "b28581a369dd714d11c417d3f3f44b8e3631e1242c1270d6fccb184540feada0" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-399-403>
            <http://www.example.org/end>    "403.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF10" ;
            <http://www.example.org/start>  "399.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[11]" .
    
    <http://covid19.aksw.org/text-444ac5291c54fe97204aa0c86b57ee00cf20b1ff5565a9fdfbd50691cece049b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"is considered as a measurement to measure how helpful feature f i is for identifying a document being related to event a than other events. Thus, we consider that p(f i |a) can reflect Property 2. For two events a and b, the more related documents of b refer to more core features of a, the stronger the reference relation from b to a. We propose a function to measure the strength degree of a reference relation from a to b as follows:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "is considered as a measurement to measure how helpful feature f i is for identifying a document being related to event a than other events. Thus, we consider that p(f i |a) can reflect Property 2. For two events a and b, the more related documents of b refer to more core features of a, the stronger the reference relation from b to a. We propose a function to measure the strength degree of a reference relation from a to b as follows:" ;
            <http://www.example.org/textHash>
                    "444ac5291c54fe97204aa0c86b57ee00cf20b1ff5565a9fdfbd50691cece049b" .
    
    <http://covid19.aksw.org/text-bb80acb167836463c447b1943ea57cfd674586243cabd121a13ab10e9ff6c6d3_refspan-326-332>
            <http://www.example.org/end>    "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF11" ;
            <http://www.example.org/start>  "326.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 8" .
    
    <http://covid19.aksw.org/text-afc8da8dc333e420504503b02c994ce6799446c6375255d1cf415cae397dede1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Sometimes, users may be interested in component events that happened in certain places. For example, some users in Japan may only be interested in component events that happened in Japan. We can do a projection of a TEM according to the location of events and obtain a sub-graph of the TEM as shown in Fig. 11 . Such a sub-graph only shows the component events that happened in user-specified places. We denote the projection based on happening places, e.g. Japan, for TEM i as π p\\u003d\\\"Japan\\\" (TEM i ). Earthquake triggered powerful tsunami waves that reached to 40.5 meters 3\",\"cite_spans\":[],\"ref_spans\":[{\"start\":302.0,\"end\":309.0,\"text\":\"Fig. 11\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-afc8da8dc333e420504503b02c994ce6799446c6375255d1cf415cae397dede1_refspan-302-309> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "Sometimes, users may be interested in component events that happened in certain places. For example, some users in Japan may only be interested in component events that happened in Japan. We can do a projection of a TEM according to the location of events and obtain a sub-graph of the TEM as shown in Fig. 11 . Such a sub-graph only shows the component events that happened in user-specified places. We denote the projection based on happening places, e.g. Japan, for TEM i as π p=\"Japan\" (TEM i ). Earthquake triggered powerful tsunami waves that reached to 40.5 meters 3" ;
            <http://www.example.org/textHash>
                    "afc8da8dc333e420504503b02c994ce6799446c6375255d1cf415cae397dede1" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1004-1008>
            <http://www.example.org/end>    "1008.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "1004.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[18]" .
    
    <http://covid19.aksw.org/text-fcf9a9909aaee16b36a3c96b69be7f175e1ec7c97695ae6c3b8c4c1cb9644d79>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"China makes effort to prevent disease spread 11\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "China makes effort to prevent disease spread 11" ;
            <http://www.example.org/textHash>
                    "fcf9a9909aaee16b36a3c96b69be7f175e1ec7c97695ae6c3b8c4c1cb9644d79" .
    
    <http://covid19.aksw.org/text-676acca31bcbfe7a6bfcf6d015f932f8c5cc458ef21eb27aee24235568ac4e6c_citespan-189-193>
            <http://www.example.org/end>    "193.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "189.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[15]" .
    
    <http://covid19.aksw.org/text-db9654fda167524cc60e71cdc487585dc0c4125376abc0603e4ee27bc2b2588d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"As the Internet develops, more and more information about various events is produced everyday, especially complex events. In daily life, a tremendous number of events happen every day, e.g., disasters, diseases, military conflicts, business events and so on. These events are reported in the form of news every day, and they are called news events. People are becoming more and more accustomed to reading their news online to keep up with current events. It is important to handle the news events that introduce emerging stories to the world. A composite/complex news event may consist of several component events, i.e., episodes. The news events usually are reported in the form of unstructured text documents. Because major news events are often emergent and complex, defining the pattern of news events is difficult and time consuming. Different from the structured events found in current Complex Event Processing, our proposed work focuses on mining the event relationships based on unstructured text documents, so as to construct the temporal event map that shows the event evolution.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Complex event recognition and processing\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Complex event recognition and processing" ;
            <http://www.example.org/text>  "As the Internet develops, more and more information about various events is produced everyday, especially complex events. In daily life, a tremendous number of events happen every day, e.g., disasters, diseases, military conflicts, business events and so on. These events are reported in the form of news every day, and they are called news events. People are becoming more and more accustomed to reading their news online to keep up with current events. It is important to handle the news events that introduce emerging stories to the world. A composite/complex news event may consist of several component events, i.e., episodes. The news events usually are reported in the form of unstructured text documents. Because major news events are often emergent and complex, defining the pattern of news events is difficult and time consuming. Different from the structured events found in current Complex Event Processing, our proposed work focuses on mining the event relationships based on unstructured text documents, so as to construct the temporal event map that shows the event evolution." ;
            <http://www.example.org/textHash>
                    "db9654fda167524cc60e71cdc487585dc0c4125376abc0603e4ee27bc2b2588d" .
    
    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_citespan-344-364>
            <http://www.example.org/end>    "364.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "344.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[1/3/2003, 30/6/2003" .
    
    <http://covid19.aksw.org/text-558d238096b22854ef8a23f408688891b00100917cc91a9d9de4a1e706330c68>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Japan gets help from many other countries 6\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "Japan gets help from many other countries 6" ;
            <http://www.example.org/textHash>
                    "558d238096b22854ef8a23f408688891b00100917cc91a9d9de4a1e706330c68" .
    
    <http://covid19.aksw.org/text-985477e9e44b94ccdfb42cfa01a28d88af8d3cf57300f19d13b2ecc3451d1ffd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To the best of our knowledge, this is the first piece of work that (1) formalizes and handles the event search problem by analyzing all temporal, content dependence and event reference relationships between events to construct an overall picture of the event\\u0027s evolution; and (2) measures the importance of events based on the interrelationships of events.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "To the best of our knowledge, this is the first piece of work that (1) formalizes and handles the event search problem by analyzing all temporal, content dependence and event reference relationships between events to construct an overall picture of the event's evolution; and (2) measures the importance of events based on the interrelationships of events." ;
            <http://www.example.org/textHash>
                    "985477e9e44b94ccdfb42cfa01a28d88af8d3cf57300f19d13b2ecc3451d1ffd" .
    
    <http://covid19.aksw.org/text-1d432e89a342c7685fb5dd85234863c0a7a904a5538a744191f1bab60275128c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"China informs and cooperates with WHO on fighting SARS 10\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "China informs and cooperates with WHO on fighting SARS 10" ;
            <http://www.example.org/textHash>
                    "1d432e89a342c7685fb5dd85234863c0a7a904a5538a744191f1bab60275128c" .
    
    <http://covid19.aksw.org/text-930cf281e081080ecc94b11a3990d766fe45f2a8166029dce14b4578d6f7a9a1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Experts find disease and SARS outbreaks 6 SARS has great impact on economy 7\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "Experts find disease and SARS outbreaks 6 SARS has great impact on economy 7" ;
            <http://www.example.org/textHash>
                    "930cf281e081080ecc94b11a3990d766fe45f2a8166029dce14b4578d6f7a9a1" .
    
    <http://covid19.aksw.org/text-056ace257364745aba1eaa4ac0360709ef63447c2ee5dc5a9a0af09ac7aadd44_refspan-146-152>
            <http://www.example.org/end>    "152.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "146.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 1" .
    
    <http://covid19.aksw.org/text-85d2631070d181b18fe5ea841549c007515e4c71a6781d12665fd11a12c2c6a1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Probable cases are quarantined and schools are closed for disinfecting Table 5 Comparison of event relationships discovered by our method and EEG for the query Q SARS , Correct is the number of correctly identified relationships by comparing to human annotated results, Incorrect is the number of incorrectly identified relationships by comparing to human annotated results, New is the number of identified relationships which are not in human annotated results and confirmed as correct by human annotators, Missed is the number of missing relationships by comparing to human annotated results, and Total is the number of identified relationships by this method (i.e., Total \\u003d Correct + Incorrect + New) [1] . \",\"cite_spans\":[{\"start\":704.0,\"end\":707.0,\"text\":\"[1]\",\"ref_id\":\"BIBREF0\"}],\"ref_spans\":[{\"start\":71.0,\"end\":78.0,\"text\":\"Table 5\"}],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-85d2631070d181b18fe5ea841549c007515e4c71a6781d12665fd11a12c2c6a1_citespan-704-707> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-85d2631070d181b18fe5ea841549c007515e4c71a6781d12665fd11a12c2c6a1_refspan-71-78> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "Probable cases are quarantined and schools are closed for disinfecting Table 5 Comparison of event relationships discovered by our method and EEG for the query Q SARS , Correct is the number of correctly identified relationships by comparing to human annotated results, Incorrect is the number of incorrectly identified relationships by comparing to human annotated results, New is the number of identified relationships which are not in human annotated results and confirmed as correct by human annotators, Missed is the number of missing relationships by comparing to human annotated results, and Total is the number of identified relationships by this method (i.e., Total = Correct + Incorrect + New) [1] . " ;
            <http://www.example.org/textHash>
                    "85d2631070d181b18fe5ea841549c007515e4c71a6781d12665fd11a12c2c6a1" .
    
    <http://covid19.aksw.org/text-d1292be2a311ee810a334d6ef7624fc0642ea9b9d99090b0b0b17a7e55269d15>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"users may only input one or two of the (I t , I p , I f ), which means we only need to take the subset of (I t , I p , I f ) into consideration.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Preliminaries\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Preliminaries" ;
            <http://www.example.org/text>  "users may only input one or two of the (I t , I p , I f ), which means we only need to take the subset of (I t , I p , I f ) into consideration." ;
            <http://www.example.org/textHash>
                    "d1292be2a311ee810a334d6ef7624fc0642ea9b9d99090b0b0b17a7e55269d15" .
    
    <http://covid19.aksw.org/text-20e06f45eedce14d174fd7358d90dabb5a353097d98397b8caec956334e37fb6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"and the TEM output of such a search task is the one shown in Fig. 1 .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":61.0,\"end\":67.0,\"text\":\"Fig. 1\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Definition 5. A Temporal Event Map is a weighted directed\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-20e06f45eedce14d174fd7358d90dabb5a353097d98397b8caec956334e37fb6_refspan-61-67> ;
            <http://www.example.org/section>
                    "Definition 5. A Temporal Event Map is a weighted directed" ;
            <http://www.example.org/text>  "and the TEM output of such a search task is the one shown in Fig. 1 ." ;
            <http://www.example.org/textHash>
                    "20e06f45eedce14d174fd7358d90dabb5a353097d98397b8caec956334e37fb6" .
    
    <http://covid19.aksw.org/text-e3c8b4102af10848c5e7599c170f05f71dfcf9692daf9b1fd48f5c2e4b20c845_refspan-80-108>
            <http://www.example.org/end>    "108.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "80.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "., a happens earlier than b)" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-502-505>
            <http://www.example.org/end>    "505.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "502.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[6]" .
    
    <http://covid19.aksw.org/text-ccea08b19084a317f5b5aa04dccc761fd145a174b14acade80d7fa4d8938cba7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To evaluate event rankings based on their importance, we adopt the metric of normalized discounted cumulative gain (i.e., NDCG [36] ) on all component events, which is defined as follows: (14) and\",\"cite_spans\":[{\"start\":127.0,\"end\":131.0,\"text\":\"[36]\",\"ref_id\":\"BIBREF35\"},{\"start\":188.0,\"end\":192.0,\"text\":\"(14)\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[],\"section\":\"Experiment setting\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-ccea08b19084a317f5b5aa04dccc761fd145a174b14acade80d7fa4d8938cba7_citespan-127-131> , <http://covid19.aksw.org/text-ccea08b19084a317f5b5aa04dccc761fd145a174b14acade80d7fa4d8938cba7_citespan-188-192> ;
            <http://www.example.org/section>
                    "Experiment setting" ;
            <http://www.example.org/text>  "To evaluate event rankings based on their importance, we adopt the metric of normalized discounted cumulative gain (i.e., NDCG [36] ) on all component events, which is defined as follows: (14) and" ;
            <http://www.example.org/textHash>
                    "ccea08b19084a317f5b5aa04dccc761fd145a174b14acade80d7fa4d8938cba7" .
    
    <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-118-121>
            <http://www.example.org/end>    "121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[6," .
    
    <http://covid19.aksw.org/text-1161307e9c4f01a9e2515ed5c7d69349c791d165ec07c7a2fc1f8d51d53f2f3d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where St a is where S ta is the earliest timestamp among all the timestamps of all documents related to a, and Et a is the latest timestamp among all documents related to a. The place set P a of an event a is a set of terms denoted by P a where P a \\u003d {t a,1 , t a,2 , . . . , t a,m } and each t a,x is a term that represents a place. . . , a n } where 1 ≤ n, a x is a component event of a and R a \\u003d R a 1 ∪ R a 2 ∪ · · · ∪ R an . \",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Definition 1.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Definition 1." ;
            <http://www.example.org/text>  "where St a is where S ta is the earliest timestamp among all the timestamps of all documents related to a, and Et a is the latest timestamp among all documents related to a. The place set P a of an event a is a set of terms denoted by P a where P a = {t a,1 , t a,2 , . . . , t a,m } and each t a,x is a term that represents a place. . . , a n } where 1 ≤ n, a x is a component event of a and R a = R a 1 ∪ R a 2 ∪ · · · ∪ R an . " ;
            <http://www.example.org/textHash>
                    "1161307e9c4f01a9e2515ed5c7d69349c791d165ec07c7a2fc1f8d51d53f2f3d" .
    
    <http://covid19.aksw.org/text-8382527cf49c0ff6e616b6d854682d85b632bfc18d337b344011c2ea71a52c63>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A TEM provides a comprehensive view of useful inter-event, relationships and event information. Sometimes, however, users may only be interested in, or focus on, certain types of relationships and event information. To enable users to perceive event evolution from multiple-perspectives, we provide some algebraic operations that the TEM must satisfy. In this section, we present a number of algebraic operations based on the temporal event map (TEM), including the following:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Algebraic operations\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Algebraic operations" ;
            <http://www.example.org/text>  "A TEM provides a comprehensive view of useful inter-event, relationships and event information. Sometimes, however, users may only be interested in, or focus on, certain types of relationships and event information. To enable users to perceive event evolution from multiple-perspectives, we provide some algebraic operations that the TEM must satisfy. In this section, we present a number of algebraic operations based on the temporal event map (TEM), including the following:" ;
            <http://www.example.org/textHash>
                    "8382527cf49c0ff6e616b6d854682d85b632bfc18d337b344011c2ea71a52c63" .
    
    <http://covid19.aksw.org/text-64a174f21f9fb2f95b14ec8740a7e8b62482d110bfc8d1566abee0c82d7bb0cc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For example, suppose that the input are I t \\u003d [1/11/2009, 23/2/2010], I p \\u003d (USA), and I f \\u003d (Toyota, recall). A set of news articles related to Toyota recall in the period from 1 November 2009 to 23 February 2010 at the USA will be identified. Latent Dirichlet Allocation (LDA) is then applied to these news articles and some events like \\u0027\\u0027Toyota sale decrease\\u0027\\u0027, \\u0027\\u0027NHTSA conducts investigation\\u0027\\u0027 will be found. After the analysis of CD, ER and temporal relationships of these events, a temporal event map will be constructed as shown in Fig. 1 .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":539.0,\"end\":545.0,\"text\":\"Fig. 1\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Event relationship analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-64a174f21f9fb2f95b14ec8740a7e8b62482d110bfc8d1566abee0c82d7bb0cc_refspan-539-545> ;
            <http://www.example.org/section>
                    "Event relationship analysis" ;
            <http://www.example.org/text>  "For example, suppose that the input are I t = [1/11/2009, 23/2/2010], I p = (USA), and I f = (Toyota, recall). A set of news articles related to Toyota recall in the period from 1 November 2009 to 23 February 2010 at the USA will be identified. Latent Dirichlet Allocation (LDA) is then applied to these news articles and some events like ''Toyota sale decrease'', ''NHTSA conducts investigation'' will be found. After the analysis of CD, ER and temporal relationships of these events, a temporal event map will be constructed as shown in Fig. 1 ." ;
            <http://www.example.org/textHash>
                    "64a174f21f9fb2f95b14ec8740a7e8b62482d110bfc8d1566abee0c82d7bb0cc" .
    
    <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-223-227>
            <http://www.example.org/end>    "227.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF25" ;
            <http://www.example.org/start>  "223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[26]" .
    
    <http://covid19.aksw.org/text-cb8db6cda368fadfb410b9bb1ada1b3bc5fe1f8cabf7a7882c0e169d30f7b43f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Formally, for two events a and b, the content dependence degree, denoted by Cd(a, b) , is an aggregation of all mutual information among all features in − → F a and in − → F b , as follows: \",\"cite_spans\":[],\"ref_spans\":[{\"start\":76.0,\"end\":84.0,\"text\":\"Cd(a, b)\"}],\"section\":\"− →\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-cb8db6cda368fadfb410b9bb1ada1b3bc5fe1f8cabf7a7882c0e169d30f7b43f_refspan-76-84> ;
            <http://www.example.org/section>
                    "− →" ;
            <http://www.example.org/text>  "Formally, for two events a and b, the content dependence degree, denoted by Cd(a, b) , is an aggregation of all mutual information among all features in − → F a and in − → F b , as follows: " ;
            <http://www.example.org/textHash>
                    "cb8db6cda368fadfb410b9bb1ada1b3bc5fe1f8cabf7a7882c0e169d30f7b43f" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-475-478>
            <http://www.example.org/end>    "478.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "475.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[7]" .
    
    <http://covid19.aksw.org/text-64a174f21f9fb2f95b14ec8740a7e8b62482d110bfc8d1566abee0c82d7bb0cc_refspan-539-545>
            <http://www.example.org/end>    "545.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "539.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 1" .
    
    <http://covid19.aksw.org/text-f7bc93b56c7d1a18804e13a84dde9bb1d0417acbbe69112b1f55284092cd577c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Beijing has SARS under control 12\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "Beijing has SARS under control 12" ;
            <http://www.example.org/textHash>
                    "f7bc93b56c7d1a18804e13a84dde9bb1d0417acbbe69112b1f55284092cd577c" .
    
    <http://covid19.aksw.org/text-e3c8b4102af10848c5e7599c170f05f71dfcf9692daf9b1fd48f5c2e4b20c845>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For two events a and b, if there exists a related document to b, denoted as d b ., a happens earlier than b) , then we say there is a reference relationship from b to a; i.e., a is a reference of b or b refers to a. Such a reference relationship is a fuzzy relationship, and the more core features of a mentioned in b, the greater the strength degree of the relationship. For two events a and b, if a refers to b and b refers to a also, then we say there is a symmetric reference relation between a and b. The strength degree of a reference relationship from b to a is determined by a function Cr(a, b) which is to be defined below. For event b referring to event a, it should follow the temporal restriction of Observation 1. For two events a and b, in order for us to find out whether b refers to a, we need to discover the core feature set of a first and then check whether the core features of a exist in the related documents of b.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":80.0,\"end\":108.0,\"text\":\"., a happens earlier than b)\"},{\"start\":594.0,\"end\":602.0,\"text\":\"Cr(a, b)\"}],\"section\":\"Event reference analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-e3c8b4102af10848c5e7599c170f05f71dfcf9692daf9b1fd48f5c2e4b20c845_refspan-80-108> , <http://covid19.aksw.org/text-e3c8b4102af10848c5e7599c170f05f71dfcf9692daf9b1fd48f5c2e4b20c845_refspan-594-602> ;
            <http://www.example.org/section>
                    "Event reference analysis" ;
            <http://www.example.org/text>  "For two events a and b, if there exists a related document to b, denoted as d b ., a happens earlier than b) , then we say there is a reference relationship from b to a; i.e., a is a reference of b or b refers to a. Such a reference relationship is a fuzzy relationship, and the more core features of a mentioned in b, the greater the strength degree of the relationship. For two events a and b, if a refers to b and b refers to a also, then we say there is a symmetric reference relation between a and b. The strength degree of a reference relationship from b to a is determined by a function Cr(a, b) which is to be defined below. For event b referring to event a, it should follow the temporal restriction of Observation 1. For two events a and b, in order for us to find out whether b refers to a, we need to discover the core feature set of a first and then check whether the core features of a exist in the related documents of b." ;
            <http://www.example.org/textHash>
                    "e3c8b4102af10848c5e7599c170f05f71dfcf9692daf9b1fd48f5c2e4b20c845" .
    
    <http://covid19.aksw.org/text-316a9c158a8199f17710a4ee2b76edc670b49e5ab7eff6c70a7e8fab1b3cbd1f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"According to studies of journalism [33] , when authors of news articles about an event a find a dependence relationship between a and b (e.g., b triggers the occurrence of a, or a is evolved from b and so on), their articles may actually refer to event b. This is in line with our observation of our data set. For instance, some news articles about the event \\u0027\\u0027Toyota recall due to safety problems from 2009 to 2010\\u0027\\u0027 refer to the event \\u0027\\u0027NHTSA conduct investigations for Toyota recall\\u0027\\u0027. Such an explicit reference relationship made by authors in their news articles reflects their viewpoints and consideration of the inter-event relationships [33] . Therefore, we may regard such event reference (ER) relationships as more meaningful and reliable than content dependence relationships, and ER relationship analysis provides a way to discover those event dependence relationships missed by CD analysis, so as to obtain a more complete temporal event map (TEM).\",\"cite_spans\":[{\"start\":35.0,\"end\":39.0,\"text\":\"[33]\",\"ref_id\":\"BIBREF32\"},{\"start\":645.0,\"end\":649.0,\"text\":\"[33]\",\"ref_id\":\"BIBREF32\"}],\"ref_spans\":[],\"section\":\"Event reference analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-316a9c158a8199f17710a4ee2b76edc670b49e5ab7eff6c70a7e8fab1b3cbd1f_citespan-35-39> , <http://covid19.aksw.org/text-316a9c158a8199f17710a4ee2b76edc670b49e5ab7eff6c70a7e8fab1b3cbd1f_citespan-645-649> ;
            <http://www.example.org/section>
                    "Event reference analysis" ;
            <http://www.example.org/text>  "According to studies of journalism [33] , when authors of news articles about an event a find a dependence relationship between a and b (e.g., b triggers the occurrence of a, or a is evolved from b and so on), their articles may actually refer to event b. This is in line with our observation of our data set. For instance, some news articles about the event ''Toyota recall due to safety problems from 2009 to 2010'' refer to the event ''NHTSA conduct investigations for Toyota recall''. Such an explicit reference relationship made by authors in their news articles reflects their viewpoints and consideration of the inter-event relationships [33] . Therefore, we may regard such event reference (ER) relationships as more meaningful and reliable than content dependence relationships, and ER relationship analysis provides a way to discover those event dependence relationships missed by CD analysis, so as to obtain a more complete temporal event map (TEM)." ;
            <http://www.example.org/textHash>
                    "316a9c158a8199f17710a4ee2b76edc670b49e5ab7eff6c70a7e8fab1b3cbd1f" .
    
    <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c_refspan-268-275>
            <http://www.example.org/end>    "275.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF5" ;
            <http://www.example.org/start>  "268.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 6" .
    
    <http://covid19.aksw.org/text-27f19c7e7dee19fb53fba4fed784026218cbe419d8bc280ee2297553843d8189>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• By only taking content dependence into consideration and measuring content dependence through simple similarity functions, previous methods are effective only when two events share enough features.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion and conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion and conclusions" ;
            <http://www.example.org/text>  "• By only taking content dependence into consideration and measuring content dependence through simple similarity functions, previous methods are effective only when two events share enough features." ;
            <http://www.example.org/textHash>
                    "27f19c7e7dee19fb53fba4fed784026218cbe419d8bc280ee2297553843d8189" .
    
    <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8_refspan-348-354>
            <http://www.example.org/end>    "354.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF8" ;
            <http://www.example.org/start>  "348.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 4" .
    
    <http://covid19.aksw.org/text-aa838c738202266a024742d6b573df7b3f1ee9f770e372da4a6982b306713ddd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"On the other hand, our method did discover some incorrect relationships. For example, there is a relationship from event 2 to event 11 in the TEM of our method. However, the annotators consider that the component event \\u0027\\u0027SARS cases are reported and updated regularly to reflect the disease seriousness\\u0027\\u0027 (i.e., event 2) has no direct or clearly meaningful causal relationship with the event \\u0027\\u0027Beijing has SARS under control\\u0027\\u0027 (i.e., event 11). Another incorrect relationship discovered by our method is the one from event 5 to event 8. The incorrect relationships discovered by our method are different that those that resulted from the EEG method. Our incorrect relationships are from event 2 to 11 and from event 5 to event 8, while the incorrect relationships of EEG are from event 6 to event 7 and from event 9 to event 6.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Case study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Case study" ;
            <http://www.example.org/text>  "On the other hand, our method did discover some incorrect relationships. For example, there is a relationship from event 2 to event 11 in the TEM of our method. However, the annotators consider that the component event ''SARS cases are reported and updated regularly to reflect the disease seriousness'' (i.e., event 2) has no direct or clearly meaningful causal relationship with the event ''Beijing has SARS under control'' (i.e., event 11). Another incorrect relationship discovered by our method is the one from event 5 to event 8. The incorrect relationships discovered by our method are different that those that resulted from the EEG method. Our incorrect relationships are from event 2 to 11 and from event 5 to event 8, while the incorrect relationships of EEG are from event 6 to event 7 and from event 9 to event 6." ;
            <http://www.example.org/textHash>
                    "aa838c738202266a024742d6b573df7b3f1ee9f770e372da4a6982b306713ddd" .
    
    <http://covid19.aksw.org/text-868442eeae64a0fecb9b9308cfd6764b9ec019292ce69c5f66fdcc4979ac9ef3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To compare our method with others, we adopt one baseline and two variational methods. The baseline is the state-of-theart method of discovering an Event Evolution Graph proposed by Yang [6] , and we denote it as EEG. The first variational method, denoted as Content Dependence Map (CDM), only considers the content dependence relationship and does not use event reference analysis to judge event dependence relationships. Different from CDM, the second variational method, denoted as Event Reference Map (ERM), considers the event reference relationship only instead of using content dependence analysis to judge event dependence relationships. For CDM and ERM, both are special cases of our proposed TEM. Each of them can be considered as a part of TEM, and TEM is a combination of CDM and ERM.\",\"cite_spans\":[{\"start\":186.0,\"end\":189.0,\"text\":\"[6]\",\"ref_id\":\"BIBREF5\"}],\"ref_spans\":[],\"section\":\"Experiment setting\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-868442eeae64a0fecb9b9308cfd6764b9ec019292ce69c5f66fdcc4979ac9ef3_citespan-186-189> ;
            <http://www.example.org/section>
                    "Experiment setting" ;
            <http://www.example.org/text>  "To compare our method with others, we adopt one baseline and two variational methods. The baseline is the state-of-theart method of discovering an Event Evolution Graph proposed by Yang [6] , and we denote it as EEG. The first variational method, denoted as Content Dependence Map (CDM), only considers the content dependence relationship and does not use event reference analysis to judge event dependence relationships. Different from CDM, the second variational method, denoted as Event Reference Map (ERM), considers the event reference relationship only instead of using content dependence analysis to judge event dependence relationships. For CDM and ERM, both are special cases of our proposed TEM. Each of them can be considered as a part of TEM, and TEM is a combination of CDM and ERM." ;
            <http://www.example.org/textHash>
                    "868442eeae64a0fecb9b9308cfd6764b9ec019292ce69c5f66fdcc4979ac9ef3" .
    
    <http://covid19.aksw.org/text-c7cef66090b3aa76907fe1476a55e39e4f9489f0b5edf486716ccd600313125a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Huge amount of damage caused by the earthquake and tsunami reported 4\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "Huge amount of damage caused by the earthquake and tsunami reported 4" ;
            <http://www.example.org/textHash>
                    "c7cef66090b3aa76907fe1476a55e39e4f9489f0b5edf486716ccd600313125a" .
    
    <http://covid19.aksw.org/text-41dcb7231599b2c48d6b566a6c76207f26f3de0e62e8383d26eff62e67f78da5>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For our purposes of analyzing content dependence (CD) and event reference (ER) relationships, we measure event importance according to these two perspectives. From the content dependence perspective, inspired by the page rank ranking method [34] , we define a content-based event ranking function CRank to measure the importance of all the component events (excluding the seminal component and ending component events), with an aim to find out the important component events. In particular, CRank is a function given below:\",\"cite_spans\":[{\"start\":241.0,\"end\":245.0,\"text\":\"[34]\",\"ref_id\":\"BIBREF33\"}],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-41dcb7231599b2c48d6b566a6c76207f26f3de0e62e8383d26eff62e67f78da5_citespan-241-245> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "For our purposes of analyzing content dependence (CD) and event reference (ER) relationships, we measure event importance according to these two perspectives. From the content dependence perspective, inspired by the page rank ranking method [34] , we define a content-based event ranking function CRank to measure the importance of all the component events (excluding the seminal component and ending component events), with an aim to find out the important component events. In particular, CRank is a function given below:" ;
            <http://www.example.org/textHash>
                    "41dcb7231599b2c48d6b566a6c76207f26f3de0e62e8383d26eff62e67f78da5" .
    
    <http://covid19.aksw.org/text-9658eb923918ec4913080d8da6048dbcffd77acefa1c5999415c4da366874ae2_refspan-34-42>
            <http://www.example.org/end>    "42.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "34.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cr(a, b)" .
    
    <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Some other research focuses on discovering stories from documents and representing the content of the stories by graphs. For example, Subasic et al. [24, 25] investigate the problem of discovering stories. Choudhary et al. [26] propose a set of transformations to capture the evolution of an actor and interactions among actors. Ishii et al. [27] classify extracted sentences to define some simple language patterns in Japanese so as to extract causal relations, but their work cannot handle cases that are not defined in their patterns.\",\"cite_spans\":[{\"start\":149.0,\"end\":153.0,\"text\":\"[24,\",\"ref_id\":\"BIBREF23\"},{\"start\":154.0,\"end\":157.0,\"text\":\"25]\",\"ref_id\":\"BIBREF24\"},{\"start\":223.0,\"end\":227.0,\"text\":\"[26]\",\"ref_id\":\"BIBREF25\"},{\"start\":342.0,\"end\":346.0,\"text\":\"[27]\",\"ref_id\":\"BIBREF26\"}],\"ref_spans\":[],\"section\":\"News event relationship analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-149-153> , <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-154-157> , <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-223-227> , <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-342-346> ;
            <http://www.example.org/section>
                    "News event relationship analysis" ;
            <http://www.example.org/text>  "Some other research focuses on discovering stories from documents and representing the content of the stories by graphs. For example, Subasic et al. [24, 25] investigate the problem of discovering stories. Choudhary et al. [26] propose a set of transformations to capture the evolution of an actor and interactions among actors. Ishii et al. [27] classify extracted sentences to define some simple language patterns in Japanese so as to extract causal relations, but their work cannot handle cases that are not defined in their patterns." ;
            <http://www.example.org/textHash>
                    "9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_refspan-1501-1508>
            <http://www.example.org/end>    "1508.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF0" ;
            <http://www.example.org/start>  "1501.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-77d0ec8b9279d5aa18cc55cf1ebdf0a065a57b342ca3d337c8553c1474c03228_citespan-13-17>
            <http://www.example.org/end>    "17.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF31" ;
            <http://www.example.org/start>  "13.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[32]" .
    
    <http://covid19.aksw.org/text-793099768baefde014f03b731f48bbbf03c4ec1020a7185d8098bb35c813f2fc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Property 2. The core features of an event a are distinguishable from those of other events; i.e., the core features should facilitate us in identifying event a from all other events easily.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "Property 2. The core features of an event a are distinguishable from those of other events; i.e., the core features should facilitate us in identifying event a from all other events easily." ;
            <http://www.example.org/textHash>
                    "793099768baefde014f03b731f48bbbf03c4ec1020a7185d8098bb35c813f2fc" .
    
    <http://covid19.aksw.org/text-22bfa85a03de724d6231304c8057686cee8070429729b34ccf1f2cb6ea9e979c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The life cycle L a of event a is the period (time interval) from the beginning time St a to the end time Et a of a, i.e.,\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Definition 1.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Definition 1." ;
            <http://www.example.org/text>  "The life cycle L a of event a is the period (time interval) from the beginning time St a to the end time Et a of a, i.e.," ;
            <http://www.example.org/textHash>
                    "22bfa85a03de724d6231304c8057686cee8070429729b34ccf1f2cb6ea9e979c" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-2221-2224>
            <http://www.example.org/end>    "2224.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "2221.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-77d0ec8b9279d5aa18cc55cf1ebdf0a065a57b342ca3d337c8553c1474c03228>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"According to [32] , variables (i.e., keywords) that are not statistically independent suggest the existence of some functional relationship among them, and mutual information provides a general measure of dependencies among variables. Thus, we adopt mutual information to measure the dependence among features, and we further use an aggregation of all mutual information between the feature sets of two events to measure the content dependence degree between them.\",\"cite_spans\":[{\"start\":13.0,\"end\":17.0,\"text\":\"[32]\",\"ref_id\":\"BIBREF31\"}],\"ref_spans\":[],\"section\":\"− →\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-77d0ec8b9279d5aa18cc55cf1ebdf0a065a57b342ca3d337c8553c1474c03228_citespan-13-17> ;
            <http://www.example.org/section>
                    "− →" ;
            <http://www.example.org/text>  "According to [32] , variables (i.e., keywords) that are not statistically independent suggest the existence of some functional relationship among them, and mutual information provides a general measure of dependencies among variables. Thus, we adopt mutual information to measure the dependence among features, and we further use an aggregation of all mutual information between the feature sets of two events to measure the content dependence degree between them." ;
            <http://www.example.org/textHash>
                    "77d0ec8b9279d5aa18cc55cf1ebdf0a065a57b342ca3d337c8553c1474c03228" .
    
    <http://covid19.aksw.org/text-d7641de052c31498106b7420eeeff31dbf051ca94ace521fc002a8527cb877d5_citespan-134-135>
            <http://www.example.org/end>    "135.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "134.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "1" .
    
    <http://covid19.aksw.org/text-deabce21fa26ee79ee724d802a4a38ae94282e380f30c5421f886bde65b2739c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Comparing EEG Result and Annotated Result. By comparing Figs. 5 and 6, we find that the EEG method missed 17 significant relationships (out of 29 total) between events. Indeed, more than 4 We do not compare the results of CDM and ERM per se since our method is essentially a combination of CDM and ERM.\",\"cite_spans\":[{\"start\":187.0,\"end\":188.0,\"text\":\"4\",\"ref_id\":\"BIBREF3\"}],\"ref_spans\":[],\"section\":\"Case study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-deabce21fa26ee79ee724d802a4a38ae94282e380f30c5421f886bde65b2739c_citespan-187-188> ;
            <http://www.example.org/section>
                    "Case study" ;
            <http://www.example.org/text>  "Comparing EEG Result and Annotated Result. By comparing Figs. 5 and 6, we find that the EEG method missed 17 significant relationships (out of 29 total) between events. Indeed, more than 4 We do not compare the results of CDM and ERM per se since our method is essentially a combination of CDM and ERM." ;
            <http://www.example.org/textHash>
                    "deabce21fa26ee79ee724d802a4a38ae94282e380f30c5421f886bde65b2739c" .
    
    <http://covid19.aksw.org/text-89fcbba3c9e73283a03f50e7d2796a49bdd59fc967a7c49c544d78505871b687>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A user query can be considered as search requirements corresponding to a target event that satisfies all the needs of the user. The related document set of the target event can be obtained by function θ:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Preliminaries\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Preliminaries" ;
            <http://www.example.org/text>  "A user query can be considered as search requirements corresponding to a target event that satisfies all the needs of the user. The related document set of the target event can be obtained by function θ:" ;
            <http://www.example.org/textHash>
                    "89fcbba3c9e73283a03f50e7d2796a49bdd59fc967a7c49c544d78505871b687" .
    
    <http://covid19.aksw.org/text-194e44d65da54bc8d40c787df925e48eb6ee5f54938a4e27549beedaf8df5a79>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"If there is a dependence relationship from event a to event b; i.e., a is dependent on b, then there is a temporal relationship between a and b such that St b \\u003c\\u003d St a , i.e., b happens earlier than or at the same time as a.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Observation 1.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Observation 1." ;
            <http://www.example.org/text>  "If there is a dependence relationship from event a to event b; i.e., a is dependent on b, then there is a temporal relationship between a and b such that St b <= St a , i.e., b happens earlier than or at the same time as a." ;
            <http://www.example.org/textHash>
                    "194e44d65da54bc8d40c787df925e48eb6ee5f54938a4e27549beedaf8df5a79" .
    
    <http://covid19.aksw.org/text-ccea08b19084a317f5b5aa04dccc761fd145a174b14acade80d7fa4d8938cba7_citespan-188-192>
            <http://www.example.org/end>    "192.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "188.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(14)" .
    
    <http://covid19.aksw.org/text-0a0f91aad1121cd704e897fa4e9cb99bc30b6bc31df0413c8d979be299653e9b_citespan-378-379>
            <http://www.example.org/end>    "379.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "378.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "2" .
    
    <http://covid19.aksw.org/text-92566130eeb8a3b60a8577552b56de815d6a1e93149cbaae7137fbf628466ca0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The Precision and Recall values of our method are approximately 0.8, meaning that most event dependence relationships discovered by our method are correct, and also that our method can discover more event dependence relationships than other three methods. Our method\\u0027s F − measure score is also approximately 0.8, since it is a combination of Precision and Recall. Note that CDM outperforms EEG slightly on all metrics, and the reason is that using mutual information to measure feature dependence is better than only matching keyword similarity (as was done in most previous research). ERM outperforms EEG and CDM on all three metrics. This indicates that using event reference analysis (i.e., ERM) to identify event dependence relationships is more effective than using content dependence relationship analysis (i.e., CDM) and content similarity analysis (i.e., EEG). Also, it is quite interesting to see that the Recall of CDM is greater than that of ERM, while both of them are smaller than those of our method. This means that the event dependence relationships identified by CDM and ERM are indeed different and complementary. Our method is a combination of CDM and ERM, and it has the strength of both methods. In other words, taking both content dependence and event reference analysis into consideration in identifying event dependence relationships produces better results than taking just one of these. For event ranking, Table 3 shows that our method obtains a higher value of NDCG than the ERM and CDM methods. In particular, the NDCG of our method is 0.9662 while that of ERM and CDM is 0.8923 and 0.8687, respectively. This means that combining both content dependence relationships and event reference relationships to rank events can also achieve a better result. SARS has a great impact on transportation, especially airlines 5\",\"cite_spans\":[],\"ref_spans\":[{\"start\":1433.0,\"end\":1440.0,\"text\":\"Table 3\",\"ref_id\":\"TABREF2\"}],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-92566130eeb8a3b60a8577552b56de815d6a1e93149cbaae7137fbf628466ca0_refspan-1433-1440> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "The Precision and Recall values of our method are approximately 0.8, meaning that most event dependence relationships discovered by our method are correct, and also that our method can discover more event dependence relationships than other three methods. Our method's F − measure score is also approximately 0.8, since it is a combination of Precision and Recall. Note that CDM outperforms EEG slightly on all metrics, and the reason is that using mutual information to measure feature dependence is better than only matching keyword similarity (as was done in most previous research). ERM outperforms EEG and CDM on all three metrics. This indicates that using event reference analysis (i.e., ERM) to identify event dependence relationships is more effective than using content dependence relationship analysis (i.e., CDM) and content similarity analysis (i.e., EEG). Also, it is quite interesting to see that the Recall of CDM is greater than that of ERM, while both of them are smaller than those of our method. This means that the event dependence relationships identified by CDM and ERM are indeed different and complementary. Our method is a combination of CDM and ERM, and it has the strength of both methods. In other words, taking both content dependence and event reference analysis into consideration in identifying event dependence relationships produces better results than taking just one of these. For event ranking, Table 3 shows that our method obtains a higher value of NDCG than the ERM and CDM methods. In particular, the NDCG of our method is 0.9662 while that of ERM and CDM is 0.8923 and 0.8687, respectively. This means that combining both content dependence relationships and event reference relationships to rank events can also achieve a better result. SARS has a great impact on transportation, especially airlines 5" ;
            <http://www.example.org/textHash>
                    "92566130eeb8a3b60a8577552b56de815d6a1e93149cbaae7137fbf628466ca0" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-1128-1132>
            <http://www.example.org/end>    "1132.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF13" ;
            <http://www.example.org/start>  "1128.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[14]" .
    
    <http://covid19.aksw.org/text-0a0f91aad1121cd704e897fa4e9cb99bc30b6bc31df0413c8d979be299653e9b_refspan-535-541>
            <http://www.example.org/end>    "541.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF3" ;
            <http://www.example.org/start>  "535.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 2" .
    
    <http://covid19.aksw.org/text-75c091447bd95ba21d9469adc79be43405f402cb9643d1349ba4f6afc1f85e5d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\". . , f x,n } about the event\\u0027s content. In the following we define an event formally.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Problem formulation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Problem formulation" ;
            <http://www.example.org/text>  ". . , f x,n } about the event's content. In the following we define an event formally." ;
            <http://www.example.org/textHash>
                    "75c091447bd95ba21d9469adc79be43405f402cb9643d1349ba4f6afc1f85e5d" .
    
    <http://covid19.aksw.org/text-a7ef78724573aa88a09927247cc68fcb40a438d4024d1fc00dd175a7cedb0e9f_citespan-433-436>
            <http://www.example.org/end>    "436.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[3]" .
    
    <http://covid19.aksw.org/text-eae9ca05558d4763ff748020c924e13c92975dc08d6d6f39fda6accf9e5393df>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where rel i is the graded relevance of the ranking result at position i, and we give value x to position x (e.g., rel 2 \\u003d 2, rel 3 \\u003d 3 and so forth). Note that iDCG is the ideal DCG that is used to normalize the result [36] . The higher the value of NDCG, the better the ranking result.\",\"cite_spans\":[{\"start\":219.0,\"end\":223.0,\"text\":\"[36]\",\"ref_id\":\"BIBREF35\"}],\"ref_spans\":[],\"section\":\"Experiment setting\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-eae9ca05558d4763ff748020c924e13c92975dc08d6d6f39fda6accf9e5393df_citespan-219-223> ;
            <http://www.example.org/section>
                    "Experiment setting" ;
            <http://www.example.org/text>  "where rel i is the graded relevance of the ranking result at position i, and we give value x to position x (e.g., rel 2 = 2, rel 3 = 3 and so forth). Note that iDCG is the ideal DCG that is used to normalize the result [36] . The higher the value of NDCG, the better the ranking result." ;
            <http://www.example.org/textHash>
                    "eae9ca05558d4763ff748020c924e13c92975dc08d6d6f39fda6accf9e5393df" .
    
    <http://covid19.aksw.org/text-0a0f91aad1121cd704e897fa4e9cb99bc30b6bc31df0413c8d979be299653e9b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To support a temporal event search, we propose a framework of event relationship analysis in this section. In our method, we first identify a set of related documents for the target event and extract component events from the related documents. We conduct content dependence (CD) and event reference (ER) relationship analysis to identify any dependence between the two events. 2 Also, we propose a ranking mechanism based on interevent relationships to rank the events. The process of a Temporal Event Map construction is shown as in Fig. 2 .\",\"cite_spans\":[{\"start\":378.0,\"end\":379.0,\"text\":\"2\",\"ref_id\":\"BIBREF1\"}],\"ref_spans\":[{\"start\":535.0,\"end\":541.0,\"text\":\"Fig. 2\",\"ref_id\":\"FIGREF3\"}],\"section\":\"Event relationship analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0a0f91aad1121cd704e897fa4e9cb99bc30b6bc31df0413c8d979be299653e9b_citespan-378-379> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-0a0f91aad1121cd704e897fa4e9cb99bc30b6bc31df0413c8d979be299653e9b_refspan-535-541> ;
            <http://www.example.org/section>
                    "Event relationship analysis" ;
            <http://www.example.org/text>  "To support a temporal event search, we propose a framework of event relationship analysis in this section. In our method, we first identify a set of related documents for the target event and extract component events from the related documents. We conduct content dependence (CD) and event reference (ER) relationship analysis to identify any dependence between the two events. 2 Also, we propose a ranking mechanism based on interevent relationships to rank the events. The process of a Temporal Event Map construction is shown as in Fig. 2 ." ;
            <http://www.example.org/textHash>
                    "0a0f91aad1121cd704e897fa4e9cb99bc30b6bc31df0413c8d979be299653e9b" .
    
    <http://covid19.aksw.org/text-aebaac6f91b823c1cc4aec21ddd331e19b43dc11a2349945a159e5ae0dec3c07>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"There are also some \\u0027\\u0027incorrect\\u0027\\u0027 inter-event relationships discovered by EEG. For example, in Fig. 5 , there are relationships from event 6 to event 7 and event 9 to event 6. No annotators however considered that such relationships exist. The event \\u0027\\u0027other countries donate and offer help to China\\u0027\\u0027 (event 6) is considered to be independent of the event \\u0027\\u0027SARS has impact on China\\u0027s economy\\u0027\\u0027 (event 7). The event \\u0027\\u0027China informs and cooperates with WHO on fighting SARS\\u0027\\u0027 (event 9) is deemed unrelated to the impact of SARS on China\\u0027s economy (i.e., event 6).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":95.0,\"end\":101.0,\"text\":\"Fig. 5\",\"ref_id\":\"FIGREF9\"}],\"section\":\"Case study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-aebaac6f91b823c1cc4aec21ddd331e19b43dc11a2349945a159e5ae0dec3c07_refspan-95-101> ;
            <http://www.example.org/section>
                    "Case study" ;
            <http://www.example.org/text>  "There are also some ''incorrect'' inter-event relationships discovered by EEG. For example, in Fig. 5 , there are relationships from event 6 to event 7 and event 9 to event 6. No annotators however considered that such relationships exist. The event ''other countries donate and offer help to China'' (event 6) is considered to be independent of the event ''SARS has impact on China's economy'' (event 7). The event ''China informs and cooperates with WHO on fighting SARS'' (event 9) is deemed unrelated to the impact of SARS on China's economy (i.e., event 6)." ;
            <http://www.example.org/textHash>
                    "aebaac6f91b823c1cc4aec21ddd331e19b43dc11a2349945a159e5ae0dec3c07" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1601-1605>
            <http://www.example.org/end>    "1605.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF20" ;
            <http://www.example.org/start>  "1601.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[21," .
    
    <http://covid19.aksw.org/text-cd6f00ff38cc269300a13be8cfeeb0373cc0542c04eb7740f62b1619f598aafe>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Although content dependence measurement can address the limitations of content similarity measurement, it can still miss some dependence relationships between events. In particular, the existence of a dependence relationship between two events does not necessarily mean that there exists a content dependence relationship between them. In many cases, although the contents of two events are very different and may even have different topics, people may still consider that there is a dependence relationship between them. For instance, \\u0027\\u0027Experts find disease and SARS outbreaks\\u0027\\u0027 (event a) has an impact on \\u0027\\u0027SARS has great impact on economy\\u0027\\u0027 (event b) and \\u0027\\u0027SARS has a great impact on Tourism\\u0027\\u0027 (event c). The latter two events are dependent on the first one, even though their content dependence degree (i.e. , CD(a, b) or CD(a, c)) is very small. While content dependence analysis depends on measuring the semantic relevance of features between two events, event reference analysis depends on whether an event contains some representative features of another event.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":812.0,\"end\":822.0,\"text\":\", CD(a, b)\"}],\"section\":\"Event reference analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-cd6f00ff38cc269300a13be8cfeeb0373cc0542c04eb7740f62b1619f598aafe_refspan-812-822> ;
            <http://www.example.org/section>
                    "Event reference analysis" ;
            <http://www.example.org/text>  "Although content dependence measurement can address the limitations of content similarity measurement, it can still miss some dependence relationships between events. In particular, the existence of a dependence relationship between two events does not necessarily mean that there exists a content dependence relationship between them. In many cases, although the contents of two events are very different and may even have different topics, people may still consider that there is a dependence relationship between them. For instance, ''Experts find disease and SARS outbreaks'' (event a) has an impact on ''SARS has great impact on economy'' (event b) and ''SARS has a great impact on Tourism'' (event c). The latter two events are dependent on the first one, even though their content dependence degree (i.e. , CD(a, b) or CD(a, c)) is very small. While content dependence analysis depends on measuring the semantic relevance of features between two events, event reference analysis depends on whether an event contains some representative features of another event." ;
            <http://www.example.org/textHash>
                    "cd6f00ff38cc269300a13be8cfeeb0373cc0542c04eb7740f62b1619f598aafe" .
    
    <http://covid19.aksw.org/text-afc8da8dc333e420504503b02c994ce6799446c6375255d1cf415cae397dede1_refspan-302-309>
            <http://www.example.org/end>    "309.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "302.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 11" .
    
    <http://covid19.aksw.org/text-03db67786ab2a9e1fb601e512a7f2418f3a1f5ab6bef8d5d1a87d5e26c44c40f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Of course, users may also be interested only in component events that happened during a particular time period. For example, some users may only be interested in component events that happened within the past three months. We can do a projection of a TEM by a particular time period to obtain a sub-graph like the one shown in Fig. 12 . Formally, we denote the projection based on time period for TEM i, say, from March, 11, 2011 to April 30, 2011, as π t\\u003d\\u0027\\u002711/03/2011-30/04/2011\\u0027\\u0027 (TEM i ).\",\"cite_spans\":[],\"ref_spans\":[{\"start\":327.0,\"end\":334.0,\"text\":\"Fig. 12\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Projection on a time period\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-03db67786ab2a9e1fb601e512a7f2418f3a1f5ab6bef8d5d1a87d5e26c44c40f_refspan-327-334> ;
            <http://www.example.org/section>
                    "Projection on a time period" ;
            <http://www.example.org/text>  "Of course, users may also be interested only in component events that happened during a particular time period. For example, some users may only be interested in component events that happened within the past three months. We can do a projection of a TEM by a particular time period to obtain a sub-graph like the one shown in Fig. 12 . Formally, we denote the projection based on time period for TEM i, say, from March, 11, 2011 to April 30, 2011, as π t=''11/03/2011-30/04/2011'' (TEM i )." ;
            <http://www.example.org/textHash>
                    "03db67786ab2a9e1fb601e512a7f2418f3a1f5ab6bef8d5d1a87d5e26c44c40f" .
    
    <http://covid19.aksw.org/text-5db9a3de760158157a6a98cbe9a94f90a2e766d7db737dd8ea0205afbd1aa64d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"x , a set of place names q d a x \\u003d {t x,1 , . . . , t x,n } and a set of terms\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Problem formulation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Problem formulation" ;
            <http://www.example.org/text>  "x , a set of place names q d a x = {t x,1 , . . . , t x,n } and a set of terms" ;
            <http://www.example.org/textHash>
                    "5db9a3de760158157a6a98cbe9a94f90a2e766d7db737dd8ea0205afbd1aa64d" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-1495-1498>
            <http://www.example.org/end>    "1498.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "1495.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[5]" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1606-1609>
            <http://www.example.org/end>    "1609.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF21" ;
            <http://www.example.org/start>  "1606.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "22]" .
    
    <http://covid19.aksw.org/text-d8cc846bd798dc22d3068e3c1a9aae868b1a78d327e88204cb7b4b6d93ac95f6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To evaluate our method for a temporal event search, we have collected 5063 English news articles (i.e., web page documents of news) from such mainstream news websites as CNN News and BBC News. We select ten queries about major events to test our method, such as \\u0027\\u0027Toyota 2009-2010 vehicle recalls\\u0027,\\u0027 \\u0027\\u00272010 Copiap mining accident\\u0027\\u0027, \\u0027\\u0027SARS in 2003\\u0027\\u0027 and so on. Among these, the event \\u0027\\u0027SARS in 2003\\u0027\\u0027 contains the highest number of related news articles (i.e., 231 articles), and the event \\u0027\\u0027Christchurch Earthquake in 2010 in New Zealand\\u0027\\u0027 contains the fewest number of related news articles (i.e., 39 articles). As mentioned before, event detection is not the major topic of this paper, so to extract events from the news documents based on user queries, we adopt the topic-based method [31] . According to our observation of the data set, when an event a refers to another event b, the number of referred core features of b is often around five. 3 Thus, we select top-5 core features to measure event reference relationships in our experiment.\",\"cite_spans\":[{\"start\":789.0,\"end\":793.0,\"text\":\"[31]\",\"ref_id\":\"BIBREF30\"},{\"start\":949.0,\"end\":950.0,\"text\":\"3\",\"ref_id\":\"BIBREF2\"}],\"ref_spans\":[],\"section\":\"Experiment setting\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-d8cc846bd798dc22d3068e3c1a9aae868b1a78d327e88204cb7b4b6d93ac95f6_citespan-789-793> , <http://covid19.aksw.org/text-d8cc846bd798dc22d3068e3c1a9aae868b1a78d327e88204cb7b4b6d93ac95f6_citespan-949-950> ;
            <http://www.example.org/section>
                    "Experiment setting" ;
            <http://www.example.org/text>  "To evaluate our method for a temporal event search, we have collected 5063 English news articles (i.e., web page documents of news) from such mainstream news websites as CNN News and BBC News. We select ten queries about major events to test our method, such as ''Toyota 2009-2010 vehicle recalls',' ''2010 Copiap mining accident'', ''SARS in 2003'' and so on. Among these, the event ''SARS in 2003'' contains the highest number of related news articles (i.e., 231 articles), and the event ''Christchurch Earthquake in 2010 in New Zealand'' contains the fewest number of related news articles (i.e., 39 articles). As mentioned before, event detection is not the major topic of this paper, so to extract events from the news documents based on user queries, we adopt the topic-based method [31] . According to our observation of the data set, when an event a refers to another event b, the number of referred core features of b is often around five. 3 Thus, we select top-5 core features to measure event reference relationships in our experiment." ;
            <http://www.example.org/textHash>
                    "d8cc846bd798dc22d3068e3c1a9aae868b1a78d327e88204cb7b4b6d93ac95f6" .
    
    <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-91-94>
            <http://www.example.org/end>    "94.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF17" ;
            <http://www.example.org/start>  "91.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "18," .
    
    <http://covid19.aksw.org/text-868442eeae64a0fecb9b9308cfd6764b9ec019292ce69c5f66fdcc4979ac9ef3_citespan-186-189>
            <http://www.example.org/end>    "189.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "186.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[6]" .
    
    <http://covid19.aksw.org/text-d6b13aa2cf6d856df470a0804eb1f79ffe8c169773ac5980909e5d7d7e19cb09_refspan-219-227>
            <http://www.example.org/end>    "227.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "219.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cr (a,b)" .
    
    <http://covid19.aksw.org/text-91bd359b1d5d20d4aae19684fd74ddda3ecf0732cb79a824d699f03c2c9830d9_refspan-165-172>
            <http://www.example.org/end>    "172.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "165.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 10" .
    
    <http://covid19.aksw.org/text-ccea08b19084a317f5b5aa04dccc761fd145a174b14acade80d7fa4d8938cba7_citespan-127-131>
            <http://www.example.org/end>    "131.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[36]" .
    
    <http://covid19.aksw.org/text-b7837b370561cd87629829bccc291caaea9ed97130cca01972574d684d69dcd3>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Based on the above properties, we propose the following function to select core features of an event a:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "Based on the above properties, we propose the following function to select core features of an event a:" ;
            <http://www.example.org/textHash>
                    "b7837b370561cd87629829bccc291caaea9ed97130cca01972574d684d69dcd3" .
    
    <http://covid19.aksw.org/text-85d2631070d181b18fe5ea841549c007515e4c71a6781d12665fd11a12c2c6a1_refspan-71-78>
            <http://www.example.org/end>    "78.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "71.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 5" .
    
    <http://covid19.aksw.org/text-20e06f45eedce14d174fd7358d90dabb5a353097d98397b8caec956334e37fb6_refspan-61-67>
            <http://www.example.org/end>    "67.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "61.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 1" .
    
    <http://covid19.aksw.org/text-44e9bcf0c640bea3b15799c6cf8d94089c501f5b963df22788a5f94f163756b6_refspan-118-124>
            <http://www.example.org/end>    "124.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "118.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 1" .
    
    <http://covid19.aksw.org/text-d7641de052c31498106b7420eeeff31dbf051ca94ace521fc002a8527cb877d5_citespan-323-324>
            <http://www.example.org/end>    "324.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "323.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "2" .
    
    <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-86-90>
            <http://www.example.org/end>    "90.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "86.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[17," .
    
    <http://covid19.aksw.org/text-2f091a2b539e39cc9ab1a885f3eed5b550e58a1e2922407b9d2ab4033c16ff1f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where Cr(a, v) is the reference degree (cf. Eq. (5)) between events a and v. Similar to CRank(v), RRank(v) is regarded as a \\u0027\\u0027vote\\u0027\\u0027 value which is set as 1 in our experiment to indicate that there is a link (ER relationship) between events a and v.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "where Cr(a, v) is the reference degree (cf. Eq. (5)) between events a and v. Similar to CRank(v), RRank(v) is regarded as a ''vote'' value which is set as 1 in our experiment to indicate that there is a link (ER relationship) between events a and v." ;
            <http://www.example.org/textHash>
                    "2f091a2b539e39cc9ab1a885f3eed5b550e58a1e2922407b9d2ab4033c16ff1f" .
    
    <http://covid19.aksw.org/text-0f7d89b1a09bc4627a5322f9fdeea1157416a6c7bfbf0e5e1633015915482e74_citespan-106-107>
            <http://www.example.org/end>    "107.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "106.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "1" .
    
    <http://covid19.aksw.org/text-52b0301bcf374ac0bf11aa3a7d51feea10207948b43f8ec4bb9b18f5f24acb9d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In this section, we conduct experiments on a real data set to evaluate our approach by comparing it with a number of baseline methods.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Evaluation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Evaluation" ;
            <http://www.example.org/text>  "In this section, we conduct experiments on a real data set to evaluate our approach by comparing it with a number of baseline methods." ;
            <http://www.example.org/textHash>
                    "52b0301bcf374ac0bf11aa3a7d51feea10207948b43f8ec4bb9b18f5f24acb9d" .
    
    <http://covid19.aksw.org/text-332ce7f55ba994dfc830c914d805ea110e28403c7cfea7d61cbeaefea9e4a933>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In this paper, we have defined three kinds of event relationships to support temporal event searches, including temporal relationships, content dependence relationships and event reference relationships, and we have applied them to measure the degrees of inter-dependencies between component events. We have also formalized the problem of event searches and proposed a framework to search events according to user queries. The search results are represented by a temporal event map (TEM), which is a global picture showing the dependence relationships between events, thereby illustrating the evolution or development of an event along the timeline. A method to measure degrees of event importance has been proposed for discovering the important component (milestone) events for a given query. Experiments on a real data set show that our proposed method outperforms the baseline methods, and it can discover relationships that are missed by previous methods and sometimes even by human annotators.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion and conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion and conclusions" ;
            <http://www.example.org/text>  "In this paper, we have defined three kinds of event relationships to support temporal event searches, including temporal relationships, content dependence relationships and event reference relationships, and we have applied them to measure the degrees of inter-dependencies between component events. We have also formalized the problem of event searches and proposed a framework to search events according to user queries. The search results are represented by a temporal event map (TEM), which is a global picture showing the dependence relationships between events, thereby illustrating the evolution or development of an event along the timeline. A method to measure degrees of event importance has been proposed for discovering the important component (milestone) events for a given query. Experiments on a real data set show that our proposed method outperforms the baseline methods, and it can discover relationships that are missed by previous methods and sometimes even by human annotators." ;
            <http://www.example.org/textHash>
                    "332ce7f55ba994dfc830c914d805ea110e28403c7cfea7d61cbeaefea9e4a933" .
    
    <http://covid19.aksw.org/text-8d117d4b57ab66b6c869c95a9b1c457265e200e72c6826d6c08f6a0169601193>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• Content dependence analysis of events cannot form a complete picture of an event\\u0027s development. According to studies in Journalism [8] and our own observation, it is not unusual for authors (reporters) to write news articles on an event by referring to other events when they notice a dependent relationship between them. For instance, some news articles about the event \\u0027\\u0027Toyota recall due to safety problems from 2009 to 2010\\u0027\\u0027 refer to the event \\u0027\\u0027NHTSA conduct investigations for Toyota recall\\u0027\\u0027. Motivated by this phenomena, we explore event reference (ER) analysis to detect whether there is an inter-event relationship specified by authors. The relationship between two events discovered by ER analysis is considered an event reference (ER) relationship, which has not been explored by previous research.\",\"cite_spans\":[{\"start\":133.0,\"end\":136.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-8d117d4b57ab66b6c869c95a9b1c457265e200e72c6826d6c08f6a0169601193_citespan-133-136> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "• Content dependence analysis of events cannot form a complete picture of an event's development. According to studies in Journalism [8] and our own observation, it is not unusual for authors (reporters) to write news articles on an event by referring to other events when they notice a dependent relationship between them. For instance, some news articles about the event ''Toyota recall due to safety problems from 2009 to 2010'' refer to the event ''NHTSA conduct investigations for Toyota recall''. Motivated by this phenomena, we explore event reference (ER) analysis to detect whether there is an inter-event relationship specified by authors. The relationship between two events discovered by ER analysis is considered an event reference (ER) relationship, which has not been explored by previous research." ;
            <http://www.example.org/textHash>
                    "8d117d4b57ab66b6c869c95a9b1c457265e200e72c6826d6c08f6a0169601193" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"An event evolution pattern discovery technique is proposed by Yang et al. in [28] . It identifies event episodes together with their temporal relationships. They consider temporal relationships instead of evolution relationships. Although the temporal relationships can help organize event episodes in sequences according to their temporal order, they do not necessarily reflect the evolutionary paths between events. Some extended examples of these methods are presented in [7] and [29] . Yang et al. [6] define the event evolution relationships between events and propose a way to measure these event evolution relationships. In their work, identifying an event evolution relationship between two events depends on the similarity of the features of the two events. Based on a small number of documents and events about a given news topic, Nallapati et al. [30] define the concept of event threading. Their definition of event threading is based on the content similarity relationship from a previous event to a later event. The event threading is organized as a tree structure rather than a graph. In order to identify event threading, they employ a simple similarity measure between documents to cluster documents into events, and they use the average document similarity to estimate the content dependencies between events. Feng and Allan [4] extend Nallapati\\u0027s work to passage threading by breaking each news story into finer granules, and they propose a model called incident threading in [5] . Table 1 shows the comparison of our methods and previous methods regarding different dependencies.\",\"cite_spans\":[{\"start\":77.0,\"end\":81.0,\"text\":\"[28]\",\"ref_id\":\"BIBREF27\"},{\"start\":475.0,\"end\":478.0,\"text\":\"[7]\",\"ref_id\":\"BIBREF6\"},{\"start\":483.0,\"end\":487.0,\"text\":\"[29]\",\"ref_id\":\"BIBREF28\"},{\"start\":502.0,\"end\":505.0,\"text\":\"[6]\",\"ref_id\":\"BIBREF5\"},{\"start\":858.0,\"end\":862.0,\"text\":\"[30]\",\"ref_id\":\"BIBREF29\"},{\"start\":1343.0,\"end\":1346.0,\"text\":\"[4]\",\"ref_id\":\"BIBREF3\"},{\"start\":1495.0,\"end\":1498.0,\"text\":\"[5]\",\"ref_id\":\"BIBREF4\"}],\"ref_spans\":[{\"start\":1501.0,\"end\":1508.0,\"text\":\"Table 1\",\"ref_id\":\"TABREF0\"}],\"section\":\"News event relationship analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-483-487> , <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-1343-1346> , <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-77-81> , <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-858-862> , <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-1495-1498> , <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-502-505> , <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-475-478> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_refspan-1501-1508> ;
            <http://www.example.org/section>
                    "News event relationship analysis" ;
            <http://www.example.org/text>  "An event evolution pattern discovery technique is proposed by Yang et al. in [28] . It identifies event episodes together with their temporal relationships. They consider temporal relationships instead of evolution relationships. Although the temporal relationships can help organize event episodes in sequences according to their temporal order, they do not necessarily reflect the evolutionary paths between events. Some extended examples of these methods are presented in [7] and [29] . Yang et al. [6] define the event evolution relationships between events and propose a way to measure these event evolution relationships. In their work, identifying an event evolution relationship between two events depends on the similarity of the features of the two events. Based on a small number of documents and events about a given news topic, Nallapati et al. [30] define the concept of event threading. Their definition of event threading is based on the content similarity relationship from a previous event to a later event. The event threading is organized as a tree structure rather than a graph. In order to identify event threading, they employ a simple similarity measure between documents to cluster documents into events, and they use the average document similarity to estimate the content dependencies between events. Feng and Allan [4] extend Nallapati's work to passage threading by breaking each news story into finer granules, and they propose a model called incident threading in [5] . Table 1 shows the comparison of our methods and previous methods regarding different dependencies." ;
            <http://www.example.org/textHash>
                    "5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b" .
    
    <http://covid19.aksw.org/text-30a31fa045265b5530b106c6f77a26d1d820435823ccf200a69f809a8bc200f1>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• Generally, people are more interested in important component events than in ordinary ones. Based on the event relationships in a TEM, we propose a method to measure the degree of importance of events, and we rank events based on their degrees of importance, thereby discovering the \\u0027\\u0027milestone\\u0027\\u0027 events for a given query. Several of the algebraic operators of a TEM are devised for users to view the target event from different perspectives.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "• Generally, people are more interested in important component events than in ordinary ones. Based on the event relationships in a TEM, we propose a method to measure the degree of importance of events, and we rank events based on their degrees of importance, thereby discovering the ''milestone'' events for a given query. Several of the algebraic operators of a TEM are devised for users to view the target event from different perspectives." ;
            <http://www.example.org/textHash>
                    "30a31fa045265b5530b106c6f77a26d1d820435823ccf200a69f809a8bc200f1" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The event processing network was first introduced in the field of modeling by Luckman [2] . The conceptual model of EPN based on this idea was further elaborated by Sharon and Etzion [9] . Artikis et al. [10] , present an event processing system called EP-IRM for recognizing composite events given multiple sources of information in order to support intelligent resource management. Artikis et al. [11] classify the different types of uncertainty found in event processing applications and discuss their implications on event representation and reasoning. A logic-based event reasoning tool to identify regions of uncertainty within a stream is introduced in [12] . In distributed systems, event derivation is hampered by uncertainty that is attributed to causes such as unreliable data sources or the inability to determine with certainty whether an event has actually occurred, given the available information. Wasserkrug et al. [13] present a solution for handling the problem by introducing a novel generic and formal mechanism and framework for managing event derivation under conditions of uncertainty Cugola and Margara [14] propose a general, unifying model to capture the different aspects of an IFP system and use it to provide a complete and precise classification of systems and mechanisms.\",\"cite_spans\":[{\"start\":86.0,\"end\":89.0,\"text\":\"[2]\",\"ref_id\":\"BIBREF1\"},{\"start\":183.0,\"end\":186.0,\"text\":\"[9]\",\"ref_id\":\"BIBREF8\"},{\"start\":204.0,\"end\":208.0,\"text\":\"[10]\",\"ref_id\":\"BIBREF9\"},{\"start\":399.0,\"end\":403.0,\"text\":\"[11]\",\"ref_id\":\"BIBREF10\"},{\"start\":660.0,\"end\":664.0,\"text\":\"[12]\",\"ref_id\":\"BIBREF11\"},{\"start\":932.0,\"end\":936.0,\"text\":\"[13]\",\"ref_id\":\"BIBREF12\"},{\"start\":1128.0,\"end\":1132.0,\"text\":\"[14]\",\"ref_id\":\"BIBREF13\"}],\"ref_spans\":[],\"section\":\"Complex event recognition and processing\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-660-664> , <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-204-208> , <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-932-936> , <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-86-89> , <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-183-186> , <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-399-403> , <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-1128-1132> ;
            <http://www.example.org/section>
                    "Complex event recognition and processing" ;
            <http://www.example.org/text>  "The event processing network was first introduced in the field of modeling by Luckman [2] . The conceptual model of EPN based on this idea was further elaborated by Sharon and Etzion [9] . Artikis et al. [10] , present an event processing system called EP-IRM for recognizing composite events given multiple sources of information in order to support intelligent resource management. Artikis et al. [11] classify the different types of uncertainty found in event processing applications and discuss their implications on event representation and reasoning. A logic-based event reasoning tool to identify regions of uncertainty within a stream is introduced in [12] . In distributed systems, event derivation is hampered by uncertainty that is attributed to causes such as unreliable data sources or the inability to determine with certainty whether an event has actually occurred, given the available information. Wasserkrug et al. [13] present a solution for handling the problem by introducing a novel generic and formal mechanism and framework for managing event derivation under conditions of uncertainty Cugola and Margara [14] propose a general, unifying model to capture the different aspects of an IFP system and use it to provide a complete and precise classification of systems and mechanisms." ;
            <http://www.example.org/textHash>
                    "567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad" .
    
    <http://covid19.aksw.org/d34c5f3a5f439702d5c04a9c11b8b5c18d869151>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "d34c5f3a5f439702d5c04a9c11b8b5c18d869151" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-cd6f00ff38cc269300a13be8cfeeb0373cc0542c04eb7740f62b1619f598aafe> , <http://covid19.aksw.org/text-107b1b542fe0c195dc86d6e890fe69191afabeb085e36cf11b4447ea6997a855> , <http://covid19.aksw.org/text-bdd2a1035cbafdfcd7f9959f4c7eeab9a85b40206835604bfa9ca0615c2ae097> , <http://covid19.aksw.org/text-aebaac6f91b823c1cc4aec21ddd331e19b43dc11a2349945a159e5ae0dec3c07> , <http://covid19.aksw.org/text-316a9c158a8199f17710a4ee2b76edc670b49e5ab7eff6c70a7e8fab1b3cbd1f> , <http://covid19.aksw.org/text-9658eb923918ec4913080d8da6048dbcffd77acefa1c5999415c4da366874ae2> , <http://covid19.aksw.org/text-fcf9a9909aaee16b36a3c96b69be7f175e1ec7c97695ae6c3b8c4c1cb9644d79> , <http://covid19.aksw.org/text-0f7d89b1a09bc4627a5322f9fdeea1157416a6c7bfbf0e5e1633015915482e74> , <http://covid19.aksw.org/text-6201111b83a0cb5b0922cb37cc442b9a40e24e3b1ce100a4bb204f4c63fd2ac0> , <http://covid19.aksw.org/text-793099768baefde014f03b731f48bbbf03c4ec1020a7185d8098bb35c813f2fc> , <http://covid19.aksw.org/text-c6da05d838902e02dc48c83ea0fff0525e19eb3d612ca98a58909180d2b46582> , <http://covid19.aksw.org/text-3db8d80872f4e842d1b7a1fff9261eb9b38cfe616b66d4074033d06a065140fe> , <http://covid19.aksw.org/text-85d2631070d181b18fe5ea841549c007515e4c71a6781d12665fd11a12c2c6a1> , <http://covid19.aksw.org/text-444ac5291c54fe97204aa0c86b57ee00cf20b1ff5565a9fdfbd50691cece049b> , <http://covid19.aksw.org/text-e3c8b4102af10848c5e7599c170f05f71dfcf9692daf9b1fd48f5c2e4b20c845> , <http://covid19.aksw.org/text-d8cc846bd798dc22d3068e3c1a9aae868b1a78d327e88204cb7b4b6d93ac95f6> , <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6> , <http://covid19.aksw.org/text-77c061e8ecc47c88035170d89cb7c6192ecb03367a34f5d735a9bda0494d85f4> , <http://covid19.aksw.org/text-59811b69e4fb9556fd348089e8d3b2800ccc6366f8799a0324305240197633ce> , <http://covid19.aksw.org/text-ec1e28e18224feb94d3f97999492dae917f522869a9d922450c95bb8ef9d4efc> , <http://covid19.aksw.org/text-85ca9d1366f9929c54310fa1032666a2fff13cd9abe7c65492640aa54d9bcefe> , <http://covid19.aksw.org/text-d7641de052c31498106b7420eeeff31dbf051ca94ace521fc002a8527cb877d5> , <http://covid19.aksw.org/text-44e9bcf0c640bea3b15799c6cf8d94089c501f5b963df22788a5f94f163756b6> , <http://covid19.aksw.org/text-deabce21fa26ee79ee724d802a4a38ae94282e380f30c5421f886bde65b2739c> , <http://covid19.aksw.org/text-558d238096b22854ef8a23f408688891b00100917cc91a9d9de4a1e706330c68> , <http://covid19.aksw.org/text-9835da118ea109d104bd9e790258efa25799d7d6b2a0a66395469937684878d7> , <http://covid19.aksw.org/text-930cf281e081080ecc94b11a3990d766fe45f2a8166029dce14b4578d6f7a9a1> , <http://covid19.aksw.org/text-f7bc93b56c7d1a18804e13a84dde9bb1d0417acbbe69112b1f55284092cd577c> , <http://covid19.aksw.org/text-ccea08b19084a317f5b5aa04dccc761fd145a174b14acade80d7fa4d8938cba7> , <http://covid19.aksw.org/text-afc8da8dc333e420504503b02c994ce6799446c6375255d1cf415cae397dede1> , <http://covid19.aksw.org/text-ea76ebfe6b6ef32448ba0c317869d7abc0d63cede1682b3ee1b0f0ca9107b422> , <http://covid19.aksw.org/text-f6f4659dc4fc897a4dafbbb6fb4d4e1c58c268ca7edd514dfab2a71ed9aba961> , <http://covid19.aksw.org/text-e3f877f7ecfc55a3fc65211b21da21602759381211f783055777452f5b13695b> , <http://covid19.aksw.org/text-30a31fa045265b5530b106c6f77a26d1d820435823ccf200a69f809a8bc200f1> , <http://covid19.aksw.org/text-eae9ca05558d4763ff748020c924e13c92975dc08d6d6f39fda6accf9e5393df> , <http://covid19.aksw.org/text-2f091a2b539e39cc9ab1a885f3eed5b550e58a1e2922407b9d2ab4033c16ff1f> , <http://covid19.aksw.org/text-27f19c7e7dee19fb53fba4fed784026218cbe419d8bc280ee2297553843d8189> , <http://covid19.aksw.org/text-de5c86bccb2580343acb9eba8205713aa248204403b6d040a8e9c2be97a8acf8> , <http://covid19.aksw.org/text-0212f53c85aac94843f53e3448c684bbe37957b618e3b5126cc384170b9fee90> , <http://covid19.aksw.org/text-75c091447bd95ba21d9469adc79be43405f402cb9643d1349ba4f6afc1f85e5d> , <http://covid19.aksw.org/text-08df682944998c62a7e95265cdf50e85e59c7879d59239d24781f468d4952174> , <http://covid19.aksw.org/text-29fd6786379b5aa4a94d32025ad178e1cf5e81c32e6c0d4e60856e7f2cc20edf> , <http://covid19.aksw.org/text-5db9a3de760158157a6a98cbe9a94f90a2e766d7db737dd8ea0205afbd1aa64d> , <http://covid19.aksw.org/text-056ace257364745aba1eaa4ac0360709ef63447c2ee5dc5a9a0af09ac7aadd44> , <http://covid19.aksw.org/text-9716ad9e48d7e92dabda88549c8b709f5a9c8d5c925f0724195a11cd6d3e7755> , <http://covid19.aksw.org/text-0ea1c9a416f264519ec85efd3243dcf3920979297c36d35312c7990cf805001a> , <http://covid19.aksw.org/text-f52336f23d9639a2d35f82f51bdd4d41c37ddd7ab0f0e42a5617126bb3518559> , <http://covid19.aksw.org/text-332ce7f55ba994dfc830c914d805ea110e28403c7cfea7d61cbeaefea9e4a933> , <http://covid19.aksw.org/text-0a0f91aad1121cd704e897fa4e9cb99bc30b6bc31df0413c8d979be299653e9b> , <http://covid19.aksw.org/text-020a5613130a3c32e639430ec339f8e977618d2cb9d9cb099f89b85b3f747fce> , <http://covid19.aksw.org/text-ed655ab8d29f463a89683dee6f78b70fce943b69d639d3fbd3664a9804004cac> , <http://covid19.aksw.org/text-1078dda99cc4fd07bd56e77801579e99b52fe883922be8d1990ca43267f3b346> , <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07> , <http://covid19.aksw.org/text-88b29cee94d3ef457803853b3a3543978604d63fad390adfb5ec76348d39bee2> , <http://covid19.aksw.org/text-8382527cf49c0ff6e616b6d854682d85b632bfc18d337b344011c2ea71a52c63> , <http://covid19.aksw.org/text-616e0a7c9ec00d18d822fa353a9fc8786c59eb9b9c3dfacad7d1a06e7341a605> , <http://covid19.aksw.org/text-bb80acb167836463c447b1943ea57cfd674586243cabd121a13ab10e9ff6c6d3> , <http://covid19.aksw.org/text-52b0301bcf374ac0bf11aa3a7d51feea10207948b43f8ec4bb9b18f5f24acb9d> , <http://covid19.aksw.org/text-6a9e4893d0154b176450c2b5a9a7fee0d0fbd086e1ce48a6c353c1e03d673f20> , <http://covid19.aksw.org/text-9c9055d2df5aa15ecd08b08a8a728a0e508871ff179bd527de099d5650e6b821> , <http://covid19.aksw.org/text-ea4f0abe8a8208e0b3f1c0531531e174e66cfda86146fb2bbec786d4d1c1a312> , <http://covid19.aksw.org/text-91bd359b1d5d20d4aae19684fd74ddda3ecf0732cb79a824d699f03c2c9830d9> , <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f> , <http://covid19.aksw.org/text-868442eeae64a0fecb9b9308cfd6764b9ec019292ce69c5f66fdcc4979ac9ef3> , <http://covid19.aksw.org/text-d0ba00ce7ded319287d328da5d6c35bc6994400ccfe5ca133357cd48a24077d8> , <http://covid19.aksw.org/text-0912a8518d83434cbc93d7c72bff31eff461d136574be84b4d42d98784e5db21> , <http://covid19.aksw.org/text-8d117d4b57ab66b6c869c95a9b1c457265e200e72c6826d6c08f6a0169601193> , <http://covid19.aksw.org/text-d09eaf023d31cdeaae458ae9d2bc511e3d6a20a2b283fdd3ee734fe78bf874ae> , <http://covid19.aksw.org/text-c5efb8cd79a3ff2da3e6df92492b28d8ad4d184857f997a25bad003b28450581> , <http://covid19.aksw.org/text-d6b13aa2cf6d856df470a0804eb1f79ffe8c169773ac5980909e5d7d7e19cb09> , <http://covid19.aksw.org/text-1161307e9c4f01a9e2515ed5c7d69349c791d165ec07c7a2fc1f8d51d53f2f3d> , <http://covid19.aksw.org/text-985477e9e44b94ccdfb42cfa01a28d88af8d3cf57300f19d13b2ecc3451d1ffd> , <http://covid19.aksw.org/text-194e44d65da54bc8d40c787df925e48eb6ee5f54938a4e27549beedaf8df5a79> , <http://covid19.aksw.org/text-d1292be2a311ee810a334d6ef7624fc0642ea9b9d99090b0b0b17a7e55269d15> , <http://covid19.aksw.org/text-0d7256456cb05d0b0e49248440968a446ea638fc3d090fbb51ccf468c1fb0694> , <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f> , <http://covid19.aksw.org/text-6f02d89dfbf7930131758f4b0f97fe4674210ab385e2a0d813af161daa3ab86d> , <http://covid19.aksw.org/text-22bfa85a03de724d6231304c8057686cee8070429729b34ccf1f2cb6ea9e979c> , <http://covid19.aksw.org/text-b7837b370561cd87629829bccc291caaea9ed97130cca01972574d684d69dcd3> , <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad> , <http://covid19.aksw.org/text-64d7c9a49afe451e02283817f2cac4540e47b1f9d793b05dbe319e88677efc1b> , <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8> , <http://covid19.aksw.org/text-abcdbaf4bf0ad5e300a0cf462fb08b3ec5c8b3c6a8850424fe7aa440538eedc6> , <http://covid19.aksw.org/text-41dcb7231599b2c48d6b566a6c76207f26f3de0e62e8383d26eff62e67f78da5> , <http://covid19.aksw.org/text-759eaae1a6a1382d201861b25e7d8a3240c5f5c33549ea70e97813acb180beda> , <http://covid19.aksw.org/text-17215a4d6408ed8fd20340d0d978f5365edac65faa801a8aba1023cfe7f0dbcd> , <http://covid19.aksw.org/text-92566130eeb8a3b60a8577552b56de815d6a1e93149cbaae7137fbf628466ca0> , <http://covid19.aksw.org/text-e195586f477664448fa032125f9b7cb75cc8e4e077583f0dfa5d2057c23ec41e> , <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b> , <http://covid19.aksw.org/text-676acca31bcbfe7a6bfcf6d015f932f8c5cc458ef21eb27aee24235568ac4e6c> , <http://covid19.aksw.org/text-5920f24189f0fda90ee5590f768011414a6e0e34e0dd5d76ef4bd989da252fa7> , <http://covid19.aksw.org/text-b2bea5f712ce86b543eedfb38907e9389775078ede9af2e9ab6ccdfee955c7ae> , <http://covid19.aksw.org/text-e91aa93ddad2c608423f1b076c7d3dbb17cacc92d05fea907900ab7eff65a455> , <http://covid19.aksw.org/text-64a174f21f9fb2f95b14ec8740a7e8b62482d110bfc8d1566abee0c82d7bb0cc> , <http://covid19.aksw.org/text-c93eb6ed6958dbe514101cd120d016315068da556bd820e2f55e69d1fbcf602b> , <http://covid19.aksw.org/text-cb8db6cda368fadfb410b9bb1ada1b3bc5fe1f8cabf7a7882c0e169d30f7b43f> , <http://covid19.aksw.org/text-1d432e89a342c7685fb5dd85234863c0a7a904a5538a744191f1bab60275128c> , <http://covid19.aksw.org/text-89fcbba3c9e73283a03f50e7d2796a49bdd59fc967a7c49c544d78505871b687> , <http://covid19.aksw.org/text-1ac35a1e3b11dbb5713fa57ce8530f88a7c2e7715c4aa38b9594cd8210a12432> , <http://covid19.aksw.org/text-558b79cf842219499dadcceb790fe651ffd5dcd0853c0c0298456be9d0957f06> , <http://covid19.aksw.org/text-77d0ec8b9279d5aa18cc55cf1ebdf0a065a57b342ca3d337c8553c1474c03228> , <http://covid19.aksw.org/text-7b45087b1f4f11bd71e72d2348dbc5acc026051ffc7d68f4dff52b96ae8fd0e0> , <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c> , <http://covid19.aksw.org/text-aa838c738202266a024742d6b573df7b3f1ee9f770e372da4a6982b306713ddd> , <http://covid19.aksw.org/text-a7ef78724573aa88a09927247cc68fcb40a438d4024d1fc00dd175a7cedb0e9f> , <http://covid19.aksw.org/text-03db67786ab2a9e1fb601e512a7f2418f3a1f5ab6bef8d5d1a87d5e26c44c40f> , <http://covid19.aksw.org/text-dfe802f9bace00522fd02a7a88968018da1801cd6861a0728f7c35245ae3793b> , <http://covid19.aksw.org/text-4d159dbd3e13beede35dacceb3d0cb4bf0de6a97a63c96c705dab24ee4ee2186> , <http://covid19.aksw.org/text-20e06f45eedce14d174fd7358d90dabb5a353097d98397b8caec956334e37fb6> , <http://covid19.aksw.org/text-6a8c0aee57495cb75c81a89c429e9dc46521493f7d2cc2ca3caa121ffc9d51e6> , <http://covid19.aksw.org/text-633d5965835fc8599542627dd5cd534f02c789a2c01cd9e2c12a18c9a6aa0dd9> , <http://covid19.aksw.org/text-a4d1b9fdb6626753ae297a7d39f129c783686b097c7784c724c20512fee50c22> , <http://covid19.aksw.org/text-e1a64c197fcc62e135cd56a6c408c51c4c006cd073847103b86d4e284a31584c> , <http://covid19.aksw.org/text-c76cc3234ff02f69917d89b59700c1a4957380dea5431b80dfeec58ecfec8dd7> , <http://covid19.aksw.org/text-a4c3a1c1ae0899e54efc49a5d96f0cfc1fbaafe3b4e4ed8b18ed884fdf8dd4c8> , <http://covid19.aksw.org/text-e730f6c262370b2a00449ebe14dd247cc7917d561399574a2680551d2123a750> , <http://covid19.aksw.org/text-db9654fda167524cc60e71cdc487585dc0c4125376abc0603e4ee27bc2b2588d> , <http://covid19.aksw.org/text-c7cef66090b3aa76907fe1476a55e39e4f9489f0b5edf486716ccd600313125a> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d> , <http://covid19.aksw.org/text-df06c21dbba4534eb39f2a45aac0ae0f5d06bc68a2ccdd5289579c0f8a508140> , <http://covid19.aksw.org/text-adf0fb9606dfe5dc3d53ee6c6f6a0f99fc17e6745b9b1b9648e944a2b948a2f0> , <http://covid19.aksw.org/text-1f6da04f0dd8ce2f4baac7cd3d00d2cd71650e6567f961b36cb48f1e2fea547c> , <http://covid19.aksw.org/text-b28581a369dd714d11c417d3f3f44b8e3631e1242c1270d6fccb184540feada0> , <http://covid19.aksw.org/text-2d950617ab74ecde011b3bd2701bcb12e7f6088aa07c84bf5d925e778d58a6cc> , <http://covid19.aksw.org/text-60a15a7c4078de2fdf8301ad167d8aea4192c4698b12dac000cb6ac9b57c9033> .
    
    <http://covid19.aksw.org/text-9716ad9e48d7e92dabda88549c8b709f5a9c8d5c925f0724195a11cd6d3e7755_refspan-46-52>
            <http://www.example.org/end>    "52.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF9" ;
            <http://www.example.org/start>  "46.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 5" .
    
    <http://covid19.aksw.org/text-cb8db6cda368fadfb410b9bb1ada1b3bc5fe1f8cabf7a7882c0e169d30f7b43f_refspan-76-84>
            <http://www.example.org/end>    "84.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "76.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cd(a, b)" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-932-936>
            <http://www.example.org/end>    "936.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF12" ;
            <http://www.example.org/start>  "932.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[13]" .
    
    <http://covid19.aksw.org/text-7b45087b1f4f11bd71e72d2348dbc5acc026051ffc7d68f4dff52b96ae8fd0e0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• Unlike all previous work in this field, our work has put forward a formal event model in which all three kinds of relationships (i.e., temporal relationships, CD relationships and ER relationships) among events are defined and captured.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion and conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion and conclusions" ;
            <http://www.example.org/text>  "• Unlike all previous work in this field, our work has put forward a formal event model in which all three kinds of relationships (i.e., temporal relationships, CD relationships and ER relationships) among events are defined and captured." ;
            <http://www.example.org/textHash>
                    "7b45087b1f4f11bd71e72d2348dbc5acc026051ffc7d68f4dff52b96ae8fd0e0" .
    
    <http://covid19.aksw.org/text-ed655ab8d29f463a89683dee6f78b70fce943b69d639d3fbd3664a9804004cac>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"x , there should be a timestamp τ d a\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Problem formulation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Problem formulation" ;
            <http://www.example.org/text>  "x , there should be a timestamp τ d a" ;
            <http://www.example.org/textHash>
                    "ed655ab8d29f463a89683dee6f78b70fce943b69d639d3fbd3664a9804004cac" .
    
    <http://covid19.aksw.org/text-d8cc846bd798dc22d3068e3c1a9aae868b1a78d327e88204cb7b4b6d93ac95f6_citespan-789-793>
            <http://www.example.org/end>    "793.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF30" ;
            <http://www.example.org/start>  "789.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[31]" .
    
    <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-154-157>
            <http://www.example.org/end>    "157.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF24" ;
            <http://www.example.org/start>  "154.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "25]" .
    
    <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-342-346>
            <http://www.example.org/end>    "346.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF26" ;
            <http://www.example.org/start>  "342.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[27]" .
    
    <http://covid19.aksw.org/text-c5efb8cd79a3ff2da3e6df92492b28d8ad4d184857f997a25bad003b28450581>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Other countries donate and offer help to China for SARS 8\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "Other countries donate and offer help to China for SARS 8" ;
            <http://www.example.org/textHash>
                    "c5efb8cd79a3ff2da3e6df92492b28d8ad4d184857f997a25bad003b28450581" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-1343-1346>
            <http://www.example.org/end>    "1346.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "1343.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[4]" .
    
    <http://covid19.aksw.org/text-64d7c9a49afe451e02283817f2cac4540e47b1f9d793b05dbe319e88677efc1b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where R is the set of related documents and E is the set of the component events.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Preliminaries\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Preliminaries" ;
            <http://www.example.org/text>  "where R is the set of related documents and E is the set of the component events." ;
            <http://www.example.org/textHash>
                    "64d7c9a49afe451e02283817f2cac4540e47b1f9d793b05dbe319e88677efc1b" .
    
    <http://covid19.aksw.org/text-9658eb923918ec4913080d8da6048dbcffd77acefa1c5999415c4da366874ae2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For the reason that the values of Cr(a, b) and Cr(b, a) may be greater than zero, a could refer to b and also b could refer to a, and the strength degree of the reference relationship from a to b could be different from the inverse (i.e., from b to a). An event can be referred by many other events. Also, one event can refer to many other events.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":34.0,\"end\":42.0,\"text\":\"Cr(a, b)\"}],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-9658eb923918ec4913080d8da6048dbcffd77acefa1c5999415c4da366874ae2_refspan-34-42> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "For the reason that the values of Cr(a, b) and Cr(b, a) may be greater than zero, a could refer to b and also b could refer to a, and the strength degree of the reference relationship from a to b could be different from the inverse (i.e., from b to a). An event can be referred by many other events. Also, one event can refer to many other events." ;
            <http://www.example.org/textHash>
                    "9658eb923918ec4913080d8da6048dbcffd77acefa1c5999415c4da366874ae2" .
    
    <http://covid19.aksw.org/text-eae9ca05558d4763ff748020c924e13c92975dc08d6d6f39fda6accf9e5393df_citespan-219-223>
            <http://www.example.org/end>    "223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF35" ;
            <http://www.example.org/start>  "219.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[36]" .
    
    <http://covid19.aksw.org/text-616e0a7c9ec00d18d822fa353a9fc8786c59eb9b9c3dfacad7d1a06e7341a605_citespan-76-80>
            <http://www.example.org/end>    "80.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF34" ;
            <http://www.example.org/start>  "76.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[35]" .
    
    <http://covid19.aksw.org/text-92566130eeb8a3b60a8577552b56de815d6a1e93149cbaae7137fbf628466ca0_refspan-1433-1440>
            <http://www.example.org/end>    "1440.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF2" ;
            <http://www.example.org/start>  "1433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 3" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-660-664>
            <http://www.example.org/end>    "664.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF11" ;
            <http://www.example.org/start>  "660.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[12]" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1087-1091>
            <http://www.example.org/end>    "1091.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF18" ;
            <http://www.example.org/start>  "1087.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[19]" .
    
    <http://covid19.aksw.org/text-616e0a7c9ec00d18d822fa353a9fc8786c59eb9b9c3dfacad7d1a06e7341a605>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For the evaluation, we use Precision, Recall and F − measure as the metrics [35] . We denote the set of event dependent relationships (i.e., edges in a TEM) annotated by annotators as R A , and the set of event dependence relationships discovered by the model as R M . The metrics used are given below: \",\"cite_spans\":[{\"start\":76.0,\"end\":80.0,\"text\":\"[35]\",\"ref_id\":\"BIBREF34\"}],\"ref_spans\":[],\"section\":\"Experiment setting\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-616e0a7c9ec00d18d822fa353a9fc8786c59eb9b9c3dfacad7d1a06e7341a605_citespan-76-80> ;
            <http://www.example.org/section>
                    "Experiment setting" ;
            <http://www.example.org/text>  "For the evaluation, we use Precision, Recall and F − measure as the metrics [35] . We denote the set of event dependent relationships (i.e., edges in a TEM) annotated by annotators as R A , and the set of event dependence relationships discovered by the model as R M . The metrics used are given below: " ;
            <http://www.example.org/textHash>
                    "616e0a7c9ec00d18d822fa353a9fc8786c59eb9b9c3dfacad7d1a06e7341a605" .
    
    <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8_refspan-179-186>
            <http://www.example.org/end>    "186.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF1" ;
            <http://www.example.org/start>  "179.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 2" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To the best of our knowledge, no work before ours has been done on temporal event searches. A related work by Jin et al. [16] focuses on something called TISE, which is a temporal search engine supporting temporal content retrieval for Web pages. TISE supports Web page searches with temporal information embedded in Web pages, and the search relies on a unified temporal ontology of Web pages. However, TISE can neither handle event searches nor discover event relationships or measure event importance. Topic detecting and tracking (TDT) is currently a hot research topic that is also related to our work. Given a stream of constantly generated new documents, TDT groups documents of the same topic together and tracks the topic to find all subsequent documents. There are several techniques for detecting news topics and tracking news articles toward a new topic. For instance, Allan et al. [17] define temporal summaries of news stories and propose methods for constructing temporal summaries. Smith [18] explores detecting and browsing events from unstructured text/s. Chieu et al. [19] present a framework and a system that extracts events according to a query from a set of documents and organize events along a timeline. Some techniques are proposed to detect particular kinds of events. For example, Fisichella et al. [20] propose an approach combining aspects from different feature-based event detection methods to detect public health events in an unsupervised manner. Modeling and discovering relationships among events is generally out of the scope of current TDT research. Mei and Zhai [21, 22] study a particular task of discovering and summarizing the evolutionary patterns of themes in a text stream. A theme in an interval may be part of an event or a combination of several events that occur in the interval. Their work does not however capture the interrelationships of major events. Fung et al. [23] propose an algorithm called Time Driven Documents-partition to construct an event hierarchy in a text corpus based on a user query, but their work catches only the subsumption relationships between events, instead of the dependence relationships that may be more interesting to users. Shahaf et al. [8] try to provide a structured way to connect documents (i.e., find a coherent chain linking various documents) for users to navigate.\",\"cite_spans\":[{\"start\":121.0,\"end\":125.0,\"text\":\"[16]\",\"ref_id\":\"BIBREF15\"},{\"start\":894.0,\"end\":898.0,\"text\":\"[17]\",\"ref_id\":\"BIBREF16\"},{\"start\":1004.0,\"end\":1008.0,\"text\":\"[18]\",\"ref_id\":\"BIBREF17\"},{\"start\":1087.0,\"end\":1091.0,\"text\":\"[19]\",\"ref_id\":\"BIBREF18\"},{\"start\":1327.0,\"end\":1331.0,\"text\":\"[20]\",\"ref_id\":\"BIBREF19\"},{\"start\":1601.0,\"end\":1605.0,\"text\":\"[21,\",\"ref_id\":\"BIBREF20\"},{\"start\":1606.0,\"end\":1609.0,\"text\":\"22]\",\"ref_id\":\"BIBREF21\"},{\"start\":1917.0,\"end\":1921.0,\"text\":\"[23]\",\"ref_id\":\"BIBREF22\"},{\"start\":2221.0,\"end\":2224.0,\"text\":\"[8]\",\"ref_id\":\"BIBREF7\"}],\"ref_spans\":[],\"section\":\"News event relationship analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1606-1609> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1327-1331> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1004-1008> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1087-1091> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-894-898> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1917-1921> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-121-125> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1601-1605> , <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-2221-2224> ;
            <http://www.example.org/section>
                    "News event relationship analysis" ;
            <http://www.example.org/text>  "To the best of our knowledge, no work before ours has been done on temporal event searches. A related work by Jin et al. [16] focuses on something called TISE, which is a temporal search engine supporting temporal content retrieval for Web pages. TISE supports Web page searches with temporal information embedded in Web pages, and the search relies on a unified temporal ontology of Web pages. However, TISE can neither handle event searches nor discover event relationships or measure event importance. Topic detecting and tracking (TDT) is currently a hot research topic that is also related to our work. Given a stream of constantly generated new documents, TDT groups documents of the same topic together and tracks the topic to find all subsequent documents. There are several techniques for detecting news topics and tracking news articles toward a new topic. For instance, Allan et al. [17] define temporal summaries of news stories and propose methods for constructing temporal summaries. Smith [18] explores detecting and browsing events from unstructured text/s. Chieu et al. [19] present a framework and a system that extracts events according to a query from a set of documents and organize events along a timeline. Some techniques are proposed to detect particular kinds of events. For example, Fisichella et al. [20] propose an approach combining aspects from different feature-based event detection methods to detect public health events in an unsupervised manner. Modeling and discovering relationships among events is generally out of the scope of current TDT research. Mei and Zhai [21, 22] study a particular task of discovering and summarizing the evolutionary patterns of themes in a text stream. A theme in an interval may be part of an event or a combination of several events that occur in the interval. Their work does not however capture the interrelationships of major events. Fung et al. [23] propose an algorithm called Time Driven Documents-partition to construct an event hierarchy in a text corpus based on a user query, but their work catches only the subsumption relationships between events, instead of the dependence relationships that may be more interesting to users. Shahaf et al. [8] try to provide a structured way to connect documents (i.e., find a coherent chain linking various documents) for users to navigate." ;
            <http://www.example.org/textHash>
                    "186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d" .
    
    <http://covid19.aksw.org/text-e730f6c262370b2a00449ebe14dd247cc7917d561399574a2680551d2123a750_refspan-177-185>
            <http://www.example.org/end>    "185.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "177.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Cr(1, 1)" .
    
    <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For the related problem of event detection, some research has been published, such as [17, 18, 31] . In this paper, we adopt the topic-model based method [31] as the preferred method to detect events.\",\"cite_spans\":[{\"start\":86.0,\"end\":90.0,\"text\":\"[17,\",\"ref_id\":\"BIBREF16\"},{\"start\":91.0,\"end\":94.0,\"text\":\"18,\",\"ref_id\":\"BIBREF17\"},{\"start\":95.0,\"end\":98.0,\"text\":\"31]\",\"ref_id\":\"BIBREF30\"},{\"start\":154.0,\"end\":158.0,\"text\":\"[31]\",\"ref_id\":\"BIBREF30\"}],\"ref_spans\":[],\"section\":\"Preliminaries\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-86-90> , <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-91-94> , <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-95-98> , <http://covid19.aksw.org/text-343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f_citespan-154-158> ;
            <http://www.example.org/section>
                    "Preliminaries" ;
            <http://www.example.org/text>  "For the related problem of event detection, some research has been published, such as [17, 18, 31] . In this paper, we adopt the topic-model based method [31] as the preferred method to detect events." ;
            <http://www.example.org/textHash>
                    "343296dd6ca20bd4eb6605cc5c3dabda3e9c72472cc8db2e442bda30a5a58b9f" .
    
    <http://covid19.aksw.org/text-c76cc3234ff02f69917d89b59700c1a4957380dea5431b80dfeec58ecfec8dd7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"We observe that there is a temporal requirement for two events to have a dependence relationship between them, as follows.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"For an event a and its component events, it is obvious that\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "For an event a and its component events, it is obvious that" ;
            <http://www.example.org/text>  "We observe that there is a temporal requirement for two events to have a dependence relationship between them, as follows." ;
            <http://www.example.org/textHash>
                    "c76cc3234ff02f69917d89b59700c1a4957380dea5431b80dfeec58ecfec8dd7" .
    
    <http://covid19.aksw.org/text-e1a64c197fcc62e135cd56a6c408c51c4c006cd073847103b86d4e284a31584c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"is the dependence degree between features f x and f y , measured as follows:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"− →\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "− →" ;
            <http://www.example.org/text>  "is the dependence degree between features f x and f y , measured as follows:" ;
            <http://www.example.org/textHash>
                    "e1a64c197fcc62e135cd56a6c408c51c4c006cd073847103b86d4e284a31584c" .
    
    <http://covid19.aksw.org/text-6a8c0aee57495cb75c81a89c429e9dc46521493f7d2cc2ca3caa121ffc9d51e6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• Our work has provided a mechanism to discover and measure event reference (ER) relationships, which are explicit relationships made by journalists in their news articles that reflect their viewpoints and consideration of the inter-event relationships. ER can complement content dependence relationships.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion and conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion and conclusions" ;
            <http://www.example.org/text>  "• Our work has provided a mechanism to discover and measure event reference (ER) relationships, which are explicit relationships made by journalists in their news articles that reflect their viewpoints and consideration of the inter-event relationships. ER can complement content dependence relationships." ;
            <http://www.example.org/textHash>
                    "6a8c0aee57495cb75c81a89c429e9dc46521493f7d2cc2ca3caa121ffc9d51e6" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-858-862>
            <http://www.example.org/end>    "862.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF29" ;
            <http://www.example.org/start>  "858.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[30]" .
    
    <http://covid19.aksw.org/text-a7ef78724573aa88a09927247cc68fcb40a438d4024d1fc00dd175a7cedb0e9f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Event processing is important in various application fields, such as data processing in web environments, networking, finance and so on. There is a need for developing systems that are capable of handling not only generic data, but also event notifications, coming from different data sources. Such processing is usually known as Complex Event Processing (CEP) [2] . Complex Event Processing requires obtaining structured event data [3] .\",\"cite_spans\":[{\"start\":361.0,\"end\":364.0,\"text\":\"[2]\",\"ref_id\":\"BIBREF1\"},{\"start\":433.0,\"end\":436.0,\"text\":\"[3]\",\"ref_id\":\"BIBREF2\"}],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a7ef78724573aa88a09927247cc68fcb40a438d4024d1fc00dd175a7cedb0e9f_citespan-361-364> , <http://covid19.aksw.org/text-a7ef78724573aa88a09927247cc68fcb40a438d4024d1fc00dd175a7cedb0e9f_citespan-433-436> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "Event processing is important in various application fields, such as data processing in web environments, networking, finance and so on. There is a need for developing systems that are capable of handling not only generic data, but also event notifications, coming from different data sources. Such processing is usually known as Complex Event Processing (CEP) [2] . Complex Event Processing requires obtaining structured event data [3] ." ;
            <http://www.example.org/textHash>
                    "a7ef78724573aa88a09927247cc68fcb40a438d4024d1fc00dd175a7cedb0e9f" .
    
    <http://covid19.aksw.org/text-08df682944998c62a7e95265cdf50e85e59c7879d59239d24781f468d4952174>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Similarly, from the event reference perspective, we propose a weighted reference-based event ranking function RRank ′ to measure the importance of the component events:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "Similarly, from the event reference perspective, we propose a weighted reference-based event ranking function RRank ′ to measure the importance of the component events:" ;
            <http://www.example.org/textHash>
                    "08df682944998c62a7e95265cdf50e85e59c7879d59239d24781f468d4952174" .
    
    <http://covid19.aksw.org/text-5920f24189f0fda90ee5590f768011414a6e0e34e0dd5d76ef4bd989da252fa7>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"(1) Order events based on their start time; (2) construct dependence relationships for which the relevance degree η(x, y) is greater than α; (3) calculate the degree of importance of events (hence their ranks) according to Eq. (9) and attach them to the corresponding events. As a summary, we adopt content dependence (CD) analysis and event reference (ER) analysis to identify event dependence relationships. In cases when users are only interested in the ER relationships between events, we can do a projection of the TEM and obtain an event reference TEM, which is a sub-graph of the entire TEM. Similarly, if users are only interested in the CD relationships between events, we also can do a projection of the TEM and obtain a content dependence TEM. In Section 6, we introduce several algebraic operations to facilitate such a multi-perspective.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Temporal event map construction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Temporal event map construction" ;
            <http://www.example.org/text>  "(1) Order events based on their start time; (2) construct dependence relationships for which the relevance degree η(x, y) is greater than α; (3) calculate the degree of importance of events (hence their ranks) according to Eq. (9) and attach them to the corresponding events. As a summary, we adopt content dependence (CD) analysis and event reference (ER) analysis to identify event dependence relationships. In cases when users are only interested in the ER relationships between events, we can do a projection of the TEM and obtain an event reference TEM, which is a sub-graph of the entire TEM. Similarly, if users are only interested in the CD relationships between events, we also can do a projection of the TEM and obtain a content dependence TEM. In Section 6, we introduce several algebraic operations to facilitate such a multi-perspective." ;
            <http://www.example.org/textHash>
                    "5920f24189f0fda90ee5590f768011414a6e0e34e0dd5d76ef4bd989da252fa7" .
    
    <http://covid19.aksw.org/text-8d117d4b57ab66b6c869c95a9b1c457265e200e72c6826d6c08f6a0169601193_citespan-133-136>
            <http://www.example.org/end>    "136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "133.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[8]" .
    
    <http://covid19.aksw.org/text-85ca9d1366f9929c54310fa1032666a2fff13cd9abe7c65492640aa54d9bcefe>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The construction of TEM is not only to capture the dependence relationships between events, but also to show the importance of different events so as to help users discover the \\u0027\\u0027milestone\\u0027\\u0027 events. Based on the content dependence matrix and event reference matrix of all the component events, we can obtain the CD degree and ER degree between any two component events. More specifically, to measure the dependence degree between two events a and b, we can aggregate the content dependence degree and event reference degree by the following equation:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Temporal event map construction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Temporal event map construction" ;
            <http://www.example.org/text>  "The construction of TEM is not only to capture the dependence relationships between events, but also to show the importance of different events so as to help users discover the ''milestone'' events. Based on the content dependence matrix and event reference matrix of all the component events, we can obtain the CD degree and ER degree between any two component events. More specifically, to measure the dependence degree between two events a and b, we can aggregate the content dependence degree and event reference degree by the following equation:" ;
            <http://www.example.org/textHash>
                    "85ca9d1366f9929c54310fa1032666a2fff13cd9abe7c65492640aa54d9bcefe" .
    
    <http://covid19.aksw.org/text-88b29cee94d3ef457803853b3a3543978604d63fad390adfb5ec76348d39bee2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"According to our observation, the core feature set of an event has the following properties.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event reference analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event reference analysis" ;
            <http://www.example.org/text>  "According to our observation, the core feature set of an event has the following properties." ;
            <http://www.example.org/textHash>
                    "88b29cee94d3ef457803853b3a3543978604d63fad390adfb5ec76348d39bee2" .
    
    <http://covid19.aksw.org/text-9716ad9e48d7e92dabda88549c8b709f5a9c8d5c925f0724195a11cd6d3e7755>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"57% of the event relationships are missing in Fig. 5 . In particular, events 1, 4, 5 and 10 do not have any relationships with other events. This is because EEG discovers the event relationships based only on the content similarity of the event documents; consequently, only a portion of the dependence relationships were found. For instance, the documents of events 1 and 4 have few keywords about SARS but more about tourism and transportation, so EEG cannot find the relationships between them.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":46.0,\"end\":52.0,\"text\":\"Fig. 5\",\"ref_id\":\"FIGREF9\"}],\"section\":\"Case study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-9716ad9e48d7e92dabda88549c8b709f5a9c8d5c925f0724195a11cd6d3e7755_refspan-46-52> ;
            <http://www.example.org/section>
                    "Case study" ;
            <http://www.example.org/text>  "57% of the event relationships are missing in Fig. 5 . In particular, events 1, 4, 5 and 10 do not have any relationships with other events. This is because EEG discovers the event relationships based only on the content similarity of the event documents; consequently, only a portion of the dependence relationships were found. For instance, the documents of events 1 and 4 have few keywords about SARS but more about tourism and transportation, so EEG cannot find the relationships between them." ;
            <http://www.example.org/textHash>
                    "9716ad9e48d7e92dabda88549c8b709f5a9c8d5c925f0724195a11cd6d3e7755" .
    
    <http://covid19.aksw.org/text-d09eaf023d31cdeaae458ae9d2bc511e3d6a20a2b283fdd3ee734fe78bf874ae>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where B a is the set of all events linked from event a by content dependence relationships, and L(v) is the number of links that point to event v. CRank(v) is a \\u0027\\u0027vote\\u0027\\u0027 value which is set as 1 in our experiment to indicate that there is a link (CD relationship) between events a and v.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event ranking\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event ranking" ;
            <http://www.example.org/text>  "where B a is the set of all events linked from event a by content dependence relationships, and L(v) is the number of links that point to event v. CRank(v) is a ''vote'' value which is set as 1 in our experiment to indicate that there is a link (CD relationship) between events a and v." ;
            <http://www.example.org/textHash>
                    "d09eaf023d31cdeaae458ae9d2bc511e3d6a20a2b283fdd3ee734fe78bf874ae" .
    
    <http://covid19.aksw.org/text-df06c21dbba4534eb39f2a45aac0ae0f5d06bc68a2ccdd5289579c0f8a508140>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Panic buying happened in many countries 9\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "Panic buying happened in many countries 9" ;
            <http://www.example.org/textHash>
                    "df06c21dbba4534eb39f2a45aac0ae0f5d06bc68a2ccdd5289579c0f8a508140" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-121-125>
            <http://www.example.org/end>    "125.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF15" ;
            <http://www.example.org/start>  "121.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[16]" .
    
    <http://covid19.aksw.org/text-d8cc846bd798dc22d3068e3c1a9aae868b1a78d327e88204cb7b4b6d93ac95f6_citespan-949-950>
            <http://www.example.org/end>    "950.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "949.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "3" .
    
    <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c_citespan-417-418>
            <http://www.example.org/end>    "418.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "417.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "5" .
    
    <http://covid19.aksw.org/text-9c9055d2df5aa15ecd08b08a8a728a0e508871ff179bd527de099d5650e6b821>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Many countries limited the import of products from Japan 7\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "Many countries limited the import of products from Japan 7" ;
            <http://www.example.org/textHash>
                    "9c9055d2df5aa15ecd08b08a8a728a0e508871ff179bd527de099d5650e6b821" .
    
    <http://covid19.aksw.org/text-6f02d89dfbf7930131758f4b0f97fe4674210ab385e2a0d813af161daa3ab86d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Economy in Japan fell \",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Projection on happening places\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Projection on happening places" ;
            <http://www.example.org/text>  "Economy in Japan fell " ;
            <http://www.example.org/textHash>
                    "6f02d89dfbf7930131758f4b0f97fe4674210ab385e2a0d813af161daa3ab86d" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-183-186>
            <http://www.example.org/end>    "186.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "183.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[9]" .
    
    <http://covid19.aksw.org/text-676acca31bcbfe7a6bfcf6d015f932f8c5cc458ef21eb27aee24235568ac4e6c>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Complex Event Processing requires structured event data. In these works, all events contain the same kind of information In these works, all the events contain the same kind of information [15] . For example, the event type definition element consists of attributes that describe the contents of the event header and payload, and a list of relationships between this event type and other event types. Also, the semantics of the pattern matching operation are determined by the pattern type.\",\"cite_spans\":[{\"start\":189.0,\"end\":193.0,\"text\":\"[15]\"}],\"ref_spans\":[],\"section\":\"Complex event recognition and processing\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-676acca31bcbfe7a6bfcf6d015f932f8c5cc458ef21eb27aee24235568ac4e6c_citespan-189-193> ;
            <http://www.example.org/section>
                    "Complex event recognition and processing" ;
            <http://www.example.org/text>  "Complex Event Processing requires structured event data. In these works, all events contain the same kind of information In these works, all the events contain the same kind of information [15] . For example, the event type definition element consists of attributes that describe the contents of the event header and payload, and a list of relationships between this event type and other event types. Also, the semantics of the pattern matching operation are determined by the pattern type." ;
            <http://www.example.org/textHash>
                    "676acca31bcbfe7a6bfcf6d015f932f8c5cc458ef21eb27aee24235568ac4e6c" .
    
    <http://covid19.aksw.org/text-316a9c158a8199f17710a4ee2b76edc670b49e5ab7eff6c70a7e8fab1b3cbd1f_citespan-35-39>
            <http://www.example.org/end>    "39.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF32" ;
            <http://www.example.org/start>  "35.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[33]" .
    
    <http://covid19.aksw.org/text-59811b69e4fb9556fd348089e8d3b2800ccc6366f8799a0324305240197633ce_refspan-349-355>
            <http://www.example.org/end>    "355.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "349.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 3" .
    
    <http://covid19.aksw.org/text-e3f877f7ecfc55a3fc65211b21da21602759381211f783055777452f5b13695b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• Our work has also laid a foundation to measure the importance of events, thereby facilitating the discovery of important events.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion and conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion and conclusions" ;
            <http://www.example.org/text>  "• Our work has also laid a foundation to measure the importance of events, thereby facilitating the discovery of important events." ;
            <http://www.example.org/textHash>
                    "e3f877f7ecfc55a3fc65211b21da21602759381211f783055777452f5b13695b" .
    
    <http://covid19.aksw.org/text-abcdbaf4bf0ad5e300a0cf462fb08b3ec5c8b3c6a8850424fe7aa440538eedc6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"graph, denoted by TEM \\u003d (N, E, W d , W i ), which consists of events as nodes, relations as edges, weights on the nodes as event important degrees, and weights on the edges as strength degrees of dependence relationships. In particular, each vertex v ∈ N is an event, each edge e x ∈ E is a dependence relationship between two events, w y ∈ W d is a weight which indicates the strength degree of a dependence relationship, and w a ∈ W i is a weight which indicates the importance degree of event a.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Definition 5. A Temporal Event Map is a weighted directed\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Definition 5. A Temporal Event Map is a weighted directed" ;
            <http://www.example.org/text>  "graph, denoted by TEM = (N, E, W d , W i ), which consists of events as nodes, relations as edges, weights on the nodes as event important degrees, and weights on the edges as strength degrees of dependence relationships. In particular, each vertex v ∈ N is an event, each edge e x ∈ E is a dependence relationship between two events, w y ∈ W d is a weight which indicates the strength degree of a dependence relationship, and w a ∈ W i is a weight which indicates the importance degree of event a." ;
            <http://www.example.org/textHash>
                    "abcdbaf4bf0ad5e300a0cf462fb08b3ec5c8b3c6a8850424fe7aa440538eedc6" .
    
    <http://covid19.aksw.org/text-77c061e8ecc47c88035170d89cb7c6192ecb03367a34f5d735a9bda0494d85f4>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Quite often, what interests people is not just a single news article on an event, but also the related events reported by other news articles. Indeed, readers are often interested in the whole picture of an event\\u0027s evolution or development along a timeline. This calls for modeling the dependence relationships among component events and identifying which component events play important roles in the evolution of the entire event. Unfortunately, most current news web sites do not facilitate users quest to discover relevant news articles, and readers may need to go through multiple news articles in order to understand the interrelationships among component events and the importance of each to the development of the overall event. This is a time consuming job for a reader, given the huge amount of news articles available online. Therefore, it is necessary to provide an effective way for users to efficiently search for events in which they are interested, and to organize their search results in an easily understandable manner syntactically, so that users can obtain an overall picture of events easily and meaningfully from a semantic perspective.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "Quite often, what interests people is not just a single news article on an event, but also the related events reported by other news articles. Indeed, readers are often interested in the whole picture of an event's evolution or development along a timeline. This calls for modeling the dependence relationships among component events and identifying which component events play important roles in the evolution of the entire event. Unfortunately, most current news web sites do not facilitate users quest to discover relevant news articles, and readers may need to go through multiple news articles in order to understand the interrelationships among component events and the importance of each to the development of the overall event. This is a time consuming job for a reader, given the huge amount of news articles available online. Therefore, it is necessary to provide an effective way for users to efficiently search for events in which they are interested, and to organize their search results in an easily understandable manner syntactically, so that users can obtain an overall picture of events easily and meaningfully from a semantic perspective." ;
            <http://www.example.org/textHash>
                    "77c061e8ecc47c88035170d89cb7c6192ecb03367a34f5d735a9bda0494d85f4" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1917-1921>
            <http://www.example.org/end>    "1921.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF22" ;
            <http://www.example.org/start>  "1917.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[23]" .
    
    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"To illustrate the performance of our proposed method more clearly, in this section, we further analyze a specific search case on the event \\u0027\\u0027SARS in 2003\\u0027\\u0027. We choose this event for our case study because it contains the highest number of related news documents (i.e., 231 news articles) in our data set. The test query is I p \\u003d (China), I t \\u003d [1/3/2003, 30/6/2003 ], I f \\u003d (SARS), and we compare the search results of our method with those of the EEG and human annotators result. 4 For convenience, we denote the query as Q SARS and discuss this query in detail. Table 4 shows all the component events that are related to Q S ARS. Fig. 5 is the Event Evolution Graph obtained by EEG. Note that in this graph, there is no strength degree for any of the relationships. Fig. 6 is the relationship graph given by the human annotators for Q S ARS.\",\"cite_spans\":[{\"start\":344.0,\"end\":364.0,\"text\":\"[1/3/2003, 30/6/2003\"},{\"start\":481.0,\"end\":482.0,\"text\":\"4\",\"ref_id\":\"BIBREF3\"}],\"ref_spans\":[{\"start\":564.0,\"end\":571.0,\"text\":\"Table 4\",\"ref_id\":\"TABREF3\"},{\"start\":632.0,\"end\":638.0,\"text\":\"Fig. 5\",\"ref_id\":\"FIGREF9\"},{\"start\":768.0,\"end\":774.0,\"text\":\"Fig. 6\"}],\"section\":\"Case study\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_citespan-344-364> , <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_citespan-481-482> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_refspan-564-571> , <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_refspan-632-638> , <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_refspan-768-774> ;
            <http://www.example.org/section>
                    "Case study" ;
            <http://www.example.org/text>  "To illustrate the performance of our proposed method more clearly, in this section, we further analyze a specific search case on the event ''SARS in 2003''. We choose this event for our case study because it contains the highest number of related news documents (i.e., 231 news articles) in our data set. The test query is I p = (China), I t = [1/3/2003, 30/6/2003 ], I f = (SARS), and we compare the search results of our method with those of the EEG and human annotators result. 4 For convenience, we denote the query as Q SARS and discuss this query in detail. Table 4 shows all the component events that are related to Q S ARS. Fig. 5 is the Event Evolution Graph obtained by EEG. Note that in this graph, there is no strength degree for any of the relationships. Fig. 6 is the relationship graph given by the human annotators for Q S ARS." ;
            <http://www.example.org/textHash>
                    "7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6" .
    
    <http://covid19.aksw.org/text-ec1e28e18224feb94d3f97999492dae917f522869a9d922450c95bb8ef9d4efc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"For each target event a corresponding to an input I and its related document set R a , we can detect several component events from R a . All component events of a should happen during I t , and their locations are contained in I p and features contained in I f . The component event detection of a target event is a function ϕ:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Preliminaries\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Preliminaries" ;
            <http://www.example.org/text>  "For each target event a corresponding to an input I and its related document set R a , we can detect several component events from R a . All component events of a should happen during I t , and their locations are contained in I p and features contained in I f . The component event detection of a target event is a function ϕ:" ;
            <http://www.example.org/textHash>
                    "ec1e28e18224feb94d3f97999492dae917f522869a9d922450c95bb8ef9d4efc" .
    
    <http://covid19.aksw.org/text-59811b69e4fb9556fd348089e8d3b2800ccc6366f8799a0324305240197633ce_refspan-427-433>
            <http://www.example.org/end>    "433.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF2" ;
            <http://www.example.org/start>  "427.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 3" .
    
    <http://covid19.aksw.org/text-e730f6c262370b2a00449ebe14dd247cc7917d561399574a2680551d2123a750>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"By measuring all component event reference degrees between any two events, we can obtain an component event reference matrix of a target event a, denoted by M r a , as follows: Cr(1, 1) , Cr(1, 2) , . . . , Cr(1, m) · · · Cr(n, 1), Cr(n, 2), . . . , Cr(n, m) } Each entry in the matrix is a reference degree between two events.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":177.0,\"end\":185.0,\"text\":\"Cr(1, 1)\",\"ref_id\":\"FIGREF0\"},{\"start\":188.0,\"end\":196.0,\"text\":\"Cr(1, 2)\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency.\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-e730f6c262370b2a00449ebe14dd247cc7917d561399574a2680551d2123a750_refspan-177-185> , <http://covid19.aksw.org/text-e730f6c262370b2a00449ebe14dd247cc7917d561399574a2680551d2123a750_refspan-188-196> ;
            <http://www.example.org/section>
                    "Property 1. The core features of an event a are the most salient and representative features of a; i.e., these features appear in the related documents of a with a high frequency." ;
            <http://www.example.org/text>  "By measuring all component event reference degrees between any two events, we can obtain an component event reference matrix of a target event a, denoted by M r a , as follows: Cr(1, 1) , Cr(1, 2) , . . . , Cr(1, m) · · · Cr(n, 1), Cr(n, 2), . . . , Cr(n, m) } Each entry in the matrix is a reference degree between two events." ;
            <http://www.example.org/textHash>
                    "e730f6c262370b2a00449ebe14dd247cc7917d561399574a2680551d2123a750" .
    
    <http://covid19.aksw.org/text-0f7d89b1a09bc4627a5322f9fdeea1157416a6c7bfbf0e5e1633015915482e74>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"An example of a temporal event map of the event \\u0027\\u0027Toyota 2009-2010 vehicle recalls\\u0027\\u0027 is shown in Fig. 1 . 1 We formulate the problem of a temporal event search as follows. The input of the search problem is a tuple (I t , I p , I f ) where I t is a time interval, I p is a set of terms denoting places, and I f is a set of keywords about an event\\u0027s content. The event that is relevant to (corresponding to) the input is named as the target event; i.e., the event happens in places I p during I t , and the feature set of the target event contains I f . A user gives a query to search an event, which is his/her target. We also name the \\u0027\\u0027target event\\u0027\\u0027 as the \\u0027\\u0027query event\\u0027\\u0027. The output of the event search problem is a TEM constituting all the component events of the target event.\",\"cite_spans\":[{\"start\":106.0,\"end\":107.0,\"text\":\"1\",\"ref_id\":\"BIBREF0\"}],\"ref_spans\":[{\"start\":97.0,\"end\":103.0,\"text\":\"Fig. 1\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Definition 5. A Temporal Event Map is a weighted directed\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-0f7d89b1a09bc4627a5322f9fdeea1157416a6c7bfbf0e5e1633015915482e74_citespan-106-107> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-0f7d89b1a09bc4627a5322f9fdeea1157416a6c7bfbf0e5e1633015915482e74_refspan-97-103> ;
            <http://www.example.org/section>
                    "Definition 5. A Temporal Event Map is a weighted directed" ;
            <http://www.example.org/text>  "An example of a temporal event map of the event ''Toyota 2009-2010 vehicle recalls'' is shown in Fig. 1 . 1 We formulate the problem of a temporal event search as follows. The input of the search problem is a tuple (I t , I p , I f ) where I t is a time interval, I p is a set of terms denoting places, and I f is a set of keywords about an event's content. The event that is relevant to (corresponding to) the input is named as the target event; i.e., the event happens in places I p during I t , and the feature set of the target event contains I f . A user gives a query to search an event, which is his/her target. We also name the ''target event'' as the ''query event''. The output of the event search problem is a TEM constituting all the component events of the target event." ;
            <http://www.example.org/textHash>
                    "0f7d89b1a09bc4627a5322f9fdeea1157416a6c7bfbf0e5e1633015915482e74" .
    
    <http://covid19.aksw.org/text-deabce21fa26ee79ee724d802a4a38ae94282e380f30c5421f886bde65b2739c_citespan-187-188>
            <http://www.example.org/end>    "188.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "187.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "4" .
    
    <http://covid19.aksw.org/text-0ea1c9a416f264519ec85efd3243dcf3920979297c36d35312c7990cf805001a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Thus, for each document d a\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Problem formulation\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Problem formulation" ;
            <http://www.example.org/text>  "Thus, for each document d a" ;
            <http://www.example.org/textHash>
                    "0ea1c9a416f264519ec85efd3243dcf3920979297c36d35312c7990cf805001a" .
    
    <http://covid19.aksw.org/text-bdd2a1035cbafdfcd7f9959f4c7eeab9a85b40206835604bfa9ca0615c2ae097_refspan-119-136>
            <http://www.example.org/end>    "136.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "119.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 7. In Fig. 7" .
    
    <http://covid19.aksw.org/text-59811b69e4fb9556fd348089e8d3b2800ccc6366f8799a0324305240197633ce>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Recall and F-measure in order to come up with the best value of α for the following experiment. In our testing, we use two query events: one is \\u0027\\u0027SARS in 2003\\u0027\\u0027, which contains the largest number of related news articles and the other is \\u0027\\u0027Christchurch Earthquake in 2010 in New Zealand\\u0027\\u0027, which contains the fewest number of related news articles. Fig. 3 shows the effect of α on Precision, Recall and F-measure. According to Fig. 3 , we find that as α increases, the Precision and F-measure increase while Recall decreases. The reason for this is that when the value α is small, there are many event dependence relationships with a dependence degree higher than α (but the dependence relationship is still actually \\u0027\\u0027weak\\u0027\\u0027), so the Recall is high and the Precision is low. We tune the parameter α based on two queries which are not in the test queries. For these two queries, we obtain the highest value of F-measure when α \\u003d 0.65. Therefore, we set α \\u003d 0.65 for all test queries.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":349.0,\"end\":355.0,\"text\":\"Fig. 3\",\"ref_id\":\"FIGREF2\"},{\"start\":427.0,\"end\":433.0,\"text\":\"Fig. 3\",\"ref_id\":\"FIGREF2\"}],\"section\":\"Experiment results\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-59811b69e4fb9556fd348089e8d3b2800ccc6366f8799a0324305240197633ce_refspan-349-355> , <http://covid19.aksw.org/text-59811b69e4fb9556fd348089e8d3b2800ccc6366f8799a0324305240197633ce_refspan-427-433> ;
            <http://www.example.org/section>
                    "Experiment results" ;
            <http://www.example.org/text>  "Recall and F-measure in order to come up with the best value of α for the following experiment. In our testing, we use two query events: one is ''SARS in 2003'', which contains the largest number of related news articles and the other is ''Christchurch Earthquake in 2010 in New Zealand'', which contains the fewest number of related news articles. Fig. 3 shows the effect of α on Precision, Recall and F-measure. According to Fig. 3 , we find that as α increases, the Precision and F-measure increase while Recall decreases. The reason for this is that when the value α is small, there are many event dependence relationships with a dependence degree higher than α (but the dependence relationship is still actually ''weak''), so the Recall is high and the Precision is low. We tune the parameter α based on two queries which are not in the test queries. For these two queries, we obtain the highest value of F-measure when α = 0.65. Therefore, we set α = 0.65 for all test queries." ;
            <http://www.example.org/textHash>
                    "59811b69e4fb9556fd348089e8d3b2800ccc6366f8799a0324305240197633ce" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-77-81>
            <http://www.example.org/end>    "81.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF27" ;
            <http://www.example.org/start>  "77.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[28]" .
    
    <http://covid19.aksw.org/text-de5c86bccb2580343acb9eba8205713aa248204403b6d040a8e9c2be97a8acf8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"where tf a,i is the frequency of term i in R a , N is the total number of component events, MAX u (tf a,u ) is the maximal value among all tf a,u and ef i is the number of component events containing term f a,i . As mentioned before, previous works use content similarity (mostly cosine similarity) to identify dependence relationships between events. However, two events may have some keywords that are dependent but not identical, which causes the previous work done in this field to be inadequate in measuring how relevant the two events are. There are several semantic techniques that are relevant to the analysis of content semantic relations, such as ontologies. However, to use ontologies for semantic analysis, we need to obtain high quality ontologies relevant to the event domain. One major way to build up high quality ontologies depends on domain experts efforts, and it is a time consuming job. Thus, there are not many high quality ontologies for various domains, and events are related to various domains. Although there are some automated ways to build up ontologies, their computation cost is relatively high, and the quality of the ontologies may not be good enough for event content dependence analysis.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"− →\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "− →" ;
            <http://www.example.org/text>  "where tf a,i is the frequency of term i in R a , N is the total number of component events, MAX u (tf a,u ) is the maximal value among all tf a,u and ef i is the number of component events containing term f a,i . As mentioned before, previous works use content similarity (mostly cosine similarity) to identify dependence relationships between events. However, two events may have some keywords that are dependent but not identical, which causes the previous work done in this field to be inadequate in measuring how relevant the two events are. There are several semantic techniques that are relevant to the analysis of content semantic relations, such as ontologies. However, to use ontologies for semantic analysis, we need to obtain high quality ontologies relevant to the event domain. One major way to build up high quality ontologies depends on domain experts efforts, and it is a time consuming job. Thus, there are not many high quality ontologies for various domains, and events are related to various domains. Although there are some automated ways to build up ontologies, their computation cost is relatively high, and the quality of the ontologies may not be good enough for event content dependence analysis." ;
            <http://www.example.org/textHash>
                    "de5c86bccb2580343acb9eba8205713aa248204403b6d040a8e9c2be97a8acf8" .
    
    <http://covid19.aksw.org/text-ea4f0abe8a8208e0b3f1c0531531e174e66cfda86146fb2bbec786d4d1c1a312>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"We also invite five human subjects to annotate the dependence relationships between events. All the annotated relationships are combined synthetically to obtain a set of relationships; i.e., the combination of all the annotated relationships. Such a set of relationships as given by the annotators is considered as a standard answer set (ground truth) of event dependence relationships. Because different people may have different viewpoints of the event relationships due to their varying levels of knowledge and background, each annotator came up with a different set of dependence relationships. Therefore, the standard answer set is an aggregation (the intersection) of the annotations given by all the annotators. Furthermore, annotators may have difficult time with complex event evolution involving many relationships when there is a large number of component events and many dependence relationships among them. Thus, some dependence relationships were missed during the annotation processes. Thus, in our experiment, we also allowed annotators to judge whether our method may help discover any \\u0027\\u0027new\\u0027\\u0027 dependence relationships between events.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Experiment setting\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Experiment setting" ;
            <http://www.example.org/text>  "We also invite five human subjects to annotate the dependence relationships between events. All the annotated relationships are combined synthetically to obtain a set of relationships; i.e., the combination of all the annotated relationships. Such a set of relationships as given by the annotators is considered as a standard answer set (ground truth) of event dependence relationships. Because different people may have different viewpoints of the event relationships due to their varying levels of knowledge and background, each annotator came up with a different set of dependence relationships. Therefore, the standard answer set is an aggregation (the intersection) of the annotations given by all the annotators. Furthermore, annotators may have difficult time with complex event evolution involving many relationships when there is a large number of component events and many dependence relationships among them. Thus, some dependence relationships were missed during the annotation processes. Thus, in our experiment, we also allowed annotators to judge whether our method may help discover any ''new'' dependence relationships between events." ;
            <http://www.example.org/textHash>
                    "ea4f0abe8a8208e0b3f1c0531531e174e66cfda86146fb2bbec786d4d1c1a312" .
    
    <http://covid19.aksw.org/text-2d950617ab74ecde011b3bd2701bcb12e7f6088aa07c84bf5d925e778d58a6cc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Note that the content dependence measurement between events is different from the content similarity measurement accomplished in previous research. The former explores the interrelationships of events from the perspective of keyword cooccurrences to measure the dependence and relevance of two events, whereas content similarity measurement only considers the keyword match between two events.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"− →\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "− →" ;
            <http://www.example.org/text>  "Note that the content dependence measurement between events is different from the content similarity measurement accomplished in previous research. The former explores the interrelationships of events from the perspective of keyword cooccurrences to measure the dependence and relevance of two events, whereas content similarity measurement only considers the keyword match between two events." ;
            <http://www.example.org/textHash>
                    "2d950617ab74ecde011b3bd2701bcb12e7f6088aa07c84bf5d925e778d58a6cc" .
    
    <http://covid19.aksw.org/text-cd6f00ff38cc269300a13be8cfeeb0373cc0542c04eb7740f62b1619f598aafe_refspan-812-822>
            <http://www.example.org/end>    "822.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "812.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   ", CD(a, b)" .
    
    <http://covid19.aksw.org/text-03db67786ab2a9e1fb601e512a7f2418f3a1f5ab6bef8d5d1a87d5e26c44c40f_refspan-327-334>
            <http://www.example.org/end>    "334.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "327.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 12" .
    
    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_citespan-481-482>
            <http://www.example.org/end>    "482.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "481.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "4" .
    
    <http://covid19.aksw.org/text-020a5613130a3c32e639430ec339f8e977618d2cb9d9cb099f89b85b3f747fce>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The rest of this paper is organized as follows: in Section 2, we formulate the event search problem; Section 3 introduces our proposed (temporal) event search framework; in Section 4, we detail the experiments that we conduct on a real data set to evaluate our proposed event search methods; in Section 5, we further illustrate and evaluate our methods, and we conduct a case study on the 2003 \\u0027\\u0027SARS\\u0027\\u0027 event; Section 6 defines several algebraic operators of a TEM that allow users to view the target event according to their various requirements; related works are studied in Section 7; and finally, Section 8 concludes the paper and introduces potential future work on this topic.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "The rest of this paper is organized as follows: in Section 2, we formulate the event search problem; Section 3 introduces our proposed (temporal) event search framework; in Section 4, we detail the experiments that we conduct on a real data set to evaluate our proposed event search methods; in Section 5, we further illustrate and evaluate our methods, and we conduct a case study on the 2003 ''SARS'' event; Section 6 defines several algebraic operators of a TEM that allow users to view the target event according to their various requirements; related works are studied in Section 7; and finally, Section 8 concludes the paper and introduces potential future work on this topic." ;
            <http://www.example.org/textHash>
                    "020a5613130a3c32e639430ec339f8e977618d2cb9d9cb099f89b85b3f747fce" .
    
    <http://covid19.aksw.org/text-c6da05d838902e02dc48c83ea0fff0525e19eb3d612ca98a58909180d2b46582_citespan-916-920>
            <http://www.example.org/end>    "920.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF36" ;
            <http://www.example.org/start>  "916.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[37]" .
    
    <http://covid19.aksw.org/text-107b1b542fe0c195dc86d6e890fe69191afabeb085e36cf11b4447ea6997a855>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"We can also observe that when a news article of an event c refers to another event a, there are usually some phrases that identify event a in the documents of event c, and we call such phrases core features of a. The definition of a core feature set of an event is defined below. Definition 6. The core feature set of an event a, denoted by F c a is a set of features which are salient (i.e., the features appear in the related documents of a with a high frequency) in the event, distinguishable from those of other events, and jointly can identify the event.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Event reference analysis\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Event reference analysis" ;
            <http://www.example.org/text>  "We can also observe that when a news article of an event c refers to another event a, there are usually some phrases that identify event a in the documents of event c, and we call such phrases core features of a. The definition of a core feature set of an event is defined below. Definition 6. The core feature set of an event a, denoted by F c a is a set of features which are salient (i.e., the features appear in the related documents of a with a high frequency) in the event, distinguishable from those of other events, and jointly can identify the event." ;
            <http://www.example.org/textHash>
                    "107b1b542fe0c195dc86d6e890fe69191afabeb085e36cf11b4447ea6997a855" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-894-898>
            <http://www.example.org/end>    "898.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF16" ;
            <http://www.example.org/start>  "894.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[17]" .
    
    <http://covid19.aksw.org/text-dfe802f9bace00522fd02a7a88968018da1801cd6861a0728f7c35245ae3793b>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• In contrast to previous work that has only considered temporal relationships and content similarity, we adopt three kinds of event relationships (temporal relationship, CD relationship obtained by CD analysis and ER relationship obtained by ER analysis) to identify the dependence relationship between two events. Note that CD and ER relationships are essentially event dependence relationships that are discovered using two different approaches. CD relationships and ER relationships can be complementary to each other in identifying event dependence relationships. Some event dependence relationships are detected by content dependence analysis, while others are detected by event reference analysis only.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "• In contrast to previous work that has only considered temporal relationships and content similarity, we adopt three kinds of event relationships (temporal relationship, CD relationship obtained by CD analysis and ER relationship obtained by ER analysis) to identify the dependence relationship between two events. Note that CD and ER relationships are essentially event dependence relationships that are discovered using two different approaches. CD relationships and ER relationships can be complementary to each other in identifying event dependence relationships. Some event dependence relationships are detected by content dependence analysis, while others are detected by event reference analysis only." ;
            <http://www.example.org/textHash>
                    "dfe802f9bace00522fd02a7a88968018da1801cd6861a0728f7c35245ae3793b" .
    
    <http://covid19.aksw.org/text-60a15a7c4078de2fdf8301ad167d8aea4192c4698b12dac000cb6ac9b57c9033>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Some dependence relationships obtained by Eq. (10) may be too weak, and we should eliminate them when constructing the TEM, so as to provide users with the main picture clearly instead of presenting a complex one. We thus set parameter α for pruning the relationships correspondingly.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Temporal event map construction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Temporal event map construction" ;
            <http://www.example.org/text>  "Some dependence relationships obtained by Eq. (10) may be too weak, and we should eliminate them when constructing the TEM, so as to provide users with the main picture clearly instead of presenting a complex one. We thus set parameter α for pruning the relationships correspondingly." ;
            <http://www.example.org/textHash>
                    "60a15a7c4078de2fdf8301ad167d8aea4192c4698b12dac000cb6ac9b57c9033" .
    
    <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-80-82>
            <http://www.example.org/end>    "82.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "80.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "5]" .
    
    <http://covid19.aksw.org/text-056ace257364745aba1eaa4ac0360709ef63447c2ee5dc5a9a0af09ac7aadd44>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"• The search results are organized by a temporal event map (TEM) that constitutes the overall picture of an event\\u0027s evolution along the timeline. Fig. 1 shows an example TEM of the event \\u0027\\u0027Toyota 2009-2010 vehicle recalls\\u0027\\u0027. A TEM provides a way to organize and represent the event search results by showing the interrelationships between/among the events. The value on the edge shows the strength of relevance between two events. It provides an easier and more efficient means for users to understand events comprehensively.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":146.0,\"end\":152.0,\"text\":\"Fig. 1\",\"ref_id\":\"FIGREF0\"}],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-056ace257364745aba1eaa4ac0360709ef63447c2ee5dc5a9a0af09ac7aadd44_refspan-146-152> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "• The search results are organized by a temporal event map (TEM) that constitutes the overall picture of an event's evolution along the timeline. Fig. 1 shows an example TEM of the event ''Toyota 2009-2010 vehicle recalls''. A TEM provides a way to organize and represent the event search results by showing the interrelationships between/among the events. The value on the edge shows the strength of relevance between two events. It provides an easier and more efficient means for users to understand events comprehensively." ;
            <http://www.example.org/textHash>
                    "056ace257364745aba1eaa4ac0360709ef63447c2ee5dc5a9a0af09ac7aadd44" .
    
    <http://covid19.aksw.org/text-17215a4d6408ed8fd20340d0d978f5365edac65faa801a8aba1023cfe7f0dbcd>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"As a summary, the following remarks can be made with respect to the previous works versus our work in this field:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Discussion and conclusions\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Discussion and conclusions" ;
            <http://www.example.org/text>  "As a summary, the following remarks can be made with respect to the previous works versus our work in this field:" ;
            <http://www.example.org/textHash>
                    "17215a4d6408ed8fd20340d0d978f5365edac65faa801a8aba1023cfe7f0dbcd" .
    
    <http://covid19.aksw.org/text-0131e27c0b974ad18b78a4dd40733b6d213daebea54aa6ed4bf916fe2625b89c_citespan-1078-1079>
            <http://www.example.org/end>    "1079.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "1078.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "5" .
    
    <http://covid19.aksw.org/text-612d0b4a44dbff175fd2bc63a17d67e84d6b0e715cf252f445379dc72d968b07_citespan-122-124>
            <http://www.example.org/end>    "124.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "122.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "7]" .
    
    <http://covid19.aksw.org/text-186c800f325cd503d9133487092b617fc7d0d6a8eae276875c422f1bc013106d_citespan-1327-1331>
            <http://www.example.org/end>    "1331.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF19" ;
            <http://www.example.org/start>  "1327.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[20]" .
    
    <http://covid19.aksw.org/text-bdd2a1035cbafdfcd7f9959f4c7eeab9a85b40206835604bfa9ca0615c2ae097_refspan-410-417>
            <http://www.example.org/end>    "417.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "410.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 5" .
    
    <http://covid19.aksw.org/text-5033d01fbbbc33a829f8443c49d152e2624dcdcadbda58a5dd01558150c9588b_citespan-483-487>
            <http://www.example.org/end>    "487.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF28" ;
            <http://www.example.org/start>  "483.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[29]" .
    
    <http://covid19.aksw.org/text-567a72f8a6da062e4b4f8e0d9ccd04376d4d82b2dd844acf18b241ad902c29ad_citespan-204-208>
            <http://www.example.org/end>    "208.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF9" ;
            <http://www.example.org/start>  "204.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[10]" .
    
    <http://covid19.aksw.org/text-4d159dbd3e13beede35dacceb3d0cb4bf0de6a97a63c96c705dab24ee4ee2186>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The problem of a temporal event search can thus be regarded as a function φ:\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Definition 5. A Temporal Event Map is a weighted directed\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Definition 5. A Temporal Event Map is a weighted directed" ;
            <http://www.example.org/text>  "The problem of a temporal event search can thus be regarded as a function φ:" ;
            <http://www.example.org/textHash>
                    "4d159dbd3e13beede35dacceb3d0cb4bf0de6a97a63c96c705dab24ee4ee2186" .
    
    <http://covid19.aksw.org/text-9449ace486452d15f58d222c7ff45462828a476bb523286aafea65edf5a5232f_citespan-149-153>
            <http://www.example.org/end>    "153.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF23" ;
            <http://www.example.org/start>  "149.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[24," .
    
    <http://covid19.aksw.org/text-41dcb7231599b2c48d6b566a6c76207f26f3de0e62e8383d26eff62e67f78da5_citespan-241-245>
            <http://www.example.org/end>    "245.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF33" ;
            <http://www.example.org/start>  "241.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[34]" .
    
    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_refspan-768-774>
            <http://www.example.org/end>    "774.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/start>  "768.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 6" .
    
    <http://covid19.aksw.org/text-7d19e2c05c0db91fa6e77df8e20e8fb0cdb89456a3823fc9ff6f8d80796407e6_refspan-632-638>
            <http://www.example.org/end>    "638.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF9" ;
            <http://www.example.org/start>  "632.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 5" .
    
    <http://covid19.aksw.org/text-0810ba601590786dd0d82954af6c87b0e298016262ace84d47234db4286daed8_refspan-168-174>
            <http://www.example.org/end>    "174.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF8" ;
            <http://www.example.org/start>  "168.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig. 4" .
    
    <http://covid19.aksw.org/text-6a9e4893d0154b176450c2b5a9a7fee0d0fbd086e1ce48a6c353c1e03d673f20>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Current search engines (Google, Yahoo and so on) allow users to input event keywords as a query and return a list of news web pages related to the query. Instead of organizing the results by events and relationships among events, these engines provide users with a ranked list of news web pages. It is difficult and time consuming for users to obtain the main picture of an event. In particular, users need to sift through and reorganize the documents returned by the search in order to extract the component events and their possible relationships.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Introduction\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Introduction" ;
            <http://www.example.org/text>  "Current search engines (Google, Yahoo and so on) allow users to input event keywords as a query and return a list of news web pages related to the query. Instead of organizing the results by events and relationships among events, these engines provide users with a ranked list of news web pages. It is difficult and time consuming for users to obtain the main picture of an event. In particular, users need to sift through and reorganize the documents returned by the search in order to extract the component events and their possible relationships." ;
            <http://www.example.org/textHash>
                    "6a9e4893d0154b176450c2b5a9a7fee0d0fbd086e1ce48a6c353c1e03d673f20" .
    
    <http://covid19.aksw.org/text-c6da05d838902e02dc48c83ea0fff0525e19eb3d612ca98a58909180d2b46582_citespan-949-953>
            <http://www.example.org/end>    "953.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF37" ;
            <http://www.example.org/start>  "949.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "[38]" .
}
<http://covid19.aksw.org/b3856f38a7316a9a494c8a73875f23676998f280> {
    <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef_citespan-88-113>
            <http://www.example.org/end>    "113.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "88.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore and Affolter 2005)" .
    
    <http://covid19.aksw.org/text-9c29dfa8e1bd92c849050d1794792c61394bd9bdf60d0616f7a19248a15d17cc>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Endoscopy of the gastrointestinal tract was performed. The oesophagus was unremarkable. The mucosa of the stomach appeared rather irregular and friable. The small intestine was grossly normal, but the colonic mucosa bled very easily. Multiple pinch biopsies were taken from the stomach, small intestine and colon. Low to moderate numbers of Helicobacter-like organisms were identified in the gastric pits, but no organisms were cultured from a gastric biopsy. The histopathology of the small and large intestine was considered normal.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Endoscopy of the gastrointestinal tract was performed. The oesophagus was unremarkable. The mucosa of the stomach appeared rather irregular and friable. The small intestine was grossly normal, but the colonic mucosa bled very easily. Multiple pinch biopsies were taken from the stomach, small intestine and colon. Low to moderate numbers of Helicobacter-like organisms were identified in the gastric pits, but no organisms were cultured from a gastric biopsy. The histopathology of the small and large intestine was considered normal." ;
            <http://www.example.org/textHash>
                    "9c29dfa8e1bd92c849050d1794792c61394bd9bdf60d0616f7a19248a15d17cc" .
    
    <http://covid19.aksw.org/text-d5bcf5ac205edcfa82f832a92e6bba90f68a7726a8541391ddc755ea56fb3812_refspan-332-338>
            <http://www.example.org/end>    "338.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF0" ;
            <http://www.example.org/start>  "332.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig 1)" .
    
    <http://covid19.aksw.org/text-3878930cad68edd9ffb11d4c7c1f32300c44a77d4b18bdf37b95800a7d6ae79f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The cat was re-presented 24 days after the initial referral. Although the gastrointestinal signs had improved, the right hind lameness had progressed. Decreased muscle tone and strength were noticed, along with decreased conscious proprioception of the right hind limb.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "The cat was re-presented 24 days after the initial referral. Although the gastrointestinal signs had improved, the right hind lameness had progressed. Decreased muscle tone and strength were noticed, along with decreased conscious proprioception of the right hind limb." ;
            <http://www.example.org/textHash>
                    "3878930cad68edd9ffb11d4c7c1f32300c44a77d4b18bdf37b95800a7d6ae79f" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-623-640>
            <http://www.example.org/end>    "640.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF0" ;
            <http://www.example.org/start>  "623.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Court et al 1993" .
    
    <http://covid19.aksw.org/text-e6ec79ccf210cc4f95135f01b4af6af5e4af1c82f34770fe8abc639d75578bca>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Serum was submitted for a coronavirus profile, including albumin:globulin ratio (0.89), coronavirus antibody titre (0) and a 1 acid glycoprotein (100 mg/ml; reference range \\u003c500 mg/ml), the results of which indicated that the cat was very unlikely to have feline infectious peritonitis.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Serum was submitted for a coronavirus profile, including albumin:globulin ratio (0.89), coronavirus antibody titre (0) and a 1 acid glycoprotein (100 mg/ml; reference range <500 mg/ml), the results of which indicated that the cat was very unlikely to have feline infectious peritonitis." ;
            <http://www.example.org/textHash>
                    "e6ec79ccf210cc4f95135f01b4af6af5e4af1c82f34770fe8abc639d75578bca" .
    
    <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55_citespan-187-207>
            <http://www.example.org/end>    "207.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "187.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Smoliga et al 2005)" .
    
    <http://covid19.aksw.org/text-1ccd55e859b931aa6f158e95a3b35e6d789e3283a5331fb2dd4450efa3fda109>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Treatments prescribed before referral consisted of antibiotics (clavulanic acid potentiated amoxicillin, 17 mg/kg q 12 h; metronidazole, 13 mg/ kg q 12 h), dietary modification (Hill\\u0027s i/d) and various courses of corticosteroids, namely prednisolone (1.7 mg/kg q 12 h), dexamethasone (0.3 mg/kg q 48 h; Dexadresson; Intervet) and methylprednisolone acetate (4 mg/kg once, 3 weeks before presentation; Depo-medrone V; Pharmacia). Initially, there had been some improvement (increased appetite and decreased frequency of vomiting) following the introduction of the prednisolone. However, the owner had been unable to administer the metronidazole due to difficulty in medicating the cat, and this also accounted for the change to injectable steroids.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Treatments prescribed before referral consisted of antibiotics (clavulanic acid potentiated amoxicillin, 17 mg/kg q 12 h; metronidazole, 13 mg/ kg q 12 h), dietary modification (Hill's i/d) and various courses of corticosteroids, namely prednisolone (1.7 mg/kg q 12 h), dexamethasone (0.3 mg/kg q 48 h; Dexadresson; Intervet) and methylprednisolone acetate (4 mg/kg once, 3 weeks before presentation; Depo-medrone V; Pharmacia). Initially, there had been some improvement (increased appetite and decreased frequency of vomiting) following the introduction of the prednisolone. However, the owner had been unable to administer the metronidazole due to difficulty in medicating the cat, and this also accounted for the change to injectable steroids." ;
            <http://www.example.org/textHash>
                    "1ccd55e859b931aa6f158e95a3b35e6d789e3283a5331fb2dd4450efa3fda109" .
    
    <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The case reported here is unusual for a number of reasons. The chronicity of the clinical signs is very different from the previously reported cases. In addition, no haematological or biochemical abnormalities were detected. Clotting times were not performed, but there was no suggestion of a bleeding disorder. The bone marrow was not examined histologically, but the absence of haematological abnormalities suggests that it is unlikely to have been involved. Pulmonary infiltration was previously reported in one cat (Kraje et al 2001) , but this is seen much more commonly in dogs (Moore and Rosin 1986) . Spinal cord involvement has recently been reported in one cat, but was attributed to extension of a histiocytic sarcoma, rather than malignant histiocytosis (Smoliga et al 2005) .\",\"cite_spans\":[{\"start\":519.0,\"end\":537.0,\"text\":\"(Kraje et al 2001)\",\"ref_id\":\"BIBREF3\"},{\"start\":584.0,\"end\":606.0,\"text\":\"(Moore and Rosin 1986)\",\"ref_id\":\"BIBREF6\"},{\"start\":766.0,\"end\":786.0,\"text\":\"(Smoliga et al 2005)\",\"ref_id\":\"BIBREF7\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d_citespan-519-537> , <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d_citespan-584-606> , <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d_citespan-766-786> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "The case reported here is unusual for a number of reasons. The chronicity of the clinical signs is very different from the previously reported cases. In addition, no haematological or biochemical abnormalities were detected. Clotting times were not performed, but there was no suggestion of a bleeding disorder. The bone marrow was not examined histologically, but the absence of haematological abnormalities suggests that it is unlikely to have been involved. Pulmonary infiltration was previously reported in one cat (Kraje et al 2001) , but this is seen much more commonly in dogs (Moore and Rosin 1986) . Spinal cord involvement has recently been reported in one cat, but was attributed to extension of a histiocytic sarcoma, rather than malignant histiocytosis (Smoliga et al 2005) ." ;
            <http://www.example.org/textHash>
                    "bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d" .
    
    <http://covid19.aksw.org/text-d8efe1efd1d1a4bf799f9618eaca20198c8c4034836a0c3e84f72e04658651d8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A n 8-year-old female neutered Somali cat was referred to the University of Edinburgh Hospital for Small Animals, for investigation of vomiting and weight loss of 9 months duration. The cat lived indoors, but had regular access outside. She was regularly wormed and routinely vaccinated against feline panleucopenia virus, feline herpesvirus, feline calicivirus and feline leukaemia virus (FeLV). Her previous medical history consisted of seasonal dermatitis, and occasional fight wounds.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "A n 8-year-old female neutered Somali cat was referred to the University of Edinburgh Hospital for Small Animals, for investigation of vomiting and weight loss of 9 months duration. The cat lived indoors, but had regular access outside. She was regularly wormed and routinely vaccinated against feline panleucopenia virus, feline herpesvirus, feline calicivirus and feline leukaemia virus (FeLV). Her previous medical history consisted of seasonal dermatitis, and occasional fight wounds." ;
            <http://www.example.org/textHash>
                    "d8efe1efd1d1a4bf799f9618eaca20198c8c4034836a0c3e84f72e04658651d8" .
    
    <http://covid19.aksw.org/text-60ad0022e3149d5c71b79ea9581a92bd7c464dfa11785c813a46288245a1cd32>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"At the time of referral, vomiting was occurring 2e3 times per week, although the signs had waxed and waned over the previous 8 months. The nature of the vomit had changed from bilious fluid to undigested food. Defecation had not been observed, but blood had occasionally been noticed at the cat\\u0027s anus. There had been a mild increase in thirst over this time period, and slow, insidious weight loss.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "At the time of referral, vomiting was occurring 2e3 times per week, although the signs had waxed and waned over the previous 8 months. The nature of the vomit had changed from bilious fluid to undigested food. Defecation had not been observed, but blood had occasionally been noticed at the cat's anus. There had been a mild increase in thirst over this time period, and slow, insidious weight loss." ;
            <http://www.example.org/textHash>
                    "60ad0022e3149d5c71b79ea9581a92bd7c464dfa11785c813a46288245a1cd32" .
    
    <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d_citespan-519-537>
            <http://www.example.org/end>    "537.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "519.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kraje et al 2001)" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-682-700>
            <http://www.example.org/end>    "700.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF2" ;
            <http://www.example.org/start>  "682.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   ", Fritz et al 1999" .
    
    <http://covid19.aksw.org/text-101ae3aaaa8b3f32eee7672fc545182cbbac2f268e56376db87d65cf41f8b025>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Histiocytic diseases other than malignant histiocytosis were considered in the differential diagnoses of this case. Systemic histiocytosis is unlikely, as skin lesions are a consistent finding in this condition (Moore 1984) . In disseminated histiocytic sarcoma, a primary histiocytic sarcoma becomes widely distributed throughout the body. Although histiocytic sarcomas often arise on the limbs, they may occur in cryptic sites such as lung, spleen or bone marrow, which Diffusely congested, with a cream, mottled appearance. Several raised, white, irregular, nodules (5e10 mm), which felt gritty when cut, and were diffusely scattered throughout the lung parenchyma.\",\"cite_spans\":[{\"start\":211.0,\"end\":223.0,\"text\":\"(Moore 1984)\",\"ref_id\":\"BIBREF4\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-101ae3aaaa8b3f32eee7672fc545182cbbac2f268e56376db87d65cf41f8b025_citespan-211-223> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Histiocytic diseases other than malignant histiocytosis were considered in the differential diagnoses of this case. Systemic histiocytosis is unlikely, as skin lesions are a consistent finding in this condition (Moore 1984) . In disseminated histiocytic sarcoma, a primary histiocytic sarcoma becomes widely distributed throughout the body. Although histiocytic sarcomas often arise on the limbs, they may occur in cryptic sites such as lung, spleen or bone marrow, which Diffusely congested, with a cream, mottled appearance. Several raised, white, irregular, nodules (5e10 mm), which felt gritty when cut, and were diffusely scattered throughout the lung parenchyma." ;
            <http://www.example.org/textHash>
                    "101ae3aaaa8b3f32eee7672fc545182cbbac2f268e56376db87d65cf41f8b025" .
    
    <http://covid19.aksw.org/text-53544db6722ed8eba42d00c6dae709c367a356876fa35f51d14a122ad5145e73>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Routine haematology and serum biochemistry were repeated, but again were found to be unremarkable. No abnormalities were detected on urinalysis, including culture. Faecal culture was negative, as was analysis for enteric parasites, Cryptosporidia, Giardia and Coccidia species. Serum levels of cobalamin, feline pancreatic lipase and trypsin-like immunoreactivity were all within the reference ranges. Serum folate level was slightly reduced (7.1 mg/l; reference range: 9.7e21.6 mg/l), consistent with small intestinal disease. Thoracic radiography revealed a generalised bronchointerstitial pattern, but abdominal radiography was unremarkable. Abdominal ultrasonography revealed prominent mesenteric lymph nodes, with one large lymph node (0.8 Â 1.7 cm) exhibiting heterogeneous echogenicity. The submucosal layer of the stomach showed generalised thickening.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Routine haematology and serum biochemistry were repeated, but again were found to be unremarkable. No abnormalities were detected on urinalysis, including culture. Faecal culture was negative, as was analysis for enteric parasites, Cryptosporidia, Giardia and Coccidia species. Serum levels of cobalamin, feline pancreatic lipase and trypsin-like immunoreactivity were all within the reference ranges. Serum folate level was slightly reduced (7.1 mg/l; reference range: 9.7e21.6 mg/l), consistent with small intestinal disease. Thoracic radiography revealed a generalised bronchointerstitial pattern, but abdominal radiography was unremarkable. Abdominal ultrasonography revealed prominent mesenteric lymph nodes, with one large lymph node (0.8 Â 1.7 cm) exhibiting heterogeneous echogenicity. The submucosal layer of the stomach showed generalised thickening." ;
            <http://www.example.org/textHash>
                    "53544db6722ed8eba42d00c6dae709c367a356876fa35f51d14a122ad5145e73" .
    
    <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d_citespan-584-606>
            <http://www.example.org/end>    "606.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "584.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore and Rosin 1986)" .
    
    <http://covid19.aksw.org/text-b071dd430cff5fdb65bbc37807ebdf680719735c4596db07e125bfd449697ed2>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"On physical examination, the cat was considered to be thin, weighing only 2.96 kg (body condition score 3/9). On abdominal palpation, there was suspicion of a mid-abdominal mass, but physical examination was otherwise unremarkable except that the cat tended to sit with her right hind limb extended cranially.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "On physical examination, the cat was considered to be thin, weighing only 2.96 kg (body condition score 3/9). On abdominal palpation, there was suspicion of a mid-abdominal mass, but physical examination was otherwise unremarkable except that the cat tended to sit with her right hind limb extended cranially." ;
            <http://www.example.org/textHash>
                    "b071dd430cff5fdb65bbc37807ebdf680719735c4596db07e125bfd449697ed2" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Malignant histiocytosis is a rare disorder, most commonly affecting Bernese Mountain Dogs. The disease is typified by systemic proliferation and invasion of tissues by morphologically atypical histiocytes, which occurs simultaneously within multiple sites. This is typically a very aggressive disease, with affected animals showing a rapid clinical course. Infiltrates are commonly identified within the lymph nodes, spleen and liver early in the course of the disease, and the bone marrow later in the course of the disease (Moore and Rosin 1986) . Reports of malignant histiocytosis in the cat amount to only seven cases (Court et al 1993 , Freeman et al 1995 , Walton et al 1997 , Fritz et al 1999 , Kraje et al 2001 . The ages of the affected cats ranged from 1 to 13 years, with weight loss, inappetence and lethargy being common presenting signs. The course of the disease was rapid, with euthanasia being performed between 2 and 7 weeks after onset of clinical signs. In the cases reported previously, anaemia, splenomegaly and icterus were consistent findings, with thrombocytopenia, hypoproteinaemia and hyperglycaemia being seen frequently. In the three cases where clotting times (prothrombin time and activated partial thromboplastin time) were performed, they were found to be prolonged (Kraje et al 2001) .\",\"cite_spans\":[{\"start\":525.0,\"end\":547.0,\"text\":\"(Moore and Rosin 1986)\",\"ref_id\":\"BIBREF6\"},{\"start\":623.0,\"end\":640.0,\"text\":\"(Court et al 1993\",\"ref_id\":\"BIBREF0\"},{\"start\":641.0,\"end\":661.0,\"text\":\", Freeman et al 1995\",\"ref_id\":\"BIBREF1\"},{\"start\":662.0,\"end\":681.0,\"text\":\", Walton et al 1997\",\"ref_id\":\"BIBREF8\"},{\"start\":682.0,\"end\":700.0,\"text\":\", Fritz et al 1999\",\"ref_id\":\"BIBREF2\"},{\"start\":701.0,\"end\":719.0,\"text\":\", Kraje et al 2001\",\"ref_id\":\"BIBREF3\"},{\"start\":1300.0,\"end\":1318.0,\"text\":\"(Kraje et al 2001)\",\"ref_id\":\"BIBREF3\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-682-700> , <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-662-681> , <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-641-661> , <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-623-640> , <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-701-719> , <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-1300-1318> , <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-525-547> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Malignant histiocytosis is a rare disorder, most commonly affecting Bernese Mountain Dogs. The disease is typified by systemic proliferation and invasion of tissues by morphologically atypical histiocytes, which occurs simultaneously within multiple sites. This is typically a very aggressive disease, with affected animals showing a rapid clinical course. Infiltrates are commonly identified within the lymph nodes, spleen and liver early in the course of the disease, and the bone marrow later in the course of the disease (Moore and Rosin 1986) . Reports of malignant histiocytosis in the cat amount to only seven cases (Court et al 1993 , Freeman et al 1995 , Walton et al 1997 , Fritz et al 1999 , Kraje et al 2001 . The ages of the affected cats ranged from 1 to 13 years, with weight loss, inappetence and lethargy being common presenting signs. The course of the disease was rapid, with euthanasia being performed between 2 and 7 weeks after onset of clinical signs. In the cases reported previously, anaemia, splenomegaly and icterus were consistent findings, with thrombocytopenia, hypoproteinaemia and hyperglycaemia being seen frequently. In the three cases where clotting times (prothrombin time and activated partial thromboplastin time) were performed, they were found to be prolonged (Kraje et al 2001) ." ;
            <http://www.example.org/textHash>
                    "a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a" .
    
    <http://covid19.aksw.org/text-b316767f5df90104871b63bf407b79ea6a11a6b592a63627754beac9b0b12af0>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Immunostaining with GFAP * : negative, S-100 y : negative, Vimentin: positive, Mac 387: positive * GFAP ¼ glial fibrillary acidic protein (to rule out glial cell tumour). y S-100 ¼ polyclonal rabbit S-100 protein (to rule out amelanotic melanoma). may delay their recognition. Unfortunately, once the condition is well advanced, differentiation from malignant histiocytosis can be extremely difficult (Moore and Affolter 2005) . While metastatic spread of a histiocytic sarcoma could explain the more insidious onset in this current case, the location of the primary lesion would remain in doubt. A reactive histiocytic disease was considered less likely due to the lack of identification of a causal agent, and the variety of organ systems involved. However, reactive histiocytic disease is poorly documented in the cat.\",\"cite_spans\":[{\"start\":401.0,\"end\":426.0,\"text\":\"(Moore and Affolter 2005)\",\"ref_id\":\"BIBREF5\"}],\"ref_spans\":[],\"section\":\"Spleen\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-b316767f5df90104871b63bf407b79ea6a11a6b592a63627754beac9b0b12af0_citespan-401-426> ;
            <http://www.example.org/section>
                    "Spleen" ;
            <http://www.example.org/text>  "Immunostaining with GFAP * : negative, S-100 y : negative, Vimentin: positive, Mac 387: positive * GFAP ¼ glial fibrillary acidic protein (to rule out glial cell tumour). y S-100 ¼ polyclonal rabbit S-100 protein (to rule out amelanotic melanoma). may delay their recognition. Unfortunately, once the condition is well advanced, differentiation from malignant histiocytosis can be extremely difficult (Moore and Affolter 2005) . While metastatic spread of a histiocytic sarcoma could explain the more insidious onset in this current case, the location of the primary lesion would remain in doubt. A reactive histiocytic disease was considered less likely due to the lack of identification of a causal agent, and the variety of organ systems involved. However, reactive histiocytic disease is poorly documented in the cat." ;
            <http://www.example.org/textHash>
                    "b316767f5df90104871b63bf407b79ea6a11a6b592a63627754beac9b0b12af0" .
    
    <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d_citespan-766-786>
            <http://www.example.org/end>    "786.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "766.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Smoliga et al 2005)" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-662-681>
            <http://www.example.org/end>    "681.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF8" ;
            <http://www.example.org/start>  "662.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   ", Walton et al 1997" .
    
    <http://covid19.aksw.org/text-b9825f2dbc3d2900a74f74dcac61eb2484264f53f6ad127c3f5d5091a3a37be6>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Cellular masses consisted of whorls and bundles of histiocytes, and occasional neutrophils, plasma cells and clusters of small lymphocytes. Aggregates of lymphocytes were present at the periphery of the two masses present in the thalamus and temporal cortex.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Spleen\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Spleen" ;
            <http://www.example.org/text>  "Cellular masses consisted of whorls and bundles of histiocytes, and occasional neutrophils, plasma cells and clusters of small lymphocytes. Aggregates of lymphocytes were present at the periphery of the two masses present in the thalamus and temporal cortex." ;
            <http://www.example.org/textHash>
                    "b9825f2dbc3d2900a74f74dcac61eb2484264f53f6ad127c3f5d5091a3a37be6" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-1300-1318>
            <http://www.example.org/end>    "1318.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "1300.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Kraje et al 2001)" .
    
    <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55_citespan-576-601>
            <http://www.example.org/end>    "601.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "576.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore and Affolter 2005)" .
    
    <http://covid19.aksw.org/text-0fc58c6a1f9a51a30d965398279fe14b4458897fe561a8cb4cd64f924566b07a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In conclusion, the spectrum of histiocytic disease is complex, and differentiation of these conditions is complicated by their rarity, particularly in the cat. Improved understanding of this spectrum of disease in this species requires further reports to aid recognition, and the development of immunophenotyping to assist with classification. This may in turn lead to identification of more effective treatments.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Spleen\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Spleen" ;
            <http://www.example.org/text>  "In conclusion, the spectrum of histiocytic disease is complex, and differentiation of these conditions is complicated by their rarity, particularly in the cat. Improved understanding of this spectrum of disease in this species requires further reports to aid recognition, and the development of immunophenotyping to assist with classification. This may in turn lead to identification of more effective treatments." ;
            <http://www.example.org/textHash>
                    "0fc58c6a1f9a51a30d965398279fe14b4458897fe561a8cb4cd64f924566b07a" .
    
    <http://covid19.aksw.org/b3856f38a7316a9a494c8a73875f23676998f280>
            a       <http://purl.org/dc/terms/BibliographicResource> ;
            <http://purl.org/dc/terms/identifier>
                    "b3856f38a7316a9a494c8a73875f23676998f280" ;
            <http://www.example.org/hasText>
                    <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef> , <http://covid19.aksw.org/text-e6ec79ccf210cc4f95135f01b4af6af5e4af1c82f34770fe8abc639d75578bca> , <http://covid19.aksw.org/text-53544db6722ed8eba42d00c6dae709c367a356876fa35f51d14a122ad5145e73> , <http://covid19.aksw.org/text-9c29dfa8e1bd92c849050d1794792c61394bd9bdf60d0616f7a19248a15d17cc> , <http://covid19.aksw.org/text-60ad0022e3149d5c71b79ea9581a92bd7c464dfa11785c813a46288245a1cd32> , <http://covid19.aksw.org/text-e819832fbeba98b3c6a3f8adbd78d396200ea11a4744c271a54ef33c8a404442> , <http://covid19.aksw.org/text-3878930cad68edd9ffb11d4c7c1f32300c44a77d4b18bdf37b95800a7d6ae79f> , <http://covid19.aksw.org/text-1e401a758d6cb127f752662300e3422076b8f76cc597024bbe1ce5533ecae744> , <http://covid19.aksw.org/text-d8efe1efd1d1a4bf799f9618eaca20198c8c4034836a0c3e84f72e04658651d8> , <http://covid19.aksw.org/text-df85f9aee568dcd893ddfd8b7a50af0bd7642b32bad5d132e319121221e6912a> , <http://covid19.aksw.org/text-8781faae1a4f438dd1073918003c2ecec577a115d6736337b832827303828a47> , <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55> , <http://covid19.aksw.org/text-290208f99ab56cc2999e309abbf4727daefc44801d169b20df30fd6e4695e06f> , <http://covid19.aksw.org/text-d5bcf5ac205edcfa82f832a92e6bba90f68a7726a8541391ddc755ea56fb3812> , <http://covid19.aksw.org/text-b9825f2dbc3d2900a74f74dcac61eb2484264f53f6ad127c3f5d5091a3a37be6> , <http://covid19.aksw.org/text-bf04c85305a5beb0a23b9b6b94ff013c3ade7dbcd1f3f58fafe184b382044e8d> , <http://covid19.aksw.org/text-1ccd55e859b931aa6f158e95a3b35e6d789e3283a5331fb2dd4450efa3fda109> , <http://covid19.aksw.org/text-b316767f5df90104871b63bf407b79ea6a11a6b592a63627754beac9b0b12af0> , <http://covid19.aksw.org/text-101ae3aaaa8b3f32eee7672fc545182cbbac2f268e56376db87d65cf41f8b025> , <http://covid19.aksw.org/text-b071dd430cff5fdb65bbc37807ebdf680719735c4596db07e125bfd449697ed2> , <http://covid19.aksw.org/text-ea4f6319e13ff9f9c7c0216986e9a9726acd5ad1bc6a2dcc2ab04005f2e6b8e8> , <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a> , <http://covid19.aksw.org/text-1f243fa568026679c9e8bc1232d13a27436814d521ee837e8d91f47cb768f675> , <http://covid19.aksw.org/text-2d4580de4bc6ae27d05d0c42cdd3a486975ea9654dd634b45120b1ec99e92e0e> , <http://covid19.aksw.org/text-f95d43b608fbd1c2dc8fdca2eb7032b5ceae05374d64d130bc1ae4c2eee5e734> , <http://covid19.aksw.org/text-932af76443cf1dd995337cea040fff1a4fa85e1d63b74e4e0085e19884e754bb> , <http://covid19.aksw.org/text-94ee3e1d6ddcfed421d8f56274ddf21da5bb7d38c5009861da22831d63f8a0ee> , <http://covid19.aksw.org/text-0fc58c6a1f9a51a30d965398279fe14b4458897fe561a8cb4cd64f924566b07a> .
    
    <http://covid19.aksw.org/text-df85f9aee568dcd893ddfd8b7a50af0bd7642b32bad5d132e319121221e6912a>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Depleted white pulp, with prominent germinal centres, containing occasional small foci of atypical histiocytes. The red pulp was markedly acellular with the few cells consisting mainly of erythrocytes and scattered foci of histiocytes in the sinusoids. These cells were histologically similar to those seen in the lungs and liver. The ileocaecal lymph node was prominent, and the mesentery contained a solitary enlarged (10 Â 5 mm) lymph node.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Spleen\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Spleen" ;
            <http://www.example.org/text>  "Depleted white pulp, with prominent germinal centres, containing occasional small foci of atypical histiocytes. The red pulp was markedly acellular with the few cells consisting mainly of erythrocytes and scattered foci of histiocytes in the sinusoids. These cells were histologically similar to those seen in the lungs and liver. The ileocaecal lymph node was prominent, and the mesentery contained a solitary enlarged (10 Â 5 mm) lymph node." ;
            <http://www.example.org/textHash>
                    "df85f9aee568dcd893ddfd8b7a50af0bd7642b32bad5d132e319121221e6912a" .
    
    <http://covid19.aksw.org/text-94ee3e1d6ddcfed421d8f56274ddf21da5bb7d38c5009861da22831d63f8a0ee_refspan-284-290>
            <http://www.example.org/end>    "290.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "FIGREF1" ;
            <http://www.example.org/start>  "284.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Fig 2)" .
    
    <http://covid19.aksw.org/text-932af76443cf1dd995337cea040fff1a4fa85e1d63b74e4e0085e19884e754bb>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"A presumptive diagnosis of deep-seated inflammatory bowel disease was made, and the cat was discharged on prednisolone (1.7 mg/ kg q 48 h), along with an exclusion diet of chicken only. In addition, when the biopsy results revealed the presence of Helicobacter-like organisms, a 10-day course of metronidazole (14 mg/kg q 24 h) and spiramycin (26 mg/kg q 24 h; Stomorgyl; Merial Animal Health) was prescribed. This formulation was chosen to try to facilitate medication of an uncooperative cat.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "A presumptive diagnosis of deep-seated inflammatory bowel disease was made, and the cat was discharged on prednisolone (1.7 mg/ kg q 48 h), along with an exclusion diet of chicken only. In addition, when the biopsy results revealed the presence of Helicobacter-like organisms, a 10-day course of metronidazole (14 mg/kg q 24 h) and spiramycin (26 mg/kg q 24 h; Stomorgyl; Merial Animal Health) was prescribed. This formulation was chosen to try to facilitate medication of an uncooperative cat." ;
            <http://www.example.org/textHash>
                    "932af76443cf1dd995337cea040fff1a4fa85e1d63b74e4e0085e19884e754bb" .
    
    <http://covid19.aksw.org/text-8781faae1a4f438dd1073918003c2ecec577a115d6736337b832827303828a47_refspan-76-83>
            <http://www.example.org/end>    "83.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF0" ;
            <http://www.example.org/start>  "76.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-525-547>
            <http://www.example.org/end>    "547.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF6" ;
            <http://www.example.org/start>  "525.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore and Rosin 1986)" .
    
    <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef_citespan-576-601>
            <http://www.example.org/end>    "601.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "576.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Moore and Affolter (2005)" .
    
    <http://covid19.aksw.org/text-1f243fa568026679c9e8bc1232d13a27436814d521ee837e8d91f47cb768f675>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The mesenteric lymph node contained a prominent cortical area with lymphoid follicles with distinct germinal centres. The follicles contained a mixed cell population of predominantly small mature lymphocytes, fewer plasma cells and macrophages, and numerous tingible body macrophages. Spinal cord An irregular area of grey discoloration of 5 Â 5 mm at the level of the first lumbar vertebra.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Spleen\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Spleen" ;
            <http://www.example.org/text>  "The mesenteric lymph node contained a prominent cortical area with lymphoid follicles with distinct germinal centres. The follicles contained a mixed cell population of predominantly small mature lymphocytes, fewer plasma cells and macrophages, and numerous tingible body macrophages. Spinal cord An irregular area of grey discoloration of 5 Â 5 mm at the level of the first lumbar vertebra." ;
            <http://www.example.org/textHash>
                    "1f243fa568026679c9e8bc1232d13a27436814d521ee837e8d91f47cb768f675" .
    
    <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The histiocytes in this case were identified by staining with vimentin, which confirmed mesenchymal origin (Smoliga et al 2005) , and Mac 387, which is a human histiocyteemonocyte marker (Smoliga et al 2005) , although the ideal marker for feline histiocytes is yet to be established. More recently, immunophenotyping has been used to differentiate lymphocytes which express CD3 or CD79a from histiocytes, which do not, and further classification of the histiocytic lineage may be achieved with immunophenotyping for CD1, CD11b, CD11c, CD11d, CD18, CD90, MHCII and E-cadherin (Moore and Affolter 2005) .\",\"cite_spans\":[{\"start\":107.0,\"end\":127.0,\"text\":\"(Smoliga et al 2005)\",\"ref_id\":\"BIBREF7\"},{\"start\":187.0,\"end\":207.0,\"text\":\"(Smoliga et al 2005)\",\"ref_id\":\"BIBREF7\"},{\"start\":576.0,\"end\":601.0,\"text\":\"(Moore and Affolter 2005)\",\"ref_id\":\"BIBREF5\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55_citespan-107-127> , <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55_citespan-187-207> , <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55_citespan-576-601> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "The histiocytes in this case were identified by staining with vimentin, which confirmed mesenchymal origin (Smoliga et al 2005) , and Mac 387, which is a human histiocyteemonocyte marker (Smoliga et al 2005) , although the ideal marker for feline histiocytes is yet to be established. More recently, immunophenotyping has been used to differentiate lymphocytes which express CD3 or CD79a from histiocytes, which do not, and further classification of the histiocytic lineage may be achieved with immunophenotyping for CD1, CD11b, CD11c, CD11d, CD18, CD90, MHCII and E-cadherin (Moore and Affolter 2005) ." ;
            <http://www.example.org/textHash>
                    "a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55" .
    
    <http://covid19.aksw.org/text-b316767f5df90104871b63bf407b79ea6a11a6b592a63627754beac9b0b12af0_citespan-401-426>
            <http://www.example.org/end>    "426.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "401.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore and Affolter 2005)" .
    
    <http://covid19.aksw.org/text-1e401a758d6cb127f752662300e3422076b8f76cc597024bbe1ce5533ecae744>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Markedly enlarged and congested.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Spleen\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Spleen" ;
            <http://www.example.org/text>  "Markedly enlarged and congested." ;
            <http://www.example.org/textHash>
                    "1e401a758d6cb127f752662300e3422076b8f76cc597024bbe1ce5533ecae744" .
    
    <http://covid19.aksw.org/text-e819832fbeba98b3c6a3f8adbd78d396200ea11a4744c271a54ef33c8a404442>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Investigations prior to referral included routine haematology and serum biochemistry, the results of which were unremarkable. Inhouse tests for FeLV antigen and feline immunodeficiency virus antibody had been negative. A lateral thoracic radiograph taken 8 months before presentation was reported to show a patchy, mixed lung pattern. An exploratory coeliotomy had been performed. No gross abnormalities were reported, and biopsies were obtained from the stomach, mesenteric lymph nodes and jejunum. Histopathology of the gastric biopsy reported the presence of nodular to coalescing infiltrates, which consisted of histiocytes with neutrophils and variable numbers of lymphocytes and plasma cells and abundant fibrosis. No multinucleated giant cells or infectious agents were detected (acid-fast and periodic acid Schiff staining were performed). The lymph node histopathology was similar to that of the gastric biopsy, and the small intestinal histopathology suggested mild to moderate lymphocytic enteritis.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Investigations prior to referral included routine haematology and serum biochemistry, the results of which were unremarkable. Inhouse tests for FeLV antigen and feline immunodeficiency virus antibody had been negative. A lateral thoracic radiograph taken 8 months before presentation was reported to show a patchy, mixed lung pattern. An exploratory coeliotomy had been performed. No gross abnormalities were reported, and biopsies were obtained from the stomach, mesenteric lymph nodes and jejunum. Histopathology of the gastric biopsy reported the presence of nodular to coalescing infiltrates, which consisted of histiocytes with neutrophils and variable numbers of lymphocytes and plasma cells and abundant fibrosis. No multinucleated giant cells or infectious agents were detected (acid-fast and periodic acid Schiff staining were performed). The lymph node histopathology was similar to that of the gastric biopsy, and the small intestinal histopathology suggested mild to moderate lymphocytic enteritis." ;
            <http://www.example.org/textHash>
                    "e819832fbeba98b3c6a3f8adbd78d396200ea11a4744c271a54ef33c8a404442" .
    
    <http://covid19.aksw.org/text-290208f99ab56cc2999e309abbf4727daefc44801d169b20df30fd6e4695e06f>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Multiple foci comprising a mixture of histiocytes, abundant small lymphocytes and occasional plasma cells and lymphocytes, randomly distributed throughout grey and white matter. Histiocytic cells were predominant and occasionally had a spindleoid appearance, forming streams and whorls. There was marked evidence of Wallerian degeneration, and widespread neuronal chromatolysis. Brain A large, well-circumscribed, non-encapsulated cellular mass was identified in the area of the lateral geniculate body and periaqueductal grey matter of the midbrain. This extended to above the third ventricle in the thalamus and the temporal cortex.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"Spleen\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "Spleen" ;
            <http://www.example.org/text>  "Multiple foci comprising a mixture of histiocytes, abundant small lymphocytes and occasional plasma cells and lymphocytes, randomly distributed throughout grey and white matter. Histiocytic cells were predominant and occasionally had a spindleoid appearance, forming streams and whorls. There was marked evidence of Wallerian degeneration, and widespread neuronal chromatolysis. Brain A large, well-circumscribed, non-encapsulated cellular mass was identified in the area of the lateral geniculate body and periaqueductal grey matter of the midbrain. This extended to above the third ventricle in the thalamus and the temporal cortex." ;
            <http://www.example.org/textHash>
                    "290208f99ab56cc2999e309abbf4727daefc44801d169b20df30fd6e4695e06f" .
    
    <http://covid19.aksw.org/text-a8420cf8bb5f31b47ef9db4dbc582b6fb1afa39aab7ab2c78d42d068da770a55_citespan-107-127>
            <http://www.example.org/end>    "127.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF7" ;
            <http://www.example.org/start>  "107.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Smoliga et al 2005)" .
    
    <http://covid19.aksw.org/text-94ee3e1d6ddcfed421d8f56274ddf21da5bb7d38c5009861da22831d63f8a0ee_refspan-272-279>
            <http://www.example.org/end>    "279.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "TABREF0" ;
            <http://www.example.org/start>  "272.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "Table 1" .
    
    <http://covid19.aksw.org/text-d5bcf5ac205edcfa82f832a92e6bba90f68a7726a8541391ddc755ea56fb3812>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The cat was anaesthetised for further investigations. Plain radiographs of the spinal column were obtained, before collection of a cerebrospinal fluid sample and performance of a myelogram. The cerebrospinal fluid was unremarkable. The myelogram demonstrated an intra-medullary lesion at the level of the first lumbar vertebra (see Fig 1) . Neoplasia was considered a significant differential diagnosis, therefore, the owner elected for euthanasia with consent given for a post-mortem examination to be performed.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":332.0,\"end\":338.0,\"text\":\"Fig 1)\",\"ref_id\":\"FIGREF0\"}],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-d5bcf5ac205edcfa82f832a92e6bba90f68a7726a8541391ddc755ea56fb3812_refspan-332-338> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "The cat was anaesthetised for further investigations. Plain radiographs of the spinal column were obtained, before collection of a cerebrospinal fluid sample and performance of a myelogram. The cerebrospinal fluid was unremarkable. The myelogram demonstrated an intra-medullary lesion at the level of the first lumbar vertebra (see Fig 1) . Neoplasia was considered a significant differential diagnosis, therefore, the owner elected for euthanasia with consent given for a post-mortem examination to be performed." ;
            <http://www.example.org/textHash>
                    "d5bcf5ac205edcfa82f832a92e6bba90f68a7726a8541391ddc755ea56fb3812" .
    
    <http://covid19.aksw.org/text-94ee3e1d6ddcfed421d8f56274ddf21da5bb7d38c5009861da22831d63f8a0ee>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"In this case, the diagnosis of malignant histiocytosis was based on the finding of populations of atypical and pleomorphic histiocytes, their presence within multiple organs, and their dissemination to organs that do not normally contain large numbers of histiocytes (see Table 1 and Fig 2) .\",\"cite_spans\":[],\"ref_spans\":[{\"start\":272.0,\"end\":279.0,\"text\":\"Table 1\",\"ref_id\":\"TABREF0\"},{\"start\":284.0,\"end\":290.0,\"text\":\"Fig 2)\",\"ref_id\":\"FIGREF1\"}],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-94ee3e1d6ddcfed421d8f56274ddf21da5bb7d38c5009861da22831d63f8a0ee_refspan-272-279> , <http://covid19.aksw.org/text-94ee3e1d6ddcfed421d8f56274ddf21da5bb7d38c5009861da22831d63f8a0ee_refspan-284-290> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "In this case, the diagnosis of malignant histiocytosis was based on the finding of populations of atypical and pleomorphic histiocytes, their presence within multiple organs, and their dissemination to organs that do not normally contain large numbers of histiocytes (see Table 1 and Fig 2) ." ;
            <http://www.example.org/textHash>
                    "94ee3e1d6ddcfed421d8f56274ddf21da5bb7d38c5009861da22831d63f8a0ee" .
    
    <http://covid19.aksw.org/text-2d4580de4bc6ae27d05d0c42cdd3a486975ea9654dd634b45120b1ec99e92e0e>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Multiple, randomly distributed, irregularly shaped foci were scattered throughout the hepatic parenchyma. These aggregates were composed mainly of large histiocytic cells and neutrophils, with fewer numbers of plasma cells. Apoptotic bodies were scattered throughout the parenchyma. Haemosiderin was abundant in the cytoplasm of hepatocytes, within sinusoidal Kupffer cells, and occasionally in the centre of inflammatory foci within the cytoplasm of the histiocytes.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Multiple, randomly distributed, irregularly shaped foci were scattered throughout the hepatic parenchyma. These aggregates were composed mainly of large histiocytic cells and neutrophils, with fewer numbers of plasma cells. Apoptotic bodies were scattered throughout the parenchyma. Haemosiderin was abundant in the cytoplasm of hepatocytes, within sinusoidal Kupffer cells, and occasionally in the centre of inflammatory foci within the cytoplasm of the histiocytes." ;
            <http://www.example.org/textHash>
                    "2d4580de4bc6ae27d05d0c42cdd3a486975ea9654dd634b45120b1ec99e92e0e" .
    
    <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Histiocytes are tissue macrophages derived from the CD34þ committed stem cell precursor (Moore and Affolter 2005) . Histiocytic disorders in dogs may be broadly divided into cutaneous and non-cutaneous diseases. The cutaneous disorders include cutaneous histiocytoma, multiple histiocytomas, metastatic histiocytoma and Langerhans cell histiocytoma (Moore and Affolter 2005) . The non-cutaneous diseases include histiocytic sarcoma, disseminated histiocytic sarcoma, systemic histiocytosis and malignant histiocytosis. A review of these histiocytic diseases has been given by Moore and Affolter (2005) .\",\"cite_spans\":[{\"start\":88.0,\"end\":113.0,\"text\":\"(Moore and Affolter 2005)\",\"ref_id\":\"BIBREF5\"},{\"start\":349.0,\"end\":374.0,\"text\":\"(Moore and Affolter 2005)\",\"ref_id\":\"BIBREF5\"},{\"start\":576.0,\"end\":601.0,\"text\":\"Moore and Affolter (2005)\",\"ref_id\":\"BIBREF5\"}],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/citeSpan>
                    <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef_citespan-88-113> , <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef_citespan-349-374> , <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef_citespan-576-601> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Histiocytes are tissue macrophages derived from the CD34þ committed stem cell precursor (Moore and Affolter 2005) . Histiocytic disorders in dogs may be broadly divided into cutaneous and non-cutaneous diseases. The cutaneous disorders include cutaneous histiocytoma, multiple histiocytomas, metastatic histiocytoma and Langerhans cell histiocytoma (Moore and Affolter 2005) . The non-cutaneous diseases include histiocytic sarcoma, disseminated histiocytic sarcoma, systemic histiocytosis and malignant histiocytosis. A review of these histiocytic diseases has been given by Moore and Affolter (2005) ." ;
            <http://www.example.org/textHash>
                    "cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-701-719>
            <http://www.example.org/end>    "719.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF3" ;
            <http://www.example.org/start>  "701.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   ", Kraje et al 2001" .
    
    <http://covid19.aksw.org/text-8781faae1a4f438dd1073918003c2ecec577a115d6736337b832827303828a47>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"The results of the gross and histopathological examinations are reported in Table 1 , and led to a pathological diagnosis of malignant histiocytosis.\",\"cite_spans\":[],\"ref_spans\":[{\"start\":76.0,\"end\":83.0,\"text\":\"Table 1\",\"ref_id\":\"TABREF0\"}],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/refSpan>
                    <http://covid19.aksw.org/text-8781faae1a4f438dd1073918003c2ecec577a115d6736337b832827303828a47_refspan-76-83> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "The results of the gross and histopathological examinations are reported in Table 1 , and led to a pathological diagnosis of malignant histiocytosis." ;
            <http://www.example.org/textHash>
                    "8781faae1a4f438dd1073918003c2ecec577a115d6736337b832827303828a47" .
    
    <http://covid19.aksw.org/text-101ae3aaaa8b3f32eee7672fc545182cbbac2f268e56376db87d65cf41f8b025_citespan-211-223>
            <http://www.example.org/end>    "223.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF4" ;
            <http://www.example.org/start>  "211.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore 1984)" .
    
    <http://covid19.aksw.org/text-cf29c7ae27deb8ba4106fc22dd05d08b9c12b7e6e33134fc9ad9e33a498cfbef_citespan-349-374>
            <http://www.example.org/end>    "374.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF5" ;
            <http://www.example.org/start>  "349.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   "(Moore and Affolter 2005)" .
    
    <http://covid19.aksw.org/text-ea4f6319e13ff9f9c7c0216986e9a9726acd5ad1bc6a2dcc2ab04005f2e6b8e8>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Negative staining with Gram\\u0027s, Grocott\\u0027s and Ziehl Neelsen stains. Immunostaining with GFAP * : negative, S-100 y : negative, Vimentin: positive, Mac 387: positive Liver Uniformly congested, containing small (5 mm), irregular white foci. The diaphragmatic surface had a 7 mm firm, creamy nodule involving the hepatic parenchyma.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Negative staining with Gram's, Grocott's and Ziehl Neelsen stains. Immunostaining with GFAP * : negative, S-100 y : negative, Vimentin: positive, Mac 387: positive Liver Uniformly congested, containing small (5 mm), irregular white foci. The diaphragmatic surface had a 7 mm firm, creamy nodule involving the hepatic parenchyma." ;
            <http://www.example.org/textHash>
                    "ea4f6319e13ff9f9c7c0216986e9a9726acd5ad1bc6a2dcc2ab04005f2e6b8e8" .
    
    <http://covid19.aksw.org/text-a35b4afb7dd871ceb5db3042b2713d6b67cab313b9468e6bf701727ac8389f2a_citespan-641-661>
            <http://www.example.org/end>    "661.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/refId>  "BIBREF1" ;
            <http://www.example.org/start>  "641.0"^^<http://www.w3.org/2001/XMLSchema#double> ;
            <http://www.example.org/text>   ", Freeman et al 1995" .
    
    <http://covid19.aksw.org/text-f95d43b608fbd1c2dc8fdca2eb7032b5ceae05374d64d130bc1ae4c2eee5e734>
            <http://www.example.org/bodyJson>
                    "{\"text\":\"Multifocal to coalescing non-encapsulated masses comprising a mixture of histiocytic cells, neutrophils, and a few plasma cells and small lymphocytes. These cell aggregates were mainly scattered throughout the pulmonary interstitium, but they were also present within the lumen of bronchi and bronchioles (admixed with desquamated lining epithelial cells and eosinophilic proteinaceous material) and occasionally within the lumen of blood vessels. The histiocytes were large, polygonal with large oval vesicular nuclei with single prominent nucleoli and abundant eosinophilic cytoplasm. Mitoses were not observed. There was mild anisokaryosis of the histiocytes.\",\"cite_spans\":[],\"ref_spans\":[],\"section\":\"\"}"^^<http://www.w3.org/2001/XMLSchema#json> ;
            <http://www.example.org/section>
                    "" ;
            <http://www.example.org/text>  "Multifocal to coalescing non-encapsulated masses comprising a mixture of histiocytic cells, neutrophils, and a few plasma cells and small lymphocytes. These cell aggregates were mainly scattered throughout the pulmonary interstitium, but they were also present within the lumen of bronchi and bronchioles (admixed with desquamated lining epithelial cells and eosinophilic proteinaceous material) and occasionally within the lumen of blood vessels. The histiocytes were large, polygonal with large oval vesicular nuclei with single prominent nucleoli and abundant eosinophilic cytoplasm. Mitoses were not observed. There was mild anisokaryosis of the histiocytes." ;
            <http://www.example.org/textHash>
                    "f95d43b608fbd1c2dc8fdca2eb7032b5ceae05374d64d130bc1ae4c2eee5e734" .
}
